datetime,title,source,link,sentiment_class,sentiment_score
8/28/2007 12:00:00 PM,Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet,PR Newswire,/news/stocks/schering-plough-merck-pharmaceuticals-announce-fda-filing-acceptance-of-new-drug-application-for-loratadine-montelukast-tablet-1028299848,positive,0.6537547707557678
6/6/2012 8:55:13 AM,"Merck KGaA, Dr. Reddy's to cooperate on biosimilars",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/z1_JTOp2hk8/drreddyslaboratories-brief-idINDEE85504520120606,neutral,0.5226828455924988
1/11/2013 2:52:36 PM,Merck withdraws cholesterol drug Tredaptive globally,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/fQaXvzw3AwU/us-merck-cholesteroldrug-withdrawal-idUSBRE90A0MB20130111,negative,0.9164746403694153
2/1/2013 2:07:07 PM,"Merck beats forecast for fourth quarter, cautious on 2013",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/tMdQTAByaRk/us-merck-results-idUSBRE9100JL20130201,negative,0.5549464225769043
2/14/2013 2:16:28 PM,Merck says to pay $688 million to settle Enhance lawsuits,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/QkMKhPQg39s/us-merck-settlements-idUSBRE91D0R520130214,neutral,0.8399858474731445
4/2/2013 5:24:46 PM,Merck unit sues Glenmark over diabetes drug,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/_iwHkbepLkk/story01.htm,negative,0.9366360306739807
5/1/2013 1:12:27 PM,Merck first-quarter sales disappoint,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/jPil6ep-SfE/story01.htm,negative,0.9611907005310059
5/9/2013 5:26:46 PM,"Merck sales rep claims sexual bias, seeks over $100 million",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/XeJsl-sfd1A/story01.htm,neutral,0.6161225438117981
5/22/2013 4:33:23 AM,Merck signs $5 billion share buyback agreement with Goldman Sachs,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/LOC_wZcBQ5E/story01.htm,positive,0.8256967067718506
6/3/2013 12:45:48 PM,"Exclusive: EU regulators to fine Lundbeck, Merck, seven other drug firms - sources",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/KORz7xF9i68/story01.htm,neutral,0.6057273745536804
6/3/2013 12:49:26 PM,"EU regulators to fine Merck, Ranbaxy, others: sources",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/o4tcEi2QP9g/story01.htm,neutral,0.5145161151885986
6/3/2013 10:48:02 PM,"Wall St ends higher on stimulus views, Merck gains",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/vLNFG8U_ypk/story01.htm,positive,0.8958783745765686
6/25/2013 1:32:59 PM,Merck & Co wins injunction against Indian firm over diabetes drugs,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/FId_IOr3hUA/story01.htm,negative,0.9032925963401794
6/26/2013 10:20:52 AM,Merck KGaA says liquid crystals momentum to slow in second half,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/sTv7_uJn3gU/story01.htm,negative,0.9529492259025574
6/27/2013 12:55:19 PM,South Africa's Aspen in $1 billion deal with Merck,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/pgDUGlpwT-4/story01.htm,positive,0.6969838738441467
7/30/2013 1:15:07 PM,"Merck revenue misses mark as diabetes, arthritis drugs lag",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/QKF-yQC5BlU/story01.htm,negative,0.9319208264350891
7/30/2013 10:10:07 PM,"Cost controls help Pfizer, Merck weather weak quarter",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/TfBef5dg-fI/story01.htm,positive,0.6507494449615479
8/16/2013 6:05:50 PM,"Exclusive: FDA says working with Merck, USDA on cattle drug Zilmax",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/SY1A73Wku7k/story01.htm,positive,0.73492431640625
8/16/2013 6:51:34 PM,"Merck halts Zilmax sales, to study cattle feed additive",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/sf8shRJG-W8/story01.htm,negative,0.8114826679229736
8/16/2013 7:33:57 PM,Merck says no safety issues found in Zilmax cattle product,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/FU6ZtXAvwAE/story01.htm,neutral,0.6534059047698975
8/30/2013 10:51:42 PM,Hundreds of Fosamax lawsuits versus Merck ordered readied for trial,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/gH6hWLASANk/story01.htm,neutral,0.5556707382202148
9/11/2013 12:57:25 PM,AstraZeneca pays $50 million for rights to Merck cancer drug,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/QLWQ3cbC6H0/story01.htm,neutral,0.8952269554138184
10/1/2013 3:31:35 PM,"Merck to cut costs by $2.5 billion, eliminate 8,500 jobs",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/dduFQ7pGAFw/story01.htm,positive,0.4745068848133087
10/1/2013 8:08:15 PM,"Merck to slash annual costs by $2.5 billion, cut 8,500 jobs",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/LBSaUYomSHA/story01.htm,negative,0.8448366522789001
10/28/2013 12:29:38 PM,"Merck third-quarter profit beats estimate, but Januvia sales slump",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/SsHpXJEOj-U/story01.htm,positive,0.882524311542511
10/28/2013 4:06:56 PM,"Wall St flat near record levels, Merck falls",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/v-JL3Vfp9HA/story01.htm,negative,0.4328089654445648
10/30/2013 2:26:11 PM,"Exclusive - Merck works toward bringing Zilmax back to U.S., Canada",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Xhvfu8-Fxo4/story01.htm,positive,0.798738956451416
10/31/2013 8:08:05 PM,"Analysis: For Merck, bringing cattle feed Zilmax back won't be easy",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/UU_5-2lS8Pg/story01.htm,neutral,0.8055959939956665
11/14/2013 11:30:33 AM,Merck KGaA says eyes acquisitions at all four units,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/q7ldUgJ8Cuw/story01.htm,neutral,0.8232967853546143
12/30/2013 10:02:08 PM,"Special Report: Lost hooves, dead cattle before Merck halted Zilmax sales",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/b9BE6dMesYs/story01.htm,negative,0.8658133745193481
1/13/2014 4:14:29 PM,Wall Street flat on earnings caution; Merck climbs,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/B7Iu_mJlFYM/story01.htm,negative,0.6937153339385986
1/13/2014 4:16:38 PM,Wall St flat on earnings caution; Merck climbs,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/sMyaAM-sHnQ/story01.htm,negative,0.7450093626976013
1/14/2014 5:46:28 PM,"Merck needs a dose of joie de vivre, research chief says",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/l4EH0RFR3mc/story01.htm,neutral,0.8379188776016235
2/5/2014 1:15:34 PM,Merck fourth-quarter sales just miss Wall St estimate,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/rfcwteqO5qU/story01.htm,negative,0.5215207934379578
4/28/2014 7:04:04 AM,Fulford India jumps 20 percent on Merck & Co's delisting offer,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/zl4AvGR-Vcw/story01.htm,negative,0.569175124168396
4/29/2014 1:51:47 PM,Futures gain on earnings; Merck shares up in premarket,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/KdnoOVeUTgQ/story01.htm,positive,0.9245989322662354
4/29/2014 5:57:58 PM,"Wall St climbs, lifted by Merck, Sprint on rosy earnings",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/YJ_nlDBLN9c/story01.htm,positive,0.6354508399963379
4/30/2014 10:11:07 PM,Exclusive: Merck explores $15 billion-plus drug portfolio sale - sources,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ipz_n9fLRKc/story01.htm,neutral,0.9090807437896729
5/6/2014 12:13:04 PM,Merck to sell consumer care business to Bayer for $14 billion,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/IZ880Zzevew/story01.htm,neutral,0.9385130405426025
5/6/2014 8:44:01 PM,Bayer wins Merck & Co's $14 billion consumer unit auction,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Q_Fdc3cmm0w/story01.htm,neutral,0.7687774300575256
6/2/2014 2:25:16 AM,Novartis appoints Merck executive as oncology chief,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/U-FWGjrwXX0/story01.htm,neutral,0.9044391512870789
6/12/2014 1:09:39 PM,"Merck, Pfizer, HSBC could be big winners from shareholder case",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/mSIeSDiKIsw/story01.htm,positive,0.7946315407752991
7/26/2014 1:41:58 PM,Merck aims to hike revenues in China to 1 bln eur by 2018,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/6OCIVRitm-s/story01.htm,positive,0.9413324594497681
7/26/2014 1:48:09 PM,Merck aims to hike revenues in China to 1 billion euro by 2018,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/PJKEAZf05uM/story01.htm,positive,0.9141878485679626
7/29/2014 1:12:30 PM,"Merck beats forecasts, as newer drugs offset generics",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/7Lss0XkmyEE/story01.htm,positive,0.9282631278038025
9/16/2014 11:54:10 AM,Merck KGaA agrees to market Lupin drugs in emerging countries,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/sYRL6dsfzXM/story01.htm,positive,0.8766124844551086
9/17/2014 4:18:10 PM,Merck licenses experimental psoriasis drug to Sun Pharma,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/_t4yklMgPis/story01.htm,neutral,0.7640567421913147
9/22/2014 12:16:05 PM,Merck KGaA to buy Sigma-Aldrich for $17 billion,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ZwRUYqb3t0I/story01.htm,neutral,0.9312509298324585
9/22/2014 4:32:49 PM,Germany's Merck to buy Sigma-Aldrich for $17 bln,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/4SZ53Taw-B8/story01.htm,neutral,0.9167909622192383
10/27/2014 2:31:56 PM,Merck beats profit forecast with deep cost cuts,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/-c_dGVsYvzg/story01.htm,positive,0.8469776511192322
11/17/2014 9:12:07 AM,"German Merck, Pfizer in cancer immunotherapy deal",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/q5ifBFCmXg4/story01.htm,neutral,0.8984612226486206
11/17/2014 3:10:07 PM,Pfizer dampens Astra bid hopes with German Merck cancer deal,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/2xV1C04An20/story01.htm,positive,0.8527934551239014
12/8/2014 2:57:39 PM,Merck to take on superbugs with Cubist Pharma buy,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/i_0KGpGOZyA/story01.htm,neutral,0.7424195408821106
12/9/2014 3:18:58 PM,"Merck says still plans Cubist purchase, despite patent setback",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/eeN3Quu7tOA/story01.htm,positive,0.8390129804611206
5/15/2015 12:55:38 PM,Supreme Court bars Glenmark from selling copies of Merck diabetes drugs - sources,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/7iDIVNbQqHs/story01.htm,neutral,0.7458361983299255
11/26/2015 11:32:38 PM,Merck plans to sell its allergy business unit to cut debt: Bloomberg,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/JkHPFNHHpcs/story01.htm,neutral,0.84328693151474
12/17/2015 11:00:14 AM,Merck KGaA CEO interested in becoming Lufthansa chairman -report,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/efWG0zriAJA/story01.htm,neutral,0.9354760050773621
2/3/2016 12:58:44 PM,Merck revenue falls as dollar strengthens,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/P4yajNpAkZM/story01.htm,negative,0.9682182669639587
3/25/2016 2:23:09 AM,Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/lQ-2-kvxB4o/story01.htm,negative,0.803180456161499
5/5/2016 2:49:34 PM,"Merck sales disappoint as Januvia, Remicade fall short",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/tHgPP5Xhiy8/us-merck-co-results-idUSKCN0XW0YK,negative,0.9702786207199097
9/27/2016 11:10:23 PM,"EU mergers and takeovers (Sept 27) (AKZA, BAS, SAN, MRK)",Reuters,/news/stocks/eu-mergers-and-takeovers-sept-27-akza-bas-san-mrk-1001421984,neutral,0.9399276375770569
10/3/2016 12:10:22 PM,"Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001431817,negative,0.642067015171051
10/3/2016 2:20:21 PM,"RPT-Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/rpt-big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001432682,negative,0.5524707436561584
10/5/2016 11:30:22 AM,"BRIEF-U.S. FDA warns about the risk of Hepatitis B (BMY, GILD, JNJ, MRK)",Reuters,/news/stocks/brief-u-s-fda-warns-about-the-risk-of-hepatitis-b-bmy-gild-jnj-mrk-1001436685,negative,0.5751609206199646
10/5/2016 10:30:23 PM,"Support for California drug spending limits stokes industry fears (MRK, PFE, AMGN)",Reuters,/news/stocks/support-for-california-drug-spending-limits-stokes-industry-fears-mrk-pfe-amgn-1001439072,negative,0.8449620008468628
10/6/2016 8:20:20 PM,BRIEF-Vaccinex announces clinical collaboration with Merck Kgaa (MRK),Reuters,/news/stocks/brief-vaccinex-announces-clinical-collaboration-with-merck-kgaa-mrk-1001441272,positive,0.5375348925590515
10/10/2016 7:10:21 AM,Merck's Keytruda achieves 24 pct response in bladder cancer study (MRK),Reuters,/news/stocks/mercks-keytruda-achieves-24-pct-response-in-bladder-cancer-study-mrk-1001444917,positive,0.9374908208847046
10/10/2016 11:20:20 AM,"Roche lung cancer drug success adds to pressure on Bristol (MRK, BMY)",Reuters,/news/stocks/roche-lung-cancer-drug-success-adds-to-pressure-on-bristol-mrk-bmy-1001445153,negative,0.78812175989151
10/10/2016 11:30:24 AM,"Merck drug shines in lung cancer and also works with chemo (MRK, BMY, AZN)",Reuters,/news/stocks/merck-drug-shines-in-lung-cancer-and-also-works-with-chemo-mrk-bmy-azn-1001445152,neutral,0.8784257769584656
10/10/2016 12:10:24 PM,"UPDATE 1-'New day' in lung cancer as Merck drug shines, works with chemo (MRK, BMY, AZN)",Reuters,/news/stocks/update-1-new-day-in-lung-cancer-as-merck-drug-shines-works-with-chemo-mrk-bmy-azn-1001445165,positive,0.741642951965332
10/10/2016 1:10:24 PM,"No silver lining in failed Bristol cancer drug trial (BMY, MRK)",Reuters,/news/stocks/no-silver-lining-in-failed-bristol-cancer-drug-trial-bmy-mrk-1001445520,neutral,0.839021623134613
10/10/2016 11:30:20 PM,"INSIGHT-Doctors grapple with best use of potent new cancer drugs (MRK, BMY, AZN)",Reuters,/news/stocks/insight-doctors-grapple-with-best-use-of-potent-new-cancer-drugs-mrk-bmy-azn-1001447119,positive,0.5750657916069031
10/11/2016 6:40:27 PM,"U.S. Supreme Court turns away companies in California tax dispute (PG, KMB, MRK)",Reuters,/news/stocks/u-s-supreme-court-turns-away-companies-in-california-tax-dispute-pg-kmb-mrk-1001449625,negative,0.8497329354286194
10/11/2016 6:50:21 PM,"BRIEF-Aetna and Merck sign a contract for Januvia and Janumet (AET, MRK)",Reuters,/news/stocks/brief-aetna-and-merck-sign-a-contract-for-januvia-and-janumet-aet-mrk-1001449662,positive,0.9111865758895874
10/11/2016 10:20:24 PM,"BRIEF-Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab (PFE, MRK, TNG)",Reuters,/news/stocks/brief-transgene-announces-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer-to-evaluate-the-combination-of-tg4001-with-avelumab-pfe-mrk-tng-1001450023,positive,0.8502280712127686
10/11/2016 10:21:09 PM,"The trillion-dollar reason why Wall Street should take gender diversity more seriously (JPM, WMT, PFE, MRK, V, RDS.A, RDSA, GSK)",Business Insider,/news/stocks/the-trillion-dollar-reason-why-wall-street-should-take-gender-diversity-more-seriously-jpm-wmt-pfe-mrk-v-rds-a-rdsa-gsk,neutral,0.8706501722335815
10/12/2016 1:40:27 PM,"BRIEF-Ablynx extends research collaboration with Merck & Co (ABLX, MRK)",Reuters,/news/stocks/brief-ablynx-extends-research-collaboration-with-merck-&-co-ablx-mrk-1001450783,positive,0.8387311100959778
10/12/2016 7:40:53 PM,"A new kind of drug is working better than chemotherapy in some lung cancer patients (BMY, MRK)",Business Insider,/news/stocks/a-new-kind-of-drug-is-working-better-than-chemotherapy-in-some-lung-cancer-patients-bmy-mrk,positive,0.8869583606719971
10/13/2016 2:00:22 PM,"BRIEF-Merck KGaA says still plan to apply for avelumab approval this year (PFE, MRK)",Reuters,/news/stocks/brief-merck-kgaa-says-still-plan-to-apply-for-avelumab-approval-this-year-pfe-mrk-1001454073,neutral,0.8037812113761902
10/13/2016 11:20:21 PM,"Experiment in monkeys raises hopes of ""functional cure"" for HIV (4502, GILD, MRK)",Reuters,/news/stocks/experiment-in-monkeys-raises-hopes-of-functional-cure-for-hiv-4502-gild-mrk-1001455438,neutral,0.5492464303970337
10/19/2016 12:20:24 PM,"Roche's lung cancer drug wins U.S. approval (MRK, BMY)",Reuters,/news/stocks/roches-lung-cancer-drug-wins-u-s-approval-mrk-bmy-1001463837,positive,0.9151583909988403
10/19/2016 2:50:23 PM,Merck's antiviral drug meets main goal in late-stage trial (MRK),Reuters,/news/stocks/mercks-antiviral-drug-meets-main-goal-in-late-stage-trial-mrk-1001465180,positive,0.8044416308403015
10/19/2016 3:00:23 PM,BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint (MRK),Reuters,/news/stocks/brief-merck-says-phase-3-study-with-letermovir-meets-its-primary-endpoint-mrk-1001465179,positive,0.9256800413131714
10/19/2016 3:30:30 PM,UPDATE 1-Merck's antiviral drug meets main goal in late-stage trial (MRK),Reuters,/news/stocks/update-1-mercks-antiviral-drug-meets-main-goal-in-late-stage-trial-mrk-1001465279,positive,0.8165894150733948
10/19/2016 9:10:20 PM,"WHO seeks new mechanism for crisis vaccine supplies at low cost (GSK, MRK, PFE)",Reuters,http://www.businessinsider.com/r-who-seeks-new-mechanism-for-crisis-vaccine-supplies-at-low-cost-2016-10,neutral,0.8287646174430847
10/20/2016 4:10:21 PM,"BRIEF-Debiopharm reports clinical collaboration with Merck KGaA and Pfizer (PFE, MRK)",Reuters,http://www.businessinsider.com/r-brief-debiopharm-reports-clinical-collaboration-with-merck-kgaa-and-pfizer-2016-10,positive,0.6363767981529236
10/21/2016 3:46:22 PM,"Merck's immunotherapy drug succeeds in key bladder cancer trial (MRK, BMY)",Reuters,http://www.businessinsider.com/r-mercks-immunotherapy-drug-succeeds-in-key-bladder-cancer-trial-2016-10,positive,0.9444848299026489
10/21/2016 4:12:26 PM,BRIEF-Merck's bladder cancer drug meets primary endpoint and stops early (MRK),Reuters,http://www.businessinsider.com/r-brief-mercks-bladder-cancer-drug-meets-primary-endpoint-and-stops-early-2016-10,positive,0.589451253414154
10/21/2016 4:32:24 PM,"UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-mercks-keytruda-succeeds-in-key-bladder-cancer-trial-2016-10,positive,0.8114346265792847
10/24/2016 11:54:19 AM,"GSK seeks U.S. approval for shingles vaccine Shingrix (GSK, MRK)",Reuters,http://www.businessinsider.com/r-gsk-seeks-us-approval-for-shingles-vaccine-shingrix-2016-10,positive,0.5957045555114746
10/24/2016 11:54:19 AM,"UPDATE 1-GSK files potential $1 bln shingles vaccine for U.S. approval (GSK, MRK, AGEN)",Reuters,http://www.businessinsider.com/r-update-1-gsk-files-potential-1-bln-shingles-vaccine-for-us-approval-2016-10,positive,0.4980863034725189
10/25/2016 12:08:18 AM,Juniper Pharma to restate results since 2013 (MRK),Reuters,http://www.businessinsider.com/r-juniper-pharma-to-restate-results-since-2013-2016-10,neutral,0.8543791174888611
10/25/2016 12:24:20 AM,BRIEF-Merck & Co says FDA also approves a labeling update for Keytruda for treatment of patients with metastatic NSCLC (MRK),Reuters,http://www.businessinsider.com/r-brief-merck--co-says-fda-also-approves-a-labeling-update-for-keytruda-for-treatment-of-patients-with-metastatic-nsclc-2016-10,positive,0.7932250499725342
10/25/2016 4:28:18 AM,U.S. FDA approves Merck's lung cancer drug as first-line treatment (MRK),Reuters,http://www.businessinsider.com/r-us-fda-approves-mercks-lung-cancer-drug-as-first-line-treatment-2016-10,positive,0.6327450275421143
10/25/2016 1:02:21 PM,Merck reports 19.6 pct jump in quarterly profit (MRK),Reuters,http://www.businessinsider.com/r-merck-reports-196-pct-jump-in-quarterly-profit-2016-10,positive,0.9431737661361694
10/25/2016 1:10:19 PM,"UPDATE 1-Merck wins early U.S. approval for Keytruda in untreated lung cancer (MRK, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-merck-wins-early-us-approval-for-keytruda-in-untreated-lung-cancer-2016-10,positive,0.9381353259086609
10/25/2016 1:30:18 PM,BRIEF-Merck & Co Q3 non-gaap EPS $1.07 (MRK),Reuters,http://www.businessinsider.com/r-brief-merck--co-q3-non-gaap-eps-107-2016-10,neutral,0.9178574085235596
10/25/2016 1:30:20 PM,"UPDATE 1-Merck quarterly revenue beats, raises full-year forecast (MRK)",Reuters,http://www.businessinsider.com/r-update-1-merck-quarterly-revenue-beats-raises-full-year-forecast-2016-10,positive,0.9402674436569214
10/25/2016 3:12:19 PM,BRIEF-Merck says aims to be leader in second-line lung cancer (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-aims-to-be-leader-in-second-line-lung-cancer-2016-10,positive,0.7990772724151611
10/26/2016 10:30:21 PM,BRIEF-Merck prices EUR 1 bln debt offering (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-prices-eur-1-bln-debt-offering-2016-10,neutral,0.8898776769638062
10/27/2016 8:14:18 PM,BRIEF-Adaptimmune announces collaboration with MSD to evaluate Keytruda (pembrolizumab) (MRK),Reuters,http://www.businessinsider.com/r-brief-adaptimmune-announces-collaboration-with-msd-to-evaluate-keytruda-pembrolizumab-2016-10,positive,0.890110969543457
10/28/2016 9:16:08 PM,Exclusive - Germany's Merck explores sale of biosimilar drug business: sources,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/zMkLqkrL1bg/merck-m-a-exclusive-idINKCN12S2GN,neutral,0.9169537425041199
11/4/2016 5:52:18 AM,"U.S. lawmakers call for probe of possible insulin price collusion (SAN, LLY, MRK, NOVO )",Reuters,http://www.businessinsider.com/r-us-lawmakers-call-for-probe-of-possible-insulin-price-collusion-2016-11,neutral,0.8774906396865845
11/7/2016 11:26:18 AM,"Buyers clubs for cheaper drugs help fight hepatitis and HIV (CIPLA, MRK, GILD)",Reuters,http://www.businessinsider.com/r-buyers-clubs-for-cheaper-drugs-help-fight-hepatitis-and-hiv-2016-11,neutral,0.7487578988075256
11/7/2016 12:38:18 PM,"RPT-Buyers clubs for cheaper drugs help fight hepatitis and HIV (CIPLA, MRK, GILD)",Reuters,http://www.businessinsider.com/r-rpt-buyers-clubs-for-cheaper-drugs-help-fight-hepatitis-and-hiv-2016-11,neutral,0.7156854867935181
11/9/2016 1:16:18 PM,"California drug pricing initiative headed for defeat (XLV, IBB, MRK, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-california-drug-pricing-initiative-headed-for-defeat-2016-11,neutral,0.6154242753982544
11/9/2016 6:28:14 PM,"Drug stocks rip higher after Trump's upset victory signals easing pressure on prices (MRK, PFE, AMGN, JNJ, AGN, ABBV, SNY, NVS, AZN, GSK, IBB)",Business Insider,http://www.businessinsider.com/drug-company-stocks-morning-after-election-2016-11,positive,0.9015561938285828
11/9/2016 9:50:20 PM,"UPDATE 1-California voters turn down drug pricing initiative (XLV, IBB, MRK, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-california-voters-turn-down-drug-pricing-initiative-2016-11,negative,0.5886991620063782
11/10/2016 12:46:18 PM,"AstraZeneca drops early head and neck cancer drug plans (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-drops-early-head-and-neck-cancer-drug-plans-2016-11,neutral,0.6714637875556946
11/11/2016 3:00:18 PM,"BRIEF-EMA says CHMP recommends approving Afstyla (MRK, PHARM, GILD, PFE)",Reuters,http://www.businessinsider.com/r-brief-ema-says-chmp-recommends-approving-afstyla-2016-11,neutral,0.8733400106430054
11/11/2016 11:40:20 PM,BRIEF-Biothera Pharma's announces new preclinical data on its immunotherapy drug (MRK),Reuters,http://www.businessinsider.com/r-brief-biothera-pharmas-announces-new-preclinical-data-on-its-immunotherapy-drug-2016-11,neutral,0.8783951997756958
11/14/2016 12:22:20 PM,"Drugmakers improve access for poor, GSK ranked top (GSK, JNJ, MRK)",Reuters,http://www.businessinsider.com/r-drugmakers-improve-access-for-poor-gsk-ranked-top-2016-11,positive,0.8904619812965393
11/14/2016 2:06:21 PM,BRIEF-OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance (MRK),Reuters,http://www.businessinsider.com/r-brief-opgen-collaborates-with-merck-to-develop-rapid-diagnostics-and-informatics-tools-to-help-combat-antimicrobial-resistance-2016-11,positive,0.8635522723197937
11/14/2016 8:22:19 PM,BRIEF-Merck KGaA says primary endpoint was not met in study population (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-says-primary-endpoint-was-not-met-in-study-population-2016-11,neutral,0.5639589428901672
11/15/2016 12:52:20 PM,"UPDATE 1-Merck KGaA expects profit gain from lower development costs (MRK, THLD)",Reuters,http://www.businessinsider.com/r-update-1-merck-kgaa-expects-profit-gain-from-lower-development-costs-2016-11,positive,0.9563563466072083
11/16/2016 3:14:20 PM,"EU mergers and takeovers (Nov 16) (DCC, MRK, HMSO, SAN)",Reuters,http://www.businessinsider.com/r-eu-mergers-and-takeovers-nov-16-2016-11,neutral,0.9432283639907837
11/16/2016 5:30:18 PM,"BRIEF-Genexine entered into a clinical research collaboration with Merck & Co (095700, MRK)",Reuters,http://www.businessinsider.com/r-brief-genexine-entered-into-a-clinical-research-collaboration-with-merck--co-2016-11,positive,0.7753947377204895
11/21/2016 12:18:19 PM,"Swiss stocks - Factors to watch on Nov. 21 (BMY, MRK, LECN, 300068, ODHN)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-nov-21-2016-11,neutral,0.9382715225219727
11/21/2016 8:54:18 PM,'Unicorn' Intarcia files U.S. approval for diabetes implant,Reuters,http://www.businessinsider.com/r-unicorn-intarcia-files-us-approval-for-diabetes-implant-2016-11,positive,0.601585328578949
11/22/2016 12:48:20 PM,"UPDATE 1-AstraZeneca cleared to resume enrolment in cancer drug trials (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-cleared-to-resume-enrolment-in-cancer-drug-trials-2016-11,positive,0.8660773038864136
11/23/2016 7:04:20 PM,"Top German supervisory board chairs earn 4.4 pct more in 2016-report (ADS, BMW, TKA, SIE, DBK, MRK)",Reuters,http://www.businessinsider.com/r-top-german-supervisory-board-chairs-earn-44-pct-more-in-2016-report-2016-11,neutral,0.8576180934906006
11/25/2016 4:48:17 PM,"BRIEF-Opexa Therapeutics receives notice from Ares Trading S.A. Unit of Merck Serono (MRK, OPXA)",Reuters,http://www.businessinsider.com/r-brief-opexa-therapeutics-receives-notice-from-ares-trading-sa-unit-of-merck-serono-2016-11,neutral,0.8476166725158691
11/28/2016 3:16:07 PM,BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-sbla-for-keytruda-2016-11,positive,0.7115169167518616
11/29/2016 3:30:10 PM,"German Merck, Pfizer get FDA priority review for cancer drug",Reuters,http://www.businessinsider.com/r-german-merck-pfizer-get-fda-priority-review-for-cancer-drug-2016-11,neutral,0.7027015686035156
11/29/2016 4:06:08 PM,"BRIEF-FDA accepts the Biologics' license application for Avelumab for priority review (PFE, MRK)",Reuters,http://www.businessinsider.com/r-brief-fda-accepts-the-biologics-license-application-for-avelumab-for-priority-review-2016-11,neutral,0.8306307196617126
11/29/2016 5:16:06 PM,"Injections, implants tested as new weapons to prevent HIV",Reuters,http://www.businessinsider.com/r-injections-implants-tested-as-new-weapons-to-prevent-hiv-2016-11,neutral,0.7877254486083984
11/30/2016 12:06:07 PM,"BRIEF-Evotec, Merck to collaborate on target discovery technologies (EVT, MRK)",Reuters,http://www.businessinsider.com/r-brief-evotec-merck-to-collaborate-on-target-discovery-technologies-2016-11,positive,0.5750925540924072
11/30/2016 6:26:06 PM,BRIEF-Devon Energy declares quarterly cash dividend of $0.06/share (DVN),Reuters,http://www.businessinsider.com/r-brief-devon-energy-declares-quarterly-cash-dividend-of-006/share-2016-11,neutral,0.8140312433242798
11/30/2016 6:34:06 PM,"BRIEF-Natrix Separations announces collaboration agreements with Merck and Sanofi (MRK, SAN)",Reuters,http://www.businessinsider.com/r-brief-natrix-separations-announces-collaboration-agreements-with-merck-and-sanofi-2016-11,positive,0.5150449275970459
12/1/2016 2:24:04 PM,BRIEF-FDA grants priority review to Merck's application to expand use of Keytruda in hodgkin lymphoma (MRK),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-to-mercks-application-to-expand-use-of-keytruda-in-hodgkin-lymphoma-2016-12,positive,0.8912962675094604
12/1/2016 3:36:06 PM,BRIEF-Roche expands distribution alliance with life science business (MRK),Reuters,http://www.businessinsider.com/r-brief-roche-expands-distribution-alliance-with-life-science-business-2016-12,positive,0.9351837038993835
12/1/2016 7:12:10 PM,BRIEF-Merck CEO Kenneth Frazier on CNBC - We continue to have great hopes for our Alzheimer's drug (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-ceo-kenneth-frazier-on-cnbc---we-continue-to-have-great-hopes-for-our-alzheimers-drug-2016-12,positive,0.8797640204429626
12/1/2016 7:26:05 PM,BRIEF-Merck CEO says importing drugs from outside U.S. not possible (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-ceo-says-importing-drugs-from-outside-us-not-possible-2016-12,neutral,0.7897382378578186
12/1/2016 10:56:05 PM,"UPDATE 1-Pharma execs weigh in on possible changes under Trump (AGN, MYL, MRK)",Reuters,http://www.businessinsider.com/r-update-1-pharma-execs-weigh-in-on-possible-changes-under-trump-2016-12,neutral,0.8848499059677124
12/2/2016 8:46:12 AM,Merck wins UK okay for Keytruda in lung cancer after price cut,Reuters,http://www.businessinsider.com/r-merck-wins-uk-okay-for-keytruda-in-lung-cancer-after-price-cut-2016-12,positive,0.7393314242362976
12/5/2016 6:04:05 PM,"BRIEF-Biothera Pharmaceuticals and Merck further expand research collaboration (MERCK, MRK)",Reuters,http://www.businessinsider.com/r-brief-biothera-pharmaceuticals-and-merck-further-expand-research-collaboration-2016-12,positive,0.9107825756072998
12/5/2016 7:34:03 PM,BRIEF-Merck presents updated findings from Keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-presents-updated-findings-from-keytruda-2016-12,neutral,0.9302873015403748
12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,negative,0.8780308961868286
12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,negative,0.9314919114112854
12/6/2016 4:30:05 PM,BRIEF-Merck presents updated Keytruda data in small cell lung cancer and mesothelioma (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-presents-updated-keytruda-data-in-small-cell-lung-cancer-and-mesothelioma-2016-12,neutral,0.9196597337722778
12/7/2016 8:46:09 PM,"BRIEF-Drugmakers trade group says government mandates wrong way to address drug costs (PFE, MRK)",Reuters,http://www.businessinsider.com/r-brief-drugmakers-trade-group-says-government-mandates-wrong-way-to-address-drug-costs-2016-12,negative,0.887956440448761
12/7/2016 10:40:07 PM,BRIEF-Merck Canada says Zostavax II showed vaccine effectiveness against shingles in observational effectiveness study (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-canada-says-zostavax-ii-showed-vaccine-effectiveness-against-shingles-in-observational-effectiveness-study-2016-12,positive,0.9172508716583252
12/12/2016 3:00:03 PM,BRIEF-Interim results from phase 1b/2 study evaluating the combination of Merck's Keytruda and Eisai's Halaven injection presented at 2016 SABCS (MRK),Reuters,http://www.businessinsider.com/r-brief-interim-results-from-phase-1b/2-study-evaluating-the-combination-of-mercks-keytruda-and-eisais-halaven-injection-presented-at-2016-sabcs-2016-12,neutral,0.689330518245697
12/12/2016 3:36:07 PM,BRIEF-Merck & Co updates on triple-negative breast cancer study (MRK),Reuters,http://www.businessinsider.com/r-brief-merck--co-updates-on-triple-negative-breast-cancer-study-2016-12,neutral,0.8904597163200378
12/15/2016 11:08:05 PM,"Gilead sciences to pay Merck $2.54 bln in hepatitis c royalties -court verdict (MRK, GILD)",Reuters,http://www.businessinsider.com/r-gilead-sciences-to-pay-merck-254-bln-in-hepatitis-c-royalties--court-verdict-2016-12,neutral,0.7553523778915405
12/15/2016 11:30:05 PM,"UPDATE 1-Gilead sciences must pay Merck $2.54 bln in hepatitis c royalties -court verdict (MRK, GILD)",Reuters,http://www.businessinsider.com/r-update-1-gilead-sciences-must-pay-merck-254-bln-in-hepatitis-c-royalties--court-verdict-2016-12,negative,0.8479961156845093
12/16/2016 2:10:05 AM,"PRESS DIGEST- Financial Times - Dec 16 (AVV, GILD, MRK, ISP)",Reuters,http://www.businessinsider.com/r-press-digest--financial-times---dec-16-2016-12,neutral,0.9401894211769104
12/16/2016 12:51:45 PM,"10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, MRK, GILD, ORCL, PCLN)",Business Insider,http://www.businessinsider.com/opening-bell-december-16-2016-2016-12,neutral,0.94583660364151
12/16/2016 1:54:05 PM,BRIEF-Europea's CHMP recommends Merck's Keytruda for lung cancer treatment (MRK),Reuters,http://www.businessinsider.com/r-brief-europeas-chmp-recommends-mercks-keytruda-for-lung-cancer-treatment-2016-12,neutral,0.6451280117034912
12/19/2016 1:30:06 PM,BRIEF-Keytruda approved in japan for first-line treatment of patients with advanced non-small cell lung cancer (MRK),Reuters,http://www.businessinsider.com/r-brief-keytruda-approved-in-japan-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-2016-12,positive,0.8381869792938232
12/23/2016 1:20:06 AM,Guinea trial shows 'historic' success for Ebola vaccine,Reuters,http://www.businessinsider.com/r-guinea-trial-shows-historic-success-for-ebola-vaccine-2016-12,positive,0.9435719847679138
12/23/2016 1:30:05 PM,PRESS DIGEST- Canada - Dec 23 (MRK),Reuters,http://www.businessinsider.com/r-press-digest--canada---dec-23-2016-12,neutral,0.9348750710487366
12/23/2016 2:45:48 PM,An Ebola vaccine gave 100% protection in a trial — and that's a great sign for the next outbreak (MRK),Reuters,http://www.businessinsider.com/ebola-vaccine-trial-gave-100-percent-protection-2016-12,positive,0.875174343585968
12/23/2016 8:42:05 PM,Migraine drugs may repeat rheumatoid arthritis success,Reuters,http://www.businessinsider.com/r-migraine-drugs-may-repeat-rheumatoid-arthritis-success-2016-12,negative,0.720610499382019
1/2/2017 9:32:06 AM,"BRIEF-Sanofi Pasteur and MSD confirm ending of joint vaccines business in Europe (SAN, MRK)",Reuters,http://www.businessinsider.com/r-brief-sanofi-pasteur-and-msd-confirm-ending-of-joint-vaccines-business-in-europe-2017-1,neutral,0.8753640055656433
1/5/2017 10:46:06 PM,BRIEF-Cerveau Technologies signs license agreement with Merck for novel investigational Tau imaging agent (MRK),Reuters,http://www.businessinsider.com/r-brief-cerveau-technologies-signs-license-agreement-with-merck-for-novel-investigational-tau-imaging-agent-2017-1,positive,0.9269275069236755
1/9/2017 2:34:05 PM,"BRIEF-Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda (INCY, MRK)",Reuters,http://www.businessinsider.com/r-brief-incyte-and-merck-to-advance-clinical-development-program-investigating-the-combination-of-epacadostat-with-keytruda-2017-1,positive,0.5860939621925354
1/10/2017 10:34:05 PM,BRIEF-Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy (MRK),Reuters,http://www.businessinsider.com/r-brief-merck--co-inc-gets-fda-acceptance-of-supplemental-biologics-license-application-for-keytruda-in-combination-with-chemotherapy-2017-1,positive,0.9228639602661133
1/11/2017 12:52:03 AM,FDA accepts Merck application for lung cancer combo therapy,Reuters,http://www.businessinsider.com/r-fda-accepts-merck-application-for-lung-cancer-combo-therapy-2017-1,positive,0.5631973147392273
1/11/2017 3:55:22 PM,Nasdaq drops with pharma stocks as Trump blasts drug prices,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/6EmlN0DJB1g/us-usa-stocks-idUSKBN14V1FS,negative,0.9442318081855774
1/11/2017 4:12:08 PM,"BRIEF-Merck KGaA, Darmstadt, Germany licenses four oncology research and development programs from Vertex (MRK, VRTX)",Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-darmstadt-germany-licenses-four-oncology-research-and-development-programs-from-vertex-2017-1,positive,0.523679792881012
1/20/2017 1:26:04 AM,"Bristol-Myers won't seek accelerated Opdivo lung cancer approval (MRK, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-wont-seek-accelerated-opdivo-lung-cancer-approval-2017-1,neutral,0.784562349319458
1/20/2017 5:06:54 PM,"Bristol-Myers shares are sliding after some bad news on its lung cancer drug (BMY, MRK)",Reuters,http://www.businessinsider.com/bristol-opdivo-yervoy-lung-cancer-no-fast-approval-2017-1,negative,0.9732322692871094
1/20/2017 10:16:07 PM,"BRIEF-Merck announces license agreement resolving Keytruda patent litigation (MRK, BMY)",Reuters,http://www.businessinsider.com/r-brief-merck-announces-license-agreement-resolving-keytruda-patent-litigation-2017-1,positive,0.8731755614280701
1/20/2017 10:24:06 PM,"BRIEF-Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck (BMY, MRK)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-ono-pharmaceutical-enters-license-agreement-with-merck-2017-1,positive,0.8483483791351318
1/21/2017 12:06:09 AM,"UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit (4528, MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-merck-bristol-myers-agree-to-settle-keytruda-patent-suit-2017-1,positive,0.49371790885925293
1/21/2017 12:14:12 AM,"Merck, Bristol-Myers agree to settle Keytruda patent suit",Reuters,http://www.businessinsider.com/r-merck-bristol-myers-agree-to-settle-keytruda-patent-suit-2017-1,positive,0.5158823728561401
1/23/2017 2:56:05 PM,"BRIEF-Merck KGaA, Darmstadt, Germany, announces research collaboration with Domain Therapeutics in immuno-oncology (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-darmstadt-germany-announces-research-collaboration-with-domain-therapeutics-in-immuno-oncology-2017-1,positive,0.732571005821228
1/26/2017 5:56:05 PM,"BRIEF-Bristol-Myers cites forex, oncology competition for outlook cut (MRK, BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-cites-forex-oncology-competition-for-outlook-cut-2017-1,negative,0.5960450172424316
1/26/2017 7:10:05 PM,"UPDATE 1-Bristol-Myers cuts 2017 outlook amid Opdivo competition (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-cuts-2017-outlook-amid-opdivo-competition-2017-1,negative,0.968569815158844
1/27/2017 12:30:06 PM,"Roche cancer drug taking bite out of Bristol's Opdivo (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-cancer-drug-taking-bite-out-of-bristols-opdivo-2017-1,neutral,0.8549370169639587
1/27/2017 8:36:08 PM,Merck reveals 7 years of its U.S. drug price increase history (MRK),Reuters,http://www.businessinsider.com/r-merck-reveals-7-years-of-its-us-drug-price-increase-history-2017-1,neutral,0.6556690335273743
1/28/2017 12:09:13 AM,A huge drugmaker just took an unprecedented move to counter criticism about rising prices (MRK),Business Insider,http://www.businessinsider.com/merck-reports-average-list-and-net-prices-2017-1,positive,0.9135545492172241
1/31/2017 4:10:07 PM,"Trump meets with drugmakers, seeks lower prices, U.S. production (MRK, JNJ, CELG, LLY, AMGN)",Reuters,http://www.businessinsider.com/r-trump-meets-with-drugmakers-seeks-lower-prices-us-production-2017-1,neutral,0.642166018486023
1/31/2017 7:06:07 PM,"UPDATE 3-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-3-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1,positive,0.909467875957489
1/31/2017 7:51:41 PM,Trump Calls For Increased Competition To Reduce Drug Prices ,RTTNews,/news/stocks/trump-calls-for-increased-competition-to-reduce-drug-prices-1001710287,positive,0.7998009324073792
1/31/2017 9:30:07 PM,"UPDATE 4-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-4-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1,positive,0.9122521281242371
1/31/2017 10:36:07 PM,BRIEF-European Commission approves Keytruda for first-line treatment of patients with metastatic non-small cell lung cancer (MRK),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-keytruda-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-2017-1,positive,0.8691614270210266
2/2/2017 12:48:09 PM,Merck & Co Inc. Earnings Drop 5% In Q4,RTTNews,/news/stocks/merck-co-inc-earnings-drop-5-in-q4-1001717225,negative,0.9734660387039185
2/2/2017 1:00:10 PM,BRIEF-Merck Q4 adjusted earnings per share $0.89 (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-q4-adjusted-earnings-per-share-089-2017-2,neutral,0.8080147504806519
2/2/2017 1:06:10 PM,Merck's quarterly sales slip 1 pct (MRK),Reuters,http://www.businessinsider.com/r-mercks-quarterly-sales-slip-1-pct-2017-2,negative,0.813701868057251
2/2/2017 1:15:46 PM,"Merck Q4 Adj. Profit Meets View, But Revenues Miss ",RTTNews,/news/stocks/merck-q4-adj-profit-meets-view-but-revenues-miss-1001717441,positive,0.5404884815216064
2/2/2017 1:46:08 PM,"UPDATE 1-Merck's sales miss as Keytruda, diabetes drugs lag estimates (MRK)",Reuters,http://www.businessinsider.com/r-update-1-mercks-sales-miss-as-keytruda-diabetes-drugs-lag-estimates-2017-2,negative,0.9723456501960754
2/2/2017 2:59:54 PM,Merck 2017 forecast reassuring; full-speed ahead with Keytruda,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/WWQ6084C-Z8/us-merck-co-results-idUSKBN15H19N,positive,0.9169765710830688
2/2/2017 3:18:13 PM,BRIEF-Merck CEO says business development a priority (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-ceo-says-business-development-a-priority-2017-2,neutral,0.8387702107429504
2/2/2017 9:02:07 PM,"BRIEF-FDA grants accelerated approval to Bristol-Myers Squibb's nivolumab (BMY, MRK)",Reuters,http://www.businessinsider.com/r-brief-fda-grants-accelerated-approval-to-bristol-myers-squibbs-nivolumab-2017-2,positive,0.9157434105873108
2/2/2017 9:34:07 PM,U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer,Reuters,http://www.businessinsider.com/r-us-fda-approves-bristol-myers-opdivo-for-bladder-cancer-2017-2,positive,0.7095040678977966
2/3/2017 12:56:49 PM,Merck: FDA Accepts For Review Two SBLAs For Keytruda  - Quick Facts ,RTTNews,/news/stocks/merck-fda-accepts-for-review-two-sblas-for-keytruda-quick-facts-1001721225,positive,0.48800939321517944
2/3/2017 1:00:10 PM,BRIEF-Merck says FDA accepts two SBLAs for Keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-fda-accepts-two-sblas-for-keytruda-2017-2,positive,0.6742753982543945
2/6/2017 6:43:23 AM,"ESPR, MDCO Riding High, New Uses For MRK's Old Drug, DBVT In Full Smile(e) ",RTTNews,/news/stocks/espr-mdco-riding-high-new-uses-for-mrk-s-old-drug-dbvt-in-full-smile-e-1001723805,positive,0.5782976150512695
2/6/2017 2:14:08 PM,"BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies (MRK, INCY)",Reuters,http://www.businessinsider.com/r-brief-immunovaccine-says-princess-margaret-cancer-centre-to-conduct-phase-2-clinical-trial-to-evaluate-use-of-co-mercks-combination-of-immunotherapies-2017-2,positive,0.6521475911140442
2/9/2017 3:30:09 PM,BRIEF-Boehringer Ingelheim - To evaluate Afatinib in combination with PD-1 inhibitor pembrolizumab (MRK),Reuters,http://www.businessinsider.com/r-brief-boehringer-ingelheim---to-evaluate-afatinib-in-combination-with-pd-1-inhibitor-pembrolizumab-2017-2,positive,0.8207160234451294
2/13/2017 11:26:10 PM,BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing (MRK),Reuters,http://www.businessinsider.com/r-brief-capital-world-investors-reports-51-pct-passive-stake-in-merck--co-as-on-dec-30---sec-filing-2017-2,neutral,0.9463698267936707
2/14/2017 11:36:13 PM,BRIEF-Merck announces Epoch study of Verubecestat (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-epoch-study-of-verubecestat-2017-2,neutral,0.9021435379981995
2/15/2017 12:22:10 AM,Merck to halt study of mild to moderate Alzheimer's drug,Reuters,http://www.businessinsider.com/r-merck-to-halt-study-of-mild-to-moderate-alzheimers-drug-2017-2,negative,0.5677351355552673
2/15/2017 12:30:45 AM,Merck To Stop EPOCH Study; Doravirine Meets Primary Efficacy Endpoint ,RTTNews,/news/stocks/merck-to-stop-epoch-study-doravirine-meets-primary-efficacy-endpoint-1001750900,negative,0.879332959651947
2/15/2017 1:08:10 AM,"UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails (MRK, LLY)",Reuters,http://www.businessinsider.com/r-update-1-merck-stopping-late-stage-study-as-another-alzheimers-drug-fails-2017-2,negative,0.851006805896759
2/15/2017 10:46:17 AM,"AXSM On Fast Track, MRK Halts Alzheimer's Drug Study, HOLX Snaps Up CYNO ",RTTNews,/news/stocks/axsm-on-fast-track-mrk-halts-alzheimer-s-drug-study-holx-snaps-up-cyno-1001752007,neutral,0.5855671167373657
2/16/2017 10:25:19 AM,A breakthrough approach to treating Alzheimer's is facing major setbacks (MRK),Business Insider,http://www.businessinsider.com/what-is-the-amyloid-hypothesis-in-alzheimers-disease-2017-2,negative,0.6063036918640137
2/21/2017 1:50:12 PM,"Export companies tell U.S. Congress to push tax code rewrite (BA, CAT, GE, DOW, CE, CELG, LLY, RTN, MRK, UTX, PFE, VAR)",Reuters,http://www.businessinsider.com/r-export-companies-tell-us-congress-to-push-tax-code-rewrite-2017-2,neutral,0.8782085180282593
2/21/2017 5:30:11 PM,"UPDATE 1-Bristol-Myers adds 3 directors in agreement with JANA Partners (BMY, MRK, VRTX, SHP)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-adds-3-directors-in-agreement-with-jana-partners-2017-2,positive,0.5899608731269836
2/21/2017 5:56:12 PM,"UPDATE 1-CEOs of 16 U.S. companies urge Congress to pass border tax (BA, CAT, GE, AAPL, IBM, INTC, DOW, CE, CELG, LLY, RTN, MRK, UTX, PFE, VAR)",Reuters,http://www.businessinsider.com/r-update-1-ceos-of-16-us-companies-urge-congress-to-pass-border-tax-2017-2,neutral,0.8676490187644958
2/21/2017 6:00:45 PM,"One of Wall Street's top equity analysts reveals his 4 favorite areas in the market (GS, HAL, MRK, HCA)",Business Insider,http://markets.businessinsider.com/news/stocks/jpmorgan-head-of-equity-strategy-on-4-favorite-areas-in-the-market-2017-2-1001762404,neutral,0.8791593313217163
2/22/2017 7:06:15 PM,"BRIEF-Merck canada says effective Feb 28, Ontario to reimburse Zepatier, will be followed by British Columbia on March 21 (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-canada-says-effective-feb-28-ontario-to-reimburse-zepatier-will-be-followed-by-british-columbia-on-march-21-2017-2,neutral,0.9464951753616333
2/23/2017 3:30:12 PM,"BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda (MRK)",Reuters,http://www.businessinsider.com/r-brief-biothera-pharmaceuticals-initiates-patient-dosing-in-phase-2-trial-investigating-imprime-pgg-mercks-keytruda-2017-2,positive,0.5444126129150391
2/23/2017 5:48:17 PM,Trump tells CEOs he plans to bring back millions of jobs,Reuters,http://www.businessinsider.com/r-trump-tells-ceos-he-plans-to-bring-back-millions-of-jobs-2017-2,neutral,0.7233976125717163
2/23/2017 5:52:12 PM,"UPDATE 1-Trump tells CEOs he plans to bring back millions of jobs (GE, LMT, DOW, IP, F, JNJ, GLW, MRK, CAT, MMM, X, ADM, GD, WHR, 067900)",Reuters,http://www.businessinsider.com/r-update-1-trump-tells-ceos-he-plans-to-bring-back-millions-of-jobs-2017-2,neutral,0.6531838774681091
2/23/2017 8:16:12 PM,Merck drug prevents serious infection after marrow transplant -study (MRK),Reuters,http://www.businessinsider.com/r-merck-drug-prevents-serious-infection-after-marrow-transplant--study-2017-2,neutral,0.5123814940452576
2/24/2017 12:00:17 AM,BRIEF-Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-to-record-29-bln-impairment-charge-related-to-uprifosbuvir-program---sec-filing-2017-2,negative,0.9422812461853027
2/24/2017 2:03:00 PM,Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen,PR Newswire,/news/stocks/merck-receives-positive-chmp-opinion-for-new-pergoveris-fertility-pen-1001781294,positive,0.9482792615890503
2/24/2017 3:20:11 PM,Merck Gets Positive CHMP Opinion For New Pergoveris Fertility Pen ,RTTNews,/news/stocks/merck-gets-positive-chmp-opinion-for-new-pergoveris-fertility-pen-1001781602,positive,0.923585832118988
2/24/2017 10:20:13 PM,BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases (MRK),Reuters,http://www.businessinsider.com/r-brief-in-first-phase-3-trial-mercks-virus-vaccine-v2120-reduced-the-incidence-of-confirmed-herpes-zoster-cases-2017-2,positive,0.9450348019599915
2/26/2017 8:48:03 PM,Merck Reports Results Of Pivotal Phase 3 Clinical Study Of Letermovir ,RTTNews,/news/stocks/merck-reports-results-of-pivotal-phase-3-clinical-study-of-letermovir-1001783851,neutral,0.7038652896881104
2/27/2017 11:43:16 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1001785169,neutral,0.7348417639732361
2/27/2017 8:50:13 PM,"J&J says kept drug price increases below 10 pct since 2012 (JNJ, MRK, AGN, NOVO )",Reuters,http://www.businessinsider.com/r-jj-says-kept-drug-price-increases-below-10-pct-since-2012-2017-2,neutral,0.7101498246192932
2/28/2017 1:00:00 PM,FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review,PR Newswire,/news/stocks/fda-accepts-the-biologics-license-application-for-avelumab-for-the-treatment-of-metastatic-urothelial-carcinoma-for-priority-review-1001789555,positive,0.5895024538040161
2/28/2017 1:17:24 PM,"Merck, Pfizer: FDA Accepts For Priority Review BLA For Avelumab - Quick Facts ",RTTNews,/news/stocks/merck-pfizer-fda-accepts-for-priority-review-bla-for-avelumab-quick-facts-1001789654,positive,0.5446059703826904
2/28/2017 1:52:13 PM,"Merck KGaA, Pfizer get priority review for bladder cancer drug",Reuters,http://www.businessinsider.com/r-merck-kgaa-pfizer-get-priority-review-for-bladder-cancer-drug-2017-2,neutral,0.7743759155273438
2/28/2017 3:20:41 PM,"The quest to find new drugs to treat Alzheimer's just suffered another blow (MRK, LLY, BIIB, AMGN)",Reuters,http://www.businessinsider.com/r-acceras-alzheimers-trial-fails-in-yet-another-setback-for-disease-2017-2,positive,0.5512112379074097
2/28/2017 6:20:16 PM,UK rejects Merck's Keytruda as initial treatment for lung cancer,Reuters,http://www.businessinsider.com/r-uk-rejects-mercks-keytruda-as-initial-treatment-for-lung-cancer-2017-2,neutral,0.7257754802703857
3/1/2017 9:18:13 AM,"UPDATE 1-UK Stocks-Factors to watch on March 1 (UKX, GKN, PSON, ULVR, UNA, SKT, VOD, F, ITV, MRK)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-march-1-2017-3,neutral,0.9424651265144348
3/1/2017 8:46:19 PM,"BRIEF-Glenmark Pharmaceuticals and Evestra announce partnership agreement for generic NuvaRing (GLENMARK, MRK)",Reuters,http://www.businessinsider.com/r-brief-glenmark-pharmaceuticals-and-evestra-announce-partnership-agreement-for-generic-nuvaring-2017-3,positive,0.9091556072235107
3/2/2017 2:33:16 AM,FDA Okays Odactra For House Dust Mite Allergies ,RTTNews,/news/stocks/fda-okays-odactra-for-house-dust-mite-allergies-1001797157,neutral,0.6881809830665588
3/2/2017 8:26:00 AM,NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type mCRC,PR Newswire,/news/stocks/nice-expands-positive-recommendation-for-erbitux-as-first-line-treatment-for-ras-wild-type-mcrc-1001797663,positive,0.8942724466323853
3/2/2017 3:26:20 PM,BRIEF-Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on BGB-283 (MRK),Reuters,http://www.businessinsider.com/r-brief-beigene-says-expects-decision-in-q1-of-2017-from-partner-merck-kgaa-on-bgb-283-2017-3,neutral,0.7673200368881226
3/6/2017 2:38:21 PM,"BRIEF-Merck and pfizer announce U.S. Fda and EMA filing acceptances (MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-merck-and-pfizer-announce-us-fda-and-ema-filing-acceptances-2017-3,neutral,0.8374234437942505
3/6/2017 3:50:21 PM,Germany to scrap plan to lower prices of new drugs: lawmakers,Reuters,http://www.businessinsider.com/r-germany-to-scrap-plan-to-lower-prices-of-new-drugs-lawmakers-2017-3,neutral,0.5136284828186035
3/7/2017 1:25:00 PM,"Drug Makers Stocks Under Scanner -- Pfizer, Merck, AbbVie, and Johnson & Johnson",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-pfizer-merck-abbvie-and-johnson-johnson-1001810747,negative,0.6821770071983337
3/7/2017 3:26:21 PM,"Drugmaker shares slip as Trump tweets about pricing system (PFE, MRK, AMGN, GILD)",Reuters,http://www.businessinsider.com/r-drugmaker-shares-slip-as-trump-tweets-about-pricing-system-2017-3,negative,0.9408032298088074
3/7/2017 4:50:21 PM,"UPDATE 1-Drugmaker shares slip as Trump tweets about pricing system (PFE, MRK, AMGN, THC, CYH, HCA, UNH, GILD)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-shares-slip-as-trump-tweets-about-pricing-system-2017-3,negative,0.9626100063323975
3/7/2017 5:50:21 PM,"UPDATE 2-Trump backs House Republican healthcare plan, aims to cut drug prices (PFE, MRK, AMGN, UNH, AET, HUM, THC, CYH)",Reuters,http://www.businessinsider.com/r-update-2-trump-backs-house-republican-healthcare-plan-aims-to-cut-drug-prices-2017-3,positive,0.46880966424942017
3/7/2017 6:14:21 PM,"GLOBAL MARKETS-Wall Street slips, U.S. dollar firm on Fed outlook (PFE, MRK, AMGN)",Reuters,http://www.businessinsider.com/r-global-markets-wall-street-slips-us-dollar-firm-on-fed-outlook-2017-3,negative,0.9469412565231323
3/7/2017 11:28:24 PM,"GLOBAL MARKETS-Stocks slip, U.S. dollar firm on Fed outlook (PFE, AMGN)",Reuters,http://www.businessinsider.com/r-global-markets-stocks-slip-us-dollar-firm-on-fed-outlook-2017-3,negative,0.962668776512146
3/8/2017 5:26:22 PM,"GLOBAL MARKETS-Dollar, stocks rise as data boosts Fed hike bets (CAT, MRK)",Reuters,http://www.businessinsider.com/r-global-markets-dollar-stocks-rise-as-data-boosts-fed-hike-bets-2017-3,positive,0.5964852571487427
3/8/2017 5:42:22 PM,"INSIGHT-'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks (JNJ, MRK, LLY, CELG, AMGN, GM, F, CPB, TGT, LUV, UAL, DAL)",Reuters,http://www.businessinsider.com/r-insight-its-like-kumbaya-trumps-genial-private-meetings-with-ceos-jar-with-public-attacks-2017-3,neutral,0.8371442556381226
3/9/2017 7:54:22 AM,"Merck KGaA predicts stable adj EBITDA in 2017 (MRK, THLD)",Reuters,http://www.businessinsider.com/r-merck-kgaa-predicts-stable-adj-ebitda-in-2017-2017-3,positive,0.8928495645523071
3/9/2017 8:54:22 AM,"UPDATE 1-Development costs to keep Merck KGaA profit flat this year (MRK, PFE, MRK, THLD)",Reuters,http://www.businessinsider.com/r-update-1-development-costs-to-keep-merck-kgaa-profit-flat-this-year-2017-3,positive,0.9040769338607788
3/9/2017 12:54:31 PM,Germany's Merck well advanced in talks to sell biosimilars unit,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/AWCI8cYjnn0/merck-results-biosimilars-idINKBN16G1EQ,positive,0.7938644289970398
3/10/2017 11:11:00 AM,New Merck Technology Aims to Further Optimize Embryo Incubation and Assessment,PR Newswire,/news/stocks/new-merck-technology-aims-to-further-optimize-embryo-incubation-and-assessment-1001823417,positive,0.7751752138137817
3/10/2017 4:50:22 PM,BRIEF-Merck KGaA announces release of two fertility technologies products (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-announces-release-of-two-fertility-technologies-products-2017-3,neutral,0.8230417966842651
3/13/2017 1:00:00 PM,OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon,PR Newswire,/news/stocks/oilprice-com-the-next-big-biotech-breakthrough-could-just-be-on-the-horizon-1001828875,neutral,0.7319250702857971
3/13/2017 5:30:24 PM,"US STOCKS-S&P, Dow tread lower as pharma stocks weigh (MRK, INTC, NVDA, HLF)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-tread-lower-as-pharma-stocks-weigh-2017-3,negative,0.9533131718635559
3/13/2017 6:52:26 PM,"US STOCKS-Wall St dips as drug stocks drag; Fed meeting in focus (MRK, BMY, INTC, NVDA, WYNN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-dips-as-drug-stocks-drag-fed-meeting-in-focus-2017-3,negative,0.9373961091041565
3/14/2017 4:30:50 PM,"An experimental vaccine could leave the world far better prepared for the next Ebola outbreak (JNJ, BAVA, MRK)",Reuters,http://www.businessinsider.com/r-two-part-ebola-vaccine-offers-long-lasting-protection-2017-3,positive,0.7419734597206116
3/14/2017 5:40:24 PM,"RPT-Two-part Ebola vaccine offers long-lasting protection (JNJ, BAVA, MRK)",Reuters,http://www.businessinsider.com/r-rpt-two-part-ebola-vaccine-offers-long-lasting-protection-2017-3,positive,0.7164936661720276
3/14/2017 10:06:24 PM,BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA® (pembrolizumab) (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-provides-update-on-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-2017-3,neutral,0.9102233052253723
3/14/2017 10:38:24 PM,BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-fda-approves-keytruda-for-treatment-of-patients-with-refractory-classical-hodgkin-lymphoma-2017-3,positive,0.9067865610122681
3/15/2017 12:04:23 AM,Merck's Keytruda wins FDA nod for treating blood cancer,Reuters,http://www.businessinsider.com/r-mercks-keytruda-wins-fda-nod-for-treating-blood-cancer-2017-3,positive,0.8854130506515503
3/15/2017 7:15:27 AM,"FDA Panel Snubs ENDP, Watch Out For TCON, MRK's Keytruda Scores Another Win ",RTTNews,/news/stocks/fda-panel-snubs-endp-watch-out-for-tcon-mrk-s-keytruda-scores-another-win-1001835932,neutral,0.605855405330658
3/19/2017 9:12:46 PM,Newer type 2 diabetes drugs show heart protective quality in study,Reuters,http://www.businessinsider.com/r-newer-type-2-diabetes-drugs-show-heart-protective-quality-in-study-2017-3,positive,0.7342519760131836
3/22/2017 1:44:47 PM,BRIEF-U.S. appeals court revives claims against Merck over Fosamax (MRK),Reuters,http://www.businessinsider.com/r-brief-us-appeals-court-revives-claims-against-merck-over-fosamax-2017-3,negative,0.7777423858642578
3/22/2017 2:04:47 PM,U.S. appeals court revives Fosamax warning claims against Merck,Reuters,http://www.businessinsider.com/r-us-appeals-court-revives-fosamax-warning-claims-against-merck-2017-3,negative,0.8851003646850586
3/22/2017 2:40:48 PM,UPDATE 1-U.S. appeals court revives Fosamax warning claims against Merck (MRK),Reuters,http://www.businessinsider.com/r-update-1-us-appeals-court-revives-fosamax-warning-claims-against-merck-2017-3,negative,0.6773326992988586
3/23/2017 7:56:45 PM,"BRIEF-FDA approves treatment for metastatic merkel cell carcinoma (MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-fda-approves-treatment-for-metastatic-merkel-cell-carcinoma-2017-3,positive,0.6329204440116882
3/23/2017 8:26:45 PM,"FDA approves Pfizer, German Merck immunotherapy for skin cancer",Reuters,http://www.businessinsider.com/r-fda-approves-pfizer-german-merck-immunotherapy-for-skin-cancer-2017-3,positive,0.753939151763916
3/24/2017 7:28:45 AM,"German stocks - Factors to watch on March 24 (DBK, DB1, LSE, MRK, PFE, CWI, SZG, ADL, TIM)",Reuters,http://www.businessinsider.com/r-german-stocks---factors-to-watch-on-march-24-2017-3,neutral,0.9475155472755432
3/24/2017 1:25:21 PM,Merck Says EMA's CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA ,RTTNews,/news/stocks/merck-says-ema-s-chmp-adopts-positive-opinion-recommending-approval-of-keytruda-1001865695,positive,0.895205020904541
3/24/2017 2:24:48 PM,BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-european-medicines-agencys-chmp-recommends-approval-of-mercks-keytruda-2017-3,neutral,0.646368682384491
3/24/2017 2:31:00 PM,"Investors: covered-call reports for Bank of America, The Home Depot Inc., Merck & Company Incorporated, Oclaro Inc. and Square Incorporated.",PR Newswire,/news/stocks/investors-covered-call-reports-for-bank-of-america-the-home-depot-inc-merck-company-incorporated-oclaro-inc-and-square-incorporated-1001865998,neutral,0.9521399140357971
3/29/2017 3:34:52 PM,"UPDATE 3-U.S. approves Roche drug that targets severe form of MS (MRK, TEVA, BIIB, SAN)",Reuters,http://www.businessinsider.com/r-update-3-us-approves-roche-drug-that-targets-severe-form-of-ms-2017-3,positive,0.8254091143608093
3/31/2017 1:16:50 PM,"BRIEF-Incyte and Merck provide additional details on previously announced collaboration (INCY, MRK)",Reuters,http://www.businessinsider.com/r-brief-incyte-and-merck-provide-additional-details-on-previously-announced-collaboration-2017-3,neutral,0.9470655918121338
3/31/2017 1:41:14 PM,"Incyte, Merck Give Further Details On Epacadostat - KEYTRUDA Clinical Program ",RTTNews,/news/stocks/incyte-merck-give-further-details-on-epacadostat-keytruda-clinical-program-1001885736,neutral,0.9476086497306824
4/3/2017 1:10:51 PM,"RPT-The cost of cancer: new drugs show success at a steep price (BMY, MRK, ESRX, PFE, AZN)",Reuters,http://www.businessinsider.com/r-rpt-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-2017-4,positive,0.8700270056724548
4/3/2017 3:56:23 PM,"New cancer drugs can cost more than $250,000 a year (BMY, MRK, ESRX, PFE, AZN)",Reuters,http://www.businessinsider.com/r-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-2017-4,neutral,0.9377228617668152
4/3/2017 4:46:09 PM,"A combination of cancer drugs work better together than on their own — but there's a catch (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-immunotherapy-combination-extends-survival-in-melanoma-2017-4,neutral,0.7886541485786438
4/7/2017 1:42:29 PM,Merck Gets CRL From FDA For TECOS Study With Sitagliptin ,RTTNews,/news/stocks/merck-gets-crl-from-fda-for-tecos-study-with-sitagliptin-1001906397,positive,0.7856312394142151
4/7/2017 1:58:53 PM,BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-receives-complete-response-letter-from-the-fda-for-tecos-study-with-sitagliptin-2017-4,positive,0.7124031186103821
4/7/2017 1:58:53 PM,"CORRECTED-US STOCKS-Futures recover from a drop after U.S. missile strike on Syria (XOM, CHK, APA, DVN, MRK, WMT)",Reuters,http://www.businessinsider.com/r-corrected-us-stocks-futures-recover-from-a-drop-after-us-missile-strike-on-syria-2017-4,negative,0.7077641487121582
4/7/2017 2:32:53 PM,UPDATE 1-FDA rejects Merck's application to add heart data on diabetes drug labels (MRK),Reuters,http://www.businessinsider.com/r-update-1-fda-rejects-mercks-application-to-add-heart-data-on-diabetes-drug-labels-2017-4,negative,0.8811820149421692
4/7/2017 2:32:53 PM,FDA rejects Merck's application to add heart safety data on diabetes drug labels (MRK),Reuters,http://www.businessinsider.com/r-fda-rejects-mercks-application-to-add-heart-safety-data-on-diabetes-drug-labels-2017-4,negative,0.5270788669586182
4/10/2017 12:10:00 PM,"Drug Makers Stocks on Investors' Radar -- Pfizer, Merck, Johnson & Johnson, and AbbVie",PR Newswire,/news/stocks/drug-makers-stocks-on-investors-radar-pfizer-merck-johnson-johnson-and-abbvie-1001909734,neutral,0.9021657705307007
4/10/2017 11:06:57 PM,BRIEF-Merck says board of directors to have 13 members (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-board-of-directors-to-have-13-members-2017-4,neutral,0.9443496465682983
4/10/2017 11:15:07 PM,BRIEF-Merck & Co Inc's CEO's 2016 total compensation was $21.8 mln (MRK),Reuters,http://www.businessinsider.com/r-brief-merck--co-incs-ceos-2016-total-compensation-was-218-mln-2017-4,negative,0.5050609707832336
4/11/2017 1:28:59 PM,BRIEF-Princess Margaret Cancer Center receives Health Canada clearance to begin investigator-sponsored phase 2 ovarian cancer study (MRK),Reuters,http://www.businessinsider.com/r-brief-princess-margaret-cancer-center-receives-health-canada-clearance-to-begin-investigator-sponsored-phase-2-ovarian-cancer-study-2017-4,positive,0.7877465486526489
4/13/2017 2:11:12 PM,"UPDATE 1-Bristol-Myers to license two drugs to Biogen, Roche (BMY, BIIB, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-to-license-two-drugs-to-biogen-roche-2017-4,positive,0.5787065029144287
4/13/2017 7:41:00 PM,"""New York Times"" Bestselling Author Tony Tjan Comments on United Airlines Incident",PR Newswire,/news/stocks/new-york-times-bestselling-author-tony-tjan-comments-on-united-airlines-incident-565468,neutral,0.9068894982337952
4/17/2017 10:45:05 PM,BRIEF-Aurinia completes licensing deal with Merck Animal Health (MRK),Reuters,http://www.businessinsider.com/r-brief-aurinia-completes-licensing-deal-with-merck-animal-health-2017-4,positive,0.8927173614501953
4/18/2017 12:09:03 PM,German Merck aims to role out child formula for schistosomiasis drug,Reuters,http://www.businessinsider.com/r-german-merck-aims-to-role-out-child-formula-for-schistosomiasis-drug-2017-4,neutral,0.758513331413269
4/18/2017 2:00:00 PM,5 Stocks to Watch as Canada Gets Hooked on Cannabis,PR Newswire,/news/stocks/5-stocks-to-watch-as-canada-gets-hooked-on-cannabis-1001926681,neutral,0.8382822871208191
4/19/2017 3:05:03 PM,"UPDATE 1-Gates backs Big Pharma push to wipe out tropical diseases (GSK, SAN, MRK, MRK)",Reuters,http://www.businessinsider.com/r-update-1-gates-backs-big-pharma-push-to-wipe-out-tropical-diseases-2017-4,positive,0.8820338845252991
4/19/2017 3:43:41 PM,The world’s largest health agency is asking big pharma to step up its donations for diseases that affect 1 billion people,Reuters,http://www.businessinsider.com/r-fight-against-neglected-tropical-diseases-needs-big-pharma-push-who-2017-4,positive,0.511046290397644
4/21/2017 2:51:06 PM,BRIEF-Atara bio announces collaboration with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-atara-bio-announces-collaboration-with-merck-2017-4,neutral,0.7996458411216736
4/21/2017 3:43:00 PM,Merck to Present Rebif® (interferon beta-1a) and Investigational Cladribine Tablets Data at AAN 2017,PR Newswire,/news/stocks/merck-to-present-rebif-interferon-beta-1a-and-investigational-cladribine-tablets-data-at-aan-2017-1001938418,neutral,0.9337592124938965
4/21/2017 5:21:09 PM,BRIEF-Merck reports results from real-world observational study in U.S. Veterans Affairs System evaluating use of ZEPATIER (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-reports-results-from-real-world-observational-study-in-us-veterans-affairs-system-evaluating-use-of-zepatier-2017-4,neutral,0.6321610808372498
4/21/2017 10:13:04 PM,"BRIEF-FDA approves Renflexis, biosimilar to Remicade (MRK, JNJ)",Reuters,http://www.businessinsider.com/r-brief-fda-approves-renflexis-biosimilar-to-remicade-2017-4,positive,0.719455897808075
4/22/2017 2:51:04 AM,"U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade -company (JNJ, AMGN, MRK, PFE, 068270)",Reuters,http://www.businessinsider.com/r-us-fda-approves-samsung-bioepis-copy-of-jjs-remicade--company-2017-4,neutral,0.6302808523178101
4/24/2017 12:16:01 PM,Biotech Stocks Facing FDA Decision In May ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-1001941383,neutral,0.8298407793045044
4/24/2017 1:11:08 PM,"RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-rpt-insight-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4,neutral,0.8234217166900635
4/24/2017 1:19:33 PM,PDL BioPharma Settles Keytruda Patent Infringement Lawsuit With Merck ,RTTNews,/news/stocks/pdl-biopharma-settles-keytruda-patent-infringement-lawsuit-with-merck-1001941686,negative,0.7912809252738953
4/24/2017 1:21:05 PM,"BRIEF-PDL BioPharma announces settlement of Keytruda lawsuit with Merck (PDLI, MRK)",Reuters,http://www.businessinsider.com/r-brief-pdl-biopharma-announces-settlement-of-keytruda-lawsuit-with-merck-2017-4,negative,0.6128847599029541
4/24/2017 8:17:06 PM,"UPDATE 1-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-update-1-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4,neutral,0.7897846698760986
4/24/2017 11:25:10 PM,"Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals (FRE, AKRX, MRK)",Reuters,http://www.businessinsider.com/r-fresenius-snaps-up-akorn-merck-kgaas-biosimilars-in-separate-deals-2017-4,neutral,0.9077176451683044
4/25/2017 1:57:05 AM,"UPDATE 1-Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals (FRE, AKRX, MRK)",Reuters,http://www.businessinsider.com/r-update-1-fresenius-snaps-up-akorn-merck-kgaas-biosimilars-in-separate-deals-2017-4,neutral,0.8809452056884766
4/25/2017 7:01:12 AM,"German stocks - Factors to watch on April 25 (CON, FRE, MRK, AKRX, SAP, AOX, AIXA, PUM, SIX2)",Reuters,http://www.businessinsider.com/r-german-stocks---factors-to-watch-on-april-25-2017-4,neutral,0.9424713850021362
4/25/2017 2:00:00 PM,America's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community,PR Newswire,/news/stocks/america-s-diabetes-challenge-unveils-common-challenges-affecting-the-type-2-diabetes-community-1001946189,neutral,0.8137407898902893
4/26/2017 10:21:13 PM,"FDA approves Impax generic of Merck's cholesterol drug Vytorin (IPXL, MRK)",Reuters,http://www.businessinsider.com/r-fda-approves-impax-generic-of-mercks-cholesterol-drug-vytorin-2017-4,positive,0.8429442644119263
4/26/2017 11:12:06 PM,"UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax, Teva generics (MRK, IPXL, TEVA)",Reuters,http://www.businessinsider.com/r-update-1-merck-cholesterol-drug-vytorin-faces-competition-from-impax-teva-generics-2017-4,negative,0.5923188924789429
4/27/2017 4:27:47 PM,"AstraZeneca wants to escape from its falling drug sales in the second half of 2017 (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-hopes-to-escape-drug-sales-trough-in-second-half-2017-4,negative,0.9427146911621094
4/27/2017 4:55:06 PM,"UPDATE 1-Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-beats-wall-st-estimates-helped-by-cancer-drug-opdivo-2017-4,positive,0.9376236796379089
4/28/2017 11:49:09 AM,"Merck KGaA says dominance in liquid crystals could be at risk (MRK, 4631)",Reuters,http://www.businessinsider.com/r-merck-kgaa-says-dominance-in-liquid-crystals-could-be-at-risk-2017-4,negative,0.5730932950973511
4/28/2017 3:00:00 PM,Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression,PR Newswire,/news/stocks/investigational-cladribine-tablets-data-show-greater-treatment-effect-in-relapsing-ms-patients-at-a-higher-risk-of-disease-progression-1001961982,positive,0.9389100074768066
5/1/2017 10:20:05 PM,"UPDATE 2-AstraZeneca immunotherapy wins first approval in bladder cancer (AZN, BMY, MRK, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-2-astrazeneca-immunotherapy-wins-first-approval-in-bladder-cancer-2017-5,positive,0.9408506155014038
5/2/2017 7:40:05 AM,"German stocks - Factors to watch on May 2 (BMW, BAYN, DBK, DPW, HEN3, SIE, SAP, VOW3, PFV, QGEN, ACX, AB1, CON, MRK)",Reuters,http://www.businessinsider.com/r-german-stocks---factors-to-watch-on-may-2-2017-5,neutral,0.9417175650596619
5/2/2017 12:53:39 PM,Merck & Co Inc. Bottom Line Drops 2% In Q1,RTTNews,/news/stocks/merck-co-inc-bottom-line-drops-2-in-q1-1001968761,negative,0.9724954962730408
5/2/2017 1:24:48 PM,Merck Q1 Results Beat Estimates; Raises 2017 Outlook ,RTTNews,/news/stocks/merck-q1-results-beat-estimates-raises-2017-outlook-1001968956,positive,0.943827748298645
5/2/2017 1:30:00 PM,Four Seasons Hotels and Resorts Appoints Julia Hartz to Board of Directors,PR Newswire,/news/stocks/four-seasons-hotels-and-resorts-appoints-julia-hartz-to-board-of-directors-625862,neutral,0.9211723208427429
5/2/2017 2:21:35 PM,Merck eyes key cancer drug growth as others lose patent protection,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/fFaEjwaGyuc/us-merck-co-results-idUSKBN17Y15D,positive,0.8061744570732117
5/2/2017 3:10:07 PM,BRIEF-Merck expecting somewhat slower animal health growth (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-expecting-somewhat-slower-animal-health-growth-2017-5,negative,0.7761921286582947
5/4/2017 5:56:04 PM,BRIEF-Cerveau Technologies says finalization of a clinical supply agreement with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-cerveau-technologies-says-finalization-of-a-clinical-supply-agreement-with-merck-2017-5,positive,0.7972517609596252
5/6/2017 3:02:05 AM,"BRIEF-Valeant announces key appointments in dermatology and corporate communications leadership (VRX, MRK)",Reuters,http://www.businessinsider.com/r-brief-valeant-announces-key-appointments-in-dermatology-and-corporate-communications-leadership-2017-5,neutral,0.8368240594863892
5/9/2017 6:50:07 PM,"BRIEF-U.S. FDA grants accelerated approval to Avelumab for Urothelial Carcinoma (MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-us-fda-grants-accelerated-approval-to-avelumab-for-urothelial-carcinoma-2017-5,positive,0.9374656081199646
5/9/2017 7:26:03 PM,"Pfizer immuno-oncology drug wins U.S. approval for bladder cancer (PFE, MRK)",Reuters,http://www.businessinsider.com/r-pfizer-immuno-oncology-drug-wins-us-approval-for-bladder-cancer-2017-5,positive,0.9039027690887451
5/9/2017 11:20:09 PM,"UPDATE 1-Pfizer immuno-oncology drug wins U.S. approval for bladder cancer (PFE, MRK, AZN)",Reuters,http://www.businessinsider.com/r-update-1-pfizer-immuno-oncology-drug-wins-us-approval-for-bladder-cancer-2017-5,positive,0.9371616244316101
5/10/2017 3:15:00 PM,European Commission Grants Approval for Merck's New Pergoveris® Pen for Fertility Treatment,PR Newswire,/news/stocks/european-commission-grants-approval-for-merck-s-new-pergoveris-pen-for-fertility-treatment-1001999542,positive,0.8314710855484009
5/10/2017 6:30:07 PM,BRIEF-European Commission grants approval for Merck's new Pergoveris Pen for fertility treatment (MRK),Reuters,http://www.businessinsider.com/r-brief-european-commission-grants-approval-for-mercks-new-pergoveris-pen-for-fertility-treatment-2017-5,positive,0.8852060437202454
5/10/2017 11:46:06 PM,U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer (MRK),Reuters,http://www.businessinsider.com/r-us-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-2017-5,positive,0.5913873314857483
5/11/2017 12:00:05 AM,"UPDATE 1-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer (MRK, LLY, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-2017-5,positive,0.8430594205856323
5/11/2017 12:10:03 AM,BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer (MRK),Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-mercks-keytruda-chemo-combo-for-lung-cancer-2017-5,positive,0.7179194688796997
5/11/2017 8:03:44 AM,"FDA Nod For MRK's Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes ",RTTNews,/news/stocks/fda-nod-for-mrk-s-keytruda-sgmo-soars-on-gene-therapy-deal-omer-catches-eyes-1002002224,positive,0.6388891935348511
5/11/2017 5:40:10 PM,"US STOCKS-Wall St on track for worst day in one month (M, WFC, BAC, VZ, T, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-on-track-for-worst-day-in-one-month-2017-5,negative,0.9311695694923401
5/11/2017 7:36:05 PM,"US STOCKS-Wall St on track to record worst day in one month (M, WFC, BAC, VZ, T, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-on-track-to-record-worst-day-in-one-month-2017-5,negative,0.9068095088005066
5/11/2017 8:26:06 PM,Merck Posting Notable Gain In Afternoon Trading ,RTTNews,/news/stocks/merck-posting-notable-gain-in-afternoon-trading-1002005632,positive,0.9449830651283264
5/11/2017 9:52:02 PM,"US STOCKS-Wall Street drops as investors worry about retail (M, KSS, JWN, JCP, WFC, VZ, T, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-drops-as-investors-worry-about-retail-2017-5,negative,0.9684669375419617
5/11/2017 10:26:05 PM,"US STOCKS-Wall Street slides as investors fret about retail (M, KSS, JWN, JCP, WFC, VZ, T, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-slides-as-investors-fret-about-retail-2017-5,negative,0.9654501676559448
5/12/2017 4:56:05 PM,"Vaccine alliance says 300,000 doses of Merck's Ebola shot available for emergencies (MRK)",Reuters,http://www.businessinsider.com/r-vaccine-alliance-says-300000-doses-of-mercks-ebola-shot-available-for-emergencies-2017-5,neutral,0.7518203854560852
5/12/2017 5:50:05 PM,UPDATE 2-Person dies of Ebola virus in Congo in first - Health Ministry (MRK),Reuters,http://www.businessinsider.com/r-update-2-person-dies-of-ebola-virus-in-congo-in-first---health-ministry-2017-5,negative,0.7806480526924133
5/12/2017 10:08:05 PM,UPDATE 4-At least one dead in new Ebola outbreak in Congo (MRK),Reuters,http://www.businessinsider.com/r-update-4-at-least-one-dead-in-new-ebola-outbreak-in-congo-2017-5,negative,0.8986362218856812
5/14/2017 11:46:08 PM,Health experts in Congo identify two more suspected Ebola cases (MRK),Reuters,http://www.businessinsider.com/r-health-experts-in-congo-identify-two-more-suspected-ebola-cases-2017-5,negative,0.8253769278526306
5/15/2017 12:15:00 PM,"Drug Makers Stocks Under Scanner -- Alliqua BioMedical, AbbVie, Johnson & Johnson, and Merck",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-alliqua-biomedical-abbvie-johnson-johnson-and-merck-1002012055,negative,0.4808368682861328
5/15/2017 12:26:05 PM,"U.S. companies push hard for lower tax rate on offshore profits (AAPL, MSFT, PFE, GE, JNJ, MRK, XOM, IBM, CSCO)",Reuters,http://www.businessinsider.com/r-us-companies-push-hard-for-lower-tax-rate-on-offshore-profits-2017-5,positive,0.5808895230293274
5/15/2017 5:06:03 PM,"WHO preparing authorisation, logistics for Ebola vaccination in Congo if needed (MRK)",Reuters,http://www.businessinsider.com/r-who-preparing-authorisation-logistics-for-ebola-vaccination-in-congo-if-needed-2017-5,neutral,0.9059060215950012
5/15/2017 7:30:02 PM,"South Korea's Celltrion sees rapid take-off for Roche drug copy (068270, JNJ, MRK)",Reuters,http://www.businessinsider.com/r-south-koreas-celltrion-sees-rapid-take-off-for-roche-drug-copy-2017-5,positive,0.8742907047271729
5/16/2017 2:56:03 PM,"UPDATE 1-Merck KGaA considers making divisions legally separate subsidiaries (MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-1-merck-kgaa-considers-making-divisions-legally-separate-subsidiaries-2017-5,neutral,0.9510486125946045
5/16/2017 11:50:05 PM,BRIEF-Syndax Pharmaceuticals announces advancement of encore 601 (MRK),Reuters,http://www.businessinsider.com/r-brief-syndax-pharmaceuticals-announces-advancement-of-encore-601-2017-5,neutral,0.8400167226791382
5/17/2017 1:34:03 AM,"Merck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case (MRK)",Reuters,http://www.businessinsider.com/r-merck-upsher-smith-to-pay-60-mln-in-pay-for-delay-drug-case-2017-5,neutral,0.8252586126327515
5/17/2017 3:26:03 PM,BRIEF-Aduro Biotech announces clinical collaboration with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-aduro-biotech-announces-clinical-collaboration-with-merck-2017-5,positive,0.6003720164299011
5/17/2017 7:50:05 PM,BRIEF-Merck's Glucophage SR receives label extension for patients at high risk of type 2 diabetes in UK (MRK),Reuters,http://www.businessinsider.com/r-brief-mercks-glucophage-sr-receives-label-extension-for-patients-at-high-risk-of-type-2-diabetes-in-uk-2017-5,positive,0.7201154828071594
5/17/2017 11:12:03 PM,"Merck says test shows Keytruda improves survival for bladder cancer patients (MRK, AZN, BMY, PFE)",Reuters,http://www.businessinsider.com/r-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-2017-5,positive,0.9524326920509338
5/17/2017 11:16:05 PM,"ImmunoGen drug moving ahead in single-agent, combination trials (IMGN, MRK)",Reuters,http://www.businessinsider.com/r-immunogen-drug-moving-ahead-in-single-agent-combination-trials-2017-5,positive,0.6348263621330261
5/17/2017 11:16:05 PM,"Merck, Incyte immunotherapy combination effective in lung cancer study (MRK, INCY)",Reuters,http://www.businessinsider.com/r-merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-2017-5,positive,0.6480696201324463
5/18/2017 12:00:10 AM,"UPDATE 1-Merck, Incyte immunotherapy combination effective in lung cancer study (MRK, INCY)",Reuters,http://www.businessinsider.com/r-update-1-merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-2017-5,positive,0.8725243806838989
5/18/2017 1:56:03 AM,"UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients (MRK, AZN, BMY, PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-2017-5,positive,0.9497457146644592
5/18/2017 1:12:03 PM,UPDATE 1-Tackling Ebola outbreak in remote Congo presents huge challenge - WHO (MRK),Reuters,http://www.businessinsider.com/r-update-1-tackling-ebola-outbreak-in-remote-congo-presents-huge-challenge---who-2017-5,neutral,0.7738661766052246
5/19/2017 2:30:05 AM,"For millions of Chinese with rare diseases, some relief in sight (CELG, BMY, JNJ, SHP, SAN, PFE, MRK, SAPL, ALXN)",Reuters,http://www.businessinsider.com/r-for-millions-of-chinese-with-rare-diseases-some-relief-in-sight-2017-5,positive,0.8676335215568542
5/19/2017 2:14:11 PM,Merck: CHMP Adopts Positive Opinion For Isentress 600 Mg In EU ,RTTNews,/news/stocks/merck-chmp-adopts-positive-opinion-for-isentress-600-mg-in-eu-1002028853,positive,0.9407224059104919
5/19/2017 2:20:10 PM,BRIEF-Merck receives CHMP positive opinion recommending approval of isentress (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-receives-chmp-positive-opinion-recommending-approval-of-isentress-2017-5,positive,0.9045872092247009
5/22/2017 2:06:07 AM,"Higher rate of heart problems with Amgen osteoporosis drug in trial (AMGN, UCB, MRK)",Reuters,http://www.businessinsider.com/r-higher-rate-of-heart-problems-with-amgen-osteoporosis-drug-in-trial-2017-5,neutral,0.4002181589603424
5/22/2017 3:08:07 AM,"UPDATE 1-Higher rate of heart problems with Amgen osteoporosis drug in trial (AMGN, UCB, MRK)",Reuters,http://www.businessinsider.com/r-update-1-higher-rate-of-heart-problems-with-amgen-osteoporosis-drug-in-trial-2017-5,positive,0.7268969416618347
5/22/2017 6:40:06 PM,BRIEF-Merck announces presentation of phase 2 results for MK-7264 (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-presentation-of-phase-2-results-for-mk-7264-2017-5,neutral,0.9110786318778992
5/23/2017 12:22:09 PM,BRIEF-UK's CMA issues statement of objections to Merck's unit (MRK),Reuters,http://www.businessinsider.com/r-brief-uks-cma-issues-statement-of-objections-to-mercks-unit-2017-5,neutral,0.5756564736366272
5/23/2017 12:22:09 PM,UK competition watchdog accuses Merck of obstructing biosimilars (MRK),Reuters,http://www.businessinsider.com/r-uk-competition-watchdog-accuses-merck-of-obstructing-biosimilars-2017-5,negative,0.9417166113853455
5/23/2017 12:22:09 PM,BRIEF-Merck unit says confident it complied with UK competition law (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-unit-says-confident-it-complied-with-uk-competition-law-2017-5,positive,0.9435834884643555
5/23/2017 12:52:02 PM,"UPDATE 1-UK competition watchdog accuses Merck of obstructing biosimilars (MRK, 068270, PFE, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-uk-competition-watchdog-accuses-merck-of-obstructing-biosimilars-2017-5,negative,0.9463047981262207
5/23/2017 1:10:41 PM,Merck: FDA To Review SBLA For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-fda-to-review-sbla-for-keytruda-quick-facts-1002035770,neutral,0.6419001817703247
5/23/2017 8:54:05 PM,BRIEF-Merck sets quarterly dividend of $0.47 per share (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-sets-quarterly-dividend-of-047-per-share-2017-5,neutral,0.8955478072166443
5/23/2017 11:28:07 PM,FDA clears Merck's Keytruda for cancer patients with certain biomarkers (MRK),Reuters,http://www.businessinsider.com/r-fda-clears-mercks-keytruda-for-cancer-patients-with-certain-biomarkers-2017-5,positive,0.7047593593597412
5/24/2017 3:39:26 AM,Merck Says FDA Approves New Indication For KEYTRUDA ,RTTNews,/news/stocks/merck-says-fda-approves-new-indication-for-keytruda-1002038043,positive,0.6519903540611267
5/24/2017 7:25:21 AM,"MRK's Keytruda Scores Another FDA Nod, NBIX Disappoints, SBPH Achieves It ",RTTNews,/news/stocks/mrk-s-keytruda-scores-another-fda-nod-nbix-disappoints-sbph-achieves-it-1002038264,positive,0.9277080297470093
5/25/2017 12:04:32 AM,"The FDA just took an entirely new approach to approving a cancer drug (LOXO, MRK)",Business Insider,http://www.businessinsider.com/fda-approves-cancer-drug-based-on-genetic-markers-2017-5,neutral,0.7607529163360596
5/25/2017 11:32:16 AM,Biotech Stocks Facing FDA Decision In June ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-1002042040,neutral,0.7687873244285583
5/25/2017 2:09:32 PM,Merck Enters Agreement To Gain Rights To Investigational Anti-tau Antibody ,RTTNews,/news/stocks/merck-enters-agreement-to-gain-rights-to-investigational-anti-tau-antibody-1002042467,positive,0.9340713620185852
5/25/2017 3:36:06 PM,"BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells (MRK, GSK)",Reuters,http://www.businessinsider.com/r-brief-adaptimmune-therapeutics-says-initiated-study-of-ny-eso-spear-tcells-2017-5,neutral,0.7444363832473755
5/25/2017 9:36:03 PM,"BRIEF-Optum and Merck collaborate to advance value-based contracting of pharmaceuticals (MRK, UNH)",Reuters,http://www.businessinsider.com/r-brief-optum-and-merck-collaborate-to-advance-value-based-contracting-of-pharmaceuticals-2017-5,positive,0.7369644045829773
5/27/2017 3:10:03 AM,"UPDATE 1-CVS's Omnicare to pay $23 million to resolve U.S. kickback case (CVS, MRK)",Reuters,http://www.businessinsider.com/r-update-1-cvss-omnicare-to-pay-23-million-to-resolve-us-kickback-case-2017-5,positive,0.8677055835723877
5/29/2017 1:32:07 PM,UPDATE 1-Congo approves use of Ebola vaccination to fight outbreak (MRK),Reuters,http://www.businessinsider.com/r-update-1-congo-approves-use-of-ebola-vaccination-to-fight-outbreak-2017-5,positive,0.8044829964637756
5/30/2017 11:30:07 AM,"Novartis has assets to sell, investors wary of what it might buy (GSK, MRK, BMY, AZN, JNJ)",Reuters,http://www.businessinsider.com/r-novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy-2017-5,negative,0.7272360920906067
5/30/2017 11:30:07 AM,"RPT-Novartis has assets to sell, investors wary of what it might buy (GSK, MRK, BMY, AZN, JNJ)",Reuters,http://www.businessinsider.com/r-rpt-novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy-2017-5,negative,0.5483747720718384
5/30/2017 1:24:50 PM,Merck: FDA OKs ISENTRESS HD In Combination With Antiretroviral Agents For HIV-1 ,RTTNews,/news/stocks/merck-fda-oks-isentress-hd-in-combination-with-antiretroviral-agents-for-hiv-1-1002050210,positive,0.681216835975647
5/30/2017 1:26:05 PM,BRIEF-Merck receives FDA approval of ISENTRESS HD for treatment of HIV-1 infection in appropriate patients (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-receives-fda-approval-of-isentress-hd-for-treatment-of-hiv-1-infection-in-appropriate-patients-2017-5,positive,0.9303818941116333
5/31/2017 2:30:03 AM,Britain backs first-line use of Merck's Keytruda under cancer fund (MRK),Reuters,http://www.businessinsider.com/r-britain-backs-first-line-use-of-mercks-keytruda-under-cancer-fund-2017-5,neutral,0.6695367097854614
5/31/2017 8:14:00 AM,"ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD ",RTTNews,/news/stocks/albo-spikes-glyc-abuzz-fda-approves-1st-generic-strattera-for-adhd-1002052929,positive,0.8213559985160828
5/31/2017 12:00:00 PM,Merck Honors World MS Day by Launching Care Partner Survey with IACO,PR Newswire,/news/stocks/merck-honors-world-ms-day-by-launching-care-partner-survey-with-iaco-1002053758,neutral,0.6151668429374695
6/2/2017 1:40:18 PM,Merck Announces Updated Longer-term Overall Survival Data From KEYNOTE-006 ,RTTNews,/news/stocks/merck-announces-updated-longer-term-overall-survival-data-from-keynote-006-1002063090,neutral,0.8861671686172485
6/2/2017 1:54:06 PM,BRIEF-Merck announces updated longer-term overall survival data from evaluating keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-updated-longer-term-overall-survival-data-from-evaluating-keytruda-2017-6,neutral,0.7727853059768677
6/3/2017 1:46:07 PM,Loxo's targeted drug helps variety of advanced cancers in small study (MRK),Reuters,http://www.businessinsider.com/r-loxos-targeted-drug-helps-variety-of-advanced-cancers-in-small-study-2017-6,neutral,0.5564303994178772
6/4/2017 1:46:03 PM,BRIEF-Merck KGaA enters immuno-oncology collaboration with F-Star (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-enters-immuno-oncology-collaboration-with-f-star-2017-6,positive,0.5157506465911865
6/4/2017 6:14:02 PM,Merck Reports Findings From Cohort 1 Of Phase 2 Registrational KEYNOTE-059 Trial ,RTTNews,/news/stocks/merck-reports-findings-from-cohort-1-of-phase-2-registrational-keynote-059-trial-1002065895,neutral,0.8896908760070801
6/5/2017 8:42:55 AM,"AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce ",RTTNews,/news/stocks/amgn-finds-new-use-for-old-drug-nlnk-disappointed-ecyt-cuts-workforce-1002066348,positive,0.8280990123748779
6/5/2017 1:14:03 PM,"BRIEF-Incyte Corp updates on Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda (INCY, MRK)",Reuters,http://www.businessinsider.com/r-brief-incyte-corp-updates-on-echo-202-trial-of-incytes-epacadostat-in-combination-with-mercks-keytruda-2017-6,neutral,0.8841210603713989
6/5/2017 1:36:05 PM,BRIEF-Merck presents positive mid-stage data from breast cancer combo therapy (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-presents-positive-mid-stage-data-from-breast-cancer-combo-therapy-2017-6,positive,0.9160137176513672
6/6/2017 9:42:03 AM,"German stocks - Factors to watch on June 6 (BAS, DBK, LIN, LHA, MRK, SAP, SAZ, VOW3, TTI, DWNI, QGEN)",Reuters,http://www.businessinsider.com/r-german-stocks---factors-to-watch-on-june-6-2017-6,neutral,0.9421910047531128
6/7/2017 1:04:03 PM,"Blood and bone marrow therapies grab spotlight at world's top cancer meeting (CELG, MRK)",Reuters,http://www.businessinsider.com/r-blood-and-bone-marrow-therapies-grab-spotlight-at-worlds-top-cancer-meeting-2017-6,positive,0.8075490593910217
6/12/2017 5:24:03 PM,"Merck KGaA: 2 bln eur pipeline potential driven by cancer, MS drugs (MRK, PFE)",Reuters,http://www.businessinsider.com/r-merck-kgaa-2-bln-eur-pipeline-potential-driven-by-cancer-ms-drugs-2017-6,neutral,0.5686936974525452
6/12/2017 10:26:03 PM,BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-provides-update-on-multiple-myeloma-studies-keynote-183-and-185-of-keytruda-in-combination-with-other-therapies-2017-6,neutral,0.9062666296958923
6/12/2017 10:44:08 PM,Merck to pause two late-stage studies testing Keytruda in myeloma (MRK),Reuters,http://www.businessinsider.com/r-merck-to-pause-two-late-stage-studies-testing-keytruda-in-myeloma-2017-6,negative,0.6428166627883911
6/12/2017 11:22:08 PM,"UPDATE 1-Merck to pause two late-stage studies testing Keytruda in myeloma (MRK, CELG)",Reuters,http://www.businessinsider.com/r-update-1-merck-to-pause-two-late-stage-studies-testing-keytruda-in-myeloma-2017-6,negative,0.8069261908531189
6/13/2017 4:09:55 AM,Merck Pauses Enrollment Of Blood Cancer Drug Study ,RTTNews,/news/stocks/merck-pauses-enrollment-of-blood-cancer-drug-study-1002087183,neutral,0.6607382297515869
6/14/2017 2:45:00 PM,Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments,PR Newswire,/news/stocks/patented-biotechnology-formulations-resulting-in-new-generation-of-animal-healthcare-medications-and-treatments-1002092780,neutral,0.5165343284606934
6/14/2017 2:45:00 PM,Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments,PR Newswire,/news/stocks/patented-biotechnology-formulations-resulting-in-new-generation-of-animal-healthcare-medications-and-treatments-1002092769,neutral,0.5165343284606934
6/15/2017 8:52:05 PM,"BRIEF-Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma (MRK)",Reuters,http://www.businessinsider.com/r-brief-human-longevity-says-agreement-with-merck-kgaa-darmstadt-germany-to-engage-in-cancer-biomarker-discovery-in-advanced-melanoma-2017-6,positive,0.9087671637535095
6/20/2017 2:58:03 PM,"BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer (MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-effector-therapeutics-to-collaborate-with-pfizer-and-merck-to-evaluate-immuno-oncology-combination-in-microsatellite-stable-colorectal-cancer-2017-6,positive,0.659702479839325
6/20/2017 7:26:03 PM,"BRIEF-Serimmune announces research, development collaboration agreement with subsidiary of Merck (MRK)",Reuters,http://www.businessinsider.com/r-brief-serimmune-announces-research-development-collaboration-agreement-with-subsidiary-of-merck-2017-6,positive,0.7946781516075134
6/20/2017 9:48:03 PM,BRIEF-PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications (MRK),Reuters,http://www.businessinsider.com/r-brief-pv-nano-cell-says-cooperating-with-merck-for-single-crystalline-metal-particles-technology-applications-2017-6,positive,0.8747064471244812
6/21/2017 3:24:06 PM,BRIEF-Leap Therapeutics announces collaboration with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-leap-therapeutics-announces-collaboration-with-merck-2017-6,neutral,0.8712482452392578
6/21/2017 11:44:03 PM,BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study (MRK),Reuters,http://www.businessinsider.com/r-brief-leap-therapeutics-says-merck-will-sponsor-and-fund-initial-trials-of-their-combo-drug-study-2017-6,neutral,0.5787212252616882
6/23/2017 1:48:03 PM,"BRIEF-EMA recommends approval of Merck's multiple sclerosis drug (MRK, AVEO)",Reuters,http://www.businessinsider.com/r-brief-ema-recommends-approval-of-mercks-multiple-sclerosis-drug-2017-6,neutral,0.6296812295913696
6/23/2017 1:56:03 PM,"Germany's Merck gets EU backing for oral MS drug (MRK, BIIB, SAN, TEVA, BAYN)",Reuters,http://www.businessinsider.com/r-germanys-merck-gets-eu-backing-for-oral-ms-drug-2017-6,positive,0.8816858530044556
6/23/2017 2:30:05 PM,"BRIEF-EU medicines agency recommends approval of Aveo's kidney cancer drug (AVEO, MRK)",Reuters,http://www.businessinsider.com/r-brief-eu-medicines-agency-recommends-approval-of-aveos-kidney-cancer-drug-2017-6,neutral,0.6677828431129456
6/23/2017 2:46:00 PM,Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis,PR Newswire,/news/stocks/cladribine-tablets-receives-positive-chmp-opinion-for-treatment-of-relapsing-forms-of-multiple-sclerosis-1002119699,positive,0.9466978311538696
6/24/2017 7:17:00 PM,Merck to Present Data on MAVENCLAD™ (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017,PR Newswire,/news/stocks/merck-to-present-data-on-mavenclad-cladribine-tablets-and-rebif-interferon-beta-1a-in-patients-with-relapsing-ms-at-ean-congress-2017-1002121542,neutral,0.7987595796585083
6/26/2017 12:10:00 PM,"Breakfast Technical Briefing on Drug Makers Stocks -- Pfizer, Merck, AbbVie, and Johnson & Johnson",PR Newswire,/news/stocks/breakfast-technical-briefing-on-drug-makers-stocks-pfizer-merck-abbvie-and-johnson-johnson-1002123019,neutral,0.9454298615455627
6/26/2017 12:30:00 PM,Data Provide Additional Insight Into the Mode of Action of MAVENCLAD™ (Cladribine Tablets) in Patients With Relapsing MS,PR Newswire,/news/stocks/data-provide-additional-insight-into-the-mode-of-action-of-mavenclad-cladribine-tablets-in-patients-with-relapsing-ms-1002123102,neutral,0.7161370515823364
6/27/2017 7:28:03 AM,"BRIEF-Ablynx achieves second milestone in immuno-oncology collaboration (ABLX, MRK)",Reuters,http://www.businessinsider.com/r-brief-ablynx-achieves-second-milestone-in-immuno-oncology-collaboration-2017-6,positive,0.9332696199417114
6/27/2017 1:18:40 PM,Merck: REVEAL Outcomes Study Of Anacetrapib Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/merck-reveal-outcomes-study-of-anacetrapib-meets-primary-endpoint-quick-facts-1002126926,positive,0.558315098285675
6/27/2017 1:30:08 PM,Merck's cholesterol drug clears main goal in late-stage study (MRK),Reuters,http://www.businessinsider.com/r-mercks-cholesterol-drug-clears-main-goal-in-late-stage-study-2017-6,neutral,0.8876274824142456
6/27/2017 1:30:08 PM,BRIEF-Merck provides update on reveal outcomes study of Anacetrapib (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-provides-update-on-reveal-outcomes-study-of-anacetrapib-2017-6,neutral,0.9048573970794678
6/27/2017 5:22:03 PM,BRIEF-Merck says in tweet company's computer network was compromised as part of global hack (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-in-tweet-companys-computer-network-was-compromised-as-part-of-global-hack-2017-6,negative,0.8779590129852295
6/27/2017 7:08:03 PM,"AstraZeneca cancer drug trial prompts investors to take options cover (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-cancer-drug-trial-prompts-investors-to-take-options-cover-2017-6,neutral,0.8400911688804626
6/29/2017 9:54:06 AM,Details on surprise Novartis heart drug success due Aug 27 (MRK),Reuters,http://www.businessinsider.com/r-details-on-surprise-novartis-heart-drug-success-due-aug-27-2017-6,neutral,0.9387367367744446
6/29/2017 1:14:00 PM,Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne,PR Newswire,/news/stocks/merck-expands-packaging-capacity-at-swiss-biotech-manufacturing-site-of-aubonne-1002134551,positive,0.9330887794494629
6/29/2017 1:28:05 PM,"UPDATE 1-Sales hopes for new Novartis, Merck heart drugs under microscope (MRK, AMGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-sales-hopes-for-new-novartis-merck-heart-drugs-under-microscope-2017-6,neutral,0.662467360496521
6/29/2017 3:16:03 PM,"BRIEF-Bayer enrolling patients into a global pulmonary arterial hypertension study (BAYN, MRK)",Reuters,http://www.businessinsider.com/r-brief-bayer-enrolling-patients-into-a-global-pulmonary-arterial-hypertension-study-2017-6,neutral,0.7874762415885925
6/30/2017 12:16:00 PM,ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children,PR Newswire,/news/stocks/alk-five-year-grazax-asthma-prevention-gap-trial-reveals-benefits-of-early-treatment-intervention-in-children-1002138213,positive,0.8824023008346558
6/30/2017 5:16:00 PM,ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children,PR Newswire,/news/stocks/alk-five-year-grazax-asthma-prevention-gap-trial-reveals-benefits-of-early-treatment-intervention-in-children-1002139432,positive,0.8824023008346558
7/3/2017 8:24:06 AM,"RPT-Big pharma turns to AI to speed drug discovery, GSK signs deal (GSK, MRK, JNJ, SAN, PFE)",Reuters,http://www.businessinsider.com/r-rpt-big-pharma-turns-to-ai-to-speed-drug-discovery-gsk-signs-deal-2017-7,positive,0.6345846056938171
7/5/2017 7:02:05 PM,"New cancer treatments that are programmed to treat a person's specific tumor just passed 2 early tests (MRK, BMY, SAN, LLY)",Reuters,http://www.businessinsider.com/r-personalised-vaccines-hold-cancer-at-bay-in-two-early-trials-2017-7,neutral,0.640192449092865
7/5/2017 10:40:08 PM,"BRIEF-Merck provides further update on 3 multiple myeloma studies evaluating Keytruda in combination with Pomalidomide, Lenalidomide (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-provides-further-update-on-3-multiple-myeloma-studies-evaluating-keytruda-in-combination-with-pomalidomide-lenalidomide-2017-7,neutral,0.7799001336097717
7/5/2017 10:52:05 PM,FDA places clinical hold on Merck's combo therapy for multiple myeloma (MRK),Reuters,http://www.businessinsider.com/r-fda-places-clinical-hold-on-mercks-combo-therapy-for-multiple-myeloma-2017-7,negative,0.7826077938079834
7/5/2017 11:42:05 PM,"UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths (MRK, BMY, CELG)",Reuters,http://www.businessinsider.com/r-update-1-fda-puts-hold-on-merck-multiple-myeloma-trials-after-deaths-2017-7,negative,0.8485674858093262
7/6/2017 2:59:37 AM,FDA Puts Hold On Merck Multiple Myeloma Trials ,RTTNews,/news/stocks/fda-puts-hold-on-merck-multiple-myeloma-trials-1002150691,negative,0.8467715382575989
7/6/2017 8:44:07 AM,"PRESS DIGEST -Wall Street Journal - July 6 (MRK, BIDU, GS)",Reuters,http://www.businessinsider.com/r-press-digest--wall-street-journal---july-6-2017-7,neutral,0.9424446225166321
7/6/2017 10:31:30 AM,"ARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG ",RTTNews,/news/stocks/arry-working-its-way-be-all-ears-for-auris-bgne-inks-deal-with-celg-1002151540,neutral,0.7100974917411804
7/6/2017 11:56:17 AM,"EU charges Merck KGaA, GE, Canon over merger rules",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/HS5ibRuBVDE/us-eu-merck-ge-canon-idUSKBN19R10R,negative,0.9364615082740784
7/6/2017 11:58:05 AM,"EU charges Merck KGaA, GE, Canon of misleading merger info (MRK, GE, 7751, 6502)",Reuters,http://www.businessinsider.com/r-eu-charges-merck-kgaa-ge-canon-of-misleading-merger-info-2017-7,negative,0.769564151763916
7/6/2017 2:26:08 PM,"UPDATE 1-EU charges Merck KGaA, GE, Canon over merger rules (GE, MRK, 7751, HON, 6502)",Reuters,http://www.businessinsider.com/r-update-1-eu-charges-merck-kgaa-ge-canon-over-merger-rules-2017-7,negative,0.9124668836593628
7/7/2017 11:51:58 AM,"ALK's GAP Trial Fails To Meet Primary Endpoint, Benefits In Early Treament ",RTTNews,/news/stocks/alk-s-gap-trial-fails-to-meet-primary-endpoint-benefits-in-early-treament-1002155455,negative,0.9275622963905334
7/7/2017 12:12:03 PM,"BRIEF-Alk-Abello ‍releases analysis of data from GAP clinical trial in children​ (ALK , MRK)",Reuters,http://www.businessinsider.com/r-brief-alk-abello-releases-analysis-of-data-from-gap-clinical-trial-in-children-2017-7,neutral,0.9334366917610168
7/10/2017 1:38:06 PM,BRIEF-PDS Biotechnology enters a clinical trial collaboration agreement with a subsidiary of Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-pds-biotechnology-enters-a-clinical-trial-collaboration-agreement-with-a-subsidiary-of-merck-2017-7,positive,0.9094173908233643
7/10/2017 10:46:11 PM,"Here’s how much the 10 largest pharmaceutical companies spend on R&D (PFE, AMGN, NVS, ROG, MRK, SNY, JNJ, GILD, GSK, ABBV)",Business Insider,http://www.businessinsider.com/largest-pharmaceutical-companies-by-prescription-sales-and-rd-2017-7,neutral,0.9493331909179688
7/13/2017 12:02:03 PM,"T-cell cancer therapy holds promise, longer-term results await (MRK, BMY, AET)",Reuters,http://www.businessinsider.com/r-t-cell-cancer-therapy-holds-promise-longer-term-results-await-2017-7,positive,0.8325119614601135
7/13/2017 2:32:06 PM,BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-aduro-biotech-reports-2-mln-milestone-payment-under-licensing-deal-with-merck-2017-7,positive,0.8924888372421265
7/14/2017 1:14:06 PM,"BRIEF-Lannett receives approval for Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL (MRK)",Reuters,http://www.businessinsider.com/r-brief-lannett-receives-approval-for-cyproheptadine-hydrochloride-syrup-2-mg-5-ml-2017-7,positive,0.9135986566543579
7/17/2017 1:26:05 PM,BRIEF-Merck announces presentations of clinical and real-world data at the Alzheimer’s Association International Conference (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference-2017-7,neutral,0.9283537268638611
7/20/2017 1:41:22 PM,"Merck:FDA Grants Tentative Approval For LUSDUNA Nexvue, Biologic Basal Insulin ",RTTNews,/news/stocks/merck-fda-grants-tentative-approval-for-lusduna-nexvue-biologic-basal-insulin-1002190737,positive,0.9214113354682922
7/20/2017 1:54:03 PM,BRIEF-Merck announces U.S. FDA grants tentative approval for Lusduna™ Nexvue™ (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-us-fda-grants-tentative-approval-for-lusduna-nexvue-2017-7,positive,0.8837523460388184
7/20/2017 6:58:08 PM,"FDA tentatively approves Merck's copycat of Sanofi's Lantus (MRK, SAN, LLY, CVS)",Reuters,http://www.businessinsider.com/r-fda-tentatively-approves-mercks-copycat-of-sanofis-lantus-2017-7,positive,0.6010927557945251
7/20/2017 9:18:03 PM,"Corning vows new jobs as part of Trump's ""Made in America"" week (GLW, MRK, PFE)",Reuters,http://www.businessinsider.com/r-corning-vows-new-jobs-as-part-of-trumps-made-in-america-week-2017-7,neutral,0.8559199571609497
7/20/2017 10:08:06 PM,"UPDATE 1-Trump unveils companies' $500 million U.S. drug packaging project (GLW, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-1-trump-unveils-companies-500-million-us-drug-packaging-project-2017-7,neutral,0.5367991328239441
7/21/2017 12:42:06 AM,"Many treatment options, most experimental, available to John McCain (MRK)",Reuters,http://www.businessinsider.com/r-many-treatment-options-most-experimental-available-to-john-mccain-2017-7,neutral,0.8558593392372131
7/21/2017 7:22:01 AM,"AEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK ",RTTNews,/news/stocks/aezs-gets-down-to-serious-work-apvo-surges-fda-tentative-nod-for-mrk-1002193692,positive,0.8483994603157043
7/21/2017 12:06:09 PM,"RPT-Many treatment options, most experimental, available to John McCain (MRK)",Reuters,http://www.businessinsider.com/r-rpt-many-treatment-options-most-experimental-available-to-john-mccain-2017-7,neutral,0.7975208163261414
7/21/2017 1:38:03 PM,"Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval (PFE, MRK)",Reuters,http://www.businessinsider.com/r-pfizer-merck-kgaa-skin-cancer-drug-gets-ema-nod-for-approval-2017-7,positive,0.5011297464370728
7/21/2017 1:42:05 PM,"BRIEF-Merck KGaA and Pfizer: CHMP recommends approval of avelumab (MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-and-pfizer-chmp-recommends-approval-of-avelumab-2017-7,neutral,0.49449434876441956
7/21/2017 1:58:03 PM,BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-european-medicines-agencys-chmp-recommends-approval-for-mercks-keytruda-2017-7,neutral,0.49248960614204407
7/21/2017 3:47:00 PM,EMA's CHMP Recommends Approval For Merck's KEYTRUDA ,RTTNews,/news/stocks/ema-s-chmp-recommends-approval-for-merck-s-keytruda-1002195422,neutral,0.5376906991004944
7/24/2017 5:21:39 AM,One Step Closer To EU Approval... ,RTTNews,/news/stocks/one-step-closer-to-eu-approval-1002197023,positive,0.5937835574150085
7/24/2017 10:28:09 AM,"HIV fight advances with new drug cocktails, fresh vaccine hopes (GILD, GSK, MRK, JNJ)",Reuters,http://www.businessinsider.com/r-hiv-fight-advances-with-new-drug-cocktails-fresh-vaccine-hopes-2017-7,positive,0.8591089844703674
7/24/2017 1:24:06 PM,BRIEF-Merck announces week 96 results from Oncemrk (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-week-96-results-from-oncemrk-2017-7,neutral,0.8971518278121948
7/24/2017 2:21:57 PM,"Merck Announces U.S. Launch Of RENFLEXIS, A Biosimilar Of Remicade ",RTTNews,/news/stocks/merck-announces-u-s-launch-of-renflexis-a-biosimilar-of-remicade-1002198476,neutral,0.5636017322540283
7/24/2017 2:22:06 PM,BRIEF-Merck announces U.S. launch of Renflexis (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-us-launch-of-renflexis-2017-7,neutral,0.91176438331604
7/24/2017 7:04:03 PM,"UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative (MRK, JNJ, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-merck-samsung-bioepis-launch-discounted-us-remicade-alternative-2017-7,positive,0.5694882273674011
7/24/2017 11:08:45 PM,Merck: Phase 3 KEYNOTE-040 Trial Fails To Meet Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/merck-phase-3-keynote-040-trial-fails-to-meet-primary-endpoint-quick-facts-1002200020,negative,0.9346978068351746
7/24/2017 11:12:03 PM,BRIEF-Merck provides update on phase 3 study of keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-provides-update-on-phase-3-study-of-keytruda-2017-7,neutral,0.9201008081436157
7/25/2017 12:12:06 AM,Merck immunotherapy fails to improve survival in head and neck cancer (MRK),Reuters,http://www.businessinsider.com/r-merck-immunotherapy-fails-to-improve-survival-in-head-and-neck-cancer-2017-7,negative,0.8581807613372803
7/25/2017 5:37:41 AM,Samsung Bioepis Says RENFLEXIS Now Available In US ,RTTNews,/news/stocks/samsung-bioepis-says-renflexis-now-available-in-us-1002200344,neutral,0.5935325622558594
7/25/2017 2:42:10 PM,"Merck' NNRTI, Doravirine, Meets Primary Endpoint Of Non-Inferiority To Efaviren ",RTTNews,/news/stocks/merck-nnrti-doravirine-meets-primary-endpoint-of-non-inferiority-to-efaviren-1002202055,positive,0.5087106227874756
7/25/2017 2:44:03 PM,"BRIEF-Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint (MRK)",Reuters,http://www.businessinsider.com/r-brief-mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-2017-7,positive,0.8963554501533508
7/25/2017 10:18:05 PM,BRIEF-Merck sets quarterly dividend of $0.47 per share (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-sets-quarterly-dividend-of-047-per-share-2017-7,neutral,0.8955478072166443
7/27/2017 9:04:23 AM,AstraZeneca Posts Q2 Profit; Backs 2017 Outlook ,RTTNews,/news/stocks/astrazeneca-posts-q2-profit-backs-2017-outlook-1002209001,negative,0.5028828978538513
7/27/2017 10:32:06 AM,"BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck (AZN, MRK)",Reuters,http://www.businessinsider.com/r-brief-astrazeneca-says-establish-strategic-oncology-collaboration-with-merck-2017-7,positive,0.7590497732162476
7/27/2017 1:06:04 PM,"Bristol-Myers quarterly sales meet Wall Street estimates (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-quarterly-sales-meet-wall-street-estimates-2017-7,neutral,0.6415187120437622
7/27/2017 2:38:05 PM,"UPDATE 1-Bristol-Myers shares fall after failed AstraZeneca drug trial (BMY, AZN, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-shares-fall-after-failed-astrazeneca-drug-trial-2017-7,negative,0.9680455923080444
7/28/2017 12:38:05 PM,"Dividends a worry at drugmakers Astra, GSK after dramatic week (AZN, GSK, MRK)",Reuters,http://www.businessinsider.com/r-dividends-a-worry-at-drugmakers-astra-gsk-after-dramatic-week-2017-7,negative,0.7686076760292053
7/28/2017 12:48:38 PM,Merck & Co Inc. Q2 Earnings Rise 7%,RTTNews,/news/stocks/merck-co-inc-q2-earnings-rise-7-1002214504,positive,0.9389844536781311
7/28/2017 12:58:06 PM,"Merck profit soars 61.5 pct as Keytruda sales surge (MRK, AZN)",Reuters,http://www.businessinsider.com/r-merck-profit-soars-615-pct-as-keytruda-sales-surge-2017-7,positive,0.9094020128250122
7/28/2017 1:08:03 PM,BRIEF-Merck reports Q2 non-GAAP earnings of $1.01/shr (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-reports-q2-non-gaap-earnings-of-101-shr-2017-7,neutral,0.8575402498245239
7/28/2017 1:13:38 PM,"Merck profit beats as Keytruda sales soar, expenses drop",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/F3-Vd-d2NMg/us-merck-co-results-idUSKBN1AD1AO,negative,0.8829830884933472
7/28/2017 1:15:48 PM,Merck Q2 Profit Beats Estimates; Worldwide Sales Up 1% ,RTTNews,/news/stocks/merck-q2-profit-beats-estimates-worldwide-sales-up-1-1002214625,positive,0.9489196538925171
7/28/2017 1:20:04 PM,"UPDATE 1-Merck profit tops estimates as Keytruda sales surge (MRK, AZN)",Reuters,http://www.businessinsider.com/r-update-1-merck-profit-tops-estimates-as-keytruda-sales-surge-2017-7,positive,0.9284710884094238
7/28/2017 1:38:03 PM,"US STOCKS-Futures lower as tech stocks take a beating (AMZN, NFLX, UPS, SBUX, MRK, BIDU)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-lower-as-tech-stocks-take-a-beating-2017-7,negative,0.9504302740097046
7/28/2017 9:36:00 PM,"Merck & Co., Inc. -- Moody's: Merck cyber attack credit negative",Moodys,/news/bonds/merck-amp-co-inc-moody-s-merck-cyber-attack-credit-negative-1002216187,neutral,0.6858522295951843
7/28/2017 10:32:05 PM,"AbbVie's drug for all types of hepatitis C wins EU approval (GILD, MRK)",Reuters,http://www.businessinsider.com/r-abbvies-drug-for-all-types-of-hepatitis-c-wins-eu-approval-2017-7,positive,0.946485698223114
7/31/2017 3:42:05 PM,BRIEF-Generex announces collaboration with Merck to evaluate Keytruda in combination with ae37 in patients with triple-negative breast cancer (MRK),Reuters,http://www.businessinsider.com/r-brief-generex-announces-collaboration-with-merck-to-evaluate-keytruda-in-combination-with-ae37-in-patients-with-triple-negative-breast-cancer-2017-7,positive,0.8796294927597046
8/2/2017 7:27:05 PM,"Cyber 'worm' attack hits global corporate earnings (MRK, FDX, MAERSK , RB.)",Reuters,http://www.businessinsider.com/r-cyber-worm-attack-hits-global-corporate-earnings-2017-8,negative,0.9299584031105042
8/2/2017 9:22:03 PM,"UPDATE 1-Corporate profits to take more hits from Ukraine cyber attack (FDX, MAERSK , BEI, DPW, MRK, RB., ROSN, WPP, SGO)",Reuters,http://www.businessinsider.com/r-update-1-corporate-profits-to-take-more-hits-from-ukraine-cyber-attack-2017-8,positive,0.4072020947933197
8/3/2017 11:17:03 PM,"Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-to-buy-ifm-therapeutics-to-strengthen-cancer-pipeline-2017-8,positive,0.6997411251068115
8/4/2017 12:07:03 PM,"Deals of the day-Mergers and acquisitions (GAS, BMY, MRK, 7261, BX, 2914, VNM)",Reuters,http://www.businessinsider.com/r-deals-of-the-day-mergers-and-acquisitions-2017-8,neutral,0.9484180808067322
8/7/2017 1:17:03 PM,"BRIEF-MSD Animal Health to purchase manufacturing facility in Krems, Austria (MRK, SHP)",Reuters,http://www.businessinsider.com/r-brief-msd-animal-health-to-purchase-manufacturing-facility-in-krems-austria-2017-8,neutral,0.8136430978775024
8/8/2017 12:10:05 PM,Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux ,RTTNews,/news/stocks/merck-kgaa-says-nice-issues-positive-fad-recommending-routine-nhs-use-of-erbitux-1002239823,positive,0.8091630339622498
8/8/2017 9:42:05 PM,"BRIEF-Sanofi files suit in U.S. to defend patent rights on Lantus (SAN, MRK)",Reuters,http://www.businessinsider.com/r-brief-sanofi-files-suit-in-us-to-defend-patent-rights-on-lantus-2017-8,neutral,0.5228914022445679
8/8/2017 9:47:03 PM,"BRIEF-Sanofi files suit in U.S. to defend patent rights on Lantus (SAN, MRK)",Reuters,http://www.businessinsider.com/r-brief-sanofi-files-suit-in-us-to-defend-patent-rights-on-lantus-2017-8,neutral,0.5228914022445679
8/9/2017 3:09:04 AM,Sanofi Files Suit In U.S. To Defend Its Patent Rights On Lantus ,RTTNews,/news/stocks/sanofi-files-suit-in-u-s-to-defend-its-patent-rights-on-lantus-1002242528,negative,0.7276210784912109
8/9/2017 7:07:03 PM,"UPDATE 1-Mexico watchdog finds big pharma faces no competition on some drugs (GSK, PFE, MRK, ABT, LLY, SAN, AZN)",Reuters,http://www.businessinsider.com/r-update-1-mexico-watchdog-finds-big-pharma-faces-no-competition-on-some-drugs-2017-8,positive,0.8694553971290588
8/10/2017 2:02:03 PM,"How AI robots hunt new drugs for crippling nerve disease (IBM, GSK, JNJ, SAN, MRK, MSFT)",Reuters,http://www.businessinsider.com/r-how-ai-robots-hunt-new-drugs-for-crippling-nerve-disease-2017-8,neutral,0.9275450706481934
8/14/2017 2:32:03 PM,"BRIEF-Merck CEO Frazier says ""I am resigning from the president's American Manufacturing Council"" - tweet (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-ceo-frazier-says-i-am-resigning-from-the-presidents-american-manufacturing-council---tweet-2017-8,negative,0.5835524797439575
8/14/2017 2:55:28 PM,Merck CEO resigns from Trump council over Charlottesville,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/ESGzotBh3dc/us-virginia-protests-merck-idUSKCN1AU1FM,negative,0.8487372994422913
8/14/2017 3:02:03 PM,Merck CEO resigns from Trump's manufacturing council (MRK),Reuters,http://www.businessinsider.com/r-merck-ceo-resigns-from-trumps-manufacturing-council-2017-8,negative,0.7936561107635498
8/14/2017 3:09:04 PM,Merck CEO quits Trump's manufacturing council over Charlottesville — and Trump immediately bashes him (MRK),Business Insider,http://www.businessinsider.com/merck-ceo-kenneth-frazier-resigns-from-trump-manufacturing-council-2017-8,negative,0.8676061630249023
8/14/2017 3:10:13 PM,Trump chides Merck CEO after resignation from presidential council over,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/T0xklFZic90/virginia-protests-merck-trump-idINKCN1AU1H1,negative,0.8003064393997192
8/14/2017 3:10:36 PM,Merck CEO resigns from Trump council after Charlottesville,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/2t0sOH1PqcE/virginia-protests-merck-idINKCN1AU1GU,negative,0.8017277121543884
8/14/2017 3:12:05 PM,"UPDATE 1-Merck CEO resigns from Trump council after Charlottesville (MRK, TSLA, DIS)",Reuters,http://www.businessinsider.com/r-update-1-merck-ceo-resigns-from-trump-council-after-charlottesville-2017-8,negative,0.7674965262413025
8/14/2017 3:12:05 PM,Trump chides Merck CEO after resignation from presidential council over (MRK),Reuters,http://www.businessinsider.com/r-trump-chides-merck-ceo-after-resignation-from-presidential-council-over-2017-8,negative,0.6917126178741455
8/14/2017 3:42:08 PM,"UPDATE 2-Merck CEO resigns from Trump council after Charlottesville (MRK, TSLA, DIS)",Reuters,http://www.businessinsider.com/r-update-2-merck-ceo-resigns-from-trump-council-after-charlottesville-2017-8,negative,0.7730944156646729
8/14/2017 4:02:04 PM,"UPDATE 1-Merck CEO pulls out of Trump panel, demands rejection of bigotry (MRK)",Reuters,http://www.businessinsider.com/r-update-1-merck-ceo-pulls-out-of-trump-panel-demands-rejection-of-bigotry-2017-8,negative,0.8818446397781372
8/14/2017 5:09:03 PM,Trump just put Merck's CEO on blast over drug prices — here's what the company's track record actually looks like (MRK),Business Insider,http://www.businessinsider.com/donald-trump-attacks-merck-ceo-ken-frazier-on-drug-prices-after-charlottesville-protest-2017-8,neutral,0.9064294695854187
8/14/2017 5:10:33 PM,Merck CEO Quits President's Council Protesting Charlottesville Incident ,RTTNews,/news/stocks/merck-ceo-quits-president-s-council-protesting-charlottesville-incident-1002255899,negative,0.8337610960006714
8/15/2017 4:02:03 AM,"UPDATE 9-Merck and Under Armour CEOs resign from Trump council over Charlottesville (MRK, ALNY, GS, TSLA, DIS)",Reuters,http://www.businessinsider.com/r-update-9-merck-and-under-armour-ceos-resign-from-trump-council-over-charlottesville-2017-8,negative,0.8100007176399231
8/15/2017 5:42:35 AM,Merck And Under Armour CEOs Resign From Trump's American Manufacturing Council ,RTTNews,/news/stocks/merck-and-under-armour-ceos-resign-from-trump-s-american-manufacturing-council-1002257107,negative,0.8792575001716614
8/15/2017 7:02:03 AM,"PRESS DIGEST- New York Times business news - Aug 15 (P, WFC, INTC, MRK)",Reuters,http://www.businessinsider.com/r-press-digest--new-york-times-business-news---aug-15-2017-8,neutral,0.9278751015663147
8/15/2017 7:02:03 AM,"PRESS DIGEST - Wall Street Journal - Aug 15 (P, MRK, INTC, WFM, AMZN, BRK., GE)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---aug-15-2017-8,neutral,0.946077823638916
8/15/2017 12:02:03 PM,"Trump faces business backlash over handling of Charlottesville upheaval (MRK, INTC)",Reuters,http://www.businessinsider.com/r-trump-faces-business-backlash-over-handling-of-charlottesville-upheaval-2017-8,negative,0.9495449066162109
8/15/2017 4:14:35 PM,Intel And Under Armour CEOs Join Exodus From Trump's Manufacturing Council ,RTTNews,/news/stocks/intel-and-under-armour-ceos-join-exodus-from-trump-s-manufacturing-council-1002259064,neutral,0.7508955597877502
8/15/2017 5:45:06 PM,"From the son of a janitor to CEO of Merck: Meet Kenneth Frazier, who's getting praised after leaving Trump's manufacturing council (MRK)",Business Insider,http://www.businessinsider.com/who-is-merck-ceo-kenneth-frazier-2017-8,neutral,0.7315279245376587
8/15/2017 6:17:03 PM,"UPDATE 1-Trump hits back at CEOs over response to Virginia violence (MRK, INTC)",Reuters,http://www.businessinsider.com/r-update-1-trump-hits-back-at-ceos-over-response-to-virginia-violence-2017-8,negative,0.9234644770622253
8/16/2017 12:52:16 AM,"U.N. chief Guterres condemns racism, xenophobia - Twitter post (MRK, WMT)",Reuters,http://www.businessinsider.com/r-un-chief-guterres-condemns-racism-xenophobia---twitter-post-2017-8,neutral,0.816620409488678
8/16/2017 2:15:00 PM,PeopleDoc joins the Inc. 5000 list of fastest-growing private companies,PR Newswire,/news/stocks/peopledoc-joins-the-inc-5000-list-of-fastest-growing-private-companies-1001598388,neutral,0.6105496883392334
8/17/2017 2:22:03 AM,"UPDATE 1-Trump's Virginia comments last straw for disenchanted CEOs (BLK, MRK, INTC, JPM, BX, DOW, MMM)",Reuters,http://www.businessinsider.com/r-update-1-trumps-virginia-comments-last-straw-for-disenchanted-ceos-2017-8,neutral,0.6830054521560669
8/17/2017 7:02:04 AM,"Trump's crisis spurs talk of White House departures (MRK, INTC, CPB, MMM, GS)",Reuters,http://www.businessinsider.com/r-trumps-crisis-spurs-talk-of-white-house-departures-2017-8,negative,0.8358643651008606
8/17/2017 12:15:00 PM,"Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi",PR Newswire,/news/stocks/technical-snapshots-for-these-drug-makers-stocks-pfizer-eli-lilly-merck-and-sanofi-1002264947,neutral,0.9307227730751038
8/17/2017 12:57:06 PM,"RPT-Trump's crisis spurs talk of White House departures (MRK, INTC, CPB, MMM, GS)",Reuters,http://www.businessinsider.com/r-rpt-trumps-crisis-spurs-talk-of-white-house-departures-2017-8,negative,0.8203957676887512
8/17/2017 1:24:59 PM,Race For A New Alzheimer's Drug ,RTTNews,/news/stocks/race-for-a-new-alzheimer-s-drug-1002265169,neutral,0.867276668548584
8/17/2017 10:37:13 PM,"FDA approves expanded use of AstraZeneca ovarian cancer drug (AZN, MRK)",Reuters,http://www.businessinsider.com/r-fda-approves-expanded-use-of-astrazeneca-ovarian-cancer-drug-2017-8,positive,0.8573595285415649
8/17/2017 11:32:11 PM,"UPDATE 1-FDA expands use of AstraZeneca/Merck ovarian cancer drug (AZN, MRK)",Reuters,http://www.businessinsider.com/r-update-1-fda-expands-use-of-astrazeneca-merck-ovarian-cancer-drug-2017-8,positive,0.8722115755081177
8/18/2017 5:12:10 AM,LYNPARZA Gets Additional And Broad Approval In U.S. For Ovarian Cancer ,RTTNews,/news/stocks/lynparza-gets-additional-and-broad-approval-in-u-s-for-ovarian-cancer-1002267266,positive,0.9372265934944153
8/18/2017 7:11:16 AM,"FDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits Goal ",RTTNews,/news/stocks/fda-nod-for-pfe-new-use-for-azn-s-ovarian-cancer-drug-elgx-s-leopard-hits-goal-1002267418,positive,0.6080707907676697
8/18/2017 7:32:03 AM,"UK Stocks-Factors to watch on Aug 18 (UKX, AZN, MRK, CVX, GLEN, BARC, DBK, LLOY, RBS, KLN, CPP)",Reuters,http://www.businessinsider.com/r-uk-stocks-factors-to-watch-on-aug-18-2017-8,neutral,0.9413446187973022
8/18/2017 10:52:04 AM,"UPDATE 1-UK Stocks-Factors to watch on Aug 18 (UKX, AZN, CVX, GLEN, BARC, DBK, LLOY, RBS, MRK)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-aug-18-2017-8,neutral,0.940694272518158
8/22/2017 2:45:00 PM,Clinical and Regulatory Progress Boosting Biotech Sector,PR Newswire,/news/stocks/clinical-and-regulatory-progress-boosting-biotech-sector-1002275220,positive,0.9124936461448669
8/22/2017 2:45:00 PM,Clinical and Regulatory Progress Boosting Biotech Sector,PR Newswire,/news/stocks/clinical-and-regulatory-progress-boosting-biotech-sector-1002275229,positive,0.9124936461448669
8/25/2017 9:48:00 AM,European Commission Grants Approval for Mavenclad (Cladribine Tablets),PR Newswire,/news/stocks/european-commission-grants-approval-for-mavenclad-cladribine-tablets-1002284660,positive,0.8070929646492004
8/28/2017 3:07:03 PM,BRIEF-Merck to acquire Natrix Separations (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-to-acquire-natrix-separations-2017-8,neutral,0.9369291663169861
8/28/2017 4:02:03 PM,"AstraZeneca taps AI for drug discovery in deal with Berg (AZN, GSK, SAN, MRK)",Reuters,http://www.businessinsider.com/r-astrazeneca-taps-ai-for-drug-discovery-in-deal-with-berg-2017-8,positive,0.8565165400505066
8/28/2017 8:02:03 PM,Drugmakers tackle 'ick' factor with fecal transplant therapies (MRK),Reuters,http://www.businessinsider.com/r-drugmakers-tackle-ick-factor-with-fecal-transplant-therapies-2017-8,neutral,0.8677529692649841
8/28/2017 11:12:03 PM,"UPDATE 1-Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers (BMY, 4568, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-daiichi-sankyo-to-test-opdivo-combo-for-cancers-2017-8,neutral,0.8390170931816101
8/29/2017 8:46:12 AM,Merck Reports Results Of REVEAL Outcomes Study Of Anacetrapib - Quick Facts ,RTTNews,/news/stocks/merck-reports-results-of-reveal-outcomes-study-of-anacetrapib-quick-facts-1002290263,neutral,0.8142402172088623
8/29/2017 9:07:04 AM,"Merck cholesterol drug cuts heart risk by 9 pct in study (MRK, PFE, LLY)",Reuters,http://www.businessinsider.com/r-merck-cholesterol-drug-cuts-heart-risk-by-9-pct-in-study-2017-8,positive,0.8817371129989624
8/29/2017 9:07:04 AM,BRIEF-Merck announces results of REVEAL outcomes study of Anacetrapib (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-2017-8,neutral,0.6282193660736084
8/29/2017 2:23:52 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1002291346,neutral,0.6874357461929321
8/31/2017 2:52:03 PM,"AstraZeneca aims to offset drug setback at big cancer congress (AZN, LLY, PFE, BMY, MRK, INCY)",Reuters,http://www.businessinsider.com/r-astrazeneca-aims-to-offset-drug-setback-at-big-cancer-congress-2017-8,positive,0.9372472763061523
8/31/2017 5:22:03 PM,BRIEF-U.S. FDA alerts about 2 clinical trials on hold evaluating Keytruda with multiple myeloma (MRK),Reuters,http://www.businessinsider.com/r-brief-us-fda-alerts-about-2-clinical-trials-on-hold-evaluating-keytruda-with-multiple-myeloma-2017-8,negative,0.699734091758728
8/31/2017 5:52:03 PM,BRIEF-CDER's Director Woodcock issues statement on investigational use of Keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-cders-director-woodcock-issues-statement-on-investigational-use-of-keytruda-2017-8,neutral,0.9329261779785156
9/5/2017 9:47:03 AM,"European shares up, led by financials, health stocks; Aveva gains on Schneider deal (UKX, MRK, AVV, SU, GXI)",Reuters,http://www.businessinsider.com/r-european-shares-up-led-by-financials-health-stocks-aveva-gains-on-schneider-deal-2017-9,positive,0.9495686292648315
9/5/2017 11:32:03 AM,"UPDATE 1-European shares up, led by health stocks, commodities; Aveva leaps (UKX, MRK, AVV, SU, GXI, ISAT)",Reuters,http://www.businessinsider.com/r-update-1-european-shares-up-led-by-health-stocks-commodities-aveva-leaps-2017-9,positive,0.947525143623352
9/5/2017 12:00:00 PM,Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment,PR Newswire,/news/stocks/mavenclad-cladribine-tablets-demonstrates-sustained-disease-control-over-4-years-with-maximum-of-only-20-days-oral-treatment-1002307918,positive,0.8600994348526001
9/5/2017 12:46:34 PM,Merck Says European Commission Approves KEYTRUDA ,RTTNews,/news/stocks/merck-says-european-commission-approves-keytruda-1002308115,neutral,0.6871334910392761
9/5/2017 1:12:05 PM,BRIEF-European Commission approves Merck’S KEYTRUDA (pembrolizumab) (MRK),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-mercks-keytruda-pembrolizumab-2017-9,positive,0.7635629773139954
9/6/2017 12:44:39 PM,Merck To Buy Rigontec ,RTTNews,/news/stocks/merck-to-buy-rigontec-1002344704,neutral,0.9349972009658813
9/6/2017 4:07:03 PM,"Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln (MRK, BMY)",Reuters,http://www.businessinsider.com/r-merck--co-snaps-up-3-yr-old-german-biotech-firm-for-up-to-550-mln-2017-9,positive,0.8173829317092896
9/7/2017 12:22:13 AM,"Bristol-Myers says FDA places partial hold on Opdivo myeloma trials (BMY, MRK, CELG)",Reuters,http://www.businessinsider.com/r-bristol-myers-says-fda-places-partial-hold-on-opdivo-myeloma-trials-2017-9,negative,0.8835951089859009
9/7/2017 1:57:06 PM,"UPDATE 1-Bristol-Myers kidney cancer drug meets main goal of late-stage trial (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-kidney-cancer-drug-meets-main-goal-of-late-stage-trial-2017-9,positive,0.6243601441383362
9/7/2017 2:32:03 PM,"UPDATE 1-FDA puts Celgene's multiple cancer trials on hold (CELG, AZN, MRK)",Reuters,http://www.businessinsider.com/r-update-1-fda-puts-celgenes-multiple-cancer-trials-on-hold-2017-9,neutral,0.5321596264839172
9/8/2017 12:07:09 AM,"Roche blood test could help 'personalize' cancer immunotherapy (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-blood-test-could-help-personalize-cancer-immunotherapy-2017-9,neutral,0.7294071912765503
9/8/2017 12:07:10 AM,"Merck's immunotherapy, chemo mix shows extended lung cancer gains (MRK, BMY, AZN)",Reuters,http://www.businessinsider.com/r-mercks-immunotherapy-chemo-mix-shows-extended-lung-cancer-gains-2017-9,positive,0.8237943649291992
9/8/2017 9:02:03 AM,"UPDATE 1-Roche blood test could help 'personalise' cancer immunotherapy (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-blood-test-could-help-personalise-cancer-immunotherapy-2017-9,positive,0.5246525406837463
9/8/2017 2:07:32 PM,Company Spotlight: Immune Design ,RTTNews,/news/stocks/company-spotlight-immune-design-1002353501,neutral,0.9194058179855347
9/8/2017 2:15:37 PM,"Merck Presents Data From Three Cohorts Of Registrational, Phase 2 KEYNOTE-059 ",RTTNews,/news/stocks/merck-presents-data-from-three-cohorts-of-registrational-phase-2-keynote-059-1002353531,neutral,0.9212758541107178
9/8/2017 6:32:09 PM,"JPMorgan CEO Jamie Dimon is starting to look like corporate America's 'shadow president' (JPM, GS, AAPL, MRK)",Reuters,http://www.businessinsider.com/r-washington-jamie-dimon-is-shadow-president-of-corporate-america-2017-9,neutral,0.9055309891700745
9/8/2017 8:07:04 PM,"Germany's Merck hires JP Morgan to advise on consumer health review (MRK, JPM)",Reuters,http://www.businessinsider.com/r-germanys-merck-hires-jp-morgan-to-advise-on-consumer-health-review-2017-9,neutral,0.7369130253791809
9/8/2017 10:37:04 PM,"UPDATE 1-Germany's Merck hires JP Morgan to sell consumer health (MRK, JPM, PG, JNJ, GSK, 4502, ABT, PFE, BAYN, MON, SAN, GIS, RB.)",Reuters,http://www.businessinsider.com/r-update-1-germanys-merck-hires-jp-morgan-to-sell-consumer-health-2017-9,neutral,0.8491860628128052
9/9/2017 12:07:13 AM,"AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9,positive,0.93507319688797
9/9/2017 11:02:03 AM,"UPDATE 1-AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9,positive,0.9298104047775269
9/10/2017 5:57:04 PM,"Bristol kidney cancer drug cut death risk 37 pct in key patients (BMY, AZN, PFE, MRK)",Reuters,http://www.businessinsider.com/r-bristol-kidney-cancer-drug-cut-death-risk-37-pct-in-key-patients-2017-9,positive,0.9072887897491455
9/10/2017 7:02:03 PM,"UPDATE 1-Bristol's drug cocktail cuts kidney cancer death risk 37 pct (BMY, AZN, PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristols-drug-cocktail-cuts-kidney-cancer-death-risk-37-pct-2017-9,positive,0.9252809286117554
9/10/2017 7:08:07 PM,Merck's KEYTRUDA Continues To Show Overall Survival Benefit Over Chemotherapy ,RTTNews,/news/stocks/merck-s-keytruda-continues-to-show-overall-survival-benefit-over-chemotherapy-1002356026,positive,0.9538966417312622
9/10/2017 9:00:00 PM,"Merck KGaA, Darmstadt, Germany, ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-grant-for-oncology-innovation-awards-recognize-recipients-for-pushing-boundaries-in-oncology-research-1002356046,neutral,0.6578487753868103
9/10/2017 9:00:00 PM,Merck ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research,PR Newswire,/news/stocks/merck-grant-for-oncology-innovation-awards-recognize-recipients-for-pushing-boundaries-in-oncology-research-1002356045,neutral,0.5221688151359558
9/11/2017 8:17:03 AM,"RPT-UPDATE 1-AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-rpt-update-1-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9,positive,0.9237903952598572
9/11/2017 9:58:59 AM,Germany's Merck hires JP Morgan to sell consumer health,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/WMQJAUTJEYE/germanys-merck-hires-jp-morgan-to-sell-consumer-health-idINKCN1BM0S1,neutral,0.8988683819770813
9/11/2017 10:07:03 AM,"RPT-UPDATE 1-Germany's Merck hires JP Morgan to sell consumer health (MRK, JPM, PG, JNJ, GSK, 4502, ABT, PFE, BAYN, MON, SAN, GIS, RB.)",Reuters,http://www.businessinsider.com/r-rpt-update-1-germanys-merck-hires-jp-morgan-to-sell-consumer-health-2017-9,neutral,0.7386980652809143
9/11/2017 12:07:03 PM,"Cancer immunotherapy proves itself in earlier-stage disease (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-cancer-immunotherapy-proves-itself-in-earlier-stage-disease-2017-9,positive,0.8216857314109802
9/11/2017 12:12:08 PM,"Deals of the day-Mergers and acquisitions (6756, KKR, TEN, MRK, JPM, 023530, INDUSINDBK)",Reuters,http://www.businessinsider.com/r-deals-of-the-day-mergers-and-acquisitions-2017-9,neutral,0.9438509941101074
9/11/2017 12:57:00 PM,"Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-set-to-join-forces-with-project-data-sphere-to-pioneer-global-oncology-big-data-alliance-1002357677,positive,0.6031168103218079
9/11/2017 3:16:40 PM,Merck Presents KEYTRUDA Phase 3 Study Findings - Quick Facts ,RTTNews,/news/stocks/merck-presents-keytruda-phase-3-study-findings-quick-facts-1002358364,neutral,0.911727249622345
9/13/2017 8:27:16 PM,"FDA panel unanimously votes to recommend GSK shingles vaccine (GSK, MRK)",Reuters,http://www.businessinsider.com/r-fda-panel-unanimously-votes-to-recommend-gsk-shingles-vaccine-2017-9,neutral,0.8106668591499329
9/13/2017 8:52:15 PM,"A new shingles vaccine just got one step closer to approval (GSK, MRK)",Reuters,http://www.businessinsider.com/r-update-1-fda-panel-unanimously-votes-to-recommend-gsk-shingles-vaccine-2017-9,positive,0.7358080148696899
9/18/2017 8:15:00 AM,"Merck KGaA, Darmstadt, Germany Announces Recipients of the Grant for Growth Innovation 2017",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-announces-recipients-of-the-grant-for-growth-innovation-2017-1002377240,positive,0.7644923329353333
9/18/2017 8:15:00 AM,Merck Announces Recipients of the Grant for Growth Innovation 2017,PR Newswire,/news/stocks/merck-announces-recipients-of-the-grant-for-growth-innovation-2017-1002377239,neutral,0.793757438659668
9/19/2017 6:12:04 PM,"BRIEF-Transgene says first patient treated in a phase 1B/2 trial of TG4001 (TNG, MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-transgene-says-first-patient-treated-in-a-phase-1b-2-trial-of-tg4001-2017-9,neutral,0.6934179663658142
9/22/2017 9:52:18 PM,BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-fda-approves-keytrudapembrolizumab-for-previously-treated-patients-2017-9,positive,0.8646695613861084
9/25/2017 4:36:05 AM,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes ",RTTNews,/news/stocks/opdivo-keytruda-back-in-the-news-fda-snubs-agn-ears-catches-eyes-1002503240,neutral,0.6159444451332092
9/25/2017 1:52:03 PM,"BRIEF-Merck KGAA appoints Paolo Carli head of Middle East, Africa & Turkey for healthcare business‍​ (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-appoints-paolo-carli-head-of-middle-east-africa--turkey-for-healthcare-business-2017-9,neutral,0.9253644347190857
9/26/2017 7:37:03 AM,"German stocks - Factors to watch on September 26 (LHA, MUV2, HNR1, SIE, ALO, TKA, TATASTEEL, VOW3, NAV, PGN, MRK)",Reuters,http://www.businessinsider.com/r-german-stocks---factors-to-watch-on-september-26-2017-9,neutral,0.9387876987457275
9/26/2017 12:02:03 PM,"UPDATE 1-European shares flat after Wall Street tech selloff, Korean tensions (GLEN, RIO, MRK, SIE, ALO, LHA, EZJ, CBG, UKX, RIO)",Reuters,http://www.businessinsider.com/r-update-1-european-shares-flat-after-wall-street-tech-selloff-korean-tensions-2017-9,negative,0.9608035087585449
9/27/2017 10:17:03 AM,"BRIEF-Bavencio approved for Merkel Cell Carcinoma in Japan (MRK, PFE)",Reuters,http://www.businessinsider.com/r-brief-bavencio-approved-for-merkel-cell-carcinoma-in-japan-2017-9,positive,0.7418619990348816
9/29/2017 1:12:06 PM,BRIEF-Merck discontinues MK-3682B and MK-3682C development programs (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-discontinues-mk-3682b-and-mk-3682c-development-programs-2017-9,neutral,0.49492147564888
9/29/2017 1:15:06 PM,"Merck Discontinues MK-3682B, MK-3682C Development Programs For HCV Infection ",RTTNews,/news/stocks/merck-discontinues-mk-3682b-mk-3682c-development-programs-for-hcv-infection-1002842058,neutral,0.5822253823280334
9/29/2017 2:07:03 PM,"Merck to stop development of hepatitis C treatments (MRK, JNJ, GILD)",Reuters,http://www.businessinsider.com/r-merck-to-stop-development-of-hepatitis-c-treatments-2017-9,negative,0.5342975854873657
9/29/2017 6:22:03 PM,"US invests $170 million in late-stage Ebola vaccines, drugs (MRK, JNJ, REGN)",Reuters,http://www.businessinsider.com/r-us-invests-170-million-in-late-stage-ebola-vaccines-drugs-2017-9,neutral,0.8104274272918701
9/29/2017 6:40:16 PM,Merck Moves Lower After Stopping Development Of Hepatitis C Treatments ,RTTNews,/news/stocks/merck-moves-lower-after-stopping-development-of-hepatitis-c-treatments-1002868864,negative,0.9580401182174683
10/5/2017 3:22:03 PM,Roche bladder cancer drug struggles as medics focus on survival (MRK),Reuters,http://www.businessinsider.com/r-roche-bladder-cancer-drug-struggles-as-medics-focus-on-survival-2017-10,negative,0.6148027777671814
10/8/2017 3:03:03 PM,"It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)",Business Insider,http://www.businessinsider.com/what-alzheimers-disease-drugs-are-in-development-next-trial-2017-10,neutral,0.9026668071746826
10/10/2017 1:27:04 PM,"UPDATE 1-Pfizer mulls options for consumer healthcare business (PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-pfizer-mulls-options-for-consumer-healthcare-business-2017-10,neutral,0.897408664226532
10/10/2017 2:32:04 PM,BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-kalvista-pharmaceuticals-announces-collaboration-with-merck-2017-10,neutral,0.8663130402565002
10/10/2017 2:52:58 PM,Merck Acquires 9.9% Stake In KalVista ,RTTNews,/news/stocks/merck-acquires-9-9-stake-in-kalvista-1003662734,neutral,0.9234268665313721
10/10/2017 2:57:07 PM,"BRIEF-Oncosec Medical Inc says has ‍initiated phase 2b registration directed trial, pisces/keynote-695 (MRK)",Reuters,http://www.businessinsider.com/r-brief-oncosec-medical-inc-says-has-initiated-phase-2b-registration-directed-trial-pisces-keynote-695-2017-10,neutral,0.5278922319412231
10/11/2017 7:45:00 PM,Myant commits $100M to the Advanced Manufacturing Supercluster,PR Newswire,/news/stocks/myant-commits-$100m-to-the-advanced-manufacturing-supercluster-476638,positive,0.5556097626686096
10/11/2017 11:12:17 PM,BRIEF-Merck provides update on Anacetrapib development program (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-provides-update-on-anacetrapib-development-program-2017-10,neutral,0.9305713772773743
10/11/2017 11:17:08 PM,"Merck says will not seek approval of cholesterol treatment (MRK, PFE, LLY)",Reuters,http://www.businessinsider.com/r-merck-says-will-not-seek-approval-of-cholesterol-treatment-2017-10,neutral,0.9214851260185242
10/12/2017 7:15:08 AM,"ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus ",RTTNews,/news/stocks/ardx-surges-after-hours-mbvx-abuzz-trvn-keeps-its-focus-1003934591,positive,0.8285031914710999
10/12/2017 2:57:11 PM,"'Double whammy' for Roche as manufacturing patent losses loom (BIIB, MYL, MRK, SAN, GSK)",Reuters,http://www.businessinsider.com/r-double-whammy-for-roche-as-manufacturing-patent-losses-loom-2017-10,negative,0.9509940147399902
10/12/2017 4:12:03 PM,"NIH partners 11 drugmakers to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-nih-partners-11-drugmakers-to-accelerate-cancer-therapy-research-2017-10,positive,0.7635126113891602
10/12/2017 6:27:06 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10,positive,0.84027498960495
10/12/2017 10:12:15 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10,positive,0.84027498960495
10/16/2017 3:32:04 PM,"Pharma and medtech industries prepare for hard Brexit (MRK, AZN)",Reuters,http://www.businessinsider.com/r-pharma-and-medtech-industries-prepare-for-hard-brexit-2017-10,neutral,0.8919806480407715
10/16/2017 4:52:04 PM,BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-aeglea-biotherapeutics-announces-clinical-collaboration-with-merck-2017-10,neutral,0.5054479837417603
10/18/2017 8:42:11 AM,"AstraZeneca, Merck Announce FDA Priority Review For Lynparza SNDA ",RTTNews,/news/stocks/astrazeneca-merck-announce-fda-priority-review-for-lynparza-snda-1004734033,neutral,0.5791898369789124
10/18/2017 8:57:03 AM,"Astra and Merck win speedy review for Lynparza in breast cancer (AZN, MRK)",Reuters,http://www.businessinsider.com/r-astra-and-merck-win-speedy-review-for-lynparza-in-breast-cancer-2017-10,positive,0.8666606545448303
10/18/2017 11:32:03 AM,"UPDATE 2-Reckitt to restructure after sales growth evaporates (RB., PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-2-reckitt-to-restructure-after-sales-growth-evaporates-2017-10,neutral,0.5951348543167114
10/18/2017 1:16:29 PM,Merck Presents Updated Overall Survival Findings From Phase 3 KEYNOTE-024 Trial ,RTTNews,/news/stocks/merck-presents-updated-overall-survival-findings-from-phase-3-keynote-024-trial-1004758469,neutral,0.9166030287742615
10/18/2017 1:17:03 PM,BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-updated-overall-survival-findings-from-phase-3-trial-of-keytruda-2017-10,neutral,0.8603488802909851
10/18/2017 3:02:03 PM,BRIEF-U.S. FDA accepts regulatory submission for lynparza (MRK),Reuters,http://www.businessinsider.com/r-brief-us-fda-accepts-regulatory-submission-for-lynparza-2017-10,neutral,0.80370032787323
10/19/2017 8:27:15 AM,UPDATE 1-Roche Q3 sales beat forecasts as Ocrevus shines (MRK),Reuters,http://www.businessinsider.com/r-update-1-roche-q3-sales-beat-forecasts-as-ocrevus-shines-2017-10,positive,0.940942108631134
10/19/2017 7:32:03 PM,"Merck cyber attack may cost insurers $275 mln -Verisk's PCS (MRK, VRSK)",Reuters,http://www.businessinsider.com/r-merck-cyber-attack-may-cost-insurers-275-mln--verisks-pcs-2017-10,negative,0.954510509967804
10/20/2017 6:12:03 PM,"Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care (MRK, LLY)",Reuters,http://www.businessinsider.com/r-merck-to-cut-1800-us-sales-jobs-add-960-jobs-in-chronic-care-2017-10,negative,0.9515475034713745
10/20/2017 6:42:11 PM,"UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care (MRK, LLY)",Reuters,http://www.businessinsider.com/r-update-1-merck-to-cut-1800-us-sales-jobs-add-960-in-chronic-care-2017-10,negative,0.9298647046089172
10/20/2017 6:45:12 PM,"Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/odWIeehKzFY/merck-to-cut-1800-u-s-sales-jobs-add-960-in-chronic-care-idUSKBN1CP26S,negative,0.9545606970787048
10/21/2017 12:52:14 AM,"GlaxoSmithKline adult shingles vaccine wins U.S. approval (GSK, MRK, AGEN)",Reuters,http://www.businessinsider.com/r-glaxosmithkline-adult-shingles-vaccine-wins-us-approval-2017-10,positive,0.9319995045661926
10/23/2017 7:49:33 AM,"DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS ",RTTNews,/news/stocks/dbvt-disappoints-gsk-gets-greenlight-aimt-catches-eyes-fda-snubs-atrs-1005302979,negative,0.37625858187675476
10/23/2017 8:30:39 AM,"Astrazeneca, Merck Advance Lynparza In Japan With Second Regulatory Submission ",RTTNews,/news/stocks/astrazeneca-merck-advance-lynparza-in-japan-with-second-regulatory-submission-1005305640,neutral,0.8422655463218689
10/23/2017 9:07:15 AM,"BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan (AZN, MRK)",Reuters,http://www.businessinsider.com/r-brief-astrazeneca-and-merck-submit-application-for-breast-cancer-drug-in-japan-2017-10,neutral,0.6657655239105225
10/23/2017 11:07:17 AM,"UPDATE 1-GSK wins U.S. shingles vaccine approval, UK nod for gene therapy (GSK, MRK, AGEN)",Reuters,http://www.businessinsider.com/r-update-1-gsk-wins-us-shingles-vaccine-approval-uk-nod-for-gene-therapy-2017-10,positive,0.8868151307106018
10/23/2017 1:07:07 PM,BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission (MRK),Reuters,http://www.businessinsider.com/r-brief-astrazeneca-and-merck-advance-lynparza-in-japan-with-a-second-regulatory-submission-2017-10,positive,0.8336249589920044
10/24/2017 2:07:18 PM,"AbbVie bets on Alzheimer's immunotherapy with big biotech deal (MRK, AMGN)",Reuters,http://www.businessinsider.com/r-abbvie-bets-on-alzheimers-immunotherapy-with-big-biotech-deal-2017-10,positive,0.7095713019371033
10/25/2017 12:22:00 AM,TSX Venture Exchange Daily Bulletins,PR Newswire,/news/stocks/tsx-venture-exchange-daily-bulletins-548556,neutral,0.9154568910598755
10/25/2017 2:37:12 PM,"UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (BAX, MRK, JNJ, PFE, GSK, MDT, DEPO, AMGN, BMY, LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-baxter-expects-70-mln-hit-to-4th-qtr-sales-from-hurricane-maria-2017-10,positive,0.8058122396469116
10/25/2017 5:12:03 PM,"BRIEF-ACIP votes 8-7 to prefer GSK's shingles vaccine Shingrix over Merck's Zostavax (GSK, MRK)",Reuters,http://www.businessinsider.com/r-brief-acip-votes-8-7-to-prefer-gsks-shingles-vaccine-shingrix-over-mercks-zostavax-2017-10,positive,0.5257693529129028
10/25/2017 6:07:03 PM,"U.S. committee recommends GSK shingles vaccine over Merck rival (GSK, MRK, AGEN)",Reuters,http://www.businessinsider.com/r-us-committee-recommends-gsk-shingles-vaccine-over-merck-rival-2017-10,neutral,0.7570796012878418
10/25/2017 7:27:10 PM,"UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival (GSK, MRK, AGEN)",Reuters,http://www.businessinsider.com/r-update-1-us-committee-recommends-gsk-shingles-vaccine-over-merck-rival-2017-10,neutral,0.6891895532608032
10/26/2017 1:42:10 AM,FDA approves intravenous version of Tesaro drug for chemotherapy nausea (MRK),Reuters,http://www.businessinsider.com/r-fda-approves-intravenous-version-of-tesaro-drug-for-chemotherapy-nausea-2017-10,positive,0.7307343482971191
10/26/2017 7:02:12 AM,"High cholesterol levels among U.S. adults declining -CDC report (PFE, AZN, MYL, MRK, TEVA)",Reuters,http://www.businessinsider.com/r-high-cholesterol-levels-among-us-adults-declining--cdc-report-2017-10,negative,0.9228916764259338
10/26/2017 9:02:17 AM,"UPDATE 1-UK Stocks-Factors to watch on Oct 26 (UKX, BARC, DEB, INCH, GSK, MRK, PFE, RB., ABX, AAL, BDEV, ITV)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-oct-26-2017-10,neutral,0.9399282932281494
10/26/2017 5:27:03 PM,"UPDATE 1-Bristol-Myers sales in line, but profit margins worsen (BMY, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-sales-in-line-but-profit-margins-worsen-2017-10,negative,0.9019613862037659
10/27/2017 12:48:54 PM,Merck & Co Inc. Reveals 2% Rise In Q3 Earnings,RTTNews,/news/stocks/merck-co-inc-reveals-2-rise-in-q3-earnings-1005823551,positive,0.9406784176826477
10/27/2017 12:57:16 PM,"Merck posts quarterly loss vs. year-ago profit (MRK, AZN)",Reuters,http://www.businessinsider.com/r-merck-posts-quarterly-loss-vs-year-ago-profit-2017-10,negative,0.9728400111198425
10/27/2017 1:22:14 PM,"UPDATE 1-Merck tops profit estimates on Keytruda sales (MRK, AZN)",Reuters,http://www.businessinsider.com/r-update-1-merck-tops-profit-estimates-on-keytruda-sales-2017-10,positive,0.914845883846283
10/27/2017 1:39:16 PM,"Merck Slips To Loss In Q3, Adj. EPS, Sales Miss View; Lifts FY17 Forecast ",RTTNews,/news/stocks/merck-slips-to-loss-in-q3-adj-eps-sales-miss-view-lifts-fy17-forecast-1005828130,negative,0.9647516012191772
10/27/2017 3:07:16 PM,BRIEF-Merck says cyber attack to impact fourth quarter results (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-cyber-attack-to-impact-fourth-quarter-results-2017-10,negative,0.9430475831031799
10/27/2017 4:07:03 PM,"US STOCKS-Microsoft, Amazon push S&P, Nasdaq higher (MSFT, AMZN, CVX, XOM, MRK, MAT, EXPE)",Reuters,http://www.businessinsider.com/r-us-stocks-microsoft-amazon-push-sp-nasdaq-higher-2017-10,positive,0.9212290048599243
10/27/2017 5:37:08 PM,"US STOCKS-Solid tech earnings, Apple lift Nasdaq higher (MSFT, AMZN, AAPL, CVX, MRK, MAT, EXPE, CVS, RAD)",Reuters,http://www.businessinsider.com/r-us-stocks-solid-tech-earnings-apple-lift-nasdaq-higher-2017-10,positive,0.9498744010925293
10/27/2017 6:52:14 PM,"US STOCKS-Strong tech earnings, Apple lift Nasdaq higher (AMZN, MSFT, AAPL, CVX, MRK, MAT, EXPE, CVS, RAD)",Reuters,http://www.businessinsider.com/r-us-stocks-strong-tech-earnings-apple-lift-nasdaq-higher-2017-10,positive,0.9485208988189697
10/27/2017 8:32:11 PM,"US STOCKS-Tech, Amazon earnings power Wall St higher (MSFT, AAPL, INTC, AMZN, CVX, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-amazon-earnings-power-wall-st-higher-2017-10,positive,0.9291309714317322
10/27/2017 10:22:13 PM,"US STOCKS-Wall St powered higher by tech, Amazon results (MSFT, AAPL, INTC, AMZN, CVX, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-powered-higher-by-tech-amazon-results-2017-10,positive,0.9379913806915283
10/27/2017 10:37:06 PM,BRIEF-Merck withdraws European application for Keytruda (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-withdraws-european-application-for-keytruda-2017-10,negative,0.7144824862480164
10/30/2017 12:22:25 PM,"US STOCKS-Futures slightly lower as Fed chair decision looms (AAPL, GM, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-slightly-lower-as-fed-chair-decision-looms-2017-10,negative,0.9546384811401367
10/30/2017 2:02:07 PM,"US STOCKS-Wall Street set to open lower amid Russia probe, Fed pick (AAPL, GM, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-set-to-open-lower-amid-russia-probe-fed-pick-2017-10,negative,0.9201405644416809
10/30/2017 3:07:14 PM,"US STOCKS-Wall Street opens lower amid Russia probe, Fed pick (AAPL, GM, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-opens-lower-amid-russia-probe-fed-pick-2017-10,negative,0.9410791993141174
10/30/2017 4:16:35 PM,Cancer-drug setback sends Merck shares down again,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/csDisvSc8Cg/cancer-drug-setback-sends-merck-shares-down-again-idUSKBN1CZ1WJ,negative,0.9690949320793152
10/30/2017 4:37:03 PM,"US STOCKS-Tech stocks rise; broader gains capped by Russia probe (AAPL, MRK, GM)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-stocks-rise-broader-gains-capped-by-russia-probe-2017-10,positive,0.9071810841560364
10/30/2017 6:02:06 PM,"US STOCKS-Wall St extends loss after report of gradual tax cuts (AAPL, MRK, GM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-extends-loss-after-report-of-gradual-tax-cuts-2017-10,negative,0.9165903925895691
10/30/2017 7:41:17 PM,"Wall St. slips amid Merck losses, tax talk",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/PeaylafWg6Y/wall-st-slips-amid-merck-losses-tax-talk-idUSKBN1CZ181,negative,0.9022650122642517
10/30/2017 10:35:46 PM,"Wall Street slips as Merck drops, tax talk rattles",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/dhGd_KY-8jg/wall-street-slips-as-merck-drops-tax-talk-rattles-idUSKBN1CZ181,negative,0.9528123736381531
10/31/2017 1:47:14 AM,"GLOBAL MARKETS-Asia sluggish after Wall St slips, dollar sags on White House woes (, MRK)",Reuters,http://www.businessinsider.com/r-global-markets-asia-sluggish-after-wall-st-slips-dollar-sags-on-white-house-woes-2017-10,negative,0.9359925985336304
10/31/2017 9:37:06 AM,"AstraZeneca plans new pivotal lung cancer trial with Incyte (AZN, INCY, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-plans-new-pivotal-lung-cancer-trial-with-incyte-2017-10,neutral,0.7332110404968262
11/2/2017 5:49:00 PM,"For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) !",PR Newswire,/news/stocks/for-the-first-time-ever-there-will-be-a-full-week-dedicated-to-plasminogen-deficiency-plgd-!-453779,neutral,0.8221766352653503
11/6/2017 3:07:04 PM,BRIEF-Merck announces any and all tender offers (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-any-and-all-tender-offers-2017-11,neutral,0.9469724893569946
11/7/2017 2:06:00 AM,Sphere Announces Unitholder Meetings,PR Newswire,/news/stocks/sphere-announces-unitholder-meetings-536221,neutral,0.9377585053443909
11/7/2017 1:52:11 PM,New Drugs Approved In October ,RTTNews,/news/stocks/new-drugs-approved-in-october-1007155027,neutral,0.569122314453125
11/9/2017 12:57:49 PM,Merck Gets FDA Approval Of Prevymis For Prevention Of CMV Infection ,RTTNews,/news/stocks/merck-gets-fda-approval-of-prevymis-for-prevention-of-cmv-infection-1007416324,positive,0.8199856877326965
11/9/2017 1:12:04 PM,BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-receives-fda-approval-of-prevymis-for-prevention-of-cmv-infection-in-allogeneic-stem-cell-transplant-patients-2017-11,positive,0.9340581297874451
11/9/2017 2:17:04 PM,UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant (MRK),Reuters,http://www.businessinsider.com/r-update-1-fda-oks-merck-drug-that-prevents-infection-post-stem-cell-transplant-2017-11,positive,0.7577083706855774
11/13/2017 2:12:04 PM,Merck Gets Positive CHMP Opinion For Prevymis In EU - Quick Facts ,RTTNews,/news/stocks/merck-gets-positive-chmp-opinion-for-prevymis-in-eu-quick-facts-1007872517,positive,0.9444605708122253
11/13/2017 2:32:03 PM,"BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting (ARRY, MRK)",Reuters,http://www.businessinsider.com/r-brief-array-biopharma-reports-initial-results-from-novel-immunotherapy-combination-at-sitc-annual-meeting-2017-11,neutral,0.8394595980644226
11/13/2017 2:37:03 PM,"BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt (OREX, MRK)",Reuters,http://www.businessinsider.com/r-brief-orexigen-therapeutics-announces-commercialization-and-distributorship-agreement-with-merck-kgaa-darmstadt-2017-11,positive,0.661012589931488
11/13/2017 8:27:07 PM,BRIEF-Merck announces pricing of any and all tender offers (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-pricing-of-any-and-all-tender-offers-2017-11,neutral,0.9390595555305481
11/13/2017 11:02:03 PM,"New blood pressure range means nearly half of Americans have hypertension (PFE, MRK)",Reuters,http://www.businessinsider.com/r-new-blood-pressure-range-means-nearly-half-of-americans-have-hypertension-2017-11,positive,0.5940026044845581
11/14/2017 1:12:03 AM,"UPDATE 1-New blood pressure range means half of Americans have hypertension (PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-new-blood-pressure-range-means-half-of-americans-have-hypertension-2017-11,neutral,0.607641339302063
11/14/2017 1:12:03 PM,BRIEF-Merck reports final results of any and all tender offers (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-reports-final-results-of-any-and-all-tender-offers-2017-11,neutral,0.9457915425300598
11/14/2017 4:12:03 PM,"UPDATE 3-Bayer agrees cancer drug deal with Loxo worth up to $1.55 bln (BAYN, MON, MRK)",Reuters,http://www.businessinsider.com/r-update-3-bayer-agrees-cancer-drug-deal-with-loxo-worth-up-to-155-bln-2017-11,positive,0.7828578948974609
11/15/2017 10:27:03 AM,"UPDATE 1-Bayer taps Nestle exec to stem eroding consumer care sales (BAYN, MRK, AMZN)",Reuters,http://www.businessinsider.com/r-update-1-bayer-taps-nestle-exec-to-stem-eroding-consumer-care-sales-2017-11,positive,0.9393077492713928
11/20/2017 7:22:03 AM,Roche says Tecentriq combination cuts lung cancer risk (MRK),Reuters,http://www.businessinsider.com/r-roche-says-tecentriq-combination-cuts-lung-cancer-risk-2017-11,positive,0.9334864616394043
11/20/2017 8:17:03 AM,"UPDATE 1-Roche says Tecentriq combination cuts lung cancer risk (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-says-tecentriq-combination-cuts-lung-cancer-risk-2017-11,positive,0.9479861259460449
11/20/2017 3:22:03 PM,"Roche win boosts case for adding chemo to cancer immunotherapy (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-roche-win-boosts-case-for-adding-chemo-to-cancer-immunotherapy-2017-11,positive,0.8871215581893921
11/20/2017 4:12:05 PM,"US STOCKS-Tech stocks help Wall Street tick higher (CSCO, CAVM, MRVL, GM, WMT, VZ, MRK)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-stocks-help-wall-street-tick-higher-2017-11,positive,0.9173730611801147
11/20/2017 5:37:03 PM,"US STOCKS-Tech stocks help Wall Street higher (VZ, CSCO, IBM, CAVM, MRVL, MRK, BMY, WMT)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-stocks-help-wall-street-higher-2017-11,positive,0.9138022661209106
11/20/2017 7:02:03 PM,"US STOCKS-Industrials, techs lift Wall St, health stocks limit gains (VZ, CAVM, MRVL, MRK, BMY, WMT)",Reuters,http://www.businessinsider.com/r-us-stocks-industrials-techs-lift-wall-st-health-stocks-limit-gains-2017-11,positive,0.8869584202766418
11/20/2017 9:47:03 PM,"US STOCKS-Telecoms rise, buoy Wall St as quiet week kicks off (VZ, CAVM, MRVL, TWX, T, MRK, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-telecoms-rise-buoy-wall-st-as-quiet-week-kicks-off-2017-11,positive,0.9105929136276245
11/20/2017 10:27:09 PM,"US STOCKS-Wall St ticks up, lifted by Verizon, chipmakers (VZ, CAVM, MRVL, TWX, T, MRK, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ticks-up-lifted-by-verizon-chipmakers-2017-11,positive,0.9360113739967346
11/27/2017 1:02:03 AM,"UK launches plan for industry as Brexit looms, wins Merck investment (MRK)",Reuters,http://www.businessinsider.com/r-uk-launches-plan-for-industry-as-brexit-looms-wins-merck-investment-2017-11,positive,0.7602918148040771
11/27/2017 11:12:04 AM,"UPDATE 1-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen (MRK, QGEN)",Reuters,http://www.businessinsider.com/r-update-1-as-brexit-looms-uk-pitches-new-industry-plan-wins-support-from-merck-qiagen-2017-11,positive,0.9374393820762634
11/27/2017 4:05:11 PM,"As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/4cn7BgowxPw/as-brexit-looms-uk-pitches-new-industry-plan-wins-support-from-merck-qiagen-idINKBN1DR12Y,positive,0.9172722697257996
11/28/2017 2:07:04 PM,"BRIEF-Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer (PFE, MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-and-pfizer-provide-update-on-phase-iii-javelin-gastric-300-study-in-patients-with-pre-treated-advanced-gastric-cancer-2017-11,neutral,0.8955103158950806
11/28/2017 2:17:03 PM,"Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial (MRK, PFE)",Reuters,http://www.businessinsider.com/r-merck-kgaa-pfizers-avelumab-misses-goal-in-gastric-cancer-trial-2017-11,neutral,0.7797214388847351
11/28/2017 3:42:03 PM,"UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial (MRK, PFE, MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-update-1-merck-kgaa-pfizers-immunotherapy-fails-in-gastric-cancer-trial-2017-11,negative,0.9397371411323547
11/28/2017 9:12:05 PM,BRIEF-Merck Announces $10 Billion Share Repurchase Authorization (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-announces-10-billion-share-repurchase-authorization-2017-11,neutral,0.5742548704147339
11/29/2017 8:05:41 AM,"EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark ",RTTNews,/news/stocks/ears-pinched-by-healos-data-eglt-does-it-again-javelin-gastric-300-misses-mark-1009889890,neutral,0.8387899994850159
11/29/2017 1:00:00 PM,CytoSorbents to Present at the LD Micro Main Event Investor Conference,PR Newswire,/news/stocks/cytosorbents-to-present-at-the-ld-micro-main-event-investor-conference-544705,neutral,0.9430203437805176
11/29/2017 1:09:07 PM,Biotech Stocks Facing FDA Decision In December ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-1009916247,neutral,0.5557605028152466
11/29/2017 5:12:04 PM,"UPDATE 1-Health secretary nominee Azar says drug pricing a top priority (LLY, SAN, MRK, NOVO )",Reuters,http://www.businessinsider.com/r-update-1-health-secretary-nominee-azar-says-drug-pricing-a-top-priority-2017-11,neutral,0.8332783579826355
11/30/2017 1:12:43 PM,"Merck To Present New And Updated Data On KEYTRUDA, Updated Data On LYNPARZA ",RTTNews,/news/stocks/merck-to-present-new-and-updated-data-on-keytruda-updated-data-on-lynparza-1010048501,neutral,0.8972931504249573
12/1/2017 12:37:03 AM,UPDATE 1-Foundation's cancer gene test gets U.S. FDA and Medicare nod (MRK),Reuters,http://www.businessinsider.com/r-update-1-foundations-cancer-gene-test-gets-us-fda-and-medicare-nod-2017-11,positive,0.6502330899238586
12/1/2017 7:57:08 PM,"Nestle, Stada prepare rival bids for Germany's Merck consumer health - sources (SAZ, MRK, PFE, SAN)",Reuters,http://www.businessinsider.com/r-nestle-stada-prepare-rival-bids-for-germanys-merck-consumer-health---sources-2017-12,neutral,0.8053815960884094
12/4/2017 9:32:04 AM,BRIEF-Merck's Mavenclad (Cladribine Tablets) Approved For Relapsing-Remitting Multiple Sclerosis In Canada (MRK),Reuters,http://www.businessinsider.com/r-brief-mercks-mavenclad-cladribine-tablets-approved-for-relapsing-remitting-multiple-sclerosis-in-canada-2017-12,positive,0.8426889777183533
12/5/2017 2:47:03 PM,"BRIEF-Merck KGAA, Darmstadt Announces FDA 510(K) Clearance Of Genea Biomedx’S Fertility Benchtop Incubator Geri (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-kgaa-darmstadt-announces-fda-510k-clearance-of-genea-biomedxs-fertility-benchtop-incubator-geri-2017-12,positive,0.8114143013954163
12/6/2017 7:37:03 PM,"UPDATE 1-Roche to seize leap-frog opportunity in lung cancer (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-to-seize-leap-frog-opportunity-in-lung-cancer-2017-12,positive,0.8292360901832581
12/7/2017 7:02:04 AM,"Roche drug cocktail doubles chance of holding lung cancer at bay (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-drug-cocktail-doubles-chance-of-holding-lung-cancer-at-bay-2017-12,neutral,0.7651481032371521
12/7/2017 8:27:03 AM,"UPDATE 1-Roche drug cocktail doubles chance of holding lung cancer at bay (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-drug-cocktail-doubles-chance-of-holding-lung-cancer-at-bay-2017-12,positive,0.8763294219970703
12/7/2017 1:32:04 PM,BRIEF-Neon Therapeutics To Collaborate with Merk on Clinical Trial (MRK),Reuters,http://www.businessinsider.com/r-brief-neon-therapeutics-to-collaborate-with-merk-on-clinical-trial-2017-12,neutral,0.5238541960716248
12/8/2017 4:48:10 AM,New Drugs Approved In November ,RTTNews,/news/stocks/new-drugs-approved-in-november-1010552162,neutral,0.6200429201126099
12/11/2017 8:02:03 AM,"UPDATE 1-Roche: Tecentriq cocktail slows kidney cancer progression (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-roche-tecentriq-cocktail-slows-kidney-cancer-progression-2017-12,neutral,0.699388325214386
12/11/2017 2:32:03 PM,BRIEF-Merck Signs Distribution Agreement With Avanti Polar Lipids (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-signs-distribution-agreement-with-avanti-polar-lipids-2017-12,positive,0.861309289932251
12/11/2017 11:37:03 PM,"BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement (MRK)",Reuters,http://www.businessinsider.com/r-brief-newlink-genetics-bps-and-merck-sharp--dohme-amended-license--collaboration-agreement-2017-12,neutral,0.8561983108520508
12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12,negative,0.7240302562713623
12/14/2017 6:42:06 PM,Perrigo preparing non-binding bid for Merck KgaA's consumer health unit -sources (MRK),Reuters,http://www.businessinsider.com/r-perrigo-preparing-non-binding-bid-for-merck-kgaas-consumer-health-unit--sources-2017-12,neutral,0.8808382153511047
12/14/2017 6:57:03 PM,"Germany's Merck to make new bid to enter U.S. MS pill market (MRK, PFE)",Reuters,http://www.businessinsider.com/r-germanys-merck-to-make-new-bid-to-enter-us-ms-pill-market-2017-12,positive,0.646277904510498
12/14/2017 7:19:00 PM,PREVYMIS™ (letermovir) Available in Canada in Late December 2017 for the Prophylaxis of Cytomegalovirus (CMV) Infection in Adult CMV-seropositive Recipients of an Allogeneic Hematopoietic Stem Cell...,PR Newswire,/news/stocks/prevymis-letermovir-available-in-canada-in-late-december-2017-for-the-prophylaxis-of-cytomegalovirus-cmv-infection-in-adult-cmv-seropositive-recipients-of-an-allogeneic-hematopoietic-stem-cell-1011425001,neutral,0.5459961295127869
12/14/2017 7:37:04 PM,"UPDATE 1-Germany's Merck to make new bid to enter U.S. MS pill market (MRK, BIIB, SAN, PFE)",Reuters,http://www.businessinsider.com/r-update-1-germanys-merck-to-make-new-bid-to-enter-us-ms-pill-market-2017-12,positive,0.8302605748176575
12/14/2017 7:37:04 PM,BRIEF-Merck Says Prevymis To Be Available In Canada By End Of December (MRK),Reuters,http://www.businessinsider.com/r-brief-merck-says-prevymis-to-be-available-in-canada-by-end-of-december-2017-12,neutral,0.9269506931304932
12/14/2017 8:32:03 PM,"UPDATE 1-Perrigo lines up bid for Merck's consumer health unit -sources (MRK, SAZ, MYL)",Reuters,http://www.businessinsider.com/r-update-1-perrigo-lines-up-bid-for-mercks-consumer-health-unit--sources-2017-12,positive,0.8747972846031189
12/14/2017 11:02:03 PM,"BRIEF-Merck Provides Update On Keynote-061, A Phase 3 Study Of Keytruda (Pembrolizumab) (MRK)",Reuters,http://www.businessinsider.com/r-brief-merck-provides-update-on-keynote-061-a-phase-3-study-of-keytruda-pembrolizumab-2017-12,neutral,0.8634315729141235
12/14/2017 11:07:03 PM,Merck's Keytruda fails pivotal gastric cancer trial (MRK),Reuters,http://www.businessinsider.com/r-mercks-keytruda-fails-pivotal-gastric-cancer-trial-2017-12,neutral,0.7299351096153259
12/14/2017 11:42:05 PM,UPDATE 1-Merck's Keytruda fails pivotal gastric cancer trial (MRK),Reuters,http://www.businessinsider.com/r-update-1-mercks-keytruda-fails-pivotal-gastric-cancer-trial-2017-12,neutral,0.8000968098640442
12/15/2017 11:22:17 AM,Germany's Merck in fresh bid to enter U.S. MS pill market,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/g3ekcQXXFd4/germanys-merck-in-fresh-bid-to-enter-u-s-ms-pill-market-idUSKBN1E82O1,positive,0.7934786677360535
12/19/2017 10:22:03 PM,"GRAPHIC-Banks, healthcare service firms among winners from U.S. tax bill (UHS, DGX, CAH, PFE, MRK, WFC, PNC, RF, MTB, CSCO, QCOM)",Reuters,http://www.businessinsider.com/r-graphic-banks-healthcare-service-firms-among-winners-from-us-tax-bill-2017-12,positive,0.653990626335144
12/20/2017 1:17:03 AM,"UPDATE 1-S.Korea's Samsung Bioepis says FDA to review Herceptin copy (MRK, MYL)",Reuters,http://www.businessinsider.com/r-update-1-skoreas-samsung-bioepis-says-fda-to-review-herceptin-copy-2017-12,neutral,0.7950756549835205
12/20/2017 10:17:04 PM,"BRIEF-U.S. Fda Approves New Diabetes Drug From Merck And Pfizer (MRK, PFE, JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12,positive,0.7861426472663879
12/20/2017 10:27:06 PM,"U.S. FDA approves new diabetes drug from Merck and Pfizer (MRK, PFE, AZN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12,positive,0.8601289391517639
12/20/2017 10:42:03 PM,"UPDATE 1-U.S. FDA approves new diabetes drug from Merck and Pfizer (MRK, PFE, AZN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12,positive,0.8735406398773193
12/21/2017 7:27:19 PM,"BRIEF-Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta (PFE, MRK)",Reuters,http://www.businessinsider.com/r-brief-pfizer-announces-breakthrough-therapy-designation-for-avelumab-in-combination-with-inlyta-2017-12,positive,0.8955047130584717
12/21/2017 7:32:04 PM,BRIEF-FDA grants second breakthrough therapy designation for Avelumab in hard-to-treat cancer​ (MRK),Reuters,http://www.businessinsider.com/r-brief-fda-grants-second-breakthrough-therapy-designation-for-avelumab-in-hard-to-treat-cancer-2017-12,positive,0.9232850670814514
12/21/2017 11:30:00 PM,FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma,PR Newswire,/news/stocks/fda-grants-breakthrough-therapy-designation-for-avelumab-in-combination-with-inlyta-in-advanced-renal-cell-carcinoma-1011759185,positive,0.9159069657325745
12/22/2017 7:02:03 AM,"Wall St Week Ahead-This year's lumps of coal could be 2018's diamonds (GE, VRTX, ILMN, KR, AMZN, VZ, IBM, XOM, BA, CAT, CSCO, PFE, CVX, MRK, KO, PG, NKE, VRSN, EMR, ROK)",Reuters,http://www.businessinsider.com/r-wall-st-week-ahead-this-years-lumps-of-coal-could-be-2018s-diamonds-2017-12,neutral,0.9232535362243652
12/22/2017 8:12:03 AM,"German stocks - Factors to watch on December 22 (ALV, ELE, DTE, LBTYA, MRK, PFE, TKA, TATASTEEL)",Reuters,http://www.businessinsider.com/r-german-stocks---factors-to-watch-on-december-22-2017-12,neutral,0.9449489712715149
12/22/2017 1:02:04 PM,"RPT-Wall St Week Ahead-This year's lumps of coal could be 2018's diamonds (GE, VRTX, ILMN, KR, AMZN, VZ, IBM, XOM, BA, CAT, CSCO, PFE, CVX, MRK, KO, PG, NKE, VRSN, EMR, ROK)",Reuters,http://www.businessinsider.com/r-rpt-wall-st-week-ahead-this-years-lumps-of-coal-could-be-2018s-diamonds-2017-12,neutral,0.9183773994445801
12/22/2017 1:13:33 PM,"Merck, Pfizer: FDA Approves Steglatro And Fixed-dose Combination Steglujan ",RTTNews,/news/stocks/merck-pfizer-fda-approves-steglatro-and-fixed-dose-combination-steglujan-1011810309,positive,0.6055468916893005
12/22/2017 1:22:04 PM,"BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes (MRK, PFIZER)",Reuters,http://www.businessinsider.com/r-brief-fda-approves-sglt2-inhibitor-steglatro-and-fixed-dose-combination-steglujan-for-adults-with-type-2-diabetes-2017-12,positive,0.867804765701294
12/24/2017 6:17:49 AM,"It's Raining FDA Approvals, SMMT Opens Wallet, AGRX Snubbed Yet Again ",RTTNews,/news/stocks/it-s-raining-fda-approvals-smmt-opens-wallet-agrx-snubbed-yet-again-1011943022,neutral,0.6607587933540344
12/26/2017 10:07:03 PM,BRIEF-HTG Molecular Diagnostics Expands Its Collaboration With Merck (MRK),Reuters,http://www.businessinsider.com/r-brief-htg-molecular-diagnostics-expands-its-collaboration-with-merck-2017-12,positive,0.9435903429985046
1/2/2018 12:02:03 PM,"New drug approvals hit 21-year high in 2017 (GILD, PFE, MRK, NOVO , AZN)",Reuters,http://www.businessinsider.com/r-new-drug-approvals-hit-21-year-high-in-2017-2018-1,positive,0.8878636956214905
1/2/2018 1:13:36 PM,Merck Reports Approval Of KEYTRUDA For Urothelial Carcinoma In Japan ,RTTNews,/news/stocks/merck-reports-approval-of-keytruda-for-urothelial-carcinoma-in-japan-1012405935,positive,0.7606567740440369
1/2/2018 1:22:04 PM,BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma (MRK),Reuters,http://www.businessinsider.com/r-brief-mercks-keytruda-approved-in-japan-for-use-in-the-treatment-of-patients-with-urothelial-carcinoma-2018-1,positive,0.8852816224098206
1/2/2018 10:12:08 PM,BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress (MRK),Reuters,http://www.businessinsider.com/r-brief-juniper-pharmaceuticals-outlines-strategic-priorities-for-2018-and-reports-recent-portfolio-progress-2018-1,neutral,0.8853818774223328
1/7/2018 3:50:22 PM,New Drugs Approved In December ,RTTNews,/news/stocks/new-drugs-approved-in-december-1012620046,neutral,0.6225224137306213
1/8/2018 12:44:58 PM,Merck Says FDA Accepts For Review Two NDAs For Doravirine - Quick Facts ,RTTNews,/news/stocks/merck-says-fda-accepts-for-review-two-ndas-for-doravirine-quick-facts-1012659698,neutral,0.8232661485671997
1/8/2018 1:02:13 PM,Merck Says Phase 3 KEYTRUDA Trial Meets Primary Endpoint ,RTTNews,/news/stocks/merck-says-phase-3-keytruda-trial-meets-primary-endpoint-1012660551,positive,0.6390436291694641
1/9/2018 12:45:00 PM,Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell...,PR Newswire,/news/stocks/eisai-and-merck-receive-breakthrough-therapy-designation-from-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumab-as-combination-therapy-for-advanced-and-or-metastatic-renal-cell-1012723117,positive,0.9254042506217957
1/14/2018 4:46:25 AM,AstraZeneca Says FDA Oks Lynparza For Metastatic Breast Cancer ,RTTNews,/news/stocks/astrazeneca-says-fda-oks-lynparza-for-metastatic-breast-cancer-1013084769,neutral,0.7672474384307861
1/16/2018 12:55:19 PM,Merck's KEYTRUDA Significantly Improved Overall Survival And PFS ,RTTNews,/news/stocks/merck-s-keytruda-significantly-improved-overall-survival-and-pfs-1013109384,positive,0.961807370185852
1/17/2018 8:06:38 AM,"EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs? ",RTTNews,/news/stocks/eigr-disappoints-exel-s-celestial-excels-juno-in-celg-s-crosshairs-1013143115,neutral,0.6830920577049255
1/18/2018 10:00:00 AM,The Consumer Health of Merck Walks the Talk with its WE100 Movement,PR Newswire,/news/stocks/the-consumer-health-of-merck-walks-the-talk-with-its-we100-movement-1013207205,neutral,0.8228662610054016
1/19/2018 8:27:49 AM,AstraZeneca Announces Approval Of Lynparza In Japan - Quick Facts ,RTTNews,/news/stocks/astrazeneca-announces-approval-of-lynparza-in-japan-quick-facts-1013286806,neutral,0.804774284362793
2/2/2018 12:52:53 PM,Merck & Co Inc. Announces Advance In Q4 Profit,RTTNews,/news/stocks/merck-co-inc-announces-advance-in-q4-profit-1014901924,positive,0.6510688066482544
2/2/2018 1:33:44 PM,Merck quarterly profit beats on Keytruda demand,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/IZt3EmvPl48/merck-quarterly-profit-beats-on-keytruda-demand-idINKBN1FM1JW,negative,0.8530341982841492
2/2/2018 1:37:18 PM,"Merck Q4 Adj. Profit Tops View, But Sales Miss; Sees 2018 Adj. EPS In Line ",RTTNews,/news/stocks/merck-q4-adj-profit-tops-view-but-sales-miss-sees-2018-adj-eps-in-line-1014904876,positive,0.6560707092285156
2/7/2018 7:03:28 AM,"GILD's Sales Wane, SGMO Safe With CHAMPIONS, All's Not Well With Veterinarians? ",RTTNews,/news/stocks/gild-s-sales-wane-sgmo-safe-with-champions-all-s-not-well-with-veterinarians-1015028820,neutral,0.5543562769889832
2/13/2018 11:16:40 PM,Merck Discontinues APECS Study On Verubecestat Following EDMC Recommendation ,RTTNews,/news/stocks/merck-discontinues-apecs-study-on-verubecestat-following-edmc-recommendation-1015684436,neutral,0.8349507451057434
2/14/2018 7:32:45 AM,"TTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again ",RTTNews,/news/stocks/ttph-implodes-on-ignite3-ec-approves-2nd-herceptin-biosimilar-ptie-at-it-again-1015730441,neutral,0.8447320461273193
2/15/2018 8:13:06 AM,AstraZeneca: FDA Grants Orphan Drug Designation For Selumetinib - Quick Facts ,RTTNews,/news/stocks/astrazeneca-fda-grants-orphan-drug-designation-for-selumetinib-quick-facts-1015861654,positive,0.8342437744140625
2/15/2018 3:30:12 PM,"Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/qZyR7EWdaxQ/merck-kgaa-pfizers-immunotherapy-fails-in-lung-cancer-trial-idINKCN1FZ1VK,neutral,0.7254384756088257
2/21/2018 10:42:31 AM,Merck To Buy Australia's Viralytics For $394 Mln In Cash - Quick Facts ,RTTNews,/news/stocks/merck-to-buy-australia-s-viralytics-for-394-mln-in-cash-quick-facts-1016556112,neutral,0.8090382218360901
2/23/2018 1:47:47 PM,Merck Says LYNPARZA Receives Positive EU CHMP Opinion ,RTTNews,/news/stocks/merck-says-lynparza-receives-positive-eu-chmp-opinion-1016845745,positive,0.9496545195579529
3/13/2018 12:23:22 PM,Merck: FDA Grants Priority Review To SBLA For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-quick-facts-1018643988,positive,0.6983336806297302
3/16/2018 1:35:00 PM,"International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018",PR Newswire,/news/stocks/international-companies-to-host-live-webcasts-at-deutsche-bank-s-depositary-receipts-virtual-investor-conference-on-march-21st-and-22nd-2018-1018854019,neutral,0.9452488422393799
3/16/2018 1:35:00 PM,"International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 21st and 22nd, 2018",PR Newswire,/news/stocks/international-companies-to-host-live-webcasts-at-deutsche-bank-s-depositary-receipts-virtual-investor-conference-on-march-21st-and-22nd-2018-1018854020,neutral,0.9452488422393799
3/20/2018 1:35:00 PM,"Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-to-present-at-the-dbvic-deutsche-bank-adr-virtual-investor-conference-on-22nd-march-2018-1018944292,neutral,0.9392256140708923
3/20/2018 1:35:00 PM,"Merck KGaA, Darmstadt, Germany to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 22nd March 2018",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-to-present-at-the-dbvic-deutsche-bank-adr-virtual-investor-conference-on-22nd-march-2018-1018944290,neutral,0.9392256140708923
3/21/2018 2:30:00 PM,S&P 500 Q4 2017 Buybacks Rose 6.0% to $137.0 Billion; Full-Year 2017 Fell 3.2% to $519.4 Billion,PR Newswire,/news/stocks/s-p-500-q4-2017-buybacks-rose-6-0-to-137-0-billion-full-year-2017-fell-3-2-to-519-4-billion-1018994087,positive,0.7472252249717712
3/23/2018 11:11:30 AM,"Eisai, Merck: LENVIMA Approved For Additional Indication In Japan - Quick Facts ",RTTNews,/news/stocks/eisai-merck-lenvima-approved-for-additional-indication-in-japan-quick-facts-1019145739,neutral,0.6750738024711609
3/26/2018 2:35:00 PM,"Merck KGaA, Darmstadt, Germany webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-webcast-presentation-now-available-for-on-demand-viewing-dbvic-deutsche-bank-adr-virtual-investor-conference-1019454481,neutral,0.9470813274383545
3/26/2018 2:35:00 PM,"Merck KGaA, Darmstadt, Germany webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-webcast-presentation-now-available-for-on-demand-viewing-dbvic-deutsche-bank-adr-virtual-investor-conference-455620,neutral,0.9470813274383545
3/27/2018 2:40:00 PM,Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan,PR Newswire,/news/stocks/merck-receives-fast-track-designation-for-tepotinib-in-non-small-cell-lung-cancer-in-japan-1019575737,positive,0.9427300691604614
3/27/2018 2:40:00 PM,Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan,PR Newswire,/news/stocks/merck-receives-fast-track-designation-for-tepotinib-in-non-small-cell-lung-cancer-in-japan-480682,positive,0.9427300691604614
3/27/2018 2:42:32 PM,BRIEF-Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/LW5Meihvmtw/brief-merck-receives-fast-track-designation-for-tepotinib-in-non-small-cell-lung-cancer-in-japan-idUSFWN1R90KJ,positive,0.9369222521781921
3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162,neutral,0.7716754078865051
3/29/2018 10:50:37 PM,BRIEF-Merck & Co Inc Files For Potential Debt Shelf Size Not Disclosed,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Oi68qMQc28k/brief-merck-co-inc-files-for-potential-debt-shelf-size-not-disclosed-idUSFWN1RB109,neutral,0.5782313942909241
4/1/2018 2:54:34 AM,An Ear To The Pharma: 5 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-5-stocks-to-watch-this-week-1020117694,neutral,0.9023820757865906
4/2/2018 1:29:34 PM,Myriad Reports Approval For BRACAnalysis Diagnostic System In Japan ,RTTNews,/news/stocks/myriad-reports-approval-for-bracanalysis-diagnostic-system-in-japan-1020239267,positive,0.8870890736579895
4/3/2018 8:39:59 AM,"AstraZeneca, Merck: European Medicines Agency To Review MAA For Lynparza ",RTTNews,/news/stocks/astrazeneca-merck-european-medicines-agency-to-review-maa-for-lynparza-1020316838,neutral,0.8636613488197327
4/3/2018 1:54:24 PM,Will These Drugs Reach Blockbuster Status? ,RTTNews,/news/stocks/will-these-drugs-reach-blockbuster-status-1020339832,neutral,0.7288854122161865
4/6/2018 1:39:13 PM,"BRIEF-Incyte, Merck Provide Update On Phase 3 Study",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JfjeqDAUI3o/brief-incyte-merck-provide-update-on-phase-3-study-idUSASC09V4M,neutral,0.9407566785812378
4/6/2018 1:42:04 PM,"Incyte, Merck Stop Phase 3 Study Of Epacadostat In Combination With KEYTRUDA ",RTTNews,/news/stocks/incyte-merck-stop-phase-3-study-of-epacadostat-in-combination-with-keytruda-1020676568,neutral,0.5658867955207825
4/6/2018 3:21:06 PM,"A cancer drugmaker just failed a key trial and its stock is crashing (INCY, MRK)",Business Insider,http://markets.businessinsider.com/news/stocks/incyte-stock-price-after-ido-cancer-drug-trial-failure-2018-4-1020683045,negative,0.8993933796882629
4/9/2018 7:20:14 AM,New Drugs Approved In March ,RTTNews,/news/stocks/new-drugs-approved-in-march-1020922359,positive,0.5716190338134766
4/9/2018 1:00:20 PM,Merck: KEYTRUDA Monotherapy Meets Primary Endpoint In Phase 3 KEYNOTE-042 Study ,RTTNews,/news/stocks/merck-keytruda-monotherapy-meets-primary-endpoint-in-phase-3-keynote-042-study-1020943359,positive,0.6390467882156372
4/13/2018 5:27:09 PM,"We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated (MRK, BMS, RHHBY)",Business Insider,http://www.businessinsider.com/merck-roche-bms-lung-cancer-combination-trial-data-at-aacr-2018-4,neutral,0.6245182752609253
4/16/2018 6:47:02 AM,"ALNY On Watch, NLNK Exhibits Caution, Keep An Eye On GKOS ",RTTNews,/news/stocks/alny-on-watch-nlnk-exhibits-caution-keep-an-eye-on-gkos-1021390176,neutral,0.8943411707878113
4/16/2018 3:30:00 PM,"Merck, Bristol-Myers immunotherapies impress in key lung cancer trials",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ulvhTRxkSuQ/merck-bristol-myers-immunotherapies-impress-in-key-lung-cancer-trials-idUSL1N1RQ297,positive,0.5842287540435791
4/16/2018 3:33:04 PM,"'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change how we treat the disease (MRK, BMY)",Business Insider,http://www.businessinsider.com/merck-bms-roche-lung-cancer-immunotherapy-data-2018-4,neutral,0.7182743549346924
4/16/2018 3:46:04 PM,"Merck, Bristol-Myers immunotherapies impress in key lung cancer trials",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/cu1ieB1J5ic/merck-bristol-myers-immunotherapies-impress-in-key-lung-cancer-trials-idINKBN1HN1W0,positive,0.5842287540435791
4/16/2018 3:53:40 PM,Merck : KEYTRUDA-pemetrexed-platinum Chemotherapy Combination Improved OS ,RTTNews,/news/stocks/merck-keytruda-pemetrexed-platinum-chemotherapy-combination-improved-os-1021399762,positive,0.9519146680831909
4/16/2018 4:27:33 PM,"2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)",Business Insider,http://markets.businessinsider.com/news/stocks/merck-bristol-myers-squibb-stock-price-lung-cancer-data-at-aacr-2018-4-1021400484,positive,0.6845755577087402
4/17/2018 8:40:29 AM,"ALKS Pulls Off Sweet Surprise, APRI Thrashed, BMY Gets FDA Nod ",RTTNews,/news/stocks/alks-pulls-off-sweet-surprise-apri-thrashed-bmy-gets-fda-nod-1021423487,positive,0.5449021458625793
4/17/2018 1:32:45 PM,BRIEF-Labcyte Reaches Agreement With Merck To Supply Acoustic-Mass Spectrometry Equipment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/IETz8lC8I1M/brief-labcyte-reaches-agreement-with-merck-to-supply-acoustic-mass-spectrometry-equipment-idUSFWN1RU0XE,positive,0.9079963564872742
4/17/2018 2:33:21 PM,"BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lbOsJ4phVDw/brief-merck-announces-first-phase-3-studies-for-pcv-15-its-investigational-pneumococcal-disease-vaccine-idUSFWN1RU0U3,neutral,0.668782651424408
4/17/2018 2:48:47 PM,Merck Begins Two Phase 3 Studies Of Pneumococcal Disease Vaccine PCV-15 (V114) ,RTTNews,/news/stocks/merck-begins-two-phase-3-studies-of-pneumococcal-disease-vaccine-pcv-15-v114-1021435607,neutral,0.6488324403762817
4/19/2018 5:50:09 AM,BRIEF-P&G Nears Deal To Acquire Merck KGaA's Consumer-Health Unit - WSJ,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Nf7AMfAdxcg/brief-pg-nears-deal-to-acquire-merck-kgaas-consumer-health-unit-wsj-idUSFWN1RV0YZ,positive,0.5944297313690186
4/19/2018 6:03:02 AM,"BRIEF-P&G Acquires the Consumer Health Business Of Merck KGaA, Darmstadt, Germany",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/8IfvU9SyzK4/brief-pg-acquires-the-consumer-health-business-of-merck-kgaa-darmstadt-germany-idUSASO0003GM,neutral,0.9256598353385925
4/19/2018 6:24:23 AM,BRIEF-Merck Says Signed Agreement To Sell Its Global Consumer Health Business To P&G For About 3.4 Bln Euros In Cash,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/1DSpgThfRg4/brief-merck-says-signed-agreement-to-sell-its-global-consumer-health-business-to-pg-for-about-3-4-bln-euros-in-cash-idUSFWN1RV0Z3,positive,0.8071215748786926
4/20/2018 3:05:30 PM,FOCUS-Germany's Merck seeks partners for cancer and immune system drugs,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/PO6nNmsXbI0/focus-germanys-merck-seeks-partners-for-cancer-and-immune-system-drugs-idUSL8N1RU5H3,neutral,0.5108473896980286
4/24/2018 3:10:21 PM,Modern Miracles: America's 10 Best-Selling Drugs ,RTTNews,/news/stocks/modern-miracles-america-s-10-best-selling-drugs-1022118861,neutral,0.849453330039978
4/25/2018 5:33:01 PM,U.S. court upholds dismissal of $200 million Merck verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/U0Q_ek3hoII/u-s-court-upholds-dismissal-of-200-million-merck-verdict-against-gilead-idUSL1N1S20WZ,negative,0.8148794174194336
4/25/2018 9:28:14 PM,REFILE-U.S. court upholds dismissal of $200 million Merck verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/CBMt39O37Bw/refile-u-s-court-upholds-dismissal-of-200-million-merck-verdict-against-gilead-idUSL1N1S20WZ,negative,0.8081111907958984
4/25/2018 11:31:40 PM,UPDATE 1-U.S. court upholds dismissal of $200 mln Merck verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/HZiA8wgp6GQ/update-1-u-s-court-upholds-dismissal-of-200-mln-merck-verdict-against-gilead-idUSL1N1S2270,negative,0.8473582863807678
4/30/2018 12:53:05 PM,Merck: FDA Grants Priority Review To SBLA For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-quick-facts-1022880137,positive,0.6983336806297302
5/1/2018 7:42:04 AM,"INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM ",RTTNews,/news/stocks/ingn-soars-on-revised-outlook-mrk-faces-fda-in-sep-kpti-taken-by-storm-1022974414,negative,0.7852576375007629
5/1/2018 12:51:01 PM,Merck posts 52.5 percent fall in quarterly profit,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZXkmFp3UOGY/merck-posts-52-5-percent-fall-in-quarterly-profit-idUSL3N1S8272,negative,0.975482702255249
5/1/2018 12:55:13 PM,Merck & Co Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q1-adjusted-earnings-beat-estimates-1023000213,positive,0.8450100421905518
5/1/2018 1:07:40 PM,UPDATE 1-Keytruda powers Merck to first-quarter beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AaizlJDdA54/update-1-keytruda-powers-merck-to-first-quarter-beat-idUSL3N1S8277,positive,0.9141023755073547
5/1/2018 1:15:54 PM,BRIEF-Merck Announces Q1 GAAP EPS Of $0.27,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZP1g_BC3Y3M/brief-merck-announces-q1-gaap-eps-of-0-27-idUSASC09YI6,neutral,0.47222813963890076
5/1/2018 1:49:57 PM,UPDATE 2-Keytruda sales power Merck to quarterly beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mHmIUbT8-zE/update-2-keytruda-sales-power-merck-to-quarterly-beat-idUSL3N1S8277,positive,0.9164905548095703
5/1/2018 2:34:57 PM,"Merck And Pfizer Q1 Adj. Profit Tops View, But Sales Miss ",RTTNews,/news/stocks/merck-and-pfizer-q1-adj-profit-tops-view-but-sales-miss-1023009302,positive,0.6790652275085449
5/1/2018 5:54:13 PM,UPDATE 3-Keytruda sales power Merck to quarterly beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xPrivQQhh2o/update-3-keytruda-sales-power-merck-to-quarterly-beat-idUSL3N1S8277,positive,0.9141278266906738
5/2/2018 2:21:13 PM,BRIEF-Merck KGaA To Develop Abituzumab In Metastatic Colorectal Cancer With SFJ Pharmaceuticals,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4_wWXTC2k0c/brief-merck-kgaa-to-develop-abituzumab-in-metastatic-colorectal-cancer-with-sfj-pharmaceuticals-idUSFWN1S90LV,positive,0.5966423153877258
5/3/2018 10:54:13 AM,Merck KGaA family says unreservedly behind the pharma unit,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-eI3iEAF4Hs/merck-kgaa-family-says-unreservedly-behind-the-pharma-unit-idUSF9N1RV00W,neutral,0.8602887988090515
5/3/2018 11:28:10 AM,UPDATE 1-Merck KGaA family says unreservedly behind the pharma unit,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/F8TwogkVKck/update-1-merck-kgaa-family-says-unreservedly-behind-the-pharma-unit-idUSL8N1SA34T,neutral,0.7035899758338928
5/3/2018 1:30:57 PM,Merck Updates On KEYNOTE-407 Trial ,RTTNews,/news/stocks/merck-updates-on-keynote-407-trial-1023257409,neutral,0.9281089901924133
5/3/2018 11:58:03 PM,BRIEF-Moderna And Merck Expand MRNA Cancer Vaccines Collaboration,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rjELIuJaRjU/brief-moderna-and-merck-expand-mrna-cancer-vaccines-collaboration-idUSB8N1LI03L,neutral,0.7064776420593262
5/8/2018 1:03:52 PM,MRK :EU Oks LYNPARZA Tablets To Treat Platinum-Sensitive Relapsed Ovarian Cancer ,RTTNews,/news/stocks/mrk-eu-oks-lynparza-tablets-to-treat-platinum-sensitive-relapsed-ovarian-cancer-1023743768,positive,0.7590680718421936
5/15/2018 7:21:27 AM,"Merck KGaA Q1 earnings down on liquid crystals, currencies",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/7oyjzaQ-0Xw/merck-kgaa-q1-earnings-down-on-liquid-crystals-currencies-idUSL5N1SL64J,negative,0.9669982194900513
5/15/2018 7:47:09 AM,"UPDATE 1-Merck KGaA Q1 earnings down on liquid crystals, currencies",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uyuhUAEYUS0/update-1-merck-kgaa-q1-earnings-down-on-liquid-crystals-currencies-idUSL5N1SM0ZH,negative,0.9709156155586243
5/17/2018 3:13:00 AM,"Merck KGaA, Darmstadt, Germany Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline",PR Newswire,/news/stocks/merck-kgaa-darmstadt-germany-data-at-asco-2018-to-showcase-progress-and-further-optionality-of-oncology-pipeline-1024779308,neutral,0.6151176691055298
5/23/2018 1:09:30 PM,Merck: KEYTRUDA Shows Improved Survival Benefit In 407 Trial - Quick Facts ,RTTNews,/news/stocks/merck-keytruda-shows-improved-survival-benefit-in-407-trial-quick-facts-1025132051,positive,0.9593013525009155
5/25/2018 1:34:00 AM,Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma,PR Newswire,/news/stocks/eisai-and-merck-provide-update-on-supplemental-new-drug-application-snda-for-lenvatinib-in-first-line-unresectable-hepatocellular-carcinoma-1025245558,neutral,0.8429995775222778
5/29/2018 1:26:49 PM,"UPDATE 1-Roche, chasing Merck, notches another lung cancer win",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NSAQhc4_aIY/update-1-roche-chasing-merck-notches-another-lung-cancer-win-idUSL5N1T0145,neutral,0.5254064202308655
5/29/2018 2:04:57 PM,Biotech Stocks Facing FDA Decision In June ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-1025708240,neutral,0.7687873244285583
5/31/2018 3:09:19 PM,"Merck, Premier Collaborate To Help Reduce Clostridium Difficile Infection ",RTTNews,/news/stocks/merck-premier-collaborate-to-help-reduce-clostridium-difficile-infection-1025981618,positive,0.7478925585746765
6/1/2018 2:04:00 PM,"EMA recommends restrictions on Merck, Roche immunotherapies",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/imW_PZcXH8s/ema-recommends-restrictions-on-merck-roche-immunotherapies-idUSFWN1T30MZ,neutral,0.6888912320137024
6/1/2018 2:44:52 PM,"REFILE-EMA recommends restrictions on Merck, Roche immunotherapies",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_Nb4RSo--GQ/refile-ema-recommends-restrictions-on-merck-roche-immunotherapies-idUSL5N1T33GZ,neutral,0.6063655018806458
6/3/2018 2:30:00 PM,Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018,PR Newswire,/news/stocks/merck-presents-update-on-tepotinib-in-advanced-lung-cancer-at-asco-2018-1026341334,neutral,0.8878089785575867
6/3/2018 2:30:00 PM,Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018,PR Newswire,/news/stocks/merck-presents-update-on-tepotinib-in-advanced-lung-cancer-at-asco-2018-1026341335,neutral,0.8878089785575867
6/3/2018 5:01:53 PM,Merck Announces Interim Results From Cohort A Of KEYNOTE-427 ,RTTNews,/news/stocks/merck-announces-interim-results-from-cohort-a-of-keynote-427-1026351458,neutral,0.6903929114341736
6/4/2018 1:06:00 AM,Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types,PR Newswire,/news/stocks/eisai-and-merck-announce-data-at-2018-asco-annual-meeting-from-investigational-studies-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-therapy-in-four-different-tumor-types-1026379650,positive,0.5454450845718384
6/4/2018 2:57:22 AM,Eisai And Merck Announce Data From Studies Of LENVIMA And KEYTRUDA ,RTTNews,/news/stocks/eisai-and-merck-announce-data-from-studies-of-lenvima-and-keytruda-1026391049,neutral,0.8964158892631531
6/4/2018 1:38:35 PM,Merck Announces Long-term Efficacy Data From Phase 3 KEYNOTE-006 Study ,RTTNews,/news/stocks/merck-announces-long-term-efficacy-data-from-phase-3-keynote-006-study-1026436430,neutral,0.8950056433677673
6/4/2018 1:54:37 PM,Merck Announces Interim Data From Cohort Of Phase 2 KEYNOTE-158 Study ,RTTNews,/news/stocks/merck-announces-interim-data-from-cohort-of-phase-2-keynote-158-study-1026437953,neutral,0.905488133430481
6/4/2018 3:00:00 PM,Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab),PR Newswire,/news/stocks/two-year-update-of-pivotal-javelin-merkel-200-trial-shows-continued-durable-responses-with-bavencio-avelumab-1026443744,positive,0.9528995156288147
6/4/2018 3:00:00 PM,Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab),PR Newswire,/news/stocks/two-year-update-of-pivotal-javelin-merkel-200-trial-shows-continued-durable-responses-with-bavencio-avelumab-1026443748,positive,0.9528995156288147
6/4/2018 8:45:03 PM,"We just got a lot of updates on the state of cancer treatments — here are the winners and losers (BLUE, NKTR, LOXO, MRK, BMY)",Business Insider,http://www.businessinsider.com/asco-updates-on-the-state-of-cancer-treatments-2018-6,neutral,0.9364539980888367
6/13/2018 12:55:20 PM,Merck: FDA To Review New SBLA For GARDASIL 9 - Quick Facts ,RTTNews,/news/stocks/merck-fda-to-review-new-sbla-for-gardasil-9-quick-facts-1026921347,neutral,0.7885770797729492
6/23/2018 7:11:18 PM,Merck Reports New Data From Comparative Trials With Sitagliptin With JANUVIA ,RTTNews,/news/stocks/merck-reports-new-data-from-comparative-trials-with-sitagliptin-with-januvia-1027312408,neutral,0.729047954082489
6/25/2018 12:42:54 PM,Merck: FDA To Review SBLA For KEYTRUDA As Adjuvant Therapy In Advanced Melanoma ,RTTNews,/news/stocks/merck-fda-to-review-sbla-for-keytruda-as-adjuvant-therapy-in-advanced-melanoma-1027313995,neutral,0.6488608717918396
6/27/2018 8:17:13 AM,"Merck, AstraZeneca: Ovarian Cancer Drug LYNPARZA Meets Primary Goal In Trial ",RTTNews,/news/stocks/merck-astrazeneca-ovarian-cancer-drug-lynparza-meets-primary-goal-in-trial-1027320941,positive,0.7672291994094849
6/27/2018 9:19:57 AM,"AstraZeneca, Merck eye wider cancer drug use after study success",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/q07EQ65h7zU/astrazeneca-merck-eye-wider-cancer-drug-use-after-study-success-idUSL8N1TT0YG,neutral,0.8947480916976929
6/27/2018 11:04:51 AM,"UPDATE 1-AstraZeneca, Merck eye $1 bln boost from cancer drug success",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lVyoQzJUSAI/update-1-astrazeneca-merck-eye-1-bln-boost-from-cancer-drug-success-idUSL8N1TT1LK,positive,0.9316948652267456
6/28/2018 3:37:14 PM,U.S. Supreme Court to hear Merck appeal over Fosamax suits,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/HaYLJTbzIX0/u-s-supreme-court-to-hear-merck-appeal-over-fosamax-suits-idUSW1N1QB01O,neutral,0.6246669888496399
6/28/2018 3:47:41 PM,UPDATE 1-U.S. Supreme Court to hear Merck appeal over Fosamax suits,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/XzZ0HBXEWn4/update-1-u-s-supreme-court-to-hear-merck-appeal-over-fosamax-suits-idUSL1N1TU0NI,neutral,0.6996013522148132
6/28/2018 4:04:28 PM,CORRECTED-UPDATE 1-U.S. Supreme Court to hear Merck appeal over Fosamax suits,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/z4d2qUAtRJg/corrected-update-1-u-s-supreme-court-to-hear-merck-appeal-over-fosamax-suits-idUSL1N1TU0NI,neutral,0.5795690417289734
7/2/2018 8:39:41 AM,"AstraZeneca: Cancer Drugs Imfinzi, Lynparza Approved In Japan ",RTTNews,/news/stocks/astrazeneca-cancer-drugs-imfinzi-lynparza-approved-in-japan-1027333778,neutral,0.6904792189598083
7/2/2018 12:57:44 PM,Merck: FDA Grants Priority Review To SBLA For KEYTRUDA Plus Chemotherapy ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-plus-chemotherapy-1027334576,positive,0.690412163734436
7/3/2018 7:44:33 AM,"FDA Nod For ALKS, TRXC Sees 4-fold Increase In Q2 Revenue, BCLI On Watch ",RTTNews,/news/stocks/fda-nod-for-alks-trxc-sees-4-fold-increase-in-q2-revenue-bcli-on-watch-1027337089,positive,0.9521991610527039
7/3/2018 11:33:36 AM,Remember When Was The Last Time A New Alzheimer's Drug Was Approved? ,RTTNews,/news/stocks/remember-when-was-the-last-time-a-new-alzheimer-s-drug-was-approved-1027337782,neutral,0.9172612428665161
7/11/2018 1:11:17 PM,Merck: FDA Grants Priority Review To SBLA For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-quick-facts-1027358020,positive,0.6983336806297302
7/12/2018 8:32:29 AM,"AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3 ",RTTNews,/news/stocks/akca-gets-ec-nod-fda-panel-to-review-malaria-drug-today-ovid-awaits-data-in-q3-1027360877,neutral,0.8872421383857727
7/13/2018 2:04:00 PM,Merck Financial Services GmbH -- Moody's affirms Merck KGaA's Baa1 ratings,Moodys,/news/bonds/merck-financial-services-gmbh-moody-s-affirms-merck-kgaa-s-baa1-ratings-1027365875,neutral,0.4912666082382202
7/19/2018 10:09:06 PM,Pharma giant Merck just lowered the prices of some of its medications (MRK),Business Insider,http://www.businessinsider.com/merck-lowers-prices-of-medications-including-hepatitis-c-drug-2018-7,negative,0.877802312374115
7/19/2018 11:22:42 PM,Merck lowers prices of some drugs after Trump calls out industry,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/e8N_FNWLugw/merck-lowers-prices-of-some-drugs-after-trump-calls-out-industry-idUSL1N1UF1NM,negative,0.928871214389801
7/20/2018 12:13:11 AM,UPDATE 1-Merck lowers prices of some drugs after Trump calls out industry,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Y5MKV2-Ll_A/update-1-merck-lowers-prices-of-some-drugs-after-trump-calls-out-industry-idUSL1N1UF21V,negative,0.9341985583305359
7/20/2018 3:01:29 AM,Merck To Cut Prices Of Some Drugs ,RTTNews,/news/stocks/merck-to-cut-prices-of-some-drugs-1027384312,negative,0.8943081498146057
7/24/2018 1:02:43 PM,Merck Announces Data From Phase 3 DRIVE-FORWARD Study Of HIV Therapy Doravirine ,RTTNews,/news/stocks/merck-announces-data-from-phase-3-drive-forward-study-of-hiv-therapy-doravirine-1027393341,neutral,0.7099618315696716
7/25/2018 6:18:02 AM,Merck: KEYTRUDA Monotherapy Meets A Primary Goal In Phase 3 Trial - Quick Facts ,RTTNews,/news/stocks/merck-keytruda-monotherapy-meets-a-primary-goal-in-phase-3-trial-quick-facts-1027396524,positive,0.656208872795105
7/26/2018 9:39:05 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1027401882,neutral,0.6419674754142761
7/26/2018 3:01:57 PM,Here's what to expect from Merck's earnings,Markets Insider Automation,/news/stocks/merckco-q2-quarterly-earnings-preview-1027403470,neutral,0.9375721216201782
7/27/2018 1:23:27 PM,Merck Q2 Profit Tops Estimates; Worldwide Sales Up 5% ,RTTNews,/news/stocks/merck-q2-profit-tops-estimates-worldwide-sales-up-5-1027406802,positive,0.9506422877311707
7/27/2018 1:58:45 PM,"UPDATE 2-Merck profit beats on Keytruda strength, raises full-year forecast",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/CPD-QPlJwi8/update-2-merck-profit-beats-on-keytruda-strength-raises-full-year-forecast-idUSL4N1UN3X3,positive,0.9307475686073303
7/27/2018 2:01:35 PM,"Merck profit beats on Keytruda strength, raises full-year forecast",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/em0vPr4dwU0/merck-profit-beats-on-keytruda-strength-raises-full-year-forecast-idUSKBN1KH180,positive,0.9112555980682373
7/27/2018 2:02:02 PM,Endo International Starts Shipment Of Generic Version Of Invanz In U.S. ,RTTNews,/news/stocks/endo-international-starts-shipment-of-generic-version-of-invanz-in-u-s-1027406949,positive,0.6977551579475403
7/27/2018 4:26:59 PM,"Merck profit beats on Keytruda strength, raises full-year forecast",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/ltlex93V_xo/merck-profit-beats-on-keytruda-strength-raises-full-year-forecast-idINKBN1KH19F,positive,0.9112555980682373
7/27/2018 5:01:10 PM,"UPDATE 3-Merck profit beats, but plan for animal health unit disappoints",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3HpI09JNRBQ/update-3-merck-profit-beats-but-plan-for-animal-health-unit-disappoints-idUSL4N1UN3X3,positive,0.6888395547866821
7/27/2018 5:05:41 PM,"Merck profit beats, but plan for animal health unit disappoints",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/mUcjdMuPDNM/merck-profit-beats-but-plan-for-animal-health-unit-disappoints-idUSKBN1KH180,negative,0.7133197784423828
7/27/2018 6:16:53 PM,"UPDATE 4-Merck profit beats, but Keytruda sales fail to impress",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xYXL3w4qBJ8/update-4-merck-profit-beats-but-keytruda-sales-fail-to-impress-idUSL4N1UN3X3,negative,0.5408703684806824
7/27/2018 6:25:23 PM,"Merck profit beats, but Keytruda sales fail to impress",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/w7xG3CXqIow/merck-profit-beats-but-keytruda-sales-fail-to-impress-idUSKBN1KH180,negative,0.8931208252906799
7/27/2018 7:49:27 PM,"Merck profit beats, but Keytruda sales fail to impress",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/mlAsa-HTCZA/merck-profit-beats-but-keytruda-sales-fail-to-impress-idINKBN1KH19F,negative,0.8931208252906799
7/30/2018 1:59:07 PM,Merck: CHMP Adopts Positive Opinion For KEYTRUDA Combination - Quick Facts ,RTTNews,/news/stocks/merck-chmp-adopts-positive-opinion-for-keytruda-combination-quick-facts-1027411284,positive,0.9402807950973511
7/31/2018 6:24:14 AM,Immutep: LAG-3 Immunostimulant Product Candidate Efti Gets FDA's IND Approval ,RTTNews,/news/stocks/immutep-lag-3-immunostimulant-product-candidate-efti-gets-fda-s-ind-approval-1027413789,positive,0.9236587882041931
7/31/2018 12:48:10 PM,Merck : FDA Grants Breakthrough Therapy Designation For LENVIMA With KEYTRUDA ,RTTNews,/news/stocks/merck-fda-grants-breakthrough-therapy-designation-for-lenvima-with-keytruda-1027415509,positive,0.9214485883712769
8/9/2018 6:46:52 AM,"Perrigo Profit Tops View, Cuts FY18 Forecast; Plans To Separate Rx Unit ",RTTNews,/news/stocks/perrigo-profit-tops-view-cuts-fy18-forecast-plans-to-separate-rx-unit-1027444795,negative,0.846720814704895
8/17/2018 6:08:57 AM,"ARAY Reports Record Revenue, PTIE Bleeds, EVOK To Face FDA In April ",RTTNews,/news/stocks/aray-reports-record-revenue-ptie-bleeds-evok-to-face-fda-in-april-1027466077,positive,0.8525552153587341
8/17/2018 2:14:18 PM,Eisai And Merck Announce FDA Approval Of Lenvima Capsules - Quick Facts ,RTTNews,/news/stocks/eisai-and-merck-announce-fda-approval-of-lenvima-capsules-quick-facts-1027467188,neutral,0.791632354259491
8/21/2018 9:16:53 AM,"AMRX Soars On Contract Win, TRPX Looks Ahead With Hope, ALXN To Face FDA In Feb ",RTTNews,/news/stocks/amrx-soars-on-contract-win-trpx-looks-ahead-with-hope-alxn-to-face-fda-in-feb-1027472447,positive,0.7652556300163269
8/23/2018 12:44:37 PM,"Eisai, Merck: LENVIMA Granted Marketing Authorization By European Commission ",RTTNews,/news/stocks/eisai-merck-lenvima-granted-marketing-authorization-by-european-commission-1027479875,positive,0.8618011474609375
8/30/2018 10:19:39 PM,FDA approves two new HIV drugs from Merck,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/youGra37eHA/fda-approves-two-new-hiv-drugs-from-merck-idUSL3N1VL692,positive,0.8248759508132935
8/30/2018 10:45:00 PM,UPDATE 1-FDA approves two new HIV drugs from Merck,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZTVhmCKwiwA/update-1-fda-approves-two-new-hiv-drugs-from-merck-idUSL3N1VL69K,positive,0.8961653709411621
9/4/2018 12:56:14 PM,Merck: FDA To Review SBLA For KEYTRUDA For Treatment Of Merkel Cell Carcinoma ,RTTNews,/news/stocks/merck-fda-to-review-sbla-for-keytruda-for-treatment-of-merkel-cell-carcinoma-1027505248,neutral,0.7414921522140503
9/5/2018 12:52:57 PM,Merck : China Okays LENVIMA To Treat Unresectable Hepatocellular Carcinoma ,RTTNews,/news/stocks/merck-china-okays-lenvima-to-treat-unresectable-hepatocellular-carcinoma-1027509171,positive,0.8115462064743042
9/10/2018 12:54:15 PM,Merck: European Commission Approves KEYTRUDA In Combination With Chemotherapy ,RTTNews,/news/stocks/merck-european-commission-approves-keytruda-in-combination-with-chemotherapy-1027520339,positive,0.7588204145431519
9/11/2018 12:56:46 PM,Merck: ZERBAXA Meets Primary Endpoints In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/merck-zerbaxa-meets-primary-endpoints-in-phase-3-study-quick-facts-1027523935,positive,0.8134762048721313
9/11/2018 3:13:50 PM,"Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JqP4LQf87Gg/merck-kgaa-pfizers-immuno-drug-shown-to-alleviate-kidney-cancer-idUSFWN1VX0HN,positive,0.8624057769775391
9/12/2018 1:29:20 PM,Merck: FDA Grants Priority Review To New SBLA For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-new-sbla-for-keytruda-quick-facts-1027527676,positive,0.764601469039917
9/18/2018 9:23:35 AM,"Pharma Companies Avoid $3.8 Bln In Tax Per Year, Says Oxfam ",RTTNews,/news/stocks/pharma-companies-avoid-3-8-bln-in-tax-per-year-says-oxfam-1027542053,positive,0.7368782758712769
9/26/2018 12:58:38 PM,Merck CEO to stay post 65 after company amends retirement policy,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/UDGbDyBW5eo/merck-ceo-to-stay-post-65-after-company-amends-retirement-policy-idUSKCN1M61EU,neutral,0.6079145669937134
9/26/2018 1:04:41 PM,Merck CEO Kenneth Frazier To Remain In His Position Beyond Dec. 2019 ,RTTNews,/news/stocks/merck-ceo-kenneth-frazier-to-remain-in-his-position-beyond-dec-2019-1027566089,neutral,0.9256049990653992
9/28/2018 11:42:28 AM,Biotech Stocks Facing FDA Decision In October ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-1027574035,neutral,0.635016918182373
10/2/2018 10:53:46 PM,Cancer center CEO leaves Merck board after disclosure scandal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/VtoEHhyty-o/cancer-center-ceo-leaves-merck-board-after-disclosure-scandal-idUSL2N1WI1N7,negative,0.7857868075370789
10/2/2018 11:20:02 PM,UPDATE 1-Cancer center CEO leaves Merck board after disclosure scandal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kZHj_XQ17pk/update-1-cancer-center-ceo-leaves-merck-board-after-disclosure-scandal-idUSL2N1WI1T6,negative,0.772159993648529
10/4/2018 1:30:41 PM,Merck: DELSTRIGO Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study ,RTTNews,/news/stocks/merck-delstrigo-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-1027590006,positive,0.9310899972915649
10/8/2018 8:00:04 PM,The CEO of Merck has an ominous warning for the middlemen who stand between drug makers and patients (MRK),Business Insider,https://www.businessinsider.com/merck-ceo-on-disintermediation-in-pharma-2018-10,negative,0.9053510427474976
10/16/2018 8:18:31 AM,"AstraZeneca, Merck Get FDA's ODD For Lynparza For Pancreatic Cancer ",RTTNews,/news/stocks/astrazeneca-merck-get-fda-s-odd-for-lynparza-for-pancreatic-cancer-1027619188,positive,0.6315233707427979
10/16/2018 12:47:12 PM,"AstraZeneca, Merck Announce Fourth Orphan Drug Designation For LYNPARZA ",RTTNews,/news/stocks/astrazeneca-merck-announce-fourth-orphan-drug-designation-for-lynparza-1027620271,neutral,0.5840681195259094
10/18/2018 1:22:36 PM,"Merck, Pfizer combo treatment meets main goals of kidney cancer trial",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xQSYUKKbxtg/merck-pfizer-combo-treatment-meets-main-goals-of-kidney-cancer-trial-idUSL3N1WY41M,positive,0.5255518555641174
10/18/2018 1:27:23 PM,"Merck, Pfizer combo treatment meets main goals of kidney cancer trial",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/xmwnHLsseW4/merck-pfizer-combo-treatment-meets-main-goals-of-kidney-cancer-trial-idINKCN1MS1OF,positive,0.5255518555641174
10/18/2018 1:36:14 PM,Merck Says Pivotal Phase 3 KEYNOTE-426 Trial Meets Both Primary Endpoints ,RTTNews,/news/stocks/merck-says-pivotal-phase-3-keynote-426-trial-meets-both-primary-endpoints-1027629567,positive,0.6148151755332947
10/21/2018 6:48:50 PM,"AstraZeneca, Merck Announce Results From Phase 3 SOLO-1 Trial On LYNPARZA 300 Mg ",RTTNews,/news/stocks/astrazeneca-merck-announce-results-from-phase-3-solo-1-trial-on-lynparza-300-mg-1027636228,neutral,0.5137504935264587
10/21/2018 9:04:24 PM,Merck KGaA says might strike partnership deal this year,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/shnzOtUj3TA/merck-kgaa-says-might-strike-partnership-deal-this-year-idUSL8N1X109G,positive,0.8302747011184692
10/22/2018 1:06:51 PM,Mark Reports Positive CHMP Opinion For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/mark-reports-positive-chmp-opinion-for-keytruda-quick-facts-1027638265,positive,0.9436787962913513
10/24/2018 3:02:28 PM,Here's what to expect from Merck's earnings report,Markets Insider Automation,/news/stocks/merckco-q3-quarterly-earnings-preview-stock-1027649674,neutral,0.9296486377716064
10/25/2018 12:50:39 PM,Merck reports third-quarter profit vs year-ago loss,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/S6ZDHG8K9V8/merck-reports-third-quarter-profit-vs-year-ago-loss-idUSL3N1X548X,positive,0.6278702020645142
10/25/2018 12:51:19 PM,Merck & Co Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q3-adjusted-earnings-beat-estimates-1027654035,positive,0.8186734318733215
10/25/2018 1:07:08 PM,UPDATE 1-Drugmaker Merck beats profit estimate on Keytruda strength,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/c0D17RlUQBE/update-1-drugmaker-merck-beats-profit-estimate-on-keytruda-strength-idUSL3N1X549E,negative,0.5464468002319336
10/25/2018 1:15:16 PM,Drugmaker Merck beats profit estimate on Keytruda strength,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/yWPiy7Gi_eU/drugmaker-merck-beats-profit-estimate-on-keytruda-strength-idINKCN1MZ1JZ,positive,0.476083368062973
10/25/2018 1:42:42 PM,"Merck Q3 Profit Tops View, But Sales Miss; Hikes Dividend ",RTTNews,/news/stocks/merck-q3-profit-tops-view-but-sales-miss-hikes-dividend-1027654428,negative,0.6021520495414734
10/25/2018 3:06:25 PM,Merck says to retain animal health business as part of company,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/P-9bM12z7vo/merck-says-to-retain-animal-health-business-as-part-of-company-idUSL3N1X556C,neutral,0.9294506311416626
10/25/2018 4:31:28 PM,"WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/OvMGGU-gAw0/wrapup-1-merck-bristol-myers-profits-rise-on-cancer-drug-sales-idUSL2N1X50QU,positive,0.9117908477783203
10/25/2018 4:43:58 PM,"Merck, Bristol-Myers profits rise on cancer drug sales",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/pc5HQS3rhF4/merck-bristol-myers-profits-rise-on-cancer-drug-sales-idUSKCN1MZ26I,positive,0.8140182495117188
10/25/2018 8:59:00 PM,"Merck & Co., Inc. -- Moody's: Merck's shareholder payouts credit negative",Moodys,/news/bonds/merck-co-inc-moody-s-merck-s-shareholder-payouts-credit-negative-1027656671,neutral,0.6748793721199036
10/29/2018 7:55:33 AM,Biotech Stocks Facing FDA Decision In November ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-1027663957,neutral,0.6474881172180176
10/30/2018 10:09:37 PM,"Merck: FDA Approves KEYTRUDA With Carboplatin, Paclitaxel/Nab-Paclitaxel ",RTTNews,/news/stocks/merck-fda-approves-keytruda-with-carboplatin-paclitaxel-nab-paclitaxel-1027673350,positive,0.7877978086471558
11/12/2018 8:25:19 AM,AstraZeneca Announces Positive Results From  DECLARE-TIMI 58 CV Outcomes Trial ,RTTNews,/news/stocks/astrazeneca-announces-positive-results-from-declare-timi-58-cv-outcomes-trial-1027714841,positive,0.9322463274002075
11/14/2018 12:55:26 PM,Merck cancer drug Keytruda succeeds in late-stage trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/y4LMBRd3WN8/merck-cancer-drug-keytruda-succeeds-in-late-stage-trial-idUSL4N1XP4X5,positive,0.7911023497581482
11/14/2018 12:57:43 PM,Merck Says KEYTRUDA Significantly Improves Overall Survival ,RTTNews,/news/stocks/merck-says-keytruda-significantly-improves-overall-survival-1027725074,positive,0.9569699168205261
11/14/2018 1:15:35 PM,UPDATE 1-Merck drug Keytruda succeeds in late-stage esophageal cancer trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/V_tOMrI3zko/update-1-merck-drug-keytruda-succeeds-in-late-stage-esophageal-cancer-trial-idUSL4N1XP4YT,neutral,0.4716354012489319
11/19/2018 2:17:44 PM,UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/PCLomQ6A2zg/update-1-palantir-to-offer-cancer-analytics-under-jv-deal-with-germanys-merck-idUSL8N1XU3S5,positive,0.8369761109352112
11/20/2018 10:27:59 AM,CORRECTED-UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/inCn9PfA9Tw/corrected-update-1-palantir-to-offer-cancer-analytics-under-jv-deal-with-germanys-merck-idUSL8N1XU3S5,positive,0.8195289373397827
11/26/2018 6:56:25 AM,Biotech Stocks Facing FDA Decision In December ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-1027753358,neutral,0.5557605028152466
11/29/2018 12:36:18 AM,Merck raised prices five drugs including Keytruda in November,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FZw9RLawzGo/merck-raised-prices-five-drugs-including-keytruda-in-november-idUSL2N1Y32BT,positive,0.8901082277297974
12/13/2018 3:16:23 AM,"Merck, Brazilian Non-profit Organization To Develop Dengue Vaccine ",RTTNews,/news/stocks/merck-brazilian-non-profit-organization-to-develop-dengue-vaccine-1027804561,neutral,0.8532177209854126
12/14/2018 12:58:17 PM,Merck to bolster animal health unit with $2.4 billion purchase of Antelliq,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Dqi_uMwveWI/merck-to-bolster-animal-health-unit-with-2-4-billion-purchase-of-antelliq-idUSL3N1YJ3VH,positive,0.8684077858924866
12/14/2018 1:02:01 PM,Merck To Buy Antelliq For EUR 2.1 Bln Plus Debt Of EUR 1.15 Bln ,RTTNews,/news/stocks/merck-to-buy-antelliq-for-eur-2-1-bln-plus-debt-of-eur-1-15-bln-1027809916,neutral,0.915763795375824
12/14/2018 1:05:44 PM,Merck to bolster animal health unit with $2.4 billion purchase of Antelliq,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/1TCvTFSM3mQ/merck-to-bolster-animal-health-unit-with-2-4-billion-purchase-of-antelliq-idUSKBN1OD1E4,positive,0.8684077858924866
12/14/2018 1:26:55 PM,UPDATE 1-Merck bolsters animal health unit with $2.4 billion Antelliq purchase,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/qtWqZScZfJI/update-1-merck-bolsters-animal-health-unit-with-2-4-billion-antelliq-purchase-idUSL3N1YJ3WG,positive,0.9148842096328735
12/14/2018 1:29:03 PM,Merck bolsters animal health unit with $2.4 billion Antelliq purchase,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/fbOwuWLrbzQ/merck-bolsters-animal-health-unit-with-2-4-billion-antelliq-purchase-idUSKBN1OD1E4,positive,0.8643823862075806
12/14/2018 1:35:07 PM,Merck to bolster animal health unit with $2.4 billion purchase of Antelliq,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Bo000QQ2XBQ/merck-to-bolster-animal-health-unit-with-2-4-billion-purchase-of-antelliq-idINKBN1OD1E1,positive,0.8684077858924866
12/14/2018 2:41:48 PM,UPDATE 2-Merck bolsters animal health unit with $2.4 bln Antelliq purchase,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/odbvM_iyWV0/update-2-merck-bolsters-animal-health-unit-with-2-4-bln-antelliq-purchase-idUSL3N1YJ3WG,positive,0.916526734828949
12/14/2018 2:57:47 PM,Merck bolsters animal health unit with $2.4 billion Antelliq purchase,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/HTDc7RCjVEw/merck-bolsters-animal-health-unit-with-2-4-billion-antelliq-purchase-idINKBN1OD1E1,positive,0.8643823862075806
12/17/2018 12:38:44 PM,Merck Announces Approval For KEYTRUDA In Adjuvant Setting In European Union ,RTTNews,/news/stocks/merck-announces-approval-for-keytruda-in-adjuvant-setting-in-european-union-1027813416,positive,0.6761705279350281
12/20/2018 8:23:20 AM,AstraZeneca & Merck & Co.: SOLO-3 Trial Of Lynparza Demonstrates Positive Result ,RTTNews,/news/stocks/astrazeneca-merck-co-solo-3-trial-of-lynparza-demonstrates-positive-result-1027823959,positive,0.9466283917427063
12/21/2018 8:12:23 PM,Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/v59G_hxXq0o/merck-kgaa-pfizer-to-terminate-late-stage-ovarian-cancer-treatment-study-idUSL3N1YQ4X8,neutral,0.7521155476570129
12/21/2018 8:30:05 PM,UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/TuQhTowtSqI/update-1-merck-kgaa-pfizer-to-end-late-stage-ovarian-cancer-treatment-study-idUSL3N1YQ4XF,positive,0.7220255732536316
12/21/2018 8:38:26 PM,CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Xcqc8-Cltgk/corrected-update-1-merck-kgaa-pfizer-to-end-late-stage-ovarian-cancer-treatment-study-idUSL3N1YQ4XF,positive,0.5893038511276245
12/21/2018 8:55:13 PM,UPDATE 2-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xWpRvg-XR6I/update-2-merck-kgaa-pfizer-to-end-late-stage-ovarian-cancer-treatment-study-idUSL3N1YQ4Z0,positive,0.6151848435401917
12/24/2018 11:13:44 AM,Biotech Stocks Facing FDA Decision In January 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2019-1027831124,neutral,0.7648583054542542
12/27/2018 9:47:47 AM,FDA Approves Sanofi And Merck's Pediatric Hexavalent Combination Vaccine Vaxelis ,RTTNews,/news/stocks/fda-approves-sanofi-and-merck-s-pediatric-hexavalent-combination-vaccine-vaxelis-1027833283,positive,0.5675104260444641
1/3/2019 12:36:59 PM,Merck Exercises Option For NGM Biopharma's Investigational Insulin Sensitizer ,RTTNews,/news/stocks/merck-exercises-option-for-ngm-biopharma-s-investigational-insulin-sensitizer-1027841264,neutral,0.5080404281616211
1/3/2019 12:56:10 PM,Merck's KEYTRUDA Gets Five New Approvals In Japan ,RTTNews,/news/stocks/merck-s-keytruda-gets-five-new-approvals-in-japan-1027841299,positive,0.8686392903327942
1/3/2019 9:16:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-reviews-bristol-myers-squibb-for-downgrade-1027842816,negative,0.7847278118133545
1/3/2019 9:26:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-reviews-bristol-myers-squibb-for-downgrade-1027842828,negative,0.7847278118133545
1/7/2019 3:48:15 PM,Merck loses bid to revive $200 mln Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ieFk6YgBhYY/merck-loses-bid-to-revive-200-mln-gilead-verdict-at-u-s-high-court-idUSW1N1TK00G,negative,0.7543098330497742
1/7/2019 3:54:08 PM,UPDATE 1-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/IdljOkdnYbo/update-1-merck-loses-bid-to-revive-200-mln-gilead-verdict-at-u-s-high-court-idUSL1N1Z70LU,negative,0.9223768711090088
1/7/2019 4:25:09 PM,UPDATE 2-Merck loses bid to revive $200 mln Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yPEib8rpEuI/update-2-merck-loses-bid-to-revive-200-mln-gilead-verdict-at-u-s-high-court-idUSL1N1Z70LU,negative,0.9188156723976135
1/7/2019 4:26:31 PM,Merck loses bid to revive $200 million Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/wVKzwv_Ffyg/merck-loses-bid-to-revive-200-million-gilead-verdict-at-u-s-high-court-idUSKCN1P11G5,negative,0.7284138798713684
1/7/2019 4:29:42 PM,Merck loses bid to revive $200 million Gilead verdict at U.S. high court,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/ZIDAPqj0Xrw/merck-loses-bid-to-revive-200-million-gilead-verdict-at-u-s-high-court-idINKCN1P11IN,negative,0.7284138798713684
1/7/2019 5:50:24 PM,U.S. Supreme Court could side with Merck over Fosamax lawsuits,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yXYJvBMqdhE/u-s-supreme-court-could-side-with-merck-over-fosamax-lawsuits-idUSL1N1Z70GU,negative,0.7026051878929138
1/7/2019 7:31:49 PM,UPDATE 1-U.S. Supreme Court could side with Merck over Fosamax lawsuits,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/K40Z5h_Zemc/update-1-u-s-supreme-court-could-side-with-merck-over-fosamax-lawsuits-idUSL1N1Z70YJ,negative,0.7700754404067993
1/18/2019 9:35:54 PM,Samsung Bioepis-Merck biosimilar to Roche's Herceptin wins FDA nod,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/I592HAdcghc/samsung-bioepis-merck-biosimilar-to-roches-herceptin-wins-fda-nod-idUSL3N1ZI49T,positive,0.9289121627807617
1/23/2019 11:49:08 AM,"Merck, Tencent Sign Deal On Intelligent Digital Healthcare Services In China ",RTTNews,/news/stocks/merck-tencent-sign-deal-on-intelligent-digital-healthcare-services-in-china-1027888760,positive,0.8596094250679016
1/30/2019 8:19:45 AM,Biotech Stocks Facing FDA Decision In February ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-1027907714,neutral,0.7358179092407227
1/30/2019 12:55:40 PM,Merck Receives FDA Breakthrough Therapy Designation For V114 - Quick Facts ,RTTNews,/news/stocks/merck-receives-fda-breakthrough-therapy-designation-for-v114-quick-facts-1027908455,positive,0.8982157111167908
1/31/2019 3:01:54 PM,Here's what Wall Street expects from Merck's earnings,Markets Insider Automation,/news/stocks/merckco-q4-earnings-preview-stock-1027913183,neutral,0.9255590438842773
2/1/2019 12:50:57 PM,Merck & Co Inc. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q4-adjusted-earnings-beat-estimates-1027916181,positive,0.8711258172988892
2/1/2019 1:08:46 PM,UPDATE 1-Merck quarterly profit beats estimates on Keytruda strength,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Imiou9LYgug/update-1-merck-quarterly-profit-beats-estimates-on-keytruda-strength-idUSL3N1ZW3Z5,neutral,0.3963485658168793
2/1/2019 1:30:12 PM,Merck Q4 Results Beat Estimates ,RTTNews,/news/stocks/merck-q4-results-beat-estimates-1027916300,positive,0.8749092221260071
2/1/2019 2:08:04 PM,UPDATE 2-Merck quarterly profit beats estimates on Keytruda strength,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/PcIhkyt8_uc/update-2-merck-quarterly-profit-beats-estimates-on-keytruda-strength-idUSL3N1ZW3Z5,negative,0.4262109100818634
2/4/2019 12:59:26 PM,Merck Gets Positive CHMP Opinion For Keytruda In Combination With Chemotherapy ,RTTNews,/news/stocks/merck-gets-positive-chmp-opinion-for-keytruda-in-combination-with-chemotherapy-1027920371,positive,0.924523651599884
2/5/2019 12:57:16 PM,Merck: FDA To Review Regulatory Filings By Company For Two Antibacterial Agents ,RTTNews,/news/stocks/merck-fda-to-review-regulatory-filings-by-company-for-two-antibacterial-agents-1027924731,negative,0.7189443707466125
2/5/2019 4:34:09 PM,GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/TVbhWyOChv4/gsk-pays-up-to-4-2-billion-for-merck-kgaa-cancer-immunotherapy-idUSKCN1PU1A9,neutral,0.8065701127052307
2/5/2019 6:58:07 PM,Merck CEO Frazier plans to testify at Senate drug pricing hearing,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uelA6Uy2jy4/merck-ceo-frazier-plans-to-testify-at-senate-drug-pricing-hearing-idUSL1N20012D,neutral,0.9315692782402039
2/5/2019 7:30:55 PM,UPDATE 1-Merck CEO Frazier plans to testify at Senate drug pricing hearing,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9POB9AfQmdk/update-1-merck-ceo-frazier-plans-to-testify-at-senate-drug-pricing-hearing-idUSL1N20013L,neutral,0.9243170619010925
2/5/2019 10:10:25 PM,Merck CEO Frazier to testify at Senate drug pricing hearing,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/9a_t8lnmNec/merck-ceo-frazier-to-testify-at-senate-drug-pricing-hearing-idUSKCN1PU23E,neutral,0.8215759992599487
2/7/2019 3:36:00 PM,Moody's -  Accelerating efforts to lower drug prices raise financial risk for drug companies,Moodys,/news/bonds/moody-s-accelerating-efforts-to-lower-drug-prices-raise-financial-risk-for-drug-companies-1027934159,positive,0.9009013772010803
2/12/2019 1:43:19 AM,"Merck, Pfizer combo treatment boosts kidney cancer survival",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/IxnI8eQTgp0/merck-pfizer-combo-treatment-boosts-kidney-cancer-survival-idUSL1N20700Q,positive,0.7883021235466003
2/12/2019 2:01:26 AM,"REFILE-Merck, Pfizer combo treatment boosts kidney cancer survival",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/K4omwek1PZM/refile-merck-pfizer-combo-treatment-boosts-kidney-cancer-survival-idUSL1N20700Q,positive,0.7729389071464539
2/14/2019 1:08:57 PM,Merck to further study Keytruda in prostate cancer after early success,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5gwr-KRMXa8/merck-to-further-study-keytruda-in-prostate-cancer-after-early-success-idUSL3N209485,positive,0.638719379901886
2/14/2019 3:45:22 PM,REFILE-Merck to further study Keytruda in prostate cancer after early success,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zwqzexh5dkE/refile-merck-to-further-study-keytruda-in-prostate-cancer-after-early-success-idUSL3N209485,positive,0.6701605916023254
2/15/2019 10:06:00 PM,"Merck Sharp & Dohme Corp. -- Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.",Moodys,/news/bonds/merck-sharp-dohme-corp-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-merck-co-inc-1027957861,neutral,0.8242955803871155
2/16/2019 11:10:00 PM,"Merck, Pfizer drug combo extends kidney cancer survival -study",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/x_xlGUpowfY/merck-pfizer-drug-combo-extends-kidney-cancer-survival-study-idUSL3N2094UY,positive,0.8723694086074829
2/20/2019 6:13:18 AM,"FDA Nod For NVO's Hemophilia A Drug, ICPT's NASH Trial Hits Goal, NVTA Abuzz ",RTTNews,/news/stocks/fda-nod-for-nvo-s-hemophilia-a-drug-icpt-s-nash-trial-hits-goal-nvta-abuzz-1027966173,positive,0.8868404626846313
2/20/2019 12:58:24 PM,Merck: FDA Grants Priority Review To SBLA For Keytruda Monotherapy ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-monotherapy-1027967372,positive,0.7272250056266785
2/21/2019 12:53:03 PM,Merck To Buy Immune Design In $300 Mln Deal ,RTTNews,/news/stocks/merck-to-buy-immune-design-in-300-mln-deal-1027971443,neutral,0.923554539680481
2/21/2019 12:56:00 PM,Merck to buy cancer drug developer Immune Design for $300 mln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uik0KMuM1Ls/merck-to-buy-cancer-drug-developer-immune-design-for-300-mln-idUSL3N20G44L,neutral,0.8857101798057556
2/21/2019 1:14:47 PM,UPDATE 1-Merck to buy immunotherapy developer Immune Design for $300 mln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/hEVI_ET07O4/update-1-merck-to-buy-immunotherapy-developer-immune-design-for-300-mln-idUSL3N20G45E,neutral,0.7423117756843567
2/22/2019 5:57:41 AM,"IMDZ Snapped Up, NVRO Falls On Dim Outlook, OPNT Ceases Bulimia Nervosa Trial ",RTTNews,/news/stocks/imdz-snapped-up-nvro-falls-on-dim-outlook-opnt-ceases-bulimia-nervosa-trial-1027974284,negative,0.932833731174469
2/26/2019 9:07:57 AM,"AstraZeneca, MSD Say Phase III POLO Trial Meets Primary Endpoint Of PFS ",RTTNews,/news/stocks/astrazeneca-msd-say-phase-iii-polo-trial-meets-primary-endpoint-of-pfs-1027983132,positive,0.829191267490387
2/27/2019 2:21:40 PM,Germany's Merck makes $5.9 bln cash counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/aIJqqhMP1Fs/germanys-merck-makes-5-9-bln-cash-counterbid-for-versum-idUSFWN20M10G,neutral,0.7056307792663574
2/27/2019 2:26:51 PM,Germany's Merck makes $5.9 billion cash counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/7IZnqQsYTOs/germanys-merck-makes-5-9-billion-cash-counterbid-for-versum-idUSKCN1QG1TN,neutral,0.7976505756378174
2/27/2019 3:00:43 PM,UPDATE 1-Germany's Merck makes $5.9 bln counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/R2-syDVwe5Q/update-1-germanys-merck-makes-5-9-bln-counterbid-for-versum-idUSL5N20M5Q7,positive,0.49791282415390015
2/27/2019 3:06:43 PM,Germany's Merck makes $5.9 billion counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/NzxXgrERusU/germanys-merck-makes-5-9-billion-counterbid-for-versum-idUSKCN1QG1TN,neutral,0.7858895063400269
2/27/2019 4:28:14 PM,UPDATE 2-Germany's Merck makes $5.9 bln counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/vkLYfzYyw74/update-2-germanys-merck-makes-5-9-bln-counterbid-for-versum-idUSL5N20M5Q7,neutral,0.47440212965011597
2/27/2019 5:55:38 PM,UPDATE 3-Germany's Merck makes $5.9 bln counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/GX71V6YK5wc/update-3-germanys-merck-makes-5-9-bln-counterbid-for-versum-idUSL5N20M5Q7,positive,0.48341959714889526
2/27/2019 8:48:31 PM,UPDATE 4-Germany's Merck makes $5.9 bln counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/C8yuMm0eWBw/update-4-germanys-merck-makes-5-9-bln-counterbid-for-versum-idUSL5N20M5Q7,positive,0.5020999312400818
2/27/2019 9:09:00 PM,Germany's Merck makes $5.9 billion countrebid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/N13mD_-s0Sc/germanys-merck-makes-5-9-billion-countrebid-for-versum-idINKCN1QG2QO,neutral,0.8636795878410339
2/27/2019 10:40:17 PM,UPDATE 5-Germany's Merck makes $5.9 bln counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/U7flIlJkscQ/update-5-germanys-merck-makes-5-9-bln-counterbid-for-versum-idUSL5N20M5Q7,positive,0.4736253023147583
2/27/2019 11:06:41 PM,Germany's Merck makes $5.9 bln counterbid for Versum,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/vYK6DoNONZE/germanys-merck-makes-5-9-bln-counterbid-for-versum-idINKCN1QG2QO,neutral,0.6991345286369324
3/1/2019 8:52:49 AM,Alzheimer's Trials That Flopped In 2018 ,RTTNews,/news/stocks/alzheimer-s-trials-that-flopped-in-2018-1027996055,neutral,0.8548865914344788
3/1/2019 5:09:48 PM,Versum Materials rejects Merck KGaA's unsolicited offer,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JSz1zeCFY3U/versum-materials-rejects-merck-kgaas-unsolicited-offer-idUSL3N20O4LU,neutral,0.8850314021110535
3/1/2019 7:23:46 PM,UPDATE 1-Versum Materials rejects Merck KGaA's unsolicited offer,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rq1eFMQpYU4/update-1-versum-materials-rejects-merck-kgaas-unsolicited-offer-idUSL3N20O4QO,neutral,0.6438336968421936
3/4/2019 12:55:03 PM,Merck : EMA Adopts Positive Opinion For KEYTRUDA ,RTTNews,/news/stocks/merck-ema-adopts-positive-opinion-for-keytruda-1028000407,positive,0.938412606716156
3/5/2019 12:44:48 PM,Merck KGaA urges Versum shareholders to pipe up for rival bid,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9CZ72u3CfOE/merck-kgaa-urges-versum-shareholders-to-pipe-up-for-rival-bid-idUSFWN20S0CH,neutral,0.7919021844863892
3/5/2019 2:14:33 PM,UPDATE 1-Merck KGaA urges Versum shareholders to support takeover bid,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2KtcvVkWxLg/update-1-merck-kgaa-urges-versum-shareholders-to-support-takeover-bid-idUSL5N20S3I4,positive,0.8433504700660706
3/5/2019 5:26:48 PM,UPDATE 2-Merck KGaA urges Versum shareholders to support takeover bid,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9u98vA4fNcU/update-2-merck-kgaa-urges-versum-shareholders-to-support-takeover-bid-idUSL5N20S3I4,positive,0.8382793068885803
3/5/2019 5:44:00 PM,"Merck & Co., Inc. -- Moody's assigns A1 rating to Merck's notes; stable outlook",Moodys,/news/bonds/merck-co-inc-moody-s-assigns-a1-rating-to-merck-s-notes-stable-outlook-1028006070,positive,0.7909275889396667
3/7/2019 1:37:12 PM,UPDATE 2-Merck KGaA encouraged by market reaction to Versum swoop,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dng5oFRy3SU/update-2-merck-kgaa-encouraged-by-market-reaction-to-versum-swoop-idUSL5N20U0TP,positive,0.9403877854347229
3/8/2019 12:05:13 PM,Merck KGaA mandates Goldman as additional advisor for Versum deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/c0YBhqPSb1s/merck-kgaa-mandates-goldman-as-additional-advisor-for-versum-deal-idUSL5N20V2B5,neutral,0.8683220744132996
3/8/2019 4:33:10 PM,"UPDATE 1-Versum, Entegris see extra merger benefits, Merck hires Goldman",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5Zgr0tro-qA/update-1-versum-entegris-see-extra-merger-benefits-merck-hires-goldman-idUSL5N20V3T1,neutral,0.4974537193775177
3/12/2019 5:02:33 PM,Merck KGaA calls on Versum investors to vote down Entegris merger,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Lz-OhE0U8bg/merck-kgaa-calls-on-versum-investors-to-vote-down-entegris-merger-idUSL8N20Z5OJ,neutral,0.801120400428772
3/14/2019 12:09:23 PM,Merck: EU Approves KEYTRUDA Plus Chemotherapy To Treat Metastatic Squamous NSCLC ,RTTNews,/news/stocks/merck-eu-approves-keytruda-plus-chemotherapy-to-treat-metastatic-squamous-nsclc-1028030241,positive,0.8966295719146729
3/18/2019 1:13:04 PM,Merck Announces Label Expansion For KEYTRUDA In Canada - Quick Facts ,RTTNews,/news/stocks/merck-announces-label-expansion-for-keytruda-in-canada-quick-facts-1028037687,neutral,0.6354654431343079
3/20/2019 12:10:19 PM,"Merck, NGM Bio Extend Broad, Strategic Collaboration To March 2022 ",RTTNews,/news/stocks/merck-ngm-bio-extend-broad-strategic-collaboration-to-march-2022-1028044757,positive,0.695001482963562
3/20/2019 12:46:19 PM,Merck To Invest EUR 1 Bln Until 2025 At Darmstadt Site - Quick Facts ,RTTNews,/news/stocks/merck-to-invest-eur-1-bln-until-2025-at-darmstadt-site-quick-facts-1028044903,neutral,0.895761251449585
3/26/2019 11:53:56 AM,Merck KGaA makes takeover offer for Versum to shareholders,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sXH1aqMFW4Q/merck-kgaa-makes-takeover-offer-for-versum-to-shareholders-idUSFWN21D0GO,neutral,0.9198601841926575
3/26/2019 12:02:30 PM,Merck KGaA makes takeover offer for Versum to shareholders,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/OzQX2Cun_Tk/merck-kgaa-makes-takeover-offer-for-versum-to-shareholders-idINKCN1R714Q,neutral,0.9198601841926575
3/26/2019 12:16:18 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1028058579,neutral,0.7716754078865051
3/26/2019 12:43:36 PM,UPDATE 1-Merck KGaA goes hostile in $5.9 bln Versum takeover battle,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/eDlSfrFnJZI/update-1-merck-kgaa-goes-hostile-in-5-9-bln-versum-takeover-battle-idUSL8N21D2X1,negative,0.6284334659576416
3/26/2019 12:50:42 PM,Merck KGaA goes hostile in $5.9 billion Versum takeover battle,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/sWP1xnJUZGA/merck-kgaa-goes-hostile-in-5-9-billion-versum-takeover-battle-idINKCN1R714Q,neutral,0.6433035135269165
3/26/2019 2:58:41 PM,UPDATE 2-Merck KGaA goes hostile in $5.9 bln Versum takeover battle,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/98vu3IdMQuk/update-2-merck-kgaa-goes-hostile-in-5-9-bln-versum-takeover-battle-idUSL8N21D2X1,negative,0.6021651029586792
3/26/2019 3:03:15 PM,Merck KGaA goes hostile in $5.9 billion Versum takeover battle,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/g9WwDzaeU6c/merck-kgaa-goes-hostile-in-5-9-billion-versum-takeover-battle-idUSKCN1R714D,neutral,0.6433035135269165
3/26/2019 5:37:31 PM,UPDATE 3-Merck KGaA goes hostile in $5.9 bln Versum takeover battle,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/suHQtlgatMc/update-3-merck-kgaa-goes-hostile-in-5-9-bln-versum-takeover-battle-idUSL8N21D2X1,negative,0.5771961212158203
3/26/2019 10:28:45 PM,UPDATE 4-Merck KGaA goes hostile in $5.9 bln Versum takeover battle,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/YXcat0bURSk/update-4-merck-kgaa-goes-hostile-in-5-9-bln-versum-takeover-battle-idUSL8N21D2X1,negative,0.602697491645813
3/29/2019 1:23:05 PM,Versum urges shareholders to reject Merck KGaA hostile bid,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wj4K1yBCUEg/versum-urges-shareholders-to-reject-merck-kgaa-hostile-bid-idUSL3N21G3D2,neutral,0.8742325901985168
3/29/2019 1:40:58 PM,UPDATE 1-Versum urges shareholders to reject Merck KGaA hostile bid,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-gkSbPBSo6s/update-1-versum-urges-shareholders-to-reject-merck-kgaa-hostile-bid-idUSL3N21G3FW,neutral,0.5622338056564331
3/29/2019 2:13:54 PM,CORRECTED-UPDATE 1-Versum urges shareholders to reject Merck KGaA hostile bid,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4JvtbzEgEs4/corrected-update-1-versum-urges-shareholders-to-reject-merck-kgaa-hostile-bid-idUSL3N21G3FW,neutral,0.7086325883865356
3/29/2019 2:26:37 PM,"Merck KGaA welcomes Versum's decision to talk, keeps tender going",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/emYWQ8JarvY/merck-kgaa-welcomes-versums-decision-to-talk-keeps-tender-going-idUSL8N21G4IP,positive,0.5871771574020386
3/29/2019 4:04:11 PM,"UPDATE 2-Versum opens books, begins to warm to rival suitor Merck KGaA",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/h9HsIe4IRPc/update-2-versum-opens-books-begins-to-warm-to-rival-suitor-merck-kgaa-idUSL3N21G3QZ,positive,0.9417685866355896
3/29/2019 4:06:07 PM,"Versum opens books, begins to warm to rival suitor Merck KGaA",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/GP1Oo3t6W-4/versum-opens-books-begins-to-warm-to-rival-suitor-merck-kgaa-idUSKCN1RA1E1,positive,0.9143325686454773
3/29/2019 7:00:26 PM,"UPDATE 3-Versum opens books, begins to warm to rival suitor Merck KGaA",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/BDhC2yzMZrk/update-3-versum-opens-books-begins-to-warm-to-rival-suitor-merck-kgaa-idUSL3N21G3QZ,positive,0.9406111240386963
4/1/2019 8:37:10 AM,AstraZeneca: Selumetinib Gets US Breakthrough Therapy Designation ,RTTNews,/news/stocks/astrazeneca-selumetinib-gets-us-breakthrough-therapy-designation-1028073332,positive,0.8720698952674866
4/1/2019 2:58:21 PM,Merck Announces Post-hoc Analysis From KEYNOTE-189 Trial - Quick Facts ,RTTNews,/news/stocks/merck-announces-post-hoc-analysis-from-keynote-189-trial-quick-facts-1028074699,neutral,0.9402921795845032
4/2/2019 1:05:00 PM,Merck Reports Successful Completion Of Cash Tender Offer For Immune Design ,RTTNews,/news/stocks/merck-reports-successful-completion-of-cash-tender-offer-for-immune-design-1028077703,positive,0.9433773159980774
4/5/2019 1:42:01 PM,Endo Unit Begins Shipping Generic Version Of Merck's PROVENTIL - Quick Facts ,RTTNews,/news/stocks/endo-unit-begins-shipping-generic-version-of-merck-s-proventil-quick-facts-1028089103,neutral,0.7811968922615051
4/8/2019 12:07:11 PM,Merck KGaA raises offer for Versum Materials to $53 per share,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/zDBlWe9OlDM/merck-kgaa-raises-offer-for-versum-materials-to-53-per-share-idUSL3N21Q2IP,positive,0.6841245293617249
4/8/2019 1:25:23 PM,UPDATE 1-Merck KGaA wins Versum's support for sweetened $6.5 bln offer,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-rEI2aWTaW4/update-1-merck-kgaa-wins-versums-support-for-sweetened-6-5-bln-offer-idUSL3N21Q2LX,positive,0.9350816607475281
4/8/2019 1:29:17 PM,Merck KGaA wins Versum's support for sweetened $6.5 billion offer,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/EUkchtuc468/merck-kgaa-wins-versums-support-for-sweetened-6-5-billion-offer-idUSKCN1RK13V,positive,0.8966401815414429
4/8/2019 4:39:18 PM,UPDATE 2-Merck KGaA wins Versum's support for sweetened $6.5 bln offer,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/m2fijcv6NXY/update-2-merck-kgaa-wins-versums-support-for-sweetened-6-5-bln-offer-idUSL3N21Q2LX,positive,0.9311015605926514
4/10/2019 8:16:29 AM,AstraZeneca: EU Spproves Lynparza As Monotherapy For Germline BRCA1/2-mutations ,RTTNews,/news/stocks/astrazeneca-eu-spproves-lynparza-as-monotherapy-for-germline-brca1-2-mutations-1028098927,neutral,0.795071542263031
4/12/2019 2:16:09 PM,Merck KGaA agrees $6.5 bln takeover of Versum,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cjJyPfuDVyg/merck-kgaa-agrees-6-5-bln-takeover-of-versum-idUSL8N21U3GH,neutral,0.8949375748634338
4/12/2019 2:20:18 PM,Merck KGaA agrees $6.5 billion takeover of Versum,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/4KoS20pOpu8/merck-kgaa-agrees-6-5-billion-takeover-of-versum-idUSKCN1RO1GI,neutral,0.8860344886779785
4/12/2019 4:02:48 PM,UPDATE 1-Merck KGaA clinches $6.5 bln Versum takeover in bet on electrochemicals,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/96tmpBmNOls/update-1-merck-kgaa-clinches-6-5-bln-versum-takeover-in-bet-on-electrochemicals-idUSL8N21U3H6,neutral,0.49695539474487305
4/12/2019 4:05:04 PM,Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/wwc9x2y16og/merck-kgaa-clinches-6-5-billion-versum-takeover-in-bet-on-electrochemicals-idUSKCN1RO1GI,neutral,0.5139013528823853
4/16/2019 12:26:00 PM,Merck Financial Services GmbH -- Moody's affirms Merck KGaA's ratings; stable outlook,Moodys,/news/bonds/merck-financial-services-gmbh-moody-s-affirms-merck-kgaa-s-ratings-stable-outlook-1028113905,positive,0.8518617153167725
4/17/2019 6:10:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-s-exchange-notes-under-review-for-downgrade-1028119344,neutral,0.6404576301574707
4/17/2019 6:43:00 PM,EMD FINANCE LLC -- Moody's affirms Merck KGaA's ratings; stable outlook,Moodys,/news/bonds/emd-finance-llc-moody-s-affirms-merck-kgaa-s-ratings-stable-outlook-1028119422,positive,0.9107165932655334
4/22/2019 2:25:33 PM,Merck: FDA Approves KEYTRUDA-Inlyta Combination - Quick Facts ,RTTNews,/news/stocks/merck-fda-approves-keytruda-inlyta-combination-quick-facts-1028126136,neutral,0.6478493213653564
4/29/2019 8:19:02 AM,AstraZeneca: Lynparza Receives Positive CHMP Opinion For Expanded Indication ,RTTNews,/news/stocks/astrazeneca-lynparza-receives-positive-chmp-opinion-for-expanded-indication-1028147077,positive,0.9459195733070374
4/29/2019 3:02:37 PM,Merck earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/merckco-q1-quarterly-earnings-preview-stock-1028148523,neutral,0.914770245552063
4/30/2019 12:53:15 PM,Merck & Co Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q1-adjusted-earnings-beat-estimates-1028152678,positive,0.8450100421905518
4/30/2019 1:01:33 PM,Merck revenue up 8 pct on higher Keytruda sales,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/01Z92uwHl5A/merck-revenue-up-8-pct-on-higher-keytruda-sales-idUSL3N22C2M3,positive,0.9478796720504761
4/30/2019 2:30:07 PM,UPDATE 2-Merck raises full-year forecasts as vaccines power profit beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pJjRWDX4KG0/update-2-merck-raises-full-year-forecasts-as-vaccines-power-profit-beat-idUSL3N22C2S0,positive,0.8282057642936707
4/30/2019 4:45:30 PM,UPDATE 3-Merck raises full-year forecasts as vaccines power profit beat,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ZcQq2z7PVC4/update-3-merck-raises-full-year-forecasts-as-vaccines-power-profit-beat-idUSL3N22C2S0,positive,0.8290237784385681
4/30/2019 4:47:52 PM,Merck raises full-year forecasts as vaccines power profit beat,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/vDKLRfKkDv4/merck-raises-full-year-forecasts-as-vaccines-power-profit-beat-idUSKCN1S616K,neutral,0.6280611157417297
4/30/2019 5:37:24 PM,Merck raises full-year forecasts as vaccines power profit beat,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/28EBCw4ARwE/merck-raises-full-year-forecasts-as-vaccines-power-profit-beat-idINKCN1S61V4,neutral,0.6280611157417297
5/1/2019 10:03:49 PM,Merck steps up U.S. measles vaccine production with increased demand,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3-YU5Qg-aKw/merck-steps-up-u-s-measles-vaccine-production-with-increased-demand-idUSL1N22D130,positive,0.9339961409568787
5/1/2019 10:09:43 PM,Merck steps up U.S. measles vaccine production with increased demand,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/_tfvTew2SlE/merck-steps-up-u-s-measles-vaccine-production-with-increased-demand-idINKCN1S74M8,positive,0.9339961409568787
5/2/2019 6:07:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-s-sr-notes-under-review-for-downgrade-1028163037,neutral,0.6136662364006042
5/7/2019 1:18:20 PM,Merck: Phase 3 Trial Of BELSOMRA C-IV Meets Primary Efficacy Endpoints ,RTTNews,/news/stocks/merck-phase-3-trial-of-belsomra-c-iv-meets-primary-efficacy-endpoints-1028175798,positive,0.8571287989616394
5/14/2019 7:20:08 AM,Merck KGaA sees currencies supporting 2019 outlook,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/h693Vdj5bqQ/merck-kgaa-sees-currencies-supporting-2019-outlook-idUSL5N22P5R3,positive,0.9184830784797668
5/20/2019 4:21:06 PM,U.S. Supreme Court tosses ruling against Merck on Fosamax osteoporosis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/HQStdz4tlm4/u-s-supreme-court-tosses-ruling-against-merck-on-fosamax-osteoporosis-drug-idUSW1N1TK02C,negative,0.8795064091682434
5/20/2019 4:33:01 PM,UPDATE 1-U.S. Supreme Court tosses ruling against Merck on Fosamax osteoporosis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uHjRup-8h60/update-1-u-s-supreme-court-tosses-ruling-against-merck-on-fosamax-osteoporosis-drug-idUSL2N22W0HT,negative,0.8576751947402954
5/20/2019 5:34:16 PM,UPDATE 2-U.S. Supreme Court tosses ruling against Merck on Fosamax osteoporosis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-cFUUfd0PCQ/update-2-u-s-supreme-court-tosses-ruling-against-merck-on-fosamax-osteoporosis-drug-idUSL2N22W0HT,negative,0.8643389344215393
5/20/2019 8:14:39 PM,UPDATE 3-U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wwMI7Zgb6pU/update-3-u-s-supreme-court-gives-merck-another-shot-to-avoid-fosamax-lawsuits-idUSL2N22W0HT,positive,0.7172900438308716
5/21/2019 1:37:26 AM,Merck's Keytruda Fails Late Stage Clinical Trial ,RTTNews,/news/stocks/merck-s-keytruda-fails-late-stage-clinical-trial-1028215930,negative,0.6729481220245361
5/21/2019 12:53:22 PM,Merck to buy cancer drug developer Peloton for $1.05 bln in cash,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AUd2tW7RltI/merck-to-buy-cancer-drug-developer-peloton-for-1-05-bln-in-cash-idUSL4N22X2VF,neutral,0.8958243131637573
5/21/2019 12:56:02 PM,Merck to buy cancer drug developer Peloton for $1.05 billion in cash,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Bo-Q9Qh43QE/merck-to-buy-cancer-drug-developer-peloton-for-1-05-billion-in-cash-idUSKCN1SR136,neutral,0.8801160454750061
5/21/2019 1:12:54 PM,UPDATE 1-Merck to buy cancer drug developer Peloton for $1.05 bln in cash,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/68OBsyzOMvs/update-1-merck-to-buy-cancer-drug-developer-peloton-for-1-05-bln-in-cash-idUSL4N22X2VR,neutral,0.8423917889595032
5/21/2019 1:18:00 PM,Merck To Acquire Peloton - Quick Facts ,RTTNews,/news/stocks/merck-to-acquire-peloton-quick-facts-1028217297,neutral,0.935604453086853
5/21/2019 4:17:17 PM,UPDATE 2-Merck buys Peloton to expand its kidney cancer treatment portfolio,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9y2ko-HqLcI/update-2-merck-buys-peloton-to-expand-its-kidney-cancer-treatment-portfolio-idUSL4N22X2VR,positive,0.9014421701431274
5/21/2019 4:18:14 PM,Merck buys Peloton to expand its kidney cancer treatment portfolio,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/pnVqDauOCv4/merck-buys-peloton-to-expand-its-kidney-cancer-treatment-portfolio-idUSKCN1SR136,positive,0.797173261642456
5/21/2019 4:42:35 PM,REFILE-UPDATE 2-Merck buys Peloton to expand its kidney cancer treatment portfolio,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/xoRKOWapTDA/refile-update-2-merck-buys-peloton-to-expand-its-kidney-cancer-treatment-portfolio-idUSL4N22X2VR,positive,0.8703302145004272
5/22/2019 8:42:16 PM,Congo wants more use of Merck vaccine rather than J&J newcomer - minister,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3RqWavnML0E/congo-wants-more-use-of-merck-vaccine-rather-than-jj-newcomer-minister-idUSL5N22Y62Q,neutral,0.8593930602073669
5/25/2019 5:16:57 AM,Biotech Stocks Facing FDA Decision In June 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2019-1028230263,neutral,0.8650785684585571
6/3/2019 8:16:00 PM,Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations,PR Newswire,/news/stocks/merck-presents-updated-results-for-investigational-therapy-tepotinib-demonstrating-durable-clinical-response-in-patients-with-advanced-nsclc-with-metex14-skipping-mutations-1028249946,positive,0.953501284122467
6/3/2019 9:35:43 PM,Merck wins U.S. FDA approval for expanded use of antibiotic,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/w7qhZYH0yvk/merck-wins-u-s-fda-approval-for-expanded-use-of-antibiotic-idUSL4N23A3YS,positive,0.862419843673706
6/3/2019 9:41:36 PM,Merck wins U.S. FDA approval for expanded use of antibiotic,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/hRSFFYLls3s/merck-wins-u-s-fda-approval-for-expanded-use-of-antibiotic-idINKCN1T42M6,positive,0.862419843673706
6/3/2019 9:59:48 PM,UPDATE 1-Merck wins U.S. FDA approval for expanded use of antibiotic,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Q3QedurshfM/update-1-merck-wins-u-s-fda-approval-for-expanded-use-of-antibiotic-idUSL4N23A3Z4,positive,0.9166457056999207
6/5/2019 11:10:17 AM,Investors Aren’t Likely to Clean up on Procter & Gamble Stock,InvestorPlace,/news/stocks/investors-clean-procter-gamble-stock-1028258521,negative,0.6199531555175781
6/10/2019 12:54:51 PM,Merck to buy Tilos Therapeutics for up to $773 mln,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/DFFkMuY2KAE/merck-to-buy-tilos-therapeutics-for-up-to-773-mln-idUSL4N23H2BS,neutral,0.8469499945640564
6/10/2019 1:39:48 PM,Merck To Acquire Tilos Therapeutics In Up To $773 Mln Deal - Quick Facts ,RTTNews,/news/stocks/merck-to-acquire-tilos-therapeutics-in-up-to-773-mln-deal-quick-facts-1028266157,neutral,0.8045182228088379
6/11/2019 2:03:00 PM,Merck Announces FDA Approval Of Two New Indications For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-announces-fda-approval-of-two-new-indications-for-keytruda-quick-facts-1028269446,positive,0.6656067967414856
6/13/2019 2:49:55 PM,"IBM, KPMG, Merck And Walmart Collaborate For Drug Supply Chain Blockchain Pilot ",RTTNews,/news/stocks/ibm-kpmg-merck-and-walmart-collaborate-for-drug-supply-chain-blockchain-pilot-1028277086,neutral,0.8136677145957947
6/14/2019 6:59:58 PM,7 Top-Rated Biotech Stocks to Invest In Today,InvestorPlace,/news/stocks/7-healthy-biotech-stocks-to-invest-in-1028281710,neutral,0.7840100526809692
6/17/2019 6:58:20 PM,The 5 Worst Dow Jones Stocks So Far in 2019,InvestorPlace,/news/stocks/the-5-worst-dow-jones-stocks-so-far-in-2019-1028285881,negative,0.9411437511444092
6/18/2019 8:20:16 AM,AstraZeneca: EC Oks Lynparza As Maintenance Treatment For Ovarian Cancer ,RTTNews,/news/stocks/astrazeneca-ec-oks-lynparza-as-maintenance-treatment-for-ovarian-cancer-1028286076,neutral,0.6873894333839417
6/18/2019 1:01:32 PM,Merck Reports First Approval For KEYTRUDA In Small Cell Lung Cancer ,RTTNews,/news/stocks/merck-reports-first-approval-for-keytruda-in-small-cell-lung-cancer-1028287061,positive,0.7851201891899109
6/18/2019 4:03:00 PM,Merck KGaA -- Moody's: Versum shareholders approve acquisition by Merck KGaA,Moodys,/news/bonds/merck-kgaa-moody-s-versum-shareholders-approve-acquisition-by-merck-kgaa-1028288376,neutral,0.826642632484436
6/19/2019 9:06:39 AM,AstraZeneca Receives Japanese Approval For Lung Disease Treatment ,RTTNews,/news/stocks/astrazeneca-receives-japanese-approval-for-lung-disease-treatment-1028290271,positive,0.9173698425292969
6/20/2019 1:35:01 PM,Merck Plans Strong Growth Over Next Five Years - Quick Facts ,RTTNews,/news/stocks/merck-plans-strong-growth-over-next-five-years-quick-facts-1028294600,positive,0.7830522060394287
6/20/2019 11:03:57 PM,Merck CEO sees legal challenge if U.S. adopts drug pricing based on  other countries,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9Vq2MtORdL4/merck-ceo-sees-legal-challenge-if-u-s-adopts-drug-pricing-based-on-other-countries-idUSL2N23R1CI,negative,0.5042737126350403
6/20/2019 11:08:59 PM,Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/7HqoDvDXE7w/merck-ceo-sees-legal-challenge-if-u-s-adopts-drug-pricing-based-on-other-countries-idUSKCN1TL2SC,negative,0.5042737126350403
6/21/2019 8:33:39 PM,Dow Jones Today: A Typical Summer Friday,InvestorPlace,/news/stocks/dow-jones-today-a-typical-summer-friday-1028299510,neutral,0.8920571208000183
6/26/2019 10:13:43 AM,Biotech Stocks Facing FDA Decision In July 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2019-1028308411,neutral,0.850616991519928
7/3/2019 5:29:45 PM,Dow Jones Today: Almost Some Half-Day Fireworks,InvestorPlace,/news/stocks/dow-jones-today-almost-some-half-day-fireworks-1028329287,neutral,0.9002112746238708
7/9/2019 1:09:42 PM,Merck Files Six SBLAs To Update Dosing Frequency For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-files-six-sblas-to-update-dosing-frequency-for-keytruda-quick-facts-1028337879,neutral,0.9427573680877686
7/9/2019 8:18:46 PM,"Dow Jones Today: Averting Catastrophe, but Nothing to Brag About",InvestorPlace,/news/stocks/dow-jones-today-averting-catastrophe-but-nothing-to-brag-about-1028340719,neutral,0.8985024094581604
7/11/2019 7:00:51 PM,4 Drug Stocks Getting Smashed,InvestorPlace,/news/stocks/4-drug-stocks-getting-smashed-1028347976,positive,0.3786204159259796
7/11/2019 8:39:40 PM,"Dow Jones Today: More Fed Fun, but Healthcare Weakness Caps Gains",InvestorPlace,/news/stocks/dow-jones-today-more-fed-fun-but-healthcare-weakness-caps-gains-1028347971,negative,0.5883103609085083
7/12/2019 12:23:19 PM,"3 Big Stock Charts for Friday: HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-hollyfrontier-activision-blizzard-and-vertex-pharmaceuticals-1028350384,neutral,0.914141833782196
7/12/2019 1:39:40 PM,"Friday’s Vital Data: Bed Bath & Beyond, CVS and Merck",InvestorPlace,/news/stocks/fridays-vital-data-bed-bath-beyond-cvs-and-merck-1028350376,neutral,0.9325429201126099
7/15/2019 2:55:21 PM,A Pairs Prescription for CVS Stock and Merck,InvestorPlace,/news/stocks/a-pairs-prescription-for-cvs-stock-and-merck-1028354761,neutral,0.813096284866333
7/15/2019 8:22:50 PM,"Dow Jones Today: China, Earnings Anticipation Stall Stocks on Monday",InvestorPlace,/news/stocks/dow-jones-today-china-earnings-anticipation-stall-stocks-on-monday-1028354735,negative,0.933067798614502
7/17/2019 1:48:20 PM,Merck: FDA Approves Recarbrio - Quick Facts ,RTTNews,/news/stocks/merck-fda-approves-recarbrio-quick-facts-1028360150,neutral,0.7976045608520508
7/18/2019 11:05:28 AM,"FDA Nod For MRK's Antibiotic; DRRX Awaits Big Day In Dec., Airxpanders Goes Bust ",RTTNews,/news/stocks/fda-nod-for-mrk-s-antibiotic-drrx-awaits-big-day-in-dec-airxpanders-goes-bust-1028363656,positive,0.5179703831672668
7/23/2019 6:03:36 PM,Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings,InvestorPlace,/news/stocks/why-bristol-myers-is-down-ahead-of-its-earnings-report-1028378737,negative,0.564351499080658
7/26/2019 3:53:32 PM,"Notable Earnings To Watch Next Week - LLY, AAPL, PG, MRK, PFE, CVX ",RTTNews,/news/stocks/notable-earnings-to-watch-next-week-lly-aapl-pg-mrk-pfe-cvx-1028388673,neutral,0.7602753639221191
7/28/2019 3:01:56 PM,Here's what to expect from Merck's earnings report,Markets Insider Automation,/news/stocks/merckco-stock-quarter-earnings-preview-q2-1028391016,neutral,0.9296486377716064
7/29/2019 12:52:32 PM,Merck: CHMP Supports KEYTRUDA Plus Inlyta To Treat Advanced Renal Cell Carcinoma ,RTTNews,/news/stocks/merck-chmp-supports-keytruda-plus-inlyta-to-treat-advanced-renal-cell-carcinoma-1028393088,positive,0.6530787348747253
7/30/2019 12:53:50 PM,"Merck profit surges on strong sales of Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mr9rdlgD-hI/merck-profit-surges-on-strong-sales-of-keytruda-vaccines-idUSL4N24V33W,positive,0.9452461004257202
7/30/2019 12:56:40 PM,Merck & Co Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q2-adjusted-earnings-beat-estimates-1028397792,positive,0.8156270384788513
7/30/2019 1:15:07 PM,"UPDATE 1-Merck profit beats on strong demand for Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-L2pOTMtq84/update-1-merck-profit-beats-on-strong-demand-for-keytruda-vaccines-idUSL4N24V34J,positive,0.9098412394523621
7/30/2019 1:19:31 PM,"Merck profit beats on strong demand for Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/FKVk-oZdhjQ/merck-profit-beats-on-strong-demand-for-keytruda-vaccines-idUSKCN1UP16J,positive,0.9424934983253479
7/30/2019 1:41:29 PM,Merck Lifts FY Adj. Profit View ,RTTNews,/news/stocks/merck-lifts-fy-adj-profit-view-1028398063,neutral,0.5770788192749023
7/30/2019 2:11:47 PM,"UPDATE 2-Merck quarterly profit beats on strong demand for Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/hpucC1CSyr4/update-2-merck-quarterly-profit-beats-on-strong-demand-for-keytruda-vaccines-idUSL4N24V34J,positive,0.8732108473777771
7/30/2019 2:22:54 PM,"Merck quarterly profit beats on strong demand for Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/gob2LWWnjCs/merck-quarterly-profit-beats-on-strong-demand-for-keytruda-vaccines-idINKCN1UP1D5,positive,0.923323392868042
7/30/2019 2:44:32 PM,"Merck quarterly profit beats on strong demand for Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/VDfn0mO7TJU/merck-quarterly-profit-beats-on-strong-demand-for-keytruda-vaccines-idUSKCN1UP16J,positive,0.923323392868042
7/30/2019 2:54:06 PM,"Merck climbs after announcing massive growth for its top cancer drug, which is now on pace to generate $10 billion a year (MRK)",Business Insider,https://markets.businessinsider.com/news/stocks/merck-2q-earnings-crushes-estimates-massive-growth-cancer-drug-keytruda-2019-7-1028398519,positive,0.939479410648346
7/30/2019 4:37:47 PM,"UPDATE 3-Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2iOaXnU7vng/update-3-cancer-drug-keytruda-vaccines-propel-merck-to-quarterly-profit-beat-idUSL4N24V34J,positive,0.9544642567634583
7/30/2019 4:40:15 PM,"Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/NSFO0s4KnKM/cancer-drug-keytruda-vaccines-propel-merck-to-quarterly-profit-beat-idUSKCN1UP16J,positive,0.9543549418449402
7/30/2019 7:01:38 PM,"UPDATE 4-Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/v_x66vRGvoI/update-4-cancer-drug-keytruda-vaccines-propel-merck-to-quarterly-profit-beat-idUSL4N24V34J,positive,0.9541848301887512
7/30/2019 7:04:27 PM,"Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/7cMGcy6Kido/cancer-drug-keytruda-vaccines-propel-merck-to-quarterly-profit-beat-idINKCN1UP1D5,positive,0.9543549418449402
7/31/2019 2:12:47 PM,Merck Says FDA Okays New Monotherapy Indication For KEYTRUDA ,RTTNews,/news/stocks/merck-says-fda-okays-new-monotherapy-indication-for-keytruda-1028403166,positive,0.8016303777694702
8/6/2019 6:29:21 AM,Fear Around Bristol-Myers Squibb Stock is Starting to Fade,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-opdivo-otezla-1028422590,negative,0.7555703520774841
8/7/2019 9:50:01 AM,"AstraZeneca, Merck Report Positive Phase III Trial Results Of Lynparza ",RTTNews,/news/stocks/astrazeneca-merck-report-positive-phase-iii-trial-results-of-lynparza-1028425341,positive,0.8955538272857666
8/8/2019 7:15:20 AM,Merck KGaA's Q2 profit bolstered by drug milestone payments,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/A1jSeqMK8kI/merck-kgaas-q2-profit-bolstered-by-drug-milestone-payments-idUSL8N2540XH,positive,0.9556667804718018
8/8/2019 8:11:31 AM,"UPDATE 1-Merck KGaA's profit bolstered by lab supplies, drug milestone payments",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/79Y_yAIBn-c/update-1-merck-kgaas-profit-bolstered-by-lab-supplies-drug-milestone-payments-idUSL8N2540ZX,positive,0.9528631567955017
8/9/2019 2:04:08 PM,Risk-Takers Have a Reasonable Shot with BMY Stock,InvestorPlace,/news/stocks/risk-takers-have-a-reasonable-shot-with-bmy-stock-1028435580,neutral,0.698043167591095
8/12/2019 4:10:53 PM,Bristol-Myers Squibb Stock Has Upside — But Mind the Risks,InvestorPlace,/news/stocks/bristol-myers-squibb-stock-upside-mind-risks-1028440085,neutral,0.878201961517334
8/13/2019 6:38:25 PM,5 More Cloud Stocks With Plenty of Potential,InvestorPlace,/news/stocks/5-more-cloud-stocks-with-plenty-of-potential-1028443985,neutral,0.8178609013557434
8/14/2019 8:35:04 AM,AstraZeneca Reports Breakthrough Therapy Designation For Calquence - Quick Facts ,RTTNews,/news/stocks/astrazeneca-reports-breakthrough-therapy-designation-for-calquence-quick-facts-1028444397,positive,0.8794489502906799
8/21/2019 7:22:10 PM,HHS to provide $23 mln to Merck for Ebola vaccine production,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/uok70BFuMKY/hhs-to-provide-23-mln-to-merck-for-ebola-vaccine-production-idUSL4N25H38B,positive,0.5169157385826111
8/23/2019 6:37:40 PM,Will Lawsuits Sink Johnson & Johnson Stock?,InvestorPlace,/news/stocks/lawsuits-jnj-stock-probably-not-1028470702,negative,0.6193097829818726
8/23/2019 7:02:34 PM,Merck Canada says new drug price regulations are unconstitutional,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/aC_ZIq5H8S8/merck-canada-says-new-drug-price-regulations-are-unconstitutional-idUSL2N25J15Y,neutral,0.5374346375465393
8/23/2019 7:19:34 PM,UPDATE 1-Merck Canada says new drug price regulations are unconstitutional,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/VocPp16vTus/update-1-merck-canada-says-new-drug-price-regulations-are-unconstitutional-idUSL2N25J17E,neutral,0.8399108648300171
8/23/2019 7:49:30 PM,UPDATE 2-Merck Canada says new drug price regulations are unconstitutional,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/opEoZYWlt0g/update-2-merck-canada-says-new-drug-price-regulations-are-unconstitutional-idUSL2N25J17E,neutral,0.8429998159408569
8/23/2019 8:07:22 PM,Merck Canada says new drug price regulations are unconstitutional,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/JoYYDSiX7SY/merck-canada-says-new-drug-price-regulations-are-unconstitutional-idINKCN1VD254,neutral,0.5374346375465393
8/25/2019 3:05:35 PM,"Congo has given over 200,000 people Merck Ebola vaccine-gov't",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yPJL6_7n2NI/congo-has-given-over-200000-people-merck-ebola-vaccine-govt-idUSL5N25L0J9,neutral,0.8198632597923279
8/28/2019 9:25:51 PM,"FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RxxW8diF-60/fda-flags-serious-risks-with-hepatitis-c-drugs-from-abbvie-gilead-and-merck-idUSL3N25O3WS,negative,0.6740937829017639
8/28/2019 9:45:05 PM,"UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_bVsv9h9HEc/update-1-fda-flags-risks-from-abbvie-gilead-merck-hepatitis-c-drugs-to-certain-patients-idUSL3N25O3X2,neutral,0.37260955572128296
9/4/2019 1:22:47 PM,"Merck: European Commission Approves KEYTRUDA, Inlyta Combination To Treat RCC ",RTTNews,/news/stocks/merck-european-commission-approves-keytruda-inlyta-combination-to-treat-rcc-1028497190,positive,0.8502854704856873
9/9/2019 2:00:00 PM,Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019,PR Newswire,/news/stocks/updated-results-for-investigational-therapy-tepotinib-presented-at-wclc-2019-1028508656,neutral,0.9283702969551086
9/11/2019 8:30:00 AM,Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations,PR Newswire,/news/stocks/merck-announces-fda-breakthrough-therapy-designation-for-investigational-therapy-tepotinib-in-patients-with-metastatic-nsclc-with-metex14-skipping-alterations-1028515156,positive,0.8938851356506348
9/11/2019 10:00:23 AM,Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/COoBN37zuTo/merck-kgaa-lung-cancer-drug-is-3rd-on-u-s-watchdogs-priority-lane-idUSL5N2621II,neutral,0.7879907488822937
9/16/2019 12:16:47 PM,"3 Big Stock Charts for Monday: Merck, Facebook and Microsoft",InvestorPlace,/news/stocks/3-big-stock-charts-for-monday-merck-facebook-and-microsoft-mrk-fb-msft-1028528701,neutral,0.92331463098526
9/17/2019 1:18:19 PM,Merck: FDA Grants Priority Review For Investigational Ebola Vaccine ,RTTNews,/news/stocks/merck-fda-grants-priority-review-for-investigational-ebola-vaccine-1028529765,neutral,0.697163462638855
9/18/2019 9:51:24 AM,"FDA Makes 1st Approval Under Project Orbis, KDMN On Watch, TBIO Down After-hrs ",RTTNews,/news/stocks/fda-makes-1st-approval-under-project-orbis-kdmn-on-watch-tbio-down-after-hrs-1028532923,negative,0.9192956686019897
9/18/2019 3:05:53 PM,"FDA, Canada, Australia Collaborate On Cancer Drugs Review ",RTTNews,/news/stocks/fda-canada-australia-collaborate-on-cancer-drugs-review-1028534156,neutral,0.9055771231651306
9/18/2019 3:41:15 PM,10 Companies Making Their CEOs Rich,InvestorPlace,/news/stocks/10-companies-making-their-ceos-rich-1028536169,neutral,0.8969774842262268
9/18/2019 8:24:25 PM,"Dow Jones Today: Fed Obliges, Stocks Don’t",InvestorPlace,/news/stocks/dow-jones-today-fed-reserve-rate-cut-1028536146,neutral,0.9142488241195679
9/20/2019 1:10:26 PM,FDA Approves Merck's SNDAs For PIFELTRO And DELSTRIGO - Quick Facts ,RTTNews,/news/stocks/fda-approves-merck-s-sndas-for-pifeltro-and-delstrigo-quick-facts-1028540622,positive,0.7131714224815369
9/20/2019 2:34:00 PM,CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma,PR Newswire,/news/stocks/chmp-adopts-positive-opinion-for-bavencio-avelumab-plus-axitinib-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma-1028540886,positive,0.9407221078872681
9/20/2019 8:02:57 PM,Dow Jones Today: Legends of the Fall,InvestorPlace,/news/stocks/stocks-closed-the-week-on-a-down-note-but-could-rally-anew-next-week-1028542239,neutral,0.9026169776916504
9/23/2019 8:00:00 AM,New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care,PR Newswire,/news/stocks/new-data-at-esmo-2019-for-merck-highlight-focused-clinical-development-and-commitment-to-patient-care-1028543360,positive,0.6419163346290588
9/24/2019 1:58:02 PM,Why Contrarians May Want to Take a Look at JNJ Stock,InvestorPlace,/news/stocks/why-contrarians-may-want-to-take-a-look-at-jnj-stock-1028550815,neutral,0.9324418902397156
9/24/2019 5:45:00 PM,Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-china-s-rising-demand-for-drugs-will-fuel-foreign-pharma-companies-growth-into-2023-1028549476,positive,0.9256461262702942
9/24/2019 10:50:00 PM,Merck Financial Services GmbH -- Moody's announces completion of a periodic review of ratings of Merck KGaA,Moodys,/news/bonds/merck-financial-services-gmbh-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-merck-kgaa-1028550277,neutral,0.8040289878845215
9/25/2019 6:36:00 AM,Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-china-s-rising-demand-for-drugs-will-fuel-foreign-pharma-companies-growth-into-2023-1028550761,positive,0.9256461262702942
9/27/2019 8:00:00 AM,New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019,PR Newswire,/news/stocks/new-data-for-bavencio-avelumab-for-advanced-cancers-to-be-presented-at-esmo-2019-1028558406,neutral,0.902334988117218
9/30/2019 8:25:08 AM,"AstraZeneca, MSD Report Positive Results From Phase III Trial With Lynparza ",RTTNews,/news/stocks/astrazeneca-msd-report-positive-results-from-phase-iii-trial-with-lynparza-1028561786,positive,0.9535670876502991
9/30/2019 8:29:32 AM,"AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/lNrUYQ5TRCk/astrazeneca-merck-cancer-treatment-attains-meaningful-improvement-in-progression-free-survival-idUSL3N26L1Q6,positive,0.9554073214530945
9/30/2019 9:07:05 AM,"UPDATE 1-AstraZeneca, Merck ovarian cancer treatment improves progression-free survival",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_Fd5Iik2ZFE/update-1-astrazeneca-merck-ovarian-cancer-treatment-improves-progression-free-survival-idUSL3N26L1WD,positive,0.9522666931152344
9/30/2019 11:23:43 AM,"AstraZeneca, Merck ovarian cancer treatment improves progression-free survival",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/_0VeiL3h4VI/astrazeneca-merck-ovarian-cancer-treatment-improves-progression-free-survival-idINKBN1WF0LF,positive,0.9496287107467651
9/30/2019 8:24:15 PM,Dow Jones Today: A Sigh of Relief on Trade,InvestorPlace,/news/stocks/apple-lifted-the-dow-jones-today-helping-lead-a-decent-rally-1028565197,positive,0.7618274688720703
9/30/2019 8:46:12 PM,US STOCKS-Apple and Merck drive Wall Street higher as trade worries abate,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kK5rDzt-cXw/us-stocks-apple-and-merck-drive-wall-street-higher-as-trade-worries-abate-idUSL2N26L12E,positive,0.9161496758460999
9/30/2019 8:50:47 PM,Apple and Merck drive Wall Street higher as trade worries abate,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/yOmUoL5Z6bA/apple-and-merck-drive-wall-street-higher-as-trade-worries-abate-idUSKBN1WF1AQ,positive,0.8904752135276794
10/1/2019 11:44:44 AM,Johnson & Johnson Can Overcome Its Legal Issues,InvestorPlace,/news/stocks/legal-issues-problem-johnson-johnson-stock-1028569362,positive,0.8247592449188232
10/1/2019 3:08:33 PM,4 Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/4-healthcare-stocks-to-buy-now-1028569344,neutral,0.8973767757415771
10/2/2019 12:58:50 PM,Merck: FDA To Review Two Applications For DIFICID - Quick Facts ,RTTNews,/news/stocks/merck-fda-to-review-two-applications-for-dificid-quick-facts-1028570216,neutral,0.6006279587745667
10/7/2019 2:48:29 PM,Merck KGaA completes acquisition of Versum Materials,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/hVoWz4pH6SE/merck-kgaa-completes-acquisition-of-versum-materials-idUSFWN26S0EK,neutral,0.8429641127586365
10/7/2019 4:17:20 PM,10 Great Biotech Stocks to Buy in Q4,InvestorPlace,/news/stocks/great-biotech-stocks-to-buy-q4-1028581895,neutral,0.7856953740119934
10/7/2019 6:51:22 PM,Why Johnson & Johnson Stock Is Not a Screaming Buy,InvestorPlace,/news/stocks/johnson-johnson-jnj-stock-not-screaming-buy-1028581887,neutral,0.9226393103599548
10/14/2019 7:59:43 PM,Johnson and Johnson Stock Still Significantly Undervalued,InvestorPlace,/news/stocks/johnson-stock-significantly-undervalued-1028597917,negative,0.918654203414917
10/16/2019 3:31:08 PM,The 10 Best Mutual Funds for Your 401k,InvestorPlace,/news/stocks/the-10-best-mutual-funds-for-your-401k-1028605009,neutral,0.8619165420532227
10/18/2019 1:15:32 PM,Merck gets EU panel nod for first ever Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/5Shr0cX3W0s/merck-gets-eu-panel-nod-for-first-ever-ebola-vaccine-idUSL3N2732YO,positive,0.5064216256141663
10/18/2019 2:07:17 PM,UPDATE 1-Merck gets EU panel nod for Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NEjj5jjrEmI/update-1-merck-gets-eu-panel-nod-for-ebola-vaccine-idUSL3N2732ZF,positive,0.6409096121788025
10/18/2019 3:30:03 PM,3 Earnings Reports to Watch Next Week,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-earnings-calendar-1028224242,neutral,0.891125500202179
10/24/2019 10:36:53 AM,"3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-cisco-systems-eli-lilly-colgate-palmolive-1028627304,neutral,0.905576229095459
10/28/2019 3:01:20 PM,Merck earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/merckco-stock-price-q3-earnings-preview-1028635514,neutral,0.9352008700370789
10/28/2019 6:00:19 PM,Can Johnson and Johnson Survive this Latest Controversy?,InvestorPlace,/news/stocks/can-johnson-and-johnson-survive-this-latest-controversy-1028636605,neutral,0.8497632741928101
10/28/2019 7:00:00 PM,European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma,PR Newswire,/news/stocks/european-commission-approves-bavencio-avelumab-plus-axitinib-combination-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma-1028636461,positive,0.9080676436424255
10/29/2019 11:57:00 AM,Merck quarterly profit falls on deal-related charge,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/awp-SPyMldM/merck-quarterly-profit-falls-on-deal-related-charge-idUSKBN1X816L,negative,0.9684560894966125
10/29/2019 12:01:55 PM,Merck & Co Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q3-adjusted-earnings-beat-estimates-1028638513,positive,0.8186734318733215
10/29/2019 12:08:47 PM,UPDATE 1-Merck profit beats estimates as Keytruda sales surge,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/X8DTt8hPu5U/update-1-merck-profit-beats-estimates-as-keytruda-sales-surge-idUSL3N27E2VP,positive,0.9057735800743103
10/29/2019 12:09:23 PM,Merck profit beats estimates as Keytruda sales surge,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/RwN0i4C1myg/merck-profit-beats-estimates-as-keytruda-sales-surge-idUSKBN1X816L,positive,0.9062585234642029
10/29/2019 12:13:46 PM,Merck Raises 2019 Non-GAAP EPS Guidance Range - Quick Facts ,RTTNews,/news/stocks/merck-raises-2019-non-gaap-eps-guidance-range-quick-facts-1028638680,neutral,0.7382757067680359
10/29/2019 1:01:31 PM,UPDATE 2-Merck beats estimates as Keytruda sales top $3 bln for first time,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/8leCgyASx0w/update-2-merck-beats-estimates-as-keytruda-sales-top-3-bln-for-first-time-idUSL3N27E2VP,positive,0.8701255321502686
10/29/2019 1:04:21 PM,Merck beats estimates as Keytruda sales top $3 billion for first time,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/37OMx4jQosg/merck-beats-estimates-as-keytruda-sales-top-3-billion-for-first-time-idUSKBN1X816L,positive,0.9121044278144836
10/29/2019 1:52:56 PM,"Merck to ramp up Gardasil vaccine production, flags ""tempered"" sales growth in 2020",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/48hr0yMzRqo/merck-to-ramp-up-gardasil-vaccine-production-flags-tempered-sales-growth-in-2020-idUSL3N27E3F1,positive,0.9392700791358948
10/29/2019 1:56:35 PM,"Merck to ramp up Gardasil vaccine production, flags 'tempered' sales growth in 2020",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/DbHf_vesDAI/merck-to-ramp-up-gardasil-vaccine-production-flags-tempered-sales-growth-in-2020-idUSKBN1X81HR,positive,0.9480578303337097
10/29/2019 3:04:40 PM,UPDATE 3-Merck sees ongoing Keytruda strength as its sales top $3 bln in quarter,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yTgLGByU-UY/update-3-merck-sees-ongoing-keytruda-strength-as-its-sales-top-3-bln-in-quarter-idUSL3N27E2VP,positive,0.9509397745132446
10/29/2019 3:09:17 PM,Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/kVbn7prWtlQ/merck-sees-ongoing-keytruda-strength-as-its-sales-top-3-billion-in-quarter-idUSKBN1X816L,positive,0.9522852897644043
10/29/2019 3:52:44 PM,"US STOCKS SNAPSHOT-Merck, Pfizer spur S&P 500 to record high; Alphabet weighs on Nasdaq",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/cul7AtWcw10/us-stocks-snapshot-merck-pfizer-spur-sp-500-to-record-high-alphabet-weighs-on-nasdaq-idUSL3N27E3XD,negative,0.5827819108963013
10/29/2019 3:55:04 PM,"Merck, Pfizer spur S&P 500 to record high; Alphabet weighs on Nasdaq",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/QSy2eR-cNQg/merck-pfizer-spur-sp-500-to-record-high-alphabet-weighs-on-nasdaq-idUSKBN1X81CC,positive,0.49066925048828125
10/29/2019 4:35:09 PM,"US STOCKS-S&P 500 squeezes higher on robust Merck, Pfizer earnings",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sp9i_g9OcTQ/us-stocks-sp-500-squeezes-higher-on-robust-merck-pfizer-earnings-idUSL3N27E3ZS,negative,0.7455416917800903
10/29/2019 4:36:49 PM,"S&P 500 squeezes higher on robust Merck, Pfizer earnings",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/70nBezUdNr8/sp-500-squeezes-higher-on-robust-merck-pfizer-earnings-idUSKBN1X81CC,negative,0.7071929574012756
10/29/2019 5:41:23 PM,"US STOCKS-S&P 500 hits record high on robust Merck, Pfizer earnings",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/h8APVhLbQHI/us-stocks-sp-500-hits-record-high-on-robust-merck-pfizer-earnings-idUSL3N27E43O,positive,0.7786363959312439
10/29/2019 5:48:31 PM,"S&P 500 hits record high on robust Merck, Pfizer earnings",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/02Zb3vyeRLc/sp-500-hits-record-high-on-robust-merck-pfizer-earnings-idUSKBN1X81CC,positive,0.7419291138648987
10/29/2019 8:29:39 PM,"Stock Market Today: Earnings, Fed Drive New Highs",InvestorPlace,/news/stocks/stock-market-today-earnings-fed-drive-new-highs-1028641491,positive,0.8553939461708069
10/29/2019 8:31:06 PM,Dow Jones Today: Struggling at the Highs,InvestorPlace,/news/stocks/merck-and-pfizer-boosted-the-dow-jones-today-thanks-to-upped-guidance-1028641490,negative,0.9591390490531921
10/30/2019 10:47:48 AM,"It's 9-7 For Withdrawal Of Makena, Roche-Spark Deal Delayed Again, MRK On Watch ",RTTNews,/news/stocks/it-s-9-7-for-withdrawal-of-makena-roche-spark-deal-delayed-again-mrk-on-watch-1028642720,negative,0.7353373765945435
10/30/2019 11:28:25 AM,"3 Big Stock Charts for Wednesday: Alibaba, Hewlett Packard, and Chipotle Mexican Grill",InvestorPlace,/news/stocks/3-big-stock-charts-wednesday-alibaba-hewlett-packard-enterprise-chipotle-mexican-grill-1028643864,neutral,0.9130274057388306
10/30/2019 3:05:45 PM,Merck loses bid to revive $2.54 billion patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/gNjPNmAla3Y/merck-loses-bid-to-revive-2-54-billion-patent-verdict-against-gilead-idUSL2N27F0NU,negative,0.8220835328102112
10/30/2019 3:12:35 PM,Merck loses bid to revive $2.54 billion patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/CFp9HQ9a_R8/merck-loses-bid-to-revive-2-54-billion-patent-verdict-against-gilead-idINKBN1X91PX,negative,0.8220835328102112
10/30/2019 3:23:41 PM,UPDATE 1-Merck loses bid to revive $2.54 bln patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/n-jU4E1tnd0/update-1-merck-loses-bid-to-revive-2-54-bln-patent-verdict-against-gilead-idUSL2N27F0PV,negative,0.9334994554519653
10/30/2019 3:27:19 PM,Merck loses bid to revive $2.54 billon patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/rR-1jTRJoRI/merck-loses-bid-to-revive-2-54-billon-patent-verdict-against-gilead-idINKBN1X91PX,negative,0.702151358127594
10/30/2019 11:50:47 PM,UPDATE 2-Merck loses bid to revive $2.54 bln patent verdict against Gilead,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SzX4NIZeFJA/update-2-merck-loses-bid-to-revive-2-54-bln-patent-verdict-against-gilead-idUSL2N27F0PV,negative,0.9307767748832703
10/31/2019 11:27:44 AM,"3 Big Stock Charts for Thursday: Merck, Anheuser-Busch InBev, and PPG Industries",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-merck-anheuser-busch-inbev-ppg-industries-1028648405,neutral,0.916330873966217
11/1/2019 6:16:10 PM,"The Good, Bad, and Ugly for Biogen Stock",InvestorPlace,/news/stocks/the-good-bad-and-ugly-for-biogen-stock-1028652569,neutral,0.5726682543754578
11/7/2019 7:05:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-confirms-bristol-myers-squibb-at-a2-negative-outlook-1028670686,negative,0.6633530855178833
11/11/2019 6:36:04 PM,Merck wins European approval for first-ever Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/VLTRtrkY2MQ/merck-wins-european-approval-for-first-ever-ebola-vaccine-idUSL4N27R3JS,positive,0.7377950549125671
11/11/2019 6:57:45 PM,UPDATE 1-Merck wins European approval for first-ever Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/twfRQzYtxW4/update-1-merck-wins-european-approval-for-first-ever-ebola-vaccine-idUSL4N27R3K6,positive,0.883989155292511
11/14/2019 7:22:49 AM,"Merck KGaA raises 2019 sales, earnings guidance in wake of Versum takeover",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/vHpWyw5mtzg/merck-kgaa-raises-2019-sales-earnings-guidance-in-wake-of-versum-takeover-idUSFWN27U03M,neutral,0.7125105857849121
11/14/2019 8:10:26 AM,"UPDATE 1-Merck KGaA raises 2019 sales, earnings guidance in wake of Versum takeover",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/_WdZPyoDGa8/update-1-merck-kgaa-raises-2019-sales-earnings-guidance-in-wake-of-versum-takeover-idUSL8N27U14F,positive,0.4926372766494751
11/14/2019 8:33:28 AM,AZN:FDA Accepts Regulatory Submission For Selumetinib In Neurofibromatosis Type1 ,RTTNews,/news/stocks/azn-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type1-1028687870,positive,0.754371166229248
11/14/2019 9:34:57 AM,UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/fJVHH9ViXH8/update-2-merck-kgaa-raises-2019-guidance-after-versum-takeover-idUSL8N27U14F,positive,0.6522239446640015
11/18/2019 12:47:47 PM,Merck and Bayer's heart drug meets main goal of late-stage study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Nhpup8AXB4I/merck-and-bayers-heart-drug-meets-main-goal-of-late-stage-study-idUSL3N27Y099,positive,0.5186620950698853
11/18/2019 1:31:18 PM,UPDATE 1-Merck and Bayer's heart drug meets main goal of late-stage study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wKRKu8wW7wU/update-1-merck-and-bayers-heart-drug-meets-main-goal-of-late-stage-study-idUSL3N27Y09J,positive,0.7048450708389282
11/22/2019 9:31:54 PM,"Dow Jones Today: Trade Progress Pushes Stocks, Healthcare Helps Dow",InvestorPlace,/news/stocks/dow-jones-today-trade-progress-pushes-stocks-healthcare-helps-dow-1028712595,positive,0.9252076745033264
11/27/2019 3:03:58 PM,What's Up With Merck Stock (MRK)? ,RTTNews,/news/stocks/what-s-up-with-merck-stock-mrk-1028721818,neutral,0.6461087465286255
12/2/2019 2:16:23 PM,"Seattle Genetics, Astellas, Merck To Evaluate Enfortumab Vedotin Plus KEYTRUDA ",RTTNews,/news/stocks/seattle-genetics-astellas-merck-to-evaluate-enfortumab-vedotin-plus-keytruda-1028729852,neutral,0.8796753883361816
12/3/2019 9:31:08 PM,Dow Jones Today: A Terrible Tuesday,InvestorPlace,/news/stocks/dow-jones-today-a-terrible-tuesday-1028735335,negative,0.7395559549331665
12/5/2019 8:11:48 AM,AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-QjjpOa5frc/astrazeneca-merck-lynparza-wins-approval-in-china-for-ovarian-cancer-treatment-idUSL4N28F1UK,positive,0.9390736818313599
12/5/2019 9:23:59 AM,REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Yel_I2cJOqo/refile-astrazeneca-merck-lynparza-wins-approval-in-china-for-ovarian-cancer-treatment-idUSL4N28F1UK,positive,0.9337335228919983
12/9/2019 12:53:33 PM,Merck to buy cancer drug developer ArQule for $2.7 bln in cash,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JLUz_M1aBik/merck-to-buy-cancer-drug-developer-arqule-for-2-7-bln-in-cash-idUSL4N28J2QI,neutral,0.8863933086395264
12/9/2019 1:11:03 PM,UPDATE 1-Merck to buy cancer drug developer ArQule for $2.7 bln in cash,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/hSa8z8qiEQE/update-1-merck-to-buy-cancer-drug-developer-arqule-for-2-7-bln-in-cash-idUSL4N28J2R7,neutral,0.8240562081336975
12/9/2019 2:51:04 PM,A cancer-drug developer's stock just surged more than 100% after Merck agreed to a multibillion-dollar takeover,Business Insider,https://www.businessinsider.com/arqule-stock-price-spikes-merck-acquisition-cancer-drug-takeover-pharma-2019-12,positive,0.9328966736793518
12/9/2019 3:04:04 PM,Merck To Acquire ArQule For $20/share In Cash - Quick Facts ,RTTNews,/news/stocks/merck-to-acquire-arqule-for-20-share-in-cash-quick-facts-1028747585,neutral,0.894572377204895
12/9/2019 3:28:12 PM,UPDATE 2-Merck pushes deeper into targeted cancer therapy with $2.7 bln ArQule deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/HUL0R9y0d8U/update-2-merck-pushes-deeper-into-targeted-cancer-therapy-with-2-7-bln-arqule-deal-idUSL4N28J2R7,positive,0.8941375613212585
12/9/2019 5:05:10 PM,UPDATE 3-Merck pushes deeper into targeted cancer therapy with $2.7 bln ArQule deal,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2QAexuAXgUY/update-3-merck-pushes-deeper-into-targeted-cancer-therapy-with-2-7-bln-arqule-deal-idUSL4N28J2R7,positive,0.8924005627632141
12/9/2019 9:20:13 PM,Dow Jones Today: The Trade Clock Ticks Away,InvestorPlace,/news/stocks/dow-jones-today-the-trade-clock-ticks-away-1028749099,neutral,0.8879916071891785
12/17/2019 11:05:37 AM,10 Small-Cap Stocks to Buy Before They Grow Up,InvestorPlace,/news/stocks/10-small-cap-stocks-to-buy-before-they-grow-up-1028395852,neutral,0.920041561126709
12/18/2019 3:29:01 AM,AstraZeneca Says FDA Panel Backs Lynparza Use For Pancreatic Cancer ,RTTNews,/news/stocks/astrazeneca-says-fda-panel-backs-lynparza-use-for-pancreatic-cancer-1028770677,neutral,0.6079328656196594
12/18/2019 9:27:08 PM,Dow Jones Today: Stocks Took a Pre-Holiday Breather,InvestorPlace,/news/stocks/dow-jones-today-stocks-took-a-pre-holiday-breather-1028773960,negative,0.5227017402648926
12/20/2019 2:47:54 AM,Merck receives FDA approval for Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/8diUvQCMapc/merck-receives-fda-approval-for-ebola-vaccine-idUSL4N28U09X,positive,0.7171974778175354
12/20/2019 3:47:12 AM,Merck receives FDA approval for Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Koiv6vLxx1U/merck-receives-fda-approval-for-ebola-vaccine-idINKBN1YO07U,positive,0.7171974778175354
12/20/2019 4:22:42 AM,UPDATE 1-Merck receives FDA approval for Ebola vaccine,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/n6RlwnqGp6g/update-1-merck-receives-fda-approval-for-ebola-vaccine-idUSL4N28U0TC,positive,0.79976487159729
12/20/2019 12:02:54 PM,FDA Grants Approval For Merck's Ebola Vaccine Ervebo - Quick Facts ,RTTNews,/news/stocks/fda-grants-approval-for-merck-s-ebola-vaccine-ervebo-quick-facts-1028778519,positive,0.8237174153327942
12/20/2019 4:02:35 PM,10 2019 Losers That Will Be 2020 Winners,InvestorPlace,/news/stocks/10-2019-losers-that-will-be-2020-winners-1028779762,neutral,0.926362931728363
12/20/2019 4:09:49 PM,7 Best Vanguard ETFs for 2020,InvestorPlace,/news/stocks/7-best-vanguard-etfs-2020-1028779761,neutral,0.7777143120765686
12/20/2019 6:58:41 PM,FDA Approves Ervebo Vaccine For Prevention Of Ebola Virus Disease ,RTTNews,/news/stocks/fda-approves-ervebo-vaccine-for-prevention-of-ebola-virus-disease-1028779872,positive,0.7948793172836304
12/20/2019 8:42:59 PM,Merck says Ebola vaccine to be available at lowest access price for poor nations,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/1hAgwfDn0eY/merck-says-ebola-vaccine-to-be-available-at-lowest-access-price-for-poor-nations-idUSL4N28U3YE,neutral,0.7759996056556702
12/20/2019 9:28:54 PM,Dow Jones Today: Data Does It Again,InvestorPlace,/news/stocks/dow-jones-today-data-does-it-again-1028780336,neutral,0.9111993908882141
12/20/2019 11:24:36 PM,UPDATE 1-Merck says Ebola vaccine to be available at lowest access price for poor nations,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/T4eHvKbl82M/update-1-merck-says-ebola-vaccine-to-be-available-at-lowest-access-price-for-poor-nations-idUSL4N28U4AR,neutral,0.6461240649223328
12/26/2019 10:01:54 AM,Embattled TEVA Has Made Headlines for All of the Wrong Reasons,InvestorPlace,/news/stocks/embattled-teva-has-made-headlines-for-all-of-the-wrong-reasons-1028785016,negative,0.8971842527389526
12/30/2019 8:27:10 AM,AstraZeneca: Lynparza Approved In US For Pancreatic Cancer - Quick Facts ,RTTNews,/news/stocks/astrazeneca-lynparza-approved-in-us-for-pancreatic-cancer-quick-facts-1028787422,neutral,0.6105035543441772
12/30/2019 10:28:10 AM,"UPDATE 2-AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JLrI8Wb_9T8/update-2-astrazeneca-merck-score-win-with-lynparza-approval-for-pancreatic-cancer-idUSL4N29414D,positive,0.9311984181404114
12/30/2019 10:38:43 AM,"AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/9LfevcCmeTk/astrazeneca-merck-score-win-with-lynparza-approval-for-pancreatic-cancer-idINKBN1YY0JC,positive,0.9129796624183655
12/30/2019 9:25:53 PM,Dow Jones Today: A Rough Way to End 2019,InvestorPlace,/news/stocks/dow-jones-today-a-rough-way-to-end-2019-1028788883,neutral,0.5003412365913391
12/31/2019 4:30:51 AM,"ARDS Turning Heads, AXSM's Momentum Continues, SVRA Abuzz, Jiankui Jailed ",RTTNews,/news/stocks/ards-turning-heads-axsm-s-momentum-continues-svra-abuzz-jiankui-jailed-1028788957,positive,0.8326769471168518
12/31/2019 8:58:59 AM,Biotech Stocks Facing FDA Decision In January 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2020-1028789072,neutral,0.730726957321167
1/2/2020 4:22:38 PM,3 of the Best Healthcare Stocks to Buy in 2020,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-2020-1028791911,neutral,0.7170337438583374
1/3/2020 5:42:32 PM,"Novartis, Merck and Allergan join those raising U.S. drug prices for 2020",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/8MRFZkg_cEU/novartis-merck-and-allergan-join-those-raising-u-s-drug-prices-for-2020-idUSL1N2980LJ,neutral,0.8232283592224121
1/3/2020 6:38:44 PM,"After Lackluster 2019, Pfizer Stock Could Rebound in 2020",InvestorPlace,/news/stocks/after-lackluster-2019-pfizer-stock-could-rebound-in-2020-1028793896,positive,0.95452880859375
1/6/2020 7:03:48 PM,A 2019 Review of Dow Jones Stocks (And What 2020 May Bring),InvestorPlace,/news/stocks/a-2019-review-of-dow-jones-stocks-and-what-2020-may-bring-1028797244,neutral,0.9407529830932617
1/7/2020 2:45:51 AM,"LIFE Gets A Boost With Kyorin Deal, XERS Up 20% After-Hrs, ITCI On Watch ",RTTNews,/news/stocks/life-gets-a-boost-with-kyorin-deal-xers-up-20-after-hrs-itci-on-watch-1028797777,positive,0.9445651173591614
1/7/2020 10:19:20 AM,BRIEF-GenOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/OdxuJHPRu60/idUSL8N29C1RA,positive,0.9300881028175354
1/8/2020 4:31:12 PM,3 Stocks to Buy That Will Hit New All-Time Highs in 2020,InvestorPlace,/news/stocks/3-stocks-to-buy-all-time-highs-2020-1028803931,positive,0.6816320419311523
1/8/2020 6:03:01 PM,Scandal-Ridden Teva Pharmaceutical Is Fishing for a Bottom,InvestorPlace,/news/stocks/scandals-opioid-teva-stock-fishing-bottom-1028804210,neutral,0.5781757831573486
1/9/2020 2:47:05 AM,"FDA Nod For MRK, All Eyes On AGTC, ACTION Boosts APLT ",RTTNews,/news/stocks/fda-nod-for-mrk-all-eyes-on-agtc-action-boosts-aplt-1028804684,positive,0.8786931037902832
1/9/2020 3:23:20 PM,A Recent FDA Approval Will Be Huge in Moving Amarin Stock,InvestorPlace,/news/stocks/fda-approval-moving-amarin-stock-1028807149,positive,0.5159583687782288
1/10/2020 4:51:43 PM,3 Biotech Stocks to Bank on for Buyouts in 2020,InvestorPlace,/news/stocks/3-biotech-stocks-buyouts-2020-1028809868,neutral,0.8042193055152893
1/10/2020 6:02:32 PM,Amarin Stock Bouncing Back After Revised Results and 2020 Guidance,InvestorPlace,/news/stocks/amarin-stock-bouncing-back-recent-results-2020-guidance-1028810094,positive,0.8504787087440491
1/13/2020 8:30:28 AM,AZN : Lynparza-bevacizumab Granted Priority Review In US For Ovarian Cancer ,RTTNews,/news/stocks/azn-lynparza-bevacizumab-granted-priority-review-in-us-for-ovarian-cancer-1028811386,positive,0.893519937992096
1/13/2020 9:21:57 PM,Dow Jones Today: Tech Lifts Stocks as Trade Deal Signing Nears,InvestorPlace,/news/stocks/dow-jones-today-tech-lifts-stocks-as-trade-deal-signing-nears-1028814122,positive,0.8567444086074829
1/14/2020 7:42:38 AM,Just - Evotec Grants MSD Access To J.POD(R) Facility - Quick Facts ,RTTNews,/news/stocks/just-evotec-grants-msd-access-to-j-pod-r-facility-quick-facts-1028814486,neutral,0.5041027069091797
1/14/2020 7:02:00 PM,"Merck Sharp & Dohme Corp. -- Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.",Moodys,/news/bonds/merck-sharp-dohme-corp-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-merck-co-inc-1028817176,neutral,0.8242955803871155
1/15/2020 4:37:07 PM,Pfizer Stock Offers Good Value to Patient Investors,InvestorPlace,/news/stocks/pfizer-stock-offers-good-value-investors-1028820483,positive,0.7911884784698486
1/16/2020 12:30:04 PM,"After FDA Approval, Amarin Stock Is Stuck in Worrisome Trading",InvestorPlace,/news/stocks/recent-trading-looks-worrisome-amarin-stock-1028822946,negative,0.9516841173171997
1/16/2020 1:27:17 PM,"Beyond the Growing Dividend, Abbvie Stock Is a Good Buy Here",InvestorPlace,/news/stocks/growing-dividend-abbvie-stock-good-buy-1028823662,positive,0.8297058343887329
1/17/2020 11:30:07 AM,Why Amarin Stock Is Poised for a Healthy 2020,InvestorPlace,/news/stocks/amarin-stock-poised-healthy-2020-1028826114,positive,0.8406236171722412
1/20/2020 8:38:28 AM,"AstraZeneca: FDA's ODD For Imfinzi, Tremelimumab; Priority Review For Lynparza ",RTTNews,/news/stocks/astrazeneca-fda-s-odd-for-imfinzi-tremelimumab-priority-review-for-lynparza-1028828283,neutral,0.6658944487571716
1/23/2020 2:05:38 PM,Merck : Canada Oks KEYTRUDA As First-Line Treatment For Advanced RCC ,RTTNews,/news/stocks/merck-canada-oks-keytruda-as-first-line-treatment-for-advanced-rcc-1028839201,neutral,0.7119414806365967
1/27/2020 3:11:27 PM,3 Healthcare Stocks Under Pressure from Bernie,InvestorPlace,/news/stocks/3-healthcare-stocks-under-pressure-from-bernie-1028847131,negative,0.9502881765365601
1/27/2020 9:29:18 PM,"Dow Jones Today: Virus Spreads, Impeachment Proceedings Infect Stocks",InvestorPlace,/news/stocks/defensives-lead-the-dow-jones-today-but-not-much-else-worked-1028848287,negative,0.9115419387817383
1/28/2020 3:41:09 AM,"XLRN Soars, FDA Approves Triple Combo Pill For Type 2 Diabetes, MGEN On Watch ",RTTNews,/news/stocks/xlrn-soars-fda-approves-triple-combo-pill-for-type-2-diabetes-mgen-on-watch-1028848386,positive,0.8125909566879272
1/28/2020 12:50:18 PM,Biotech Stocks Facing FDA Decision In February 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-2020-1028849887,neutral,0.7928071618080139
1/29/2020 3:26:09 PM,5 Great Blue-Chip Stocks to Buy,InvestorPlace,/news/stocks/5-great-blue-chip-stocks-to-buy-today-1028224240,neutral,0.8442279696464539
2/3/2020 5:39:04 PM,"Here's why one expert says the US has been immune to the latest coronavirus stock meltdown (NKE, DIS, MRK)",Business Insider,https://markets.businessinsider.com/news/stocks/us-stock-indices-immune-coronavirus-chinese-markets-dow-sp-nasdaq-2020-2-1028868693,neutral,0.5097612738609314
2/4/2020 12:30:56 PM,Johnson & Johnson Stock Looks Like a Safe Place to Hide Out,InvestorPlace,/news/stocks/jnj-stock-looks-safe-place-hide-1028871756,neutral,0.8869536519050598
2/4/2020 3:01:59 PM,Merck earnings: here's what to expect,Markets Insider Automation,/news/stocks/merck_co-stock-quarter-earnings-preview-q4-1028872275,neutral,0.9406796097755432
2/4/2020 9:27:48 PM,"Dow Jones Today: Coronavirus, Caucus Uncertainties and Stocks Don’t Care",InvestorPlace,/news/stocks/dow-jones-today-coronavirus-caucus-uncertainties-and-stocks-dont-care-1028874081,neutral,0.6474465727806091
2/5/2020 12:53:20 PM,"Merck to spin-off women's health, biosimilar businesses",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/2_M5EHeOKYU/merck-to-spin-off-womens-health-biosimilar-businesses-idUSL4N2A539L,neutral,0.9333223700523376
2/5/2020 1:02:17 PM,Merck & Co Inc. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q4-adjusted-earnings-beat-estimates-1028876021,positive,0.8711258172988892
2/5/2020 1:14:42 PM,"UPDATE 1-Merck to spin off women's health and biosimilar products, keep Keytruda",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/s8leb_WWg_4/update-1-merck-to-spin-off-womens-health-and-biosimilar-products-keep-keytruda-idUSL4N2A53A5,neutral,0.9065228700637817
2/5/2020 2:06:22 PM,"UPDATE 2-Merck to spin off women's health and biosimilar drugs, focus on Keytruda",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ySPgr327hU8/update-2-merck-to-spin-off-womens-health-and-biosimilar-drugs-focus-on-keytruda-idUSL4N2A53A5,neutral,0.8639244437217712
2/5/2020 2:25:14 PM,"Merck Q4 Profit Tops; Plans Spin-off Of Women's Health, Biosimilar Businesses ",RTTNews,/news/stocks/merck-q4-profit-tops-plans-spin-off-of-women-s-health-biosimilar-businesses-1028876473,neutral,0.8748771548271179
2/5/2020 4:48:37 PM,"UPDATE 3-Merck to slim down with asset spinoff, focus on Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/3SYBZZp9rWk/update-3-merck-to-slim-down-with-asset-spinoff-focus-on-keytruda-vaccines-idUSL4N2A53A5,neutral,0.49407193064689636
2/5/2020 5:24:41 PM,3 Up-and-Coming Drug Stocks to Buy Now,InvestorPlace,/news/stocks/3-up-and-coming-drug-stocks-to-buy-now-1028878125,neutral,0.8881027102470398
2/5/2020 5:41:00 PM,"Merck & Co., Inc. -- Moody's affirms Merck's A1/Prime-1 ratings; stable outlook",Moodys,/news/bonds/merck-co-inc-moody-s-affirms-merck-s-a1-prime-1-ratings-stable-outlook-1028877817,positive,0.8992360234260559
2/5/2020 7:03:01 PM,"REFILE-UPDATE 3-Merck to slim down with asset spinoff, focus on Keytruda, vaccines",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/AcjK_fiV8uE/refile-update-3-merck-to-slim-down-with-asset-spinoff-focus-on-keytruda-vaccines-idUSL4N2A53A5,neutral,0.6271460652351379
2/5/2020 8:45:39 PM,Merck Earnings: MRK Stock Moves 4% Lower on Spin-Off News,InvestorPlace,/news/stocks/merck-earnings-drop-mrk-stock-1028878404,negative,0.9652462601661682
2/5/2020 9:20:15 PM,Dow Jones Today: Stocks Continue Shrugging Off Virus Fears,InvestorPlace,/news/stocks/dow-jones-today-stocks-continue-shrugging-off-virus-fears-1028878846,positive,0.7648213505744934
2/6/2020 6:43:58 AM,"BTAI Hits A High, TNXP's RECOVERY Fails, MRK Plans A Spin-off ",RTTNews,/news/stocks/btai-hits-a-high-tnxp-s-recovery-fails-mrk-plans-a-spin-off-1028879088,negative,0.6817653775215149
2/6/2020 11:11:00 AM,Merck Sharp & Dohme Corp. -- Moody's affirms Merck's A1/Prime-1 ratings; stable outlook,Moodys,/news/bonds/merck-sharp-dohme-corp-moody-s-affirms-merck-s-a1-prime-1-ratings-stable-outlook-1028880148,positive,0.906648576259613
2/6/2020 4:49:53 PM,Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda,InvestorPlace,/news/stocks/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-1028882432,neutral,0.7825398445129395
2/6/2020 6:06:01 PM,Bristol-Myers Squibb and Merck going opposite ways with PD-1 inhibitors,Seeking Alpha,https://seekingalpha.com/news/3539335-bristol-myers-squibb-and-merck-going-opposite-ways-pdminus-1-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8771260380744934
2/11/2020 9:17:20 PM,Dow Jones Today: China-Sensitive Names Lead the Way,InvestorPlace,/news/stocks/dow-jones-today-china-sensitive-names-lead-the-way-1028895820,neutral,0.8110054135322571
2/13/2020 4:52:35 PM,Merck’s Spinoff Promises Higher Dividends and Big Upside,InvestorPlace,/news/stocks/mrk-stock-earnings-spin-off-upside-1028904164,positive,0.9398862719535828
2/13/2020 7:25:33 PM,3 Dow Jones Industrial Average Stocks to Sell,InvestorPlace,/news/stocks/3-dow-jones-industrial-average-stocks-to-sell-1028904779,neutral,0.9174598455429077
2/14/2020 3:12:39 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3542264-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9446426630020142
2/14/2020 4:52:29 PM,Merck Ebola vaccine OK'd in four African countries,Seeking Alpha,https://seekingalpha.com/news/3542292-merck-ebola-vaccine-okd-in-four-african-countries?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6507188081741333
2/18/2020 12:24:10 PM,"3 Big Stock Charts for Tuesday: Merck, Nucor, and BorgWarner",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-merck-nucor-and-borgwarner-1028913472,neutral,0.9182239770889282
2/19/2020 4:37:20 PM,"Merck KGaA sells allergy unit to Dermapharm, keeps autoinjector project",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/FGFBNGbnGAk/merck-kgaa-sells-allergy-unit-to-dermapharm-keeps-autoinjector-project-idUSFWN2AJ0JA,neutral,0.9105859398841858
2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9021157026290894
2/24/2020 4:18:27 PM,3 Healthcare Stocks to Buy This Year,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-this-year-1028932507,neutral,0.8341861963272095
3/2/2020 9:25:58 PM,Dow Jones Today: 5 Stocks Stole the Show and Rose More Than 5%,InvestorPlace,/news/stocks/dow-jones-today-5-stocks-stole-the-show-and-rose-more-than-5-1028957213,positive,0.9129014015197754
3/4/2020 8:42:38 PM,FDA adds boxed warning to Merck's asthma med Singulair,Seeking Alpha,https://seekingalpha.com/news/3548701-fda-adds-boxed-warning-to-mercks-asthma-med-singulair?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8361550569534302
3/5/2020 7:21:08 AM,"Merck KGaA forecasts strong profit growth on healthcare, lab gear",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/SHrswwj-Rds/merck-kgaa-forecasts-strong-profit-growth-on-healthcare-lab-gear-idUSFWN2AY05Y,positive,0.8975766897201538
3/5/2020 8:27:06 AM,"UPDATE 1-Merck KGaA forecasts strong profit growth on healthcare, lab gear",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/0G76J0EQwRo/update-1-merck-kgaa-forecasts-strong-profit-growth-on-healthcare-lab-gear-idUSL8N2AY11U,positive,0.9539069533348083
3/6/2020 11:50:52 AM,Amarin Stock Looks Like a Heart-Healthy Buy on the Dip,InvestorPlace,/news/stocks/amarin-stock-looks-like-a-heart-healthy-buy-on-the-dip-1028971862,positive,0.7207629680633545
3/6/2020 1:09:09 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3549367-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9446426630020142
3/12/2020 10:58:49 AM,AstraZeneca's Lynparza doublet therapy flunks ovarian cancer study,Seeking Alpha,https://seekingalpha.com/news/3550890-astrazenecas-lynparza-doublet-therapy-flunks-ovarian-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5902189016342163
3/12/2020 2:06:48 PM,Merck extends research term of first program with Sutro,Seeking Alpha,https://seekingalpha.com/news/3551061-merck-extends-research-term-of-first-program-sutro?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5445483922958374
3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6742608547210693
3/13/2020 8:47:02 PM,Dow Jones Today: Stocks Rally as Coronavirus National Emergency Looms,InvestorPlace,/news/stocks/goldman-sachs-led-a-rally-for-the-dow-jones-today-1028995544,negative,0.9283227920532227
3/16/2020 4:25:23 PM,UK cost watchdog thumbs down on Merck's Keytruda for bladder cancer,Seeking Alpha,https://seekingalpha.com/news/3552103-uk-cost-watchdog-thumbs-down-on-mercks-keytruda-for-bladder-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9489901661872864
3/17/2020 11:08:30 AM,Merck's gafapixant successful in late-stage cough studies,Seeking Alpha,https://seekingalpha.com/news/3552392-mercks-gafapixant-successful-in-late-stage-cough-studies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7752097249031067
3/22/2020 8:07:13 PM,Merck donates 500K masks to support Covid-19 response in NYC,Seeking Alpha,https://seekingalpha.com/news/3554045-merck-donates-500k-masks-to-support-covidminus-19-response-in-nyc?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7668842673301697
3/24/2020 4:43:15 PM,FDA backs telemedicine for vets,Seeking Alpha,https://seekingalpha.com/news/3554743-fda-backs-telemedicine-for-vets?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7639567255973816
3/26/2020 11:13:15 AM,Merck donates 300K masks to support COVID-19 response in New Jersey,Seeking Alpha,https://seekingalpha.com/news/3555382-merck-donates-300k-masks-to-support-covidminus-19-response-in-new-jersey?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7734354138374329
3/27/2020 3:34:52 PM,7 Big Data Stocks Fighting Coronavirus On and Off the Charts,InvestorPlace,/news/stocks/7-big-data-stocks-fighting-coronavirus-on-and-off-the-charts-1029040387,neutral,0.816736102104187
3/28/2020 3:21:53 PM,Merck's vericiguat shows positive effect in large-scale CV outcomes study,Seeking Alpha,https://seekingalpha.com/news/3556074-mercks-vericiguat-shows-positive-effect-in-large-scale-cv-outcomes-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9541071057319641
3/28/2020 4:50:54 PM,Merck and Bayer's heart drug vericiguat meets primary efficacy endpoint in Phase 3 study,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/NUIt0kBng_8/merck-and-bayers-heart-drug-vericiguat-meets-primary-efficacy-endpoint-in-phase-3-study-idUSL4N2BL0BI,positive,0.8478640913963318
3/29/2020 3:53:50 PM,"CORRECTED-BRIEF-Merck Says Vericiguat Significantly Reduced Risk Of Composite Endpoint Of HF Hospitalization Or Cardiovascular Death, Vs Placebo",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/RovLsnt4Rcw/idUSFWN2BK1S0,positive,0.938971996307373
3/30/2020 8:42:07 PM,"Dow Jones Today: Healthcare Help, Hopes Worst May be Over Lift Stocks",InvestorPlace,/news/stocks/dow-jones-today-healthcare-help-hopes-worst-may-be-over-lift-stocks-1029046563,negative,0.43877658247947693
4/2/2020 10:59:29 AM,Merck's Keytruda shows positive effect in highly mutating colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3557704-mercks-keytruda-shows-positive-effect-in-highly-mutating-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9430643916130066
4/8/2020 6:43:27 AM,"KPTI To Test XPOVIO In COVID-19, PTCT Will Have To Wait, SAGE Slashes Workforce ",RTTNews,/news/stocks/kpti-to-test-xpovio-in-covid-19-ptct-will-have-to-wait-sage-slashes-workforce-1029074280,neutral,0.8999512195587158
4/8/2020 6:12:09 PM,FDA OKs generic version of Merck bronchospasm med,Seeking Alpha,https://seekingalpha.com/news/3559435-fda-oks-generic-version-of-merck-bronchospasm-med?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.831243634223938
4/9/2020 1:54:35 PM,"Big names open cash spigot to fight COVID-19, many others active",Seeking Alpha,https://seekingalpha.com/news/3559692-big-names-open-cash-spigot-to-fight-covidminus-19-many-others-active?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8462515473365784
4/10/2020 8:55:37 PM,FDA OKs AstraZeneca and Merck's selumetinib for rare nervous system disorder,Seeking Alpha,https://seekingalpha.com/news/3559946-fda-oks-astrazeneca-and-mercks-selumetinib-for-rare-nervous-system-disorder?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5424332618713379
4/13/2020 1:34:49 PM,AstraZeneca & Merck Announce FDA Approval Of KOSELUGO - Quick Facts ,RTTNews,/news/stocks/astrazeneca-merck-announce-fda-approval-of-koselugo-quick-facts-1029085381,neutral,0.7045437097549438
4/14/2020 8:24:13 AM,AstraZeneca-Merck genetic disorder treatment wins FDA nod,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/A6q8SjcYJ5g/astrazeneca-merck-genetic-disorder-treatment-wins-fda-nod-idUSL3N2C21O0,positive,0.8739147186279297
4/14/2020 11:48:44 AM,Stock Alert: Will Uptrend At Merck & Co. Continue? ,RTTNews,/news/stocks/stock-alert-will-uptrend-at-merck-co-continue-1029088538,negative,0.55244380235672
4/20/2020 1:46:26 PM,"Trading at 52-Week Highs, LLY Stock Is Already Priced to Perfection",InvestorPlace,/news/stocks/hold-off-overvalued-lly-stock-1029107790,positive,0.5579317808151245
4/21/2020 11:36:25 AM,Merck expands $0 co-pay program amid pandemic disruptions,Seeking Alpha,https://seekingalpha.com/news/3562448-merck-expands-0-co-pay-program-amid-pandemic-disruptions?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9218618273735046
4/21/2020 9:00:16 PM,Dow Jones Today: Stocks Are Already Acting Like a Recession Is Here,InvestorPlace,/news/stocks/dow-jones-today-stocks-are-already-acting-like-a-recession-is-here-1029114539,negative,0.9380084872245789
4/22/2020 11:50:30 AM,"3 Big Stock Charts for Wednesday: Coca-Cola, Mastercard, and Merck",InvestorPlace,/news/stocks/3-big-stock-charts-for-wednesday-coca-cola-mastercard-and-merck-1029117302,neutral,0.912606418132782
4/23/2020 9:00:34 PM,This Stock Points to the Massive China Biotech Trend,InvestorPlace,/news/stocks/zlab-stock-points-to-massive-china-biotech-stock-trend-1029124959,neutral,0.8943907618522644
4/24/2020 9:06:17 AM,AZN : Lynparza Shows Overall Survival Benefit In Late-stage Trial On MCRPC ,RTTNews,/news/stocks/azn-lynparza-shows-overall-survival-benefit-in-late-stage-trial-on-mcrpc-1029125765,positive,0.9567339420318604
4/27/2020 8:35:40 AM,Heartburn meds for COVID-19? NY is trying it,Seeking Alpha,https://seekingalpha.com/news/3564475-heartburn-meds-for-covidminus-19-ny-is-trying?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8303530216217041
4/27/2020 3:01:50 PM,Merck earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/merck_co-stock-quarter-earnings-preview-q1-1029133053,neutral,0.9352008700370789
4/28/2020 4:29:38 AM,Biotech Stocks Facing FDA Decision In May 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2020-1029135147,neutral,0.862282931804657
4/28/2020 11:28:34 AM,"3 Big Stock Charts for Tuesday: Johnson & Johnson, Merck, and Bristol-Myers Squibb",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-johnson-johnson-merck-and-bristol-myers-squibb-1029137983,neutral,0.9059588313102722
4/28/2020 11:51:18 AM,Merck Keytruda sales up 45%; guidance lowered due to COVID-19 impact,Seeking Alpha,https://seekingalpha.com/news/3565196-merck-keytruda-sales-up-45-guidance-lowered-due-to-covidminus-19-impact?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8952717781066895
4/28/2020 12:59:34 PM,"Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yJs93nKd_6s/merck-profit-rises-cuts-2020-forecast-over-covid-19-uncertainty-idUSL3N2CG36Q,negative,0.6593225002288818
4/28/2020 1:02:23 PM,Merck & Co Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q1-adjusted-earnings-beat-estimates-1029137477,positive,0.8450100421905518
4/28/2020 1:18:38 PM,"Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/mfprLbVnJV0/merck-profit-rises-cuts-2020-forecast-over-covid-19-uncertainty-idINKCN22A1LS,negative,0.6593225002288818
4/28/2020 1:29:37 PM,"UPDATE 1-Merck profit beats, coronavirus uncertainty weighs on forecast",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/6cQngd9SmTs/update-1-merck-profit-beats-coronavirus-uncertainty-weighs-on-forecast-idUSL3N2CG39E,negative,0.8826034069061279
4/28/2020 1:38:49 PM,"Merck profit beats, coronavirus uncertainty weighs on forecast",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/voeUZFCcqiQ/merck-profit-beats-coronavirus-uncertainty-weighs-on-forecast-idINKCN22A1LS,negative,0.8956305980682373
4/28/2020 1:39:07 PM,"Merck profit beats, coronavirus uncertainty weighs on forecast",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/adYnXsxr760/merck-profit-beats-coronavirus-uncertainty-weighs-on-forecast-idUSKCN22A1M9,negative,0.8956305980682373
4/28/2020 1:48:20 PM,Merck Q1 Results Top Estimates; But Cuts 2020 Outlook ,RTTNews,/news/stocks/merck-q1-results-top-estimates-but-cuts-2020-outlook-1029137751,negative,0.7512980699539185
4/28/2020 2:35:35 PM,UPDATE 2-Merck sees $2.1 bln hit to full-year sales from coronavirus pandemic,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/otUhrKY2_s8/update-2-merck-sees-2-1-bln-hit-to-full-year-sales-from-coronavirus-pandemic-idUSL3N2CG39E,negative,0.8193191289901733
4/28/2020 2:36:28 PM,Merck sees $2.1 billion hit to full-year sales from coronavirus pandemic,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/Tt7le1RQEOc/merck-sees-2-1-billion-hit-to-full-year-sales-from-coronavirus-pandemic-idINKCN22A1LS,negative,0.6576151251792908
4/28/2020 2:36:34 PM,Merck sees $2.1 billion hit to full-year sales from coronavirus pandemic,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/9QZ7EVwDiRY/merck-sees-2-1-billion-hit-to-full-year-sales-from-coronavirus-pandemic-idUSKCN22A1M9,negative,0.6576151251792908
4/28/2020 4:54:05 PM,UPDATE 3-Merck sees $2.1 bln coronavirus hit to 2020 sales,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/GtYEOGdJdE4/update-3-merck-sees-2-1-bln-coronavirus-hit-to-2020-sales-idUSL3N2CG39E,positive,0.7960290312767029
4/28/2020 4:56:18 PM,Merck sees $2.1 billion coronavirus hit to 2020 sales,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/Wm7GlSlYxIQ/merck-sees-2-1-billion-coronavirus-hit-to-2020-sales-idUSKCN22A1M9,positive,0.516501247882843
4/28/2020 4:57:45 PM,Merck sees $2.1 billion coronavirus hit to 2020 sales,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/IGC5mGM7_ec/merck-sees-2-1-billion-coronavirus-hit-to-2020-sales-idINKCN22A1LS,positive,0.516501247882843
4/28/2020 6:57:57 PM,Merck Earnings: Why MRK Stock Is 3% Lower Despite Q1 Beats,InvestorPlace,/news/stocks/merck-earnings-hit-mrk-stock-despite-beat-1029140370,negative,0.9647497534751892
4/28/2020 8:53:02 PM,Dow Jones Today: Stocks Sag Under Predictions Q2 Will Be Worst of 2020,InvestorPlace,/news/stocks/dow-jones-today-stocks-sag-under-predictions-q2-will-be-worst-of-2020-1029140796,negative,0.9610785841941833
4/30/2020 2:00:00 PM,Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care,PR Newswire,/news/stocks/data-from-merck-at-asco-2020-to-showcase-significant-clinical-advances-in-cancer-care-1029149852,positive,0.8369863629341125
5/9/2020 4:21:07 PM,FDA OKs new use of AstraZeneca and Merck's Lynparza,Seeking Alpha,https://seekingalpha.com/news/3572389-fda-oks-new-use-of-astrazeneca-and-mercks-lynparza?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6722736954689026
5/11/2020 8:44:06 AM,AstraZeneca: FDA Approves Lynparza In Treatment Of HRD-positive Ovarian Cancer ,RTTNews,/news/stocks/astrazeneca-fda-approves-lynparza-in-treatment-of-hrd-positive-ovarian-cancer-1029186035,positive,0.9088389277458191
5/13/2020 8:52:28 PM,Dow Jones Today: Stocks Swoon as the Fed Rejects Negative Rates,InvestorPlace,/news/stocks/dow-jones-today-stocks-swoon-as-the-fed-rejects-negative-rates-1029199604,negative,0.9287999272346497
5/14/2020 12:27:00 AM,Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020,PR Newswire,/news/stocks/breakthrough-innovation-in-cancer-care-from-emd-serono-pipeline-to-be-presented-at-asco-2020-1029199654,positive,0.5100501179695129
5/14/2020 12:46:00 AM,Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020,PR Newswire,/news/stocks/breakthrough-innovation-in-cancer-care-from-merck-pipeline-to-be-presented-at-asco-2020-1029199666,positive,0.5029300451278687
5/14/2020 1:40:00 AM,/C O R R E C T I O N -- EMD Serono/,PR Newswire,/news/stocks/c-o-r-r-e-c-t-i-o-n-emd-serono-1029199706,neutral,0.9292722940444946
5/14/2020 7:20:19 AM,Merck KGaA says profit could slip in 2020,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/qtvfbtOLbv8/merck-kgaa-says-profit-could-slip-in-2020-idUSS8N2CO027,negative,0.9706625938415527
5/14/2020 8:37:39 AM,UPDATE 1-Merck KGaA says profit could slip as fertility treatments shunned,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wkOLZJrqU4c/update-1-merck-kgaa-says-profit-could-slip-as-fertility-treatments-shunned-idUSL8N2CW146,negative,0.9733953475952148
5/14/2020 8:41:46 AM,Merck KGaA says profit could slip as fertility treatments shunned,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/kmX5HWILuL8/merck-kgaa-says-profit-could-slip-as-fertility-treatments-shunned-idUSKBN22Q0IW,negative,0.972905695438385
5/14/2020 2:44:16 PM,Merck KGaA says profit could slip as fertility treatments shunned,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/1tU-WSVUKdM/merck-kgaa-says-profit-could-slip-as-fertility-treatments-shunned-idINKBN22Q1ZO,negative,0.972905695438385
5/14/2020 9:02:26 PM,Dow Jones Today: More Bleak Jobs Data Didn’t Ding Stocks,InvestorPlace,/news/stocks/dow-jones-today-more-bleak-jobs-data-didnt-ding-stocks-1029204506,negative,0.9033660888671875
5/18/2020 8:30:31 PM,Dow Jones Today: Vaccine News And Fed Talk Powered Markets Higher,InvestorPlace,/news/stocks/dow-jones-today-vaccine-news-and-fed-talk-powered-markets-higher-1029212694,neutral,0.8665386438369751
5/18/2020 8:50:32 PM,Merck names new CFO and CIO for Organon spinoff,Seeking Alpha,https://seekingalpha.com/news/3575734-merck-names-new-cfo-and-cio-for-organon-spinoff?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9420282244682312
5/19/2020 12:07:33 PM,AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions,InvestorPlace,/news/stocks/whole-of-abbv-stock-more-than-sum-of-parts-1029214731,neutral,0.9493720531463623
5/19/2020 9:09:36 PM,Does Moderna Stock’s Rally Hold Up Under the Microscope?,InvestorPlace,/news/stocks/mrna-stock-rally-microscope-coronavirus-vaccine-1029217325,neutral,0.8170806765556335
5/20/2020 9:18:33 AM,AstraZeneca: Lynparza Approved In US For HRR Gene-mutated Prostate Cancer ,RTTNews,/news/stocks/astrazeneca-lynparza-approved-in-us-for-hrr-gene-mutated-prostate-cancer-1029218213,positive,0.6157163977622986
5/20/2020 11:37:12 AM,Surface Oncology collaborates with Merck for immuno-oncology study; shares up 35%,Seeking Alpha,https://seekingalpha.com/news/3576255-surface-oncology-collaborates-merck-for-immuno-oncology-study-shares-up-35?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7650074362754822
5/21/2020 9:16:53 AM,The Virus Vaccine Race is Fueling Moderna Stock to New Highs,InvestorPlace,/news/stocks/the-virus-vaccine-race-is-fueling-moderna-stock-to-new-highs-1029222715,positive,0.700281023979187
5/25/2020 3:18:50 PM,Vaxcyte files for IPO,Seeking Alpha,https://seekingalpha.com/news/3577367-vaxcyte-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9386510252952576
5/26/2020 7:38:19 AM,Biotech Stocks Facing FDA Decision In June 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2020-1029231771,neutral,0.8592117428779602
5/26/2020 11:28:23 AM,Merck jumps into COVID-19 arena with three initiatives,Seeking Alpha,https://seekingalpha.com/news/3577443-merck-jumps-covidminus-19-arena-three-initiatives?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6966368556022644
5/26/2020 12:45:00 PM,"Merck leaps into COVID-19 development fray with vaccine, drug deals",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/S_JH372Y3uw/merck-leaps-into-covid-19-development-fray-with-vaccine-drug-deals-idUSL1N2D801G,neutral,0.6881794333457947
5/26/2020 1:24:02 PM,"UPDATE 1-Merck leaps into COVID-19 development fray with vaccine, drug deals",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/pOuTwEtZjCE/update-1-merck-leaps-into-covid-19-development-fray-with-vaccine-drug-deals-idUSL1N2D80J3,neutral,0.5194215178489685
5/26/2020 1:26:20 PM,"Merck leaps into COVID-19 development fray with vaccine, drug deals",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/dqtAy0x551M/merck-leaps-into-covid-19-development-fray-with-vaccine-drug-deals-idINKBN2321HP,neutral,0.6881794333457947
5/26/2020 2:23:05 PM,Merck To Buy Privately-held Themis - Quick Facts ,RTTNews,/news/stocks/merck-to-buy-privately-held-themis-quick-facts-1029233213,neutral,0.8632458448410034
5/26/2020 2:34:52 PM,"Merck, Ridgeback Bio Collaborate To Develop Novel Antiviral Candidate EIDD-2801 ",RTTNews,/news/stocks/merck-ridgeback-bio-collaborate-to-develop-novel-antiviral-candidate-eidd-2801-1029233287,positive,0.5553173422813416
5/26/2020 3:37:34 PM,"Merck Inks Deals, Joins Coronavirus Vaccine Race ",RTTNews,/news/stocks/merck-inks-deals-joins-coronavirus-vaccine-race-1029233737,neutral,0.8109079003334045
5/26/2020 3:41:27 PM,COVID-19 vaccine timeframe 'very aggressive' - Merck CEO,Seeking Alpha,https://seekingalpha.com/news/3577567-covidminus-19-vaccine-timeframe-very-aggressive-merck-ceo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5286369919776917
5/26/2020 3:48:25 PM,UPDATE 2-Merck to buy Austrian vaccine maker as it jumps into COVID-19 race,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/yM7RGrflbiY/update-2-merck-to-buy-austrian-vaccine-maker-as-it-jumps-into-covid-19-race-idUSL1N2D80J3,positive,0.7682815194129944
5/26/2020 3:51:27 PM,Merck to buy Austrian vaccine maker as it jumps into COVID-19 race,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/JI-1q_SJIlw/merck-to-buy-austrian-vaccine-maker-as-it-jumps-into-covid-19-race-idUSKBN2321CU,neutral,0.5587137937545776
5/26/2020 4:58:50 PM,Merck to buy Austrian vaccine maker as it jumps into COVID-19 race,Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/uTRpYWIgY-M/merck-to-buy-austrian-vaccine-maker-as-it-jumps-into-covid-19-race-idINKBN2321HP,neutral,0.5587137937545776
5/26/2020 9:50:56 PM,UPDATE 3-Merck to buy Austrian vaccine maker as it jumps into COVID-19 race,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/05koonmI9wU/update-3-merck-to-buy-austrian-vaccine-maker-as-it-jumps-into-covid-19-race-idUSL1N2D80J3,positive,0.7717155814170837
5/27/2020 5:30:00 AM,"ARGX Soars On ADAPT Trial Data, MRK's Deals & Collaborations To Fight COVID-19, ALNY ON Watch ",RTTNews,/news/stocks/argx-soars-on-adapt-trial-data-mrk-s-deals-collaborations-to-fight-covid-19-alny-on-watch-1029235524,positive,0.5685214400291443
5/27/2020 5:51:47 PM,The Trip Aboard Carnival Cruises Stock Will Be Stormy,InvestorPlace,/news/stocks/the-trip-aboard-the-ccl-stock-will-be-stormy-1029239120,neutral,0.9066834449768066
5/27/2020 7:08:26 PM,"Biotech Stocks Have Been on Fire, But Timing Is Everything",InvestorPlace,/news/stocks/biotech-stocks-have-been-on-fire-but-timing-is-everything-1029239422,neutral,0.6861351132392883
5/28/2020 10:00:00 AM,Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS,PR Newswire,/news/stocks/merck-and-twitch-join-forces-on-world-multiple-sclerosis-day-to-connect-people-living-with-ms-1029240545,neutral,0.7562255859375
5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9381866455078125
5/29/2020 11:26:05 AM,Keytruda/Lenvima combo shows benefit liver and kidney cancers,Seeking Alpha,https://seekingalpha.com/news/3578587-keytruda-lenvima-combo-shows-benefit-liver-and-kidney-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9221064448356628
5/29/2020 3:43:22 PM,Why Moderna Stock Is Still Only Good for Speculators,InvestorPlace,/news/stocks/mrna-stock-for-speculators-only-1029264082,neutral,0.9210073947906494
5/30/2020 12:41:10 PM,"The Week That Was: MRK Enters COVID Space, GSK's 1Bln Dose Target, Roche, GILD Team Up For REMDACTA ",RTTNews,/news/stocks/the-week-that-was-mrk-enters-covid-space-gsk-s-1bln-dose-target-roche-gild-team-up-for-remdacta-1029265264,neutral,0.9208623766899109
6/1/2020 8:15:04 AM,AstraZeneca-Merck Lynparza gets EMA's positive recommendation,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/u3FBNxtjANo/astrazeneca-merck-lynparza-gets-emas-positive-recommendation-idUSL4N2DE1N1,positive,0.9346396923065186
6/1/2020 8:43:19 AM,UPDATE 1-AstraZeneca-Merck Lynparza gets EMA's positive recommendation,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/1mUwU2MIM_U/update-1-astrazeneca-merck-lynparza-gets-emas-positive-recommendation-idUSL4N2DE1OS,positive,0.9521716237068176
6/4/2020 6:37:03 AM,"List Of 'Operation Warp Speed' Finalists, SAVA To Reassess AD Study Results; KZR Jumps  On MISSION ",RTTNews,/news/stocks/list-of-operation-warp-speed-finalists-sava-to-reassess-ad-study-results-kzr-jumps-on-mission-1029279089,neutral,0.5100464224815369
6/4/2020 8:41:01 PM,FDA OKs Merck combo antibiotic for bacterial pneumonia,Seeking Alpha,https://seekingalpha.com/news/3580626-fda-oks-merck-combo-antibiotic-for-bacterial-pneumonia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6127095818519592
6/5/2020 5:32:57 AM,"CYCN Awaits Sickle Cell Disease Data, TTPH Finalizes Its Suitor, ADMS Faces FDA In Feb ",RTTNews,/news/stocks/cycn-awaits-sickle-cell-disease-data-ttph-finalizes-its-suitor-adms-faces-fda-in-feb-1029283085,neutral,0.9003450870513916
6/5/2020 1:52:42 PM,China in thick of race for COVID-19 vaccine,Seeking Alpha,https://seekingalpha.com/news/3580791-china-in-thick-of-race-for-covidminus-19-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.748111367225647
6/8/2020 4:08:25 PM,Inovio Slumps as Its Setbacks Pile Up,InvestorPlace,/news/stocks/inovio-slumps-as-its-setbacks-pile-up-1029289728,negative,0.9717625379562378
6/8/2020 4:14:39 PM,The Odds For Long Shot Inovio Stock Just Got Longer,InvestorPlace,/news/stocks/the-odds-for-long-shot-ino-stock-just-got-longer-1029290046,neutral,0.5252552628517151
6/9/2020 3:10:56 PM,Aggressive Investors Can Do Much Better Than Merck Stock,InvestorPlace,/news/stocks/aggressive-investors-better-mrk-stock-1029293865,positive,0.7292519807815552
6/9/2020 3:49:54 PM,7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-buy-coronavirus-gains-1029293862,neutral,0.8380296230316162
6/10/2020 3:19:36 PM,Three key studies of COVID-19 vaccines to launch in summer,Seeking Alpha,https://seekingalpha.com/news/3581971-three-key-studies-of-covidminus-19-vaccines-to-launch-in-summer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8121580481529236
6/12/2020 5:34:11 AM,Japan's PeptiDream to work with Merck in developing COVID-19 therapies,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/sBCcvnMlOsA/japans-peptidream-to-work-with-merck-in-developing-covid-19-therapies-idUSFWN2DO0VJ,positive,0.7272324562072754
6/12/2020 6:12:56 PM,Avoid Merck Stock Until Shares Pull Back,InvestorPlace,/news/stocks/mrk-stock-limited-upside-despite-higher-earnings-1029305081,neutral,0.6540296673774719
6/13/2020 1:45:29 PM,FDA OKs new indication for Merck HPV vaccine,Seeking Alpha,https://seekingalpha.com/news/3582825-fda-oks-new-indication-for-merck-hpv-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5228146910667419
6/16/2020 5:49:43 PM,Pfizer and Merck's diabetes med Steglatro shows mixed results in cardiovascular outcomes study,Seeking Alpha,https://seekingalpha.com/news/3583523-pfizer-and-mercks-diabetes-med-steglatro-shows-mixed-results-in-cardiovascular-outcomes-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9532431364059448
6/16/2020 6:42:00 PM,"Merck & Co., Inc. -- Moody's assigns A1 rating to Merck's new notes; stable outlook",Moodys,/news/bonds/merck-co-inc-moody-s-assigns-a1-rating-to-merck-s-new-notes-stable-outlook-1029314294,positive,0.8520951867103577
6/16/2020 9:04:43 PM,FDA OKs Merck's Keytruda for second application based on biomarker,Seeking Alpha,https://seekingalpha.com/news/3583617-fda-oks-mercks-keytruda-for-second-application-based-on-biomarker?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.812400221824646
6/17/2020 1:03:40 PM,Merck Prices $4.5 Bln Public Debt Offering Of Senior Unsecured Notes - Quick Facts ,RTTNews,/news/stocks/merck-prices-4-5-bln-public-debt-offering-of-senior-unsecured-notes-quick-facts-1029316626,neutral,0.8236584663391113
6/17/2020 1:42:17 PM,Merck: FDA Approves Second Biomarker-Based Indication For KEYTRUDA ,RTTNews,/news/stocks/merck-fda-approves-second-biomarker-based-indication-for-keytruda-1029316832,positive,0.7630581259727478
6/22/2020 1:20:06 PM,Merck: KEYTRUDA Approved For New Indication In China - Quick Facts ,RTTNews,/news/stocks/merck-keytruda-approved-for-new-indication-in-china-quick-facts-1029328916,positive,0.760286271572113
6/25/2020 6:05:00 PM,8 Cash-Rich Stocks to Get You Through the Year and Beyond,InvestorPlace,/news/stocks/the-8-best-cash-cow-stocks-to-buy-for-stable-returns-1028336829,neutral,0.7683794498443604
6/29/2020 7:28:17 AM,Novo Nordisk Announces Approval Of Rybelsus In Japan For Treatment Of Type 2 Diabetes ,RTTNews,/news/stocks/novo-nordisk-announces-approval-of-rybelsus-in-japan-for-treatment-of-type-2-diabetes-1029348521,positive,0.6967026591300964
6/30/2020 2:58:10 PM,FDA OKs Merck's Keytruda As First-line Treatment For Metastatic Colorectal Cancer ,RTTNews,/news/stocks/fda-oks-merck-s-keytruda-as-first-line-treatment-for-metastatic-colorectal-cancer-1029354151,positive,0.515058159828186
7/2/2020 5:02:06 PM,"Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO",InvestorPlace,/news/stocks/keep-eye-rprx-stock-2020-1029363917,neutral,0.9034902453422546
7/6/2020 7:25:44 AM,"Ascentage, Merck To Evaluate APG-115 In Combination With KEYTRUDA In Advanced Solid Tumors ",RTTNews,/news/stocks/ascentage-merck-to-evaluate-apg-115-in-combination-with-keytruda-in-advanced-solid-tumors-1029367563,positive,0.6333495378494263
7/6/2020 10:40:08 AM,Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years,InvestorPlace,/news/stocks/rprx-stock-is-likely-to-reach-new-highs-coming-years-1029368649,positive,0.9159573912620544
7/6/2020 1:38:07 PM,"Merck: New Analyses Show Additional Efficacy Data For Islatravir, Doravirine Combination ",RTTNews,/news/stocks/merck-new-analyses-show-additional-efficacy-data-for-islatravir-doravirine-combination-1029368540,positive,0.8259756565093994
7/6/2020 5:56:43 PM,7 Healthcare ETFs Which Should Continue Growing Into 2021,InvestorPlace,/news/stocks/7-healthcare-etfs-growing-into-2021-1029369965,positive,0.5999964475631714
7/6/2020 6:43:12 PM,Moderna Stock Has a Bright Future After the Coronavirus,InvestorPlace,/news/stocks/moderna-mrna-stock-coronavirus-vaccine-drug-discovery-1029370223,positive,0.7788195610046387
7/8/2020 8:15:36 AM,AstraZeneca: Lynparza Gets EU Approval For BRCA-mutated Metastatic Pancreatic Cancer ,RTTNews,/news/stocks/astrazeneca-lynparza-gets-eu-approval-for-brca-mutated-metastatic-pancreatic-cancer-1029375058,positive,0.9321945309638977
7/8/2020 2:10:46 PM,"Foghorn Therapeutics, Merck Enter Strategic Collaboration - Quick Facts ",RTTNews,/news/stocks/foghorn-therapeutics-merck-enter-strategic-collaboration-quick-facts-1029376334,neutral,0.8217777013778687
7/8/2020 2:23:41 PM,"FDA Issues CRL To Merck, Eisai For Keytruda Plus Lenvima Combination - Quick Facts ",RTTNews,/news/stocks/fda-issues-crl-to-merck-eisai-for-keytruda-plus-lenvima-combination-quick-facts-1029376358,neutral,0.8394690155982971
7/10/2020 8:18:52 AM,"Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here ",RTTNews,/news/stocks/botox-keytruda-get-fda-approval-for-new-uses-bvxv-abuzz-first-droopy-eyelid-treatment-is-here-1029382741,neutral,0.509865939617157
7/14/2020 6:15:53 PM,iBio Stock Is Worth the Gamble in the Covid-19 Vaccine Race,InvestorPlace,/news/stocks/ibio-stock-is-worth-the-gamble-in-the-covid-19-vaccine-raceibio-is-worth-the-gamble-in-the-covid-19-vaccine-race-1029402220,neutral,0.7740674614906311
7/16/2020 1:19:44 PM,FDA Accepts Merck's NDA For Vericiguat For Priority Review - Quick Facts ,RTTNews,/news/stocks/fda-accepts-merck-s-nda-for-vericiguat-for-priority-review-quick-facts-1029400964,neutral,0.5794062614440918
7/17/2020 7:13:18 AM,"ACIU'S Alzheimer's Vaccine Study Chugs Along, LCI Up On Distribution Deal, TLSA Hits New High ",RTTNews,/news/stocks/aciu-s-alzheimer-s-vaccine-study-chugs-along-lci-up-on-distribution-deal-tlsa-hits-new-high-1029403921,positive,0.9158546924591064
7/22/2020 12:27:19 PM,The Curtain Is Coming Down on Inovio Pharmaceuticals’ Vaccine Candidate,InvestorPlace,/news/stocks/curtain-coming-down-on-ino-stock-1029420801,neutral,0.5067680478096008
7/22/2020 1:54:28 PM,Sell Overpriced Novavax Stock While You Still Can,InvestorPlace,/news/stocks/why-you-should-sell-nvax-stock-while-you-still-can-1029420794,neutral,0.9357196688652039
7/30/2020 3:02:56 PM,Merck earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/merck_co-stock-price-quarter-earnings-preview-q2-1029451253,neutral,0.914770245552063
7/31/2020 12:53:44 PM,Merck & Co Inc. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q2-adjusted-earnings-beat-estimates-1029454852,positive,0.8156270384788513
7/31/2020 1:26:54 PM,Merck Q2 Results Top Estimates; Boosts FY20 Outlook ,RTTNews,/news/stocks/merck-q2-results-top-estimates-boosts-fy20-outlook-1029455000,positive,0.9290620684623718
7/31/2020 7:45:47 PM,Merck Earnings: MRK Stock Pops 1% on Better-Than-Expected Q2,InvestorPlace,/news/stocks/merck-earnings-bump-mrk-stock-up-1029456795,positive,0.9198591709136963
8/4/2020 4:44:42 PM,Keytruda Powers a Stellar Q2 for Merck,InvestorPlace,/news/stocks/keytruda-powers-a-stellar-second-quarter-for-mrk-stock-1029468691,positive,0.877044141292572
8/5/2020 4:01:08 PM,Merck Stock Remains a Dull Biotech Play Despite Earnings Success,InvestorPlace,/news/stocks/merck-mrk-stock-remains-a-dull-biotech-play-despite-earnings-success-1029474241,negative,0.9247965812683105
8/6/2020 5:51:20 PM,5 Biotech Stocks That Offer Long-Term Growth and Value,InvestorPlace,/news/stocks/5-biotech-stocks-that-offer-long-term-growth-and-value-1029479695,neutral,0.7105634212493896
8/7/2020 1:36:32 PM,This Company is the Landlord of Life Sciences,InvestorPlace,/news/stocks/this-company-is-the-landlord-of-life-sciences-1029482490,neutral,0.9439411759376526
8/11/2020 4:38:00 PM,Merck Financial Services GmbH -- Moody's announces completion of a periodic review of ratings of Merck KGaA,Moodys,/news/bonds/merck-financial-services-gmbh-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-merck-kgaa-1029492646,neutral,0.8040289878845215
8/19/2020 1:58:31 PM,Merck : Phase 3 Study Of KEYTRUDA - Chemotherapy On Metastatic Esophageal Cancer Meets Main Goal ,RTTNews,/news/stocks/merck-phase-3-study-of-keytruda-chemotherapy-on-metastatic-esophageal-cancer-meets-main-goal-1029516289,neutral,0.8796330094337463
8/20/2020 8:43:27 AM,"JNJ Acquires MNTA, FDA Strikes Down BMRN's Gene Therapy, BLRX's GENESIS On Track, TPTX On Watch ",RTTNews,/news/stocks/jnj-acquires-mnta-fda-strikes-down-bmrn-s-gene-therapy-blrx-s-genesis-on-track-tptx-on-watch-1029519157,negative,0.8946521282196045
8/21/2020 3:31:12 PM,Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma,InvestorPlace,/news/stocks/lly-stock-still-looks-like-best-buy-large-cap-pharma-1029524567,positive,0.805871844291687
9/2/2020 10:33:08 AM,"Highlight, Merck Partner To To Evaluate Combination Of BO-112 And KEYTRUDA ",RTTNews,/news/stocks/highlight-merck-partner-to-to-evaluate-combination-of-bo-112-and-keytruda-1029555094,positive,0.514387309551239
9/2/2020 1:29:51 PM,Merck To Present New Data From Oncology Development Program At ESMO Virtual Congress ,RTTNews,/news/stocks/merck-to-present-new-data-from-oncology-development-program-at-esmo-virtual-congress-1029555667,neutral,0.8887002468109131
9/3/2020 12:54:31 PM,10 Blue-Chip Stocks Ideal for Any Investor,InvestorPlace,/news/stocks/10-blue-chip-stocks-ideal-for-any-investor-1029560529,neutral,0.8295894861221313
9/3/2020 2:00:00 PM,"Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis",PR Newswire,/news/stocks/merck-to-showcase-new-data-at-actrims-ectrims-msvirtual2020-meeting-furthering-innovation-in-multiple-sclerosis-1029559875,positive,0.7614089250564575
9/8/2020 2:57:47 PM,Merck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 Trials ,RTTNews,/news/stocks/merck-gefapixant-significantly-reduced-cough-frequency-compared-to-placebo-in-two-phase-3-trials-1029569600,negative,0.784392774105072
9/9/2020 2:52:05 PM,Merck Reports Positive Topline Results From Two Adult Studies Evaluating V114 ,RTTNews,/news/stocks/merck-reports-positive-topline-results-from-two-adult-studies-evaluating-v114-1029573813,positive,0.9491879343986511
9/10/2020 2:00:00 PM,Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis,PR Newswire,/news/stocks/merck-announces-positive-phase-ii-results-for-investigational-sonelokinab-m1095-in-patients-with-moderate-to-severe-chronic-plaque-type-psoriasis-1029577728,positive,0.933941662311554
9/10/2020 2:35:39 PM,5 Hot Growth Stocks to Buy With Fido in Mind,InvestorPlace,/news/stocks/5-hot-growth-stocks-buy-for-fido-pet-stocks-1029579293,neutral,0.8845946192741394
9/11/2020 2:00:00 PM,New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety,PR Newswire,/news/stocks/new-mavenclad-data-at-actrims-ectrims-msvirtual2020-meeting-highlight-rapid-onset-of-action-and-compelling-post-approval-safety-1029581710,positive,0.9417619705200195
9/14/2020 4:41:00 AM,Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020,PR Newswire,/news/stocks/merck-advances-oncology-portfolio-and-pipeline-with-new-and-long-term-data-in-multiple-cancers-at-esmo-2020-1029584081,positive,0.5985508561134338
9/14/2020 1:07:46 PM,"Seattle Genetics, Merck Announce Two New Strategic Oncology Collaborations - Quick Facts ",RTTNews,/news/stocks/seattle-genetics-merck-announce-two-new-strategic-oncology-collaborations-quick-facts-1029585384,neutral,0.5281126499176025
9/15/2020 8:39:54 AM,"MRNS Catches Eye, SAVA Soars On Alzheimer's Study, ETNB Abuzz Over NASH Trial, GILD Snaps Up IMMU ",RTTNews,/news/stocks/mrns-catches-eye-sava-soars-on-alzheimer-s-study-etnb-abuzz-over-nash-trial-gild-snaps-up-immu-1029588464,positive,0.6621375679969788
9/15/2020 1:52:57 PM,Merck: Health Canada Approves BRENZYS For Four New Indications ,RTTNews,/news/stocks/merck-health-canada-approves-brenzys-for-four-new-indications-1029589600,positive,0.7781438231468201
9/15/2020 2:27:27 PM,"With Its Vaccine Trail, Moderna Addresses Racial Disparity Head On",InvestorPlace,/news/stocks/with-its-vaccine-mrna-stock-can-also-help-heal-racial-wounds-1029591483,neutral,0.8752989768981934
9/15/2020 6:28:05 PM,Merck Could Be the Covid-19 Investment You’re Missing,InvestorPlace,/news/stocks/merck-stock-could-be-the-covid-19-vaccine-investment-youre-missing-1029592091,neutral,0.9405147433280945
9/16/2020 10:04:11 AM,3 Pet Stocks to Buy for Your Furry Friend,InvestorPlace,/news/stocks/3-pet-stocks-to-buy-for-your-furry-friend-1029596091,neutral,0.9286616444587708
9/16/2020 8:20:39 PM,Merger Mania: 4 Major Deals to Watch,InvestorPlace,/news/stocks/merger-mania-4-major-deals-to-watch-1029596613,neutral,0.9321483373641968
9/17/2020 2:28:38 PM,Vaccinex In Clinical Collaboration Deal With Merck To Evaluate Pepinemab And KEYTRUDA ,RTTNews,/news/stocks/vaccinex-in-clinical-collaboration-deal-with-merck-to-evaluate-pepinemab-and-keytruda-1029598568,positive,0.733593225479126
9/18/2020 1:22:38 PM,AstraZeneca: LYNPARZA Shows Progression-free Survival Benefit In Five-year Follow-up Data ,RTTNews,/news/stocks/astrazeneca-lynparza-shows-progression-free-survival-benefit-in-five-year-follow-up-data-1029602173,positive,0.9520829916000366
9/18/2020 3:34:34 PM,4 Biotech Stocks to Buy for Big Gains in 2020,InvestorPlace,/news/stocks/4-biotech-stocks-to-buy-for-big-gains-in-2020-1029603327,positive,0.8859114646911621
9/21/2020 8:54:05 AM,"AstraZeneca: Lynparza Recommended For Approval In EU For Prostate Cancer, Ovarian Cancer ",RTTNews,/news/stocks/astrazeneca-lynparza-recommended-for-approval-in-eu-for-prostate-cancer-ovarian-cancer-1029605651,positive,0.6839354634284973
9/26/2020 7:59:23 PM,Biotech Stocks Facing FDA Decision In October 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2020-1029624668,neutral,0.7615611553192139
9/28/2020 12:24:14 PM,The 10 Best Mutual Funds for Your 401k,InvestorPlace,/news/stocks/the-best-mutual-funds-for-your-401k-1028789807,neutral,0.8619165420532227
9/29/2020 7:38:13 AM,Celyad Collaborates With Merck To Evaluate CYAD-101 With KEYTRUDA On Microsatellite Stable MCRC ,RTTNews,/news/stocks/celyad-collaborates-with-merck-to-evaluate-cyad-101-with-keytruda-on-microsatellite-stable-mcrc-1029629031,positive,0.7491927146911621
10/2/2020 6:40:33 PM,7 Maturing Growth Stocks to Buy You Can Rely On,InvestorPlace,/news/stocks/7-maturing-growth-stocks-to-rely-on-1029645239,neutral,0.9326309561729431
10/6/2020 2:00:00 PM,Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis,PR Newswire,/news/stocks/merck-announces-out-licensing-agreement-for-phase-ii-ready-anti-adamts5-nanobody-for-osteoarthritis-1029651952,positive,0.8812386989593506
10/6/2020 2:12:30 PM,FDA Ad Com this month to clarify COVID-19 vaccine authorization requirements,Seeking Alpha,https://seekingalpha.com/news/3620151-fda-ad-com-this-month-to-clarify-covidminus-19-vaccine-authorization-requirements?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9083845615386963
10/6/2020 2:44:51 PM,The 7 Best New Stocks From 2020 to Buy Now,InvestorPlace,/news/stocks/the-7-best-new-stocks-from-2020-to-buy-now-1029653691,neutral,0.8444294929504395
10/7/2020 4:27:48 PM,7 Biotech Stocks To Buy For Profit From The Vaccine Crunch,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-profit-from-the-vaccine-crunch-1029658673,neutral,0.8608307242393494
10/8/2020 11:01:08 AM,Merck returns rights to RSV vaccine to Moderna,Seeking Alpha,https://seekingalpha.com/news/3620705-merck-returns-rights-to-rsv-vaccine-to-moderna?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9064600467681885
10/8/2020 11:45:47 AM,Merck HIV combo regimen shows sustained benefit in mid-stage HIV study,Seeking Alpha,https://seekingalpha.com/news/3620729-merck-hiv-combo-regimen-shows-sustained-benefit-in-mid-stage-hiv-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9509952068328857
10/8/2020 1:13:03 PM,Moderna Regains Rights To Respiratory Syncytial Virus Vaccine From Merck - Quick Facts ,RTTNews,/news/stocks/moderna-regains-rights-to-respiratory-syncytial-virus-vaccine-from-merck-quick-facts-1029660841,neutral,0.6809408664703369
10/8/2020 2:28:26 PM,Merck Mid-stage HIV Study On Islatravir- Doravirine Shows Viral Suppression Maintained ,RTTNews,/news/stocks/merck-mid-stage-hiv-study-on-islatravir-doravirine-shows-viral-suppression-maintained-1029661441,neutral,0.6044315695762634
10/9/2020 10:45:57 AM,7 Index Funds to Hold Through Thick and Thin,InvestorPlace,/news/stocks/7-index-funds-to-hold-through-thick-and-thin-1029665545,neutral,0.43010562658309937
10/9/2020 8:25:25 PM,COVID-19 drug developer Atea Pharmaceuticals files for IPO,Seeking Alpha,https://seekingalpha.com/news/3621228-covidminus-19-drug-developer-atea-pharmaceuticals-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9147786498069763
10/12/2020 8:58:31 PM,7 Highly Rated Pharmaceutical Stocks for Q4,InvestorPlace,/news/stocks/7-highly-rated-pharmaceutical-stocks-for-q4-1029679826,neutral,0.8309608697891235
10/15/2020 11:01:51 AM,FDA OKs expanded use of Merck’s Keytruda in adults with classical Hodgkin lymphoma,Seeking Alpha,https://seekingalpha.com/news/3622350-fda-oks-expanded-use-of-merck-s-keytruda-in-adults-classical-hodgkin-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.881828248500824
10/15/2020 1:04:48 PM,7 Value Stocks To Buy in an Overvalued Market,InvestorPlace,/news/stocks/7-value-stocks-to-buy-in-overvalued-market-1029684752,neutral,0.857827365398407
10/15/2020 1:33:40 PM,Merck's KEYTRUDA Approved By Health Canada As First-line Treatment In Metastatic Recurrent HNSCC ,RTTNews,/news/stocks/merck-s-keytruda-approved-by-health-canada-as-first-line-treatment-in-metastatic-recurrent-hnscc-1029683371,positive,0.6840417981147766
10/16/2020 7:43:43 PM,"Merck's Keytruda/chemo combo shows durable, sustained benefit in long term lung cancer study",Seeking Alpha,https://seekingalpha.com/news/3623001-mercks-keytruda-chemo-combo-shows-durable-sustained-benefit-in-long-term-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9423996210098267
10/16/2020 11:02:00 PM,JPM picks big pharma names to benefit with busy catalyst calendar ahead,Seeking Alpha,https://seekingalpha.com/news/3623038-jpm-picks-big-pharma-names-to-benefit-busy-catalyst-calendar-ahead?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6425066590309143
10/19/2020 4:58:50 PM,Pfizer and Moderna pivotal studies on COVID-19 vaccines near enrollment targets,Seeking Alpha,https://seekingalpha.com/news/3623326-pfizer-and-moderna-pivotal-studies-on-covidminus-19-vaccines-near-enrollment-targets?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9210036396980286
10/20/2020 11:15:37 AM,Merck's 15-valent pneumonia vaccine successful in two more late-stage studies,Seeking Alpha,https://seekingalpha.com/news/3623574-mercks-15-valent-pneumonia-vaccine-successful-in-two-late-stage-studies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9018535614013672
10/20/2020 1:17:04 PM,Merck Reports Positive Data From 2 Trials Of V114 Pneumococcal Conjugate Vaccine ,RTTNews,/news/stocks/merck-reports-positive-data-from-2-trials-of-v114-pneumococcal-conjugate-vaccine-1029697896,positive,0.9399218559265137
10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001,neutral,0.7490039467811584
10/26/2020 12:46:36 PM,Advaxis down 12% despite ADXS-503 shows sustained tumor control in mid-stage lung cancer trial,Seeking Alpha,https://seekingalpha.com/news/3625698-advaxis-down-12-despite-adxsminus-503-shows-sustained-tumor-control-in-mid-stage-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9696993231773376
10/26/2020 3:01:39 PM,Merck is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/merck_co-q3-earnings-preview-1029721529,neutral,0.9351592063903809
10/26/2020 4:13:39 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3625836-notable-earnings-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8660826683044434
10/26/2020 5:58:57 PM,Merck Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3625953-merck-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8349311351776123
10/27/2020 10:46:53 AM,"Merck EPS beats by $0.31, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3626229-merck-eps-beats-0_31-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5239113569259644
10/27/2020 11:40:56 AM,Merck up 2% premarket on Q3 beat; FY20 non-GAAP EPS guidance raised,Seeking Alpha,https://seekingalpha.com/news/3626302-merck-up-2-premarket-on-q3-beat-fy20-non-gaap-eps-guidance-raised?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.941954493522644
10/27/2020 12:31:16 PM,Merck Updates FY20 Guidance; Q3 Profit Tops Estimates - Quick Facts ,RTTNews,/news/stocks/merck-updates-fy20-guidance-q3-profit-tops-estimates-quick-facts-1029726052,positive,0.740523099899292
10/29/2020 9:09:34 AM,Sanofi teams up with Merck to evaluate THOR-707 and Keytruda in cancer,Seeking Alpha,https://seekingalpha.com/news/3627955-sanofi-teams-up-merck-to-evaluate-thorminus-707-and-keytruda-in-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7082854509353638
10/31/2020 4:30:00 AM,Merck sets ultra-high bar with impressive development of Keytruda,Seeking Alpha,https://seekingalpha.com/news/3628459-merck-sets-ultra-high-bar-impressive-development-of-keytruda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8943354487419128
10/31/2020 4:30:00 AM,Merck sets ulta-high bar with impressive development of Keytruda,Seeking Alpha,https://seekingalpha.com/news/3628459-merck-sets-ulta-high-bar-impressive-development-of-keytruda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9025489091873169
10/31/2020 6:00:00 AM,"Vaccine developers take varied approaches to COVID-19, next-gen platforms may not be better than more traditional technologies",Seeking Alpha,https://seekingalpha.com/news/3629098-vaccine-developers-take-varied-approaches-to-covidminus-19-next-gen-platforms-may-not-be?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7795732617378235
11/2/2020 11:05:35 AM,3 Biotech Stocks With Eye-Catching Pipelines,InvestorPlace,/news/stocks/3-biotech-stocks-with-eye-catching-pipelines-1029752447,neutral,0.5421434044837952
11/2/2020 4:11:03 PM,5 Industries Biden Would Destroy as President,InvestorPlace,/news/stocks/election-stocks-sell-5-industries-threatened-biden-victory-1029754646,neutral,0.8998605608940125
11/3/2020 1:26:59 PM,Early-stage study commences on ADC antibody-drug conjugate in solid tumors,Seeking Alpha,https://seekingalpha.com/news/3630323-early-stage-study-commences-on-adc-antibody-drug-conjugate-in-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8270219564437866
11/5/2020 1:58:34 PM,Pappas Capital's VelosBio To Be Acquired By Merck In $2.75 Bln Cash Deal ,RTTNews,/news/stocks/pappas-capital-s-velosbio-to-be-acquired-by-merck-in-2-75-bln-cash-deal-1029770140,neutral,0.9206240773200989
11/5/2020 2:46:54 PM,India races ahead with COVID-19 vaccine as AstraZeneca deliveries lag,Seeking Alpha,https://seekingalpha.com/news/3632254-india-races-ahead-covidminus-19-vaccine-astrazeneca-deliveries-lag?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8641549348831177
11/5/2020 6:27:12 PM,Merck to acquire VelosBio for $2.75B,Seeking Alpha,https://seekingalpha.com/news/3632368-merck-to-acquire-velosbio-for-2_75b?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9357669353485107
11/6/2020 12:31:32 PM,"Pre-market Movers In Healthcare Sector: RGLS, ASMB, GBT, ONCT… ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-rgls-asmb-gbt-onct-1029774521,neutral,0.9379501938819885
11/9/2020 12:07:49 PM,"Pfizer/BioNTech COVID-19 vaccine 90% effective, U.S. EUA application expected this month",Seeking Alpha,https://seekingalpha.com/news/3633509-pfizer-biontech-covidminus-19-vaccine-90-effective-u-s-eua-application-expected-this-month?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8656361103057861
11/9/2020 2:00:00 PM,Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics,PR Newswire,/news/stocks/merck-announces-out-licensing-agreement-for-investigational-atacicept-with-vera-therapeutics-1029781207,neutral,0.5561241507530212
11/9/2020 2:20:48 PM,OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma,Seeking Alpha,https://seekingalpha.com/news/3633684-oncosec-drops-11-despite-positive-data-from-tavo-mercks-keytruda-in-metastatic-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9680030345916748
11/9/2020 9:50:39 PM,Bristol Myers' Yervoy shows no incremental benefit over Merck's Keytruda alone in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3634036-bristol-myers-yervoy-shows-no-incremental-benefit-over-mercks-keytruda-alone-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8773894906044006
11/10/2020 12:16:29 PM,Merck/Eisai's Keytruda + Lenvima meets endpoints in late-stage kidney disease study,Seeking Alpha,https://seekingalpha.com/news/3634251-merck-eisais-keytruda-lenvima-meets-endpoints-in-late-stage-kidney-disease-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7645143270492554
11/10/2020 2:37:15 PM,Agenus secures $10M in milestone payment related to MK-4830,Seeking Alpha,https://seekingalpha.com/news/3634382-agenus-secures-10m-in-milestone-payment-related-to-mkminus-4830?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9311097264289856
11/11/2020 1:03:04 PM,Moderna cancer vaccine shows encouraging action in head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/3634891-moderna-cancer-vaccine-shows-encouraging-action-in-head-and-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9434158802032471
11/11/2020 2:24:45 PM,9 Outbreak-Fueled Stocks to Buy This Week,InvestorPlace,/news/stocks/stocks-to-buy-this-week-second-coronavirus-wave-1029421408,neutral,0.7889739274978638
11/11/2020 9:32:20 PM,Know Why You’re Buying (Or Not Buying) Palantir Technologies,InvestorPlace,/news/stocks/know-why-you-are-buying-or-not-buying-pltr-stock-1029793916,neutral,0.9241772294044495
11/13/2020 8:00:17 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3636251-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
11/13/2020 9:22:53 PM,FDA OKs Merck's Keytruda for triple-negative breast cancer,Seeking Alpha,https://seekingalpha.com/news/3636313-fda-oks-mercks-keytruda-for-triple-negative-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6605525016784668
11/16/2020 8:28:01 AM,FDA OKs expanded use of Agilent's PD-L1 IHC 22C3 pharmDx in breast cancer,Seeking Alpha,https://seekingalpha.com/news/3636418-fda-oks-expanded-use-of-agilents-pd-l1-ihc-22c3-pharmdx-in-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8681334853172302
11/16/2020 12:20:35 PM,"Moderna shares jump 12% as COVID-19 vaccine shows 94.5% efficacy, expects EUA submission shortly",Seeking Alpha,https://seekingalpha.com/news/3636472-moderna-shares-jump-12-covidminus-19-vaccine-shows-94_5-efficacy-expects-eua-submission?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9234064221382141
11/16/2020 1:49:34 PM,Merck: Bill & Melinda Foundation To Support Islatravir Phase 3 Trial - Quick Facts ,RTTNews,/news/stocks/merck-bill-melinda-foundation-to-support-islatravir-phase-3-trial-quick-facts-1029805733,neutral,0.659468412399292
11/17/2020 10:41:52 AM,"Buffett’s Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks",InvestorPlace,/news/stocks/buffets-berkshire-hathaway-stock-buys-new-stakes-in-vaccine-makers-cut-banks-1029809986,neutral,0.8204633593559265
11/17/2020 11:45:38 AM,Is messenger RNA technology in COVID-19 a new tool to success?,Seeking Alpha,https://seekingalpha.com/news/3636976-is-messenger-rna-technology-in-covidminus-19-new-tool-to-success?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7902471423149109
11/17/2020 6:41:47 PM,Merck increases dividend by ~7% to $0.65,Seeking Alpha,https://seekingalpha.com/news/3637214-merck-increases-dividend-7-to-0_65?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9414018392562866
11/19/2020 10:02:20 AM,FDA plans early advisory meetings in December to discuss COVID-19 vaccines - CNBC,Seeking Alpha,https://seekingalpha.com/news/3637799-fda-plans-early-advisory-meetings-in-december-to-discuss-covidminus-19-vaccines-cnbc?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.930812418460846
11/23/2020 11:31:46 AM,Take Your Victory Lap and Take Your Profits in Moderna,InvestorPlace,/news/stocks/moderna-mrna-stock-take-your-victory-lap-1029829432,neutral,0.921023964881897
11/23/2020 11:54:22 AM,Merck adds to suite of COVID-19 clinical programs through OncoImmune acquistion,Seeking Alpha,https://seekingalpha.com/news/3638577-merck-adds-to-suite-of-covidminus-19-clinical-programs-through-oncoimmune-acquistion?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6934171319007874
11/23/2020 12:14:58 PM,Merck files for licensure of V114 in U.S. and Europe,Seeking Alpha,https://seekingalpha.com/news/3638590-merck-files-for-licensure-of-v114-in-u-s-and-europe?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9096477627754211
11/23/2020 1:43:39 PM,Merck To Buy OncoImmune; Submits Applications For 15-valent Pneumococcal Conjugate Vaccine ,RTTNews,/news/stocks/merck-to-buy-oncoimmune-submits-applications-for-15-valent-pneumococcal-conjugate-vaccine-1029829316,neutral,0.8566677570343018
11/23/2020 8:00:26 PM,7 Upcoming IPOs to Watch Heading Into 2021,InvestorPlace,/news/stocks/7-upcoming-ipos-to-watch-1029273035,neutral,0.9287413954734802
11/24/2020 7:55:02 AM,"AZN's COVID Shot 70% Effective On Average, ARQT Aces Scalp Psoriasis Study, BLRX' BLAST Fizzles ",RTTNews,/news/stocks/azn-s-covid-shot-70-effective-on-average-arqt-aces-scalp-psoriasis-study-blrx-blast-fizzles-1029832359,positive,0.5223150849342346
11/25/2020 6:25:04 PM,Merck and Biotech’s Swashbuckling Era,InvestorPlace,/news/stocks/swashbuckling-era-merck-mrk-stock-1029839832,neutral,0.9027481079101562
11/27/2020 1:42:00 AM,European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations,PR Newswire,/news/stocks/european-medicines-agency-validates-application-for-tepotinib-for-the-treatment-of-advanced-nsclc-with-metex14-skipping-alterations-1029843179,neutral,0.5473389029502869
11/30/2020 2:21:45 PM,7 Stocks to Sell for Christmas Giving,InvestorPlace,/news/stocks/7-stocks-to-sell-for-christmas-giving-1029849249,neutral,0.8936886787414551
12/2/2020 12:44:46 PM,Merck unloaded stake in Moderna earlier this quarter,Seeking Alpha,https://seekingalpha.com/news/3640755-merck-unloaded-stake-in-moderna-earlier-this-quarter?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9177157282829285
12/2/2020 2:36:40 PM,Merck Sells Direct Holding In Moderna - Quick Facts ,RTTNews,/news/stocks/merck-sells-direct-holding-in-moderna-quick-facts-1029857631,neutral,0.9448516368865967
12/3/2020 2:31:25 PM,85 Million & Climbing: Why Pets = Profits for These 6 Companies,InvestorPlace,/news/stocks/85-million-climbing-why-pet-stocks-profits-1029862266,neutral,0.8842548131942749
12/4/2020 1:49:16 PM,9 Best Stocks to Buy for the Santa Claus Rally,InvestorPlace,/news/stocks/9-best-stocks-to-buy-for-santa-claus-rally-1029865916,neutral,0.892253041267395
12/4/2020 4:46:01 PM,Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company,InvestorPlace,/news/stocks/sutro-biopharma-what-to-know-about-stro-stock-1029865897,neutral,0.9380685091018677
12/7/2020 10:52:00 AM,Moody's - Outlook for global pharmaceutical industry revised to positive as COVID-19 vaccines and treatments boost earnings,Moodys,/news/bonds/moody-s-outlook-for-global-pharmaceutical-industry-revised-to-positive-as-covid-19-vaccines-and-treatments-boost-earnings-1029868484,positive,0.9331789612770081
12/7/2020 2:12:34 PM,Aligos enters into an agreement with Merck to discover and develop an oligonucleotide therapy for NASH,Seeking Alpha,https://seekingalpha.com/news/3642082-aligos-enters-agreement-merck-to-discover-and-develop-oligonucleotide-therapy-for-nash?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8305396437644958
12/8/2020 8:41:39 AM,U.K. rolls out COVID-19 vaccine to public - report,Seeking Alpha,https://seekingalpha.com/news/3642355-u-k-rolls-out-covidminus-19-vaccine-to-public-report?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7050290107727051
12/9/2020 4:50:44 PM,Intec Pharma News: Why NTEC Stock Is on Fire Today,InvestorPlace,/news/stocks/intec-pharma-news-why-ntec-stock-is-on-fire-today-1029878470,negative,0.7490983605384827
12/10/2020 7:47:53 PM,Coalition Of CEOs Pledge 1 Mln Jobs For Black Americans ,RTTNews,/news/stocks/coalition-of-ceos-pledge-1-mln-jobs-for-black-americans-1029882974,neutral,0.7025613188743591
12/11/2020 12:20:59 PM,EMA backs Merck's Keytruda as first-line treatment in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3643641-ema-backs-mercks-keytruda-first-line-treatment-in-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.570434033870697
12/11/2020 1:40:34 PM,Merck Reports Positive CHMP Opinion For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-reports-positive-chmp-opinion-for-keytruda-quick-facts-1029885153,positive,0.9403774738311768
12/15/2020 6:35:20 AM,First COVID-19 shot given in U.S. as roll-out begins - WSJ,Seeking Alpha,https://seekingalpha.com/news/3644277-first-covidminus-19-shot-given-in-u-s-roll-out-begins-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7453948259353638
12/15/2020 4:01:00 PM,"Merck Sharp & Dohme Corp. -- Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.",Moodys,/news/bonds/merck-sharp-dohme-corp-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-merck-co-inc-1029894520,neutral,0.8242955803871155
12/16/2020 10:47:45 AM,Micro-cap oncology biotech Scopus Biopharma prices downsized $2.75M IPO,Seeking Alpha,https://seekingalpha.com/news/3644762-micro-cap-oncology-biotech-scopus-biopharma-prices-downsized-2_75m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4526408910751343
12/16/2020 11:30:19 AM,BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer,Seeking Alpha,https://seekingalpha.com/news/3644773-biolinerx-jumps-22-on-promising-triple-combination-data-of-motixafortide-in-pancreatic-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9337621331214905
12/16/2020 12:25:37 PM,Merck/Eisai's Keytruda and Lenvima combo meet endpoints in late-stage uterine cancer study,Seeking Alpha,https://seekingalpha.com/news/3644799-merck-eisais-keytruda-and-lenvima-combo-meet-endpoints-in-late-stage-uterine-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6811532378196716
12/16/2020 1:45:06 PM,Merck : Keytruda Plus Lenvima Meets Primary Goal In Phase 3 Trial On Advanced Endometrial Cancer ,RTTNews,/news/stocks/merck-keytruda-plus-lenvima-meets-primary-goal-in-phase-3-trial-on-advanced-endometrial-cancer-1029897875,positive,0.8533580899238586
12/16/2020 8:43:27 PM,4 Dividend Stocks That Will Refill Your Wallet After Holiday Spending,InvestorPlace,/news/stocks/4-dividend-stocks-that-will-refill-your-wallet-after-holiday-spending-1029900152,neutral,0.9218928217887878
12/17/2020 11:55:51 AM,FDA accepts Merck's application for Keytruda + chemotherapy in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3645215-fda-accepts-mercks-application-for-keytruda-chemotherapy-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8694559335708618
12/17/2020 1:51:46 PM,Merck: FDA Grants Priority Review To SBLA For Keytruda Plus Chemotherapy ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-plus-chemotherapy-1029902070,positive,0.690412163734436
12/18/2020 11:33:08 AM,EU set to rollout COVID-19 vaccine from December 27 - NYT,Seeking Alpha,https://seekingalpha.com/news/3645629-eu-set-to-rollout-covidminus-19-vaccine-from-december-27-nyt?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5515856146812439
12/18/2020 4:24:00 PM,IWH UK Midco Limited -- Moody's downgrades IWH UK Finco Limited's ('Theramex') ratings to B3; changes outlook to stable from negative,Moodys,/news/bonds/iwh-uk-midco-limited-moody-s-downgrades-iwh-uk-finco-limited-s-theramex-ratings-to-b3-changes-outlook-to-stable-from-negative-1029906834,negative,0.5034213662147522
12/22/2020 7:03:31 PM,The 7 Worst Dow Jones Stocks of 2020,InvestorPlace,/news/stocks/the-7-worst-dow-jones-stocks-of-2020-1029915113,negative,0.8475598096847534
12/22/2020 9:45:08 PM,5 Rational Biotech Stocks to Buy,InvestorPlace,/news/stocks/5-rational-biotech-stocks-to-buy-1029915560,neutral,0.805504560470581
12/23/2020 12:19:26 PM,Merck inks supply deal for up to 100K doses of MK-7110 for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3646907-merck-inks-supply-deal-for-up-to-100k-doses-of-mkminus-7110-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9077932834625244
12/23/2020 1:31:35 PM,Merck Collaborates With U.S. Government To Advance Investigational Biological Therapy For COVID-19 ,RTTNews,/news/stocks/merck-collaborates-with-u-s-government-to-advance-investigational-biological-therapy-for-covid-19-1029916752,positive,0.7833337783813477
12/23/2020 2:30:53 PM,"The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut",Benzinga,/news/stocks/the-daily-biotech-pulse-supernus-issues-positive-adhd-readout-sorrento-files-for-emergency-use-authorization-for-rapid-covid-19-test-inhibikase-to-make-wall-street-debut-1029916943,positive,0.7712023258209229
12/23/2020 6:08:33 PM,"Merck, A2 Bio in development pact for allogeneic cell therapy candidates for cancer",Seeking Alpha,https://seekingalpha.com/news/3647078-merck-a2-bio-in-development-pact-for-allogeneic-cell-therapy-candidates-for-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6165453791618347
12/23/2020 7:03:57 PM,Why Pfizer Stock Deserves a Spot In Your Portfolio,InvestorPlace,/news/stocks/why-pfizer-stock-deserves-a-spot-in-your-portfolio-1029917859,neutral,0.830133855342865
12/28/2020 11:35:55 AM,"As Vaccine Excitement Fades, Buy the Pullback in Pfizer",InvestorPlace,/news/stocks/vaccine-excitement-fades-buy-pullback-pfizer-pfe-stock-1029921274,neutral,0.8600408434867859
12/28/2020 12:16:20 PM,"AstraZeneca, Merck’s Lynparza OK'd in Japan for cancers",Seeking Alpha,https://seekingalpha.com/news/3647466-astrazeneca-merck-s-lynparza-okd-in-japan-for-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6261963248252869
12/28/2020 1:06:40 PM,AstraZeneca : Japan Approves Lynparza To Treat Three Types Of Advanced Cancer ,RTTNews,/news/stocks/astrazeneca-japan-approves-lynparza-to-treat-three-types-of-advanced-cancer-1029921157,positive,0.8611050248146057
12/29/2020 7:53:14 AM,Biotech Stocks Facing FDA Decision In January 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2021-1029922365,neutral,0.6815580725669861
12/31/2020 3:20:20 PM,6 Cannabis Stocks to Buy as the U.S. Softens Its Stance,InvestorPlace,/news/stocks/6-cannabis-stocks-to-buy-as-the-u-s-softens-its-stance-1029927336,positive,0.829277515411377
1/1/2021 9:27:40 AM,Energy and travel among worst S&P 500 performers of 2020,Seeking Alpha,https://seekingalpha.com/news/3648163-energy-and-travel-among-worst-s-and-p-500-performers-of-2020?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6290715932846069
1/2/2021 4:45:58 PM,Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-january-pdufa-dates-1029928632,neutral,0.9451626539230347
1/7/2021 12:09:27 PM,Merck Acquires AmpTec - Quick Facts ,RTTNews,/news/stocks/merck-acquires-amptec-quick-facts-1029939984,neutral,0.9402194619178772
1/7/2021 2:20:50 PM,"The Daily Biotech Pulse: CureVac COVID-19 Vaccine Deal, Argenx Out-Licenses Neuromuscular Disorder Drug, Xencor's Oncology Collaboration",Benzinga,/news/stocks/the-daily-biotech-pulse-curevac-covid-19-vaccine-deal-argenx-out-licenses-neuromuscular-disorder-drug-xencor-s-oncology-collaboration-1029940542,neutral,0.875293493270874
1/7/2021 2:31:46 PM,Immutep completes recruitment in efti mid-stage study in head & neck cancer,Seeking Alpha,https://seekingalpha.com/news/3649631-immutep-completes-recruitment-in-efti-mid-stage-study-in-head-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8404406309127808
1/7/2021 4:57:52 PM,Why Nextleaf Solutions Is Betting That Patents Are The Future Of Cannabis,Benzinga,/news/stocks/why-nextleaf-solutions-is-betting-that-patents-are-the-future-of-cannabis-1029941294,neutral,0.9055585265159607
1/7/2021 9:30:51 PM,"Moderna Is An Example of Why You Should Buy Systems, Not Drugs",InvestorPlace,/news/stocks/mrna-stock-is-an-example-of-why-you-should-buy-systems-not-drugs-1029942264,neutral,0.9299733638763428
1/8/2021 3:45:12 PM,Dosing underway in OncoSec's Tavo combo trial in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3649976-dosing-underway-in-oncosecs-tavo-combo-trial-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7495699524879456
1/11/2021 2:37:11 PM,AbbVie rated buy at Mizuho despite patent cliff for Humira,Seeking Alpha,https://seekingalpha.com/news/3650303-abbvie-rated-buy-mizuho-despite-patent-cliff-for-humira?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9436819553375244
1/12/2021 11:59:20 AM,Merck's V114 nabs accelerated review in U.S. for invasive pneumococcal disease in adults,Seeking Alpha,https://seekingalpha.com/news/3650608-mercks-v114-nabs-accelerated-review-in-u-s-for-invasive-pneumococcal-disease-in-adults?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.544754683971405
1/12/2021 1:17:06 PM,Merck : FDA Accepts For Priority Review BLA For Adult Invasive Pneumococcal Vaccine ,RTTNews,/news/stocks/merck-fda-accepts-for-priority-review-bla-for-adult-invasive-pneumococcal-vaccine-1029959201,positive,0.48274752497673035
1/12/2021 2:15:54 PM,"The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue",Benzinga,/news/stocks/the-daily-biotech-pulse-gsk-vir-to-start-covid-19-antibody-study-novartis-in-licenses-beigene-s-cancer-drug-earnings-preannouncements-continue-1029959657,neutral,0.9257159233093262
1/12/2021 4:32:16 PM,"Even In This Market, There Are Better Choices Than Pfizer Stock",InvestorPlace,/news/stocks/better-choices-than-pfe-stock-1029961129,neutral,0.7564706206321716
1/13/2021 4:30:31 PM,7 Great Speculations for 2021,InvestorPlace,/news/stocks/7-great-speculations-top-stocks-for-2021-1029965553,neutral,0.9039639234542847
1/15/2021 6:40:02 PM,Seagen is seen heading towards a ‘catalyst-rich 2021’ - BofA,Seeking Alpha,https://seekingalpha.com/news/3651916-seagen-is-seen-heading-towards-catalyst-rich-2021-bofa?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7559238076210022
1/15/2021 8:00:04 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3651929-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
1/16/2021 7:20:16 PM,The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications,Benzinga,/news/stocks/the-week-ahead-in-biotech-fda-to-issue-decisions-on-merck-and-aurinia-drug-applications-1029975084,neutral,0.9203998446464539
1/19/2021 2:05:51 PM,Cocrystal Pharma further develops influenza A/B antiviral compounds under collaboration with Merck,Seeking Alpha,https://seekingalpha.com/news/3652228-cocrystal-pharma-further-develops-influenza-ab-antiviral-compounds-under-collaboration-with-merck?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5852608680725098
1/19/2021 9:47:15 PM,Gilead up nearly 6% on Morgan Stanley upgrade to overweight,Seeking Alpha,https://seekingalpha.com/news/3652416-gilead-up-6-on-morgan-stanley-upgrade-to-overweight?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9429033994674683
1/20/2021 12:14:38 PM,Merck/Bayer's Verquvo OK'd in U.S. for chronic heart failure,Seeking Alpha,https://seekingalpha.com/news/3652583-merckbayers-verquvo-okd-in-us-for-chronic-heart-failure?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5688678026199341
1/20/2021 1:04:47 PM,Merck : FDA Approves Soluble Guanylate Cyclase Stimulator Verquvo To Treat Heart Failure ,RTTNews,/news/stocks/merck-fda-approves-soluble-guanylate-cyclase-stimulator-verquvo-to-treat-heart-failure-1029985740,positive,0.8955364227294922
1/20/2021 1:11:00 PM,Oncorus' ONCR-177 shows encouraging action in antitumor activity in solid tumors,Seeking Alpha,https://seekingalpha.com/news/3652615-oncorus-oncr-177-shows-encouraging-action-in-antitumor-activity-in-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9493451118469238
1/20/2021 1:32:35 PM,"The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-greenlights-merck-s-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study-1029985849,neutral,0.48656928539276123
1/20/2021 3:24:21 PM,The 7 Best Healthcare Stocks to Buy for 2021,InvestorPlace,/news/stocks/the-7-best-healthcare-stocks-to-buy-for-2021-1029987247,neutral,0.817572295665741
1/20/2021 4:12:07 PM,"Merck KGaA, GSK end Phase 3 trial for cancer drug; shares fall",Seeking Alpha,https://seekingalpha.com/news/3652737-merck-kgaa-gsk-end-phase-3-trial-for-cancer-drug-shares-fall?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7695243954658508
1/23/2021 3:14:04 PM,"The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-24-30-j-j-lilly-to-kickstart-big-pharma-earnings-amgen-fda-decision-and-more-1029996049,positive,0.6939177513122559
1/25/2021 11:30:01 AM,Embrace the ProShares Pet Care ETF as People Add Pets to the Family,InvestorPlace,/news/stocks/proshares-pet-care-etf-pawz-pet-spending-1029999865,neutral,0.7945043444633484
1/25/2021 11:57:02 AM,Merck discontinues development of V590 and V591 COVID-19 vaccine candidates,Seeking Alpha,https://seekingalpha.com/news/3653781-merck-discontinues-development-of-v590-and-v591-covid-19-vaccine-candidates?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6217171549797058
1/25/2021 1:05:11 PM,Merck To Discontinue Development Of SARS-CoV-2 Vaccine Candidates Based On Phase 1 Study Findings ,RTTNews,/news/stocks/merck-to-discontinue-development-of-sars-cov-2-vaccine-candidates-based-on-phase-1-study-findings-1029998590,neutral,0.8799819946289062
1/25/2021 2:47:40 PM,Merck’s COVID-19 setback is not a surprise – BofA,Seeking Alpha,https://seekingalpha.com/news/3653912-mercks-covid-19-setback-is-not-a-surprise-bofa?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6139485239982605
1/26/2021 7:28:43 AM,"AZN Rejects Media Reports, MRK Quits COVID-19 Vaccine Work, MRNA Sets Eyes On New SARS-CoV-2 Strains ",RTTNews,/news/stocks/azn-rejects-media-reports-mrk-quits-covid-19-vaccine-work-mrna-sets-eyes-on-new-sars-cov-2-strains-1030002506,neutral,0.66801917552948
1/26/2021 12:24:35 PM,Merck’s Keytruda gets European approval in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3654260-mercks-keytruda-gets-european-approval-in-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9041675329208374
1/26/2021 1:22:30 PM,Merck: European Commission Approves KEYTRUDA For Treatment Of MSI-H Or DMMR Colorectal Cancer ,RTTNews,/news/stocks/merck-european-commission-approves-keytruda-for-treatment-of-msi-h-or-dmmr-colorectal-cancer-1030003620,positive,0.86262047290802
1/26/2021 2:07:40 PM,"The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-misses-j-j-beats-in-big-pharma-earnings-vaccine-developer-curevac-taps-equity-market-1030004007,positive,0.7611163854598999
1/26/2021 3:04:30 PM,Merck posts encouraging interim data from mid-stage HIV study,Seeking Alpha,https://seekingalpha.com/news/3654399-merck-announces-positive-interim-data-from-mid-stage-hiv-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9465349316596985
1/26/2021 5:53:53 PM,Merck Presents Interim Data From Phase 2a Trial Of Treatment For Pre-exposure Prophylaxis ,RTTNews,/news/stocks/merck-presents-interim-data-from-phase-2a-trial-of-treatment-for-pre-exposure-prophylaxis-1030005639,neutral,0.9138436913490295
1/26/2021 6:19:09 PM,Merck declares $0.65 dividend,Seeking Alpha,https://seekingalpha.com/news/3654526-merck-declares-0_65-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9264159202575684
1/29/2021 12:02:52 AM,"Major pharma set for strong 2021, and trading at a 35% discount to market - J.P. Morgan",Seeking Alpha,https://seekingalpha.com/news/3655985-major-pharma-set-for-strong-2021-and-trading-at-a-35-discount-to-market-jp-morgan?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.795691967010498
1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250,neutral,0.8783656358718872
1/31/2021 4:49:07 AM,Merck’s Keytruda with Yervoy fail to add clinical benefit in non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3656446-mercks-keytruda-with-yervoy-fail-to-add-clinical-benefit-in-non-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8346370458602905
1/31/2021 11:22:18 AM,Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-february-pdufa-dates-1030022689,neutral,0.9469277858734131
2/1/2021 2:01:38 PM,Merck Gets Positive EU CHMP Opinion For Expanded Approval Of Keytruda ,RTTNews,/news/stocks/merck-gets-positive-eu-chmp-opinion-for-expanded-approval-of-keytruda-1030027309,positive,0.9501698613166809
2/2/2021 3:01:46 PM,Here's what Wall Street expects from Merck's earnings,Markets Insider Automation,/news/stocks/merck_co-q4-earnings-preview-stock-1030033283,neutral,0.9255590438842773
2/3/2021 5:04:29 PM,Merck Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3657836-merck-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8482018709182739
2/3/2021 5:06:11 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3657838-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8825733065605164
2/4/2021 12:19:39 PM,"Merck Q4 Keytruda sales up 28%, 2021 guidance tops consensus",Seeking Alpha,https://seekingalpha.com/news/3658301-merck-q4-keytruda-sales-up-28-2021-guidance-tops-consensus?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9517515897750854
2/4/2021 1:01:34 PM,Merck Names Robert Davis CEO Effective July 1; Kenneth Frazier To Continue As Exe. Chairman ,RTTNews,/news/stocks/merck-names-robert-davis-ceo-effective-july-1-kenneth-frazier-to-continue-as-exe-chairman-1030042990,neutral,0.9452537298202515
2/4/2021 1:03:01 PM,Merck Issues FY21 Outlook; Elects Robert Davis As CEO ,RTTNews,/news/stocks/merck-issues-fy21-outlook-elects-robert-davis-as-ceo-1030042994,neutral,0.8931722044944763
2/4/2021 1:21:58 PM,"The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-covid-19-drug-readout-merck-and-roche-earnings-3-ipos-1030043134,neutral,0.9448729157447815
2/4/2021 3:36:25 PM,Negative impacts of COVID-19 pandemic weigh heavily on Merck Q4 results,Seeking Alpha,https://seekingalpha.com/news/3658453-negative-impacts-of-covid-19-pandemic-weigh-heavily-on-merck-q4-results?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.715064287185669
2/4/2021 4:16:13 PM,Citius Pharmaceuticals Is Addressing Several Unmet Needs In The Medical Field,Benzinga,/news/stocks/citius-pharmaceuticals-is-addressing-several-unmet-needs-in-the-medical-field-1030044503,positive,0.7931448221206665
2/5/2021 8:38:02 AM,"JNJ Single-shot COVID-19 Vaccine At FDA Altar, KPTI Expands Xpovio's Footprint, OTLK On Track ",RTTNews,/news/stocks/jnj-single-shot-covid-19-vaccine-at-fda-altar-kpti-expands-xpovio-s-footprint-otlk-on-track-1030047435,positive,0.9038208723068237
2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6293289065361023
2/5/2021 4:44:32 PM,Merck price target cut at RBC citing lack of near-term drivers,Seeking Alpha,https://seekingalpha.com/news/3659130-merck-price-target-cut-at-rbc-citing-lack-of-near-term-drivers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9324068427085876
2/6/2021 6:42:05 PM,"The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-7-13-regeneron-fda-decision-earnings-ipos-and-conference-presentations-in-the-spotlight-1030050676,neutral,0.9400112628936768
2/8/2021 2:41:10 PM,3 Under-the-Radar Biotech Stocks to Buy After Dull Earnings Reactions,InvestorPlace,/news/stocks/3-under-the-radar-biotech-stocks-to-buy-after-earnings-1030055864,neutral,0.687945544719696
2/9/2021 4:49:14 PM,Merck antiviral molnupiravir effective in preventing COVID-19 in lung tissue,Seeking Alpha,https://seekingalpha.com/news/3660020-merck-antiviral-molnupiravir-effective-in-preventing-covid-19-in-lung-tissue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9051259756088257
2/10/2021 12:36:08 PM,Merck’s Keytruda decision deferred,Seeking Alpha,https://seekingalpha.com/news/3660463-mercks-keytruda-decision-deferred?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8296063542366028
2/11/2021 1:26:22 PM,"The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-dermtech-soars-on-contract-fluidigm-plunges-on-earnings-decision-day-for-regeneron-bioventus-debuts-1030072237,negative,0.9134436845779419
2/14/2021 3:56:57 AM,COVID-19 reshapes global vaccine landscape: Barron’s,Seeking Alpha,https://seekingalpha.com/news/3661953-covid-19-reshapes-global-vaccine-landscape-barrons?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8485727906227112
2/17/2021 8:52:10 AM,AstraZeneca: IDMC Recommends Primary Analysis For OlympiA Phase III Trial ,RTTNews,/news/stocks/astrazeneca-idmc-recommends-primary-analysis-for-olympia-phase-iii-trial-1030090614,neutral,0.89014732837677
2/17/2021 1:26:55 PM,"The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-funding-for-gene-therapy-research-priority-review-for-amgen-cancer-drug-pfizer-biontech-vaccine-supply-deal-1030091631,neutral,0.8941707015037537
2/17/2021 2:32:22 PM,Nektar Collaborates With SFJ Pharma For Bempegaldesleukin In Head And Neck Cancer ,RTTNews,/news/stocks/nektar-collaborates-with-sfj-pharma-for-bempegaldesleukin-in-head-and-neck-cancer-1030092206,neutral,0.6480140686035156
2/17/2021 3:59:44 PM,Nektar and Merck team up in mid-stage cancer combo study,Seeking Alpha,https://seekingalpha.com/news/3662897-nektar-and-merck-team-up-in-mid-stage-cancer-combo-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7830985188484192
2/17/2021 8:44:10 PM,"Q4 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q4-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030093945,neutral,0.8798474073410034
2/18/2021 5:58:36 AM,"NKTR Teams Up With MRK, Pfizer Initiates Multiple Myeloma Trial, PCSA On Watch ",RTTNews,/news/stocks/nktr-teams-up-with-mrk-pfizer-initiates-multiple-myeloma-trial-pcsa-on-watch-1030094876,neutral,0.7950220108032227
2/23/2021 5:21:45 PM,Veru Files US Application For TADFIN Combo For Prostate Enlargement,Benzinga,/news/stocks/veru-files-us-application-for-tadfin-combo-for-prostate-enlargement-1030114252,neutral,0.7021368741989136
2/25/2021 12:59:14 PM,Merck To Acquire Pandion Therapeutics - Quick Facts ,RTTNews,/news/stocks/merck-to-acquire-pandion-therapeutics-quick-facts-1030123091,neutral,0.9217614531517029
2/25/2021 2:00:00 PM,New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines,PR Newswire,/news/stocks/new-data-presented-at-actrims-forum-2021-indicate-mavenclad-treated-rms-patients-mount-protective-antibody-response-to-common-vaccines-1030123646,positive,0.8927407264709473
2/25/2021 2:08:03 PM,"The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-goes-shopping-decision-day-for-sarepta-pfizer-moderna-unveil-vaccine-strategies-for-coronavirus-variants-1030123681,neutral,0.9286142587661743
2/25/2021 3:16:10 PM,PAND Stock: Why Pandion Therapeutics Shares Have Skyrocketed Today,InvestorPlace,/news/stocks/pand-stock-why-pandion-therapeutics-shares-have-skyrocketed-today-1030125310,negative,0.8960229158401489
2/25/2021 4:16:14 PM,Why Merck Is Buying Autoimmune Disease Drug Company Pandion For $1.85B,Benzinga,/news/stocks/why-merck-is-buying-autoimmune-disease-drug-company-pandion-for-1-85b-1030124864,neutral,0.9411280155181885
2/26/2021 3:32:49 AM,Why Pandion Therapeutics Stock Shot Up 133% Today,Benzinga,/news/stocks/why-pandion-therapeutics-stock-shot-up-133-today-1030126716,positive,0.9509401321411133
2/26/2021 2:16:52 PM,"The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-test-awaits-j-j-s-covid-19-vaccine-lilly-to-supply-additional-antibody-therapy-doses-to-us-regulatory-setback-for-tricida-1030129439,negative,0.9285117387771606
2/26/2021 3:41:20 PM,Merck requested to give more data on COVID-19 therapy for marketing approval,Seeking Alpha,https://seekingalpha.com/news/3667219-merck-requested-to-give-more-data-on-covid-19-therapy-for-marketing-approval?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8937855958938599
2/27/2021 5:58:02 PM,"The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-28-march-6-kempharm-gilead-fda-decisions-and-more-earnings-1030131919,neutral,0.9394730925559998
2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296,neutral,0.9465387463569641
3/1/2021 12:54:46 PM,Merck: FDA To Review NDA For Gefapixant - Quick Facts ,RTTNews,/news/stocks/merck-fda-to-review-nda-for-gefapixant-quick-facts-1030134622,neutral,0.8012312054634094
3/1/2021 1:00:05 PM,Merck’s marketing application for cough therapy goes under FDA review,Seeking Alpha,https://seekingalpha.com/news/3667515-mercks-marketing-application-for-cough-therapy-goes-under-fda-review?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8615623712539673
3/1/2021 9:10:02 PM,Merck gives update on U.S. KEYTRUDA indication in metastatic small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3667883-merck-gives-update-on-us-keytruda-indication-in-metastatic-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9006606340408325
3/2/2021 1:21:01 PM,Merck to help Johnson & Johnson in COVID-19 vaccine production,Seeking Alpha,https://seekingalpha.com/news/3668226-merck-to-help-johnson-johnson-in-covid-19-vaccine-production?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6223598718643188
3/2/2021 2:01:23 PM,"The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data",Benzinga,/news/stocks/the-daily-biotech-pulse-roxadustat-delay-for-fibrogen-astrazeneca-decision-day-for-kempharm-nanoviricides-jumps-on-covid-19-drug-data-1030140074,neutral,0.851780116558075
3/2/2021 3:00:28 PM,What Will the Stock Market Do Today? 3 Big Stories to Watch.,InvestorPlace,/news/stocks/what-will-the-stock-market-do-today-3-big-stories-warren-wealth-tax-gme-rkt-stock-1030141280,neutral,0.9298974871635437
3/2/2021 10:01:45 PM,Merck to receive $269 million for production of COVID-19 vaccines and drugs,Seeking Alpha,https://seekingalpha.com/news/3668535-merck-to-receive-269-million-for-production-of-covid-19-vaccines-and-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.826619565486908
3/2/2021 10:11:13 PM,"Texas, Mississippi roll back mask mandates, pandemic business restrictions",Seeking Alpha,https://seekingalpha.com/news/3668542-texas-mississippi-roll-back-mask-mandates-pandemic-business-restrictions?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8283343315124512
3/3/2021 1:46:17 PM,"The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study",Benzinga,/news/stocks/the-daily-biotech-pulse-kempharm-adhd-drug-gets-the-nod-medicinova-shelves-vaccine-study-1030144928,neutral,0.7064564228057861
3/3/2021 2:31:53 PM,7 Blue-Chip Stocks That May Be Perfect For Retirement,InvestorPlace,/news/stocks/7-blue-chip-stocks-that-may-be-perfect-for-retirement-1030146050,neutral,0.8465081453323364
3/3/2021 5:02:46 PM,"U.S. government to provide $100M to Merck, J&J to double COVID-19 vaccine output",Seeking Alpha,https://seekingalpha.com/news/3668862-us-government-to-provide-100m-to-merck-johnson-and-johnson-to-double-covid-19-vaccine-output?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9191229343414307
3/7/2021 2:07:57 AM,Merck announces positive mid-stage trial data for COVID-19 antiviral drug,Seeking Alpha,https://seekingalpha.com/news/3670088-merck-announces-positive-mid-stage-trial-data-for-covid-19-antiviral-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.944011390209198
3/8/2021 5:01:48 PM,Merck posts early-stage islatravir HIV-1 study results,Seeking Alpha,https://seekingalpha.com/news/3670336-merck-posts-early-stage-islatravir-hiv-1-study-results?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7616245150566101
3/8/2021 5:51:34 PM,"Biden event with J&J, Merck moved over Emergent controversy - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3670344-biden-event-with-jj-merck-moved-over-emergent-controversy-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7927644848823547
3/8/2021 6:28:13 PM,Merck wins Health Canada approval for Keytruda in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3670369-merck-wins-health-canada-approval-for-keytruda-in-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9326354265213013
3/9/2021 1:38:17 PM,Merck and Surface Oncology partner for Keytruda combination in cancer trial,Seeking Alpha,https://seekingalpha.com/news/3670681-merck-and-surface-oncology-partner-for-keytruda-combination-in-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7357344627380371
3/9/2021 5:32:44 PM,"Why AnPac Bio-Medical, Surface Oncology, CorMedix Are Rallying Today",Benzinga,/news/stocks/why-anpac-bio-medical-surface-oncology-cormedix-are-rallying-today-1030164963,neutral,0.5104371309280396
3/10/2021 2:58:14 PM,Biden to order 100 million additional J&J COVID-19 vaccine doses - NBC News,Seeking Alpha,https://seekingalpha.com/news/3671220-biden-to-order-100-million-additional-jj-covid-19-vaccine-doses-nbc-news?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7856127619743347
3/11/2021 1:41:15 PM,Dow Jones owes its record high to just six stocks: At the Open,Seeking Alpha,https://seekingalpha.com/news/3671645-dow-jones-hits-record-high-going-back-to-its-industrial-roots?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8055610060691833
3/12/2021 5:53:27 PM,Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study,Benzinga,/news/stocks/inhibrx-s-inbrx-105-shows-dose-limiting-toxicities-in-early-stage-solid-tumors-study-1030180562,neutral,0.6688535809516907
3/12/2021 6:04:49 PM,Merck and Pfizer among top picks to lead 2021 biopharma M&A activity: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3672343-merck-and-pfizer-among-top-picks-to-lead-2021-biopharma-ma-activity-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7542275190353394
3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6729742884635925
3/15/2021 2:50:37 PM,Merck and Gilead announce partnership for long-acting HIV treatments,Seeking Alpha,https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7411401271820068
3/16/2021 8:00:00 AM,Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer,PR Newswire,/news/stocks/merck-reports-topline-data-for-bintrafusp-alfa-as-second-line-monotherapy-treatment-in-biliary-tract-cancer-1030212319,positive,0.6298491358757019
3/16/2021 11:01:54 AM,FDA accepts Merck's Belzutifan application for Von Hippel-Lindau,Seeking Alpha,https://seekingalpha.com/news/3673000-fda-accepts-merck-belzutifan-application-for-treatment-of-von-hippel-lindau?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8152310252189636
3/16/2021 11:54:50 AM,Merck: FDA Grants Priority Review For NDA For Belzutifan - Quick Facts ,RTTNews,/news/stocks/merck-fda-grants-priority-review-for-nda-for-belzutifan-quick-facts-1030213949,positive,0.5583357810974121
3/17/2021 12:07:45 PM,EC OKs expanded use of Merck’s Keytruda in classical hodgkin lymphoma,Seeking Alpha,https://seekingalpha.com/news/3673536-ec-oks-expanded-use-of-mercks-keytruda-in-classical-hodgkin-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7815244197845459
3/17/2021 12:09:38 PM,Merck: European Commission Approves Expanded Indication For KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/merck-european-commission-approves-expanded-indication-for-keytruda-quick-facts-1030218782,positive,0.8672491312026978
3/17/2021 12:43:08 PM,"The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-keytruda-gets-label-expansion-in-europe-pfizer-to-sell-chinese-biologics-unit-celcuity-spikes-1030219036,positive,0.6757802963256836
3/17/2021 1:16:51 PM,"Merck Names Frank Clyburn President, Human Health - Quick Facts ",RTTNews,/news/stocks/merck-names-frank-clyburn-president-human-health-quick-facts-1030219291,neutral,0.9483622312545776
3/18/2021 8:42:08 AM,Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research,Benzinga,/news/stocks/laryngeal-cancer-therapeutics-market-to-see-635m-growth-by-2025-and-these-2-companies-will-be-key-drivers-research-1030222527,positive,0.5240167379379272
3/18/2021 1:16:32 PM,"The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq",Benzinga,/news/stocks/the-daily-biotech-pulse-translate-bio-s-cystic-fibrosis-study-disappoints-adverum-nominates-directors-gain-therapeutics-to-debut-on-nasdaq-1030223684,neutral,0.7376444935798645
3/19/2021 11:06:33 AM,Merck's Keytruda combo shines in late-stage endometrial cancer study,Seeking Alpha,https://seekingalpha.com/news/3674343-mercks-keytruda-combo-shines-in-late-stage-endometrial-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5374727845191956
3/19/2021 12:46:47 PM,"The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-sarepta-gene-therapy-data-idera-plunges-on-failed-skin-cancer-study-3-ipos-1030227585,neutral,0.8705222010612488
3/23/2021 12:13:10 PM,"Merck: FDA Approves KEYTRUDA With Chemotherapy For First-Line Treatment Of Esophageal, GEJ Carcinoma ",RTTNews,/news/stocks/merck-fda-approves-keytruda-with-chemotherapy-for-first-line-treatment-of-esophageal-gej-carcinoma-1030235712,positive,0.896613359451294
3/23/2021 1:18:20 PM,"The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approvals-for-merck-pacira-and-zealand-roche-regeneron-ace-late-stage-covid-19-study-allovir-appoints-gilead-virology-chief-as-ceo-1030236141,neutral,0.853547990322113
3/23/2021 4:46:16 PM,Drug pricing legislation introduced by Sanders weighs on pharmas,Seeking Alpha,https://seekingalpha.com/news/3675361-drug-pricing-legislation-introduced-by-sanders-weighs-on-pharmas?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8964442610740662
3/24/2021 10:56:48 AM,Merck names new CFO,Seeking Alpha,https://seekingalpha.com/news/3675566-merck-names-new-cfo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9176548719406128
3/24/2021 11:54:57 AM,Merck Names Caroline Litchfield CFO - Quick Facts ,RTTNews,/news/stocks/merck-names-caroline-litchfield-cfo-quick-facts-1030240149,neutral,0.940282940864563
3/26/2021 2:59:55 PM,"Kindred Biosciences may be deal target after results on Tirnovetmab, CEO says",Seeking Alpha,https://seekingalpha.com/news/3676808-kindred-biosciences-may-be-deal-target-after-results-on-tirnovetmab-ceo-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6984207034111023
3/26/2021 7:15:40 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3676932-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
3/27/2021 6:09:12 AM,Biotech Stocks Facing FDA Decision In April 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2021-1030251629,neutral,0.7787618637084961
3/27/2021 3:40:07 PM,"The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-28-april-3-acadia-s-dementia-drug-update-clinical-readouts-few-earnings-in-holiday-shortened-week-1030251902,negative,0.8516549468040466
3/30/2021 12:06:55 PM,Merck's Organon acquires Alydia Health for $240M,Seeking Alpha,https://seekingalpha.com/news/3677527-mercks-mrk-organon-acquires-alydia-health-for-240m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9102649688720703
3/30/2021 1:40:33 PM,Merck: CHMP Adopts Positive Opinion For Updated Label Of KEYTRUDA To Include Data From KEYNOTE-361 ,RTTNews,/news/stocks/merck-chmp-adopts-positive-opinion-for-updated-label-of-keytruda-to-include-data-from-keynote-361-1030258351,positive,0.8960134387016296
3/30/2021 1:48:55 PM,Organon To Acquire Alydia Health For Up To $240 Mln ,RTTNews,/news/stocks/organon-to-acquire-alydia-health-for-up-to-240-mln-1030258370,neutral,0.8554367423057556
3/30/2021 2:06:26 PM,"The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-wave-life-sciences-pulls-plug-on-2-assets-amarin-s-vascepa-snags-european-approval-biocept-jumps-on-earnings-1030258478,positive,0.7632596492767334
4/1/2021 3:06:13 PM,Merck Completes Acquisition Of Pandion - Quick Facts ,RTTNews,/news/stocks/merck-completes-acquisition-of-pandion-quick-facts-1030269208,neutral,0.8341082334518433
4/1/2021 3:34:35 PM,7 Tech Stocks Becoming Healthcare Stocks,InvestorPlace,/news/stocks/7-tech-stocks-becoming-healthcare-stocks-1030269996,neutral,0.8932220935821533
4/1/2021 6:29:05 PM,7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-to-prepare-your-portfolio-for-the-next-pandemic-1030270707,neutral,0.9073498249053955
4/2/2021 4:05:41 PM,The 7 Best Blue-Chip Stocks in the Dow Jones,InvestorPlace,/news/stocks/blue-chip-stocks-seven-best-dow-jones-1030272175,neutral,0.6102495193481445
4/5/2021 8:46:07 PM,"'Halftime Report' Traders Weigh In On Merck, Lennar And More",Benzinga,/news/stocks/halftime-report-traders-weigh-in-on-merck-lennar-and-more-1030274629,neutral,0.6458202004432678
4/6/2021 2:03:27 PM,8 Retirement Stocks to Buy for Any Market Conditions,InvestorPlace,/news/stocks/8-retirement-stocks-to-buy-for-any-market-conditions-1030277583,neutral,0.9273015260696411
4/6/2021 2:55:42 PM,Is Silicon Valley Replacing Big Pharma In Neuroscience?,Benzinga,/news/stocks/is-silicon-valley-replacing-big-pharma-in-neuroscience-1030277135,neutral,0.8876467347145081
4/7/2021 2:08:54 PM,IMV to advance its lead asset with Keytruda in mid-stage blood cancer study,Seeking Alpha,https://seekingalpha.com/news/3679859-imv-to-advance-its-lead-asset-with-keytruda-in-mid-stage-blood-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9313568472862244
4/7/2021 2:47:36 PM,Alkermes and Merck team up for late-stage ovarian cancer study,Seeking Alpha,https://seekingalpha.com/news/3679887-alkermes-and-merck-team-up-for-late-stage-ovarian-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.814628005027771
4/8/2021 12:29:05 PM,IMMP Stock: The Big Patent News Boosting Immutep Today,InvestorPlace,/news/stocks/immp-stock-the-big-patent-news-boosting-immutep-today-1030286138,positive,0.9349989891052246
4/8/2021 1:01:40 PM,Merck Says Phase 3 KEYNOTE-564 Trial Evaluating KEYTRUDA Met Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/merck-says-phase-3-keynote-564-trial-evaluating-keytruda-met-primary-endpoint-quick-facts-1030284898,neutral,0.7694661021232605
4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466,neutral,0.8932459950447083
4/8/2021 6:00:54 PM,Merck’s Keytruda succeeds in late-stage trial as monotherapy in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3680476-mercks-keytruda-succeeds-in-late-stage-trial-as-monotherapy-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7473589777946472
4/9/2021 5:25:37 PM,Sanofi confirms partial response for cancer therapy in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3680754-sanofi-confirms-partial-response-for-cancer-therapy-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8046166300773621
4/10/2021 6:14:58 PM,6 Pet Stocks And An ETF For National Pet Day,Benzinga,/news/etf/6-pet-stocks-and-an-etf-for-national-pet-day-1030290895,neutral,0.9229822158813477
4/14/2021 1:51:00 PM,"The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-cfo-departs-zai-lab-inks-cancer-drug-collaboration-fda-nod-for-gilead-1030303096,neutral,0.9114657044410706
4/14/2021 3:42:24 PM,PLTR Stock News: 11 Things for Palantir Investors to Know Today,InvestorPlace,/news/stocks/pltr-stock-news-11-things-for-palantir-investors-to-know-today-1030304753,neutral,0.941382646560669
4/15/2021 11:06:09 AM,Merck nixes development plans for MK-7110 in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682019-merck-nixes-development-plans-for-mk-7110-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8227710127830505
4/15/2021 11:38:39 AM,Merck advances molnupiravir into Phase 3 MOVe-OUT study in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682044-merck-advances-molnupiravir-into-phase-3-move-out-study-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5076331496238708
4/15/2021 1:49:24 PM,"The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-shelves-2-covid-19-studies-bristol-myers-squibb-gets-european-regulatory-nod-inspiremd-s-reverse-split-1030307762,neutral,0.8539385199546814
4/15/2021 2:17:01 PM,Merck To Discontinue Development Of COVID-19 Drug 'MK-7110' ,RTTNews,/news/stocks/merck-to-discontinue-development-of-covid-19-drug-mk-7110-1030308090,neutral,0.6685027480125427
4/15/2021 2:19:59 PM,"Merck, Ridgeback Biotherapeutics Update Covid Drug Development Program ",RTTNews,/news/stocks/merck-ridgeback-biotherapeutics-update-covid-drug-development-program-1030308088,neutral,0.926836371421814
4/15/2021 4:20:09 PM,Nabriva commences exclusive distribution of SIVEXTRO in the U.S.,Seeking Alpha,https://seekingalpha.com/news/3682246-nabriva-commences-exclusive-distribution-of-sivextro-in-the-us?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7969416975975037
4/15/2021 5:39:05 PM,Merck hurt by another setback in its battle against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682287-merck-hurt-by-another-setback-in-its-battle-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9712752103805542
4/15/2021 6:15:32 PM,BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing,Benzinga,/news/stocks/bofa-says-glaxosmithkline-s-decision-to-halt-feladilimab-studies-is-disappointing-1030309683,negative,0.8586673140525818
4/18/2021 1:18:56 AM,AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy,Seeking Alpha,https://seekingalpha.com/news/3682763-eli-lillys-kras-battle-affimeds-new-cell-therapy-graced-aacr-2021?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6620304584503174
4/19/2021 2:55:05 PM,Covid-19 Antiviral Oral Drug Found Effective In Hamster Study ,RTTNews,/news/stocks/covid-19-antiviral-oral-drug-found-effective-in-hamster-study-1030317769,positive,0.9112554788589478
4/19/2021 4:58:40 PM,Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19,Seeking Alpha,https://seekingalpha.com/news/3683056-large-nih-funded-study-to-explore-repurposed-drugs-for-mild-to-moderate-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4961980879306793
4/20/2021 1:49:10 PM,"Push for Merck to work with GSK on vaccine, Ovid price target halved, and more in today's analyst action action",Seeking Alpha,https://seekingalpha.com/news/3683370-push-for-merck-to-work-with-gsk-on-vaccine-ovid-price-target-halved-and-more-in-todays-analyst-action-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8991924524307251
4/22/2021 11:52:27 AM,Alibaba Stock Is Spring-Loaded After an Unimpressive Start to 2021,InvestorPlace,/news/stocks/baba-stock-spring-loaded-unimpressive-start-1030332965,positive,0.796701192855835
4/22/2021 7:47:21 PM,House Democrats reintroduce bill to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3684755-house-democrats-reintroduce-bill-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6614382266998291
4/23/2021 11:03:32 AM,"Accelerated approvals for cancer therapies from Merck, Bristol-Myers and Roche to come under FDA review next week",Seeking Alpha,https://seekingalpha.com/news/3685007-merck-bristol-myers-and-roche-cancer-therapies-to-come-under-fda-review-next-week?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7591323852539062
4/23/2021 1:28:48 PM,"The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-quidel-slides-on-negative-pre-announcement-roche-gets-positive-ema-committee-recommendation-3-ipos-1030338292,negative,0.6960046291351318
4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692,neutral,0.9154146313667297
4/26/2021 10:19:17 AM,European advisory group backs AstraZeneca/Merck's selumetinib for neurofibromatosis in children,Seeking Alpha,https://seekingalpha.com/news/3685341-european-advisory-group-backs-astrazenecamercks-selumetinib-for-neurofibromatosis-in-children?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.537160336971283
4/26/2021 1:40:14 PM,Merck Aims To Achieve Carbon Neutrality Across Operations By 2025 ,RTTNews,/news/stocks/merck-aims-to-achieve-carbon-neutrality-across-operations-by-2025-1030344923,positive,0.6472929120063782
4/26/2021 3:06:57 PM,7 Healthcare Stocks for a Reopening World,InvestorPlace,/news/stocks/7-healthcare-stocks-for-a-reopening-world-1030346737,neutral,0.827012300491333
4/26/2021 5:30:41 PM,3 Top Blue-Chip Healthcare Stocks With Healthy Dividends,InvestorPlace,/news/stocks/3-top-blue-chip-healthcare-stocks-with-healthy-dividends-1030347105,positive,0.7900867462158203
4/27/2021 11:35:09 AM,Merck to expand molnupiravir access in India for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3685988-merck-to-expand-molnupiravir-access-in-india-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9247572422027588
4/27/2021 2:04:51 PM,Merck To License COVID-19 Treatment Molnupiravir To Five Indian Generics Makers ,RTTNews,/news/stocks/merck-to-license-covid-19-treatment-molnupiravir-to-five-indian-generics-makers-1030351043,neutral,0.5673574805259705
4/27/2021 3:02:23 PM,What Wall Street expects from Merck's earnings,Markets Insider Automation,/news/stocks/merck_co-stock-price-quarter-earnings-preview-q1-1030351677,neutral,0.9308241009712219
4/29/2021 11:29:38 AM,Merck slips 2% as Q1 trails estimates; Pharma sales hit by COVID-19,Seeking Alpha,https://seekingalpha.com/news/3687736-merck-slips-2-as-q1-trails-estimates-pharma-sales-hit-by-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9479898810386658
4/29/2021 1:02:11 PM,Merck Q1 Adj. Profit Declines ,RTTNews,/news/stocks/merck-q1-adj-profit-declines-1030363972,negative,0.9263584017753601
4/29/2021 2:15:50 PM,"The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx",Benzinga,/news/stocks/the-daily-biotech-pulse-clinical-setback-for-adverum-galera-posts-data-readout-moderna-to-invest-in-vaccine-manufacturing-decision-day-for-ardelyx-1030364740,neutral,0.7717582583427429
4/29/2021 6:10:51 PM,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,InvestorPlace,/news/stocks/7-health-focused-etfs-to-buy-now-for-the-post-covid-future-1030366420,neutral,0.847977340221405
4/30/2021 11:58:15 AM,"FDA panel votes to keep indications for Merck, Roche bladder cancer drugs",Seeking Alpha,https://seekingalpha.com/news/3688588-fda-panel-votes-to-keep-indications-for-merck-roche-bladder-cancer-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8228116035461426
5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608,neutral,0.8418352007865906
5/3/2021 10:52:25 AM,Pfizer in discussions with India for 'expedited approval' of COVID-19 vaccine,Seeking Alpha,https://seekingalpha.com/news/3689059-pfizer-in-discussions-with-india-for-expedited-approval-of-covid-19-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8074544668197632
5/3/2021 12:27:19 PM,Merck spinoff Organon to begin trading in June,Seeking Alpha,https://seekingalpha.com/news/3689150-merck-spinoff-organon-to-begin-trading-on-june-03?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9540501236915588
5/3/2021 2:05:53 PM,Merck: Spinoff Organon Expected To Drive Sustainable Growth ,RTTNews,/news/stocks/merck-spinoff-organon-expected-to-drive-sustainable-growth-1030378118,positive,0.7410725951194763
5/3/2021 8:07:48 PM,"Despite spinoff from Merck, Organon unit expected to continue revenue decline this year",Seeking Alpha,https://seekingalpha.com/news/3689661-despite-spinoff-from-merck-organon-unit-expected-to-continue-revenue-decline-this-year?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.973000705242157
5/4/2021 12:59:50 PM,COCP Stock: Cocrystal Pharma Gains 40% on Big Covid-19 News,InvestorPlace,/news/stocks/cocp-stock-cocrystal-pharma-gains-40-on-big-covid-19-news-1030385436,positive,0.9493622183799744
5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6773343086242676
5/4/2021 5:05:54 PM,Merck seeks to protect Nexplanon implant in patent case,Seeking Alpha,https://seekingalpha.com/news/3690270-merck-seeks-to-protect-nexplanon-implant-in-patent-case?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8842036724090576
5/6/2021 1:07:08 PM,"FDA grants accelerated review to Merck, Eisai's Keytruda + Lenvima applications in kidney and endometrial cancer",Seeking Alpha,https://seekingalpha.com/news/3692263-fda-grants-accelerated-review-to-merck-eisais-keytruda-lenvima-applications-in-kidney-and-endometrial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8240647912025452
5/6/2021 1:49:39 PM,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-keytruda-snags-another-fda-approval-moderna-slips-on-revenue-miss-chemocentryx-adcom-1030395950,negative,0.9611167907714844
5/6/2021 3:50:15 PM,"Fusion, Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA ",RTTNews,/news/stocks/fusion-merck-to-evaluate-fusion-s-targeted-alpha-therapy-in-combination-with-merck-s-keytruda-1030397022,neutral,0.68912273645401
5/6/2021 4:46:52 PM,Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study,Benzinga,/news/stocks/fusion-pharma-shares-move-higher-after-trial-collab-with-merck-for-igf-1r-expressing-cancer-study-1030397473,positive,0.9415823221206665
5/7/2021 1:40:08 PM,"The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-split-verdict-for-chemocentryx-nkarta-crispr-in-cell-therapy-collaboration-orphazyme-s-clinical-trial-setback-2-ipos-1030401885,neutral,0.7262563705444336
5/10/2021 1:53:56 PM,Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/3693868-dosing-underway-in-alx-oncologys-alx148-combo-study-in-head-and-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7123111486434937
5/12/2021 7:41:15 PM,Viatris earns mixed views from analysts despite more clarity in Q1 results,Seeking Alpha,https://seekingalpha.com/news/3695446-viatris-earns-mixed-views-from-analysts-despite-more-clarity-in-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9464383721351624
5/13/2021 1:41:16 PM,Merck Says Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint In Patients With Breast Cancer ,RTTNews,/news/stocks/merck-says-phase-3-keynote-522-trial-met-dual-primary-endpoint-in-patients-with-breast-cancer-1030425511,positive,0.8994715809822083
5/13/2021 2:10:52 PM,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-positive-keytruda-data-in-breast-cancer-curis-evoke-slump-on-earnings-qiagen-s-rapid-covid-19-antibody-test-ok-ed-for-emergency-use-1030425724,positive,0.5881754159927368
5/17/2021 4:28:17 PM,CLOV and 6 Other Reddit Stocks Drinking the Short-Squeeze Juice,InvestorPlace,/news/stocks/clov-and-6-other-reddit-stocks-drinking-the-short-squeeze-juice-1030437964,neutral,0.6234927177429199
5/18/2021 6:39:22 PM,"Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q1-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030442901,neutral,0.8799788951873779
5/20/2021 11:45:14 AM,Merck's V114-027 met primary immunogenicity endpoints in late-stage pneumococcal disease studies,Seeking Alpha,https://seekingalpha.com/news/3698586-mercks-v114-027-met-primary-immunogenicity-endpoints-in-late-stage-pneumococcal-disease-studies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8747887015342712
5/20/2021 1:15:50 PM,Merck Reports Positive Results From Two Trials Of V114 Phase 3 Pediatric Clinical Program ,RTTNews,/news/stocks/merck-reports-positive-results-from-two-trials-of-v114-phase-3-pediatric-clinical-program-1030450293,positive,0.9492295384407043
5/20/2021 2:12:01 PM,"Merck downgraded to hold at Argus, Allogene upped at Truist, and more in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3698655-merck-downgraded-to-hold-at-argus-allogene-upped-at-truist-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6200331449508667
5/20/2021 4:02:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-20-2021-1030451423,negative,0.5674557685852051
5/20/2021 5:20:15 PM,Immutep Stock Gains on Encouraging Data from Early-Stage Solid Cancer Studies,Benzinga,/news/stocks/immutep-stock-gains-on-encouraging-data-from-early-stage-solid-cancer-studies-1030451909,positive,0.9387258291244507
5/21/2021 10:37:18 PM,Disney And Chevron Lead The Dow Jones Higher Friday,Benzinga,/news/stocks/disney-and-chevron-lead-the-dow-jones-higher-friday-1030456371,positive,0.7414541840553284
5/24/2021 11:01:29 AM,Merck's Keytruda + chemotherapy wins positive CHMP opinion for esophageal and gastric cancer,Seeking Alpha,https://seekingalpha.com/news/3699350-mercks-keytruda-chemotherapy-wins-positive-chmp-opinion-for-esophageal-and-gastric-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9502593278884888
5/24/2021 12:39:13 PM,NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?,Benzinga,/news/stocks/ngm-biopharma-to-release-mid-stage-nash-data-monday-what-to-expect-1030458150,neutral,0.9221133589744568
5/24/2021 1:09:00 PM,Merck Gets Positive EU CHMP Opinion For KEYTRUDA Plus Chemotherapy For Gastrointestinal Cancers ,RTTNews,/news/stocks/merck-gets-positive-eu-chmp-opinion-for-keytruda-plus-chemotherapy-for-gastrointestinal-cancers-1030458228,positive,0.9259725213050842
5/25/2021 11:04:22 AM,Merck joins Xilio to study KEYTRUDA/ XTX101 combo in patients with solid tumors,Seeking Alpha,https://seekingalpha.com/news/3699740-merck-joins-xilio-to-study-keytruda-xtx101-combo-in-patients-with-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8206862211227417
5/25/2021 6:12:32 PM,Merck declares $0.65 dividend,Seeking Alpha,https://seekingalpha.com/news/3699990-merck-declares-0_65-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9264159202575684
5/27/2021 9:25:46 PM,"Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon",Seeking Alpha,https://seekingalpha.com/news/3701054-lannett-down-55-svc-gains-57-as-sp-500-makes-room-for-organon?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9405890703201294
5/28/2021 5:24:26 AM,Organon Set To Join S&P 500 ,RTTNews,/news/stocks/organon-set-to-join-s-p-500-1030473773,neutral,0.9453594088554382
5/28/2021 7:00:20 PM,Amgen's Lumakras can target 13% of the NSCLC market,Seeking Alpha,https://seekingalpha.com/news/3701338-amgen-mirati-lumakras-can-target-13-of-the-nsclc-market?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.850368320941925
5/31/2021 5:06:35 PM,"The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes",Benzinga,/news/stocks/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-liminal-and-alkermes-1030479173,neutral,0.9343029260635376
6/1/2021 1:06:49 PM,"Sanofi, Merck Announce Availability Of Six-in-one Pediatric Combination Vaccine Vaxelis In The U.S. ",RTTNews,/news/stocks/sanofi-merck-announce-availability-of-six-in-one-pediatric-combination-vaccine-vaxelis-in-the-u-s-1030481005,positive,0.8368119597434998
6/1/2021 7:18:38 PM,7 Best Stocks To Buy To Hedge Against A Potential Downturn,InvestorPlace,/news/stocks/7-best-stocks-to-buy-to-hedge-against-a-potential-downturn-1030484539,neutral,0.8428159952163696
6/2/2021 5:44:20 PM,Merck Spinoff Organon Will Do Well Over Time,InvestorPlace,/news/stocks/ogn-stock-merck-spinoff-will-do-well-over-time-for-investors-who-hold-on-1030488694,positive,0.9057209491729736
6/3/2021 1:54:27 PM,Merck Spins Off Organon ,RTTNews,/news/stocks/merck-spins-off-organon-1030490896,negative,0.5068138241767883
6/3/2021 2:02:55 PM,Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics,Benzinga,/news/stocks/diversifying-to-conquer-fortress-biotech-fbio-partnering-expansion-driving-progress-in-cancer-immunotherapy-and-rare-disease-therapeutics-1030490924,positive,0.7314746379852295
6/3/2021 2:23:31 PM,"The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-completes-organon-spin-off-auris-repositions-as-rna-therapeutic-company-with-trasir-purchase-replimune-s-readout-1030491248,neutral,0.8467225432395935
6/3/2021 2:23:36 PM,The Mind Medicine Stock Story Has an Awful Lot of Holes in It,InvestorPlace,/news/stocks/mnmd-stock-story-has-an-awful-lot-of-holes-in-it-1030492377,neutral,0.5381304621696472
6/3/2021 9:33:12 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-chamath-spacs-xers-stock-ogn-stock-1030493287,neutral,0.9254742860794067
6/3/2021 9:40:37 PM,AstraZeneca shows clinical benefit of Lynparza in late-stage trial for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3703153-astrazeneca-shows-clinical-benefit-of-lynparza-in-late-stage-trial-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9326605200767517
6/4/2021 4:11:58 AM,"AstraZeneca : Late-stage Trial Shows Lynparza Reduces Recurrence, Death In Breast Cancer Patients ",RTTNews,/news/stocks/astrazeneca-late-stage-trial-shows-lynparza-reduces-recurrence-death-in-breast-cancer-patients-1030493503,positive,0.698891818523407
6/4/2021 12:11:53 PM,Immutep posts positive interim data from mid-stage IMP321 cancer study,Seeking Alpha,https://seekingalpha.com/news/3703263-immutep-posts-positive-interim-data-from-mid-stage-imp321-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9419963955879211
6/4/2021 12:23:14 PM,Merck spinoff closes higher despite neutral views; Mirati gains on Citi upgrade; more in today’s analyst action,Seeking Alpha,https://seekingalpha.com/news/3703272-merck-spinoff-closes-higher-despite-neutral-views-mirati-gains-on-citi-upgrade-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9228965044021606
6/4/2021 3:39:13 PM,"The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-astrazeneca-novartis-among-early-presenters-at-asco-sanofi-strikes-breast-cancer-study-pact-1030495387,neutral,0.9197812080383301
6/4/2021 4:31:40 PM,Immutep Highlights Encouraging Data from Lead Oncology Candidate at ASCO 2021,Benzinga,/news/stocks/immutep-highlights-encouraging-data-from-lead-oncology-candidate-at-asco-2021-1030495616,positive,0.9427626729011536
6/4/2021 7:30:04 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3703423-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
6/7/2021 11:38:35 AM,"Merck, Eisai report new Keytruda/Lenvima data in kidney cancer at ASCO21",Seeking Alpha,https://seekingalpha.com/news/3703597-merck-eisai-report-new-keytrudalenvima-data-in-kidney-cancer-at-asco21?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.917353093624115
6/7/2021 1:55:03 PM,Merck Releases New Data From Late-stage Study Of Clear/Keynote-51 ,RTTNews,/news/stocks/merck-releases-new-data-from-late-stage-study-of-clear-keynote-51-1030499171,neutral,0.9211627244949341
6/7/2021 2:52:10 PM,"The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck",Benzinga,/news/stocks/the-week-ahead-in-biotech-biogen-alexion-and-vertex-fda-decisions-multiple-conference-presentations-on-the-deck-1030499585,neutral,0.9329092502593994
6/7/2021 4:29:26 PM,"Janux Therapeutics expects $15-$17/share IPO, valuing biotech at some $670M",Seeking Alpha,https://seekingalpha.com/news/3703782-janux-therapeutics-stock-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7882446050643921
6/7/2021 8:51:59 PM,MSD Animal Health to acquire a dairy automation and technology company,Seeking Alpha,https://seekingalpha.com/news/3703911-msd-animal-health-to-acquire-a-dairy-automation-and-technology-company?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8793400526046753
6/8/2021 6:51:45 PM,"5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing",Benzinga,/news/stocks/5-biogen-analysts-on-fda-approval-of-alzheimer-s-drug-aduhelm-broad-label-pricing-1030504841,neutral,0.8534533381462097
6/9/2021 11:21:56 AM,Merck inks supply deal with U.S. government for molnupiravir in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3704460-merck-inks-supply-deal-with-us-government-for-molnupiravir-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8959593176841736
6/9/2021 1:07:06 PM,Merck Inks Deal With U.S. Government To Supply 1.7 Mln Courses Of Molnupiravir - Quick Facts ,RTTNews,/news/stocks/merck-inks-deal-with-u-s-government-to-supply-1-7-mln-courses-of-molnupiravir-quick-facts-1030506892,positive,0.9020750522613525
6/9/2021 3:14:20 PM,"The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US",Benzinga,/news/stocks/the-daily-biotech-pulse-lyra-gains-on-positive-regulatory-outcome-fda-nod-for-pfizer-s-prevnar-vaccine-merck-inks-covid-19-treatment-supply-deal-with-us-1030507884,positive,0.933498740196228
6/9/2021 4:47:29 PM,Pfizer’s new pneumococcal jab highlights “underappreciated” pipeline: Cantor,Seeking Alpha,https://seekingalpha.com/news/3704696-pfizers-new-pneumococcal-jab-underscores-underappreciated-pipeline-cantor?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8115097284317017
6/9/2021 9:32:46 PM,Merck nabs ~$1.21B U.S. Army contract for treatment courses of the oral antiviral,Seeking Alpha,https://seekingalpha.com/news/3704839-merck-nabs-121b-us-army-contract-for-treatment-courses-of-the-oral-antiviral?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8214607238769531
6/11/2021 12:24:22 PM,Janux Therapeutics stock set to begin trading after upsized IPO prices at top of range,Seeking Alpha,https://seekingalpha.com/news/3705593-janux-therapeutics-stock-set-to-begin-trading-after-upsized-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7233389019966125
6/14/2021 4:07:45 PM,7 Dividend Stocks Offering Juicy Yields and Short-Squeeze Potential,InvestorPlace,/news/stocks/7-dividend-stocks-offering-juicy-yields-and-squeeze-potential-1030520591,negative,0.43800637125968933
6/15/2021 1:20:25 PM,Fusion Pharma's Stock Moves Higher As Radiopharmaceutical Candidate Shows Early Promising Action In Solid Tumor Study,Benzinga,/news/stocks/fusion-pharma-s-stock-moves-higher-as-radiopharmaceutical-candidate-shows-early-promising-action-in-solid-tumor-study-1030523003,positive,0.9525781273841858
6/15/2021 2:25:26 PM,Hold Merck for Its Solid Dividend and Covid-19 Treatment Prospects,InvestorPlace,/news/stocks/hold-mrk-stock-for-solid-dividend-and-covid-19-treatment-prospects-1030525034,positive,0.8403745889663696
6/17/2021 1:03:41 PM,Motivation Really Matters When It Comes to Organon,InvestorPlace,/news/stocks/motivation-matters-for-ogn-stock-1030532336,neutral,0.9318773746490479
6/17/2021 4:27:04 PM,U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs,Seeking Alpha,https://seekingalpha.com/news/3707379-us-to-invest-more-than-3b-to-boost-development-of-covid-19-antiviral-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9287871718406677
6/17/2021 4:38:00 PM,"MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19",PR Newswire,/news/stocks/msd-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19-1030532789,positive,0.9411163926124573
6/17/2021 4:40:00 PM,"MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19",PR Newswire,/news/stocks/msd-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19-1030532788,positive,0.9411163926124573
6/21/2021 1:53:40 PM,Organon reaffirms full year 2021 revenue guidance,Seeking Alpha,https://seekingalpha.com/news/3708178-organon-reaffirms-full-year-2021-revenue-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8197190761566162
6/22/2021 8:25:04 AM,AstraZeneca : EU Oks Koselugo For Children With Neurofibromatosis Type 1 & Plexiform Neurofibromas ,RTTNews,/news/stocks/astrazeneca-eu-oks-koselugo-for-children-with-neurofibromatosis-type-1-plexiform-neurofibromas-1030541497,neutral,0.8655707836151123
6/22/2021 10:03:34 AM,AstraZeneca/Merck's Koselugo secures conditional approval in Europe for children with NF1,Seeking Alpha,https://seekingalpha.com/news/3708538-astrazenecamercks-koselugo-secures-conditional-approval-in-europe-for-children-with-nf1?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9443787932395935
6/22/2021 1:31:27 PM,Merck Says Phase III Keynote-826 Study Of Keytruda In Cervical Cancer Met Primar Endpoints ,RTTNews,/news/stocks/merck-says-phase-iii-keynote-826-study-of-keytruda-in-cervical-cancer-met-primar-endpoints-1030542431,positive,0.8884859085083008
6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8699349761009216
6/23/2021 12:59:28 PM,Don’t Miss the Opportunity Presented by Organon Stock,InvestorPlace,/news/stocks/dont-miss-the-opportunity-even-as-wall-street-ho-hums-ogn-stock-1030547140,neutral,0.9213680028915405
6/23/2021 3:25:01 PM,Citius Shows a Promising Future as Share Prices Keep Going up,Benzinga,/news/stocks/citius-shows-a-promising-future-as-share-prices-keep-going-up-1030547404,positive,0.9269535541534424
6/23/2021 6:44:55 PM,14 Biotech Stocks To Watch Over The Next 6 Months,Benzinga,/news/stocks/14-biotech-stocks-to-watch-over-the-next-6-months-1030548271,neutral,0.9149301052093506
6/24/2021 7:42:17 AM,Biotech Stocks Facing FDA Decision In July 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2021-1030549382,neutral,0.818015456199646
6/24/2021 8:28:41 AM,AZN : China Oks Lynparza To Treat BRCA-mutated Metastatic Castration-resistant Prostate Cancer ,RTTNews,/news/stocks/azn-china-oks-lynparza-to-treat-brca-mutated-metastatic-castration-resistant-prostate-cancer-1030549449,positive,0.7591213583946228
6/24/2021 11:09:05 AM,AstraZeneca/Merck's Lynparza OK'd in China BRCA-mutated prostate cancer,Seeking Alpha,https://seekingalpha.com/news/3709455-astrazenecamercks-lynparza-okd-in-china-brca-mutated-prostate-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7733242511749268
6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889,neutral,0.93064284324646
6/24/2021 4:06:34 PM,Jefferies starts Vaxcyte at buy seeing 133% upside,Seeking Alpha,https://seekingalpha.com/news/3709702-jefferies-starts-vaxcyte-at-buy-seeing-133-upside?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9004946947097778
6/25/2021 7:58:31 PM,"Organon, Microspherix make headway on Nexplanon patents dispute",Seeking Alpha,https://seekingalpha.com/news/3710261-organon-microspherix-make-headway-on-nexplanon-patents-dispute?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7959395051002502
6/29/2021 11:12:16 AM,Merck's Keytruda + chemo combo OK'd in Europe for esophageal/gastric cancer,Seeking Alpha,https://seekingalpha.com/news/3710846-mercks-keytruda-chemo-combo-okd-in-europe-for-esophagealgastric-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5713858604431152
6/29/2021 1:19:45 PM,EC Oks Merck's Keytruda Plus Chemotherapy For Treatment Of Certain Patients With Esophageal Cancer ,RTTNews,/news/stocks/ec-oks-merck-s-keytruda-plus-chemotherapy-for-treatment-of-certain-patients-with-esophageal-cancer-1030562215,neutral,0.7843456268310547
6/29/2021 3:05:00 PM,Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy,PR Newswire,/news/stocks/merck-animal-health-survey-reveals-pet-owners-need-advice-navigating-their-pets-transition-to-normalcy-1030563027,neutral,0.8297394514083862
6/29/2021 4:38:57 PM,Merck joined by Indian drugmakers to conduct domestic trial for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3711055-merck-joined-by-indian-drugmakers-to-conduct-domestic-trial-for-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7296178936958313
6/30/2021 12:07:34 PM,Alpine Immune shares rise on clinical trial collaboration agreement with Merck,Seeking Alpha,https://seekingalpha.com/news/3711291-alpine-immune-shares-rise-on-clinical-trial-collaboration-agreement-with-merck?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9431247711181641
7/1/2021 11:41:43 AM,NGM Bio amends collaboration with Merck to advance medicines for retinal and CVM diseases,Seeking Alpha,https://seekingalpha.com/news/3711747-ngm-bio-amends-collaboration-with-merck-to-advance-medicines-for-retinal-and-cvm-diseases?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8090799450874329
7/1/2021 6:50:48 PM,Eisai and Lilly among top H1 gainers in big pharma; Viatris and Merck trail,Seeking Alpha,https://seekingalpha.com/news/3712052-eisai-and-lilly-among-top-h1-gainers-in-big-pharma-as-viatris-and-merck-trail?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8283566832542419
7/1/2021 7:50:05 PM,"NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic Targets",Benzinga,/news/stocks/ngm-biopharma-merck-amend-development-pact-to-focus-on-retinal-cardiovascular-metabolic-targets-1030572932,neutral,0.5467188954353333
7/1/2021 11:07:05 PM,Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-july-pdufa-dates-1030573631,neutral,0.9455710649490356
7/2/2021 1:38:37 PM,"The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures",Benzinga,/news/stocks/the-daily-biotech-pulse-iterum-s-regulatory-setback-decision-day-for-provention-bio-cidara-outset-medical-announce-cfo-departures-1030575170,negative,0.8319647908210754
7/2/2021 7:47:00 PM,Merck Financial Services GmbH -- Moody's announces completion of a periodic review of ratings of Merck KGaA,Moodys,/news/bonds/merck-financial-services-gmbh-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-merck-kgaa-1030576345,neutral,0.8040289878845215
7/4/2021 4:16:47 PM,"Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021",Benzinga,/news/stocks/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021-1030577378,positive,0.744825541973114
7/6/2021 11:06:55 AM,FDA approves expanded indication for Merck’s Keytruda in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3712804-fda-approves-expanded-indication-for-mercks-keytruda-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8224091529846191
7/6/2021 1:04:56 PM,FDA OKs Expanded Indication For Merck's KEYTRUDA In Locally Advanced CSCC - Quick Facts ,RTTNews,/news/stocks/fda-oks-expanded-indication-for-merck-s-keytruda-in-locally-advanced-cscc-quick-facts-1030581260,positive,0.8452852368354797
7/6/2021 8:13:18 PM,OncoSec surges 20% after teaming up with Merck for late-stage TAVO/Keytruda trial,Seeking Alpha,https://seekingalpha.com/news/3713086-oncosec-shares-surge-after-teaming-up-with-merck-for-late-stage-tavokeytruda-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9389398694038391
7/7/2021 10:49:38 AM,Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year,Seeking Alpha,https://seekingalpha.com/news/3713185-mid-size-pharmaceutical-firms-lead-bigger-rivals-in-acquisitions-this-year?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6112593412399292
7/7/2021 1:41:27 PM,"The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend",Benzinga,/news/stocks/the-daily-biotech-pulse-opiant-spikes-on-data-oncosec-rallies-on-merck-collaboration-xbiotech-special-dividend-1030585208,neutral,0.8819314241409302
7/7/2021 2:49:38 PM,Nextleaf Solutions Forges Unique Path in the Cannabis  Industry with its IP Strategy,Benzinga,/news/stocks/nextleaf-solutions-forges-unique-path-in-the-cannabis-industry-with-its-ip-strategy-1030585735,positive,0.7415828108787537
7/8/2021 4:02:32 PM,The Coronavirus Pill Makes Merck a Solid Buy,InvestorPlace,/news/stocks/the-coronavirus-pill-makes-mrk-stock-a-solid-buy-1030590757,positive,0.8422687649726868
7/8/2021 4:27:00 PM,Stay Away From Low-Growth Organon,InvestorPlace,/news/stocks/low-growth-weak-catalysts-ogn-stock-unattractive-1030590811,neutral,0.9079623818397522
7/8/2021 4:48:34 PM,3 Blue-Chip Stocks to Trade Right Now,InvestorPlace,/news/stocks/3-blue-chip-stocks-to-trade-right-now-1030590867,neutral,0.9188586473464966
7/8/2021 7:38:27 PM,"House Oversight report says pharmas spend more on buybacks, dividends than R&D",Seeking Alpha,https://seekingalpha.com/news/3713778-house-oversight-report-says-pharmas-spend-more-on-buybacks-dividends-than-research-development?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8492424488067627
7/9/2021 9:41:48 AM,India's Hetero seeks emergency use authorization for Merck's COVID-19 therapy- Reuters,Seeking Alpha,https://seekingalpha.com/news/3713883-indias-hetero-seeks-emergency-use-authorization-for-mercks-covid-19-therapy-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7327304482460022
7/9/2021 12:18:58 PM,Galectin Therapeutics shares soar on early-stage Belapectin cancer study data,Seeking Alpha,https://seekingalpha.com/news/3713939-galectin-therapeutics-shares-soar-on-early-stage-belapectin-cancer-study-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9116920232772827
7/9/2021 6:55:04 PM,GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring,InvestorPlace,/news/stocks/galt-stock-the-big-trial-news-that-has-galectin-therapeutics-soaring-1030593987,neutral,0.7549995183944702
7/11/2021 1:00:00 PM,"Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714139-biotech-ma-may-heat-up-with-potential-targets-horizon-therapeutics-arrowhead-pharma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8715733885765076
7/18/2021 2:09:46 AM,Merck wins FDA approval for new pneumonia vaccine (updated),Seeking Alpha,https://seekingalpha.com/news/3716142-merck-wins-fda-approval-for-new-pneumonia-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6130591034889221
7/18/2021 4:25:56 PM,"The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-earnings-kickstart-with-j-j-and-biogen-albireo-awaits-fda-decisions-more-ipos-1030617574,positive,0.5948063731193542
7/20/2021 10:08:18 AM,Merck presents new data from mid-stage oral islatravir study for HIV-1 prevention,Seeking Alpha,https://seekingalpha.com/news/3716696-merck-presents-new-data-from-mid-stage-oral-islatravir-study-for-hiv-1-prevention?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8060749769210815
7/20/2021 2:19:56 PM,"The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street",Benzinga,/news/stocks/the-daily-biotech-pulse-ardelyx-sinks-on-regulatory-setback-anpac-issues-positive-preannouncement-european-nod-for-myovant-hcw-biologics-debuts-on-wall-street-1030624862,negative,0.431514173746109
7/22/2021 12:10:05 PM,FDA OKs Merck/Eisai's Keytruda + Lenvima combo in endometrial cancer,Seeking Alpha,https://seekingalpha.com/news/3717972-fda-oks-merckeisais-keytruda-lenvima-combo-in-endometrial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5870619416236877
7/22/2021 2:18:49 PM,"The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-merck-eisai-seres-ulcerative-colitis-drug-flunks-midstage-study-pfizer-to-invest-in-arvinas-absci-ipo-1030634923,neutral,0.8168380260467529
7/22/2021 2:51:46 PM,Merck : FDA Approves Keytruda - Lenvima For Advanced Endometrial Carcinoma Treatment ,RTTNews,/news/stocks/merck-fda-approves-keytruda-lenvima-for-advanced-endometrial-carcinoma-treatment-1030635131,positive,0.8584221601486206
7/22/2021 3:28:32 PM,Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors,Benzinga,/news/stocks/adagene-to-test-its-anti-ctla-4-monoclonal-antibodies-in-combination-with-keytruda-in-solid-tumors-1030635423,positive,0.5109822750091553
7/23/2021 7:30:52 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3718717-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
7/25/2021 3:26:31 PM,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-july-25-31-big-pharma-earnings-iterum-fda-decision-alzheimer-s-conference-ipos-and-more-1030641744,neutral,0.9177685976028442
7/27/2021 7:45:55 AM,Biotech Stocks Facing FDA Decision In August 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2021-1030648567,neutral,0.7672383189201355
7/27/2021 10:48:27 AM,FDA OKs Merck's Keytruda/Chemotherapy combo in triple-negative breast cancer,Seeking Alpha,https://seekingalpha.com/news/3719482-fda-oks-mercks-keytrudachemotherapy-combo-in-triple-negative-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.47218355536460876
7/27/2021 11:53:34 AM,Merck's late-stage KEYNOTE-355 trial met endpoint of overall survival in breast cancer study,Seeking Alpha,https://seekingalpha.com/news/3719555-mercks-late-stage-keynote-355-trial-met-endpoint-of-overall-survival-in-breast-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8890787959098816
7/27/2021 1:48:33 PM,"The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-obseva-surges-on-out-licensing-deal-eyegate-appoints-new-ceo-2-positive-catalysts-for-merck-candel-therapeutics-debuts-1030649705,positive,0.7360387444496155
7/27/2021 3:02:14 PM,Merck earnings preview: what to expect,Markets Insider Automation,/news/stocks/merck_co-stock-price-quarter-earnings-preview-q2-1030650329,neutral,0.9224230051040649
7/27/2021 3:08:51 PM,Merck : Phase 3 Trial On Metastatic Triple-Negative Breast Cancer Meets Primary Endpoint ,RTTNews,/news/stocks/merck-phase-3-trial-on-metastatic-triple-negative-breast-cancer-meets-primary-endpoint-1030650796,positive,0.660159707069397
7/27/2021 3:23:51 PM,FDA Approves Merck's KEYTRUDA To Treat High-Risk Early-Stage Triple-Negative Breast Cancer ,RTTNews,/news/stocks/fda-approves-merck-s-keytruda-to-treat-high-risk-early-stage-triple-negative-breast-cancer-1030651032,positive,0.9030688405036926
7/28/2021 12:00:50 PM,Dosing underway in ALX Oncology/Merck's mid-stage ASPEN-04 study for head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/3720388-dosing-underway-in-alx-oncologymercks-mid-stage-aspen-04-study-for-head-and-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7429621815681458
7/28/2021 2:01:13 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3720521-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8825733065605164
7/29/2021 10:31:48 AM,"Merck EPS misses by $0.04, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3721253-merck-eps-misses-0_04-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.3883562982082367
7/29/2021 11:26:10 AM,Merck narrows 2021 revenue guidance; records $600M benefit due to pandemic recovery,Seeking Alpha,https://seekingalpha.com/news/3721357-merck-narrows-2021-revenue-guidance-records-600m-benefit-due-to-pandemic-recovery?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7947775721549988
7/29/2021 1:02:53 PM,Merck & Co Inc. Q2 adjusted earnings of $1.31 per share,RTTNews,/news/stocks/merck-co-inc-q2-adjusted-earnings-of-1-31-per-share-1030661593,neutral,0.725731611251831
7/29/2021 1:25:36 PM,Merck Q2 Profit Down; Cuts FY21 Outlook Below Market Estimates ,RTTNews,/news/stocks/merck-q2-profit-down-cuts-fy21-outlook-below-market-estimates-1030661828,negative,0.9701447486877441
7/29/2021 2:18:48 PM,"The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210,negative,0.9680227041244507
7/29/2021 8:36:37 PM,These two dividend ETFs have generated 20% annualized returns for five years,Seeking Alpha,https://seekingalpha.com/news/3721698-best-dividend-etfs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8089562654495239
8/1/2021 4:13:48 PM,"The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-aug-1-7-biopharma-earnings-pick-up-pace-eton-awaits-fda-decision-focus-on-pending-clinical-readouts-and-ipos-1030671679,positive,0.8824636936187744
8/2/2021 4:48:17 PM,GlaxoSmithKline submits marketing application for MMR vaccine in the U.S.,Seeking Alpha,https://seekingalpha.com/news/3723202-glaxosmithkline-submits-marketing-application-for-mmr-vaccine-in-the-us?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5170884728431702
8/2/2021 5:26:54 PM,Moderna gains access to Autolus' binder technology for mRNA immuno-oncology targets,Seeking Alpha,https://seekingalpha.com/news/3723241-moderna-gains-access-to-autolus-binder-technology-for-mrna-immuno-oncology-targets?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7570009231567383
8/3/2021 12:10:40 AM,Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-august-pdufa-dates-1030679352,neutral,0.946641743183136
8/5/2021 12:32:19 PM,Merck’s Keytruda prolonged recurrence-free survival in late-stage melanoma study,Seeking Alpha,https://seekingalpha.com/news/3726071-mercks-keytruda-prolonged-recurrence-free-survival-in-late-stage-melanoma-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7617698311805725
8/5/2021 2:07:56 PM,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-positive-keytruda-readout-moderna-slips-despite-q2-beat-bayer-to-buy-vividion-for-up-to-2b-glycomimetics-gets-new-ceo-1030695873,positive,0.8679100871086121
8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.935555636882782
8/7/2021 6:34:16 PM,UBS highlights 20 top dividend stocks in tough times for yield: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3727237-ubs-highlights-top-divident-stocks-in-tough-times-for-yield?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8619096279144287
8/10/2021 1:55:36 PM,"The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-arcturus-soars-on-covid-19-vaccine-updates-merck-s-keytruda-on-track-for-more-label-expansions-eliem-debuts-1030712978,positive,0.8045278787612915
8/10/2021 2:07:09 PM,Merck: FDA Grants Priority Review To SBLA For KEYTRUDA As Adjuvant Immunotherapy In RCC ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-as-adjuvant-immunotherapy-in-rcc-1030713035,positive,0.8420552015304565
8/10/2021 2:24:51 PM,Merck: FDA To Review KEYTRUDA As Single Agent For Patients With MSI-H/dMMR Endometrial Carcinoma ,RTTNews,/news/stocks/merck-fda-to-review-keytruda-as-single-agent-for-patients-with-msi-h-dmmr-endometrial-carcinoma-1030713172,neutral,0.6986115574836731
8/10/2021 4:55:01 PM,Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst,Benzinga,/news/stocks/moderna-s-stock-valuation-goes-from-unreasonable-to-ridiculous-analyst-1030714344,neutral,0.543989360332489
8/11/2021 4:57:52 PM,7 Biotech Stocks to Buy Amid the Delta Variant’s Onslaught,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-amid-rising-covid-19-cases-1030719978,neutral,0.5603510141372681
8/12/2021 2:09:26 PM,"The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma",Benzinga,/news/stocks/the-daily-biotech-pulse-xeris-gets-ok-for-initiating-hyperthyroidism-study-merck-eisai-snag-fda-approval-for-drug-combo-decision-day-for-jazz-pharma-1030724099,positive,0.575188934803009
8/14/2021 12:39:00 AM,"Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19",PR Newswire,/news/stocks/merck-canada-initiates-rolling-submission-to-health-canada-for-molnupiravir-an-investigational-oral-therapeutic-agent-for-the-treatment-of-covid-19-1030730408,positive,0.6028389930725098
8/14/2021 12:39:00 AM,"Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19",PR Newswire,/news/stocks/merck-canada-initiates-rolling-submission-to-health-canada-for-molnupiravir-an-investigational-oral-therapeutic-agent-for-the-treatment-of-covid-19-1030730407,positive,0.6028389930725098
8/15/2021 5:06:13 PM,"The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow",Benzinga,/news/stocks/the-week-ahead-in-biotech-aug-15-21-fate-therapeutics-data-readout-renovorx-ipo-in-focus-amid-tapering-earnings-news-flow-1030731355,negative,0.868375837802887
8/17/2021 6:50:26 PM,"Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q2-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030739447,neutral,0.8887203335762024
8/17/2021 7:04:09 PM,7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire,InvestorPlace,/news/stocks/7-buffett-stocks-to-buy-and-sell-if-you-want-to-be-like-berkshire-1030739695,neutral,0.9384809136390686
8/18/2021 11:44:33 AM,Werewolf Therapeutics teams up with Merck for WTX-124/Keytruda combo cancer study,Seeking Alpha,https://seekingalpha.com/news/3731763-werewolf-therapeutics-teams-up-with-merck-for-wtx-124keytruda-combo-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6974340081214905
8/18/2021 2:02:24 PM,Werewolf Collaborates With Merck On WTX-124 In Combination With KEYTRUDA - Quick Facts ,RTTNews,/news/stocks/werewolf-collaborates-with-merck-on-wtx-124-in-combination-with-keytruda-quick-facts-1030741650,neutral,0.6378539204597473
8/18/2021 3:58:00 PM,Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck,Benzinga,/news/stocks/werewolf-therapeutics-inks-solid-tumor-trial-collaboration-with-merck-1030742444,neutral,0.7468539476394653
8/19/2021 1:37:27 PM,"The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck",Benzinga,/news/stocks/the-daily-biotech-pulse-coherus-soars-on-lung-cancer-data-illumina-closes-on-grail-buy-without-regulatory-clearance-adagene-strikes-collaboration-with-merck-1030745371,negative,0.7770193219184875
8/19/2021 2:16:03 PM,Adagene Inks Third Cancer Trial Collaboration With Merck,Benzinga,/news/stocks/adagene-inks-third-cancer-trial-collaboration-with-merck-1030745594,positive,0.5608289241790771
8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7850372195243835
8/20/2021 7:43:25 PM,Johnson & Johnson sets a 52-week high after announcing leadership transition,Seeking Alpha,https://seekingalpha.com/news/3732818-johnson-johnson-sets-a-52-week-high-after-announcing-leadership-transition?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.799869179725647
8/23/2021 1:27:52 PM,COVID-19 vaccinations pick up as some states face with a ‘tsunami of patients’,Seeking Alpha,https://seekingalpha.com/news/3733039-covid-19-vaccinations-pick-up-as-some-states-face-with-a-tsunami-of-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.791989803314209
8/23/2021 3:13:31 PM,Agilent companion diagnostic expands CE-IVD mark in Europe to include esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3733091-agilent-companion-diagnostic-expands-ce-ivd-mark-in-europe-to-include-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7179781198501587
8/25/2021 1:30:14 PM,"The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-strikes-1-6b-r-d-collaboration-fsd-pulls-plug-on-covid-19-program-cassava-sinks-on-questions-about-alzheimer-s-drug-1030757345,negative,0.8795362114906311
8/25/2021 1:34:03 PM,Merck: VAXNEUVANCE Meets Endpoints In Phase 3 Trial Evaluating Use In Infants ,RTTNews,/news/stocks/merck-vaxneuvance-meets-endpoints-in-phase-3-trial-evaluating-use-in-infants-1030757356,positive,0.5489084124565125
8/26/2021 2:04:21 PM,"Merck's Keytruda Gets Approvals For Recurrent Breast, Colorectal Cancer Treatments In  Japan ",RTTNews,/news/stocks/merck-s-keytruda-gets-approvals-for-recurrent-breast-colorectal-cancer-treatments-in-japan-1030760554,positive,0.932638943195343
8/26/2021 2:09:14 PM,"The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-early-approval-for-ascendis-pediatric-growth-hormone-deficiency-treatment-redhill-biopharma-spikes-on-positive-covid-19-drug-data-renovorx-ipo-1030760636,positive,0.7406299114227295
8/27/2021 1:06:42 PM,"CBO: Drug pricing bill could stymie pharma, biotech R&D",Seeking Alpha,https://seekingalpha.com/news/3734838-cbo-drug-pricing-bill-could-stymie-pharma-biotech-research-development?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9226203560829163
8/27/2021 7:00:23 PM,"Catalyst watch for next week: OPEC meeting, Autodesk event and semis/IT conference",Seeking Alpha,https://seekingalpha.com/news/3734937-catalyst-watch-for-next-week-opec-meeting-autodesk-event-and-semisit-conference?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9392601847648621
9/1/2021 1:07:43 PM,"Merck, Ridgeback Initiate Phase 3 MOVe-AHEAD Study Of Molnupiravir For COVID-19 - Quick Facts ",RTTNews,/news/stocks/merck-ridgeback-initiate-phase-3-move-ahead-study-of-molnupiravir-for-covid-19-quick-facts-1030772588,neutral,0.6828137040138245
9/1/2021 1:32:13 PM,"The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-releases-twin-dose-of-positive-tidings-astellas-voluntarily-pauses-gene-therapy-study-ascendis-offering-1030772643,neutral,0.8366305232048035
9/1/2021 2:03:56 PM,Pfizer starts dosing in pivotal trial for oral COVID-19 drug,Seeking Alpha,https://seekingalpha.com/news/3736091-pfizer-starts-dosing-in-pivotal-trial-for-oral-covid-19-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.746040940284729
9/1/2021 3:50:24 PM,Healthcare groups ask Democrats to back drug pricing reforms in reconciliation package,Seeking Alpha,https://seekingalpha.com/news/3736163-healthcare-groups-ask-democrats-to-back-drug-pricing-reforms-in-reconciliation-package?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7003874778747559
9/1/2021 5:01:20 PM,"3 Reasons To Buy Organon Stock, Says BofA Analyst",Benzinga,/news/stocks/3-reasons-to-buy-organon-stock-says-bofa-analyst-1030773655,neutral,0.911837637424469
9/7/2021 1:37:25 PM,Merck: KEYTRUDA Regimen Approved In China For First-Line Treatment In Esophageal Cancer ,RTTNews,/news/stocks/merck-keytruda-regimen-approved-in-china-for-first-line-treatment-in-esophageal-cancer-1030783753,positive,0.7401685118675232
9/7/2021 3:48:39 PM,Illumina Partners With Merck To Develop Tests For Use In Identifying Specific Cancer Mutations ,RTTNews,/news/stocks/illumina-partners-with-merck-to-develop-tests-for-use-in-identifying-specific-cancer-mutations-1030784423,positive,0.6936072111129761
9/7/2021 4:02:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-7-2021-1030784466,negative,0.5165024399757385
9/9/2021 9:51:05 AM,Merck To Grow Group Sales Organically By More Than 6% Annually - Quick Facts ,RTTNews,/news/stocks/merck-to-grow-group-sales-organically-by-more-than-6-annually-quick-facts-1030789192,positive,0.8928371071815491
9/10/2021 1:43:16 PM,"Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin",Benzinga,/news/stocks/codexis-merck-extend-supply-pact-for-enzyme-used-to-manufacture-sitagliptin-1030792447,positive,0.7950445413589478
9/12/2021 10:04:17 PM,"The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-12-18-calliditas-fda-decision-adcom-review-for-pfizer-biontech-covid-19-vaccine-oncology-conference-and-ipos-1030794269,neutral,0.9348464608192444
9/13/2021 9:19:56 PM,Why Are Silverback Therapeutics Shares Falling On Monday?,Benzinga,/news/stocks/why-are-silverback-therapeutics-shares-falling-on-monday-1030796594,negative,0.9585641026496887
9/15/2021 12:29:12 PM,Oral version of Gilead's remdesivir demonstrates promising preclinical results,Seeking Alpha,https://seekingalpha.com/news/3739900-oral-version-of-gilead-remdesivir-demonstrates-promising-preclinical-results?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9484257698059082
9/15/2021 1:38:39 PM,"The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-calliditas-theravance-to-cut-75-jobs-4-ipos-1030801226,negative,0.9463478326797485
9/15/2021 8:23:34 PM,Narrower drug pricing bill introduced in House by centrist Democrats,Seeking Alpha,https://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6811553239822388
9/15/2021 9:20:09 PM,House committee approves portion of spending package that includes drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5973886251449585
9/16/2021 7:48:49 AM,"France's BIOCORP, Merck Sign Partnership To Develop Specific Version Of Mallya Device ",RTTNews,/news/stocks/france-s-biocorp-merck-sign-partnership-to-develop-specific-version-of-mallya-device-1030803443,positive,0.8088124394416809
9/16/2021 1:45:15 PM,Silverback Therapeutics Presents Initial Safety Data From Solid Tumor Combo Therapy Trial,Benzinga,/news/stocks/silverback-therapeutics-presents-initial-safety-data-from-solid-tumor-combo-therapy-trial-1030804310,neutral,0.6096464395523071
9/16/2021 1:48:49 PM,"The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study",Benzinga,/news/stocks/the-daily-biotech-pulse-leap-phio-silverback-among-early-movers-on-oncology-conference-presentations-aerie-slumps-on-mixed-data-axsome-commences-phase-3-sleep-disorder-study-1030804309,negative,0.5086374282836914
9/16/2021 2:04:16 PM,Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial,Benzinga,/news/stocks/athenex-shares-are-trading-higher-on-positive-oral-paclitaxel-data-from-solid-tumor-trial-1030804435,positive,0.9528669714927673
9/17/2021 3:06:16 PM,Merck Gets Positive CHMP Opinion For Keytruda Plus Chemotherapy For Triple-Negative Breast Cancer ,RTTNews,/news/stocks/merck-gets-positive-chmp-opinion-for-keytruda-plus-chemotherapy-for-triple-negative-breast-cancer-1030807271,positive,0.9233586192131042
9/18/2021 5:01:01 PM,Merck's Keytruda Shows Recurrence-free Survival In Resected High-Risk Stage II Melanoma ,RTTNews,/news/stocks/merck-s-keytruda-shows-recurrence-free-survival-in-resected-high-risk-stage-ii-melanoma-1030808217,positive,0.914880096912384
9/18/2021 5:26:56 PM,Merck's Keytruda Plus Chemotherapy Reduces Risk Of Death By One-Third In Metastatic Cervical Cancer ,RTTNews,/news/stocks/merck-s-keytruda-plus-chemotherapy-reduces-risk-of-death-by-one-third-in-metastatic-cervical-cancer-1030808219,positive,0.8815450072288513
9/24/2021 8:20:00 AM,AstraZeneca/Merck's Lynparza + abiraterone delayed disease progression in prostate cancer,Seeking Alpha,https://seekingalpha.com/news/3743867-astrazenecas-lynparza-abiraterone-delayed-disease-progression-in-prostate-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4873700737953186
9/24/2021 8:30:48 AM,AstraZeneca: Lynparza PROpel Phase III Trial In 1st-line MCRPC Meets Primary Endpoint ,RTTNews,/news/stocks/astrazeneca-lynparza-propel-phase-iii-trial-in-1st-line-mcrpc-meets-primary-endpoint-1030820887,neutral,0.5080066919326782
9/27/2021 1:16:51 PM,Merck: Phase 3 Trial With KEYTRUDA Meets Endpoint In Patients With Advanced Hepatocellular Carcinoma ,RTTNews,/news/stocks/merck-phase-3-trial-with-keytruda-meets-endpoint-in-patients-with-advanced-hepatocellular-carcinoma-1030825238,neutral,0.6546640396118164
9/28/2021 2:18:52 PM,"The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive",Benzinga,/news/stocks/the-daily-biotech-pulse-eisai-biogen-pursue-approval-of-second-alzheimer-s-treatment-sanofi-changes-mrna-strategy-gsk-subsidiary-to-develop-long-acting-hiv-preventive-1030827880,neutral,0.5831677317619324
9/28/2021 3:29:40 PM,Why Are I-Mab Shares Trading Higher On Tuesday?,Benzinga,/news/stocks/why-are-i-mab-shares-trading-higher-on-tuesday-1030828279,neutral,0.5766633152961731
9/28/2021 7:30:23 PM,7 Biotech Stocks Entering the Golden Boom Phase,InvestorPlace,/news/stocks/7-biotech-stocks-entering-the-golden-boom-phase-1030829968,neutral,0.7444129586219788
9/30/2021 1:43:13 PM,"The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-confirms-acceleron-purchase-regeneron-touts-covid-19-antibody-cocktail-data-takeda-in-licenses-huntington-s-disease-drug-1030833761,neutral,0.8744046688079834
9/30/2021 2:04:43 PM,Merck To Buy Acceleron Pharma For $11.5 Bln ,RTTNews,/news/stocks/merck-to-buy-acceleron-pharma-for-11-5-bln-1030833823,neutral,0.9324897527694702
9/30/2021 3:18:52 PM,"Merck, Sutro Biopharma Extends Cytokine Derivative Research Program",Benzinga,/news/stocks/merck-sutro-biopharma-extends-cytokine-derivative-research-program-1030834250,neutral,0.7108141183853149
9/30/2021 4:20:02 PM,Acceleron downgraded by Piper Sandler on $11.5B Merck acquisition,Seeking Alpha,https://seekingalpha.com/news/3746658-acceleron-downgraded-by-piper-sandler-on-115b-merck-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6792033910751343
9/30/2021 6:01:30 PM,House Judiciary Committee approves bill to expedite biosimilar drugs to market,Seeking Alpha,https://seekingalpha.com/news/3746703-house-judiciary-committee-approves-bill-to-expedite-biosimilar-drugs-to-market?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5914813876152039
10/1/2021 11:51:27 AM,Sutro Biopharma and Merck extend research term for cytokine derivative program,Seeking Alpha,https://seekingalpha.com/news/3746892-sutro-biopharma-and-merck-extend-research-term-for-cytokine-derivative-program?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5050154328346252
10/1/2021 12:27:14 PM,Atea jumps after Merck data for coronavirus pill,Seeking Alpha,https://seekingalpha.com/news/3746910-atea-jumps-after-merck-data-for-coronavirus-pill?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.459390789270401
10/1/2021 12:28:20 PM,"RIOT, HIVE and CAN among pre market gainers",Seeking Alpha,https://seekingalpha.com/news/3746913-riot-hive-and-can-among-pre-market-gainers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6958342790603638
10/1/2021 12:45:11 PM,Merck Reports Positive Data From Molnupiravir Phase 3 Trial In Mild Or Moderate COVID-19 Patients ,RTTNews,/news/stocks/merck-reports-positive-data-from-molnupiravir-phase-3-trial-in-mild-or-moderate-covid-19-patients-1030836718,positive,0.9291146993637085
10/1/2021 1:56:15 PM,"The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-rallies-on-antiviral-pill-data-gilead-files-for-yescarta-label-expansion-exscientia-ipo-1030836939,neutral,0.8665687441825867
10/1/2021 2:30:32 PM,Merck data for coronavirus pill pressures developers of antibody therapies,Seeking Alpha,https://seekingalpha.com/news/3747028-merck-data-for-coronavirus-pill-pressure-developers-of-antibody-therapies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.897942841053009
10/1/2021 2:43:51 PM,Merck News: The ‘Game-Changer’ Making MRK Stock the No. 1 Trending Ticker Today,InvestorPlace,/news/stocks/merck-news-the-game-changer-making-mrk-stock-the-no-1-trending-ticker-today-1030837597,positive,0.8876031041145325
10/1/2021 3:00:09 PM,BMRA Stock: The Big Walmart Deal That Has Biomerica Investors Smiling Today,InvestorPlace,/news/stocks/bmra-stock-the-big-walmart-deal-that-has-biomerica-investors-smiling-today-1030837629,neutral,0.8807488679885864
10/1/2021 3:24:05 PM,AMC Stock Alert: 2 Reasons Why Investors Are Buzzing About AMC Entertainment Today,InvestorPlace,/news/stocks/amc-stock-alert-2-reasons-why-investors-are-buzzing-about-amc-entertainment-today-1030837696,neutral,0.9067433476448059
10/1/2021 4:23:28 PM,Novavax News: Why NVAX Stock Investors Have a Tough Pill to Swallow Today,InvestorPlace,/news/stocks/novavax-news-why-nvax-stock-investors-have-a-tough-pill-to-swallow-today-1030837879,neutral,0.6832003593444824
10/1/2021 4:51:30 PM,Merck Announcement Helps Prompt Positive Pre-Market Price Moves,Benzinga,/news/stocks/merck-announcement-helps-prompt-positive-pre-market-price-moves-1030837612,positive,0.9073411226272583
10/1/2021 6:41:16 PM,35 Stocks Moving In Friday's Mid-Day Session,Benzinga,/news/stocks/35-stocks-moving-in-friday-s-mid-day-session-1030837916,negative,0.5616492629051208
10/1/2021 7:54:59 PM,Enanta Pharma joins Merck’s COVID-pill rally to reach a record high,Seeking Alpha,https://seekingalpha.com/news/3747282-enanta-pharma-joins-mercks-covid-pill-rally-to-reach-a-record-high?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.902535617351532
10/1/2021 8:17:08 PM,Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-october-pdufa-dates-1030838143,neutral,0.9432098269462585
10/1/2021 9:44:59 PM,"4 Top Stock Trades for Monday: BTC, ETH, NVAX, MRNA",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-btc-eth-nvax-mrna-1030838585,neutral,0.9414652585983276
10/1/2021 9:52:00 PM,Merck Sharp & Dohme Corp. -- Moody's affirms Merck's A1 ratings; revises outlook to negative,Moodys,/news/bonds/merck-sharp-dohme-corp-moody-s-affirms-merck-s-a1-ratings-revises-outlook-to-negative-1030838348,neutral,0.5558491945266724
10/2/2021 2:00:00 PM,"Moderna, BioNTech top performing pharmas in Q3; Alzheimer's drug developers lag",Seeking Alpha,https://seekingalpha.com/news/3747328-moderna-biontech-top-best-performing-pharmas-in-q3-alzheimers-drug-developers-lag?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5793244242668152
10/3/2021 8:21:49 PM,"The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-3-9-chemocentryx-fda-decision-conference-presentations-ipos-and-more-1030839161,neutral,0.9412301182746887
10/4/2021 1:21:07 PM,Todos Medical re-evaluates Tollovir COVID-19 trial designs,Seeking Alpha,https://seekingalpha.com/news/3748054-todos-medical-re-evaluates-tollovir-covid-19-trial-designs?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7550265789031982
10/4/2021 4:01:33 PM,Why Merck Shares Are Rising,Benzinga,/news/stocks/why-merck-shares-are-rising-1030841025,neutral,0.9027014970779419
10/4/2021 9:05:58 PM,"Despite Game-Changing Treatment News, It’s Not Over for Novavax Yet",InvestorPlace,/news/stocks/despite-game-changing-treatment-news-not-over-nvax-stock-yet-1030842087,neutral,0.7486116290092468
10/5/2021 2:01:45 PM,"The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-files-for-booster-dose-authorization-gemini-restructures-strata-skin-cfo-departs-kaleido-reports-positive-readout-1030843466,neutral,0.4234638810157776
10/5/2021 5:16:48 PM,Merck’s Good News Doesn’t End the Bullish Story for Novavax,InvestorPlace,/news/stocks/mercks-good-news-doesnt-end-the-bullish-story-for-novavax-1030844852,neutral,0.3743162751197815
10/6/2021 3:33:39 PM,Latest Bad News Suggests Novavax Stock Might Be Cursed,InvestorPlace,/news/stocks/latest-bad-news-suggests-nvax-stock-might-be-cursed-1030847958,negative,0.9194989204406738
10/6/2021 4:03:52 PM,Why Investing in VXRT Stock is a Coin Flip,InvestorPlace,/news/stocks/why-investing-in-vxrt-stock-is-a-coin-flip-1030848053,neutral,0.9408310055732727
10/6/2021 5:58:57 PM,Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst,Benzinga,/news/stocks/merck-s-oral-covid-19-treatment-could-be-game-changer-bofa-analyst-1030848005,neutral,0.9073443412780762
10/6/2021 8:54:50 PM,Some Q3 pharma stock superstars start Q4 off on wrong foot,Seeking Alpha,https://seekingalpha.com/news/3750414-some-q3-pharma-stock-superstars-start-q4-off-on-wrong-foot?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9409963488578796
10/6/2021 9:57:30 PM,"Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT",Benzinga,/news/stocks/merck-keeps-m-a-mode-on-with-mirati-biogen-mrna-companies-on-radar-ft-1030848508,neutral,0.8931920528411865
10/8/2021 10:00:11 AM,Once-Cinderella Novavax Stock Could Be Poisoned by Merck’s Covid Pill,InvestorPlace,/news/stocks/if-nvax-stock-dead-cat-bounces-take-the-bounce-1030852531,negative,0.7392678260803223
10/8/2021 12:53:16 PM,"Moderna Stock Looks Fully Valued Here, But It Has a Great Future",InvestorPlace,/news/stocks/mrna-stock-looks-fully-valued-here-but-it-has-a-great-future-1030852948,positive,0.8353980779647827
10/8/2021 3:43:24 PM,7 Defensive Stocks to Buy and Forget About In Times of Volatility,InvestorPlace,/news/stocks/7-defensive-stocks-to-buy-and-forget-about-in-times-of-volatility-1030853320,neutral,0.9234777688980103
10/11/2021 12:34:35 PM,Merck Seeks Emergency Nod In US For Molnupiravir To Treat Mild-to-moderate COVID-19 ,RTTNews,/news/stocks/merck-seeks-emergency-nod-in-us-for-molnupiravir-to-treat-mild-to-moderate-covid-19-1030855676,positive,0.9126396775245667
10/11/2021 2:11:29 PM,"Cassava Sciences: Fine Trading Stock, Terrible Investment",InvestorPlace,/news/stocks/sava-stock-sciences-fine-trading-stock-terrible-investment-1030856331,negative,0.7722252011299133
10/11/2021 3:38:23 PM,"Novavax Stock Got Merck-ed, but Don’t Dump Your Shares Now",InvestorPlace,/news/stocks/nvax-stock-got-merck-ed-but-dont-dump-your-shares-now-1030856541,neutral,0.8150359988212585
10/11/2021 7:02:44 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1030856717,neutral,0.9218418598175049
10/12/2021 10:00:08 AM,"Novavax Stock Will Find Its Bottom, But Probably not Soon",InvestorPlace,/news/stocks/nvax-stock-will-find-its-bottom-but-probably-not-soon-1030858438,negative,0.6969290971755981
10/12/2021 4:25:17 PM,Winners and Losers of Rising Energy Prices,Benzinga,/news/stocks/winners-and-losers-of-rising-energy-prices-1030859637,neutral,0.7471303939819336
10/12/2021 5:37:48 PM,Novavax Will Be Volatile Until the Company Delivers Answers,InvestorPlace,/news/stocks/nvax-stock-will-be-volatile-until-company-delivers-answers-1030860145,neutral,0.7307533025741577
10/12/2021 6:22:42 PM,Expert Ratings For Merck & Co,Benzinga,/news/stocks/expert-ratings-for-merck-co-1030859983,neutral,0.8768600821495056
10/12/2021 6:29:59 PM,Bristol-Myers said to have weighed offer for Acceleron before Merck deal,Seeking Alpha,https://seekingalpha.com/news/3752108-bristol-myers-said-to-have-weighed-offer-for-acceleron-before-merck-deal?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9094681739807129
10/13/2021 10:00:12 AM,Can Carnival Stock Buck the Delta Variant and Gain Traction?,InvestorPlace,/news/stocks/can-ccl-stock-buck-delta-variant-and-gain-traction-1030862256,positive,0.5818172097206116
10/13/2021 2:02:11 PM,Novavax Stock Fortunes Are Still Awaiting the Magical Headline,InvestorPlace,/news/stocks/nvax-stock-novavax-fortunes-awaiting-the-magical-headline-1030863418,neutral,0.6994365453720093
10/13/2021 7:18:19 PM,Bill Gross sees 10-year Treasury yield rising to 2% over the next year,Seeking Alpha,https://seekingalpha.com/news/3752552-bill-gross-sees-10-year-treasury-yield-rising-to-2-over-the-next-year?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9442713260650635
10/14/2021 1:25:31 PM,7 Biotech Penny Stocks With Huge Catalysts Coming in 2022,InvestorPlace,/news/stocks/7-biotech-penny-stocks-with-huge-catalysts-coming-in-2022-1030866800,neutral,0.6686177253723145
10/15/2021 1:46:44 PM,"Merck, Eisai Receive Positive CHMP Opinions For Keytruda + Lenvima In Two Different Types Of Cancer ",RTTNews,/news/stocks/merck-eisai-receive-positive-chmp-opinions-for-keytruda-lenvima-in-two-different-types-of-cancer-1030869310,positive,0.9164496064186096
10/15/2021 4:45:33 PM,Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings,Benzinga,/news/stocks/health-care-sector-appears-to-be-a-drag-on-positive-unitedhealth-earnings-1030869859,negative,0.9385509490966797
10/19/2021 6:10:09 PM,Abbott Laboratories Q3 earnings preview and review,Seeking Alpha,https://seekingalpha.com/news/3755153-abbott-laboratories-q3-earnings-preview-and-review?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8984233736991882
10/20/2021 2:16:15 PM,It’s Time to Secure Those Profits You Earned from Novavax,InvestorPlace,/news/stocks/take-your-nvax-stock-profits-1030882297,neutral,0.5517584085464478
10/20/2021 2:16:25 PM,"The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-retreats-amid-vaccine-issues-lumiradx-covid-test-approved-in-india-sesen-shines-on-positive-bladder-cancer-review-1030881679,positive,0.555168092250824
10/21/2021 1:17:00 PM,Merck Financial Services GmbH -- Moody's upgrades Merck KGaA's rating to A3; stable outlook,Moodys,/news/bonds/merck-financial-services-gmbh-moody-s-upgrades-merck-kgaa-s-rating-to-a3-stable-outlook-1030885269,positive,0.9398305416107178
10/21/2021 2:05:16 PM,"The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-moderna-j-j-booster-shots-regulatory-approvals-for-bristol-myers-squibb-sanofi-regeneron-ventyx-ipo-1030885538,neutral,0.8053775429725647
10/21/2021 3:13:52 PM,PDS Biotech Pauses Recruitment In PDS0101 Combo Cancer Trial,Benzinga,/news/stocks/pds-biotech-pauses-recruitment-in-pds0101-combo-cancer-trial-1030885972,neutral,0.7259686589241028
10/21/2021 4:44:16 PM,Merck Recalls About 22K Vials Of Antibiotic Injection Cubicin ,RTTNews,/news/stocks/merck-recalls-about-22k-vials-of-antibiotic-injection-cubicin-1030886344,neutral,0.8368585109710693
10/22/2021 1:48:17 PM,EU Approves Merck's Keytruda Plus Chemotherapy To Treat Triple-Negative Breast Cancer ,RTTNews,/news/stocks/eu-approves-merck-s-keytruda-plus-chemotherapy-to-treat-triple-negative-breast-cancer-1030888830,positive,0.8908270001411438
10/22/2021 6:20:19 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1030889622,neutral,0.9218418598175049
10/22/2021 8:18:50 PM,Aurinia Pharma jumps on potential bid from Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3756800-aurinia-pharma-jumps-on-potential-bid-from-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8194186687469482
10/22/2021 9:17:52 PM,Novavax Is Set to Win on the Increasing Necessity of Booster Shots,InvestorPlace,/news/stocks/nvax-stock-set-to-win-on-increased-necessity-of-booster-shots-1030890110,positive,0.8870501518249512
10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741,neutral,0.9414970874786377
10/25/2021 11:51:43 AM,Evaxion Announces Collaboration With Merck & Co. To Evaluate EVX-01 With KEYTRUDA ,RTTNews,/news/stocks/evaxion-announces-collaboration-with-merck-co-to-evaluate-evx-01-with-keytruda-1030893967,positive,0.8775234222412109
10/25/2021 1:54:05 PM,Merck : Positive Results From Phase 3 Trial Of Doravirine/Islatravir For HIV-1  Infection Treatment ,RTTNews,/news/stocks/merck-positive-results-from-phase-3-trial-of-doravirine-islatravir-for-hiv-1-infection-treatment-1030894352,positive,0.9492546319961548
10/25/2021 2:01:42 PM,Merck Announces Initiation Of Rolling Review By EMA For Molnupiravir For COVID-19   Treatment ,RTTNews,/news/stocks/merck-announces-initiation-of-rolling-review-by-ema-for-molnupiravir-for-covid-19-treatment-1030894403,neutral,0.6500594019889832
10/25/2021 2:17:00 PM,Xeris Biopharma In Collaboration With Merck On XeriJect; Stock Up 18% - Quick Facts ,RTTNews,/news/stocks/xeris-biopharma-in-collaboration-with-merck-on-xeriject-stock-up-18-quick-facts-1030894486,positive,0.94651198387146
10/25/2021 7:20:44 PM,"Novavax is Now a Riskier Play, but Still One to Keep Your Eye On",InvestorPlace,/news/stocks/nvax-stock-is-now-a-riskier-play-but-still-one-to-keep-your-eye-on-1030896008,neutral,0.8857182860374451
10/26/2021 2:30:47 PM,"The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-gains-on-vaccine-news-novartis-reports-q3-beat-adcom-reviews-authorization-of-pfizer-biontech-s-vaccine-for-children-1030899570,positive,0.6003707051277161
10/26/2021 3:02:03 PM,Here's what Wall Street expects from Merck's earnings report,Markets Insider Automation,/news/stocks/merck_co-stock-quarter-earnings-preview-q3-1030899792,neutral,0.9062901735305786
10/26/2021 6:41:37 PM,"Evaxion Biotech gives back gains following collaboration, supply agreement with Merck",Seeking Alpha,https://seekingalpha.com/news/3758387-evaxion-biotech-gives-back-gains-following-collaboration-supply-agreement-with-merck?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9428579211235046
10/27/2021 2:40:31 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3759027-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8825733065605164
10/27/2021 3:05:01 PM,Merck To Share License For Oral COVID-19 Antiviral Medicine With Developing Countries ,RTTNews,/news/stocks/merck-to-share-license-for-oral-covid-19-antiviral-medicine-with-developing-countries-1030905511,positive,0.7884021401405334
10/27/2021 3:41:54 PM,Merck : Phase 2b Data Shows Islatravir - Doravirine Maintains Viral Suppression In HIV-1 Treatment ,RTTNews,/news/stocks/merck-phase-2b-data-shows-islatravir-doravirine-maintains-viral-suppression-in-hiv-1-treatment-1030905734,positive,0.8625937104225159
10/28/2021 10:33:44 AM,"Merck EPS beats by $0.20, beats on revenue, boost outlook",Seeking Alpha,https://seekingalpha.com/news/3759766-merck-eps-beats-0_20-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9319310784339905
10/28/2021 10:57:04 AM,Merck to double down on COVID-19 pill in 2022; raised guidance lags expectations,Seeking Alpha,https://seekingalpha.com/news/3759811-merck-to-double-down-on-covid-19-pill-in-2022-raised-guidance-lags-expectations?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8930984139442444
10/28/2021 12:55:35 PM,Merck & Co Inc. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/merck-co-inc-q3-adjusted-earnings-beat-estimates-1030909567,positive,0.8186734318733215
10/28/2021 1:07:21 PM,Merck Q3 Results Top Estimates; Boosts FY21 Outlook - Quick Facts ,RTTNews,/news/stocks/merck-q3-results-top-estimates-boosts-fy21-outlook-quick-facts-1030909730,positive,0.9435197710990906
10/28/2021 2:26:10 PM,"The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-beat-and-raise-quarter-pfizer-biontech-snag-orders-for-additional-vaccine-doses-hcw-cleared-for-phase-1-study-of-pancreatic-cancer-drug-1030910260,positive,0.8363469839096069
10/28/2021 3:41:47 PM,Pharma stocks rally as White House drops plan to lower drug pricing,Seeking Alpha,https://seekingalpha.com/news/3760155-pharma-stocks-rally-as-white-house-drops-plan-to-lower-drug-pricing?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8904983997344971
10/28/2021 5:35:14 PM,Merck hits 52-week high after earnings; sees up to $7B sales for COVID-19 pill through 2022,Seeking Alpha,https://seekingalpha.com/news/3760239-merck-hits-52-week-high-after-earnings-sees-up-to-7b-sales-for-covid-19-pill-through-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9385268092155457
10/28/2021 8:19:31 PM,Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study,Seeking Alpha,https://seekingalpha.com/news/3760378-gilead-and-merck-ink-collaboration-agreement-for-keytrudatrodelvy-breast-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8816500902175903
10/29/2021 2:19:39 PM,Novavax Just Caught a Big Break,InvestorPlace,/news/stocks/nvax-stock-just-caught-a-big-break-1030915657,positive,0.6648101806640625
10/29/2021 3:35:26 PM,Xeris gains 6% following H.C. Wainwright buy initiation; sees 122% return,Seeking Alpha,https://seekingalpha.com/news/3760934-xeris-gains-6-following-hc-wainwright-buy-initiation-sees-122-return?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.938506543636322
10/29/2021 6:14:23 PM,Expert Ratings For Merck & Co,Benzinga,/news/stocks/expert-ratings-for-merck-co-1030916008,neutral,0.8768600821495056
10/30/2021 8:00:00 PM,"BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards",Seeking Alpha,https://seekingalpha.com/news/3761145-biontech-gsk-top-pharma-performers-in-october-bristol-amgen-biggest-laggards?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.88188636302948
10/31/2021 7:23:54 PM,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-31-nov-6-earnings-pick-up-pace-eton-awaits-seizure-drug-approval-kidney-conference-more-ipos-in-the-pipeline-1030917750,positive,0.939061164855957
11/1/2021 10:00:15 AM,Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone,InvestorPlace,/news/stocks/nvax-stock-is-a-buy-for-long-term-investors-on-its-pipeline-alone-1030920757,neutral,0.6589827537536621
11/1/2021 3:37:12 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-1-2021-1030922174,negative,0.49766579270362854
11/1/2021 5:21:50 PM,Analyst Ratings For Merck & Co,Benzinga,/news/stocks/analyst-ratings-for-merck-co-1030922519,neutral,0.9076553583145142
11/1/2021 10:54:11 PM,ANI Pharma's Purified Cortrophin Gel Scores FDA Approval; Q3 Earnings Beat Estimates,Benzinga,/news/stocks/ani-pharma-s-purified-cortrophin-gel-scores-fda-approval-q3-earnings-beat-estimates-1030923518,positive,0.9420145153999329
11/2/2021 8:38:02 AM,"Pfizer, Moderna investors watching vaccine sales outlook and production expectations",Seeking Alpha,https://seekingalpha.com/news/3762130-pfizer-moderna-investors-watching-vaccine-sales-outlook-and-production-expectations?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9357653856277466
11/3/2021 5:31:42 PM,7 Best Stocks to Buy Now If You Have Faith in These Analyst Upgrades,InvestorPlace,/news/stocks/7-best-stocks-to-buy-now-if-you-have-faith-in-these-analyst-upgrades-1030933659,neutral,0.8329241871833801
11/3/2021 8:04:19 PM,Moderna’s Outlook Is Directly Tied to the Eventual Receding of Covid-19,InvestorPlace,/news/stocks/mrna-stock-outlook-is-directly-tied-to-the-eventual-receding-of-covid-19-1030934115,neutral,0.8584824204444885
11/4/2021 10:48:16 AM,Merck COVID-19 pill granted regulatory nod in the U.K.,Seeking Alpha,https://seekingalpha.com/news/3764927-merck-covid-19-pill-granted-regulatory-nod-in-the-uk?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9490277171134949
11/4/2021 1:00:58 PM,Moderna drags COVID-19 vaccine developers lower after slashing outlook,Seeking Alpha,https://seekingalpha.com/news/3765159-moderna-drags-covid-19-vaccine-developers-lower-after-slashing-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9672327041625977
11/4/2021 1:14:49 PM,"The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-oral-covid-19-pill-authorized-in-uk-novartis-cashes-out-of-roche-chimerix-plunges-on-data-evotec-ipo-1030937079,negative,0.8839086890220642
11/4/2021 3:16:29 PM,Evaxion Biotech shares up 169% on massively higher than normal volume,Seeking Alpha,https://seekingalpha.com/news/3765284-evaxion-biotech-shares-up-169-on-massively-higher-than-normal-volume?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9431094527244568
11/4/2021 7:56:01 PM,"Why is Moderna stock down today? Earnings miss, lowered 2021 guidance",Seeking Alpha,https://seekingalpha.com/news/3765409-why-is-moderna-stock-down-today-earnings-miss-lowered-2021-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9420512318611145
11/5/2021 10:00:00 AM,The Novavax Rebound Is Just Warming Up,InvestorPlace,/news/stocks/nvax-stock-rebound-is-just-warming-up-1030942042,neutral,0.7882605195045471
11/5/2021 12:58:25 PM,"Merck & Co, Moderna, BioNTech among premarket losers' pack",Seeking Alpha,https://seekingalpha.com/news/3766106-merck-co-moderna-biontech-among-premarket-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8947142362594604
11/5/2021 3:14:55 PM,"Regeneron, Eli Lilly join selloff as Pfizer hopes for a COVID-19 pill",Seeking Alpha,https://seekingalpha.com/news/3766206-regeneron-eli-lilly-join-selloff-as-pfizer-hopes-for-a-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8121302723884583
11/5/2021 3:52:55 PM,Biden says U.S. has access to millions of doses of Pfizer’s new COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3766230-biden-says-us-has-access-to-millions-of-doses-of-pfizers-new-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5976303219795227
11/5/2021 7:24:26 PM,Pfizer data for COVID-19 pill drags other developers of oral COVID-19 therapies,Seeking Alpha,https://seekingalpha.com/news/3766416-pfizer-data-for-covid-19-pill-drags-other-developers-of-oral-covid-19-therapies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.940730094909668
11/5/2021 8:07:06 PM,Why did Merck shares fall today?,Seeking Alpha,https://seekingalpha.com/news/3766435-why-did-merck-shares-fall-today?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8392989039421082
11/8/2021 2:24:25 PM,"The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-7-nov-13-earnings-taper-off-multiple-conference-presentations-ipos-and-more-1030949001,negative,0.9685659408569336
11/8/2021 4:49:36 PM,Are Vaccine Stocks A Buy On Earnings?,InvestorPlace,/news/stocks/are-vaccine-stocks-a-buy-on-earnings-1030951369,neutral,0.8077834844589233
11/8/2021 8:08:52 PM,EMA: Review of Merck's molnupiravir for COVID in 'shortest possible timeframe',Seeking Alpha,https://seekingalpha.com/news/3767123-ema-review-of-mercks-molnupiravir-for-covid-in-shortest-possible-timeframe?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8430562019348145
11/9/2021 11:41:39 AM,Merck says U.S. govt. to purchase 1.4M additional courses of its COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3767524-merck-say-us-govt-to-purchase-14m-additional-courses-of-its-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.584715723991394
11/9/2021 12:53:24 PM,Merck And Ridgeback: U.S. Government To Buy 1.4 Mln Addl Courses Of Molnupiravir After FDA Approval ,RTTNews,/news/stocks/merck-and-ridgeback-u-s-government-to-buy-1-4-mln-addl-courses-of-molnupiravir-after-fda-approval-1030953114,positive,0.6321927309036255
11/9/2021 2:13:10 PM,"The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data",Benzinga,/news/stocks/the-daily-biotech-pulse-double-dose-of-positive-tidings-for-merck-alkermes-slips-on-partial-termination-of-j-j-licensing-deal-amgen-migraine-drug-data-1030953661,negative,0.8833059072494507
11/9/2021 4:25:19 PM,"Regeneron, Roche COVID-19 cocktail likely to win EU ok this week - Reuters",Seeking Alpha,https://seekingalpha.com/news/3767845-regeneron-roche-covid-19-cocktail-likely-to-win-eu-ok-this-week-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7374584674835205
11/9/2021 5:13:58 PM,ALX Oncology Falls After Updated Data For Solid Tumors Candidate,Benzinga,/news/stocks/alx-oncology-falls-after-updated-data-for-solid-tumors-candidate-1030954839,negative,0.9499671459197998
11/10/2021 1:27:37 PM,Merck and Ridgeback in pact with Japan to deliver 1.6M courses of COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3768614-merck-and-ridgeback-in-pact-with-japan-to-deliver-16m-courses-of-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8892146348953247
11/10/2021 2:19:29 PM,"The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance",Benzinga,/news/stocks/the-daily-biotech-pulse-valneva-inks-covid-19-vaccine-supply-contract-in-europe-i-mab-spikes-on-china-deal-dermtech-sinks-on-guidance-1030959349,positive,0.6633683443069458
11/11/2021 11:00:29 AM,Moderna Stock Could Have a Lot Further to Fall After Disasterous Earnings,InvestorPlace,/news/stocks/moderna-stock-could-have-a-lot-further-to-fall-after-disasterous-earnings-1030964470,negative,0.9591974020004272
11/11/2021 2:48:54 PM,Merck Initiates Phase 3 Study Of VERQUVO In Chronic Heart Failure And Reduced Ejection Fraction ,RTTNews,/news/stocks/merck-initiates-phase-3-study-of-verquvo-in-chronic-heart-failure-and-reduced-ejection-fraction-1030965227,positive,0.7225460410118103
11/12/2021 3:27:10 PM,Johnson & Johnson gains as analysts cheer consumer spinoff,Seeking Alpha,https://seekingalpha.com/news/3770123-johnson-johnson-gains-as-analysts-cheer-consumer-spinoff?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8513222932815552
11/14/2021 2:00:00 PM,Merck potential animal health spin could be next after J&J split up,Seeking Alpha,https://seekingalpha.com/news/3770354-merck-potential-animal-health-spin-could-be-next-after-jj-split-up?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9016319513320923
11/15/2021 9:11:05 PM,Dr. Reddy's mulls production of Pfizer COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3770903-dr-reddys-mulls-production-of-pfizer-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9319334626197815
11/16/2021 11:00:42 AM,Merck Is a Dividend Play Ready to Get Back in Gear,InvestorPlace,/news/stocks/mrk-stock-dividend-play-ready-get-back-in-gear-1030979591,neutral,0.7099084854125977
11/16/2021 2:04:33 PM,Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower,Seeking Alpha,https://seekingalpha.com/news/3771400-pfizer-moves-to-allow-cheaper-covid-19-pills-sending-shares-of-rivals-lower?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9393699169158936
11/16/2021 7:00:50 PM,U.S. to buy 10 million courses of Pfizer COVID-19 pill - WaPo,Seeking Alpha,https://seekingalpha.com/news/3771584-us-to-buy-10-million-courses-of-pfizer-covid-19-pill-wapo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6997290253639221
11/16/2021 7:15:22 PM,Pfizer seeks FDA authorization for COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3771589-pfizer-seeks-fda-authorization-for-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.856785237789154
11/17/2021 2:16:02 PM,COVID-19 pill Paxlovid could add $15B-$22B to Pfizer 2022 revenue - Barclays,Seeking Alpha,https://seekingalpha.com/news/3771910-covid-19-pill-paxlovid-could-add-15b-22b-to-pfizer-2022-revenue-barclays?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7626579403877258
11/18/2021 12:03:03 PM,Merck granted FDA approval for Keytruda as adjuvant therapy in renal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3772322-merck-granted-fda-approval-for-keytruda-as-adjuvant-therapy-in-renal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.919177234172821
11/19/2021 12:13:14 PM,Merck halts development of HIV drug after decreases in white blood cells in phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/3772781-merck-halts-development-of-hiv-drug-after-decreases-in-white-blood-cells-in-phase-2-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9391278028488159
11/19/2021 2:20:15 PM,"The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-connect-biopharma-sinks-on-eczema-drug-readout-enanta-pulls-plug-on-hbv-drug-clinical-setback-for-merck-in-hiv-trial-1030991438,negative,0.4585235118865967
11/19/2021 3:34:38 PM,3 Recent Spin-Off Stocks Worth A Spot in Your Portfolio,InvestorPlace,/news/stocks/3-recent-spin-off-stocks-worth-a-spot-in-your-portfolio-1030991913,neutral,0.8516474366188049
11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825,negative,0.6235842108726501
11/19/2021 6:06:51 PM,EMA recommends Merck's COVID antiviral molnupiravir for those at risk of severe illness,Seeking Alpha,https://seekingalpha.com/news/3772994-ema-recommends-mercks-covid-antiviral-molnupiravir-for-those-at-risk-of-severe-illness?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7906177043914795
11/19/2021 8:00:11 PM,"Catalyst watch for next week: Zoom Video and Best Buy earnings, Merck R&D Day and UiPath event",Seeking Alpha,https://seekingalpha.com/news/3773010-catalyst-watch-for-next-week-zoom-video-and-best-buy-earnings-merck-rd-day-and-uipath-event?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9356232285499573
11/22/2021 11:00:35 AM,Covid Stand-out Pfizer’s Albert Bourla Gets My Vote for CEO of the Year,InvestorPlace,/news/stocks/covid-stand-out-pfizers-albert-bourla-gets-my-vote-for-ceo-of-the-year-1030994237,neutral,0.6566935777664185
11/22/2021 12:43:20 PM,Merck announces completion of Acceleron Pharma acquisition,Seeking Alpha,https://seekingalpha.com/news/3773190-merck-announces-completion-of-acceleron-pharma-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8432250022888184
11/22/2021 4:57:05 PM,3 Falling-Star Stocks to Buy Into the Holidays,InvestorPlace,/news/stocks/3-falling-star-stocks-to-buy-into-the-holidays-1030995663,neutral,0.7574781179428101
11/22/2021 5:14:33 PM,Orally Administered Covid-19 Treatment Should Bolster Merck’s Value,InvestorPlace,/news/stocks/orally-administered-covid-19-treatment-should-bolster-mrk-stocks-value-1030995734,positive,0.9540592432022095
11/23/2021 4:48:51 PM,Merck secures Health Canada approval for Keytruda and chemo combo for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3773882-merck-stock-rises-after-health-canada-approved-keytruda-and-chemo-combo-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9243133068084717
11/23/2021 5:16:33 PM,EMA begins review of Merck's COVID pill molnupiravir; opinion possible within weeks,Seeking Alpha,https://seekingalpha.com/news/3773898-ema-begins-review-of-mercks-covid-pill-molnupiravir-opinion-possible-within-weeks?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8910632729530334
11/23/2021 10:31:25 PM,"Gilead, Merck pause enrollment in phase 2 HIV combination therapy trial",Seeking Alpha,https://seekingalpha.com/news/3774062-gilead-merck-pause-enrollment-in-phase-2-hiv-combination-therapy-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5914499759674072
11/25/2021 10:04:37 PM,Goldman pinpoints rising and falling stars held by hedge funds,Seeking Alpha,https://seekingalpha.com/news/3774351-goldman-pinpoints-rising-and-falling-stars-held-by-hedge-funds?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.874489426612854
11/26/2021 11:58:04 AM,COVID-19 vaccine stocks surge on worries over new variant,Seeking Alpha,https://seekingalpha.com/news/3774537-covid-19-vaccine-stocksbiotechs-surge-on-worries-over-new-covid-19-variant?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8936194777488708
11/26/2021 12:48:27 PM,Merck stock down 3% after its COVID-19 pill shows lower efficacy in updated data,Seeking Alpha,https://seekingalpha.com/news/3774551-mercks-covid-19-pill-reduces-risk-of-hospitalizationdeath-by-30-shares-down-3?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9728326201438904
11/26/2021 1:17:12 PM,"Merck: Interim Analysis, Additional Analyses Support Efficacy Of Molnupiravir ",RTTNews,/news/stocks/merck-interim-analysis-additional-analyses-support-efficacy-of-molnupiravir-1031005409,neutral,0.7077760100364685
11/26/2021 2:19:14 PM,U.S. must study data before deciding on travel ban over new COVID-19 variant: Fauci,Seeking Alpha,https://seekingalpha.com/news/3774591-us-must-study-data-before-deciding-on-travel-ban-over-new-covid-19-variant-fauci?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.908190906047821
11/26/2021 4:12:59 PM,COVID vaccines' effectiveness against Nu variant may not be known for two weeks,Seeking Alpha,https://seekingalpha.com/news/3774637-covid-vaccines-effectiveness-against-nu-variant-may-not-be-known-for-two-weeks?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9187087416648865
11/28/2021 3:43:16 PM,"The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-28-dec-4-fda-decisions-for-vbi-vaccines-beyondspring-cti-biopharma-and-merck-take-the-spotlight-in-a-light-calendar-week-1031007148,neutral,0.6618114113807678
11/29/2021 8:53:36 AM,Biotech Stocks Facing FDA Decision In December 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2021-1031007771,neutral,0.6823662519454956
11/29/2021 12:56:32 PM,European Commission approves Merck's Keytruda + Lenvima for kidney and endometrial cancer,Seeking Alpha,https://seekingalpha.com/news/3774800-european-commission-approves-mercks-keytruda-lenvima-for-kidney-and-endometrial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7233784794807434
11/29/2021 1:27:46 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031008514,neutral,0.7998325824737549
11/29/2021 1:36:24 PM,"Merck : EU Approves KEYTRUDA Plus LENVIMA For Certain Types Of Endometrial Carcinoma, Advanced RCC ",RTTNews,/news/stocks/merck-eu-approves-keytruda-plus-lenvima-for-certain-types-of-endometrial-carcinoma-advanced-rcc-1031008553,positive,0.8026465177536011
11/29/2021 4:02:44 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-29-2021-1031009229,negative,0.6090698838233948
11/29/2021 4:06:10 PM,Merck dips further to reach a two-month low amid Citi downgrade,Seeking Alpha,https://seekingalpha.com/news/3774955-merck-dips-further-to-reach-a-two-month-low-amid-citi-downgrade?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9589263200759888
11/29/2021 6:48:57 PM,"While Merck's COVID pill molnupiravir is poised for authorization, efficacy could hamper use",Seeking Alpha,https://seekingalpha.com/news/3775015-as-fda-is-set-to-review-merck-covid-pill-molnupiravir-efficacy-could-hamper-use?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9474865198135376
11/29/2021 6:58:45 PM,3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries,Benzinga,/news/stocks/3-pharma-stocks-morgan-stanley-says-will-be-omicron-variant-beneficiaries-1031009763,neutral,0.9128556847572327
11/30/2021 8:33:08 AM,AstraZeneca's Lynparza Granted Priority Review In U.S. For High-risk Early Breast Cancer ,RTTNews,/news/stocks/astrazeneca-s-lynparza-granted-priority-review-in-u-s-for-high-risk-early-breast-cancer-1031010717,positive,0.9128967523574829
11/30/2021 12:12:37 PM,Merck’s Keytruda + chemotherapy OK'd in Japan for esophageal carcinoma,Seeking Alpha,https://seekingalpha.com/news/3775252-mercks-keytruda-chemotherapy-okd-in-japan-for-esophageal-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5415502786636353
11/30/2021 12:31:18 PM,Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors,Benzinga,/news/stocks/adagene-shares-jump-after-fda-signs-off-adg116-keytruda-combo-therapy-trial-in-solid-tumors-1031011380,negative,0.8511836528778076
11/30/2021 2:12:23 PM,"The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-cumberland-jumps-on-fda-nod-regeneron-says-antibody-treatment-may-be-less-effective-against-omicron-immunogen-readout-1031011982,negative,0.6165551543235779
11/30/2021 5:07:19 PM,Merck expects COVID-19 pill to be effective against any COVID-19 variant - Reuters,Seeking Alpha,https://seekingalpha.com/news/3775492-merck-expects-covid-19-pill-to-be-effective-against-any-covid-19-variant-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5721625685691833
11/30/2021 8:03:56 PM,Merck raises dividend by ~6% to $0.69,Seeking Alpha,https://seekingalpha.com/news/3775528-merck-raises-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9225497245788574
11/30/2021 10:13:22 PM,FDA advisors recommend authorization of Merck COVID antiviral pill molnupiravir,Seeking Alpha,https://seekingalpha.com/news/3775610-fda-advisors-recommend-authorization-of-merck-covid-antiviral-pill-molnupiravir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6448588967323303
12/1/2021 12:08:55 PM,"FDA accepts for priority review Merck's Vaxneuvance application for use in infants, children",Seeking Alpha,https://seekingalpha.com/news/3775712-fda-accepts-for-priority-review-mercks-vaxneuvance-application-for-use-in-infants-children?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8427525758743286
12/1/2021 2:29:42 PM,Merck draws mixed views on Street despite backing from FDA panel for COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3775810-merck-draws-mixed-views-on-street-despite-backing-from-fda-panel-for-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9037825465202332
12/1/2021 2:41:54 PM,"The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-backs-merck-s-oral-covid-19-treatment-regulatory-setbacks-for-cti-biopharma-bioxcel-favorable-ruling-for-viatris-in-tecfidera-patent-case-1031016008,positive,0.928840160369873
12/1/2021 10:30:37 PM,FDA Panel Narrowly Recommends Use Of Merck's Covid-19 Pill ,RTTNews,/news/stocks/fda-panel-narrowly-recommends-use-of-merck-s-covid-19-pill-1031017623,neutral,0.8870221376419067
12/2/2021 6:02:11 PM,Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-december-pdufa-dates-1031020805,neutral,0.9439957737922668
12/2/2021 6:44:27 PM,"Regeneron: Surfing on Covid, With More Under the Surface",InvestorPlace,/news/stocks/regn-stock-regeneron-surfing-on-covid-1031021097,neutral,0.9220339059829712
12/3/2021 1:40:11 PM,"The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-protagonist-pulls-plug-on-phase-1-asset-xenon-aces-mid-stage-epilepsy-study-esperion-prices-offering-1031022833,neutral,0.8068130016326904
12/3/2021 9:55:32 PM,"Merck's Keytruda approved as adjuvant therapy for stage IIb, IIc melanoma",Seeking Alpha,https://seekingalpha.com/news/3777099-merck-keytruda-approved-as-adjuvant-therapy-for-stage-iib-iic-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7664921879768372
12/6/2021 11:00:09 AM,7 Stocks to Buy to Give Your Portfolio a Booster Shot,InvestorPlace,/news/stocks/7-stocks-to-buy-to-give-portfolio-booster-shot-1031025563,neutral,0.8892467617988586
12/6/2021 12:07:24 PM,"The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-6-dec-11-daré-fda-decision-adcom-tryst-for-reata-multiple-conference-presentations-and-more-1031025543,neutral,0.9361634850502014
12/6/2021 5:47:14 PM,Thermo Fisher in pact with Merck to manufacture its COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3777461-thermo-fisher-in-pact-with-merck-to-manufacture-its-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7481129169464111
12/6/2021 10:35:35 PM,Merck halts enrollment in two late-stage trials for HIV drug islatravir,Seeking Alpha,https://seekingalpha.com/news/3777569-merck-halts-enrollment-in-two-late-stage-trials-for-hiv-drug-islatravir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9601167440414429
12/7/2021 2:18:13 PM,"The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré",Benzinga,/news/stocks/the-daily-biotech-pulse-acadia-jumps-on-data-vtv-shelves-psoriasis-study-more-setbacks-for-merck-s-hiv-program-decision-day-for-daré-1031029061,neutral,0.8369230031967163
12/7/2021 4:03:07 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-7-2021-1031029567,negative,0.5651478171348572
12/7/2021 6:51:58 PM,7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts,InvestorPlace,/news/stocks/7-best-drug-stocks-buy-2022-without-covid-catalysts-1031030186,neutral,0.8384881019592285
12/8/2021 9:24:48 AM,Merck prices $8B of debt offering,Seeking Alpha,https://seekingalpha.com/news/3778096-merck-prices-8b-of-debt-offering?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9319419264793396
12/8/2021 2:19:09 PM,"The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom",Benzinga,/news/stocks/the-daily-biotech-pulse-valneva-strikes-deal-to-supply-covid-vaccine-to-bahrain-therapeuticsmd-amneal-settle-patent-lawsuit-reata-awaits-adcom-1031032240,neutral,0.6858616471290588
12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,negative,0.5978407859802246
12/10/2021 11:00:33 AM,Why You Should Buy Moderna Stock at Every Dip,InvestorPlace,/news/stocks/why-you-should-buy-mrna-stock-at-every-dip-1031038543,neutral,0.9308883547782898
12/13/2021 4:48:27 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-13-2021-1031041906,negative,0.58290696144104
12/13/2021 9:18:56 PM,Merck cut to neutral at UBS on negative updates for two key drug candidates,Seeking Alpha,https://seekingalpha.com/news/3779666-merck-cut-to-neutral-at-ubs-on-negative-updates-for-two-key-drug-candidates?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9561809301376343
12/13/2021 10:37:36 PM,Merck now facing IND clinical holds on trials for HIV drug islatravir,Seeking Alpha,https://seekingalpha.com/news/3779714-merck-now-facing-ind-clinical-holds-on-trials-for-hiv-drug-islatravir?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8595048785209656
12/14/2021 8:00:36 AM,"Merck's HIV Trials Put On Clinical Hold, Vifor Gets A Suitor, VERU Scores FDA Nod... ",RTTNews,/news/stocks/merck-s-hiv-trials-put-on-clinical-hold-vifor-gets-a-suitor-veru-scores-fda-nod-1031042764,neutral,0.8497503399848938
12/15/2021 12:34:24 PM,Famed Robot-Run ETF Says This Is Why It Now Has Tesla As Its Top Holding,Benzinga,/news/stocks/famed-robot-run-etf-says-this-is-why-it-now-has-tesla-as-its-top-holding-1031046687,neutral,0.8171719312667847
12/15/2021 12:37:29 PM,EC approves Merck’s pneumonia vaccine for adults 18 years of age and older,Seeking Alpha,https://seekingalpha.com/news/3780273-ec-approves-mercks-pneumonia-vaccine-for-adults-18-years-of-age-and-older?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5634833574295044
12/16/2021 4:13:40 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-16-2021-1031050813,negative,0.6107218861579895
12/17/2021 2:00:58 AM,Christian Angermayer-backed Australian firm Bionomics soars 78% intraday after U.S. IPO,Seeking Alpha,https://seekingalpha.com/news/3781146-christian-angermayer-bionomics-stock-price-soars-after-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.890902578830719
12/17/2021 12:02:41 PM,EMA advisory committee backs Merck's Keytruda for kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3781213-ema-advisory-committee-backs-mercks-keytruda-for-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7359251976013184
12/17/2021 1:11:10 PM,Merck: CHMP Adopts Positive Opinion For KEYTRUDA As Monotherapy For Adjuvant Treatment Of RCC ,RTTNews,/news/stocks/merck-chmp-adopts-positive-opinion-for-keytruda-as-monotherapy-for-adjuvant-treatment-of-rcc-1031052987,positive,0.9297325611114502
12/17/2021 1:54:07 PM,"The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx",Benzinga,/news/stocks/the-daily-biotech-pulse-genfit-spikes-on-liver-disease-drug-licensing-deal-lyell-gets-nod-for-solid-tumor-study-decision-day-for-intra-cellular-argenx-1031053175,neutral,0.7439902424812317
12/19/2021 2:00:00 PM,"Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022",Seeking Alpha,https://seekingalpha.com/news/3781488-alnylam-pharma-crispr-therapeutics-among-goldmans-healthcare-targets-for-2022?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7041938304901123
12/21/2021 3:55:18 PM,"Pfizer, Merck could receive FDA OK for COVID-19 pills this week - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3782385-pfizer-merck-could-receive-fda-ok-for-covid-19-pills-this-week-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6855446100234985
12/22/2021 9:08:01 AM,"COVID roundup: More mandates, halving quarantine, FDA pill approval?",Seeking Alpha,https://seekingalpha.com/news/3782556-covid-roundup-israels-fourth-dose-halving-quarantine-fda-pill-approval?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7903928756713867
12/22/2021 11:00:59 AM,Buy Palantir Stock While the Analysts Remain Bearish,InvestorPlace,/news/stocks/buy-pltr-stock-while-the-analysts-remain-bearish-1031061330,neutral,0.8463932871818542
12/22/2021 11:43:15 AM,U.K. to purchase additional 1.75M courses on Merck's COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3782594-uk-to-purchase-additional-175m-courses-on-mercks-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7794578671455383
12/22/2021 12:57:37 PM,"Merck, Ridgeback Say British Govt. Agrees To Procure Further 1.75 Mln Molnupiravir Pills ",RTTNews,/news/stocks/merck-ridgeback-say-british-govt-agrees-to-procure-further-1-75-mln-molnupiravir-pills-1031061461,positive,0.8532586693763733
12/22/2021 10:12:32 PM,Merck’s order for COVID-19 pill canceled by France,Seeking Alpha,https://seekingalpha.com/news/3782873-mercks-order-for-covid-19-pill-cancelled-by-france?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9368370771408081
12/23/2021 11:16:40 AM,Philippines OKs Merck's COVID-19 pill for at-risk patients - Reuters,Seeking Alpha,https://seekingalpha.com/news/3782924-philippines-oks-mercks-covid-19-pill-for-at-risk-patients-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8043199777603149
12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755,neutral,0.7226237654685974
12/23/2021 2:28:39 PM,Merck and Ridgeback win FDA clearance for COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3783035-merck-and-ridgeback-win-fda-clearance-for-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.864262580871582
12/23/2021 7:41:04 PM,"FDA Gives Emergency Use Authorization For Merck's Molnupiravir, Second Covid-19 Pill To Get Approval ",RTTNews,/news/stocks/fda-gives-emergency-use-authorization-for-merck-s-molnupiravir-second-covid-19-pill-to-get-approval-1031064964,positive,0.6652975082397461
12/23/2021 9:01:22 PM,How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?,Benzinga,/news/stocks/how-much-revenue-could-pfizer-s-oral-covid-19-pill-fetch-1031065030,neutral,0.8741986155509949
12/25/2021 3:32:22 PM,"Benzinga's Bulls And Bears Of The Past Week: Alibaba, Disney, NVDIA, Coinbase, Hubspot, JD.com And More",Benzinga,/news/stocks/benzinga-s-bulls-and-bears-of-the-past-week-alibaba-disney-nvdia-coinbase-hubspot-jd-com-and-more-1031065844,neutral,0.9415821433067322
12/26/2021 3:53:01 PM,"The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-26-jan-1-xeris-fda-decision-pending-clinical-readouts-in-focus-in-final-week-of-year-1031066069,neutral,0.8738000392913818
12/27/2021 12:21:25 PM,Pardes to make public debut after SPAC deal with FS Development Corp. II,Seeking Alpha,https://seekingalpha.com/news/3783374-pardes-to-make-public-debut-after-spac-deal-with-fs-development-corp-ii?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8527580499649048
12/27/2021 5:44:12 PM,Moderna and Novavax extend losses after FDA authorization of COVID-19 pills,Seeking Alpha,https://seekingalpha.com/news/3783471-moderna-and-novavax-extend-losses-after-fda-authorization-of-covid-19-pills?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9630160927772522
12/28/2021 7:35:25 AM,India OKs emergency use of Merck's COVID-19 pill - Reuters,Seeking Alpha,https://seekingalpha.com/news/3783537-india-oks-emergency-use-of-mercks-covid-19-pill-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.47916898131370544
12/28/2021 11:57:18 AM,"Market positioning is too bearish, J.P. Morgan says: At the Open",Seeking Alpha,https://seekingalpha.com/news/3783465-market-positioning-is-too-bearish-jp-morgan-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6056981682777405
12/28/2021 8:12:18 PM,Moderna sheds over half of its market cap in less than five months,Seeking Alpha,https://seekingalpha.com/news/3783760-moderna-sheds-over-half-of-its-market-cap-in-less-than-five-months?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8239003419876099
12/29/2021 10:12:35 PM,"Walmart set to dispense Pfizer, Merck COVID antiviral pills at certain stores",Seeking Alpha,https://seekingalpha.com/news/3784041-walmart-set-to-dispense-pfizer-merck-covid-antiviral-pills-at-certain-stores?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9272099137306213
1/3/2022 1:13:17 PM,Genprex wins FDA’s Fast Track Designation for lead asset,Seeking Alpha,https://seekingalpha.com/news/3784519-genprex-wins-fdas-fast-track-designation-for-lead-asset-for-the-second-time?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.832240104675293
1/3/2022 3:12:54 PM,Genprex Receives FDA Fast Track Designation For REQORSA - Keytruda For NSCLC Treatment ,RTTNews,/news/stocks/genprex-receives-fda-fast-track-designation-for-reqorsa-keytruda-for-nsclc-treatment-1031074248,positive,0.8845036625862122
1/3/2022 5:25:04 PM,GNPX Stock: 5 Things to Know as Genprex Rockets Higher,InvestorPlace,/news/stocks/gnpx-stock-5-things-to-know-as-genprex-rockets-higher-1031074640,neutral,0.6415839195251465
1/4/2022 2:18:40 PM,Vaccinex/Merck reports interim data from Phase Ib KEYNOTE B84 combo study in head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/3784937-vaccinexmerck-reports-interim-data-from-phase-ib-keynote-b84-combo-study-in-head-and-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8931466341018677
1/4/2022 9:15:57 PM,"Eli Lilly, Bristol Myers in Cowen's list of big pharma with notable catalysts in Q1 2022",Seeking Alpha,https://seekingalpha.com/news/3785213-eli-lilly-bristol-myers-in-cowens-list-of-big-pharma-with-notable-catalysts-in-q1-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5352686643600464
1/7/2022 10:53:18 AM,Absci shares jump 44% on collaboration with Merck,Seeking Alpha,https://seekingalpha.com/news/3786104-absci-shares-jump-44-on-collaboration-with-merck?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9262897968292236
1/7/2022 12:35:39 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-jan-7-1031083585,neutral,0.50490802526474
1/7/2022 3:33:31 PM,Why Absci Shares Are Soaring Today,Benzinga,/news/stocks/why-absci-shares-are-soaring-today-1031087763,neutral,0.7151466608047485
1/7/2022 4:29:21 PM,ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today,InvestorPlace,/news/stocks/absi-stock-7-things-for-investors-to-know-about-the-merck-deal-that-has-absci-shares-flying-today-1031088018,neutral,0.9213721752166748
1/7/2022 6:17:06 PM,Biden administration to ask Congress for more COVID funding - WaPo,Seeking Alpha,https://seekingalpha.com/news/3786338-biden-administration-to-ask-congress-for-more-covid-funding?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7112752199172974
1/7/2022 7:00:35 PM,"Catalyst watch for next week: Biogen, Five Below, Tritium and Monster Beverage in the spotlight",Seeking Alpha,https://seekingalpha.com/news/3786173-catalyst-watch-for-next-week-biogen-five-below-tritium-and-monster-beverage-in-the-spotlight?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9277867674827576
1/10/2022 1:50:05 PM,Merck in pact with Neoleukin to study Keytruda combo in cancer trial,Seeking Alpha,https://seekingalpha.com/news/3786593-merck-in-pact-with-neoleukin-to-study-keytruda-combo-in-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6027595400810242
1/10/2022 2:13:47 PM,Merck says Keytruda met main goal in a first-of-its-kind trial for lung cancer,Seeking Alpha,https://seekingalpha.com/news/3786621-merck-says-keytruda-met-main-goal-in-a-first-of-its-kind-trial-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6635499596595764
1/10/2022 2:27:02 PM,Gilead to work with Merck on combination of Trodelvy and Keytruda for lung cancer,Seeking Alpha,https://seekingalpha.com/news/3786630-gilead-to-work-with-merck-on-combination-of-trodelvy-and-keytruda-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.53365159034729
1/10/2022 3:26:24 PM,Gilead Announces Clinical Trial Collaborations With Merck - Quick Facts ,RTTNews,/news/stocks/gilead-announces-clinical-trial-collaborations-with-merck-quick-facts-1031091081,neutral,0.5837490558624268
1/11/2022 3:53:38 PM,Aligos expands collaboration with Merck to develop oligonucleotide therapies for NASH,Seeking Alpha,https://seekingalpha.com/news/3787161-aligos-expands-collaboration-with-merck-to-develop-oligonucleotide-therapies-for-nash?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8223727345466614
1/13/2022 5:22:52 PM,Committee advances FDA chief nominee Robert Califf for full Senate vote,Seeking Alpha,https://seekingalpha.com/news/3788000-committee-advances-fda-chief-nominee-robert-califf-for-full-senate-vote?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8766841888427734
1/14/2022 8:49:39 AM,Indonesia OKs Merck's COVID-19 pill for emergency use - Reuters,Seeking Alpha,https://seekingalpha.com/news/3788167-indonesia-oks-mercks-covid-19-pill-for-emergency-use-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8372639417648315
1/18/2022 12:51:02 PM,"Merck, Ridgeback in agreement with UNICEF to supply 3M courses of COVID-19 pill",Seeking Alpha,https://seekingalpha.com/news/3788613-merck-ridgeback-in-agreement-with-unicef-to-supply-3m-courses-of-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8705377578735352
1/18/2022 1:13:59 PM,"Merck, Ridgeback In Supply Agreement With UNICEF For 'molnupiravir' To Treat Covid ",RTTNews,/news/stocks/merck-ridgeback-in-supply-agreement-with-unicef-for-molnupiravir-to-treat-covid-1031108515,positive,0.9328330159187317
1/18/2022 1:50:56 PM,"HOOKIPA HB-200 drug combo gets FDA fast track status for head, neck cancer",Seeking Alpha,https://seekingalpha.com/news/3788678-hookipa-hb-200-drug-combo-gets-fda-fast-track-status-for-head-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9385818243026733
1/18/2022 2:02:00 PM,Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among Veterinarians,PR Newswire,/news/stocks/merck-animal-health-s-third-veterinarian-wellbeing-study-reveals-increased-health-challenges-and-psychological-distress-among-veterinarians-1031108817,negative,0.8842847347259521
1/18/2022 11:05:02 PM,Late-stage data buoys Merck's Keytruda as second-line hepatocellular carcinoma treatment,Seeking Alpha,https://seekingalpha.com/news/3789014-late-stage-data-buoys-mercks-keytruda-as-second-line-hepatocellular-carcinoma-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4537467062473297
1/19/2022 9:57:51 PM,Palantir’s Long-Term Bull Case Looks Compelling,InvestorPlace,/news/stocks/pltr-stocks-long-term-bull-case-looks-highly-compelling-at-this-stage-1031114134,neutral,0.5158545970916748
1/20/2022 2:28:42 PM,"The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-covid-shot-authorized-in-australia-zymeworks-restructures-orphan-drug-designation-for-marker-s-pancreatic-cancer-drug-1031116000,neutral,0.6560553312301636
1/20/2022 2:50:50 PM,Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag,Benzinga,/news/stocks/casi-pharma-partnered-bioinvent-s-lead-cancer-program-gets-fda-orphan-drug-tag-1031116088,positive,0.5163777470588684
1/20/2022 8:45:40 PM,Agreement allows 27 generic manufacturers to produce Merck COVID pill molnupiravir,Seeking Alpha,https://seekingalpha.com/news/3790007-agreement-allows-27-generic-manufacturers-to-produce-merck-covid-pill-molnupiravir?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8272676467895508
1/24/2022 11:57:19 AM,Merck candidate for chronic cough rejected by FDA,Seeking Alpha,https://seekingalpha.com/news/3790563-merck-candidate-for-chronic-cough-rejected-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8300708532333374
1/24/2022 1:42:36 PM,FDA Refuses To Approve Merck's 'gefapixant' To Treat Chronic Cough ,RTTNews,/news/stocks/fda-refuses-to-approve-merck-s-gefapixant-to-treat-chronic-cough-1031122391,negative,0.8607907295227051
1/25/2022 6:40:59 PM,Merck declares $0.69 dividend,Seeking Alpha,https://seekingalpha.com/news/3791438-merck-and-co-inc-declares-0_69-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9274508357048035
1/25/2022 8:31:54 PM,Merck’s setback for cough candidate bodes well for BELLUS - H.C. Wainwright,Seeking Alpha,https://seekingalpha.com/news/3791469-mercks-setback-for-cough-candidate-bodes-well-for-bellus-hc-wainwright?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9262582659721375
1/26/2022 1:25:03 PM,Is Merck's new COVID-19 pill enough to make the stock a buy?,Seeking Alpha,https://seekingalpha.com/news/3791605-does-mercks-new-covid-19-pill-make-the-stock-a-buy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6720960140228271
1/26/2022 9:24:15 PM,Cue reports two objective responses in CUE-101 combo for head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/3792109-cue-reports-two-objective-responses-in-cue-101-combo-for-head-and-neck-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8999546766281128
1/27/2022 12:03:26 PM,Merck’s Keytruda is cleared in Europe as adjuvant therapy in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3792321-mercks-keytruda-is-cleared-in-europe-as-adjuvant-therapy-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4960154891014099
1/27/2022 12:53:31 PM,Cue Pharma Posts Two Responses From CUE-101 Combo In Head & Neck Cancer,Benzinga,/news/stocks/cue-pharma-posts-two-responses-from-cue-101-combo-in-head-neck-cancer-1031134883,neutral,0.9104536175727844
1/27/2022 1:57:50 PM,"The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study",Benzinga,/news/stocks/the-daily-biotech-pulse-galapagos-appoints-j-j-exec-as-ceo-aridis-gets-funding-for-antiviral-treatment-moderna-starts-omicron-specific-booster-study-1031135162,neutral,0.7180495262145996
1/27/2022 2:11:41 PM,EU Approves Merck's KEYTRUDA As Adjuvant Therapy For Renal Cell Carcinoma ,RTTNews,/news/stocks/eu-approves-merck-s-keytruda-as-adjuvant-therapy-for-renal-cell-carcinoma-1031135295,positive,0.8805343508720398
1/27/2022 3:15:48 PM,EMA advisors recommend conditional approval of Pfizer COVID antiviral pill Paxlovid,Seeking Alpha,https://seekingalpha.com/news/3792541-ema-advisors-recommend-conditional-approval-of-pfizer-covid-antiviral-pill-paxlovid?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.526138424873352
1/27/2022 3:52:46 PM,Research indicates Merck cancer drug Keytruda may also treat HIV,Seeking Alpha,https://seekingalpha.com/news/3792566-research-indicates-merck-cancer-drug-keytruda-may-also-treat-hiv?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5112877488136292
1/27/2022 6:57:41 PM,Say Hello to 2022’s Dogs of the Dow: 10 Dividend Stocks to Watch,InvestorPlace,/news/stocks/say-hello-to-2022s-dogs-of-the-dow-10-dividend-stocks-to-watch-1031136826,neutral,0.9087088108062744
1/28/2022 12:03:37 PM,Merck and Ridgeback say COVID-19 pill effective against Omicron,Seeking Alpha,https://seekingalpha.com/news/3792953-merck-ridgeback-say-covid-19-pill-effective-against-omicron?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9083355665206909
1/28/2022 2:04:31 PM,Merck target price cut at JPMorgan to $95 ahead of Q4 2021 results,Seeking Alpha,https://seekingalpha.com/news/3793055-merck-target-price-cut-at-jpmorgan-to-95-ahead-of-q4-2021-results?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5269191265106201
1/28/2022 2:21:16 PM,"The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-liquidates-out-of-biosimilar-jv-provention-bio-plots-diabetes-drug-resubmission-merck-finds-covid-pill-effective-against-omicron-1031139273,positive,0.8550984263420105
1/28/2022 2:57:50 PM,Merck: Molnupiravir Shows Consistent Antiviral Activity Against Omicron In Multiple In Vitro Studies ,RTTNews,/news/stocks/merck-molnupiravir-shows-consistent-antiviral-activity-against-omicron-in-multiple-in-vitro-studies-1031139434,positive,0.9489207863807678
1/28/2022 3:39:39 PM,EC formally authorizes Pfizer's COVID antiviral pill Paxlovid,Seeking Alpha,https://seekingalpha.com/news/3793130-ec-formally-authorizes-pfizer-coivid-antiviral-pill-paxlovid?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9004026055335999
1/28/2022 6:15:32 PM,7 Technology Stocks Reporting Earnings the Week of January 31,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-1028709625,neutral,0.5936208367347717
1/28/2022 8:02:06 PM,Analyst Ratings For Merck & Co,Benzinga,/news/stocks/analyst-ratings-for-merck-co-1031140205,neutral,0.9076553583145142
1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7369604110717773
1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,neutral,0.9110234379768372
1/31/2022 2:21:45 PM,Shionogi reports Phase 2 data for oral antiviral candidate for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3793517-shionogi-reports-phase-2-data-for-oral-antiviral-candidate-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5301706790924072
1/31/2022 4:47:57 PM,Will Gilead Sciences Q4 results bring positive earnings surprise?,Seeking Alpha,https://seekingalpha.com/news/3793596-will-gilead-sciences-q4-results-bring-positive-earnings-surprise?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7144703269004822
1/31/2022 5:41:18 PM,Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19,Benzinga,/news/stocks/veru-s-cancer-candidate-sabizabulin-gets-fda-fast-track-tag-for-covid-19-1031145166,positive,0.882138729095459
2/1/2022 5:19:32 PM,Can Thermo Fisher Scientific maintain EPS beat run in Q4?,Seeking Alpha,https://seekingalpha.com/news/3794246-can-thermo-fisher-scientific-maintain-eps-beat-run-in-q4?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7476558089256287
2/1/2022 8:03:51 PM,"Sellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancer",Seeking Alpha,https://seekingalpha.com/news/3794448-sellas-merck-complete-enrollment-in-gps-keytruda-combo-phase-12-trial-in-ovarian-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.782844603061676
2/2/2022 2:35:33 PM,Will Merck beat Q4 forecast amid COVID-19 pill buzz?,Seeking Alpha,https://seekingalpha.com/news/3794881-will-merck-beat-q4-forecast-amid-covid-19-pill-buzz?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7265467047691345
2/2/2022 3:01:13 PM,Here's what to expect from Merck's earnings report,Markets Insider Automation,/news/stocks/merck_co-stock-q4-earnings-preview-1031154139,neutral,0.9296486377716064
2/2/2022 3:47:17 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3794923-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8825733065605164
2/2/2022 4:17:23 PM,PDS Biotech to further advance mid-stage trial for head and neck cancer after early win,Seeking Alpha,https://seekingalpha.com/news/3794954-pds-biotech-to-further-advance-mid-stage-trial-for-head-and-neck-cancer-after-early-win?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8987047672271729
2/2/2022 9:13:21 PM,"Avoid Novavax for Now, Until the Picture Clears Up",InvestorPlace,/news/stocks/avoid-novavax-for-now-until-the-picture-clears-up-1031155602,neutral,0.8661519289016724
2/3/2022 11:31:30 AM,"Merck Non-GAAP EPS of $1.80 beats by $0.28, revenue of $13.52B beats by $380M",Seeking Alpha,https://seekingalpha.com/news/3795363-merck-non-gaap-eps-of-1_80-beats-0_28-revenue-of-13_52b-beats-380m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5759330987930298
2/3/2022 12:44:26 PM,Merck tops Q4 forecast; sees COVID-19 pill sales of $5B-$6B in FY22,Seeking Alpha,https://seekingalpha.com/news/3795456-merck-tops-q4-forecast-sees-covid-19-pill-sales-of-5b-6b-in-fy22?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9441254138946533
2/3/2022 1:14:42 PM,Merck Q4 Profit Beats Estimates ,RTTNews,/news/stocks/merck-q4-profit-beats-estimates-1031158352,positive,0.8171327710151672
2/3/2022 2:13:03 PM,"The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation",Benzinga,/news/stocks/the-daily-biotech-pulse-big-pharma-earnings-prove-lackluster-mersana-inks-1b-adc-r-d-deal-syros-gets-orphan-drug-designation-1031158702,negative,0.9289477467536926
2/3/2022 4:18:25 PM,Mid-Morning Market Update: US Stocks Open Lower After Disappointing Earnings From Meta Platforms,Benzinga,/news/stocks/mid-morning-market-update-us-stocks-open-lower-after-disappointing-earnings-from-meta-platforms-1031159459,negative,0.9706791043281555
2/3/2022 6:07:58 PM,Mid-Day Market Update: Nasdaq Down 2%; Biophytis Shares Spike Higher,Benzinga,/news/stocks/mid-day-market-update-nasdaq-down-2-biophytis-shares-spike-higher-1031159857,negative,0.7619301676750183
2/3/2022 8:12:55 PM,"Carnival’s Outlook Has Greatly Improved, But CCL Stock Remains Very Risky",InvestorPlace,/news/stocks/carnivals-outlook-has-greatly-improved-but-ccl-stock-remains-very-risky-1031160170,positive,0.9564800262451172
2/4/2022 4:36:55 PM,5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-to-benefit-from-bidens-new-cancer-cabinet-1031163083,neutral,0.7185425758361816
2/7/2022 1:02:40 AM,Shionogi COVID-19 pill under consideration in Japan for use as early as this spring,Seeking Alpha,https://seekingalpha.com/news/3796317-shionogi-covid-19-pill-under-consideration-in-japan-for-use-as-early-as-this-spring?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8678749203681946
2/7/2022 4:06:56 PM,NGM Bio Shares Rise After Vision Disorder Candidate Receives FDA Fast Track Tag,Benzinga,/news/stocks/ngm-bio-shares-rise-after-vision-disorder-candidate-receives-fda-fast-track-tag-1031167614,positive,0.9187909960746765
2/8/2022 12:44:57 PM,"Merck, Ridgeback supply ~3.1M COVID-19 oral drug molnupiravir to US government",Seeking Alpha,https://seekingalpha.com/news/3797119-merck-ridgeback-supply-31m-covid-19-oral-drug-molnupiravir-to-us-government?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5385559797286987
2/9/2022 5:41:44 PM,Will AstraZeneca's Q4 earnings bring positive surprise?,Seeking Alpha,https://seekingalpha.com/news/3797953-will-astrazenecas-q4-earnings-bring-positive-surprise?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5716301202774048
2/10/2022 2:29:52 PM,"The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-q4-gets-covid-boost-seagen-plunges-on-earnings-adcom-test-awaits-lilly-1031182008,negative,0.7779287695884705
2/11/2022 7:36:40 PM,Palantir Technologies Stock Is Poised for a Strong Comeback,InvestorPlace,/news/stocks/palantir-technologies-pltr-stock-poised-for-comeback-1031187448,positive,0.9212906956672668
2/14/2022 9:35:53 PM,"Buffett's Berkshire Hathaway adds Activision Blizzard stake, exists Teva",Seeking Alpha,https://seekingalpha.com/news/3799802-buffetts-berkshire-hathaway-adds-activision-blizzard-stake-exists-teva?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9212615489959717
2/15/2022 8:46:44 AM,AstraZeneca: Lynparza Plus Abiraterone In Phase III Trial Show Positive Results In MCRPC Patients ,RTTNews,/news/stocks/astrazeneca-lynparza-plus-abiraterone-in-phase-iii-trial-show-positive-results-in-mcrpc-patients-1031194399,positive,0.9514239430427551
2/15/2022 1:48:40 PM,BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer,Benzinga,/news/stocks/bioxcel-bxcl701-combo-therapy-shows-encouraging-response-rates-in-prostate-cancer-1031195345,positive,0.9478518962860107
2/15/2022 4:41:51 PM,Pfizer wins European approval for next-gen pneumococcal vaccine,Seeking Alpha,https://seekingalpha.com/news/3800215-pfizer-stock-lower-despite-eu-approval-for-pneumococcal-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9215337038040161
2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8565000891685486
2/15/2022 6:46:54 PM,ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting,Benzinga,/news/stocks/immunitybio-s-ankitva-shows-100-survival-at-two-years-in-bladder-cancer-setting-1031196981,positive,0.8643351793289185
2/15/2022 7:13:39 PM,Robert Califf confirmed as next FDA commissioner by narrow margin,Seeking Alpha,https://seekingalpha.com/news/3800313-robert-califf-confirmed-as-next-fda-commissioner-by-narrow-margin?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.876629114151001
2/16/2022 1:55:20 PM,Organon acquires rights for oral contraceptive pills in China from Bayer,Seeking Alpha,https://seekingalpha.com/news/3800698-organon-acquires-oral-contraceptive-pills-in-china-from-bayer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.686775267124176
2/16/2022 8:26:14 PM,7 Value Stocks Primed to Take Off in a Rising Rate Environment,InvestorPlace,/news/stocks/7-value-stocks-primed-to-take-off-in-a-rising-rate-environment-1031202125,positive,0.7397916913032532
2/17/2022 12:49:09 PM,3 Dow Stocks To Avoid,InvestorPlace,/news/stocks/3-dow-stocks-to-avoid-1031204784,neutral,0.9327320456504822
2/20/2022 2:06:46 PM,"The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-20-26-reata-awaits-fda-decision-bausch-health-moderna-lead-earnings-news-flow-1031210514,neutral,0.9087624549865723
2/22/2022 11:00:51 AM,Is Moderna the Next Gilead or the Next Regeneron?,InvestorPlace,/news/stocks/mrna-stock-is-moderna-the-next-gilead-or-the-next-regeneron-1031215173,neutral,0.9160948395729065
2/24/2022 9:30:02 AM,AstraZeneca signs deal to supply Canada 100k doses of COVID antibody therapy Evusheld,Seeking Alpha,https://seekingalpha.com/news/3804839-astrazeneca-signs-deal-to-supply-canada-100k-doses-of-covid-antibody-therapy-evusheld?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8332064747810364
2/24/2022 7:10:16 PM,"PDS Biotech posts early safety data for PDS0101, Keytruda combo in head and neck cancer",Seeking Alpha,https://seekingalpha.com/news/3805343-pdsb-stock-gains-after-early-safety-data-for-pds0101-keytruda-combo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7522968649864197
2/25/2022 12:13:25 PM,Merck-Eisai's Keytruda/Lenvima combo gets approval in Japan for kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3805827-merck-eisais-keytrudalenvima-combo-gets-approval-in-japan-for-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9249873161315918
2/25/2022 4:46:48 PM,Healthcare leads a rally in S&P 500 amid hopes of Russia - Ukraine talks,Seeking Alpha,https://seekingalpha.com/news/3806014-healthcare-leads-a-rally-in-sp-500-amid-hopes-of-russia-ukraine-talks?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7153167128562927
2/28/2022 7:41:42 AM,Biotech Stocks Facing FDA Decision In March 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2022-1031236842,neutral,0.9167487025260925
2/28/2022 11:00:02 AM,7 Safe Defensive Stocks to Buy as Market Agitation Rises,InvestorPlace,/news/stocks/7-safe-defensive-stocks-to-buy-as-market-agitation-rises-1031237456,positive,0.5079342722892761
3/2/2022 11:58:33 AM,Sanofi in multi-billion-dollar deal with Adagene for immuno-oncology candidates,Seeking Alpha,https://seekingalpha.com/news/3808316-adag-stock-rises-after-multi-billion-dollar-deal-with-sanofi?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7549816370010376
3/2/2022 1:08:52 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1031247139,neutral,0.9465387463569641
3/2/2022 3:52:08 PM,Biden launching 'Test to Treat' initiative providing free COVID pills,Seeking Alpha,https://seekingalpha.com/news/3808490-biden-launching-test-to-treat-initiative-providing-free-covid-pills?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6540806293487549
3/3/2022 10:07:49 AM,WHO backs Merck/Ridgeback's pill molnupiravir for certain COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3808844-who-backs-merckridgebacks-pill-molnupiravir-for-certain-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7823694348335266
3/3/2022 10:56:57 AM,Pfizer to supply 10M courses of COVID drug Paxlovid to developing nations in 2022- Reuters,Seeking Alpha,https://seekingalpha.com/news/3808852-pfizer-to-supply-10m-courses-of-covid-drug-paxlovid-to-developing-nations-in-2022-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5848161578178406
3/3/2022 3:57:17 PM,U.S. to share government-backed COVID-19 tech with WHO - Washington Post,Seeking Alpha,https://seekingalpha.com/news/3809199-us-to-share-government-backed-covid-19-tech-with-who-washington-post?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.697287917137146
3/4/2022 2:51:18 AM,"Genome, Merck To Evaluate GEN-001 - KEYTRUDA Combination In Phase 2 Trial In Biliary Tract Cancer ",RTTNews,/news/stocks/genome-merck-to-evaluate-gen-001-keytruda-combination-in-phase-2-trial-in-biliary-tract-cancer-1031253328,positive,0.5656814575195312
3/4/2022 1:38:12 PM,"The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan",Benzinga,/news/stocks/the-daily-biotech-pulse-ocugen-faces-regulatory-setback-vtv-ceo-quits-biogen-eisai-make-headway-with-second-alzheimer-s-antibody-treatment-in-japan-1031255069,negative,0.8938955068588257
3/4/2022 1:48:11 PM,Humanigen gains as CEO more than doubles stake,Seeking Alpha,https://seekingalpha.com/news/3809582-hgen-stock-gains-as-ceo-more-than-doubles-stake?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8993645906448364
3/4/2022 4:00:47 PM,Atreca spikes as H.C. Wainwright welcomes updated data for cancer drug,Seeking Alpha,https://seekingalpha.com/news/3809653-atreca-spikes-as-hc-wainwright-welcomes-updated-cancer-drug-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6179184913635254
3/7/2022 12:02:01 PM,Merck says late-stage melanoma trial for Keytruda met main secondary goal,Seeking Alpha,https://seekingalpha.com/news/3810089-merck-says-late-stage-melanoma-trial-for-keytruda-met-main-secondary-goal?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8919989466667175
3/10/2022 12:35:12 PM,7 Drug Stocks to Consider After the Viatris Plunge,InvestorPlace,/news/stocks/7-drug-stocks-to-consider-after-the-viatris-plunge-abbv-bmy-gsk-vtrs-jnj-teva-pfe-nvs-mrk-1031269941,neutral,0.926745593547821
3/11/2022 10:08:58 AM,Pfizer's COVID-19 drug Paxlovid gets emergency use nod in The Philippines - Reuters,Seeking Alpha,https://seekingalpha.com/news/3812593-pfizers-covid-19-drug-paxlovid-gets-emergency-use-nod-in-the-philippines-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5625605583190918
3/11/2022 11:42:19 PM,AstraZeneca and Merck's Lynparza gets FDA nod for early breast cancer,Seeking Alpha,https://seekingalpha.com/news/3812883-astrazeneca-and-merck-lynparza-gets-fda-nod-for-early-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6890285611152649
3/12/2022 7:20:14 PM,Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict,Seeking Alpha,https://seekingalpha.com/news/3812903-drugmakers-face-clinical-trial-disruptions-amid-russia-ukraine-conflict?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9664651155471802
3/12/2022 9:00:00 PM,"Pharma companies still supplying medicines to Russia, but some impact being felt",Seeking Alpha,https://seekingalpha.com/news/3812889-large-pharmaceutical-companies-still-supplying-medicines-to-russia-some-impact-felt?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7648188471794128
3/13/2022 10:37:36 PM,"The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-13-19-bristol-myers-squibb-s-melanoma-drug-decision-multiple-conference-presentations-and-earnings-dominate-proceedings-1031275983,negative,0.702629566192627
3/15/2022 5:09:28 AM,"Imugene, Merck To Evaluate HER-Vaxx - KEYTRUDA Combination In Phase 2 Trial For Gastric Cancer ",RTTNews,/news/stocks/imugene-merck-to-evaluate-her-vaxx-keytruda-combination-in-phase-2-trial-for-gastric-cancer-1031279404,positive,0.7925119996070862
3/15/2022 11:51:29 AM,Merck halts late-stage prostate cancer trial for Keytruda combo,Seeking Alpha,https://seekingalpha.com/news/3813523-merck-halts-late-stage-prostate-cancer-trial-for-keytruda-combo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8725014925003052
3/15/2022 12:32:46 PM,Merck Stoping Phase 3 KEYLYNK-010 Trial Investigating KEYTRUDA In Combination With LYNPARZA ,RTTNews,/news/stocks/merck-stoping-phase-3-keylynk-010-trial-investigating-keytruda-in-combination-with-lynparza-1031280819,neutral,0.5435605645179749
3/15/2022 12:46:20 PM,"The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-eisai-amend-aduhelm-agreement-anaptys-acne-drug-flunks-midstage-study-merck-astrazeneca-discontinue-prostate-cancer-trial-1031280887,neutral,0.9103145003318787
3/15/2022 7:23:25 PM,Amarin recovers amid positive views from Piper Sandler on European strategy,Seeking Alpha,https://seekingalpha.com/news/3813782-amrn-stock-gains-with-positive-views-from-piper-sandler?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9408310651779175
3/16/2022 1:02:21 PM,"The Daily Biotech Pulse:  Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-apply-for-authorization-of-3rd-booster-shot-sanofi-seagen-strike-cancer-therapy-pact-iovance-gets-nod-for-cancer-study-1031284787,positive,0.5291966795921326
3/16/2022 9:00:05 PM,AstraZeneca and Merck's Lynparza shows survival benefit in early breast cancer,Seeking Alpha,https://seekingalpha.com/news/3814343-astrazeneca-and-merck-lynparza-shows-survival-benefit-in-early-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9326819777488708
3/18/2022 8:55:51 AM,Merck Keytruda's add on use in early-stage lung cancer cuts death risk by 24% in study,Seeking Alpha,https://seekingalpha.com/news/3814881-mercks-keytruda-add-on-use-in-early-stage-lung-cancer-cuts-death-risk-by-24-in-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9416226148605347
3/18/2022 12:50:39 PM,"The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-files-for-2nd-covid-booster-shot-authorization-lexicon-secures-debt-funding-amneal-gets-sub-license-to-manufacture-generic-covid-pill-1031291535,positive,0.6417161226272583
3/18/2022 3:18:52 PM,Ivermectin had no clinical benefit against COVID-19 in largest study to date - WSJ,Seeking Alpha,https://seekingalpha.com/news/3815030-ivermectin-had-no-clinical-benefit-against-covid-19-in-largest-study-so-far?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8688141107559204
3/21/2022 8:45:08 PM,Merck announces FDA approval of Keytruda for second indication in endometrial cancer,Seeking Alpha,https://seekingalpha.com/news/3815775-merck-says-fda-approved-keytruda-for-second-indication-in-endometrial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8017914295196533
3/22/2022 1:31:50 PM,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-keytruda-snags-another-fda-approval-pfizer-strikes-covid-19-pill-supply-deal-argenx-reports-positive-late-stage-readout-1031298122,positive,0.8023924827575684
3/23/2022 8:37:15 AM,"Merck, Ridgeback's COVID-19 oral pill gets emergency use nod in South Korea - Yonhap",Seeking Alpha,https://seekingalpha.com/news/3816306-merck-ridgebacks-covid-19-oral-pill-gets-emergency-use-nod-in-south-korea-yonhap?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7063933610916138
3/23/2022 11:41:13 AM,4D pharma stock soars 56% as drug combo meets efficacy goal early in kidney cancer group,Seeking Alpha,https://seekingalpha.com/news/3816365-4d-pharma-stock-soars-53-as-drug-combo-meets-efficacy-goal-early-in-kidney-cancer-group?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9429803490638733
3/23/2022 12:43:16 PM,"The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-positive-ulcerative-colitis-study-data-novavax-covid-shot-authorized-for-adolescents-in-india-argenx-stock-sale-1031301077,neutral,0.5290573239326477
3/24/2022 1:10:16 PM,"The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-prostate-cancer-drug-lands-fda-approval-ligand-announces-spac-deal-to-spin-off-antibody-business-lilly-s-lung-cancer-therapy-hit-with-crl-1031304689,neutral,0.8169834613800049
3/25/2022 12:19:39 PM,Bristol Myers Squibb: FDA Extends PDUFA Goal Date For Reblozy By Three Months For Full Review ,RTTNews,/news/stocks/bristol-myers-squibb-fda-extends-pdufa-goal-date-for-reblozy-by-three-months-for-full-review-1031307751,positive,0.49015477299690247
3/25/2022 12:50:02 PM,"The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-mei-pharma-wilts-on-adverse-regulatory-development-decision-day-for-zogenix-an2-therapeutics-ipo-1031307839,negative,0.8759180903434753
3/25/2022 1:49:32 PM,Merck's Keytruda gets EMA panel nod for expanded use in certain tumors in 5 cancers,Seeking Alpha,https://seekingalpha.com/news/3817481-mercks-keytruda-gets-ema-panel-nod-for-expanded-use-in-certain-tumors-in-5-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7868430614471436
3/27/2022 10:40:40 PM,"The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck  Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-for-amylyx-biontech-earnings-and-more-1031310198,neutral,0.9233649373054504
3/28/2022 7:31:43 AM,Biotech Stocks Facing FDA Decision In April 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2022-1031310826,neutral,0.9148067831993103
3/29/2022 8:47:27 AM,"US agency pauses distribution of GSK, Vir's COVID-19 therapy sotrovimab in certain states",Seeking Alpha,https://seekingalpha.com/news/3818262-us-agency-pauses-distribution-of-gsk-virs-covid-19-antibody-therapy-in-certain-states?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8007267713546753
3/31/2022 6:14:41 PM,Merck cuts staff at Acceleron after completing the acquisition,Seeking Alpha,https://seekingalpha.com/news/3819484-merck-cuts-staff-at-acceleron-after-completing-the-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9528143405914307
3/31/2022 11:49:14 PM,3 Cash Cow Stocks to Buy for Stable Returns,InvestorPlace,/news/stocks/3-cash-cow-stocks-to-buy-for-stable-returns-1031324305,neutral,0.810230016708374
4/1/2022 10:37:35 AM,World's 1st COVID human challenge trial suggests spread of virus not correlated to symptoms,Seeking Alpha,https://seekingalpha.com/news/3819725-worlds-1st-covid-human-challenge-trial-suggests-spread-of-virus-not-correlated-to-symptoms?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8839459419250488
4/1/2022 11:22:52 AM,Merck/ Ridgeback say COVID-19 pill cleared virus faster in infected people,Seeking Alpha,https://seekingalpha.com/news/3819748-merck-ridgeback-say-covid-19-pill-cleared-virus-faster-in-infected-people?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5374522805213928
4/1/2022 11:46:33 AM,Merck says  FDA extended review period for pediatric pneumococcal vaccine,Seeking Alpha,https://seekingalpha.com/news/3819774-merck-says-fda-extended-review-period-for-pediatric-pneumococcal-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.447946697473526
4/1/2022 1:13:42 PM,Merck: FDA Extends PDUFA Date Of SBLA For VAXNEUVANCE - Quick Facts ,RTTNews,/news/stocks/merck-fda-extends-pdufa-date-of-sbla-for-vaxneuvance-quick-facts-1031326092,neutral,0.7024631500244141
4/1/2022 1:41:08 PM,"Merck, Ridgeback: COVID Antiviral LAGEVRIO Clears Infectious SARS-CoV-2 Faster Than Placebo ",RTTNews,/news/stocks/merck-ridgeback-covid-antiviral-lagevrio-clears-infectious-sars-cov-2-faster-than-placebo-1031326170,positive,0.8607032299041748
4/1/2022 3:08:28 PM,"The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study",Benzinga,/news/stocks/the-daily-biotech-pulse-sella-in-licenses-oncology-asset-merck-s-pneumococcal-vaccine-review-extended-arc-biopharma-covid-drug-flunks-mid-stage-study-1031326502,neutral,0.8199916481971741
4/1/2022 6:06:44 PM,NGM Biopharma rebounds on dosing initiation of cancer trial,Seeking Alpha,https://seekingalpha.com/news/3820076-ngm-stock-rebounds-on-dosing-initiation-of-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.648762583732605
4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374,neutral,0.9468021392822266
4/4/2022 11:22:22 AM,Merck expands Virginia manufacturing facility to bolster supply of HPV vaccine,Seeking Alpha,https://seekingalpha.com/news/3820270-merck-expands-virginia-manufacturing-facility-to-bolster-supply-of-hpv-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.944269061088562
4/4/2022 9:00:38 PM,Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated),Seeking Alpha,https://seekingalpha.com/news/3820489-lawmakers-set-to-announce-10-billion-additional-funding-for-us-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6900182366371155
4/5/2022 11:12:16 AM,Merck to target $10 billion peak revenue opportunity from cardiovascular portfolio,Seeking Alpha,https://seekingalpha.com/news/3820667-merck-to-target-10-billion-peak-revenue-from-cardiovascular-portfolio?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8471671938896179
4/5/2022 4:24:27 PM,Global group calls for $15 billion this year for long term COVID response,Seeking Alpha,https://seekingalpha.com/news/3820854-global-group-call-for-15-billion-this-year-for-long-term-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5450633764266968
4/5/2022 9:37:56 PM,MindMed Appoints Francois Lilienthal As New CCO,Benzinga,/news/stocks/mindmed-appoints-francois-lilienthal-as-new-cco-1031334555,neutral,0.931117832660675
4/6/2022 1:58:22 PM,Don’t Bet on New Highs for Novavax Stock,InvestorPlace,/news/stocks/dont-bet-on-new-highs-for-nvax-stock-1031337059,neutral,0.8862025141716003
4/6/2022 2:02:15 PM,"The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy",Benzinga,/news/stocks/the-daily-biotech-pulse-bioxcel-s-igalmi-gets-fda-nod-citius-spikes-on-positive-phase-3-data-iovance-receives-positive-regulatory-feedback-for-skin-cancer-therapy-1031336312,positive,0.939556896686554
4/6/2022 9:06:43 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1031337906,neutral,0.9218418598175049
4/7/2022 7:38:30 PM,Life sciences companies drive healthcare stocks to lead S&P 500,Seeking Alpha,https://seekingalpha.com/news/3821820-life-sciences-companies-drive-healthcare-stocks-to-lead-sp-500?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8493631482124329
4/8/2022 10:57:31 AM,Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks,InvestorPlace,/news/stocks/layoffs-at-blue-stock-highlight-the-current-struggles-of-biotech-picks-1031342692,negative,0.9662711024284363
4/10/2022 10:42:49 PM,"The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-10-april-16-regeneron-fda-decision-cancer-conference-presentations-and-more-1031344759,neutral,0.9415993690490723
4/11/2022 2:16:00 PM,Merck: GARDASIL 9 Approved In Canada To Prevent Oropharyngeal And Other Head And Neck Cancers ,RTTNews,/news/stocks/merck-gardasil-9-approved-in-canada-to-prevent-oropharyngeal-and-other-head-and-neck-cancers-1031346328,positive,0.7567746639251709
4/11/2022 7:09:34 PM,Rubius price targets slashed on underwhelming cancer data,Seeking Alpha,https://seekingalpha.com/news/3822444-rubius-price-targets-slashed-on-underwhelming-cancer-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9409723877906799
4/12/2022 2:16:40 PM,IO Biotech begins mid-stage trial of NSCLC candidate IO102-IO103,Seeking Alpha,https://seekingalpha.com/news/3822699-io-biotech-begins-mid-stage-trial-of-nsclc-candidate-io102-io103?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.595583438873291
4/14/2022 11:05:15 AM,Merck's pneumococcal vaccine V116 gets FDA breakthrough therapy designation,Seeking Alpha,https://seekingalpha.com/news/3823344-merck-pneumococcal-vaccine-v116-gets-fda-breakthrough-therapy-designation?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8646969199180603
4/14/2022 3:05:20 PM,Merck's 21-valent Pneumococcal Conjugate Vaccine Gets FDA Breakthrough Therapy Designation ,RTTNews,/news/stocks/merck-s-21-valent-pneumococcal-conjugate-vaccine-gets-fda-breakthrough-therapy-designation-1031356919,positive,0.8790255784988403
4/15/2022 11:33:29 AM,3 Healthcare Stocks That Are Looking Even Healthier,InvestorPlace,/news/stocks/3-healthcare-stocks-that-are-looking-even-healthier-1031358670,positive,0.7373132705688477
4/17/2022 4:00:26 PM,Pfizer draws skeptics amid concerns over outlook for COVID-related sales,Seeking Alpha,https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9677929878234863
4/18/2022 1:48:38 PM,Merck's Keytruda Scores Another Regulatory Nod In Canada ,RTTNews,/news/stocks/merck-s-keytruda-scores-another-regulatory-nod-in-canada-1031360806,positive,0.8422470688819885
4/22/2022 2:42:08 PM,EMA panel recommends extending indication for Merck's cancer therapy Keytruda,Seeking Alpha,https://seekingalpha.com/news/3825815-ema-panel-recommends-extending-indication-for-mercks-cancer-therapy-keytruda?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7931495308876038
4/22/2022 7:34:58 PM,Pfizer to add nearly $24 billion revenue with COVID-19 pill in 2022- Airfinity,Seeking Alpha,https://seekingalpha.com/news/3825925-pfizer-set-to-add-nearly-24-billion-revenue-with-covid-19-pill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8170008659362793
4/25/2022 7:48:12 PM,Pfizer and Gilead earn preferred status for COVID-19 antivirals in new CDC advisory,Seeking Alpha,https://seekingalpha.com/news/3826382-pfe-gild-stocks-up-on-preferred-status-for-covid-19-antivirals-in-cdc-advisory?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7187273502349854
4/26/2022 11:36:17 AM,7 Retirement Stocks to Buy to Sleep Soundly at Night,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-to-sleep-soundly-at-night-kmb-lmt-mrk-abbv-dlr-gis-pg-1031384356,neutral,0.8780571818351746
4/27/2022 3:01:13 PM,Merck earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/merck_co-q1-quarterly-earnings-preview-stock-1031391106,neutral,0.914770245552063
4/27/2022 3:25:48 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3827680-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8825733065605164
4/27/2022 3:26:58 PM,Merck Q1 result a litmus test for COVID-19 pill demand,Seeking Alpha,https://seekingalpha.com/news/3827681-merck-q1-result-a-litmus-test-for-covid-19-pill-demand?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8804663419723511
4/27/2022 3:52:54 PM,Organon wins Buy rating at Goldman Sachs on undervalued Women's Health unit,Seeking Alpha,https://seekingalpha.com/news/3827692-ogn-stock-gains-on-buy-rating-at-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.908699631690979
4/27/2022 5:42:36 PM,Veru leads Cantor’s biopharma stocks with largest increases in short interest,Seeking Alpha,https://seekingalpha.com/news/3827854-veru-stock-leads-biopharma-stocks-with-largest-increases-in-short-interest?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.849178671836853
4/28/2022 10:31:44 AM,"Merck Non-GAAP EPS of $2.14 beats by $0.31, revenue of $15.9B beats by $1.26B",Seeking Alpha,https://seekingalpha.com/news/3828369-merck-non-gaap-eps-of-2_14-beats-0_31-revenue-of-15_9b-beats-1_26b?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7471906542778015
4/28/2022 11:31:15 AM,Merck 1Q revenue jumps 50% as COVID pill generates over $3 billion sales,Seeking Alpha,https://seekingalpha.com/news/3828472-mrk-stock-higher-as-1q-revenue-jumps-50?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9442337155342102
4/28/2022 1:08:34 PM,"Merck Raises, Narrows Full-year Guidance ",RTTNews,/news/stocks/merck-raises-narrows-full-year-guidance-1031396688,neutral,0.5010764002799988
4/28/2022 2:52:43 PM,"The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-seeks-fda-approval-for-covid-19-shot-for-children-2-6-tax-disclosure-for-amgen-fast-track-tags-for-sqz-biotech-timber-pharma-candidates-1031397312,neutral,0.7427427768707275
4/29/2022 11:09:54 AM,Merck wins European approval to market Keytruda for more cancer indications,Seeking Alpha,https://seekingalpha.com/news/3829276-merck-wins-european-approval-to-market-keytruda-for-more-cancer-indications?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8776513338088989
4/29/2022 3:00:32 PM,"The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approves-bristol-myers-oral-heart-disease-drug-european-approval-for-merck-s-keytruda-genocea-restructures-zymeworks-takeover-bid-1031402592,positive,0.6426587700843811
4/29/2022 3:23:05 PM,What 7 Analyst Ratings Have To Say About Merck & Co,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-merck-co-1031402681,neutral,0.9330793023109436
4/29/2022 7:42:55 PM,"Pfizer vaccine chief, who led COVID-19 vaccine research, to retire",Seeking Alpha,https://seekingalpha.com/news/3829635-pfe-stock-lower-as-vaccine-chief-plans-to-retire?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.937465488910675
5/2/2022 10:15:12 AM,7 Safe Stocks to Buy in May 2022,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-in-may-2022-1031407898,neutral,0.9226328134536743
5/2/2022 1:16:21 PM,Gilead to develop Dragonfly natural killer cell engager immunotherapy; $300M upfront,Seeking Alpha,https://seekingalpha.com/news/3829992-gilead-to-develop-dragonfly-natural-killer-cell-engager-immunotherapy-300m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7901163697242737
5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.786922812461853
5/5/2022 12:23:37 PM,Nabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in US,Seeking Alpha,https://seekingalpha.com/news/3833292-nabriva-extends-exclusive-contract-to-sell-mercks-antibacterial-drug-sivextro-in-us?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.90184086561203
5/5/2022 12:44:23 PM,Organon posts Q1 beat as topline growth returns thanks to established brands,Seeking Alpha,https://seekingalpha.com/news/3833318-ogn-stock-higher-after-q1-beat?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9524029493331909
5/6/2022 11:33:52 AM,7 Defensive Dividend Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/7-defensive-healthcare-stocks-to-buy-now-1031430769,neutral,0.8179723024368286
5/11/2022 4:49:10 PM,Merck gains after setback for Roche’s immunotherapy in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3837004-merck-gains-after-setback-for-roches-immunotherapy-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5672094225883484
5/12/2022 2:14:54 PM,Federal flags to fly at half-staff to mark one million COVID deaths,Seeking Alpha,https://seekingalpha.com/news/3837849-federal-flags-to-fly-at-half-staff-to-mark-one-million-covid-deaths?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9106363654136658
5/16/2022 10:00:57 AM,7 Retirement Stocks for Steady Long-Term Income Growth,InvestorPlace,/news/stocks/7-retirement-stocks-for-steady-long-term-income-growth-1031463769,positive,0.7566248774528503
5/16/2022 1:13:42 PM,Merck in pact to study Keytruda in combination with Athenex’s lead asset,Seeking Alpha,https://seekingalpha.com/news/3839163-merck-in-pact-to-study-keytruda-in-combination-with-athenexs-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5429674983024597
5/17/2022 4:42:38 PM,New York City reaches “high” COVID alert level; indoor masking urged,Seeking Alpha,https://seekingalpha.com/news/3840091-new-york-city-reaches-high-covid-alert-level-indoor-masking-urged?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6301854848861694
5/17/2022 8:16:19 PM,Pfizer COVID-19 antiviral use jumps over 300%: U.S. health department,Seeking Alpha,https://seekingalpha.com/news/3840191-pfizer-covid-19-antiviral-use-jumps-over-300-us-health-department?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8933601379394531
5/18/2022 2:59:43 PM,Merck in up to $1.4B licensing deal with China's Kelun Pharma for cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3840491-merck-in-up-to-14b-licensing-deal-with-chinas-kelun-pharma-for-cancer-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8680194020271301
5/19/2022 9:08:43 AM,"Bayer, Merck's Verquvo gets approval in China to treat certain patients with heart failure",Seeking Alpha,https://seekingalpha.com/news/3840751-bayer-mercks-verquvo-gets-approval-in-china-to-treat-certain-patients-with-heart-failure?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9364551305770874
5/19/2022 11:43:19 AM,7 Dividend Stocks to Boost Your Retirement Savings,InvestorPlace,/news/stocks/7-dividend-stocks-to-boost-your-retirement-savings-1031475396,positive,0.4952034652233124
5/20/2022 1:20:52 PM,Merck's blockbuster Keytruda gets EMA panel nod for expanded use in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3841354-mercks-blockbuster-keytruda-gets-ema-panel-nod-for-expanded-use-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8334783911705017
5/21/2022 11:31:40 AM,7 Retirement Stocks to Buy for Any Market Conditions,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-for-any-market-conditions-1031479718,neutral,0.9313405156135559
5/21/2022 3:00:44 PM,7 Quality Dividend Stocks to Buy on the Dip,InvestorPlace,/news/stocks/7-quality-dividend-stocks-to-buy-on-the-dip-1031479756,neutral,0.9070187211036682
5/23/2022 7:59:59 PM,"Liquidia slumps as United, MannKind get FDA nod for rival therapy",Seeking Alpha,https://seekingalpha.com/news/3841932-liquidia-slumps-as-united-mannkind-get-fda-nod-for-rival-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8940197825431824
5/24/2022 10:09:04 AM,7 Blue-Chip Stocks With Dividends to Buy Before June,InvestorPlace,/news/stocks/7-blue-chip-stocks-with-dividends-to-buy-before-june-1031484299,neutral,0.9371261596679688
5/24/2022 11:07:23 AM,Merck's blockbuster drug Keytruda gets approval in EU for expanded use in breast cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3842105-mercks-blockbuster-drug-keytruda-gets-approval-in-eu-for-expanded-use-in-breast-cancer-subtype?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9180591106414795
5/24/2022 1:29:05 PM,COVID-19 sales boom for vaccine and drug makers might be over - analysts,Seeking Alpha,https://seekingalpha.com/news/3842211-covid-19-sales-boom-for-vaccine-and-drug-makers-might-be-over?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.39463990926742554
5/24/2022 2:16:27 PM,EU Approves Merck's Keytruda Combination For Early-stage Triple-negative Breast Cancer ,RTTNews,/news/stocks/eu-approves-merck-s-keytruda-combination-for-early-stage-triple-negative-breast-cancer-1031484846,positive,0.8998118042945862
5/24/2022 2:24:47 PM,"The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-inmune-bio-s-planned-alzheimer-s-trial-on-fda-hold-caladrius-stops-enrollment-in-heart-disease-study-biomx-restructures-1031484881,negative,0.7328180074691772
5/24/2022 5:50:02 PM,Merck declares $0.69 dividend,Seeking Alpha,https://seekingalpha.com/news/3842345-merck-and-co-inc-declares-0_69-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9274508357048035
5/25/2022 11:24:42 AM,Oncotelic gets FDA nod for mid-stage trial design for lead asset and Keytruda combo,Seeking Alpha,https://seekingalpha.com/news/3842546-otlc-stock-on-watch-after-fda-nod-for-mid-stage-trial-design-for-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8371690511703491
5/26/2022 1:28:33 PM,Sellas announces topline data for lead asset in Ovarian cancer,Seeking Alpha,https://seekingalpha.com/news/3843106-sls-stock-gains-on-topline-data-for-lead-asset-in-ovarian-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5019059181213379
5/26/2022 2:41:14 PM,"GCOW, the dividend ETF that's +10% in 2022 while the broader markets plunge",Seeking Alpha,https://seekingalpha.com/news/3843134-gcow-the-dividend-etf-thats-10-on-the-year-is-getting-noticed?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8514460921287537
5/26/2022 2:45:54 PM,"The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review",Benzinga,/news/stocks/the-daily-biotech-pulse-setback-for-nrx-pharma-s-covid-study-fast-track-tag-for-pfizer-s-nash-combo-therapy-reata-s-ataxia-drug-in-fda-review-1031490976,positive,0.6595115065574646
5/28/2022 4:22:39 PM,BioPharma M&A premiums could moderate amid rate hikes – Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3843664-biopharma-ma-premiums-could-moderate-amid-rate-hikes?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9036207795143127
5/31/2022 11:16:18 AM,Pfizer antiviral pill leads Merck’s as top at-home COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3843832-pfizer-antiviral-pill-leads-mercks-as-top-at-home-covid-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7055022716522217
5/31/2022 3:03:43 PM,Fujifilm begins U.S. study of its drug candidate FF-10832 in combination with Keytruda,Seeking Alpha,https://seekingalpha.com/news/3844020-fujifilm-begins-us-study-of-its-drug-candidate-ff-10832-in-combination-with-keytruda?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6919559240341187
5/31/2022 3:19:30 PM,PDS Biotech gets UK drug regulator nod to start trial of PDS0101/Keytruda combo,Seeking Alpha,https://seekingalpha.com/news/3844025-pds-biotech-gets-uk-drug-regulator-nod-to-start-trial-of-pds0101keytruda-combo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5523250699043274
5/31/2022 5:14:59 PM,I-Mab draws mixed views at H.C. Wainwright after ASCO readout for lung cancer drug,Seeking Alpha,https://seekingalpha.com/news/3844070-imab-stock-price-target-lowered-at-hc-wainwright-after-asco-readout?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8767261505126953
5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9459705948829651
5/31/2022 9:42:54 PM,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates-1031499656,neutral,0.9482179284095764
6/1/2022 10:23:12 AM,7 Stocks to Buy and Hold Forever in This Bear Market,InvestorPlace,/news/stocks/7-stocks-to-buy-and-hold-forever-in-this-bear-market-1031501084,neutral,0.915076494216919
6/2/2022 12:17:14 PM,PDS Biotech wins FDA Fast Track status for head and neck cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3844937-pds-biotech-wins-fda-fast-track-status-for-head-and-neck-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9248473644256592
6/3/2022 10:45:01 AM,The 3 Best Long-Term Stocks to Add to Your Q2 Buy List,InvestorPlace,/news/stocks/the-3-best-long-term-stocks-to-add-to-your-q2-buy-list-gm-intc-mrk-1031508061,neutral,0.9141049981117249
6/3/2022 7:44:29 PM,Immutep posts Phase 2 data for lung cancer therapy to support late-stage studies,Seeking Alpha,https://seekingalpha.com/news/3845649-immutep-posts-data-for-lung-cancer-drug-to-back-late-stage-studies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8126582503318787
6/3/2022 9:11:37 PM,6 Biotech Stocks to Buy Now Ahead of These June Catalysts,InvestorPlace,/news/stocks/6-biotech-stocks-june-catalysts-1031509381,neutral,0.8837399482727051
6/5/2022 11:34:32 AM,7 Blue-Chip Stocks With Dividends to Add to Your Q2 Buy List,InvestorPlace,/news/stocks/7-blue-chip-stocks-with-dividends-to-add-to-your-q2-buy-list-1031509681,neutral,0.9124227166175842
6/6/2022 11:21:47 AM,Yumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26M,Seeking Alpha,https://seekingalpha.com/news/3845832-yumanity-stock-soars-46-on-all-stock-merger-with-kineta-lead-product-sale-to-jj-for-26m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7774589657783508
6/6/2022 4:54:09 PM,IMX score falls in May to 5.86,Seeking Alpha,https://seekingalpha.com/news/3846010-imx-score-falls-in-may?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9663779735565186
6/7/2022 11:24:10 AM,"Merck, Ridgeback say COVID-19 pill cut risk of hospitalizations by 34%",Seeking Alpha,https://seekingalpha.com/news/3846184-merck-ridgeback-say-covid-19-pill-cut-risk-of-hospitalizations?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.93352210521698
6/7/2022 5:03:19 PM,Fulcrum gains as Merck ends deal for lung disease candidates,Seeking Alpha,https://seekingalpha.com/news/3846398-fulc-stock-gains-as-merck-ends-deal-for-lung-disease-candidates?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.37413278222084045
6/9/2022 10:15:05 AM,7 of the Hottest ETFs to Buy Right Now,InvestorPlace,/news/stocks/7-of-the-hottest-etfs-to-buy-right-now-1031518693,neutral,0.8981585502624512
6/9/2022 6:26:10 PM,Wells Fargo highlights potential targets as biotech M&A accelerates,Seeking Alpha,https://seekingalpha.com/news/3847403-wells-fargo-highlights-potential-targets-as-biotech-ma-accelerates?utm_source=businessinsider&utm_medium=referral,positive,0.8801780343055725
6/10/2022 2:57:48 PM,7 Great ETFs to Buy Now for Momentum in Q2,InvestorPlace,/news/stocks/7-great-etfs-to-buy-now-for-momentum-in-q2-1031522477,positive,0.6736835837364197
6/10/2022 8:13:29 PM,FDA requires suicide warning on Organon’s male hair loss therapy,Seeking Alpha,https://seekingalpha.com/news/3847800-ogn-stock-on-watch-as-fda-requires-suicide-warning-on-anti-baldness-drug?utm_source=businessinsider&utm_medium=referral,negative,0.5358274579048157
6/10/2022 8:30:14 PM,One High-Quality Stock You Need to Buy Right Now,InvestorPlace,/news/stocks/one-high-quality-stock-you-need-to-buy-right-now-1031522988,neutral,0.9149664044380188
6/13/2022 11:45:58 AM,Teladoc Can’t Rely On Hype To Attract Investors,InvestorPlace,/news/stocks/teladoc-cant-rely-on-hype-to-attract-investors-tdoc-stock-1031524937,neutral,0.8871526122093201
6/13/2022 11:58:41 AM,Merck's Keytruda to get FDA review as adjuvant non-small cell lung cancer treatment,Seeking Alpha,https://seekingalpha.com/news/3847929-merck-keytruda-to-get-fda-review-as-adjuvant-non-small-cell-lung-cancer-treatment?utm_source=businessinsider&utm_medium=referral,positive,0.8600515127182007
6/13/2022 8:43:01 PM,HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications,Benzinga,/news/stocks/hc-wainwright-says-this-lymphoma-candidate-has-better-response-rates-than-approved-medications-1031526010,positive,0.9443436861038208
6/14/2022 1:57:38 PM,Wells Fargo unveils its recession stock portfolio,Seeking Alpha,https://seekingalpha.com/news/3848418-wells-fargo-unveils-its-recession-stock-portfolio?utm_source=businessinsider&utm_medium=referral,neutral,0.9255277514457703
6/15/2022 10:46:27 AM,7 Seriously Undervalued Dow Stocks to Buy Before Wall Street Catches On,InvestorPlace,/news/stocks/7-undervalued-dow-stocks-to-buy-as-wall-street-takes-summer-break-csco-cvx-gs-mmm-mrk-trv-wba-1031530142,negative,0.5886573791503906
6/15/2022 8:51:05 PM,Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock,Benzinga,/news/stocks/chardan-sees-over-200-upside-on-this-small-cap-cancer-focused-stock-1031531673,positive,0.8908907771110535
6/16/2022 10:15:17 AM,7 Retirement Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-for-a-bear-market-1031532764,neutral,0.9013557434082031
6/17/2022 10:30:16 AM,The 7 Smartest Dow Stocks to Buy if You Have $250 Right Now,InvestorPlace,/news/stocks/7-smartest-dow-stocks-to-buy-if-you-have-250-dollars-1031535124,neutral,0.9148288369178772
6/17/2022 6:07:31 PM,Biotech posts biggest intraday gain since 2020 as deal making heats up,Seeking Alpha,https://seekingalpha.com/news/3849687-biotech-outperforms-as-deal-making-heats-up?utm_source=businessinsider&utm_medium=referral,positive,0.9270321130752563
6/17/2022 6:48:31 PM,SGEN Stock Alert: Is Merck About to Buy Seagen?,InvestorPlace,/news/stocks/sgen-stock-alert-is-merck-about-to-buy-seagen-1031536228,neutral,0.9312665462493896
6/21/2022 11:04:30 AM,Merck posts Phase 1/2 data for 21-valent pneumococcal vaccine,Seeking Alpha,https://seekingalpha.com/news/3849960-merck-posts-phase-12-data-for-21-valent-pneumococcal-vaccine?utm_source=businessinsider&utm_medium=referral,neutral,0.8841607570648193
6/21/2022 2:01:08 PM,Merck Presents Positive Results From Phase 1/2 Study Of Pneumococcal Conjugate Vaccine ,RTTNews,/news/stocks/merck-presents-positive-results-from-phase-1-2-study-of-pneumococcal-conjugate-vaccine-1031539830,positive,0.9467649459838867
6/21/2022 6:30:03 PM,Seagen draws Street high target at Oppenheimer on M&A prospects,Seeking Alpha,https://seekingalpha.com/news/3850397-sgen-stock-draws-street-high-target-at-oppenheimer-on-ma-prospects?utm_source=businessinsider&utm_medium=referral,positive,0.5623254776000977
6/21/2022 7:25:06 PM,SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know,Benzinga,/news/stocks/svb-leerink-s-pro-forma-analysis-of-speculated-merck-seagen-deal---what-investors-need-to-know-1031541208,neutral,0.947458803653717
6/21/2022 11:38:14 PM,Recap of Tuesday's Biotech Catalysts - End of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031541740,neutral,0.9340888261795044
6/22/2022 10:46:21 AM,Illumina launches research only cancer genomic test co-developed with Merck,Seeking Alpha,https://seekingalpha.com/news/3850638-illumina-launches-research-only-cancer-genomic-test-co-developed-with-merck?utm_source=businessinsider&utm_medium=referral,neutral,0.7392309308052063
6/22/2022 12:15:20 PM,Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money,InvestorPlace,/news/stocks/economic-hurricane-ahead-7-profitable-places-to-hide-your-money-1031543188,neutral,0.8941921591758728
6/22/2022 1:41:29 PM,FDA Approves Merck's Vaxneuvance For Prevention Of Invasive Pneumococcal Disease In Children ,RTTNews,/news/stocks/fda-approves-merck-s-vaxneuvance-for-prevention-of-invasive-pneumococcal-disease-in-children-1031542903,positive,0.6923258304595947
6/23/2022 12:45:00 PM,Merck wins CDC backing for pneumococcal vaccine to include children,Seeking Alpha,https://seekingalpha.com/news/3850646-merck-wins-fda-approval-for-pneumococcal-vaccine-to-include-children?utm_source=businessinsider&utm_medium=referral,positive,0.8905802965164185
6/23/2022 4:31:42 PM,"The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise",Benzinga,/news/stocks/the-daily-biotech-pulse-f-star-therapeutics-buyout-orphan-drug-tag-for-vbi-s-brain-cancer-vaccine-xenon-s-epilepsy-candidate-shows-promise-1031546577,positive,0.842239499092102
6/23/2022 5:29:22 PM,6 Dividend Income Stocks With Better Yields Than the S&P 500,InvestorPlace,/news/stocks/6-dividend-income-stocks-with-better-yields-than-the-sp-500-1031547070,positive,0.9284015893936157
6/24/2022 10:51:48 AM,Shionogi faces delay in Japan for regulatory decision on COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3851452-shionogi-faces-delay-in-japan-for-regulatory-decision-on-covid-19-pill?utm_source=businessinsider&utm_medium=referral,negative,0.742828905582428
6/24/2022 1:27:39 PM,"Merck: EU Approves KEYTRUDA For Patients Above 12 Years In Stage IIB, IIC And III Melanoma ",RTTNews,/news/stocks/merck-eu-approves-keytruda-for-patients-above-12-years-in-stage-iib-iic-and-iii-melanoma-1031548477,positive,0.8054599165916443
6/24/2022 2:38:47 PM,"Merck - Seagen deal clouded by questions over regulatory risk, valuation - BMO",Seeking Alpha,https://seekingalpha.com/news/3851606-merck-seagen-deal-clouded-by-questions-over-regulatory-risk-valuation-bmo?utm_source=businessinsider&utm_medium=referral,negative,0.9480463266372681
6/24/2022 2:46:22 PM,EMA panel recommends extending indications for Merck's Zerbaxa medicine to include kids,Seeking Alpha,https://seekingalpha.com/news/3851609-ema-panel-recommends-extending-indications-for-mercks-zerbaxa-medicine-to-include-kids?utm_source=businessinsider&utm_medium=referral,neutral,0.7565191388130188
6/24/2022 4:30:58 PM,3 Dow Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/3-dow-stocks-to-buy-for-a-bear-market-1031549357,neutral,0.9174609780311584
6/27/2022 8:46:18 AM,AstraZeneca : Lynparza Recommended For Approval In EU For High-risk Early Breast Cancer ,RTTNews,/news/stocks/astrazeneca-lynparza-recommended-for-approval-in-eu-for-high-risk-early-breast-cancer-1031550829,positive,0.7741373181343079
6/27/2022 3:38:11 PM,"Tesla To $1,150? Here's The Biggest Price Target Changes For Monday",Benzinga,/news/stocks/tesla-to-1-150-here-s-the-biggest-price-target-changes-for-monday-1031552024,neutral,0.9365189075469971
6/27/2022 4:50:54 PM,"The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies",Benzinga,/news/stocks/the-daily-biotech-pulse-chmp-backs-astrazeneca-s-breast-cancer-therapies-ipsen-buys-epizyme-fda-holds-for-nuvation-bio-astellas-studies-1031552234,neutral,0.8291833400726318
6/27/2022 4:55:50 PM,8 Analysts Have This to Say About Merck & Co,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-merck-co-1031552266,neutral,0.9187144637107849
6/29/2022 12:04:28 PM,Merck launches Digital Sciences Studio for tech-driven startups,Seeking Alpha,https://seekingalpha.com/news/3852781-merck-launches-digital-sciences-studio-for-tech-driven-startups?utm_source=businessinsider&utm_medium=referral,neutral,0.7906079292297363
6/29/2022 3:39:51 PM,Seagen draws bullish view at Raymond James after Merck interest,Seeking Alpha,https://seekingalpha.com/news/3852913-seagen-draws-bullish-view-at-raymond-james-after-merck-interest?utm_source=businessinsider&utm_medium=referral,positive,0.6634769439697266
6/29/2022 9:27:03 PM,This Analyst Believes Seagen Is Evaluating Strategic Alternatives,Benzinga,/news/stocks/this-analyst-believes-seagen-is-evaluating-strategic-alternatives-1031558732,positive,0.6915569305419922
6/30/2022 10:00:35 AM,7 Beaten-Down S&P 500 Stocks to Buy Before They Rebound,InvestorPlace,/news/stocks/7-beaten-down-sp-500-stocks-to-buy-before-they-rebound-1031559904,neutral,0.6280189752578735
7/1/2022 10:45:50 PM,"Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?",Benzinga,/news/etf/only-8-of-the-30-dow-jones-stocks-were-positive-in-the-first-half-of-2022-chevron-leads-but-who-else-was-up-1031564229,neutral,0.8625626564025879
7/5/2022 10:48:34 AM,Merck beats Pfizer with COVID-19 pill in certain countries,Seeking Alpha,https://seekingalpha.com/news/3854044-merck-beats-pfizer-with-covid-19-pills-in-certain-countries?utm_source=businessinsider&utm_medium=referral,positive,0.6661329865455627
7/5/2022 2:26:32 PM,6 Recession-Proof Stocks to Buy as the Market Boom Ends,InvestorPlace,/news/stocks/6-recession-proof-stocks-to-buy-as-the-market-boom-ends-1031567895,neutral,0.7803198099136353
7/5/2022 3:11:41 PM,6 Recession-Proof Stocks to Buy as the Market Boom Ends,InvestorPlace,/news/stocks/recession-proof-stocks-to-buy-in-down-market-1031567998,neutral,0.7803198099136353
7/5/2022 3:59:15 PM,Seagen's Tukysa garners promising results in mid-stage colorectal cancer trial,Seeking Alpha,https://seekingalpha.com/news/3854241-seagen-tukysa-garners-promising-results-in-mid-stage-colorectal-cancer-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9456217885017395
7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral,positive,0.7087149620056152
7/7/2022 3:05:53 AM,Merck in advanced talks to buy Seagen in a deal worth over $40B – WSJ,Seeking Alpha,https://seekingalpha.com/news/3854845-sgen-stock-in-focus-as-merck-eyes-buyout-deal-worth-over-40b?utm_source=businessinsider&utm_medium=referral,neutral,0.49562034010887146
7/7/2022 6:05:39 AM,Merck Reportedly In Advanced Talks To Buy Seagen ,RTTNews,/news/stocks/merck-reportedly-in-advanced-talks-to-buy-seagen-1031571820,neutral,0.9002599716186523
7/7/2022 1:20:06 PM,Merck could pay in the $215/share range for Seagen - report,Seeking Alpha,https://seekingalpha.com/news/3854996-merck-could-pay-in-the-215share-range-for-seagen-report?utm_source=businessinsider&utm_medium=referral,neutral,0.917977511882782
7/7/2022 1:29:12 PM,Merck - Seagen deal makes sense even at $250 per share – Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3855003-merck-seagen-deal-makes-senses-even-at-250-per-share-price?utm_source=businessinsider&utm_medium=referral,neutral,0.6618404388427734
7/7/2022 1:53:40 PM,This Analyst Cuts Price Target On Microsoft; Here's The Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/this-analyst-cuts-price-target-on-microsoft-here-s-the-biggest-price-target-changes-for-thursday-1031572813,neutral,0.9334458112716675
7/7/2022 4:03:38 PM,"The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-seagen-buyout-advances-adverum-restructures-pharmacists-get-ok-to-prescribe-pfizer-covid-19-pill-1031573375,neutral,0.8647336363792419
7/7/2022 4:04:41 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-7-2022-1031573381,neutral,0.5409944653511047
7/13/2022 10:30:33 AM,Merck in pact with Finish pharma Orion Corporation for cancer agents,Seeking Alpha,https://seekingalpha.com/news/3856300-merck-in-pact-with-finish-pharma-orion-corporation-for-cancer-agents?utm_source=businessinsider&utm_medium=referral,neutral,0.573265790939331
7/13/2022 1:12:41 PM,"Merck, Orion In Deal To Develop Orion's Prostate Cancer Drug ODM-208 ",RTTNews,/news/stocks/merck-orion-in-deal-to-develop-orion-s-prostate-cancer-drug-odm-208-1031584153,neutral,0.6321558356285095
7/13/2022 2:53:24 PM,6 Dow Stocks to Buy on the Dip,InvestorPlace,/news/stocks/dow-stocks-to-buy-on-the-dip-1031585132,neutral,0.877483069896698
7/18/2022 12:27:31 PM,PMV Pharma joins Merck to study lead candidate with Keytruda,Seeking Alpha,https://seekingalpha.com/news/3857509-pmvp-stock-gains-as-merck-joins-to-study-lead-candidate-with-keytruda?utm_source=businessinsider&utm_medium=referral,neutral,0.8327459692955017
7/18/2022 1:49:37 PM,Seagen drops most since May on reports of delayed Merck deal,Seeking Alpha,https://seekingalpha.com/news/3857580-sgen-stock-drops-on-reports-of-delayed-merck-deal?utm_source=businessinsider&utm_medium=referral,negative,0.963907778263092
7/18/2022 4:47:54 PM,"PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors",Benzinga,/news/stocks/pmv-pharma-merck-ink-clinical-trial-collaboration-for-combination-study-in-solid-tumors-1031594353,positive,0.6753475069999695
7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral,positive,0.9346281290054321
7/18/2022 8:20:05 PM,Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility,Seeking Alpha,https://seekingalpha.com/news/3857762-merck-to-stop-phase-3-trial-of-lynparza-drug-in-colorectal-cancer-for-futility?utm_source=businessinsider&utm_medium=referral,negative,0.8012205958366394
7/20/2022 11:18:56 AM,2nd setback for Merck in a week as Keytruda fails phase 3 study in head/neck cancer,Seeking Alpha,https://seekingalpha.com/news/3858422-2nd-setback-for-merck-in-a-week-as-keytruda-fails-phase-3-study-in-headneck-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9675113558769226
7/20/2022 1:23:32 PM,Merck: Phase 3 KEYNOTE-412 Trial With KEYTRUDA Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/merck-phase-3-keynote-412-trial-with-keytruda-fails-to-meet-primary-endpoint-1031600568,negative,0.9528368711471558
7/20/2022 4:16:37 PM,"The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study",Benzinga,/news/stocks/the-daily-biotech-pulse-cdc-adcomm-backs-novavax-covid-19-vaccine-european-approval-for-ptc-therapeutics-gene-therapy-merck-s-keytruda-flunks-in-head-neck-cancer-study-1031601508,positive,0.7314300537109375
7/20/2022 4:40:55 PM,What's In The Offing For Infosys (INFY) This Earnings Season?,Benzinga,/news/stocks/what-s-in-the-offing-for-infosys-infy-this-earnings-season-1031601549,neutral,0.6808964610099792
7/20/2022 5:44:19 PM,"Pfizer (PFE), BioNTech Seek EU Nod For Omicron-Based COVID Jab",Benzinga,/news/stocks/pfizer-pfe-biontech-seek-eu-nod-for-omicron-based-covid-jab-1031601786,positive,0.7433514595031738
7/20/2022 11:59:56 PM,Recap of Wednesday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-wednesday-s-biotech-catalysts---end-of-the-day-summary-1031602618,neutral,0.9346833229064941
7/21/2022 3:49:50 PM,AstraZeneca COVID-19 therapy less effective against new Omicron strains: study,Seeking Alpha,https://seekingalpha.com/news/3859171-astrazeneca-covid-19-therapy-less-protection-against-new-omicron-strains?utm_source=businessinsider&utm_medium=referral,negative,0.845219612121582
7/22/2022 11:02:03 PM,Market Predictions 2022: When Will Stocks Go Back Up?,InvestorPlace,/news/stocks/market-predictions-2022-when-will-stocks-go-back-up-1031608661,neutral,0.7453240752220154
7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral,neutral,0.8448383808135986
7/24/2022 12:41:04 PM,"6 Penny Stocks With 1,000% Upside Potential",InvestorPlace,/news/stocks/penny-stocks-with-1000-percent-upside-potential-1031609277,neutral,0.8358181118965149
7/24/2022 10:37:06 PM,"Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earnings Pick Up Pace",Benzinga,/news/stocks/apple-meta-pfizer-among-key-companies-reporting-in-the-week-ahead-as-earning-picks-up-pace-1031609526,positive,0.8915560245513916
7/25/2022 11:19:52 AM,China greenlights homegrown COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3859917-china-greenlights-homegrown-covid-19-pill?utm_source=businessinsider&utm_medium=referral,neutral,0.9014589190483093
7/25/2022 5:49:18 PM,"SEC accuses two men of insider trading, profiting more than $1.3M from Merck/Pandion deal",Seeking Alpha,https://seekingalpha.com/news/3860175-sec-accuses-two-men-of-insider-trading-profiting-more-than-13m-from-merck?utm_source=businessinsider&utm_medium=referral,negative,0.8660776615142822
7/26/2022 9:14:14 AM,"Astellas/Seagen, Merck drug combo shows promise in bladder cancer subtype in trial",Seeking Alpha,https://seekingalpha.com/news/3860353-astellasseagen-merck-drug-combo-shows-promise-in-bladder-cancer-subtype-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9404239654541016
7/26/2022 11:22:28 AM,"Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer ",RTTNews,/news/stocks/astellas-seagen-report-positive-topline-results-for-padcev-with-keytruda-to-treat-urothelial-cancer-1031614484,positive,0.9519340991973877
7/26/2022 11:24:39 AM,Merck to pay Kelun-Biotech $35M upfront in pact to develop antibody drug conjugate for tumors,Seeking Alpha,https://seekingalpha.com/news/3860413-merck-to-pay-kelun-biotech-35m-upfront-in-pact-to-develop-antibody-drug-conjugate-for-tumors?utm_source=businessinsider&utm_medium=referral,positive,0.7223768830299377
7/26/2022 2:23:05 PM,"Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate",Benzinga,/news/stocks/daily-biotech-pulse-eu-approval-for-abbvie-s-ulcerative-colitis-treatment-angion-biomedica-evaluates-alternatives-clinical-hold-for-immuron-s-bacterial-infection-candidate-1031615201,positive,0.6602172255516052
7/26/2022 4:58:59 PM,Merck declares $0.69 dividend,Seeking Alpha,https://seekingalpha.com/news/3860672-merck-and-co-inc-declares-0_69-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.9274508357048035
7/26/2022 8:16:10 PM,Surge in use of Pfizer's COVID antiviral Paxlovid since May,Seeking Alpha,https://seekingalpha.com/news/3860833-nearly-28m-courses-of-pfizer-covid-antiviral-paxlovid-administered-so-far?utm_source=businessinsider&utm_medium=referral,positive,0.9445315003395081
7/26/2022 8:28:43 PM,Sutro to get $10M payment from Merck after first patient dosed in collaboration trial,Seeking Alpha,https://seekingalpha.com/news/3860936-sutro-to-get-10m-payment-from-merck-after-first-patient-dosed-in-collaboration-trial?utm_source=businessinsider&utm_medium=referral,positive,0.8578461408615112
7/27/2022 1:36:30 PM,The 3 Best Market Sectors for the Second Half of 2022,InvestorPlace,/news/stocks/best-market-sectors-2-1031621062,neutral,0.92616206407547
7/27/2022 2:34:21 PM,COVID-19 pill demand in focus for Merck's Q2 earnings,Seeking Alpha,https://seekingalpha.com/news/3861393-covid-19-pill-demand-in-focus-for-mercks-q2-earnings?utm_source=businessinsider&utm_medium=referral,neutral,0.48376449942588806
7/27/2022 2:38:51 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3861395-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8825733065605164
7/27/2022 3:01:13 PM,Merck is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/merck_co-q2-quarterly-earnings-preview-1031620776,neutral,0.9405920505523682
7/27/2022 3:28:18 PM,"Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy",Benzinga,/news/stocks/daily-biotech-pulse-teva-s-opioids-settlement-criminal-investigation-against-cassava-durable-responses-for-in8bio-s-leukemia-therapy-1031621034,neutral,0.7511836290359497
7/27/2022 5:48:54 PM,"Abbott, Merck under Wyden scrutiny for not providing offshore taxable income info",Seeking Alpha,https://seekingalpha.com/news/3861579-abbott-merck-under-wyden-scrutiny-for-not-providing-offshore-taxable-income-info?utm_source=businessinsider&utm_medium=referral,negative,0.9057963490486145
7/27/2022 11:30:01 PM,8 Dividend ETFs to Buy and Hold Forever,InvestorPlace,/news/stocks/dividend-etfs-to-buy-and-hold-1031622787,neutral,0.9430360198020935
7/28/2022 10:33:14 AM,"Merck Non-GAAP EPS of $1.87 beats by $0.16, revenue of $14.6B beats by $750M, raises FY22 revenue guidance",Seeking Alpha,https://seekingalpha.com/news/3862116-merck-non-gaap-eps-of-1_87-beats-0_16-revenue-of-14_6b-beats-750m?utm_source=businessinsider&utm_medium=referral,positive,0.9009726047515869
7/28/2022 11:38:00 AM,"Merck Q2 sales soar on back of COVID drug Lagevrio, Keytruda; raises/narrows FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3862218-merck-q2-sales-soar-on-back-of-covid-drug-lagevrio-keytruda-raisesnarrows-fy22-outlook?utm_source=businessinsider&utm_medium=referral,positive,0.8914714455604553
7/28/2022 1:04:27 PM,7 Stocks to Buy on the Dip,InvestorPlace,/news/stocks/stocks-to-buy-on-the-dip-1031626064,neutral,0.8541347980499268
7/28/2022 1:07:48 PM,Merck Updates FY22 Guidance ,RTTNews,/news/stocks/merck-updates-fy22-guidance-1031625187,neutral,0.9116531014442444
7/28/2022 3:28:28 PM,Pfizer sends rivals lower with unchanged guidance for COVID-19 franchise,Seeking Alpha,https://seekingalpha.com/news/3862495-pfizer-sends-rivals-lower-with-unchanged-guidance-for-covid-19-franchise?utm_source=businessinsider&utm_medium=referral,negative,0.9156041741371155
7/28/2022 8:20:28 PM,Senate Democrats propose $21B funding for next phase of COVID-19 response,Seeking Alpha,https://seekingalpha.com/news/3862718-senate-democrats-propose-21b-funding-for-next-phase-of-covid-19-response?utm_source=businessinsider&utm_medium=referral,positive,0.6786968111991882
7/29/2022 3:22:33 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1031630161,neutral,0.9218418598175049
8/1/2022 10:40:56 AM,Celyad stock soars 35% as FDA lifts hold on colorectal cancer trial of CYAD-101/Keytruda,Seeking Alpha,https://seekingalpha.com/news/3863579-celyad-stock-soars-35-as-fda-lifts-hold-on-colorectal-cancer-trial-of-cyad-101keytruda?utm_source=businessinsider&utm_medium=referral,negative,0.8342324495315552
8/1/2022 11:35:51 AM,ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer,Seeking Alpha,https://seekingalpha.com/news/3863615-alx-oncology-stock-rises-on-fda-fast-track-status-for-evorpacept-to-treat-headneck-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.9322171211242676
8/1/2022 3:03:05 PM,"Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial",Benzinga,/news/stocks/daily-biotech-pulse-celyad-resumes-colorectal-cancer-trial-setback-for-otonomy-astrazeneca-halts-phase-3-head-neck-cancer-trial-1031635570,negative,0.9241388440132141
8/3/2022 11:11:14 AM,"Merck on backfoot as blockbuster Keytruda fails another phase 3 study, this time in prostate cancer",Seeking Alpha,https://seekingalpha.com/news/3865570-merck-on-backfoot-as-blockbuster-keytruda-fails-another-phase-3-study-this-time-in-prostate-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9622446298599243
8/3/2022 1:29:49 PM,Merck : Phase 3 Trial Of Keytruda Combination In Liver Cancer Fails To Meet Main Goal ,RTTNews,/news/stocks/merck-phase-3-trial-of-keytruda-combination-in-liver-cancer-fails-to-meet-main-goal-1031644781,negative,0.9302518963813782
8/3/2022 2:12:12 PM,Organon Q2 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3865775-organon-q2-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.917853057384491
8/4/2022 12:24:06 AM,Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-wednesday-s-biotech-catalysts---end-of-the-day-summary-1031647807,neutral,0.9346833229064941
8/4/2022 9:41:05 AM,AstraZeneca/Merck's Lynparza gets approval in EU for expanded use in breast cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3866864-astrazenecamercks-lynparza-gets-approval-in-eu-for-expanded-use-in-breast-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.9151225090026855
8/4/2022 2:30:04 PM,Organon tightens 2022 revenue guidance on forex headwinds,Seeking Alpha,https://seekingalpha.com/news/3867321-organon-tightens-2022-revenue-guidance-on-forex-headwinds?utm_source=businessinsider&utm_medium=referral,negative,0.9247259497642517
8/4/2022 3:06:29 PM,"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",Benzinga,/news/stocks/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazeneca-s-lynparza-in-early-stage-breast-cancer-decision-day-for-alzheimer-s-associated-hallucinations-candidate-1031651306,neutral,0.8657047748565674
8/4/2022 5:04:08 PM,PDS Biotech spikes as panel backs continuation of cancer trial for lead asset,Seeking Alpha,https://seekingalpha.com/news/3867384-pdsb-stock-spikes-as-panel-backs-continuation-of-cancer-trial-for-lead-asset?utm_source=businessinsider&utm_medium=referral,negative,0.8790498375892639
8/5/2022 12:08:49 AM,Recap Of Thursday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-thursday-s-biotech-catalysts---end-of-the-day-summary-1031653111,neutral,0.9353505373001099
8/7/2022 1:24:26 PM,Amgen data for new cancer agent shows liver toxicity with immunotherapies,Seeking Alpha,https://seekingalpha.com/news/3868535-amgen-data-for-new-cancer-agent-shows-liver-toxicity-with-immunotherapies?utm_source=businessinsider&utm_medium=referral,neutral,0.5263691544532776
8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral,neutral,0.5326845645904541
8/9/2022 1:38:04 AM,The 3 Best Vanguard Funds to Buy in August,InvestorPlace,/news/stocks/best-vanguard-funds-1031663161,neutral,0.8945893049240112
8/9/2022 11:10:51 AM,"AstraZeneca, Daiichi Sankyo drug, Keytruda combo shows promise in early stage lung cancer trial",Seeking Alpha,https://seekingalpha.com/news/3869602-astrazeneca-daiichi-sankyo-drug-keytruda-combo-shows-promise-in-early-stage-lung-cancer-trial?utm_source=businessinsider&utm_medium=referral,positive,0.8531872630119324
8/9/2022 8:00:42 PM,Merck diabetes drug linked to possible carcinogen – FDA,Seeking Alpha,https://seekingalpha.com/news/3870047-merck-diabetes-drug-linked-to-possible-carcinogen-fda?utm_source=businessinsider&utm_medium=referral,neutral,0.7897182106971741
8/10/2022 8:46:26 AM,"Merck, Starpharma expand partnership to develop antibody drug conjugates",Seeking Alpha,https://seekingalpha.com/news/3870451-merck-starpharma-expand-partnership-to-develop-antibody-drug-conjugates?utm_source=businessinsider&utm_medium=referral,positive,0.906192421913147
8/10/2022 5:33:08 PM,"Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial",Benzinga,/news/stocks/biotech-daily-cancer-causing-impurities-in-merck-s-diabetic-drug-vir-bio-gsk-shun-fda-submission-plans-for-covid-19-treatment-aethlon-s-monkeypox-trial-1031671419,neutral,0.831649899482727
8/11/2022 7:52:19 AM,Roche Announces FDA Approval Of Label Expansion For VENTANA MMR RxDx Panel ,RTTNews,/news/stocks/roche-announces-fda-approval-of-label-expansion-for-ventana-mmr-rxdx-panel-1031674474,positive,0.7443175911903381
8/11/2022 4:52:13 PM,ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off,Benzinga,/news/stocks/alx-oncology-shares-climb-as-mid-stage-triple-combination-colorectal-cancer-study-kicks-off-1031676485,positive,0.911541759967804
8/11/2022 7:26:06 PM,CDC eases COVID guidance for unvaccinated people,Seeking Alpha,https://seekingalpha.com/news/3871779-cdc-eases-covid-guidance-for-unvaccinated-people?utm_source=businessinsider&utm_medium=referral,negative,0.8480912446975708
8/11/2022 9:22:02 PM,"J&J, Merck, Regeneron most exposed to Medicare drug price negotiation - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3871983-johnson-johnson-merck-regeneron-most-exposed-to-medicare-drug-price-negotiation-bloomberg?utm_source=businessinsider&utm_medium=referral,neutral,0.9089527726173401
8/12/2022 12:07:01 AM,Recap Of Thursday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-thursday-s-biotech-catalysts---end-of-the-day-summary-1031677667,neutral,0.9353505373001099
8/12/2022 5:25:48 PM,Seagen falls as arbitrator rules in favor of Daiichi Sankyo,Seeking Alpha,https://seekingalpha.com/news/3872471-sgen-stock-falls-as-arbitrator-rules-in-favor-of-daiichi-sankyo?utm_source=businessinsider&utm_medium=referral,negative,0.8942620158195496
8/14/2022 1:13:21 PM,Merck potential purchase of Seagen likely back in focus after Daiichi arbitration loss,Seeking Alpha,https://seekingalpha.com/news/3872628-merck-potential-purchase-of-seagen-likely-back-in-focus-after-daiichi-arbitration-loss?utm_source=businessinsider&utm_medium=referral,neutral,0.8859530091285706
8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.8447362780570984
8/16/2022 8:20:19 AM,AstraZeneca/Merck's Lynparza gets FDA priority review to treat prostate cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3873395-astrazenecamercks-lynparza-gets-fda-priority-review-to-treat-prostate-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.8315348029136658
8/16/2022 8:27:46 AM,AstraZeneca: FDA Grants Priority Review To SNDA For Lynparza With Abiraterone For MCRPC ,RTTNews,/news/stocks/astrazeneca-fda-grants-priority-review-to-snda-for-lynparza-with-abiraterone-for-mcrpc-1031686162,positive,0.8206647634506226
8/16/2022 10:58:26 AM,Merck and Orna in pact to advance circular RNA technology,Seeking Alpha,https://seekingalpha.com/news/3873507-merck-and-orna-in-pact-to-advance-circular-rna-technology?utm_source=businessinsider&utm_medium=referral,positive,0.4962347447872162
8/16/2022 11:56:27 AM,Seagen upgraded at RBC citing buyout prospects after arbitration outcome,Seeking Alpha,https://seekingalpha.com/news/3873553-seagen-upgraded-at-rbc-citing-buyout-prospects-after-arbitration-outcome?utm_source=businessinsider&utm_medium=referral,positive,0.8191056847572327
8/16/2022 1:29:40 PM,"Merck And Orna  In Deal To Develop Vaccines And Treatments For Infectious Diseases, Cancer ",RTTNews,/news/stocks/merck-and-orna-in-deal-to-develop-vaccines-and-treatments-for-infectious-diseases-cancer-1031686794,positive,0.5185746550559998
8/16/2022 5:03:44 PM,"Seagen For Sale? This Acquisition Target Is 'Too Intriguing To Ignore,' RBC Says",Benzinga,/news/stocks/seagen-for-sale-this-acquisition-target-is-too-intriguing-to-ignore-rbc-says-1031687735,neutral,0.8021063804626465
8/16/2022 5:58:13 PM,3 Top Stocks to Invest In Right Now,InvestorPlace,/news/stocks/3-top-stocks-to-invest-in-right-now-1031688113,neutral,0.9305989742279053
8/16/2022 11:54:55 PM,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031688509,neutral,0.9340888261795044
8/17/2022 10:54:23 AM,"U.S. govt. to stop buying COVID-19 vaccines, therapies, tests from this fall – Jha",Seeking Alpha,https://seekingalpha.com/news/3874012-us-govt-to-stop-buying-covid-19-vaccines-therapies-tests-from-this-fall-jha?utm_source=businessinsider&utm_medium=referral,neutral,0.7759352922439575
8/17/2022 5:10:23 PM,CDC seeks reforms to correct COVID missteps,Seeking Alpha,https://seekingalpha.com/news/3874241-cdc-to-implement-reforms-to-correct-covid-missteps?utm_source=businessinsider&utm_medium=referral,positive,0.785580039024353
8/18/2022 7:16:33 PM,What's In The Cards For Medtronic (MDT) In Q1 Earnings?,Benzinga,/news/stocks/what-s-in-the-cards-for-medtronic-mdt-in-q1-earnings-1031693776,neutral,0.8877297639846802
8/19/2022 12:31:52 PM,"HHS sets Aug. 30 meeting as costs for COVID products to shift to payors, individuals – WSJ",Seeking Alpha,https://seekingalpha.com/news/3875015-hhs-sets-aug-meeting-as-covid-products-head-for-commercialization-wsj?utm_source=businessinsider&utm_medium=referral,neutral,0.9202150106430054
8/21/2022 4:00:16 PM,Biotech in recovery; but Piper Sandler cites negative fund flows,Seeking Alpha,https://seekingalpha.com/news/3875226-biotech-in-recovery-but-piper-sandler-cites-negative-fund-flows?utm_source=businessinsider&utm_medium=referral,negative,0.9548234343528748
8/22/2022 2:28:02 PM,"Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday,...",Benzinga,/news/stocks/benzinga-before-the-bell-apple-employees-resist-calls-for-return-to-office-tesla-about-to-hike-fsd-prices-again-mgm-china-injects-594m-into-macau-unit-and-other-top-financial-stories-monday-august-22-1031697874,neutral,0.4117203950881958
8/23/2022 11:30:58 AM,Merck's blood clot preventing drug for kidney patients gets FDA fast track status,Seeking Alpha,https://seekingalpha.com/news/3875719-mercks-blood-clot-preventing-drug-for-use-in-kidney-patients-gets-fda-fast-track-status?utm_source=businessinsider&utm_medium=referral,positive,0.6770305037498474
8/23/2022 1:53:22 PM,Merck & Co Gets Fast Track Status For Investigational Anticoagulant Therapy MK-2060 ,RTTNews,/news/stocks/merck-co-gets-fast-track-status-for-investigational-anticoagulant-therapy-mk-2060-1031700252,positive,0.918595016002655
8/24/2022 12:53:43 AM,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031701797,neutral,0.9340888261795044
8/25/2022 8:23:55 AM,AstraZeneca/Merck's Lynparza gets approval in Japan for early breast cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3876446-astrazenecamercks-lynparza-gets-approval-in-japan-for-early-breast-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.8859267234802246
8/25/2022 8:27:44 AM,"AstraZeneca Reports Approval Of Tagrisso, Ultomiris & Lynparza In Japan ",RTTNews,/news/stocks/astrazeneca-reports-approval-of-tagrisso-ultomiris-lynparza-in-japan-1031704870,positive,0.8965136408805847
8/26/2022 12:43:59 AM,Recap Of Thursday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-thursday-s-biotech-catalysts---end-of-the-day-summary-1031707079,neutral,0.9353505373001099
8/26/2022 1:07:37 AM,Merck's talks with Seagen said to hit obstacle over price - report,Seeking Alpha,https://seekingalpha.com/news/3876888-mercks-talks-with-seagen-said-to-hit-obstacle-over-price-report?utm_source=businessinsider&utm_medium=referral,negative,0.8199723362922668
8/26/2022 11:33:08 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-26-1031708091,neutral,0.50490802526474
8/26/2022 1:56:59 PM,Seagen down 9% following report Merck purchase hits snag,Seeking Alpha,https://seekingalpha.com/news/3877080-seagen-down-9-following-report-merck-purchase-hits-snag?utm_source=businessinsider&utm_medium=referral,negative,0.9570534825325012
8/26/2022 2:36:56 PM,"Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial...",Benzinga,/news/stocks/benzinga-before-the-bell-elon-musk-s-demand-for-broad-twitter-data-dismissed-xiaomi-wants-to-join-ev-race-bed-bath-beyond-plans-to-share-turnaround-strategy-next-week-and-other-top-financial-stories-friday-august-26-1031708224,neutral,0.8018451929092407
8/31/2022 2:27:50 PM,"U.S. outlines plans to move COVID-19 drugs, vaccines to commercial market",Seeking Alpha,https://seekingalpha.com/news/3878943-us-outlines-plans-to-move-covid-19-drugs-vaccines-to-commercial-market?utm_source=businessinsider&utm_medium=referral,positive,0.5740588307380676
9/1/2022 8:28:57 AM,Novartis hires Merck executive as research head,Seeking Alpha,https://seekingalpha.com/news/3879169-novartis-hires-merck-exec-as-research-head?utm_source=businessinsider&utm_medium=referral,neutral,0.9042466282844543
9/1/2022 6:41:56 PM,"Merck, GSK to face new shot for cervical cancer from world’s largest vaccine maker",Seeking Alpha,https://seekingalpha.com/news/3879491-merck-gsk-to-face-new-shot-for-cervical-cancer-from-worlds-largest-vaccine-maker?utm_source=businessinsider&utm_medium=referral,positive,0.857144832611084
9/4/2022 1:18:40 PM,"M&A may be a tailwind for biotech sector into end of year, analyst says",Seeking Alpha,https://seekingalpha.com/news/3880197-ma-may-be-a-tailwind-for-biotech-sector-into-end-of-year-analyst-says?utm_source=businessinsider&utm_medium=referral,negative,0.929253339767456
9/5/2022 11:40:16 PM,"BofA screens for dividends that are secure, not stretched",Seeking Alpha,https://seekingalpha.com/news/3880200-bofa-screens-for-dividends-that-are-secure-not-stretched?utm_source=businessinsider&utm_medium=referral,neutral,0.947599470615387
9/6/2022 7:12:48 AM,The 7 Best Vanguard ETFs to Buy Now,InvestorPlace,/news/stocks/the-best-vanguard-etfs-1028807655,neutral,0.9007076025009155
9/6/2022 2:42:21 PM,Organon upgraded at Piper on strength of established brands segment,Seeking Alpha,https://seekingalpha.com/news/3880463-ogn-stock-upgraded-at-piper-on-strength-of-established-brands-segment?utm_source=businessinsider&utm_medium=referral,positive,0.95414137840271
9/9/2022 1:25:07 PM,AstraZeneca/Merck's Lynparza shows survival benefit in ovarian cancer patients in long-term data,Seeking Alpha,https://seekingalpha.com/news/3881639-astrazenecamercks-lynparza-shows-survival-benefit-in-ovarian-cancer-patients-in-long-term-data?utm_source=businessinsider&utm_medium=referral,positive,0.953819751739502
9/9/2022 2:58:35 PM,AstraZeneca Says LYNPARZA Combination Shows Meaningful OS In Ovarian Cancer Across Phase III Trials ,RTTNews,/news/stocks/astrazeneca-says-lynparza-combination-shows-meaningful-os-in-ovarian-cancer-across-phase-iii-trials-1031734663,positive,0.9520381689071655
9/9/2022 11:47:11 PM,"Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-9-2022---end-of-the-day-summary-1031735560,neutral,0.942810595035553
9/12/2022 1:51:43 PM,"Astellas/Seagen, Merck Padcev/Keytruda combo shows promise in urothelial cancer in trial",Seeking Alpha,https://seekingalpha.com/news/3882015-astellasseagen-merck-padcevkeytruda-combo-shows-promise-in-urothelial-cancer-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9283961653709412
9/12/2022 2:55:00 PM,"Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothe...",PR Newswire,/news/stocks/astellas-seagen-and-merck-announce-results-of-clinical-trial-investigating-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-and-padcev-as-monotherapy-in-first-line-advanced-urothe-1031737272,positive,0.8046085834503174
9/12/2022 3:26:03 PM,"Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab ",RTTNews,/news/stocks/seagen-astellas-merck-ev-103-results-support-investigation-of-enfortumab-vedotin-pembrolizumab-1031737451,positive,0.4941295385360718
9/12/2022 4:16:48 PM,"BP To $47? Plus UBS Sees $2,260 For This Stock",Benzinga,/news/stocks/bp-to-47-plus-ubs-sees-2-260-for-this-stock-1031737641,neutral,0.751653254032135
9/12/2022 5:03:29 PM,Analyst Ratings for Merck & Co,Benzinga,/news/stocks/analyst-ratings-for-merck-co-1031737763,neutral,0.9076553583145142
9/13/2022 12:10:11 PM,Merck's Keytruda gets approval in Canada for certain skin cancer patients following surgery,Seeking Alpha,https://seekingalpha.com/news/3882274-mercks-keytruda-gets-approval-in-canada-for-certain-skin-cancer-patients-following-surgery?utm_source=businessinsider&utm_medium=referral,positive,0.9156987071037292
9/13/2022 1:24:07 PM,Merck: KEYTRUDA Approved In Canada For Adjuvant Treatment Of Patients With Stage IIB Or IIC Melanoma ,RTTNews,/news/stocks/merck-keytruda-approved-in-canada-for-adjuvant-treatment-of-patients-with-stage-iib-or-iic-melanoma-1031739479,positive,0.6036472320556641
9/13/2022 5:21:51 PM,"Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment",Seeking Alpha,https://seekingalpha.com/news/3882444-medicenna-merck-enter-clinical-trial-collaboration-to-evaluate-combo-cancer-treatment?utm_source=businessinsider&utm_medium=referral,positive,0.6217092275619507
9/14/2022 12:45:16 AM,"Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-13-2022---end-of-the-day-summary-1031741339,neutral,0.9436256289482117
9/14/2022 2:09:06 PM,"Evercore ISI Group Boosts PT On This Stock By Around 400%, Plus This Analyst Predicts $100 For Merck",Benzinga,/news/stocks/evercore-isi-group-boosts-pt-on-this-stock-by-around-400-plus-this-analyst-predicts-100-for-merck-1031742578,positive,0.9291188716888428
9/14/2022 2:18:38 PM,"End in sight for COVID-19 pandemic, WHO chief says",Seeking Alpha,https://seekingalpha.com/news/3882728-end-in-sight-for-covid-19-pandemic-who-chief-says?utm_source=businessinsider&utm_medium=referral,neutral,0.8521955013275146
9/14/2022 4:07:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-14-2022-1031743148,neutral,0.5372793078422546
9/14/2022 5:12:58 PM,Seagen ticks lower as management suggests it could look at acquisitions,Seeking Alpha,https://seekingalpha.com/news/3882796-seagen-ticks-lower-as-management-suggests-it-could-look-at-acquisitions?utm_source=businessinsider&utm_medium=referral,negative,0.9139232635498047
9/14/2022 7:37:01 PM,Merck upgraded at Berenberg; named top value pick in large pharma,Seeking Alpha,https://seekingalpha.com/news/3882814-merck-upgraded-at-berenberg-named-top-value-pick-in-large-pharma?utm_source=businessinsider&utm_medium=referral,positive,0.7902408838272095
9/15/2022 10:54:55 AM,"Merck, Qurient team up to evaluate Keytruda/Q901 combo for solid tumors",Seeking Alpha,https://seekingalpha.com/news/3882927-merck-qurient-team-up-to-evaluate-keytrudaq901-combo-for-solid-tumors?utm_source=businessinsider&utm_medium=referral,neutral,0.6242098808288574
9/15/2022 1:02:36 PM,Syapse collaborates with Merck for cancer treatments,Seeking Alpha,https://seekingalpha.com/news/3883016-syapse-collaborates-with-merck-for-cancer-treatments?utm_source=businessinsider&utm_medium=referral,neutral,0.7105172276496887
9/16/2022 11:16:42 AM,"Merck (MRK), Exxon (XOM): 2 “Strong Buy” Dividend Achievers You Can’t Ignore",TipRanks,/news/stocks/merck-mrk-exxon-xom-2-strong-buy-dividend-achievers-you-can-t-ignore-1031747952,positive,0.6581465005874634
9/16/2022 12:13:25 PM,Merck's pneumococcal vaccine gets EMA panel nod for use in infants,Seeking Alpha,https://seekingalpha.com/news/3883373-mercks-pneumococcal-vaccine-gets-ema-panel-nod-for-use-in-infants?utm_source=businessinsider&utm_medium=referral,positive,0.708309531211853
9/16/2022 5:05:17 PM,7 Undervalued Stock Picks to Beat the September Market Slump,InvestorPlace,/news/stocks/7-undervalued-stock-picks-to-beat-the-september-market-slump-1031748784,positive,0.9164482355117798
9/19/2022 10:00:06 AM,7 Penny Stocks That Actually Have a Buy Rating,InvestorPlace,/news/stocks/7-penny-stocks-with-buy-ratings-to-keep-your-eye-on-1031750175,neutral,0.9222167730331421
9/19/2022 7:00:53 PM,COVID-19 vaccine makers fall as Biden says pandemic is over (update),Seeking Alpha,https://seekingalpha.com/news/3883793-mrna-stock-lead-selloff-covid-vaccine-makers-biden-says-pandemic-over?utm_source=businessinsider&utm_medium=referral,negative,0.961385190486908
9/20/2022 1:29:14 PM,Mohamed El-Erian Says Stagflation Is Coming; Here Are 2 ‘Strong Buy’ Dividend Stocks to Protect Your Portfolio,TipRanks,/news/stocks/mohamed-el-erian-says-stagflation-is-coming-here-are-2-strong-buy-dividend-stocks-to-protect-your-portfolio-1031753846,neutral,0.8063704967498779
9/20/2022 1:32:34 PM,Merck To Begin Phase 3 Program With Lower Dose Of Islatravir With Doravirine ,RTTNews,/news/stocks/merck-to-begin-phase-3-program-with-lower-dose-of-islatravir-with-doravirine-1031753126,positive,0.5284286737442017
9/20/2022 2:47:22 PM,Merck to start new late-stage studies of investigational HIV drug with a lower dose,Seeking Alpha,https://seekingalpha.com/news/3884407-merck-to-start-new-late-stage-studies-of-investigational-hiv-drug-with-a-lower-dose?utm_source=businessinsider&utm_medium=referral,neutral,0.6034477353096008
9/20/2022 5:45:25 PM,The 7 Best Biotech Stocks to Buy,InvestorPlace,/news/stocks/best-biotech-stocks-1031575358,neutral,0.6688135266304016
9/20/2022 8:18:52 PM,3 Stocks That Could Rocket on Biden’s Cancer Moonshot,InvestorPlace,/news/stocks/3-stocks-that-could-rocket-on-bidens-cancer-moonshot-1031754919,neutral,0.813847541809082
9/21/2022 12:21:07 PM,Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer,Seeking Alpha,https://seekingalpha.com/news/3884766-evaxion-stock-rises-as-enrollment-begins-in-trial-of-immunotherapy-evx-01-for-skin-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.9444174766540527
9/21/2022 6:10:21 PM,Why Is Evaxion Biotech (EVAX) Stock Up Today?,InvestorPlace,/news/stocks/why-is-evaxion-biotech-evax-stock-up-today-1031757496,neutral,0.7529017329216003
9/22/2022 8:18:11 AM,AstraZeneca Announces Approval Of Lynparza In China ,RTTNews,/news/stocks/astrazeneca-announces-approval-of-lynparza-in-china-1031758297,neutral,0.7579439282417297
9/22/2022 8:23:46 AM,AstraZeneca/Merck's Lynparza gets approval in China for ovarian cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3885135-astrazenecamercks-lynparza-gets-approval-in-china-for-ovarian-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.9072204232215881
9/22/2022 11:45:01 AM,Viatris faces legal setback to market generics for Merck’s diabetic drugs,Seeking Alpha,https://seekingalpha.com/news/3885200-viatris-faces-legal-setback-to-market-generics-for-mercks-diabetic-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.9569201469421387
9/22/2022 12:01:17 PM,Merck Animal Health to acquire virtual fencing tech maker Vence,Seeking Alpha,https://seekingalpha.com/news/3885202-merck-animal-health-to-acquire-virtual-fencing-tech-maker-vence?utm_source=businessinsider&utm_medium=referral,neutral,0.8608930110931396
9/22/2022 1:46:08 PM,U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris ,RTTNews,/news/stocks/u-s-district-court-rules-in-favor-of-merck-in-patent-infringement-suit-against-viatris-1031759015,negative,0.4640287756919861
9/22/2022 1:59:56 PM,Merck Animal Health To Buy Vence; Financial Terms Not Disclosed ,RTTNews,/news/stocks/merck-animal-health-to-buy-vence-financial-terms-not-disclosed-1031759034,neutral,0.9471274018287659
9/22/2022 3:55:15 PM,"WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed",Seeking Alpha,https://seekingalpha.com/news/3885339-who-chief-reiterates-belief-that-covid-19-pandemic-end-near-says-work-still-needed?utm_source=businessinsider&utm_medium=referral,neutral,0.5798600316047668
9/22/2022 7:25:05 PM,Healthcare outperforms S&P 500 as large cap pharma rebounds,Seeking Alpha,https://seekingalpha.com/news/3885399-healthcare-outperforms-sp-500-as-large-cap-pharma-rebounds?utm_source=businessinsider&utm_medium=referral,positive,0.6939451694488525
9/23/2022 1:41:33 PM,Citius gains on clinical collaboration to study cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3885642-ctxr-stock-gains-on-clinical-collaboration-to-study-cancer-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.8969911932945251
9/23/2022 2:26:49 PM,US to create clearinghouse of medical supplies to help other countries fight COVID,Seeking Alpha,https://seekingalpha.com/news/3885647-us-to-create-clearinghouse-of-medical-supplies-to-help-other-countries-fight-covid?utm_source=businessinsider&utm_medium=referral,neutral,0.6444892883300781
9/26/2022 12:18:32 PM,Seagen in licensing deal with Lava Therapeutics for cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3885984-lvtx-stock-jumps-on-licensing-deal-with-seagen-for-cancer-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.5421366691589355
9/26/2022 8:22:33 PM,7 Dow Sleeper Stocks to Buy Before Wall Street Wakes Up,InvestorPlace,/news/stocks/7-dow-sleeper-stocks-to-buy-before-wall-street-wakes-up-1031765516,neutral,0.869033932685852
9/27/2022 8:34:05 AM,"AstraZeneca, Merck's Koselugo gets approval in Japan for rare genetic disorder in kids",Seeking Alpha,https://seekingalpha.com/news/3886234-astrazeneca-mercks-koselugo-gets-approval-in-japan-for-rare-genetic-disorder-in-kids?utm_source=businessinsider&utm_medium=referral,positive,0.7888510823249817
9/27/2022 8:50:52 AM,AstraZeneca : Japan Approves Koselugo For Rare Genetic Disease In Paediatric Patients ,RTTNews,/news/stocks/astrazeneca-japan-approves-koselugo-for-rare-genetic-disease-in-paediatric-patients-1031766068,positive,0.8235523700714111
9/27/2022 11:16:51 AM,Merck wins four new approvals for Keytruda in Japan,Seeking Alpha,https://seekingalpha.com/news/3886260-merck-wins-four-new-approvals-for-keytruda-in-japan?utm_source=businessinsider&utm_medium=referral,positive,0.9227002859115601
9/27/2022 2:00:38 PM,7 Profitable Places to Hide Your Money as We Enter a Bear Market,InvestorPlace,/news/stocks/7-profitable-places-to-hide-your-money-during-a-bear-market-1031459868,neutral,0.9188072085380554
9/28/2022 10:00:08 AM,7 Blue-Chip Sleeper Stocks to Buy Before Wall Street Wakes Up,InvestorPlace,/news/stocks/7-blue-chip-sleeper-stocks-to-buy-before-wall-street-wakes-up-1031769357,neutral,0.8864754438400269
9/28/2022 1:06:55 PM,Merck in pact with Sinopharm to launch oral COVID-19 therapy in China,Seeking Alpha,https://seekingalpha.com/news/3886726-merck-stock-on-watch-after-partnership-with-sinopharm-for-oral-covid-19-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.838412344455719
9/29/2022 7:45:38 PM,Merck wins appeals court ruling against Viatris over generic diabetic drugs,Seeking Alpha,https://seekingalpha.com/news/3887242-merck-wins-appeals-court-ruling-against-viatris-over-generic-diabetic-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.7449671626091003
9/30/2022 12:15:42 PM,Biotech Stocks Facing FDA Decision In October 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2022-1031775243,neutral,0.915293276309967
9/30/2022 2:32:00 PM,10 Analysts Have This to Say About Merck & Co,Benzinga,/news/stocks/10-analysts-have-this-to-say-about-merck-co-1031775551,neutral,0.9286388158798218
9/30/2022 4:10:44 PM,"'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company",Benzinga,/news/stocks/right-now-you-ve-still-got-to-avoid-the-stock-jim-cramer-says-about-this-aerospace-company-1031775908,neutral,0.7329362630844116
9/30/2022 8:11:00 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK), AbbVie (ABBV) and Intercept Pharma (ICPT)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-merck-company-mrk-abbvie-abbv-and-intercept-pharma-icpt-1031776731,negative,0.9366409778594971
10/2/2022 3:49:45 PM,"AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know",Benzinga,/news/stocks/astrazeneca-merck-s-prostate-cancer-combo-drug-3rd-try-for-scpharma-3-fda-panel-decisions-and-more-october-s-key-pdufa-catalysts-biotech-investors-must-know-1031777495,neutral,0.8742386102676392
10/3/2022 12:52:54 PM,PDS Biotech jumps 13% as FDA clears further development of lead asset,Seeking Alpha,https://seekingalpha.com/news/3887912-pdsb-stock-jumps-as-fda-clears-further-development-of-lead-asset?utm_source=businessinsider&utm_medium=referral,positive,0.8763917684555054
10/3/2022 11:56:59 PM,The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short,Benzinga,/news/etf/the-short-list-of-dow-jones-stocks-that-are-actually-up-this-year-hint-—-it-s-very-short-1031780150,neutral,0.6578128337860107
10/4/2022 1:07:04 PM,Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3888453-immutep-stock-climbs-on-fda-fast-track-status-for-eftilagimod-to-treat-lung-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.933364748954773
10/4/2022 6:09:33 PM,HHS change to Medicare payments for biosimilars aims to spur uptake,Seeking Alpha,https://seekingalpha.com/news/3888611-hhs-change-to-medicare-payments-for-biosimilars-aims-to-spur-uptake?utm_source=businessinsider&utm_medium=referral,positive,0.9251478314399719
10/5/2022 8:40:58 AM,GSK Jemperli meets main goal of phase 2 trial to treat lung cancer,Seeking Alpha,https://seekingalpha.com/news/3888724-gsk-jemperli-meets-main-goal-of-phase-2-trial-to-treat-lung-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.6131075620651245
10/5/2022 5:31:11 PM,AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial,Benzinga,/news/stocks/anaptysbio-gsk-partnered-immuno-oncology-agent-meets-primary-goal-in-lung-cancer-trial-1031785184,positive,0.7115055918693542
10/6/2022 9:10:00 AM,"Merck boosts Singapore presence, opens new site, sets stage for another in $500 expansion",Seeking Alpha,https://seekingalpha.com/news/3889108-merck-boosts-singapore-presence-opens-new-site-sets-stage-for-another-in-500-expansion?utm_source=businessinsider&utm_medium=referral,positive,0.7811304330825806
10/6/2022 9:49:53 PM,"Verve's Stock Price Could Continue To Rise Through Clinical Progress - Despite Worries About ""DeeperPocketed"" Competition",Benzinga,/news/stocks/verve-s-stock-price-could-continue-to-rise-through-clinical-progress---despite-worries-about-deeperpocketed-competition-1031788580,positive,0.9496306777000427
10/7/2022 10:58:39 AM,"Merck, Ridgeback COVID pill Lagevrio fails to show benefit in older adults in UK study, mixed show in Israel data",Seeking Alpha,https://seekingalpha.com/news/3889570-merck-ridgeback-covid-pill-lagevrio-fails-to-show-benefit-in-older-adults-in-uk-study-mixed-show-in-israel-data?utm_source=businessinsider&utm_medium=referral,negative,0.7919235825538635
10/10/2022 11:35:59 AM,Merck's Acceleron buy shows results as sotatercept meets main goal in trial to treat high pressure in lungs,Seeking Alpha,https://seekingalpha.com/news/3889939-mercks-acceleron-buy-shows-results-as-sotatercept-meets-main-goal-in-trial-to-treat-high-pressure-in-lungs?utm_source=businessinsider&utm_medium=referral,positive,0.875679612159729
10/10/2022 12:20:45 PM,Merck raised to Buy at Guggenheim citing earnings beats ahead,Seeking Alpha,https://seekingalpha.com/news/3889960-merck-raised-to-buy-at-guggenheim-citing-earnings-beats-ahead?utm_source=businessinsider&utm_medium=referral,negative,0.675652801990509
10/10/2022 4:08:11 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-10-2022-1031793370,neutral,0.508715808391571
10/10/2022 4:40:00 PM,Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish',Benzinga,/news/stocks/failure-of-this-merck-study-is-a-material-risk-but-analysts-are-extremely-bullish-1031793468,negative,0.6270881295204163
10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral,neutral,0.5134317874908447
10/10/2022 6:25:57 PM,Merck (MRK) Stock Jumps 4% on Positive Trial Data,InvestorPlace,/news/stocks/merck-mrk-stock-jumps-4-percent-on-positive-trial-data-1031793943,positive,0.9339905381202698
10/11/2022 8:11:39 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nevro Crop (NVRO) and NuVasive (NUVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-nevro-crop-nvro-and-nuvasive-nuva-1031795047,neutral,0.920221745967865
10/11/2022 11:47:40 AM,"Ginkgo, Merck team up to improve pharma manufacturing process",Seeking Alpha,https://seekingalpha.com/news/3890262-ginkgo-merck-team-up-to-improve-pharma-manufacturing-process?utm_source=businessinsider&utm_medium=referral,positive,0.8574474453926086
10/11/2022 12:41:33 PM,"Analysts’ Top Healthcare Picks: Merck & Company (MRK), Xenon (XENE)",TipRanks,/news/stocks/analysts-top-healthcare-picks-merck-company-mrk-xenon-xene-1031795963,positive,0.5564817786216736
10/11/2022 1:08:28 PM,"Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial",Seeking Alpha,https://seekingalpha.com/news/3890318-compass-therapeutics-merck-ink-collaboration-deal-for-early-stage-cancer-trial?utm_source=businessinsider&utm_medium=referral,positive,0.6733008623123169
10/11/2022 1:45:42 PM,Merck To Rally Over 29%? Here Are 5 Other Price Target Changes For Tuesday,Benzinga,/news/stocks/merck-to-rally-over-29-here-are-5-other-price-target-changes-for-tuesday-1031795605,neutral,0.925809919834137
10/11/2022 3:10:42 PM,What Is Going on With Ginkgo Bioworks (DNA) Stock Today?,InvestorPlace,/news/stocks/what-is-going-on-with-ginkgo-bioworks-dna-stock-today-3-1031796604,negative,0.556456983089447
10/11/2022 8:38:58 PM,"With Meaningful Upside, This Cancer Stock Earns Analyst Upgrade",Benzinga,/news/stocks/with-meaningful-upside-this-cancer-stock-earns-analyst-upgrade-1031797089,positive,0.6986216902732849
10/11/2022 8:45:37 PM,"Vaxcyte appoints new CBO, CMO",Seeking Alpha,https://seekingalpha.com/news/3890505-vaxcyte-appoints-new-cbo-cmo?utm_source=businessinsider&utm_medium=referral,neutral,0.91988205909729
10/12/2022 6:21:26 AM,"Analysts’ Top Healthcare Picks: Insmed (INSM), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-insmed-insm-merck-company-mrk-1031798464,neutral,0.49911749362945557
10/12/2022 12:26:53 PM,Moderna stock rises as Merck uses option to jointly develop personalized cancer vaccine,Seeking Alpha,https://seekingalpha.com/news/3890670-moderna-stock-rises-as-merck-uses-option-to-jointly-develop-personalized-cancer-vaccine?utm_source=businessinsider&utm_medium=referral,positive,0.7469168305397034
10/12/2022 1:14:44 PM,Merck Keytruda gets approval in Canada for post-surgery use in certain kidney cancer patients,Seeking Alpha,https://seekingalpha.com/news/3890703-merck-keytruda-gets-approval-in-canada-for-post-surgery-use-in-certain-kidney-cancer-patients?utm_source=businessinsider&utm_medium=referral,positive,0.9280385375022888
10/12/2022 1:29:54 PM,Merck Says Health Canada Granted Approval For KEYTRUDA To Treat Renal Cell Carcinoma ,RTTNews,/news/stocks/merck-says-health-canada-granted-approval-for-keytruda-to-treat-renal-cell-carcinoma-1031799126,positive,0.9281975626945496
10/12/2022 3:23:51 PM,Why Is Moderna (MRNA) Stock Up 10% Today?,InvestorPlace,/news/stocks/why-is-moderna-mrna-stock-up-10-today-1031800283,positive,0.7252136468887329
10/12/2022 4:20:25 PM,Royalty Pharma to co-fund development of schizophrenia drug with Merck,Seeking Alpha,https://seekingalpha.com/news/3890788-royalty-pharma-to-co-fund-development-of-schizophrenia-drug-with-merck?utm_source=businessinsider&utm_medium=referral,neutral,0.6470693945884705
10/13/2022 3:29:36 PM,Celyad touches 52-week low after William Blair downgrades rating as company scraps colorectal cancer therapy trial,Seeking Alpha,https://seekingalpha.com/news/3891136-celyad-touches-52-week-low-after-william-blair-downgrades-rating-as-company-scraps-colorectal-cancer-therapy-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9457532167434692
10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral,positive,0.8669121861457825
10/17/2022 5:10:07 PM,5 Top Stocks Cathie Wood Is Buying This Week,InvestorPlace,/news/stocks/5-top-stocks-cathie-wood-is-buying-this-week-4-1031810836,neutral,0.9060774445533752
10/18/2022 11:41:25 AM,Merck to license TB drug candidates to Gates Foundation's research arm,Seeking Alpha,https://seekingalpha.com/news/3892134-merck-to-license-tb-drug-candidates-to-gates-foundations-research-arm?utm_source=businessinsider&utm_medium=referral,neutral,0.8453352451324463
10/18/2022 2:26:09 PM,Merck Animal Health launches monitor for dogs with GPS tracker,Seeking Alpha,https://seekingalpha.com/news/3892259-merck-animal-health-launches-monitor-for-dogs-with-gps-tracker?utm_source=businessinsider&utm_medium=referral,neutral,0.9032630920410156
10/18/2022 3:07:00 PM,Merck Animal Health Launches Sure Petcare Animo® GPS,PR Newswire,/news/stocks/merck-animal-health-launches-sure-petcare-animo-gps-1031813627,neutral,0.8151642084121704
10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral,neutral,0.7574050426483154
10/20/2022 6:25:25 PM,Can Acquisitions and Partnerships Take Ginkgo Bioworks (DNA) Stock Higher?,InvestorPlace,/news/stocks/can-acquisitions-and-partnerships-take-ginkgo-bioworks-dna-stock-higher-1031822285,positive,0.7936777472496033
10/21/2022 1:27:45 PM,Moderna upgraded to market perform at SVB Securities on likely higher COVID shot pricing,Seeking Alpha,https://seekingalpha.com/news/3893693-moderna-upgraded-to-market-perform-at-svb-securities-on-likely-higher-covid-shot-pricing?utm_source=businessinsider&utm_medium=referral,positive,0.9503877758979797
10/21/2022 5:16:55 PM,"Earnings week ahead: Apple, Alphabet, Amazon, Meta, Boeing and more",Seeking Alpha,https://seekingalpha.com/news/3893730-earnings-week-ahead-apple-alphabet-amazon-meta-boeing-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9336963295936584
10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral,neutral,0.6700782775878906
10/21/2022 6:00:33 PM,"Catalyst Watch: Tech heavyweights report, Mobileye IPO and Twitter-Tesla-Musk drama redux",Seeking Alpha,https://seekingalpha.com/news/3893787-catalyst-watch-tech-heavyweights-report-mobileye-ipo-and-twitter-tesla-musk-drama-redux?utm_source=businessinsider&utm_medium=referral,neutral,0.8056232929229736
10/21/2022 6:26:19 PM,"Catalyst Watch: Tech heavyweights report, Mobileye IPO and Twitter-Tesla-Musk drama redux",Seeking Alpha,https://seekingalpha.com/news/3893799-catalyst-watch-tech-heavyweights-report-mobileye-ipo-and-twitter-tesla-musk-drama-redux?utm_source=businessinsider&utm_medium=referral,neutral,0.8056232929229736
10/21/2022 7:04:03 PM,"Catalyst Watch: Tech heavyweights report, Mobileye IPO and Twitter-Tesla-Musk drama redux",Seeking Alpha,https://seekingalpha.com/news/3893812-catalyst-watch-tech-heavyweights-report-mobileye-ipo-and-twitter-tesla-musk-drama-redux?utm_source=businessinsider&utm_medium=referral,neutral,0.8056232929229736
10/24/2022 11:12:30 AM,7 Stocks to Sell Before They Give Back This Year’s Gain,InvestorPlace,/news/stocks/7-stocks-to-sell-before-they-give-back-gains-1031828064,neutral,0.9072326421737671
10/24/2022 11:41:37 AM,Merck's pneumococcal vaccine approved in EU for use in infants,Seeking Alpha,https://seekingalpha.com/news/3894012-mercks-pneumococcal-vaccine-approved-in-eu-for-use-in-infants?utm_source=businessinsider&utm_medium=referral,positive,0.6681885123252869
10/24/2022 12:24:32 PM,Alpine Immune ends enrollments for cancer studies after patient death,Seeking Alpha,https://seekingalpha.com/news/3894045-alpn-stock-drops-on-plans-to-end-enrollments-for-cancer-studies?utm_source=businessinsider&utm_medium=referral,negative,0.6229164600372314
10/24/2022 1:38:36 PM,Merck: European Commission Approves Expanded Indication For VAXNEUVANCE ,RTTNews,/news/stocks/merck-european-commission-approves-expanded-indication-for-vaxneuvance-1031828110,positive,0.7456961870193481
10/26/2022 3:01:13 PM,Here's what to expect from Merck's earnings,Markets Insider Automation,/news/stocks/merck_co-q3-quarterly-earnings-preview-stock-1031838368,neutral,0.9375721216201782
10/26/2022 9:04:59 PM,Merck names CEO Robert Davis as chairman,Seeking Alpha,https://seekingalpha.com/news/3896006-merck-names-ceo-robert-davis-as-chairman?utm_source=businessinsider&utm_medium=referral,neutral,0.9261509776115417
10/27/2022 10:31:55 AM,"Merck Non-GAAP EPS of $1.85 beats by $0.14, revenue of $15B beats by $950M, raises FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3896248-merck-non-gaap-eps-of-185-beats-by-014-revenue-of-15b-beats-by-950m-raises-fy22-outlook?utm_source=businessinsider&utm_medium=referral,positive,0.8921061754226685
10/27/2022 11:09:01 AM,Merck posts Q3 beat as Keytruda offsets sales impact on COVID-19 pill,Seeking Alpha,https://seekingalpha.com/news/3896313-merck-posts-q3-beat-as-keytruda-offset-sales-impact-on-covid-19-pill?utm_source=businessinsider&utm_medium=referral,positive,0.9389420747756958
10/27/2022 11:45:13 AM,Mizuho Securities Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-merck-company-mrk-1031843010,neutral,0.9361416697502136
10/27/2022 2:01:30 PM,Merck Boosts Outlook As Q3 Results Top Estimates ,RTTNews,/news/stocks/merck-boosts-outlook-as-q3-results-top-estimates-1031843089,positive,0.9374200105667114
10/27/2022 3:54:30 PM,Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’,InvestorPlace,/news/stocks/midterm-elections-2022-3-stocks-to-avoid-like-the-plague-for-a-blue-wave-1031844449,neutral,0.8777721524238586
10/28/2022 12:35:53 PM,Wells Fargo Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-merck-company-mrk-1031848320,neutral,0.7996698021888733
10/28/2022 12:36:20 PM,Merck & Company (MRK) Receives a Buy from Atlantic Equities,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-atlantic-equities-1031848318,positive,0.729107141494751
10/28/2022 12:36:52 PM,SVB Securities Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-merck-company-mrk-1031848314,neutral,0.8164269328117371
10/28/2022 12:37:04 PM,Pfizer COVID-19 therapy picked for long COVID study in U.S.,Seeking Alpha,https://seekingalpha.com/news/3897216-pfizer-covid-19-therapy-undergoes-long-covid-study-in-us?utm_source=businessinsider&utm_medium=referral,positive,0.6339743733406067
10/28/2022 3:12:28 PM,What 7 Analyst Ratings Have To Say About Merck & Co,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-merck-co-1031848486,neutral,0.9330793023109436
10/31/2022 11:42:01 AM,Bristol Myers says Merck-partnered blood cancer therapy met main goal in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3897653-bristol-myers-merck-partnered-blood-cancer-therapy-succeeds-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.5755215287208557
10/31/2022 12:12:46 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Resmed (RMD) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-insulet-podd-resmed-rmd-and-merck-company-mrk-1031853390,negative,0.8243154287338257
11/1/2022 12:03:00 PM,Veeva and Merck Form Long-Term Strategic Partnership,PR Newswire,/news/stocks/veeva-and-merck-form-long-term-strategic-partnership-1031857693,neutral,0.9262332916259766
11/1/2022 12:24:55 PM,"Merck engages Veeva to help reduce cost, improve data capabilities",Seeking Alpha,https://seekingalpha.com/news/3898463-merck-engages-veeva-to-help-reduce-cost-improve-data-capabilities?utm_source=businessinsider&utm_medium=referral,positive,0.8885944485664368
11/3/2022 1:20:22 AM,"Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Staar Surgical (STAA)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-merck-company-mrk-staar-surgical-staa-1031866866,neutral,0.6929236054420471
11/3/2022 2:19:03 PM,Organon gains after earnings beat despite contraction in topline,Seeking Alpha,https://seekingalpha.com/news/3901051-ogn-stock-gains-after-earnings-beat-despite-contraction-in-topline?utm_source=businessinsider&utm_medium=referral,positive,0.908846914768219
11/4/2022 3:31:28 PM,Eli Lilly COVID-19 therapy unlikely to neutralize new Omicron subvariants - FDA,Seeking Alpha,https://seekingalpha.com/news/3902025-eli-lilly-covid-19-therapy-unlikely-to-neutralize-new-omicron-subvariants?utm_source=businessinsider&utm_medium=referral,positive,0.7704504728317261
11/8/2022 1:45:58 PM,Portage surges 12% on team up with Merck to test PORT-2/ Keytruda combo,Seeking Alpha,https://seekingalpha.com/news/3903494-portage-surges-on-team-up-with-merck-to-test-port-2-keytruda-combo?utm_source=businessinsider&utm_medium=referral,positive,0.947794497013092
11/8/2022 7:47:03 PM,"Eli Lilly, Merck reach new 52-week highs",Seeking Alpha,https://seekingalpha.com/news/3903867-eli-lilly-merck-reach-new-52-week-highs?utm_source=businessinsider&utm_medium=referral,positive,0.6138051152229309
11/8/2022 8:37:59 PM,Election Day Is Here: Which Politicians Are Profiting (Or Losing) On Stocks?,Benzinga,/news/stocks/election-day-is-here-which-politicians-are-profiting-or-losing-on-stocks-1031888216,neutral,0.7142788767814636
11/8/2022 11:44:09 PM,7 No-Brainer Retirement Stocks to Buy for 2023 and Beyond,InvestorPlace,/news/stocks/7-no-brainer-retirement-stocks-to-buy-for-2023-and-beyond-1031888986,neutral,0.8955941796302795
11/10/2022 2:31:52 PM,"Sellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial",Seeking Alpha,https://seekingalpha.com/news/3905615-sellas-rises-as-gpskeytruda-combo-shows-survival-disease-control-benefit-in-ovarian-cancer-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9503385424613953
11/11/2022 1:35:42 PM,AstraZeneca/Merck's Lynparza gets EMA panel's greenlight for expanded use in prostate cancer,Seeking Alpha,https://seekingalpha.com/news/3906396-astrazenecamercks-lynparza-gets-ema-panels-greenlight-for-expanded-use-in-prostate-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.9274449348449707
11/11/2022 2:17:50 PM,OncoSec jumps 19% after positive Phase 2 data for melanoma candidate,Seeking Alpha,https://seekingalpha.com/news/3906440-onsc-stock-jumps-after-positive-phase-2-data-for-melanoma-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.853660523891449
11/11/2022 8:16:39 PM,"Healthcare stocks come off lows, worst performing sector among defensive losers (update)",Seeking Alpha,https://seekingalpha.com/news/3906637-healthcare-stocks-fall-across-the-board-as-traders-move-out-of-defensive-sectors?utm_source=businessinsider&utm_medium=referral,negative,0.8541243672370911
11/11/2022 9:31:43 PM,Why Are Healthcare Stocks Down Today?,InvestorPlace,/news/stocks/why-are-healthcare-stocks-down-today-1031905660,negative,0.944724440574646
11/11/2022 11:34:31 PM,"These 2 Dividend Paying ETFs Have A Track Record For Increasing Payments, Can Help Diversify Against Industry Risk",Benzinga,/news/etf/these-2-dividend-paying-etfs-have-a-track-record-for-increasing-payments-can-help-diversify-against-industry-risk-1031905724,positive,0.9117457270622253
11/13/2022 1:59:54 AM,U.S. COVID health emergency to stay in place,Seeking Alpha,https://seekingalpha.com/news/3906753-us-covid-health-emergency-to-stay-in-place?utm_source=businessinsider&utm_medium=referral,negative,0.6932174563407898
11/14/2022 8:35:11 AM,"AstraZeneca: CHMP Recommends Approval Of Lynparza In Combination With Abiraterone, Prednisone ",RTTNews,/news/stocks/astrazeneca-chmp-recommends-approval-of-lynparza-in-combination-with-abiraterone-prednisone-1031908878,positive,0.7745907306671143
11/15/2022 8:25:54 PM,7 Value Stocks to Buy Before They Pop Off,InvestorPlace,/news/stocks/7-value-stocks-to-buy-before-they-pop-off-1031916410,neutral,0.9235542416572571
11/17/2022 8:37:35 PM,Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial,Benzinga,/news/stocks/analyst-expects-somewhat-smaller-effect-size-from-gossamer-bio-s-upcoming-pah-trial-1031923417,positive,0.7967486381530762
11/18/2022 4:02:50 PM,What 13 Analyst Ratings Have To Say About Merck & Co,Benzinga,/news/stocks/what-13-analyst-ratings-have-to-say-about-merck-co-1031925560,neutral,0.927879810333252
11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925,negative,0.5206902027130127
11/18/2022 8:08:40 PM,Credit Suisse Believes In This Pharma Giant's Low Risk Growth Against Uncertain Backdrop,Benzinga,/news/stocks/credit-suisse-believes-in-this-pharma-giant-s-low-risk-growth-against-uncertain-backdrop-1031926174,positive,0.827784538269043
11/19/2022 8:54:10 PM,The 25 Best Stocks to Buy for Retirement,InvestorPlace,/news/stocks/the-25-best-stocks-to-buy-for-retirement-1031926626,neutral,0.8740954399108887
11/21/2022 1:00:43 PM,Merck To Acquire Imago BioSciences ,RTTNews,/news/stocks/merck-to-acquire-imago-biosciences-1031928170,neutral,0.9421008229255676
11/21/2022 1:55:11 PM,Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1031928793,neutral,0.716327965259552
11/21/2022 2:55:20 PM,Cancer-Focused Imago BioSciences Shares Soar After Merck Deal,Benzinga,/news/stocks/cancer-focused-imago-biosciences-shares-soar-after-merck-deal-1031928648,negative,0.4518947899341583
11/21/2022 4:10:49 PM,Why Is Imago Biosciences (IMGO) Stock Up 105% Today?,InvestorPlace,/news/stocks/why-is-imago-biosciences-imgo-stock-up-105-today-1031929093,positive,0.8266316056251526
11/21/2022 7:23:41 PM,Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated',Benzinga,/news/stocks/analyst-says-io-biotech-s-cancer-treatment-approach-differentiated-1031929374,positive,0.6674297451972961
11/22/2022 2:53:53 PM,Merck: Phase 3 KEYNOTE-859 Trial Meets Primary Endpoint Of Overall Survival ,RTTNews,/news/stocks/merck-phase-3-keynote-859-trial-meets-primary-endpoint-of-overall-survival-1031931298,positive,0.7924836874008179
11/22/2022 11:59:07 PM,3 Undervalued Dow Stocks to Buy Before Wall Street Catches On,InvestorPlace,/news/stocks/undervalued-dow-stocks-1031585407,positive,0.5948197841644287
11/23/2022 3:35:16 AM,Merck & Company (MRK) Gets a Buy from SVB Securities,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-svb-securities-1031932749,neutral,0.7731749415397644
11/23/2022 11:47:47 PM,7 Stocks on the Perfect 10 List,InvestorPlace,/news/stocks/7-stocks-on-the-perfect-10-list-1031935181,neutral,0.5972025394439697
11/24/2022 6:51:39 AM,3 Biotech Stocks Smart Investors Should Be Buying Up Now,InvestorPlace,/news/stocks/3-biotech-stocks-smart-investors-should-be-buying-up-now-1031935520,neutral,0.575271725654602
11/28/2022 10:28:43 PM,Wall Street Loves These 4 “Strong Buy” Stocks Right Now,TipRanks,/news/stocks/wall-street-loves-these-4-strong-buy-stocks-right-now-1031940806,neutral,0.7561403512954712
11/29/2022 2:41:47 PM,3 Dow Stocks to Take Seriously in 2023,InvestorPlace,/news/stocks/3-dow-stocks-to-take-seriously-in-2023-1031942435,neutral,0.9237651824951172
12/6/2022 3:51:03 PM,Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?,InvestorPlace,/news/stocks/why-is-gossamer-bio-goss-stock-down-over-70-today-1031955799,negative,0.9622565507888794
12/6/2022 5:03:25 PM,Gossamer Bio selloff is an overreaction - Piper Sandler,Seeking Alpha,https://seekingalpha.com/news/3914434-goss-stock-in-selloff-piper-sandler-says-overreaction?utm_source=businessinsider&utm_medium=referral,neutral,0.6009430885314941
12/7/2022 1:08:10 PM,Gossamer Bio downgraded to Equal Weight at Barclays after PAH readout,Seeking Alpha,https://seekingalpha.com/news/3914835-goss-stock-downgraded-to-equal-weight-at-barclays-after-pah-readout?utm_source=businessinsider&utm_medium=referral,negative,0.6745539903640747
12/7/2022 7:47:08 PM,Mirati slumps for second day on adagrasib lung cancer data; down 30%,Seeking Alpha,https://seekingalpha.com/news/3915018-mirati-slumps-for-second-day-on-adagrasib-lung-cancer-data-down-30?utm_source=businessinsider&utm_medium=referral,negative,0.9690792560577393
12/8/2022 1:35:24 PM,Rapt FLX475 shows antitumor activity in advanced lung cancer in phase 1/2 trial,Seeking Alpha,https://seekingalpha.com/news/3915266-rapt-flx475-shows-antitumor-activity-in-phase-12-trial-in-advanced-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.7781500220298767
12/8/2022 4:19:07 PM,Mirati Therapeutics down for third day as cancer data leads to analyst downgrades,Seeking Alpha,https://seekingalpha.com/news/3915373-mirati-therapeutics-down-for-third-day-as-cancer-data-leads-to-analyst-downgrades?utm_source=businessinsider&utm_medium=referral,negative,0.9672159552574158
12/9/2022 5:55:53 AM,SVB Securities Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-merck-company-mrk-1031962072,neutral,0.9139111042022705
12/12/2022 11:59:26 AM,Merck initiates tender offer to acquire Imago BioSciences,Seeking Alpha,https://seekingalpha.com/news/3916028-merck-initiates-tender-offer-to-acquire-imago-biosciences?utm_source=businessinsider&utm_medium=referral,neutral,0.7891905903816223
12/12/2022 12:57:03 PM,Merck Commences Tender Offer To Acquire Imago BioSciences ,RTTNews,/news/stocks/merck-commences-tender-offer-to-acquire-imago-biosciences-1031965014,neutral,0.896818220615387
12/13/2022 10:29:18 AM,"Merck, Bio Farma ink contract to produce HPV vaccine in Indonesia",Seeking Alpha,https://seekingalpha.com/news/3916404-merck-bio-farma-ink-contract-to-produce-hpv-vaccine-in-indonesia?utm_source=businessinsider&utm_medium=referral,positive,0.8133169412612915
12/13/2022 1:17:46 PM,Moderna stock rises as mRNA vaccine/Keytruda combo shows promise in skin cancer trial,Seeking Alpha,https://seekingalpha.com/news/3916468-moderna-stock-rises-as-mrna-vaccinekeytruda-combo-shows-promise-in-mid-stage-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9491716027259827
12/13/2022 2:07:46 PM,"Moderna, Merck's Phase 2b Trial Of MRNA-4157/V940 Combination In Melanoma Meets Primary Endpoint ",RTTNews,/news/stocks/moderna-merck-s-phase-2b-trial-of-mrna-4157-v940-combination-in-melanoma-meets-primary-endpoint-1031969030,positive,0.8194171786308289
12/13/2022 2:31:36 PM,Moderna (MRNA) Stock Soars on Cancer Vaccine News,InvestorPlace,/news/stocks/moderna-mrna-stock-soars-on-cancer-vaccine-news-1031969407,positive,0.5962517857551575
12/13/2022 3:09:51 PM,"Inflation Cools Down: Which Stocks Will Benefit, and Which Won’t",TipRanks,/news/stocks/inflation-cools-down-which-stocks-will-benefit-and-which-won-t-1031969542,neutral,0.7590286731719971
12/13/2022 4:35:26 PM,Shionogi to deliver additional 1M courses of COVID pills to Japan,Seeking Alpha,https://seekingalpha.com/news/3916574-shionogi-to-deliver-additional-1m-courses-of-covid-pills-to-japan?utm_source=businessinsider&utm_medium=referral,positive,0.5544115304946899
12/13/2022 7:04:10 PM,"mRNA cancer vaccines could be in greater focus after Moderna, Merck candidate shines",Seeking Alpha,https://seekingalpha.com/news/3916642-mrna-cancer-vaccines-could-be-in-greater-focus-after-moderna-merck-candidate-shines?utm_source=businessinsider&utm_medium=referral,neutral,0.6820481419563293
12/13/2022 7:52:04 PM,Pfizer COVID-19 pill sold out in China as health app begins online sales,Seeking Alpha,https://seekingalpha.com/news/3916606-pfizer-covid-19-pill-sold-out-in-china-as-health-app-begins-online-sales?utm_source=businessinsider&utm_medium=referral,positive,0.9188224077224731
12/13/2022 7:53:05 PM,The 7 Best Investment Funds to Navigate a Possible Recession,InvestorPlace,/news/stocks/the-7-best-investment-funds-to-navigate-possible-recession-1031970170,neutral,0.6435859203338623
12/13/2022 8:13:21 PM,"Moderna's Data From Personalized Cancer Vaccine Provides Relief To Investors, Analyst Says",Benzinga,/news/stocks/moderna-s-data-from-personalized-cancer-vaccine-provides-relief-to-investors-analyst-says-1031970136,positive,0.9384973049163818
12/14/2022 2:35:11 PM,Moderna cools as Chardan Capital downgrades after 20% rally,Seeking Alpha,https://seekingalpha.com/news/3916939-mrna-stock-cools-as-chardan-capital-downgrades-after-20-rally?utm_source=businessinsider&utm_medium=referral,negative,0.7358198165893555
12/14/2022 5:23:02 PM,WHO chief hopeful COVID emergency will end next year,Seeking Alpha,https://seekingalpha.com/news/3917016-who-chief-hopeful-covid-emergency-will-end-next-year?utm_source=businessinsider&utm_medium=referral,neutral,0.8428406715393066
12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral,neutral,0.7342972755432129
12/14/2022 9:25:18 PM,Mizuho Securities Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-keeps-their-buy-rating-on-merck-company-mrk-1031973030,neutral,0.9022791981697083
12/14/2022 10:27:49 PM,7 Stocks to Buy on the Dip as the S&P 500 Falters,InvestorPlace,/news/stocks/7-stocks-to-buy-on-the-dip-as-the-sp-500-falters-1031976372,negative,0.8405872583389282
12/15/2022 8:57:08 AM,AstraZeneca: FDA To Extend PDUFA Date Regarding SNDA For Lynparza With Abiraterone ,RTTNews,/news/stocks/astrazeneca-fda-to-extend-pdufa-date-regarding-snda-for-lynparza-with-abiraterone-1031973767,neutral,0.772167980670929
12/15/2022 9:34:46 AM,FDA extends review of AstraZeneca/Merck's Lynparza's expanded use in prostate cancer,Seeking Alpha,https://seekingalpha.com/news/3917418-fda-extends-review-of-astrazenecamercks-lynparzas-expanded-use-in-prostate-cancer?utm_source=businessinsider&utm_medium=referral,neutral,0.8040944933891296
12/15/2022 11:08:17 AM,"J&J, Merck Ebola vaccines show lasting antibody response in kids, adults in trials",Seeking Alpha,https://seekingalpha.com/news/3917434-jj-merck-ebola-vaccines-show-lasting-antibody-response-in-kids-and-adults-in-trials?utm_source=businessinsider&utm_medium=referral,positive,0.85991370677948
12/15/2022 2:21:06 PM,BioNTech upgraded at Bank of America citing Moderna data for cancer vaccine,Seeking Alpha,https://seekingalpha.com/news/3917575-bntx-stock-upgraded--bank-of-america-moderna-cancer-vaccine?utm_source=businessinsider&utm_medium=referral,neutral,0.5502591729164124
12/15/2022 7:15:07 PM,"BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities",Benzinga,/news/stocks/biontech-stock-gets-upgrade-analyst-sees-multiple-upside-opportunities-1031975632,positive,0.690212070941925
12/16/2022 5:25:25 AM,Merck & Company (MRK) Gets a Buy from SVB Securities,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-svb-securities-1031976242,neutral,0.7731749415397644
12/16/2022 11:25:27 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/large-cap-stocks-to-buy-and-hold-1031827937,neutral,0.8808764219284058
12/18/2022 5:00:26 PM,"mRNA-based cancer vaccines have limits, pioneer of the technology says",Seeking Alpha,https://seekingalpha.com/news/3918253-mrna-based-cancer-vaccines-have-limits-pioneer-of-the-technology-says?utm_source=businessinsider&utm_medium=referral,neutral,0.8898115158081055
12/18/2022 9:34:20 PM,The 7 Best Retirement Stocks to Buy Now,InvestorPlace,/news/stocks/best-retirement-stocks-1031562793,neutral,0.8736042380332947
12/18/2022 10:12:08 PM,The 7 Most Undervalued Long-Term Stocks to Buy Now,InvestorPlace,/news/stocks/undervalued-long-term-stocks-1031691221,neutral,0.7136157751083374
12/19/2022 3:17:28 PM,What's Going On With Moderna Stock Monday?,Benzinga,/news/stocks/what-s-going-on-with-moderna-stock-monday-1031980208,neutral,0.5052963495254517
12/20/2022 12:45:00 PM,"Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ...",PR Newswire,/news/stocks/astellas-seagen-and-merck-announce-fda-acceptance-of-supplemental-biologics-license-applications-for-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-for-the-first-line-treatment-1031982064,positive,0.9156583547592163
12/20/2022 1:08:25 PM,"Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer ",RTTNews,/news/stocks/astellas-padcev-keytruda-granted-priority-review-in-treatment-of-metastatic-urothelial-cancer-1031982132,positive,0.8718492984771729
12/20/2022 1:41:49 PM,"Merck, Seagen, Astellas combo bladder cancer treatment sBLAs accepted by FDA",Seeking Alpha,https://seekingalpha.com/news/3918891-merck-seagen-astellas-combo-bladder-cancer-treatment-sblas-accepted-by-fda?utm_source=businessinsider&utm_medium=referral,neutral,0.827815592288971
12/20/2022 8:10:02 PM,Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data,InvestorPlace,/news/stocks/gilead-sciences-gild-stock-falls-on-lung-cancer-drug-data-1031983382,negative,0.9549485445022583
12/20/2022 9:00:54 PM,"Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says",Benzinga,/news/stocks/top-m-a-target-madrigal-pharmaceuticals-could-be-next-after-successful-nash-data-analyst-says-1031983372,positive,0.7063286304473877
12/21/2022 9:29:31 AM,"AstraZeneca, Merck's Lynparza gets approval in EU for expanded use in prostate cancer",Seeking Alpha,https://seekingalpha.com/news/3919299-astrazeneca-mercks-lynparza-gets-approval-in-eu-for-expanded-use-in-prostate-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.913720428943634
12/21/2022 4:22:21 PM,Top 10 Dividend Growth Stocks and How to Choose Them,TipRanks,/news/stocks/top-10-dividend-growth-stocks-and-how-to-choose-them-1031985324,neutral,0.9481043219566345
12/21/2022 4:34:08 PM,"After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm",Benzinga,/news/stocks/after-disappointing-phase-2-data-merck-drops-eye-disease-related-pact-with-ngm-biopharm-1031985203,negative,0.9373731017112732
12/21/2022 9:57:02 PM,7 Perfect Presents to Gift Your 2023 Stock Portfolio ,InvestorPlace,/news/stocks/7-perfect-presents-to-gift-your-2023-stock-portfolio-stocks-to-buy-1031985916,neutral,0.9044191837310791
12/22/2022 11:00:42 AM,7 Drug Stocks That Will Soar in 2023,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-in-2023-1031986698,neutral,0.4993487596511841
12/22/2022 12:19:13 PM,Merck to pay Kelun $175M upfront in licensing deal to develop antibody drugs for cancer,Seeking Alpha,https://seekingalpha.com/news/3919747-merck-to-pay-kelun-175m-upfront-in-licensing-deal-to-develop-antibody-drugs-for-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.7874894142150879
12/22/2022 12:59:27 PM,"Merck, Kelun-Biotech Collaborate To Develop Seven Preclinical ADC For Treatment Of Cancer ",RTTNews,/news/stocks/merck-kelun-biotech-collaborate-to-develop-seven-preclinical-adc-for-treatment-of-cancer-1031986787,positive,0.702794075012207
12/23/2022 4:51:10 PM,Immune-evasive Omicron subvariant XBB rapidly gaining ground in U.S.,Seeking Alpha,https://seekingalpha.com/news/3920398-immune-evasive-omicron-subvariant-xbb-rapidly-gaining-ground-in-us?utm_source=businessinsider&utm_medium=referral,positive,0.9495846629142761
12/25/2022 5:00:44 PM,Goldman Sachs highlights key healthcare themes for 2023,Seeking Alpha,https://seekingalpha.com/news/3920634-goldman-sachs-micro-over-macro-healthcare-themes-2023?utm_source=businessinsider&utm_medium=referral,neutral,0.7464402914047241
12/27/2022 9:50:22 AM,"Merck, Antengene team up to test Keytruda/ATG-037 combo for solid tumors in phase 1 trial",Seeking Alpha,https://seekingalpha.com/news/3920666-merck-antengene-team-up-to-test-keytrudaatg-037-combo-for-solid-tumors-in-phase-1-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.5148199796676636
12/27/2022 10:57:30 AM,Biotech Stocks Facing FDA Decision In January 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2023-1031990821,neutral,0.901383638381958
12/27/2022 11:49:48 AM,Amgen in licensing deal with LegoChem for antibody drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3920683-amgen-in-licensing-deal-with-legochem-for-antibody-drug-conjugates?utm_source=businessinsider&utm_medium=referral,positive,0.6801367402076721
12/27/2022 1:09:58 PM,Merck inks licensing deal with PeptiDream for peptide drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3920701-merck-inks-licensing-deal-with-peptidream-for-peptide-drug-conjugates?utm_source=businessinsider&utm_medium=referral,positive,0.9039243459701538
12/27/2022 2:12:49 PM,PeptiDream signs licensing deal with Lilly for peptide drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3920726-peptidream-signs-licensing-deal-with-lilly-for-peptide-drug-conjugates?utm_source=businessinsider&utm_medium=referral,positive,0.8612983226776123
12/27/2022 3:11:57 PM,"Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors",Benzinga,/news/stocks/biogen-s-2nd-alzheimer-s-antibody-beigene-s-cancer-drug-label-expansion-adcom-test-for-regeneron-and-more-january-pdufa-catalysts-for-biotech-investors-1031991144,neutral,0.86749267578125
12/28/2022 1:57:16 PM,Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?,InvestorPlace,/news/stocks/why-is-jounce-therapeutics-jnce-stock-up-70-today-1031992397,positive,0.8578581809997559
12/30/2022 11:29:08 AM,China Approves Merck's Covid-19 Drug For Emergency Use ,RTTNews,/news/stocks/china-approves-merck-s-covid-19-drug-for-emergency-use-1031994599,positive,0.7349950075149536
12/30/2022 12:20:02 PM,Merck COVID-19 therapy granted emergency nod in China,Seeking Alpha,https://seekingalpha.com/news/3921247-merck-covid-19-therapy-granted-emergency-nod-in-china?utm_source=businessinsider&utm_medium=referral,positive,0.5151126384735107
12/30/2022 1:43:53 PM,Evaxion jumps 22% as FDA clears mid-stage trial for melanoma candidate,Seeking Alpha,https://seekingalpha.com/news/3921262-evax-stock-jumps-fda-clears-mid-stage-trial-for-melanoma-drug?utm_source=businessinsider&utm_medium=referral,positive,0.8748799562454224
12/30/2022 5:11:21 PM,Diabetes rates in children set to skyrocket by 2060 - study,Seeking Alpha,https://seekingalpha.com/news/3921303-diabetes-rates-in-children-set-to-skyrocket-by-2060-study?utm_source=businessinsider&utm_medium=referral,neutral,0.8470563888549805
12/30/2022 5:45:22 PM,Merck is best performing large U.S. pharma of 2022,Seeking Alpha,https://seekingalpha.com/news/3921306-merck-is-best-performing-large-us-pharma-of-2022?utm_source=businessinsider&utm_medium=referral,positive,0.9400242567062378
12/30/2022 6:19:49 PM,Omicron subvariant XBB becomes dominant COVID strain in U.S.,Seeking Alpha,https://seekingalpha.com/news/3921324-omicron-subvariant-xbb-becomes-dominant-covid-strain-in-us?utm_source=businessinsider&utm_medium=referral,positive,0.8420141339302063
12/31/2022 2:37:49 PM,The 7 Best Retirement Stocks for Investors Over 50,InvestorPlace,/news/stocks/best-retirement-stocks-for-investors-over-50-1031581892,neutral,0.8301514387130737
1/2/2023 5:12:45 AM,2 Defensive Stocks to Protect Your Portfolio Through 2023,TipRanks,/news/stocks/2-defensive-stocks-to-protect-your-portfolio-through-2023-1031996050,neutral,0.9222078323364258
1/4/2023 12:16:20 PM,3 Top Stocks of 2022 That Will Shine Again in 2023,InvestorPlace,/news/stocks/3-top-stocks-of-2022-that-will-shine-again-in-2023-1031999635,neutral,0.7777255177497864
1/4/2023 2:47:04 PM,Merck raised to Buy at BofA on growth prospects despite Keytruda risk,Seeking Alpha,https://seekingalpha.com/news/3921983-merck-raised-to-buy-at-bofa-on-growth-prospects-despite-keytruda-risk?utm_source=businessinsider&utm_medium=referral,positive,0.8982958197593689
1/4/2023 4:01:18 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-4-2023-1032000156,negative,0.5327688455581665
1/4/2023 6:00:27 PM,Analyst Ratings for Merck & Co,Benzinga,/news/stocks/analyst-ratings-for-merck-co-1032000460,neutral,0.9076553583145142
1/4/2023 7:22:33 PM,"Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another",Benzinga,/news/stocks/merck-vs-pfizer-why-analyst-upgrades-one-pharmaceutical-stock-while-downgrading-another-1032000620,neutral,0.6550794243812561
1/6/2023 6:30:04 PM,"Catalyst watch: ICR Conference, JPMorgan Healthcare Conference, CPI, major bank reports",Seeking Alpha,https://seekingalpha.com/news/3922727-catalyst-watch-icr-conference-jpmorgan-healthcare-conference-cpi-major-banks-report?utm_source=businessinsider&utm_medium=referral,neutral,0.9261020421981812
1/6/2023 6:59:28 PM,Omicron subvariant XBB.1.5 continues to increase share of COVID-19 cases - CDC,Seeking Alpha,https://seekingalpha.com/news/3922767-omicron-subvariant-xbb-15-continues-increasing-share-of-covid-19-cases-cdc?utm_source=businessinsider&utm_medium=referral,positive,0.9582667946815491
1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182,neutral,0.8010979890823364
1/9/2023 1:27:59 PM,"Moderna expects $5B COVID vaccine sales in 2023, down from $18B in 2022",Seeking Alpha,https://seekingalpha.com/news/3922929-moderna-expects-5b-covid-vaccine-sales-2023-down-18b-2022?utm_source=businessinsider&utm_medium=referral,negative,0.975167453289032
1/10/2023 1:08:28 PM,WHO sets Jan. 27 meeting to decide on COVID emergency,Seeking Alpha,https://seekingalpha.com/news/3923286-who-sets-jan-27-meeting-to-decide-on-covid-emergency?utm_source=businessinsider&utm_medium=referral,neutral,0.9474840760231018
1/10/2023 6:45:11 PM,Cosmos extends and updates deal to acquire Cana Laboratories,Seeking Alpha,https://seekingalpha.com/news/3923434-cosmos-extends-and-updates-deal-to-acquire-cana-laboratories?utm_source=businessinsider&utm_medium=referral,neutral,0.5548141598701477
1/11/2023 11:05:10 AM,Merck mulls legal action against unsanctioned distributors of its COVID drug in China,Seeking Alpha,https://seekingalpha.com/news/3923580-merck-mulls-legal-action-against-unsanctioned-distributors-of-its-covid-drug-in-china?utm_source=businessinsider&utm_medium=referral,negative,0.9331508278846741
1/11/2023 12:10:20 PM,Merck completes tender offer for $1.35B acquisition of Imago,Seeking Alpha,https://seekingalpha.com/news/3923595-merck-completes-tender-offer-for-135b-acquisition-of-imago?utm_source=businessinsider&utm_medium=referral,positive,0.697081446647644
1/11/2023 12:33:42 PM,"BioXcel's BXCL701, Keytruda combo shows promise in mid-stage trial for prostate cancer",Seeking Alpha,https://seekingalpha.com/news/3923614-bioxcels-bxcl701-keytruda-combo-shows-promise-in-mid-stage-trial-for-prostate-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.9374079704284668
1/11/2023 12:57:02 PM,Merck To Complete Acquisition Of Imago ,RTTNews,/news/stocks/merck-to-complete-acquisition-of-imago-1032011999,neutral,0.8172777891159058
1/11/2023 6:06:37 PM,7 Hot Healthcare Stocks to Watch in 2023,InvestorPlace,/news/stocks/7-hot-healthcare-stocks-to-watch-in-2023-1032013193,neutral,0.8813204169273376
1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral,neutral,0.9117305874824524
1/12/2023 6:52:33 PM,White House COVID coordinator warns winter surges of infections will be new normal,Seeking Alpha,https://seekingalpha.com/news/3924266-white-house-covid-coordinator-warns-winter-surges-of-infections-will-be-new-normal?utm_source=businessinsider&utm_medium=referral,negative,0.9300765991210938
1/13/2023 3:54:22 PM,Omicron subvariant XBB.1.5 makes up 43% of COVID cases in U.S. – CDC,Seeking Alpha,https://seekingalpha.com/news/3924549-omicron-subvariant-xbb15-makes-up-43-of-covid-cases-in-us-cdc?utm_source=businessinsider&utm_medium=referral,neutral,0.933558464050293
1/13/2023 4:16:22 PM,Johnson & Johnson is scaling back COVID-19 vaccine production – WSJ,Seeking Alpha,https://seekingalpha.com/news/3924553-jnj-stock-falls-as-company-scaling-back-covid-19-vaccine-production?utm_source=businessinsider&utm_medium=referral,negative,0.9495651721954346
1/13/2023 7:22:37 PM,"Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot",Benzinga,/news/stocks/johnson-johnson-cuts-production-ends-contracts-for-not-so-successful-covid-19-shot-1032018165,negative,0.9613111615180969
1/13/2023 8:00:03 PM,"Catalyst watch: Eyes on Virgin Galactic, Monster Beverage, Procter & Gamble and Netflix",Seeking Alpha,https://seekingalpha.com/news/3924558-catalyst-watch-eyes-on-virgin-galactic-monster-beverage-procter-gamble-and-netflix?utm_source=businessinsider&utm_medium=referral,neutral,0.9412474632263184
1/14/2023 9:00:00 PM,"Type 2 diabetes market to surpass $136B in 2029 from new therapies, increased diagnoses",Seeking Alpha,https://seekingalpha.com/news/3924584-type-2-diabetes-market-to-surpass-136b-in-2029-from-new-therapies-increased-diagnoses?utm_source=businessinsider&utm_medium=referral,positive,0.8843289017677307
1/17/2023 8:41:14 PM,Merck to address cancer claims linked to diabetes drugs by year-end – Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3925165-merck-address-cancer-claims-linked-to-diabetes-drugs-by-year-end?utm_source=businessinsider&utm_medium=referral,neutral,0.6421480178833008
1/18/2023 4:58:00 AM,Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort,PR Newswire,/news/stocks/merck-selects-perceiv-ai-for-inaugural-digital-sciences-studio-cohort-1032023954,neutral,0.8551648855209351
1/19/2023 2:14:26 PM,Evaxion rises ~15% as personalized cancer immunotherapy gets FDA fast track status,Seeking Alpha,https://seekingalpha.com/news/3925882-evaxion-rises-15-as-personalized-cancer-immunotherapy-gets-fda-fast-track-status?utm_source=businessinsider&utm_medium=referral,positive,0.9408408999443054
1/19/2023 7:37:18 PM,Seagen wins FDA accelerated approval for colorectal cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3926075-sgen-stock-gains-fda-clears-colorectal-cancer-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.9180983901023865
1/20/2023 3:54:28 AM,Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer  Treatment ,RTTNews,/news/stocks/seagen-fda-grants-accelerated-approval-to-tukysa-combination-for-colorectal-cancer-treatment-1032029763,positive,0.936622679233551
1/20/2023 2:13:04 PM,Sinopharm unit cleared to study first mRNA COVID shot in China,Seeking Alpha,https://seekingalpha.com/news/3926331-sinopharm-unit-cleared-to-study-first-mrna-covid-shot-in-china?utm_source=businessinsider&utm_medium=referral,neutral,0.6989799737930298
1/20/2023 6:25:13 PM,Genexine's DNA vaccine for cervical cancer gets fast track status in South Korea,Seeking Alpha,https://seekingalpha.com/news/3926444-genexines-dna-vaccine-for-cervical-cancer-gets-fast-track-status-in-south-korea?utm_source=businessinsider&utm_medium=referral,positive,0.9248484969139099
1/21/2023 3:13:23 PM,Disinflation could be a slow roll - take shelter in these stocks,Seeking Alpha,https://seekingalpha.com/news/3926546-disinflation-could-be-a-slow-roll-take-shelter-in-these-stocks?utm_source=businessinsider&utm_medium=referral,neutral,0.8687314391136169
1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,positive,0.8150349855422974
1/23/2023 12:30:38 PM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Marinus (MRNS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-intellia-therapeutics-ntla-and-marinus-mrns-1032033717,neutral,0.921277642250061
1/23/2023 12:48:22 PM,Merck updates on financial impact of recent transactions,Seeking Alpha,https://seekingalpha.com/news/3926646-merck-updates-financial-impact-recent-transactions?utm_source=businessinsider&utm_medium=referral,neutral,0.9257327914237976
1/23/2023 9:01:01 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1032034842,neutral,0.9218418598175049
1/24/2023 6:26:57 PM,Merck declares $0.73 dividend,Seeking Alpha,https://seekingalpha.com/news/3927334-merck-declares-073-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.9289058446884155
1/24/2023 7:36:56 PM,"CDC chief to add new offices, leadership in organizational revamp",Seeking Alpha,https://seekingalpha.com/news/3927373-cdc-chief-to-add-new-offices-leadership-in-organizational-revamp?utm_source=businessinsider&utm_medium=referral,positive,0.5872244238853455
1/25/2023 12:27:38 PM,Merck to stop phase 3 trial of Keytruda combo in prostate cancer on lack of survival benefit,Seeking Alpha,https://seekingalpha.com/news/3927649-merck-to-stop-phase-3-trial-of-keytruda-combo-in-prostate-cancer-on-lack-of-survival-benefit?utm_source=businessinsider&utm_medium=referral,negative,0.9356604814529419
1/25/2023 12:50:01 PM,"Merck's Keytruda shows survival benefit in biliary tract cancer, meeting phase 3 study goal",Seeking Alpha,https://seekingalpha.com/news/3927673-mercks-keytruda-shows-survival-benefit-in-biliary-tract-cancer-meeting-phase-3-study-goal?utm_source=businessinsider&utm_medium=referral,positive,0.9444770216941833
1/26/2023 1:51:23 PM,FDA approves expanded use of Merck's Bravecto Chews for dogs,Seeking Alpha,https://seekingalpha.com/news/3928383-fda-approves-expanded-use-of-mercks-bravecto-chews-for-dogs?utm_source=businessinsider&utm_medium=referral,positive,0.7644450068473816
1/26/2023 2:22:52 PM,Merck Animal Health: FDA Approves Expanded Indication For BRAVECTO Chews For Dogs ,RTTNews,/news/stocks/merck-animal-health-fda-approves-expanded-indication-for-bravecto-chews-for-dogs-1032043716,positive,0.8015946745872498
1/26/2023 10:57:46 PM,Merck's Keytruda approved as adjuvant therapy for non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3928796-mercks-keytruda-approved-as-adjuvant-therapy-for-non-small-cell-lung-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.8071566820144653
1/26/2023 11:06:46 PM,The 3 Best Biotech Stocks Under $1 to Buy for January,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-under-1-to-buy-for-january-1032045234,neutral,0.7229993939399719
1/27/2023 2:15:19 AM,Mizuho Securities Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-merck-company-mrk-1032045317,neutral,0.9361416697502136
1/27/2023 12:19:52 PM,Bristol Myers wins EU backing to expand label for anemia therapy,Seeking Alpha,https://seekingalpha.com/news/3928887-bristol-myers-wins-eu-backing-to-expand-label-for-anemia-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.9191467761993408
1/27/2023 12:39:46 PM,Mizuho picks its top stocks for 2023,Seeking Alpha,https://seekingalpha.com/news/3928578-mizuho-picks-its-top-stocks-for-2023?utm_source=businessinsider&utm_medium=referral,neutral,0.925223171710968
1/27/2023 1:14:11 PM,"Merck's KEYTRUDA Gets FDA Approval To Treat Stage IB, II, IIIA Non-small Cell Lung Cancer Patients ",RTTNews,/news/stocks/merck-s-keytruda-gets-fda-approval-to-treat-stage-ib-ii-iiia-non-small-cell-lung-cancer-patients-1032046543,positive,0.9052789211273193
1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.936018705368042
1/27/2023 7:15:05 PM,"Catalyst watch: Eyes on tech earnings, Chinese EV stocks, Peloton and Church & Dwight",Seeking Alpha,https://seekingalpha.com/news/3929095-catalyst-watch-eyes-on-tech-earnings-chinese-ev-stocks-peloton-and-church-dwight?utm_source=businessinsider&utm_medium=referral,neutral,0.9359208345413208
1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678,neutral,0.745915949344635
1/30/2023 5:11:19 AM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Catalent (CTLT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-catalent-ctlt-1032048996,neutral,0.9118014574050903
1/30/2023 11:56:02 AM,China OKs two locally developed oral COVID-19 drugs,Seeking Alpha,https://seekingalpha.com/news/3929273-china-oks-two-locally-developed-oral-covid-19-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.5594388842582703
1/30/2023 12:00:56 PM,WHO maintains public health emergency on COVID but sees pandemic at 'transition point',Seeking Alpha,https://seekingalpha.com/news/3929274-who-maintains-public-health-emergency-on-covid-with-3-years-into-pandemic?utm_source=businessinsider&utm_medium=referral,neutral,0.743737518787384
1/30/2023 4:43:19 PM,"AstraZeneca begins late-stage trial of datopotamab, Keytruda combo for NSC lung cancer",Seeking Alpha,https://seekingalpha.com/news/3929458-astrazeneca-begins-late-stage-trial-of-datopotamab-keytruda-combo-for-nsc-lung-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.7420310974121094
1/31/2023 3:06:19 PM,7 Healthcare Stocks That Will Be Big Winners in 2023,InvestorPlace,/news/stocks/7-healthcare-stocks-that-will-be-big-winners-in-2023-1032054711,positive,0.49766457080841064
1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559,neutral,0.8971438407897949
2/1/2023 3:01:13 PM,Merck earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/merck_co-stock-quarter-earnings-preview-q4-1032058991,neutral,0.914770245552063
2/1/2023 3:55:38 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3930495-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8825733065605164
2/1/2023 4:18:05 PM,Merck Q4 results in focus with eye on future beyond Keytruda,Seeking Alpha,https://seekingalpha.com/news/3930505-merck-q4-results-in-focus-with-eye-on-future-beyond-keytruda?utm_source=businessinsider&utm_medium=referral,neutral,0.6456108093261719
2/1/2023 8:55:56 PM,Merck COVID-19 pill linked to virus mutations – study,Seeking Alpha,https://seekingalpha.com/news/3930787-merck-covid-19-pill-linked-to-virus-mutations-study?utm_source=businessinsider&utm_medium=referral,neutral,0.6873711347579956
2/2/2023 11:31:09 AM,"Merck Non-GAAP EPS of $1.62 beats by $0.08, revenue of $13.8B beats by $140M",Seeking Alpha,https://seekingalpha.com/news/3931090-merck-non-gaap-eps-of-1_62-beats-0_08-revenue-of-13_8b-beats-140m?utm_source=businessinsider&utm_medium=referral,neutral,0.5282192826271057
2/2/2023 11:56:25 AM,"FDA removes positive COVID test requirement for Pfizer, Merck COVID-19 pills",Seeking Alpha,https://seekingalpha.com/news/3931117-fda-removes-positive-covid-test-pfizer-merck-covid-19-pills?utm_source=businessinsider&utm_medium=referral,neutral,0.4959636330604553
2/2/2023 12:18:16 PM,"Merck stock dips as Q4 earnings decline, FY23 outlook seen below estimates",Seeking Alpha,https://seekingalpha.com/news/3931151-merck-stock-dips-as-q4-earnings-decline-fy23-outlook-seen-below-estimates?utm_source=businessinsider&utm_medium=referral,negative,0.9683805108070374
2/2/2023 12:34:23 PM,"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",Benzinga,/news/stocks/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-line-1032062305,neutral,0.7443466782569885
2/2/2023 12:35:05 PM,Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-sticks-to-its-buy-rating-for-merck-company-mrk-1032062608,neutral,0.521315336227417
2/2/2023 1:35:20 PM,"Merck Q4 Profit Down, Adj. EPS Tops View; Sees Weak FY23 Adj. EPS, Below Market ",RTTNews,/news/stocks/merck-q4-profit-down-adj-eps-tops-view-sees-weak-fy23-adj-eps-below-market-1032062581,negative,0.9660014510154724
2/2/2023 4:10:28 PM,"US Stocks Higher, NASDAQ Adds Over 230 Points",Benzinga,/news/stocks/us-stocks-higher-nasdaq-adds-over-230-points-1032063320,positive,0.9013417363166809
2/2/2023 6:12:11 PM,"Merck, GM among BofA's latest Alpha Surprise picks",Seeking Alpha,https://seekingalpha.com/news/3931429-merck-gm-among-bofas-latest-alpha-surprise-picks?utm_source=businessinsider&utm_medium=referral,neutral,0.8229635953903198
2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral,negative,0.9276774525642395
2/2/2023 7:35:34 PM,The 7 Most Undervalued Dow Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-dow-stocks-to-buy-in-february-2023-1032064008,neutral,0.7555125951766968
2/2/2023 8:20:04 PM,"Nasdaq, S&P off session highs but on track to extend post-Fed rally; Dow in the red",Seeking Alpha,https://seekingalpha.com/news/3931346-sp500-nasdaq-dow-jones-stock-market-meta-earnings-post-fed-rally?utm_source=businessinsider&utm_medium=referral,positive,0.7363039255142212
2/2/2023 9:11:03 PM,Meta drives surge in Nasdaq and S&P 500; Dow slips,Seeking Alpha,https://seekingalpha.com/news/3931524-meta-drives-surge-in-nasdaq-and-sp-500-dow-slips?utm_source=businessinsider&utm_medium=referral,neutral,0.5618246793746948
2/3/2023 11:05:22 AM,Merck & Company (MRK) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-bank-of-america-securities-1032065669,neutral,0.6524797081947327
2/3/2023 12:15:16 PM,"Merck’s Keytruda shows survival benefit in uterus cancer, meeting main goal of phase 3 trial",Seeking Alpha,https://seekingalpha.com/news/3931768-mercks-keytruda-shows-survival-benefit-in-uterus-cancer-meeting-main-goal-of-phase-3-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9242979288101196
2/3/2023 12:15:47 PM,Barclays Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-merck-company-mrk-1032065947,neutral,0.8047251105308533
2/3/2023 12:26:30 PM,BMO Capital Keeps Their Hold Rating on Merck & Company (MRK),TipRanks,/news/stocks/bmo-capital-keeps-their-hold-rating-on-merck-company-mrk-1032065893,neutral,0.9115080833435059
2/3/2023 12:30:25 PM,"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-and-merck-company-mrk-1032066009,neutral,0.9203616976737976
2/3/2023 1:59:03 PM,Merck's KEYTRUDA Plus Chemotherapy Meets Primary Goal As First-Line Therapy In Endometrial Carcinoma ,RTTNews,/news/stocks/merck-s-keytruda-plus-chemotherapy-meets-primary-goal-as-first-line-therapy-in-endometrial-carcinoma-1032066042,positive,0.7779130339622498
2/3/2023 3:14:50 PM,"Personalis, Moderna Continue Partnership On Personalized Cancer Vaccine Program ",RTTNews,/news/stocks/personalis-moderna-continue-partnership-on-personalized-cancer-vaccine-program-1032066259,neutral,0.6033672094345093
2/3/2023 4:46:14 PM,"Analysts Conflicted on These Healthcare Names: Becton Dickinson (BDX), Gilead Sciences (GILD) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-becton-dickinson-bdx-gilead-sciences-gild-and-merck-company-mrk-1032066676,negative,0.49767860770225525
2/5/2023 2:45:14 PM,The 7 Most Undervalued Blue-Chip Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-blue-chip-stocks-to-buy-in-february-2023-1032067971,neutral,0.8083428740501404
2/5/2023 5:00:57 PM,Drug price inflation continues upward momentum at 3.8% – report,Seeking Alpha,https://seekingalpha.com/news/3932101-drug-price-inflation-continues-upward-momentum-at-38-report?utm_source=businessinsider&utm_medium=referral,positive,0.9158604145050049
2/6/2023 1:21:33 PM,"Merck, Nabriva terminate distribution agreement for antibacterial",Seeking Alpha,https://seekingalpha.com/news/3932262-nbrv-stock-watch-merck-ends-distribution-agreement?utm_source=businessinsider&utm_medium=referral,negative,0.7010368704795837
2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral,neutral,0.6935389041900635
2/6/2023 7:41:35 PM,"Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down",Benzinga,/news/stocks/analyst-upgrades-personalis-says-biopharma-is-strong-cash-burn-is-down-1032071196,positive,0.9024577140808105
2/8/2023 8:27:38 PM,Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023,Benzinga,/news/stocks/analyst-reiterates-this-alzheimer-s-candidate-as-top-idea-for-2023-1032079929,neutral,0.8290999531745911
2/8/2023 10:44:27 PM,"Aligos Therapeutics in portfolio reorganization focused on NASH, COVID assets",Seeking Alpha,https://seekingalpha.com/news/3933956-aligos-therapeutics-in-portfolio-reorganization-focused-on-nash-covid-assets?utm_source=businessinsider&utm_medium=referral,neutral,0.9352024793624878
2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,neutral,0.5336910486221313
2/10/2023 12:37:52 PM,"Hillstream stock surges ~70% as HSB-1216, Keytruda combo shows promise in lung cancer cells",Seeking Alpha,https://seekingalpha.com/news/3934739-hillstream-surges-70-as-hsb-1216-keytruda-combo-shows-promise-in-lung-cancer-cells?utm_source=businessinsider&utm_medium=referral,positive,0.94758540391922
2/10/2023 2:27:47 PM,"Pfizer, BioNTech start trial for first mRNA-based shingles vaccine",Seeking Alpha,https://seekingalpha.com/news/3934803-pfizer-biontech-start-trial-first-mrna-based-shingles-vaccine?utm_source=businessinsider&utm_medium=referral,neutral,0.7130166888237
2/12/2023 5:00:59 PM,COVID-19 emergency is ending; What it means for free vaccines and drugs,Seeking Alpha,https://seekingalpha.com/news/3935039-pandemic-emergency-ending-impact-covid-shots-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.908437192440033
2/13/2023 11:35:17 AM,Credit Suisse Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/credit-suisse-reaffirms-their-buy-rating-on-merck-company-mrk-1032090839,neutral,0.7718588709831238
2/13/2023 6:51:52 PM,"Stellar Opportunity For Merck At Upcoming Data Presentation, Analyst Says While Boosting Price Target",Benzinga,/news/stocks/stellar-opportunity-for-merck-at-upcoming-data-presentation-analyst-says-while-boosting-price-target-1032091972,positive,0.9450384378433228
2/14/2023 1:15:18 PM,Bicycle Therapeutics posts Phase 1 data for cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3935695-bcyc-stock-on-watch-after-phase-1-data-for-cancer-candidate?utm_source=businessinsider&utm_medium=referral,neutral,0.7708919644355774
2/14/2023 3:05:50 PM,"Keros Therapeutics a buy at Cowen on candidates for PAH, myelofibrosis",Seeking Alpha,https://seekingalpha.com/news/3935749-keros-therapeutics-a-buy-at-cowen-on-candidates-for-pah-myelofibrosis?utm_source=businessinsider&utm_medium=referral,neutral,0.7974503040313721
2/14/2023 3:50:56 PM,BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype,Benzinga,/news/stocks/bioxcel-therapeutics-unveils-complete-data-from-bxcl701-keytruda-combo-study-in-prostate-cancer-subtype-1032095178,neutral,0.9022746682167053
2/14/2023 8:26:04 PM,Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-top-ships-are-trading-lower-by-45-here-are-other-stocks-moving-in-tuesday-s-mid-day-session-1032095837,negative,0.6539891958236694
2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,neutral,0.4218192398548126
2/16/2023 8:24:30 PM,Seagen nears six-month high as Wall Street cheers Q4 results,Seeking Alpha,https://seekingalpha.com/news/3937368-sgen-stock-jumps-wall-street-cheers-q4-results?utm_source=businessinsider&utm_medium=referral,positive,0.8282086253166199
2/16/2023 8:27:35 PM,"Nasdaq, S&P, Dow set to end in the red as traders digest more inflation data, Fed talk",Seeking Alpha,https://seekingalpha.com/news/3937279-nasdaq-sp500-dow-jones-stock-market-ppi-report-economic-data?utm_source=businessinsider&utm_medium=referral,neutral,0.8255547285079956
2/17/2023 9:15:15 AM,Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-merck-company-mrk-1032105369,neutral,0.5667999982833862
2/17/2023 12:22:04 PM,Merck wins FDA priority review for label expansion of cytomegalovirus therapy,Seeking Alpha,https://seekingalpha.com/news/3937616-merck-wins-fda-priority-review-for-label-expansion-of-cytomegalovirus-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.902755856513977
2/17/2023 2:44:20 PM,Gilead updates Phase 2 data for bladder cancer therapy Trodelvy,Seeking Alpha,https://seekingalpha.com/news/3937727-gilead-updates-phase-2-data-for-bladder-cancer-therapy-trodelvy?utm_source=businessinsider&utm_medium=referral,neutral,0.8920766711235046
2/17/2023 6:35:08 PM,I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.,InvestorPlace,/news/stocks/i-tricked-chatgpt-into-picking-stocks-to-buy-heres-what-it-said-1032106844,neutral,0.9173052310943604
2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral,positive,0.9136704802513123
2/20/2023 12:37:27 AM,3 Large-Cap Biotech Stocks to Hold for the Long Haul,InvestorPlace,/news/stocks/dhr-mrk-tmo-3-large-cap-biotech-stocks-to-hold-for-the-long-haul-1032107630,neutral,0.854254961013794
2/21/2023 9:15:15 AM,Mizuho Securities Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-sticks-to-its-buy-rating-for-merck-company-mrk-1032110847,neutral,0.521315336227417
2/21/2023 1:25:56 PM,Merck says late-stage trial for COVID pill failed in disease prevention,Seeking Alpha,https://seekingalpha.com/news/3938331-merck-says-late-stage-trial-covid-pill-failed-disease-prevention?utm_source=businessinsider&utm_medium=referral,neutral,0.3740980923175812
2/22/2023 5:32:47 AM,Jim Cramer Lists 6 Conditions For Market Selloff To End Amid 'Discouraging' Inflation Data,Benzinga,/news/stocks/jim-cramer-lists-6-conditions-for-market-selloff-to-end-amid-discouraging-inflation-data-1032113576,negative,0.8842825293540955
2/22/2023 3:01:48 PM,Expert Ratings for Merck & Co,Benzinga,/news/stocks/expert-ratings-for-merck-co-1032116015,neutral,0.8768600821495056
2/22/2023 4:00:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-22-2023-1032116274,negative,0.5363326668739319
2/23/2023 10:51:30 AM,"Moderna, Merck's mRNA cancer vaccine/Keytruda combo gets FDA breakthrough therapy tag",Seeking Alpha,https://seekingalpha.com/news/3939727-moderna-mercks-mrna-cancer-vaccinekeytruda-combo-gets-fda-breakthrough-therapy-tag?utm_source=businessinsider&utm_medium=referral,positive,0.7822355628013611
2/23/2023 11:41:46 AM,Top dividend stocks picked using a UBS machine-learning model,Seeking Alpha,https://seekingalpha.com/news/3939207-top-dividend-stocks-machine-learning-ai-screen-picks?utm_source=businessinsider&utm_medium=referral,neutral,0.9306975603103638
2/23/2023 5:15:28 PM,Merck under lawmakers' scrutiny over Keytruda patents,Seeking Alpha,https://seekingalpha.com/news/3940086-merck-under-lawmakers-scrutiny-over-keytruda-patents?utm_source=businessinsider&utm_medium=referral,negative,0.6920412182807922
2/24/2023 12:17:41 PM,Merck/ Ridgeback COVID-19 pill rejected in Europe,Seeking Alpha,https://seekingalpha.com/news/3940575-merck-ridgeback-covid-pill-rejected-in-europe?utm_source=businessinsider&utm_medium=referral,negative,0.7375708222389221
2/24/2023 1:48:21 PM,Merck: CHMP Recommends Against Approval Of Lagevrio For Treatment Of Certain Adults With COVID-19 ,RTTNews,/news/stocks/merck-chmp-recommends-against-approval-of-lagevrio-for-treatment-of-certain-adults-with-covid-19-1032123482,negative,0.7361183762550354
2/27/2023 3:33:48 AM,Pfizer said in early stage talks to acquire Seagen - WSJ,Seeking Alpha,https://seekingalpha.com/news/3940958-pfizer-said-in-early-stake-talks-to-acquire-seagen-wsj?utm_source=businessinsider&utm_medium=referral,neutral,0.860884964466095
2/27/2023 6:43:09 PM,Analyst Cautions Investors On Overreacting To 'Early-Stage' Pfizer/Seagen Discussions,Benzinga,/news/stocks/analyst-cautions-investors-on-overreacting-to-early-stage-pfizer-seagen-discussions-1032128598,negative,0.9430363178253174
2/27/2023 7:44:20 PM,Shionogi CEO sees $2B in sales of COVID pill following US approval - Reuters,Seeking Alpha,https://seekingalpha.com/news/3941348-shionogi-ceo-sees-2b-in-sales-of-covid-pill-following-us-approval-reuters?utm_source=businessinsider&utm_medium=referral,positive,0.8215122818946838
2/28/2023 11:30:12 AM,Stocks most and least liked by hedge funds and mutual funds -  Goldman,Seeking Alpha,https://seekingalpha.com/news/3941168-stocks-most-and-least-liked-by-hedge-funds-and-mutual-funds-goldman?utm_source=businessinsider&utm_medium=referral,neutral,0.8097005486488342
2/28/2023 12:34:09 PM,"Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer",Seeking Alpha,https://seekingalpha.com/news/3941714-merck-keytruda-combo-fails-lung-cancer-trial-sees-another-setback-in-prostate-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9419342279434204
3/1/2023 11:39:48 AM,FBI Director says novel coronavirus likely originated from China lab leak,Seeking Alpha,https://seekingalpha.com/news/3942433-fbi-director-says-novel-coronavirus-likely-originated-from-china-lab-leak?utm_source=businessinsider&utm_medium=referral,neutral,0.9219886064529419
3/1/2023 12:26:06 PM,Merck says Keytruda trial met main goal as perioperative therapy in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3942480-merck-says-keytruda-trial-met-main-goal-perioperative-therapy-lung-cancer?utm_source=businessinsider&utm_medium=referral,neutral,0.7866211533546448
3/1/2023 12:59:57 PM,Merck: Phase 3 KEYNOTE-671 Trial With KEYTRUDA Meets One Of Its Dual Primary Endpoints ,RTTNews,/news/stocks/merck-phase-3-keynote-671-trial-with-keytruda-meets-one-of-its-dual-primary-endpoints-1032135710,positive,0.396410197019577
3/1/2023 5:45:53 PM,Gossamer initiated Neutral at Guggenheim citing challenges for PAH therapy,Seeking Alpha,https://seekingalpha.com/news/3942757-goss-stock-initiated-neutral-guggenheim-challenges-pah-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.9159705638885498
3/1/2023 9:41:07 PM,Moderna initiated at outperform at RBC on potential of cancer vaccine candidates,Seeking Alpha,https://seekingalpha.com/news/3942927-moderna-initiated-at-outperform-at-rbc-on-potential-of-cancer-vaccine-candidates?utm_source=businessinsider&utm_medium=referral,positive,0.9443633556365967
3/2/2023 2:39:19 PM,Merck and AstraZeneca to face FDA AdCom meeting for prostate cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3943282-merck-astrazeneca-face-fda-adcom-meeting-prostate-cancer-therapy?utm_source=businessinsider&utm_medium=referral,neutral,0.9068241715431213
3/2/2023 7:05:16 PM,Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1032141653,neutral,0.716327965259552
3/4/2023 6:45:00 PM,Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines,Seeking Alpha,https://seekingalpha.com/news/3944195-pharma-research-developmeny-funding-soared-to-a-new-record-in-2022-as-oncology-candidates-dominate-pipelines?utm_source=businessinsider&utm_medium=referral,positive,0.9410833716392517
3/5/2023 5:00:42 PM,Why Seagen is a top acquisition target?,Seeking Alpha,https://seekingalpha.com/news/3944254-pfizer-merck-fighting-acquire-seagen?utm_source=businessinsider&utm_medium=referral,neutral,0.9217467308044434
3/6/2023 11:56:07 AM,FDA approves intramuscular administration for Merck’s MMRV family of vaccines,Seeking Alpha,https://seekingalpha.com/news/3944331-fda-approves-intramuscular-administration-for-mercks-mmrv-family-of-vaccines?utm_source=businessinsider&utm_medium=referral,positive,0.5465539693832397
3/6/2023 4:00:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-6-2023-1032147650,negative,0.4970482587814331
3/6/2023 5:43:03 PM,"Merck, initiated at buy, is Jefferies top pharma pick",Seeking Alpha,https://seekingalpha.com/news/3944549-merck-initiated-at-buy-is-jefferies-top-pharma-pick?utm_source=businessinsider&utm_medium=referral,neutral,0.8992868661880493
3/6/2023 6:45:59 PM,Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results,Seeking Alpha,https://seekingalpha.com/news/3944574-merck-to-start-phase-3-of-oral-pcsk9-inhibitor-for-cholesterol-following-mid-stage-results?utm_source=businessinsider&utm_medium=referral,positive,0.7322389483451843
3/6/2023 7:25:08 PM,Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-merck-company-mrk-1032148321,neutral,0.5667999982833862
3/6/2023 7:38:41 PM,Seagen seesaws amid report that Pfizer only bidder for the cancer-focused biotech,Seeking Alpha,https://seekingalpha.com/news/3944587-seagen-seesaws-amid-report-that-pfizer-only-bidder-for-the-cancer-focused-biotech?utm_source=businessinsider&utm_medium=referral,negative,0.9428960084915161
3/6/2023 8:09:50 PM,Moderna hopes for FDA accelerated approval of cancer vaccine,Seeking Alpha,https://seekingalpha.com/news/3944596-moderna-hopes-fda-accelerated-approval-cancer-vaccine?utm_source=businessinsider&utm_medium=referral,positive,0.6964219212532043
3/7/2023 9:50:28 AM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Adaptimmune Therapeutics (ADAP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-adaptimmune-therapeutics-adap-1032149575,neutral,0.9174153208732605
3/7/2023 10:30:22 AM,Merck posts full Phase 3 data for sotatercept in pulmonary arterial hypertension,Seeking Alpha,https://seekingalpha.com/news/3944755-merck-posts-full-phase-3-data-pulmonary-arterial-hypertension-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.8842406272888184
3/7/2023 10:40:35 AM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1032149691,negative,0.700346827507019
3/7/2023 10:45:09 AM,Merck & Company (MRK) Receives a Buy from Bank of America Securities,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-bank-of-america-securities-1032149731,neutral,0.5672414302825928
3/7/2023 12:30:42 PM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Stoke Therapeutics (STOK) and Day One Biopharmaceuticals (DAWN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-stoke-therapeutics-stok-and-day-one-biopharmaceuticals-dawn-1032150131,neutral,0.9109208583831787
3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral,positive,0.533659815788269
3/7/2023 1:39:16 PM,DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday,Benzinga,/news/stocks/docusign-to-rally-around-25-here-are-10-other-analyst-forecasts-for-tuesday-1032150135,neutral,0.9176536798477173
3/7/2023 5:08:06 PM,Gossamer downgraded at Raymond James after Merck data for PAH candidate,Seeking Alpha,https://seekingalpha.com/news/3944979-goss-stock-downgraded-raymond-james-merck-data-for-pah-candidate?utm_source=businessinsider&utm_medium=referral,negative,0.6907030344009399
3/7/2023 7:37:52 PM,Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success,Benzinga,/news/stocks/analyst-downgrades-gossamer-bio-as-merck-s-sotatercept-might-overshadow-seralutinib-s-success-1032151404,negative,0.9419155120849609
3/8/2023 1:34:07 AM,Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason,Benzinga,/news/stocks/health-care-etfs-have-lost-in-the-last-month---these-top-pharma-stocks-are-the-reason-1032151775,negative,0.9652082920074463
3/8/2023 11:41:29 AM,Sleep-at-night stocks for those hedging or risk averse,Seeking Alpha,https://seekingalpha.com/news/3945026-sleep-at-night-stocks-for-those-hedging-or-risk-averse?utm_source=businessinsider&utm_medium=referral,neutral,0.7829471826553345
3/8/2023 1:38:01 PM,Opko stock surges ~25% on license deal with Merck for potential EBV vaccine,Seeking Alpha,https://seekingalpha.com/news/3945312-opko-stock-surges-25-on-license-deal-with-merck-for-potential-ebv-vaccine?utm_source=businessinsider&utm_medium=referral,positive,0.905101478099823
3/8/2023 4:01:43 PM,OPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck,Benzinga,/news/stocks/opko-health-s-cancer-infectious-disease-focused-subsidiary-inks-vaccine-development-pact-with-merck-1032154034,positive,0.7820820808410645
3/8/2023 8:27:38 PM,Dividend Stocks Alert: 10 Top Holdings From the SCHD ETF,InvestorPlace,/news/stocks/dividend-stocks-alert-10-top-holdings-from-the-schd-etf-1032154796,neutral,0.9226071238517761
3/8/2023 9:07:58 PM,Why did OPKO Health stock jump today? Vaccine license deal with Merck,Seeking Alpha,https://seekingalpha.com/news/3945603-why-did-opko-health-stock-jump-today-vaccine-license-deal-with-merck?utm_source=businessinsider&utm_medium=referral,neutral,0.9092050194740295
3/9/2023 4:05:54 AM,SVB Securities Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-sticks-to-their-buy-rating-for-merck-company-mrk-1032155145,neutral,0.8361806869506836
3/9/2023 6:55:10 PM,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,Seeking Alpha,https://seekingalpha.com/news/3946094-biden-budget-to-save-160b-by-allowing-medicare-to-negotiate-prices-for-more-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.8639830946922302
3/10/2023 12:12:35 PM,Merck’s Keytruda succeeds in pleural mesothelioma study with chemotherapy,Seeking Alpha,https://seekingalpha.com/news/3946398-mercks-keytruda-pleural-mesothelioma-study-chemotherapy?utm_source=businessinsider&utm_medium=referral,neutral,0.6692419648170471
3/10/2023 1:11:14 PM,Merck: Phase 2/3 CCTG IND.227/KEYNOTE-483 Trial With KEYTRUDA Meets Primary Endpoint ,RTTNews,/news/stocks/merck-phase-2-3-cctg-ind-227-keynote-483-trial-with-keytruda-meets-primary-endpoint-1032159754,neutral,0.7211681604385376
3/10/2023 1:13:37 PM,United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/united-airlines-to-rally-around-54-here-are-10-other-analyst-forecasts-for-friday-1032159750,neutral,0.9134487509727478
3/10/2023 2:01:31 PM,Expert Ratings for Merck & Co,Benzinga,/news/stocks/expert-ratings-for-merck-co-1032159899,neutral,0.8768600821495056
3/13/2023 11:02:51 AM,Pfizer to acquire cancer drugmaker Seagen for $43B,Seeking Alpha,https://seekingalpha.com/news/3946759-pfizer-deal-to-acquire-seagen-sends-shares-higher?utm_source=businessinsider&utm_medium=referral,neutral,0.8854126334190369
3/13/2023 11:55:12 AM,Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows,Benzinga,/news/stocks/nasdaq-futures-climb-solidly-after-past-week-s-rout-analyst-flags-key-s-p-500-support-to-stay-above-october-lows-1032162772,positive,0.8695937991142273
3/13/2023 1:11:41 PM,Merck downgraded at Wells Fargo on valuation,Seeking Alpha,https://seekingalpha.com/news/3946828-merck-downgraded-wells-fargo-valuation?utm_source=businessinsider&utm_medium=referral,negative,0.7354688048362732
3/13/2023 2:28:58 PM,Moderna gains as Cowen upgrades citing a favorable catalyst path,Seeking Alpha,https://seekingalpha.com/news/3946874-moderna-gains-cowen-upgrades-favorable-catalyst-path?utm_source=businessinsider&utm_medium=referral,positive,0.9184334874153137
3/13/2023 4:00:45 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-13-2023-1032163649,negative,0.4953747093677521
3/13/2023 6:26:10 PM,Merck asks EMA to reconsider recommendation to reject authorizing COVID pill molnupiravir,Seeking Alpha,https://seekingalpha.com/news/3946974-merck-asks-ema-to-reconsider-recommendation-to-reject-authorizing-covid-pill-molnupiravir-lagevrio?utm_source=businessinsider&utm_medium=referral,neutral,0.7936170101165771
3/13/2023 7:48:45 PM,Pfizer CEO doesn't see antitrust as stumbling block for Seagen acquisition,Seeking Alpha,https://seekingalpha.com/news/3947002-pfizer-ceo-doesnt-see-antitrust-as-stumbling-block-for-seagen-acquisition?utm_source=businessinsider&utm_medium=referral,neutral,0.8940973281860352
3/15/2023 8:15:17 AM,Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1032168566,neutral,0.716327965259552
3/15/2023 1:10:29 PM,"AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation",Seeking Alpha,https://seekingalpha.com/news/3947647-abbvie-gilead-seagen-among-firms-fined-for-raising-prices-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,negative,0.6228245496749878
3/16/2023 12:34:23 PM,Organon draws bullish views at Raymond James on Humira biosimilar launch,Seeking Alpha,https://seekingalpha.com/news/3948150-organon-draws-bullish-views-raymond-james-humira-biosimilar-launch?utm_source=businessinsider&utm_medium=referral,neutral,0.7328687310218811
3/16/2023 6:15:32 PM,Medicare publishes initial guidance on drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3948265-medicare-publishes-initial-guidance-on-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.9513846635818481
3/17/2023 9:01:14 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Quest Diagnostics (DGX) and Fusion Pharmaceuticals (FUSN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-quest-diagnostics-dgx-and-fusion-pharmaceuticals-fusn-1032175076,neutral,0.9141526818275452
3/17/2023 3:37:24 PM,"Merck Keytruda, anti-TIGIT therapy coformulation hits setback in mid-stage trial",Seeking Alpha,https://seekingalpha.com/news/3948569-merck-keytruda-anti-tigit-therapy-coformulation-vibostolimab-mk-7684-hits-setback-mid-stage-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9214010238647461
3/20/2023 1:47:12 PM,SVB Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1032179117,neutral,0.7829649448394775
3/20/2023 9:02:23 PM,"Merck, Viatris settle patent dispute over Januvia",Seeking Alpha,https://seekingalpha.com/news/3949220-merck-viatris-settle-patent-dispute-over-januvia?utm_source=businessinsider&utm_medium=referral,neutral,0.6210030317306519
3/20/2023 10:31:05 PM,7 Defensive Stocks to Buy During This Chaotic Spell,InvestorPlace,/news/stocks/7-defensive-stocks-to-buy-during-this-chaotic-spell-1032180410,neutral,0.8788079619407654
3/21/2023 8:13:55 PM,7 Healthcare Stocks to Buy for Long-Term Growth and Stability,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-for-long-term-growth-and-stability-1032183221,neutral,0.7752803564071655
3/23/2023 12:39:20 PM,"Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval",Benzinga,/news/stocks/incyte-would-now-compete-with-merck-pfizer-as-its-skin-cancer-treatment-scores-fda-accelerated-approval-1032187438,positive,0.8117837309837341
3/23/2023 6:33:09 PM,White House seeking alternative supply chains for pharmaceutical ingredients,Seeking Alpha,https://seekingalpha.com/news/3950575-white-house-alternative-supply-chains-pharmaceutical-ingredients-drug-shortages?utm_source=businessinsider&utm_medium=referral,neutral,0.6495422124862671
3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.6456917524337769
3/27/2023 6:17:01 PM,Cullinan Oncology wins FDA nod to run studies for another cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3951588-cullinan-oncology-stock-wins-fda-nod-to-study-cancer-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.6966593861579895
3/27/2023 10:16:04 PM,Merck's Keytruda successful in multiple types of endometrial cancer,Seeking Alpha,https://seekingalpha.com/news/3951691-mercks-keytruda-successful-in-multiple-types-of-endometrial-cancer?utm_source=businessinsider&utm_medium=referral,neutral,0.6924498677253723
3/28/2023 5:41:06 PM,Gritstone bio draws Buy rating at B. Riley on mRNA potential,Seeking Alpha,https://seekingalpha.com/news/3951963-gritstone-stock-draws-buy-b-riley-mrna-potential?utm_source=businessinsider&utm_medium=referral,neutral,0.9214349985122681
3/28/2023 6:35:20 PM,FDA strategy aims to avoid another baby formula shortage,Seeking Alpha,https://seekingalpha.com/news/3951979-fda-strategy-aims-to-avoid-another-baby-formula-shortage-abbott?utm_source=businessinsider&utm_medium=referral,neutral,0.9227812886238098
3/28/2023 6:55:51 PM,"Merck downgraded to hold at Societe Generale on Keytruda patent, pipeline concerns",Seeking Alpha,https://seekingalpha.com/news/3951984-merck-downgraded-to-hold-at-societe-generale-on-keytruda-patent-pipeline-concerns?utm_source=businessinsider&utm_medium=referral,neutral,0.6822570562362671
3/29/2023 9:11:23 PM,Merck Keytruda granted full approval for certain tumor types,Seeking Alpha,https://seekingalpha.com/news/3952495-merck-keytruda-granted-full-approval-for-certain-tumor-types?utm_source=businessinsider&utm_medium=referral,positive,0.8818681240081787
4/3/2023 12:48:27 PM,"OncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trial",Seeking Alpha,https://seekingalpha.com/news/3953592-oncosec-stock-falls-tavo-epkeytruda-combo-fails-skin-cancer-trial?utm_source=businessinsider&utm_medium=referral,positive,0.6407162547111511
4/3/2023 8:47:21 PM,Delaware court finds in favor of Bayer in talc disagreement with Merck,Seeking Alpha,https://seekingalpha.com/news/3953932-delaware-court-finds-in-favor-of-bayer-in-talc-disagreement-with-merck?utm_source=businessinsider&utm_medium=referral,negative,0.8480780720710754
4/3/2023 10:16:59 PM,FDA approves Merck and Astellas-Seagen's combination treatment for bladder cancer,Seeking Alpha,https://seekingalpha.com/news/3953995-fda-approves-merck-and-astellas-seagens-combination-treatment-for-bladder-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.8404742479324341
4/4/2023 12:48:47 PM,"Pfizer, Merck said to have cut prices of COVID-19 pills in China",Seeking Alpha,https://seekingalpha.com/news/3954185-pfizer-merck-said-have-cut-prices-covid-19-pills-china?utm_source=businessinsider&utm_medium=referral,negative,0.934297502040863
4/5/2023 8:52:56 AM,"AstraZeneca Imfinzi, Lynparza combo improves progression-free survival in ovarian cancer trial",Seeking Alpha,https://seekingalpha.com/news/3954578-astrazeneca-imfinzilynparza-combo-improves-survival-ovarian-cancer-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9477359652519226
4/5/2023 1:29:15 PM,Gilead said to be in late-stage trials for oral COVID therapy,Seeking Alpha,https://seekingalpha.com/news/3954672-gilead-said-to-be-in-late-stage-trials-for-oral-covid-therapy?utm_source=businessinsider&utm_medium=referral,neutral,0.6941813230514526
4/6/2023 1:19:05 AM,MRK vs. BMY: Which Pharmaceutical Stock is Better?,TipRanks,/news/stocks/mrk-vs-bmy-which-pharmaceutical-stock-is-better-1032217882,neutral,0.8298037648200989
4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral,negative,0.8911572694778442
4/6/2023 6:14:11 PM,WHO chief expects COVID emergency to end this year,Seeking Alpha,https://seekingalpha.com/news/3955102-who-chief-expects-covid-emergency-end-this-year?utm_source=businessinsider&utm_medium=referral,neutral,0.9115643501281738
4/6/2023 9:20:22 PM,What To Expect When Merus Presents Petosemtamab Data Update At AACR,Benzinga,/news/stocks/what-to-expect-when-merus-presents-petosemtamab-data-update-at-aacr-1032219940,neutral,0.9483116865158081
4/7/2023 12:53:00 PM,"Merck, Eisai end two Keytruda combination trials after missing main goals",Seeking Alpha,https://seekingalpha.com/news/3955184-merck-eisai-end-two-keytruda-combination-trials-after-missing-main-goals?utm_source=businessinsider&utm_medium=referral,negative,0.8945250511169434
4/7/2023 2:23:12 PM,"Merck, Eisai Announce Disappointing Results From Phase 3 LEAP-003 And LEAP-017 Trials ",RTTNews,/news/stocks/merck-eisai-announce-disappointing-results-from-phase-3-leap-003-and-leap-017-trials-1032220534,negative,0.9723870158195496
4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral,neutral,0.9218350052833557
4/9/2023 4:00:00 PM,"Premier cancer research event, AACR is starting this week; Here is what to expect",Seeking Alpha,https://seekingalpha.com/news/3955202-aacr-2023-is-starting-this-week-here-is-what-to-expect?utm_source=businessinsider&utm_medium=referral,neutral,0.9468868374824524
4/10/2023 8:15:12 AM,Merck & Company (MRK) Gets a Buy from Mizuho Securities,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-mizuho-securities-1032221731,neutral,0.5613883137702942
4/10/2023 11:46:37 AM,"Moderna, Merck win priority designation for personalized cancer vaccine in EU",Seeking Alpha,https://seekingalpha.com/news/3955248-moderna-stock-gains-eu-designation-personalized-cancer-shot?utm_source=businessinsider&utm_medium=referral,positive,0.8888188004493713
4/10/2023 7:00:48 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1032222445,neutral,0.9218418598175049
4/11/2023 2:25:44 AM,U.S. launches $5B program to speed up development of next-gen COVID vaccines,Seeking Alpha,https://seekingalpha.com/news/3955481-us-launches-5b-program-develop-next-gen-covid-vaccines?utm_source=businessinsider&utm_medium=referral,positive,0.8896018862724304
4/11/2023 12:00:38 PM,Biden signs bill to end COVID national emergency,Seeking Alpha,https://seekingalpha.com/news/3955581-biden-signs-bill-end-covid-national-emergency?utm_source=businessinsider&utm_medium=referral,negative,0.536685049533844
4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral,negative,0.7583171725273132
4/12/2023 11:18:54 AM,Merck: FDA Places Partial Clinical Hold On Initiation Of New Patients On Evobrutinib ,RTTNews,/news/stocks/merck-fda-places-partial-clinical-hold-on-initiation-of-new-patients-on-evobrutinib-1032226662,negative,0.9240801930427551
4/12/2023 12:45:22 PM,Jefferies Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-merck-company-mrk-1032227314,neutral,0.8511101603507996
4/12/2023 3:24:09 PM,These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/these-3-health-care-stocks-delivering-high-dividend-yields-are-recommended-by-wall-street-s-most-accurate-analysts-1032227483,neutral,0.7178788185119629
4/13/2023 8:25:35 AM,Merck & Company (MRK) was upgraded to a Buy Rating at Citigroup,TipRanks,/news/stocks/merck-company-mrk-was-upgraded-to-a-buy-rating-at-citigroup-1032229423,positive,0.8717471957206726
4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral,neutral,0.5150908827781677
4/13/2023 11:19:25 AM,"Merck's Keytruda combo gets FDA review for initial therapy in gastric, esophagus cancer",Seeking Alpha,https://seekingalpha.com/news/3956215-merck-keytruda-combo-gets-fda-review-for-gastric-esophagus-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.8855946063995361
4/13/2023 12:30:27 PM,Merck upgraded at Citi despite Keytruda patent cliff,Seeking Alpha,https://seekingalpha.com/news/3956254-merck-stock-upgraded-citi-despite-keytruda-patent-cliff?utm_source=businessinsider&utm_medium=referral,positive,0.8534742593765259
4/13/2023 2:09:44 PM,Why Is Merck (MRK) Stock Up Today?,InvestorPlace,/news/stocks/why-is-merck-mrk-stock-up-today-1032230495,neutral,0.785879909992218
4/13/2023 2:14:47 PM,Merck's KEYTRUDA One Step Closer To Gastric Cancer Treatment Expansion ,RTTNews,/news/stocks/merck-s-keytruda-one-step-closer-to-gastric-cancer-treatment-expansion-1032229993,positive,0.4959210157394409
4/13/2023 2:24:44 PM,Apple To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Thursday,Benzinga,/news/stocks/apple-to-rally-around-18-here-are-10-other-analyst-forecasts-for-thursday-1032230009,neutral,0.9078480005264282
4/13/2023 2:32:58 PM,AMZN Stock Alert: 12 Takeaways From the 2023 Amazon Shareholder Letter,InvestorPlace,/news/stocks/amzn-stock-alert-12-takeaways-from-the-2023-amazon-shareholder-letter-1032230584,neutral,0.8713039755821228
4/13/2023 3:15:45 PM,Pfizer collaborates with Sinopharm to expand in China,Seeking Alpha,https://seekingalpha.com/news/3956335-pfizer-stock-pact-sinopharm-expand-in-china?utm_source=businessinsider&utm_medium=referral,positive,0.8354645371437073
4/13/2023 4:26:37 PM,Hot Stocks: PGR drops on earnings; CNSL rises on buyout offer; MRK higher on analyst upgrade; EDIT gains; HOG slides,Seeking Alpha,https://seekingalpha.com/news/3956354-hot-stocks-pgr-drops-on-earnings-cnsl-rises-on-buyout-offer-mrk-higher-on-analyst-upgrade-edit-gains-hog-slides?utm_source=businessinsider&utm_medium=referral,negative,0.6413080096244812
4/13/2023 5:00:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-13-2023-1032230656,neutral,0.5060959458351135
4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral,positive,0.6195566058158875
4/15/2023 1:38:31 PM,3 Dividend Stocks to Buy for a Recession-Proof Portfolio,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-for-a-recession-proof-portfolio-1032234092,neutral,0.834452748298645
4/16/2023 9:25:27 AM,Merck said to be close to acquiring Prometheus Biosciences - WSJ,Seeking Alpha,https://seekingalpha.com/news/3956762-merck-close-acquiring-prometheus-biosciences-wsj?utm_source=businessinsider&utm_medium=referral,neutral,0.8457171320915222
4/16/2023 12:30:05 PM,Merck inks ~$11B all-cash deal to acquire Prometheus,Seeking Alpha,https://seekingalpha.com/news/3956764-merck-stock-11b-cash-deal-acquire-prometheus?utm_source=businessinsider&utm_medium=referral,neutral,0.607556164264679
4/16/2023 5:07:04 PM,Prometheus Biosciences To Be Acquired By Merck ,RTTNews,/news/stocks/prometheus-biosciences-to-be-acquired-by-merck-1032234575,neutral,0.9473671317100525
4/17/2023 1:58:09 AM,"Moderna, Merck post detailed Phase 2 data for mRNA cancer shot in melanoma",Seeking Alpha,https://seekingalpha.com/news/3956769-moderna-merck-mrna-cancer-shot-cut-relapse-death-melanoma?utm_source=businessinsider&utm_medium=referral,neutral,0.8182693719863892
4/17/2023 3:15:03 AM,Merck & Company (MRK) Receives a Buy from Mizuho Securities,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-mizuho-securities-1032234736,neutral,0.5269083380699158
4/17/2023 6:45:12 AM,Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/goldman-sachs-reaffirms-their-buy-rating-on-merck-company-mrk-1032235469,neutral,0.8487255573272705
4/17/2023 7:20:14 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: UnitedHealth (UNH), Johnson & Johnson (JNJ) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-unitedhealth-unh-johnson-johnson-jnj-and-merck-company-mrk-1032235548,negative,0.8450902700424194
4/17/2023 10:10:46 AM,"Analysts Are Bullish on Top Healthcare Stocks: UnitedHealth (UNH), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-unitedhealth-unh-merck-company-mrk-1032235870,neutral,0.5960186123847961
4/17/2023 10:25:14 AM,Merck & Company (MRK) Receives a Buy from Citigroup,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-citigroup-1032235907,positive,0.6221969723701477
4/17/2023 10:35:04 AM,Merck & Company (MRK) Receives a Hold from Wells Fargo,TipRanks,/news/stocks/merck-company-mrk-receives-a-hold-from-wells-fargo-1032235944,neutral,0.629916787147522
4/17/2023 11:34:07 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-4-1032236074,neutral,0.497906357049942
4/17/2023 12:43:22 PM,Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?,InvestorPlace,/news/stocks/why-is-prometheus-biosciences-rxdx-stock-up-70-today-1032236373,positive,0.8569079637527466
4/17/2023 1:47:58 PM,Prometheus Biosciences had other bidders besides Merck - report,Seeking Alpha,https://seekingalpha.com/news/3956939-prometheus-biosciences-had-other-other-bidders-besides-merck-report?utm_source=businessinsider&utm_medium=referral,neutral,0.9004549980163574
4/17/2023 1:50:17 PM,RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today,InvestorPlace,/news/stocks/rxdx-stock-alert-the-10-8-billion-reason-prometheus-biosciences-is-surging-today-1032236645,neutral,0.4237099885940552
4/17/2023 1:59:02 PM,"Prometheus soars 70%, Merck dips after ~$11B buyout deal",Seeking Alpha,https://seekingalpha.com/news/3956824-rxdx-stock-jumps-merck-stock-dips-after-11b-buyout-deal?utm_source=businessinsider&utm_medium=referral,negative,0.9401127099990845
4/17/2023 2:00:38 PM,Moderna (MRNA) Stock Sinks Despite Positive Cancer Vaccine Update,InvestorPlace,/news/stocks/moderna-mrna-stock-sinks-despite-positive-cancer-vaccine-update-1032236738,negative,0.7610612511634827
4/17/2023 11:08:32 PM,Why did Moderna stock drop today? mRNA cancer therapy data,Seeking Alpha,https://seekingalpha.com/news/3957144-why-did-moderna-stock-drop-today-mrna-cancer-therapy-data?utm_source=businessinsider&utm_medium=referral,negative,0.6310122013092041
4/18/2023 12:39:30 PM,Merck & Company (MRK) Gets a Buy from Jefferies,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-jefferies-1032239607,neutral,0.7569203972816467
4/18/2023 12:59:59 PM,Guardant Health cancer immunotherapy response test covered by Medicare,Seeking Alpha,https://seekingalpha.com/news/3957308-guardant-health-cancer-immunotherapy-response-test-covered-medicare?utm_source=businessinsider&utm_medium=referral,neutral,0.9468145966529846
4/18/2023 6:26:12 PM,Vaxcyte initiated at outperform at TD Cowen on pneumococcal vaccine,Seeking Alpha,https://seekingalpha.com/news/3957456-vaxcyte-initiated-outperform-td-cowen-pneumococcal-vaccine?utm_source=businessinsider&utm_medium=referral,positive,0.8721319437026978
4/19/2023 5:55:41 AM,SVB Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1032242298,neutral,0.7829649448394775
4/21/2023 12:26:11 PM,SVB Securities Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-remains-a-buy-on-merck-company-mrk-1032249785,neutral,0.9460416436195374
4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9372532963752747
4/21/2023 7:00:36 PM,"Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut",Seeking Alpha,https://seekingalpha.com/news/3958768-catalyst-watch-earnings-blitz-mobileye-lockup-expiration-and-the-new-one-day-vix-debut?utm_source=businessinsider&utm_medium=referral,neutral,0.9063062071800232
4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral,neutral,0.9020150899887085
4/24/2023 7:55:10 PM,3 Pharma Stocks That Could See a Surge in Demand in 2023,InvestorPlace,/news/stocks/3-pharma-stocks-that-could-see-a-surge-in-demand-in-2023-1032255429,positive,0.8981978297233582
4/25/2023 3:38:42 PM,Bipartisan agreement reached in Senate prescription drug price legislation,Seeking Alpha,https://seekingalpha.com/news/3959793-bipartisan-agreement-reached-senate-prescription-drug-price-legislation?utm_source=businessinsider&utm_medium=referral,positive,0.8105085492134094
4/26/2023 3:01:13 PM,Merck earnings preview: what to expect,Markets Insider Automation,/news/stocks/merck_co-stock-price-q1-earnings-preview-1032263657,neutral,0.9224230051040649
4/26/2023 3:07:35 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3960517-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8825733065605164
4/26/2023 3:43:56 PM,The 7 Best Stocks From Schwab’s Dividend ETF,InvestorPlace,/news/stocks/the-7-best-stocks-from-schwabs-dividend-etf-1032264454,neutral,0.8908190727233887
4/26/2023 3:48:01 PM,Will the Keytruda wave buoy Merck's Q1 results once again?,Seeking Alpha,https://seekingalpha.com/news/3960538-will-the-keytruda-wave-buoy-mercks-q1-results-once-again?utm_source=businessinsider&utm_medium=referral,positive,0.8685818314552307
4/26/2023 5:15:33 PM,"Pfizer, BioNTech hit new 52-week lows",Seeking Alpha,https://seekingalpha.com/news/3960630-pfizer-stock-biontech-stock-hit-new-52-week-lows?utm_source=businessinsider&utm_medium=referral,negative,0.8583164215087891
4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.8721349239349365
4/27/2023 12:14:00 AM,Looking to Invest in Stocks With High Free Cash Flow Margins? Here’s an ETF That Fits the Bill,TipRanks,/news/stocks/looking-to-invest-in-stocks-with-high-free-cash-flow-margins-here-s-an-etf-that-fits-the-bill-1032259962,neutral,0.8737333416938782
4/27/2023 10:31:36 AM,"Merck Non-GAAP EPS of $1.40 beats by $0.03, revenue of $14.48B beats by $660M",Seeking Alpha,https://seekingalpha.com/news/3961145-merck-non-gaap-eps-of-1_40-beats-0_03-revenue-of-14_48b-beats-660m?utm_source=businessinsider&utm_medium=referral,neutral,0.5732975602149963
4/27/2023 11:35:19 AM,"Merck trades higher as Keytruda, Gardasil drive Q1 growth amid COVID pill decline",Seeking Alpha,https://seekingalpha.com/news/3961247-merck-stock-rises-as-keytruda-gardasil-drive-q1-sales-growth?utm_source=businessinsider&utm_medium=referral,positive,0.9417479038238525
4/27/2023 11:50:08 AM,"Analysts Offer Insights on Healthcare Companies: Accuray (ARAY), Alnylam Pharma (ALNY) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-accuray-aray-alnylam-pharma-alny-and-merck-company-mrk-1032268365,neutral,0.9194609522819519
4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050,positive,0.7996723055839539
4/27/2023 1:14:07 PM,Merck Q1 Results Top Estimates; Boosts FY23 Outlook ,RTTNews,/news/stocks/merck-q1-results-top-estimates-boosts-fy23-outlook-1032268136,positive,0.9232921600341797
4/28/2023 6:40:27 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC) and Merck & Company (MRK),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-centene-cnc-and-merck-company-mrk-1032272388,negative,0.939032256603241
4/28/2023 8:25:41 AM,Barclays Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/barclays-sticks-to-their-buy-rating-for-merck-company-mrk-1032272679,neutral,0.8385382294654846
4/28/2023 9:25:08 AM,Merck & Company (MRK) Receives a Hold from Morgan Stanley,TipRanks,/news/stocks/merck-company-mrk-receives-a-hold-from-morgan-stanley-1032272872,neutral,0.7861171960830688
4/28/2023 12:30:19 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Dexcom (DXCM) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-dexcom-dxcm-and-merck-company-mrk-1032273730,neutral,0.9202548861503601
4/28/2023 10:14:11 PM,"Merck, AstraZeneca Lynparza wins limited label expansion endorsement",Seeking Alpha,https://seekingalpha.com/news/3962365-merck-astrazeneca-lynparza-limited-label-expansion-endorsement-prostate-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.7930711507797241
4/29/2023 8:00:00 PM,"Pfizer, GSK, AbbVie among pharmas set to rise with May catalysts",Seeking Alpha,https://seekingalpha.com/news/3962345-pfizer-gsk-abbvie-among-pharmas-rise-may-catalysts?utm_source=businessinsider&utm_medium=referral,positive,0.9250966310501099
5/1/2023 9:30:24 AM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Dexcom (DXCM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-dexcom-dxcm-1032277571,neutral,0.9164958000183105
5/1/2023 11:51:02 AM,"Bristol Myers, Merck anemia therapy undergoes U.S. and EU review for label expansion",Seeking Alpha,https://seekingalpha.com/news/3962527-bristol-myers-merck-anemia-drug-us-eu-reviews-label-expansion?utm_source=businessinsider&utm_medium=referral,neutral,0.6842166185379028
5/1/2023 2:55:47 PM,SVB Securities Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/svb-securities-sticks-to-their-buy-rating-for-merck-company-mrk-1032278582,neutral,0.8361806869506836
5/1/2023 3:00:30 PM,Where Merck & Co Stands With Analysts,Benzinga,/news/stocks/where-merck-co-stands-with-analysts-1032278301,neutral,0.9218418598175049
5/1/2023 4:31:01 PM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Day One Biopharmaceuticals (DAWN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-day-one-biopharmaceuticals-dawn-1032278889,neutral,0.9100643396377563
5/1/2023 5:29:00 PM,"Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report",Seeking Alpha,https://seekingalpha.com/news/3962788-abbvie-bristol-myers-competed-with-merck-in-sale-of-prometheus-report?utm_source=businessinsider&utm_medium=referral,positive,0.8889114856719971
5/2/2023 6:25:36 PM,"Eli Lilly, Merck hit new 52-week highs",Seeking Alpha,https://seekingalpha.com/news/3963709-eli-lilly-merck-hit-new-52-week-highs?utm_source=businessinsider&utm_medium=referral,positive,0.82575923204422
5/3/2023 10:08:01 AM,"Fentanyl overdose deaths rose 279%, oxycodone deaths fell in 5 years",Seeking Alpha,https://seekingalpha.com/news/3964240-fentanyl-overdose-deaths-rose-279-oxycodone-deaths-fell-in-5-years?utm_source=businessinsider&utm_medium=referral,positive,0.9210435748100281
5/4/2023 6:28:34 PM,WHO meeting is set to decide whether to end COVID emergency,Seeking Alpha,https://seekingalpha.com/news/3965903-who-meeting-is-set-to-decide-whether-to-end-covid-emergency?utm_source=businessinsider&utm_medium=referral,neutral,0.8873199820518494
5/5/2023 6:24:36 PM,7 Hot Growth Stocks Poised to Triple in 2023,InvestorPlace,/news/stocks/7-hot-growth-stocks-poised-to-triple-in-2023-1032298483,positive,0.8558738827705383
5/6/2023 8:00:00 PM,"Eli Lilly, Humana among best health care names in defensive environment - BofA",Seeking Alpha,https://seekingalpha.com/news/3966792-eli-lilly-humana-among-best-health-care-names-defensive-environment?utm_source=businessinsider&utm_medium=referral,positive,0.6749860644340515
5/8/2023 8:36:39 AM,"AstraZeneca, Merck's Koselugo gets approval in China for rare genetic disorder in kids",Seeking Alpha,https://seekingalpha.com/news/3966887-astrazeneca-merck-koselugo-gets-china-nod-for-rare-disorder-in-kids?utm_source=businessinsider&utm_medium=referral,positive,0.8133702874183655
5/8/2023 3:09:19 PM,CDC COVID data collection to decline once public health emergency ends,Seeking Alpha,https://seekingalpha.com/news/3967125-cdc-covid-data-collection-to-decline-once-public-health-emergency-ends?utm_source=businessinsider&utm_medium=referral,negative,0.9657461047172546
5/10/2023 8:33:44 PM,Is ChatGPT A Better Financial Advisor? We're Going To Find Out,Benzinga,/news/etf/is-chatgpt-a-better-financial-advisor-we-re-going-to-find-out-1032313893,neutral,0.8116571307182312
5/11/2023 10:09:45 AM,The 3 Best MedTech Stocks to Watch in May 2023,InvestorPlace,/news/stocks/the-3-best-medtech-stocks-to-watch-in-may-2023-1032317056,neutral,0.8671631813049316
5/11/2023 8:40:00 PM,3 Penny Stocks That Could Make You a Millionaire by 2025,InvestorPlace,/news/stocks/3-penny-stocks-that-could-make-you-a-millionaire-by-2025-1032319676,neutral,0.8846798539161682
5/13/2023 8:00:00 PM,Cancer therapies spending set to surge through end of decade,Seeking Alpha,https://seekingalpha.com/news/3971001-cancer-therapies-spending-set-surge-through-end-decade?utm_source=businessinsider&utm_medium=referral,positive,0.9407323002815247
5/16/2023 12:41:41 PM,"Seagen, Prometheus Biosciences fall amid news of FTC planned block of Horizon/Amgen deal",Seeking Alpha,https://seekingalpha.com/news/3972034-seagen-prometheus-biosciences-fall-amid-news-of-ftc-planned-block-of-horizonamgen-deal?utm_source=businessinsider&utm_medium=referral,negative,0.9247511029243469
5/16/2023 12:52:10 PM,AstraZeneca to exit leading U.S. drug industry group PhRMA,Seeking Alpha,https://seekingalpha.com/news/3972045-astrazeneca-stock-exits-leading-us-drug-lobby-phrma?utm_source=businessinsider&utm_medium=referral,neutral,0.6984096169471741
5/17/2023 4:56:59 PM,Immutep surges 106% on mid-stage data for lead asset in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3972529-immutep-stock-jumps-mid-stage-data-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral,positive,0.9196776747703552
5/17/2023 8:47:25 PM,Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs,InvestorPlace,/news/stocks/shhh-3-healthcare-stocks-quietly-hitting-52-week-highs-1032336112,positive,0.6872825622558594
5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral,negative,0.7930806875228882
5/19/2023 3:27:21 PM,3 Undervalued Pharma Stocks to Buy for High Total Returns,InvestorPlace,/news/stocks/3-undervalued-pharma-stocks-to-buy-for-high-total-returns-1032340158,positive,0.9090120792388916
5/19/2023 7:00:19 PM,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",Seeking Alpha,https://seekingalpha.com/news/3973501-catalyst-watch-eyes-on-ford-event-virgin-galactic-launch-nvidia-earnings-and-microsoft-conference?utm_source=businessinsider&utm_medium=referral,neutral,0.9428636431694031
5/19/2023 10:59:40 PM,Intensity Therapeutics upsizes proposed IPO to $15M from $8M,Seeking Alpha,https://seekingalpha.com/news/3973606-intensity-therapeutics-upsizes-proposed-ipo-to-15m-from-8m?utm_source=businessinsider&utm_medium=referral,positive,0.9375888109207153
5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.7357143759727478
5/23/2023 2:02:42 PM,Prometheus Biosciences gains after HSR waiting for sale to Merck expires (update),Seeking Alpha,https://seekingalpha.com/news/3974152-prometheus-biosciences-gains-after-hsr-waiting-for-sale-to-merck-expires?utm_source=businessinsider&utm_medium=referral,neutral,0.7489250898361206
5/23/2023 6:52:41 PM,Merck declares $0.73 dividend,Seeking Alpha,https://seekingalpha.com/news/3974314-merck-and-co-inc-declares-0_73-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.9289058446884155
5/24/2023 12:18:40 AM,7 Stocks That Could Be the Next $2 Trillion-Dollar Companies,InvestorPlace,/news/stocks/7-stocks-that-could-be-the-next-2-trillion-dollar-companies-1032346826,neutral,0.939713716506958
5/25/2023 7:23:24 PM,Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades,Seeking Alpha,https://seekingalpha.com/news/3975194-mirati-stock-falls-study-failure-oppenheimer-upgrades?utm_source=businessinsider&utm_medium=referral,negative,0.8996388912200928
5/26/2023 2:45:16 AM,Mizuho Securities Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-merck-company-mrk-1032353082,neutral,0.9361416697502136
5/26/2023 10:30:48 AM,"Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eledon-pharmaceuticals-eldn-merck-company-mrk-1032353997,neutral,0.8111205697059631
5/26/2023 10:41:02 AM,What Do the SPY ETF’s Technical Indicators Suggest?,TipRanks,/news/stocks/what-do-the-spy-etf-s-technical-indicators-suggest-1032353991,neutral,0.9311667084693909
5/26/2023 10:53:18 AM,PDS Biotech gains 20% after Phase 2 data for lead asset in head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/3975346-pds-biotech-stock-gains-after-cancer-data-lead-asset?utm_source=businessinsider&utm_medium=referral,positive,0.9267600774765015
5/26/2023 12:47:30 PM,"Dividend Roundup: Bank of America, Kellogg, eBay, Nvidia and more",Seeking Alpha,https://seekingalpha.com/news/3975335-dividend-roundup-bank-of-america-kellogg-ebay-nvidia-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9435454607009888
5/26/2023 4:36:09 PM,Cullinan gains as early trial for cancer drug indicates complete remission,Seeking Alpha,https://seekingalpha.com/news/3975496-cullinan-oncology-stock-ancer-drug-data?utm_source=businessinsider&utm_medium=referral,positive,0.9410320520401001
5/30/2023 4:30:23 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN), Merck & Company (MRK) and Lexicon Pharmaceuticals (LXRX)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-rain-therapeutics-rain-merck-company-mrk-and-lexicon-pharmaceuticals-lxrx-1032358954,negative,0.9367054104804993
5/30/2023 9:01:27 PM,Analyst Ratings for Merck & Co,Benzinga,/news/stocks/analyst-ratings-for-merck-co-1032359170,neutral,0.9076553583145142
5/31/2023 12:54:58 PM,3 Innovative Growth Stocks to Buy for Next-Gen Profits,InvestorPlace,/news/stocks/3-innovative-growth-stocks-to-buy-for-next-gen-profits-1032360945,neutral,0.8067752122879028
5/31/2023 9:22:11 PM,AstraZeneca/Merck's Lynparza gains expanded prostate cancer indication,Seeking Alpha,https://seekingalpha.com/news/3976412-astrazeneca-merck-lynparza-gains-expanded-prostate-cancer-indication?utm_source=businessinsider&utm_medium=referral,positive,0.7644969820976257
6/1/2023 1:11:56 AM,7 Dividend Stocks to Buy (and Never Sell),InvestorPlace,/news/stocks/7-of-the-best-long-term-dividend-stocks-to-buy-and-never-sell-1032362747,neutral,0.9450306296348572
6/2/2023 10:00:43 AM,3 Undervalued Dow Stocks to Buy Before Wall Street Does,InvestorPlace,/news/stocks/3-best-undervalued-dow-stocks-to-buy-before-wall-street-does-1032366783,positive,0.6084189414978027
6/2/2023 7:00:55 PM,"Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display",Seeking Alpha,https://seekingalpha.com/news/3977170-catalyst-watch-apples-wwdc-event-opec-fallout-and-reits-on-display?utm_source=businessinsider&utm_medium=referral,neutral,0.8603395819664001
6/3/2023 4:00:00 PM,ASCO 2023: What to look for at oncology's biggest meeting,Seeking Alpha,https://seekingalpha.com/news/3976898-asco-2023-what-look-for-oncology-biggest-meeting?utm_source=businessinsider&utm_medium=referral,neutral,0.9382763504981995
6/5/2023 4:45:09 AM,Merck & Company (MRK) Receives a Buy from Bank of America Securities,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-bank-of-america-securities-1032369284,neutral,0.5672414302825928
6/5/2023 11:15:12 AM,Merck & Company (MRK) Gets a Hold from BMO Capital,TipRanks,/news/stocks/merck-company-mrk-gets-a-hold-from-bmo-capital-1032369988,neutral,0.9332118630409241
6/6/2023 8:35:18 AM,Barclays Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-merck-company-mrk-1032372115,neutral,0.9102963209152222
6/6/2023 10:25:31 AM,Mizuho Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1032372398,neutral,0.716327965259552
6/6/2023 1:58:51 PM,Merck sues US Government to halt Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3977904-merck-sues-us-government-to-halt-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral,negative,0.9116592407226562
6/7/2023 9:55:45 AM,Merck & Company (MRK) Gets a Buy from SVB Securities,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-svb-securities-1032375289,neutral,0.7731749415397644
6/8/2023 12:10:12 AM,The 3 Best Defensive Stocks to Buy in June 2023,InvestorPlace,/news/stocks/the-3-best-defensive-stocks-to-buy-in-june-2023-1032377119,neutral,0.8921303749084473
6/8/2023 11:07:34 AM,Merck marketing application for Keytruda in liver cancer granted FDA review,Seeking Alpha,https://seekingalpha.com/news/3978565-merck-keytruda-combo-liver-cancer-undergoes-fda-review?utm_source=businessinsider&utm_medium=referral,neutral,0.694860577583313
6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral,neutral,0.5447219014167786
6/9/2023 8:58:01 PM,US Chamber of Commerce sues US government over drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3979033-us-chamber-of-commerce-sues-us-government-over-drug-pricing-program?utm_source=businessinsider&utm_medium=referral,negative,0.9389665722846985
6/12/2023 12:10:29 PM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-biogen-biib-1032383345,neutral,0.9119682908058167
6/13/2023 8:23:53 PM,Merck patent on Bridion affirmed through 2026,Seeking Alpha,https://seekingalpha.com/news/3979646-merck-patent-bridion-affirmed-through-2026?utm_source=businessinsider&utm_medium=referral,neutral,0.8842989206314087
6/14/2023 1:12:07 PM,PDS Biotech meets efficacy threshold in mid-stage trial for head and neck cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3979810-pds-biotech-stock-hits-success-head-neck-cancer-drug?utm_source=businessinsider&utm_medium=referral,positive,0.9458374977111816
6/14/2023 10:45:57 PM,ChatGPT Portfolio Is Beating Most Funds: Is AI The Future Of Investing?,Benzinga,/news/etf/chatgpt-portfolio-is-beating-most-funds-is-ai-the-future-of-investing-1032390107,neutral,0.8630553483963013
6/16/2023 11:12:21 AM,Merck's Keytruda meets primary endpoint in gastric cancer trial,Seeking Alpha,https://seekingalpha.com/news/3980415-merck-keytruda-meets-primary-endpoint-gastric-cancer-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.8816081285476685
6/16/2023 10:11:45 PM,Bristol Meyers reportedly sues over new Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3980604-bristol-meyers-reportedly-sues-over-new-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral,negative,0.9449897408485413
6/17/2023 8:00:00 PM,Biologic drugs will lead European pharmas to surpass US counterparts in sales,Seeking Alpha,https://seekingalpha.com/news/3979912-biologic-drugs-lead-european-pharmas-surpass-us-counterparts-sales?utm_source=businessinsider&utm_medium=referral,positive,0.9524824023246765
6/20/2023 11:31:43 AM,Merck fails in late-stage trial for Keytruda in stomach cancer,Seeking Alpha,https://seekingalpha.com/news/3980784-merck-stock-fails-trial-keytruda-stomach-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.7963690757751465
6/20/2023 12:12:53 PM,Bristol Myers reportedly sues over new Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3980604-bristol-myers-reportedly-sues-over-new-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral,negative,0.9511773586273193
6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,negative,0.9452309608459473
6/22/2023 3:19:29 PM,"Dear SCHD ETF Fans, Mark Your Calendars for June 26",InvestorPlace,/news/stocks/dear-schd-etf-fans-mark-your-calendars-for-june-26-1032405068,neutral,0.9381810426712036
6/23/2023 8:41:05 AM,SCHD ETF: Technical Indicators Signal Further Upside Potential,TipRanks,/news/stocks/schd-etf-technical-indicators-signal-further-upside-potential-1032406368,positive,0.7398825883865356
6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral,negative,0.6917394399642944
6/28/2023 1:12:28 PM,Genprex jumps ~15% on third FDA fast track tag for lead asset,Seeking Alpha,https://seekingalpha.com/news/3983649-genprex-stock-jumps-fda-fast-track-tag-lead-asset?utm_source=businessinsider&utm_medium=referral,positive,0.9198164343833923
6/28/2023 8:53:46 PM,"Terns Pharmaceuticals Is ""Attractively Priced"" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says",Benzinga,/news/stocks/terns-pharmaceuticals-is-attractively-priced-despite-pressure-from-eli-lilly-s-obesity-data-analyst-says-1032416121,positive,0.9473310708999634
6/29/2023 9:08:31 AM,Morgan Stanley shakes up its global dividend portfolio,Seeking Alpha,https://seekingalpha.com/news/3983853-morgan-stanley-shakes-up-its-global-dividend-portfolio?utm_source=businessinsider&utm_medium=referral,negative,0.947080135345459
6/30/2023 4:39:00 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023,InvestorPlace,/news/stocks/pharma-stocks-to-buy-1032421255,neutral,0.9032686352729797
6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.901573121547699
7/4/2023 1:07:40 AM,The 3 Best Dividend ETFs to Buy for July,InvestorPlace,/news/stocks/the-3-best-dividend-etfs-to-buy-for-july-1032424343,neutral,0.83551025390625
7/5/2023 12:10:13 PM,"Analysts’ Top Healthcare Picks: Merck & Company (MRK), PTC Therapeutics (PTCT)",TipRanks,/news/stocks/analysts-top-healthcare-picks-merck-company-mrk-ptc-therapeutics-ptct-1032427316,positive,0.5290594696998596
7/7/2023 8:00:38 PM,"Retirement Stocks: Here’s Where to Invest $1,000 Right Now",InvestorPlace,/news/stocks/retirement-stocks-heres-where-to-invest-1000-right-now-1032432946,neutral,0.9447411298751831
7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral,positive,0.937191367149353
7/12/2023 12:15:25 AM,Morgan Stanley Reaffirms Their Hold Rating on Merck & Company (MRK),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-hold-rating-on-merck-company-mrk-1032439043,neutral,0.8328593969345093
7/12/2023 6:05:31 PM,Merck intensifies legal fight to halt Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3987148-merck-files-motion-in-suit-halt-medicare-drug-pricing-law?utm_source=businessinsider&utm_medium=referral,negative,0.775958240032196
7/13/2023 5:03:43 PM,3 Penny Stocks to Catapult You Into the Millionaires’ Club,InvestorPlace,/news/stocks/3-penny-stocks-to-catapult-you-into-the-millionaires-club-1032445532,neutral,0.7920975685119629
7/13/2023 7:10:40 PM,Calliditas interim phase 2 data positive for head and neck cancer asset setanaxib,Seeking Alpha,https://seekingalpha.com/news/3987507-calliditas-interim-phase-2-data-positive-head-neck-cancer-asset-setanaxib?utm_source=businessinsider&utm_medium=referral,positive,0.6757572293281555
7/14/2023 5:02:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-14-2023-1032447974,neutral,0.4949893355369568
7/14/2023 8:44:13 PM,Why Are Dow Stocks Up Today?,InvestorPlace,/news/stocks/why-are-dow-stocks-up-today-1032448428,neutral,0.6809260249137878
7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.4974316656589508
7/18/2023 4:15:13 AM,7 Safe Stocks to Buy as Fed Gears Up for Disinflation,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-as-fed-gears-up-for-disinflation-1032453279,neutral,0.8111875653266907
7/18/2023 10:22:03 AM,3 Biotech Stocks for Getting Rich in 2023,InvestorPlace,/news/stocks/3-biotech-stocks-for-getting-rich-in-2023-1032454309,neutral,0.7535070776939392
7/18/2023 5:33:04 PM,J&J becomes latest Big Pharma to sue over Medicare drug pricing,Seeking Alpha,https://seekingalpha.com/news/3988476-jj-becomes-latest-big-pharma-to-sue-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,negative,0.9197932481765747
7/19/2023 8:20:34 AM,"Analysts’ Top Healthcare Picks: Terns Pharmaceuticals (TERN), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-terns-pharmaceuticals-tern-merck-company-mrk-1032458062,positive,0.5324180126190186
7/19/2023 1:52:24 PM,Merck: Phase 3 KEYTRUDA Trial Meets Primary Endpoint Of PFS In Advanced Cervical Cancer ,RTTNews,/news/stocks/merck-phase-3-keytruda-trial-meets-primary-endpoint-of-pfs-in-advanced-cervical-cancer-1032458593,positive,0.7074897885322571
7/21/2023 12:57:34 PM,Merck gets EU nod for new therapies in cough and gastric cancer,Seeking Alpha,https://seekingalpha.com/news/3989610-merck-gets-eu-nod-new-therapies-cough-gastric-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.896190345287323
7/21/2023 2:51:16 PM,Merck's Gefapixant Drug For Chronic Cough A Step Away From Approval In Europe ,RTTNews,/news/stocks/merck-s-gefapixant-drug-for-chronic-cough-a-step-away-from-approval-in-europe-1032465835,negative,0.9253675937652588
7/21/2023 10:29:33 PM,"Dow Jones Hits Milestone: 10th Straight Day In Green, Longest Winning Streak Since 2017",Benzinga,/news/etf/dow-jones-hits-milestone-10th-straight-day-in-green-longest-winning-streak-since-early-2017-1032466940,neutral,0.6383927464485168
7/24/2023 5:39:37 PM,"Moderna Is Fairly Valued, Balancing Declining COVID-19 Base Business with Promising Future Pipeline: Analyst",Benzinga,/news/stocks/moderna-is-fairly-valued-balancing-declining-covid-19-base-business-with-promising-future-pipeline-analyst-1032470927,negative,0.4545869827270508
7/24/2023 8:14:07 PM,"Analyst Cuts Nurix Therapeutics Price Target By 38%, Cites Lymphoma Data",Benzinga,/news/stocks/analyst-cuts-nurix-therapeutics-price-target-by-38-cites-lymphoma-data-1032471320,neutral,0.5101257562637329
7/25/2023 1:46:00 PM,"Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement",PR Newswire,/news/stocks/data-vault-holdings-inc-and-p-chip-corporation-to-connect-platforms-through-enabling-ip-licensing-agreement-1032474019,positive,0.5422716736793518
7/25/2023 6:07:12 PM,Merck declares $0.73 dividend,Seeking Alpha,https://seekingalpha.com/news/3990683-merck-and-co-inc-declares-0_73-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.9289058446884155
7/26/2023 8:47:20 AM,Moderna On Cathie Wood's Radar Ahead Of Q2 Results: Ark Boosts Stake In COVID-19 Vaccine Maker By $12M This Week,Benzinga,/news/etf/moderna-on-cathie-wood-s-radar-ahead-of-q2-results-ark-boosts-stake-in-covid-19-vaccine-maker-by-12m-this-week-1032478123,positive,0.9467118978500366
7/26/2023 1:26:51 PM,"Moderna, Merck begin phase 3 trial on mRNA melanoma combo treatment",Seeking Alpha,https://seekingalpha.com/news/3991182-moderna-merck-begin-phase-3-trial-mrna-melanoma-combo-treatment?utm_source=businessinsider&utm_medium=referral,neutral,0.5607835054397583
7/27/2023 12:04:51 AM,VTI ETF’s Simple but Powerful Strategy is a Long-Term Winner,TipRanks,/news/stocks/vti-etf-s-simple-but-powerful-strategy-is-a-long-term-winner-1032481766,neutral,0.7039119601249695
7/27/2023 2:25:16 AM,Truist Financial Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-merck-company-mrk-1032481936,neutral,0.756365954875946
7/27/2023 2:51:33 PM,"Merck Says 21-valent Pneumococcal Conjugate Vaccine,V116, Meets Key Endpoints In Phase 3 Trials ",RTTNews,/news/stocks/merck-says-21-valent-pneumococcal-conjugate-vaccine-v116-meets-key-endpoints-in-phase-3-trials-1032484506,positive,0.9273879528045654
7/27/2023 5:01:32 PM,"Jim Cramer Recommends Holding This Health Care Stock: 'Re-Inventing Itself, Doing A Terrific Job'",Benzinga,/news/stocks/jim-cramer-recommends-holding-this-health-care-stock-re-inventing-itself-doing-a-terrific-job-1032485463,positive,0.8897175192832947
7/27/2023 5:10:10 PM,Merck pneumococcal vaccine outperforms PCV20 in Phase 3 trials,Seeking Alpha,https://seekingalpha.com/news/3992254-merck-pneumococcal-shot-outperforms-pcv20-in-phase-3-trials?utm_source=businessinsider&utm_medium=referral,positive,0.9348018765449524
7/28/2023 11:24:59 AM,"Dividend Roundup: Wells Fargo, Visa, IBM, Hasbro, and more",Seeking Alpha,https://seekingalpha.com/news/3992759-dividend-roundup-wells-fargo-visa-ibm-hasbro-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9483283162117004
7/28/2023 11:34:12 AM,Merck succeeds in Phase 3 trial for Keytruda in new breast cancer indication,Seeking Alpha,https://seekingalpha.com/news/3992767-merck-keytruda-succeeds-new-breast-cancer-indication?utm_source=businessinsider&utm_medium=referral,positive,0.8904756903648376
7/28/2023 1:04:50 PM,"Merck: Phase 3 KEYNOTE-756 Trial Meets Primary Endpoint In Early-Stage ER+/HER2- 
Breast Cancer ",RTTNews,/news/stocks/merck-phase-3-keynote-756-trial-meets-primary-endpoint-in-early-stage-er-her2-breast-cancer-1032489580,positive,0.8061286807060242
7/28/2023 6:00:40 PM,"Catalyst Watch: Amazon earnings, jobs report, and will Apple talk AI?",Seeking Alpha,https://seekingalpha.com/news/3992944-catalyst-watch-amazon-earnings-jobs-report-and-will-apple-talk-ai?utm_source=businessinsider&utm_medium=referral,neutral,0.9321873188018799
7/30/2023 7:24:28 PM,7 Dow Stocks to Buy as Recession Fears Roll Back,InvestorPlace,/news/stocks/7-dow-stocks-to-buy-as-recession-fears-roll-back-1032492376,neutral,0.43502503633499146
7/31/2023 9:34:27 AM,3 Pharma Stocks to Buy for Their Promising Progress,InvestorPlace,/news/stocks/3-pharma-stocks-to-buy-for-their-promising-progress-1032494547,positive,0.7185419797897339
7/31/2023 2:46:05 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3993451-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8660826683044434
7/31/2023 3:01:13 PM,Merck earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/merck_co-stock-q2-earnings-preview-1032495398,neutral,0.914770245552063
7/31/2023 8:30:50 PM,Merck looks to continue streak of EPS beats with Q2 results,Seeking Alpha,https://seekingalpha.com/news/3993681-merck-looks-continue-streak-eps-beats-q2-results?utm_source=businessinsider&utm_medium=referral,positive,0.8123006224632263
8/1/2023 8:45:15 AM,Bank of America Securities Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/bank-of-america-securities-remains-a-buy-on-merck-company-mrk-1032499646,neutral,0.9385826587677002
8/1/2023 10:32:09 AM,"Merck Non-GAAP EPS of -$2.06, revenue of $15B beats by $560M",Seeking Alpha,https://seekingalpha.com/news/3993977-merck-non-gaap-eps-of-2_06-revenue-of-15b-beats-560m?utm_source=businessinsider&utm_medium=referral,positive,0.5173007249832153
8/1/2023 11:26:39 AM,Merck raises sales guidance despite buyout impact on bottom line,Seeking Alpha,https://seekingalpha.com/news/3994060-merck-raises-guidance-despite-buyout-impact-on-bottom-line?utm_source=businessinsider&utm_medium=referral,positive,0.9169455170631409
8/1/2023 12:10:42 PM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Neurocrine (NBIX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-neurocrine-nbix-1032500402,neutral,0.9187737107276917
8/1/2023 12:58:14 PM,Merck & Co Inc. Q2 Earnings Summary,RTTNews,/news/stocks/merck-co-inc-q2-earnings-summary-1032500015,neutral,0.6699074506759644
8/2/2023 9:25:35 AM,Barclays Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/barclays-remains-a-buy-on-merck-company-mrk-1032505711,neutral,0.9307043552398682
8/2/2023 11:15:46 AM,BMO Capital Reaffirms Their Hold Rating on Merck & Company (MRK),TipRanks,/news/stocks/bmo-capital-reaffirms-their-hold-rating-on-merck-company-mrk-1032506215,neutral,0.8188301920890808
8/2/2023 2:40:31 PM,"Analysts’ Top Healthcare Picks: Exact Sciences (EXAS), IQVIA Holdings (IQV)",TipRanks,/news/stocks/analysts-top-healthcare-picks-exact-sciences-exas-iqvia-holdings-iqv-1032507641,positive,0.6541486978530884
8/2/2023 5:00:12 PM,Can Moderna spring a surprise for Q2 2023 despite falling vaccine demand?,Seeking Alpha,https://seekingalpha.com/news/3995395-can-moderna-surprise-q2-2023-amid-falling-vaccine-demand?utm_source=businessinsider&utm_medium=referral,positive,0.4750106930732727
8/2/2023 5:00:31 PM,Expert Ratings for Merck & Co,Benzinga,/news/stocks/expert-ratings-for-merck-co-1032507687,neutral,0.8768600821495056
8/3/2023 2:47:09 PM,Merck Ebola vaccine gets expanded indication for younger population,Seeking Alpha,https://seekingalpha.com/news/3996651-merck-ebola-vaccine-expanded-indication-younger-population?utm_source=businessinsider&utm_medium=referral,positive,0.8575841784477234
8/6/2023 7:35:00 PM,2023 shaping up to be biggest year for biopharma M&A since pandemic,Seeking Alpha,https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic?utm_source=businessinsider&utm_medium=referral,positive,0.8588072657585144
8/7/2023 2:30:00 PM,Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial,PR Newswire,/news/stocks/anixa-biosciences-announces-opening-of-enrollment-for-keytruda-arm-in-ongoing-breast-cancer-vaccine-clinical-trial-1032523713,positive,0.7377593517303467
8/9/2023 7:10:42 PM,"Analysts’ Top Healthcare Picks: Organon (OGN), Agenus (AGEN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-organon-ogn-agenus-agen-1032536411,neutral,0.54120272397995
8/9/2023 11:00:37 PM,The 3 Best Healthcare Stocks to Buy in August,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-august-1032537003,neutral,0.8423783183097839
8/10/2023 2:20:13 PM,Atea downgraded at JPMorgan on shrinking COVID opportunity,Seeking Alpha,https://seekingalpha.com/news/4000990-atea-stock-downgraded-jpmorgan-covid-concerns?utm_source=businessinsider&utm_medium=referral,neutral,0.63306725025177
8/10/2023 3:00:00 PM,Medicare Part D drug price increases far exceed inflation - AARP,Seeking Alpha,https://seekingalpha.com/news/4000101-medicare-part-d-drug-price-increases-far-exceed-inflation?utm_source=businessinsider&utm_medium=referral,positive,0.8962883353233337
8/11/2023 1:20:35 AM,The 3 Best ESG Stocks to Buy in August,InvestorPlace,/news/stocks/the-3-best-esg-stocks-to-buy-in-august-1032542532,neutral,0.8659203052520752
8/11/2023 7:44:56 PM,Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare,InvestorPlace,/news/stocks/buy-merck-mrk-stock-now-to-ride-a-wave-higher-in-healthcare-1032547879,positive,0.6766013503074646
8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.5231574177742004
8/14/2023 1:26:13 PM,PDS Biotech gains after updates on pivotal trial for lead asset,Seeking Alpha,https://seekingalpha.com/news/4002265-pds-biotech-stock-up-after-updates-on-trial-for-lead-asset?utm_source=businessinsider&utm_medium=referral,positive,0.8505547642707825
8/14/2023 7:51:58 PM,The 3 Most Undervalued Penny Stocks to Buy Now: August 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-penny-stocks-to-buy-now-august-2023-1032552785,neutral,0.8733919262886047
8/15/2023 1:10:08 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032555295,positive,0.5521676540374756
8/15/2023 8:20:35 PM,Sanofi was mystery suitor in Reata Pharma bidding war - report,Seeking Alpha,https://seekingalpha.com/news/4003207-sanofi-was-mystery-bidder-in-reata-pharma-bidding-war-report?utm_source=businessinsider&utm_medium=referral,neutral,0.7306931614875793
8/18/2023 11:20:04 AM,Merck succeeds in Phase 3 trial for kidney cancer drug,Seeking Alpha,https://seekingalpha.com/news/4004283-merck-wins-phase-3-trial-kidney-cancer-drug-welireg?utm_source=businessinsider&utm_medium=referral,positive,0.8717818856239319
8/18/2023 1:30:03 PM,Merck Announces First Positive Phase 3 Results For WELIREG From LITESPARK-005 ,RTTNews,/news/stocks/merck-announces-first-positive-phase-3-results-for-welireg-from-litespark-005-1032566241,positive,0.581098735332489
8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral,neutral,0.8961257338523865
8/21/2023 9:30:10 AM,The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-now-august-2023-1032569068,neutral,0.8989936709403992
8/21/2023 5:53:35 PM,Vaccine makers light up as COVID hospitalizations rise,Seeking Alpha,https://seekingalpha.com/news/4004883-vaccine-makers-light-up-covid-hospitalizations-rise?utm_source=businessinsider&utm_medium=referral,neutral,0.7403080463409424
8/21/2023 7:26:37 PM,Lawsuits unlikely to hinder Medicare drug price negotiations – UBS,Seeking Alpha,https://seekingalpha.com/news/4004908-lawsuits-wont-hurt-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.8472158908843994
8/21/2023 7:58:31 PM,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",Seeking Alpha,https://seekingalpha.com/news/4004913-lillys-market-cap-soared-in-q2-eclipsing-jnj-merck-novo-nordisk?utm_source=businessinsider&utm_medium=referral,positive,0.9460121989250183
8/22/2023 7:00:18 PM,What 7 Analyst Ratings Have To Say About Merck & Co,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-merck-co-1032574077,neutral,0.9330793023109436
8/23/2023 8:25:29 AM,Cantor Fitzgerald Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-merck-company-mrk-1032575469,neutral,0.9171469211578369
8/23/2023 2:27:22 PM,Roche sends anti-TIGIT developers higher after cancer drug data (update),Seeking Alpha,https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?utm_source=businessinsider&utm_medium=referral,positive,0.6301690936088562
8/23/2023 9:05:15 PM,Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update,Benzinga,/news/stocks/who-are-other-players-gaining-from-roche-s-accidental-lung-cancer-data-update-1032577703,neutral,0.8956717252731323
8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral,neutral,0.9293889403343201
8/24/2023 4:05:42 PM,Werewolf gains as Wedbush cites bullish views ahead of key readout,Seeking Alpha,https://seekingalpha.com/news/4006070-werewolf-stock-gains-wedbush-issues-bullish-view?utm_source=businessinsider&utm_medium=referral,positive,0.6228266954421997
8/25/2023 12:31:39 PM,"Merck, Eisai end phase 3 combo treatment trial for head and neck cancer",Seeking Alpha,https://seekingalpha.com/news/4006309-merck-eisai-end-phase-3-combo-treatment-trial-head-neck-cancer?utm_source=businessinsider&utm_medium=referral,neutral,0.6265227198600769
8/25/2023 2:43:48 PM,Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol,Seeking Alpha,https://seekingalpha.com/news/4006430-merck-starts-phase-3-oral-pcsk9-inhibitor-lower-cholesterol?utm_source=businessinsider&utm_medium=referral,positive,0.7989184856414795
8/25/2023 3:54:51 PM,AstraZeneca latest drugmaker to challenge Medicare drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/4006445-astrazeneca-latest-drugmaker-challenge-medicare-drug-price-negotiation?utm_source=businessinsider&utm_medium=referral,negative,0.43026378750801086
8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.8904427886009216
8/29/2023 10:53:40 AM,"Bristol Myers, Merck win U.S. label expansion for Reblozyl",Seeking Alpha,https://seekingalpha.com/news/4006945-bristol-myers-merck-win-us-label-expansion-reblozyl?utm_source=businessinsider&utm_medium=referral,positive,0.774684727191925
8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral,neutral,0.9310519099235535
8/29/2023 12:38:17 PM,Merck wins EU approval for Keytruda combo in gastric cancer,Seeking Alpha,https://seekingalpha.com/news/4006990-merck-wins-eu-approval-keytruda-combo-gastric-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.9208875894546509
8/29/2023 4:29:31 PM,Steady Eddies: 7 Unshakeable Stocks for Any Type of Market,InvestorPlace,/news/stocks/steady-eddies-7-unshakeable-stocks-for-any-type-of-market-safe-stocks-1032590194,neutral,0.9151720404624939
8/29/2023 7:29:57 PM,Republicans say Medicare drug negotiations will mean fewer new meds,Seeking Alpha,https://seekingalpha.com/news/4007245-republicans-say-medicare-drug-negotiations-fewer-new-meds?utm_source=businessinsider&utm_medium=referral,negative,0.8554677963256836
8/30/2023 12:58:15 AM,SPLG: The Market’s Lowest-Cost S&P 500 ETF,TipRanks,/news/stocks/splg-the-market-s-lowest-cost-s-p-500-etf-1032590792,neutral,0.7738195657730103
9/2/2023 6:00:00 PM,"Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag",Seeking Alpha,https://seekingalpha.com/news/4008548-lilly-novo-nordisk-top-pharma-performers-august-astrazeneca-roche-lag?utm_source=businessinsider&utm_medium=referral,positive,0.8847639560699463
9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral,neutral,0.7872201800346375
9/5/2023 8:55:09 AM,Merck Animal Health Recalls Banamine/Banamine-S Injection ,RTTNews,/news/stocks/merck-animal-health-recalls-banamine-banamine-s-injection-1032603974,negative,0.52779620885849
9/6/2023 12:26:54 AM,Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-merck-company-mrk-1032607023,neutral,0.8239803910255432
9/7/2023 11:08:02 AM,7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth,InvestorPlace,/news/stocks/7-pharma-stocks-to-buy-for-groundbreaking-treatments-and-robust-revenue-growth-1032612381,positive,0.9394681453704834
9/7/2023 7:39:56 PM,Astellas withdraws federal lawsuit over Medicare drug pricing,Seeking Alpha,https://seekingalpha.com/news/4010044-astellas-withdraws-federal-lawsuit-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8975496888160706
9/8/2023 7:00:57 PM,"Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates",Seeking Alpha,https://seekingalpha.com/news/4010342-catalyst-watch-arm-ipo-apple-event-and-senate-ai-forum-with-musk-zuckerberg-and-gates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9412830471992493
9/8/2023 7:09:33 PM,BriaCell falls after Phase 2 data for lead asset in breast cancer,Seeking Alpha,https://seekingalpha.com/news/4010382-briacell-stock-falls-data-breast-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9549291729927063
9/10/2023 9:30:39 AM,Gilead says Trodelvy with Merck’s Keytruda controls lung cancer,Seeking Alpha,https://seekingalpha.com/news/4010428-gilead-trodelvy-mercks-keytruda-controls-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7239658236503601
9/10/2023 10:25:35 AM,Gilead : Phase 2 Study Of Trodelvy Combination Shows Promising Clinical Activity In  Lung Cancer ,RTTNews,/news/stocks/gilead-phase-2-study-of-trodelvy-combination-shows-promising-clinical-activity-in-lung-cancer-1032617815,positive,0.9350793361663818
9/12/2023 1:38:17 PM,Geron rises as Goldman Sachs upgrades citing FDA nod for imetelstat,Seeking Alpha,https://seekingalpha.com/news/4010966-geron-stock-rises-goldman-sachs-upgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.4903319478034973
9/13/2023 11:33:44 AM,Moderna sees $10B – $15B sales from launching new products by 2028,Seeking Alpha,https://seekingalpha.com/news/4011279-moderna-stock-gains-updates-rd-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7008398771286011
9/13/2023 5:21:50 PM,Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm,InvestorPlace,/news/stocks/flu-vaccine-results-give-moderna-mrna-stock-a-shot-in-the-arm-1032628153,positive,0.6125820279121399
9/15/2023 4:12:31 PM,Merck Gets Positive CHMP Opinion For Approval Of KEYTRUDA To Treat Non-Small Cell Lung Cancer ,RTTNews,/news/stocks/merck-gets-positive-chmp-opinion-for-approval-of-keytruda-to-treat-non-small-cell-lung-cancer-1032634186,positive,0.9510012269020081
9/15/2023 9:26:39 PM,"VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks",TipRanks,/news/stocks/vti-etf-this-diversified-powerhouse-owns-over-3-800-stocks-1032634771,neutral,0.9168491959571838
9/18/2023 5:33:10 PM,Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?,Benzinga,/news/stocks/is-this-250-year-old-japanese-big-pharma-giant-selling-for-half-price-right-now-1032637731,neutral,0.815968930721283
9/18/2023 9:00:48 PM,Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy Rating,Benzinga,/news/stocks/promising-preclinical-results-from-blood-cancer-propel-oncternal-to-buy-rating-1032638088,positive,0.8334927558898926
9/19/2023 1:36:13 PM,Merck: FDA Grants Priority Review For SNDA Seeking Approval For WELIREG ,RTTNews,/news/stocks/merck-fda-grants-priority-review-for-snda-seeking-approval-for-welireg-1032639618,positive,0.5870945453643799
9/20/2023 1:45:10 PM,Merck Says FDA Grants Priority Review For KEYTRUDA+Concurrent Chemoradiotherapy For Cervical Cancer ,RTTNews,/news/stocks/merck-says-fda-grants-priority-review-for-keytruda-concurrent-chemoradiotherapy-for-cervical-cancer-1032643103,positive,0.7019928693771362
9/22/2023 12:59:35 PM,Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints ,RTTNews,/news/stocks/merck-says-phase-3-keynote-a39-ev-302-trial-meets-dual-primary-endpoints-1032649341,positive,0.7726414799690247
9/22/2023 2:14:13 PM,"Merck: LEAP-006, LEAP-008 Trials Fails To Meet Dual Primary Endpoints ",RTTNews,/news/stocks/merck-leap-006-leap-008-trials-fails-to-meet-dual-primary-endpoints-1032649530,negative,0.8911618590354919
9/28/2023 1:51:44 PM,Merck Gets Priority Review For Biologics License Application For Sotatercept ,RTTNews,/news/stocks/merck-gets-priority-review-for-biologics-license-application-for-sotatercept-1032662612,positive,0.5406352877616882
10/2/2023 2:30:35 AM,"Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Keros Therapeutics (KROS) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-point-biopharma-global-pnt-keros-therapeutics-kros-and-merck-company-mrk-1032668553,neutral,0.912267804145813
10/3/2023 4:15:28 AM,Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-buy-rating-on-merck-company-mrk-1032672065,neutral,0.8452711701393127
10/3/2023 6:30:19 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Maravai Lifesciences Holdings (MRVI) and Karuna Therapeutics (KRTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-maravai-lifesciences-holdings-mrvi-and-karuna-therapeutics-krtx-1032672261,neutral,0.9197489619255066
10/3/2023 2:58:30 PM,Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?,Benzinga,/news/stocks/why-cancer-focused-alx-oncology-stock-gained-over-100-today-1032674452,positive,0.6460390686988831
10/4/2023 10:00:24 PM,9 Analysts Have This to Say About Merck & Co,Benzinga,/news/stocks/9-analysts-have-this-to-say-about-merck-co-1032679308,neutral,0.9217051267623901
10/5/2023 2:19:51 PM,Merck: KEYTRUDA Positive Trial Results In Certain Patients With Muscle-Invasive Urothelial Carcinoma ,RTTNews,/news/stocks/merck-keytruda-positive-trial-results-in-certain-patients-with-muscle-invasive-urothelial-carcinoma-1032681207,positive,0.9303468465805054
10/5/2023 4:01:05 PM,"Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power: Today's Top Stories",Benzinga,/news/stocks/disney-slashes-ticket-prices-for-children-us-government-ceases-free-distribution-of-merck-covid-pill-uk-deep-dives-into-amazon-and-microsoft-s-cloud-power-today-s-top-stories-1032681988,negative,0.8959554433822632
10/9/2023 6:46:32 PM,3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’,InvestorPlace,/news/stocks/3-artificial-intelligence-stocks-that-could-outperform-the-godfather-of-ai-1032689930,neutral,0.5206442475318909
10/10/2023 2:30:13 AM,"Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), ImmunoGen (IMGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-merck-company-mrk-immunogen-imgn-1032690203,neutral,0.8125964403152466
10/10/2023 1:14:31 PM,Merck: KEYNOTE-671 Trial Meets Dual Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/merck-keynote-671-trial-meets-dual-primary-endpoint-quick-facts-1032691863,neutral,0.7676942944526672
10/13/2023 8:40:25 AM,"Analysts Are Bullish on Top Healthcare Stocks: Terns Pharmaceuticals (TERN), BridgeBio Pharma (BBIO)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-terns-pharmaceuticals-tern-bridgebio-pharma-bbio-1032703076,neutral,0.4679132401943207
10/15/2023 5:30:00 PM,7 Safe Stocks to Steady Your Portfolio in 2024,InvestorPlace,/news/stocks/7-safe-stocks-to-steady-your-portfolio-in-2024-1032705994,positive,0.6776443123817444
10/16/2023 7:06:21 AM,Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need.,InvestorPlace,/news/stocks/got-recession-jitters-mitigate-your-portfolios-risk-with-mrk-stock-1032707051,neutral,0.8850075006484985
10/16/2023 1:16:12 PM,EC Approves Merck's KEYTRUDA As Adjuvant Treatment For Non-Small Cell Lung Cancer ,RTTNews,/news/stocks/ec-approves-merck-s-keytruda-as-adjuvant-treatment-for-non-small-cell-lung-cancer-1032708015,positive,0.888787567615509
10/17/2023 4:46:01 AM,Promising Oncology and Vaccine Catalysts Drive Buy Rating for Merck & Company: An Analysis of Daina Graybosch’s Recommendation,TipRanks,/news/stocks/promising-oncology-and-vaccine-catalysts-drive-buy-rating-for-merck-company-an-analysis-of-daina-graybosch-s-recommendation-1032710805,neutral,0.8303723931312561
10/17/2023 4:56:06 AM,Maintaining Buy Rating for Merck & Co.: Unaffected by Pfizer’s Revenue Cut and Anticipated Growth in Non-COVID Business,TipRanks,/news/stocks/maintaining-buy-rating-for-merck-co-unaffected-by-pfizer-s-revenue-cut-and-anticipated-growth-in-non-covid-business-1032710791,positive,0.7042355537414551
10/17/2023 1:02:17 PM,"Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Black Diamond Therapeutics (BDTX) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-omnicell-omcl-black-diamond-therapeutics-bdtx-and-merck-company-mrk-1032712631,neutral,0.9174391031265259
10/17/2023 1:11:15 PM,"Analysts’ Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-top-healthcare-picks-black-diamond-therapeutics-bdtx-ultragenyx-pharmaceutical-rare-1032712630,positive,0.6832736134529114
10/20/2023 3:32:03 AM,"Daiichi Sankyo, Merck Reach Up To $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates ",RTTNews,/news/stocks/daiichi-sankyo-merck-reach-up-to-22-bln-worth-agreement-on-antibody-drug-conjugate-candidates-1032722560,positive,0.8759364485740662
10/20/2023 3:32:45 AM,"Daiichi Sankyo, Merck Reach $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates ",RTTNews,/news/stocks/daiichi-sankyo-merck-reach-22-bln-worth-agreement-on-antibody-drug-conjugate-candidates-1032722559,positive,0.9057816863059998
10/20/2023 10:36:03 AM,Merck & Company’s Stock: A Buy Recommendation due to Favorable Collaborations and Promising ADC Portfolio,TipRanks,/news/stocks/merck-company-s-stock-a-buy-recommendation-due-to-favorable-collaborations-and-promising-adc-portfolio-1032723921,positive,0.9505113959312439
10/20/2023 12:45:53 PM,7 Healthcare Stocks to invest in for a Healthy Future,InvestorPlace,/news/stocks/7-healthcare-stocks-to-invest-in-for-a-healthy-future-1032724266,positive,0.6432576179504395
10/20/2023 3:25:34 PM,Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers ,RTTNews,/news/stocks/merck-reveals-positive-results-from-phase-3-keytruda-trials-in-various-cancers-1032724383,positive,0.9497858285903931
10/20/2023 5:25:41 PM,Buy Rating Assigned to Merck & Co.: Strategic Collaboration for Anti-Cancer ADCs Promises Revenue Diversification and Long-Term Value,TipRanks,/news/stocks/buy-rating-assigned-to-merck-co-strategic-collaboration-for-anti-cancer-adcs-promises-revenue-diversification-and-long-term-value-1032725050,positive,0.9303560256958008
10/20/2023 10:08:03 PM,"Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets",Benzinga,/news/etf/investor-risk-sentiment-wavers-amid-war-interest-rate-concerns-tesla-earnings-disappoint-the-week-in-the-markets-1032725210,negative,0.9567456245422363
10/21/2023 1:31:39 PM,"Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), American Well (AMWL) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-exelixis-exel-american-well-amwl-and-merck-company-mrk-1032725614,neutral,0.9117377996444702
10/23/2023 5:07:07 AM,Immutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLC ,RTTNews,/news/stocks/immutep-efti-keytruda-generates-excellent-os-benefit-in-phase-ii-trial-in-metastatic-nsclc-1032726154,positive,0.9460513591766357
10/23/2023 12:06:35 PM,Promising Collaborations and Emerging Treatments Reinforce Buy Rating for Merck & Company: An Analysis,TipRanks,/news/stocks/promising-collaborations-and-emerging-treatments-reinforce-buy-rating-for-merck-company-an-analysis-1032733077,positive,0.5118899345397949
10/23/2023 12:35:49 PM,Merck & Company’s Stock Receives a Buy Rating: Analysis of Growth Opportunities and Strategic Partnerships,TipRanks,/news/stocks/merck-company-s-stock-receives-a-buy-rating-analysis-of-growth-opportunities-and-strategic-partnerships-1032733066,neutral,0.8892180919647217
10/24/2023 12:15:57 AM,Cantor Fitzgerald Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-their-buy-rating-for-merck-company-mrk-1032734735,neutral,0.8325695991516113
10/25/2023 1:43:12 AM,VTV: A Must-Watch ETF for Value Investors,TipRanks,/news/stocks/vtv-a-must-watch-etf-for-value-investors-1032739060,neutral,0.8936381340026855
10/25/2023 6:07:05 AM,Merck’s Oncology Strategy: Pembrolizumab Success and Promising ADC Pipeline – A Buy Recommendation,TipRanks,/news/stocks/merck-s-oncology-strategy-pembrolizumab-success-and-promising-adc-pipeline-–-a-buy-recommendation-1032740113,positive,0.9456344842910767
10/25/2023 6:20:26 AM,Merck & Company: A Buy Rating Driven by Oncology Portfolio Diversification and Strategic Collaborations,TipRanks,/news/stocks/merck-company-a-buy-rating-driven-by-oncology-portfolio-diversification-and-strategic-collaborations-1032740149,neutral,0.685634195804596
10/25/2023 2:11:01 PM,Merck: KEYTRUDA Plus LENVIMA Is Available In Canada To Treat Advanced Or Metastatic Kidney Cancer ,RTTNews,/news/stocks/merck-keytruda-plus-lenvima-is-available-in-canada-to-treat-advanced-or-metastatic-kidney-cancer-1032738407,neutral,0.6782444715499878
10/25/2023 3:01:13 PM,Merck is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/merck_co-q3-quarterly-earnings-preview-1032738713,neutral,0.9351592063903809
10/26/2023 9:46:27 AM,"Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Merck & Company (MRK) and Integra Lifesciences (IART)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ionis-pharmaceuticals-ions-merck-company-mrk-and-integra-lifesciences-iart-1032745787,neutral,0.9125137329101562
10/26/2023 1:10:37 PM,Merck Reports Higher Profit For Q3; Revises Full-year Outlook ,RTTNews,/news/stocks/merck-reports-higher-profit-for-q3-revises-full-year-outlook-1032743384,positive,0.939934492111206
10/26/2023 7:23:50 PM,"US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Path: What's Driving Markets Thursday?",Benzinga,/news/stocks/us-stocks-sink-vix-soars-as-overheated-economy-mixed-earnings-complicate-fed-s-action-what-s-driving-markets-thursday-1032745198,negative,0.9391444325447083
10/27/2023 6:18:33 AM,Merck & Company: A Buy Recommendation Based on Consistent Outperformance and Promising Future Growth Potential,TipRanks,/news/stocks/merck-company-a-buy-recommendation-based-on-consistent-outperformance-and-promising-future-growth-potential-1032749670,positive,0.8966751098632812
10/27/2023 11:01:36 AM,"Analysts Conflicted on These Healthcare Names: Blueprint Medicines (BPMC), Abbott Labs (ABT) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-blueprint-medicines-bpmc-abbott-labs-abt-and-merck-company-mrk-1032750111,negative,0.6481534242630005
10/27/2023 12:41:02 PM,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Aclaris Therapeutics (ACRS) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-dexcom-dxcm-aclaris-therapeutics-acrs-and-merck-company-mrk-1032750235,neutral,0.9116067290306091
10/27/2023 4:28:02 PM,3 Deeply Undervalued Growth Stocks to Buy in November,InvestorPlace,/news/stocks/3-deeply-undervalued-growth-stocks-1032749511,positive,0.540998637676239
10/28/2023 5:15:33 PM,Biotech Stocks Facing FDA Decision In November 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2023-1032750454,neutral,0.9118582606315613
10/30/2023 2:35:10 AM,Merck & Company (MRK) Receives a Buy from Truist Financial,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-truist-financial-1032754636,positive,0.5044788718223572
10/31/2023 6:20:50 AM,"Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), AbbVie (ABBV) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-dexcom-dxcm-abbvie-abbv-and-merck-company-mrk-1032760927,neutral,0.9172101020812988
10/31/2023 7:10:30 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Abcam (ABCM), Viridian Therapeutics (VRDN) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-abcam-abcm-viridian-therapeutics-vrdn-and-merck-company-mrk-1032761016,negative,0.7797560095787048
10/31/2023 11:00:00 AM,2 No-Brainer AI Stocks to Buy and One to Run Away From,InvestorPlace,/news/stocks/2-no-brainer-ai-stocks-to-buy-and-one-to-run-away-from-1032758734,neutral,0.884799063205719
11/2/2023 5:17:25 AM,Merck & Company: A Promising Investment Driven by Diversification and Innovative Pipeline,TipRanks,/news/stocks/merck-company-a-promising-investment-driven-by-diversification-and-innovative-pipeline-1032771702,positive,0.857572078704834
11/3/2023 12:20:41 PM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nuvation Bio (NUVB) and Generation Bio (GBIO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-nuvation-bio-nuvb-and-generation-bio-gbio-1032777951,neutral,0.9171955585479736
11/4/2023 1:00:00 PM,3 Trustworthy Blue-Chip Stocks to Buy Now,InvestorPlace,/news/stocks/3-trustworthy-blue-chip-stocks-to-buy-now-1032778305,neutral,0.8620845079421997
11/9/2023 1:00:18 PM,10 Analysts Have This to Say About Merck & Co,Benzinga,/news/stocks/10-analysts-have-this-to-say-about-merck-co-1032800153,neutral,0.9286388158798218
11/9/2023 2:26:17 PM,7 Safe Stocks to Buy if You Think Q3’s Gangbuster Growth Won’t Last,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-if-you-think-q3s-gangbuster-growth-wont-last-1032801059,neutral,0.7254765033721924
11/10/2023 12:00:00 PM,7 Biotech Stocks to Buy for Big-Time Gains,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-big-time-gains-1032806584,neutral,0.8238290548324585
11/14/2023 12:12:38 AM,The 3 Best Defensive Stocks for Uncertain Times,InvestorPlace,/news/stocks/the-3-best-defensive-stocks-for-uncertain-times-1032814859,neutral,0.8376801609992981
11/14/2023 2:21:06 PM,Agilent Technologies Announces FDA Approval For PD-L1 IHC 22C3 PharmDx - Quick Facts ,RTTNews,/news/stocks/agilent-technologies-announces-fda-approval-for-pd-l1-ihc-22c3-pharmdx-quick-facts-1032817673,positive,0.7340952754020691
11/14/2023 2:40:58 PM,Natera Signs Real-World Data Collaboration With Merck ,RTTNews,/news/stocks/natera-signs-real-world-data-collaboration-with-merck-1032817766,neutral,0.69386887550354
11/16/2023 8:25:39 AM,Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-merck-company-mrk-1032829149,neutral,0.8239803910255432
11/17/2023 6:09:55 AM,"5 Top Growth Stocks to Buy Now, According to Analysts – November 2023",TipRanks,/news/stocks/5-top-growth-stocks-to-buy-now-according-to-analysts-–-november-2023-1032832463,neutral,0.8522096276283264
11/20/2023 7:10:11 AM,"Analysts Conflicted on These Healthcare Names: Fresenius Medical Care (FMS), Solid Biosciences (SLDB) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-fresenius-medical-care-fms-solid-biosciences-sldb-and-merck-company-mrk-1032836800,negative,0.681412398815155
11/21/2023 8:25:50 AM,Merck & Company (MRK) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-cantor-fitzgerald-1032840640,neutral,0.774139940738678
11/21/2023 1:09:54 PM,Merck To Acquire Caraway Therapeutics ,RTTNews,/news/stocks/merck-to-acquire-caraway-therapeutics-1032838853,neutral,0.9330809712409973
11/22/2023 12:02:19 PM,"Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Merck & Company (MRK) and Twist Bioscience (TWST)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-axsome-therapeutics-axsm-merck-company-mrk-and-twist-bioscience-twst-1032844314,neutral,0.919026255607605
11/22/2023 12:19:05 PM,Strategic Acquisition of Caraway Therapeutics Bolsters Merck’s Portfolio: An In-depth Analysis and Buy Rating Recommendation,TipRanks,/news/stocks/strategic-acquisition-of-caraway-therapeutics-bolsters-merck-s-portfolio-an-in-depth-analysis-and-buy-rating-recommendation-1032844328,positive,0.8485655188560486
11/22/2023 5:54:59 PM,"Merck's Caraway Deal: Analyst Says ""Timely, Anchored By Novel Programs & Management Team""",Benzinga,/news/stocks/merck-s-caraway-deal-analyst-says-timely-anchored-by-novel-programs-management-team-1032843636,positive,0.831667959690094
11/23/2023 9:02:53 PM,Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times,InvestorPlace,/news/stocks/stability-seekers-7-low-volatility-stocks-for-uncertain-times-1032846591,neutral,0.8807854056358337
11/28/2023 6:03:11 PM,"Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's",Benzinga,/news/stocks/merck-highlights-data-on-new-vaccine-compares-tolerability-and-safety-to-pfizer-s-1032855892,positive,0.745261013507843
11/29/2023 4:00:59 PM,Analyst Ratings for Merck & Co,Benzinga,/news/stocks/analyst-ratings-for-merck-co-1032859198,neutral,0.9076553583145142
11/30/2023 8:15:08 AM,Cantor Fitzgerald Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-their-buy-rating-for-merck-company-mrk-1032864213,neutral,0.8325695991516113
11/30/2023 8:53:23 AM,Biotech Stocks Facing FDA Decision In December 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2023-1032861195,neutral,0.8986747860908508
12/5/2023 7:15:33 AM,Buy Rating for Merck & Co. on Strong Prospects for New Pneumococcal Vaccine V116,TipRanks,/news/stocks/buy-rating-for-merck-co-on-strong-prospects-for-new-pneumococcal-vaccine-v116-1032875784,positive,0.952488362789154
12/7/2023 12:17:59 PM,Merck Reports Data From Phase 2 KeyVibe-002 Trial - Quick Facts ,RTTNews,/news/stocks/merck-reports-data-from-phase-2-keyvibe-002-trial-quick-facts-1032881354,neutral,0.9218642711639404
12/7/2023 2:24:06 PM,Merck Stops KEYTRUDA Trial After Failing To Meet Secondary Endpoint In Metastatic Lung Cancer ,RTTNews,/news/stocks/merck-stops-keytruda-trial-after-failing-to-meet-secondary-endpoint-in-metastatic-lung-cancer-1032881835,negative,0.953072726726532
12/8/2023 10:26:03 AM,Hold Rating on Merck Amid Uncertainty Over TIGIT Program’s Efficacy,TipRanks,/news/stocks/hold-rating-on-merck-amid-uncertainty-over-tigit-program-s-efficacy-1032886908,negative,0.6744699478149414
12/8/2023 1:35:25 PM,Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints ,RTTNews,/news/stocks/merck-says-phase-3-leap-001-trial-evaluating-keytruda-plus-lenvima-did-not-meet-endpoints-1032885349,negative,0.6694675087928772
12/11/2023 6:48:33 AM,Merck & Company: A Strong Buy on Diverse Portfolio and Promising Pipeline,TipRanks,/news/stocks/merck-company-a-strong-buy-on-diverse-portfolio-and-promising-pipeline-1032890709,positive,0.9092946648597717
12/11/2023 1:05:12 PM,Merck Animal Health Gets Positive CVMP Opinion For BRAVECTO Injectable Formulation For Use In Dogs ,RTTNews,/news/stocks/merck-animal-health-gets-positive-cvmp-opinion-for-bravecto-injectable-formulation-for-use-in-dogs-1032889207,positive,0.9424188733100891
12/12/2023 1:24:36 PM,"C4 Therapeutics, Merck Join To Develop Degrader-Antibody Conjugates ",RTTNews,/news/stocks/c4-therapeutics-merck-join-to-develop-degrader-antibody-conjugates-1032892783,neutral,0.7979212403297424
12/12/2023 3:13:43 PM,Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?,InvestorPlace,/news/stocks/why-is-c4-therapeutics-cccc-stock-up-72-today-1032894062,positive,0.8083537220954895
12/13/2023 10:31:56 AM,Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now,TipRanks,/news/stocks/goldman-sachs-says-these-3-healthcare-giants-look-very-attractive-right-now-1032898893,positive,0.7411935925483704
12/13/2023 10:13:55 PM,"Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance",Benzinga,/news/etf/dow-jones-skyrockets-to-record-heights-shatters-37-000-mark-fueled-by-fed-s-dovish-stance-1032898701,negative,0.6639979481697083
12/14/2023 1:16:05 PM,"Moderna, Merck Announce Follow-up Data From Phase 2b KEYNOTE-942/mRNA-4157-P201 Study ",RTTNews,/news/stocks/moderna-merck-announce-follow-up-data-from-phase-2b-keynote-942-mrna-4157-p201-study-1032900667,neutral,0.9175077080726624
12/14/2023 2:26:20 PM,Why Is Moderna (MRNA) Stock Up 11% Today?,InvestorPlace,/news/stocks/why-is-moderna-mrna-stock-up-11-today-1032901353,positive,0.663420557975769
12/14/2023 9:30:51 PM,MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer,InvestorPlace,/news/stocks/mrna-stock-surges-as-moderna-teams-up-with-merck-to-fight-cancer-1032902845,positive,0.7755407691001892
12/21/2023 5:58:01 AM,"Merck: FDA Says Gefapixant NDA Did Not Meet Substantial Evidence Of Effectiveness To Treat RCC, UCC ",RTTNews,/news/stocks/merck-fda-says-gefapixant-nda-did-not-meet-substantial-evidence-of-effectiveness-to-treat-rcc-ucc-1032917909,negative,0.8971773386001587
12/21/2023 1:23:00 PM,"Merck: KEYTRUDA, LENVIMA Combination Receive Public Listing ",RTTNews,/news/stocks/merck-keytruda-lenvima-combination-receive-public-listing-1032918935,neutral,0.9397668838500977
12/21/2023 2:12:05 PM,7 Best Dow Jones Stocks to Buy for Conservative Investors,InvestorPlace,/news/stocks/7-best-dow-jones-stocks-to-buy-for-conservative-investors-1032919399,neutral,0.8600435853004456
12/22/2023 2:47:58 PM,"Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan ",RTTNews,/news/stocks/merck-daiichi-sankyo-say-fda-grants-priority-review-in-u-s-for-patritumab-deruxtecan-1032922206,positive,0.7339999675750732
12/22/2023 9:21:22 PM,7 Small-Cap Stocks That Wall Street Loves for Good Reason ,InvestorPlace,/news/stocks/7-small-cap-stocks-that-analysts-are-upgrading-1032923323,neutral,0.7156015038490295
12/24/2023 2:00:00 PM,January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump,InvestorPlace,/news/stocks/january-effect-3-under-the-radar-stocks-poised-for-a-new-year-jump-1032923746,negative,0.5457691550254822
12/28/2023 8:18:25 AM,Biotech Stocks Facing FDA Decision In January 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2024-1032929267,neutral,0.9060015678405762
1/3/2024 4:26:53 PM,Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth,Benzinga,/news/etf/tech-sell-off-triggers-market-reset-value-stocks-reach-7-month-high-versus-growth-1032940596,positive,0.8445466160774231
1/3/2024 9:00:19 PM,Revenge of the Boring Stocks! Dividends Are Sexy Again.,InvestorPlace,/news/stocks/revenge-of-the-boring-stocks-dividends-are-sexy-again-1032941212,neutral,0.7992129921913147
1/4/2024 11:00:45 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Immunome (IMNM) and Simulations Plus (SLP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-immunome-imnm-and-simulations-plus-slp-1032944619,neutral,0.9071053266525269
1/4/2024 1:31:10 PM,AMD To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Thursday,Benzinga,/news/stocks/amd-to-rally-over-25-here-are-10-top-analyst-forecasts-for-thursday-1032942874,neutral,0.917546272277832
1/5/2024 6:35:24 AM,"Strong Buy: Merck’s Growth, Pipeline, and Financial Stability Highlighted by Analyst Chris Shibutani",TipRanks,/news/stocks/strong-buy-merck-s-growth-pipeline-and-financial-stability-highlighted-by-analyst-chris-shibutani-1032946890,positive,0.5587528347969055
1/5/2024 6:20:23 PM,Dry January Investing: Trading Pints For Portfolio Growth,Benzinga,/news/etf/dry-january-investing-trading-pints-for-portfolio-growth-1032946780,neutral,0.8352900147438049
1/8/2024 9:10:12 AM,Merck In Talks To Acquire Harpoon Therapeutics: Reports ,RTTNews,/news/stocks/merck-in-talks-to-acquire-harpoon-therapeutics-reports-1032949013,neutral,0.9327831268310547
1/8/2024 1:04:48 PM,Why Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?,Benzinga,/news/stocks/why-is-cancer-focused-harpoon-therapeutics-stock-shooting-higher-today-1032949871,neutral,0.5425034165382385
1/8/2024 1:06:52 PM,Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?,InvestorPlace,/news/stocks/why-is-harpoon-therapeutics-harp-stock-up-111-today-1032950179,positive,0.8218858242034912
1/8/2024 2:11:08 PM,Merck To Acquire Harpoon - Quick Facts ,RTTNews,/news/stocks/merck-to-acquire-harpoon-quick-facts-1032950205,neutral,0.9299852252006531
1/8/2024 4:18:52 PM,Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal,Benzinga,/news/stocks/today-is-cancer-focused-deals-day-johnson-johnson-scoops-up-ambrx-biopharma-as-merck-boosts-cancer-portfolio-with-harpoon-deal-1032950939,positive,0.5216545462608337
1/8/2024 8:12:24 PM,Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?,Benzinga,/news/stocks/why-is-7b-valued-cancer-focused-exelixis-trading-lower-today-1032951424,negative,0.8913092017173767
1/9/2024 10:19:18 AM,Merck & Co: A Strong Buy on Robust Performance and Promising Growth Prospects,TipRanks,/news/stocks/merck-co-a-strong-buy-on-robust-performance-and-promising-growth-prospects-1032955182,positive,0.9497552514076233
1/9/2024 12:17:55 PM,Cantor Fitzgerald Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-merck-company-mrk-1032955322,neutral,0.8239803910255432
1/9/2024 1:26:52 PM,Buy Rating for Merck on Strategic Acquisition of Harpoon Therapeutics and Promising Drug Efficacy,TipRanks,/news/stocks/buy-rating-for-merck-on-strategic-acquisition-of-harpoon-therapeutics-and-promising-drug-efficacy-1032955393,positive,0.9195107221603394
1/9/2024 4:01:15 PM,Demystifying Merck & Co: Insights From 9 Analyst Reviews,Benzinga,/news/stocks/demystifying-merck-co-insights-from-9-analyst-reviews-1032954203,neutral,0.8890396356582642
1/10/2024 11:04:56 PM,The 3 Best Blue-Chip Stocks to Buy in January 2024,InvestorPlace,/news/stocks/the-3-best-blue-chip-stocks-to-buy-in-january-2024-1032958709,neutral,0.8342704176902771
1/11/2024 5:40:37 PM,"Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance",Benzinga,/news/stocks/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lilly-s-dominance-1032961467,positive,0.9427829384803772
1/13/2024 4:35:08 PM,Merck : FDA Approves KEYTRUDA Combination For Advanced Cervical Cancer Treatment ,RTTNews,/news/stocks/merck-fda-approves-keytruda-combination-for-advanced-cervical-cancer-treatment-1032965141,positive,0.8839093446731567
1/14/2024 5:54:56 PM,7 Healthcare Stocks Taking Medicine to the Next Level,InvestorPlace,/news/stocks/7-healthcare-stocks-taking-medicine-to-the-next-level-1032965617,neutral,0.8588945865631104
1/17/2024 3:47:16 PM,The 3 Best Dividend Growth Stocks to Buy in January 2024,InvestorPlace,/news/stocks/the-3-best-dividend-growth-stocks-to-buy-in-january-2024-1032974623,neutral,0.8540071249008179
1/19/2024 1:05:15 PM,Senate panel to consider subpoenas for J&J and Merck CEOs,Seeking Alpha,https://seekingalpha.com/news/4056351-sen-bernie-sanders-weighs-subpoenas-jj-merck-ceos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.576749861240387
1/19/2024 10:03:58 PM,S&P 500 Shatters Records: The Top-Performing Stocks In January 2024,Benzinga,/news/etf/s-p-500-shatters-records-the-top-performing-stocks-in-january-2024-1032981017,negative,0.6330354809761047
1/22/2024 11:30:00 AM,7 Exciting Stocks Poised for Explosive Growth in Key Sectors,InvestorPlace,/news/stocks/7-exciting-stocks-poised-for-explosive-growth-in-key-sectors-1032986982,positive,0.8361707329750061
1/23/2024 6:18:58 PM,Merck inks $220M deal for cancer drug discovery,Seeking Alpha,https://seekingalpha.com/news/4057502-merck-inks-deal-ai-cancer-drug-discovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6531141996383667
1/23/2024 8:14:14 PM,Merck declares $0.77 dividend,Seeking Alpha,https://seekingalpha.com/news/4057516-merck-and-co-inc-declares-0_77-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.928073525428772
1/24/2024 11:28:10 AM,TipRanks’ All-Star Analyst – Who is the Best on MRK Stock?,TipRanks,/news/stocks/tipranks-all-star-analyst-–-who-is-the-best-on-mrk-stock-1032992648,neutral,0.8963989615440369
1/24/2024 12:37:25 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-jan-24th-1032991991,negative,0.5243479013442993
1/24/2024 6:58:21 PM,3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-as-the-sector-benefits-from-the-aging-boom-1032993880,neutral,0.7051398754119873
1/25/2024 1:11:38 PM,LAVA stock rises on clinical trial collaboration with Merck,Seeking Alpha,https://seekingalpha.com/news/4058430-lava-stock-rises-on-clinical-trial-collaboration-with-merck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9143895506858826
1/25/2024 2:07:31 PM,LAVA Therapeutics In Deal With Merck For Clinical Trial Collaboration; Stock Surges In Pre-market ,RTTNews,/news/stocks/lava-therapeutics-in-deal-with-merck-for-clinical-trial-collaboration-stock-surges-in-pre-market-1032996565,positive,0.9085918664932251
1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9376139640808105
1/26/2024 1:01:28 PM,"Dividend Roundup: Merck, Costco, Lockheed Martin, Comcast, and more",Seeking Alpha,https://seekingalpha.com/news/4058980-dividend-roundup-merck-costco-lockheed-martin-comcast-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9501565098762512
1/26/2024 5:58:45 PM,Merck’s Keytruda cuts bladder cancer risk by 31% in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/4059223-mercks-keytruda-cuts-bladder-cancer-risk-31?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8827193975448608
1/26/2024 8:00:55 PM,"Catalyst watch: Apple earnings, Boeing on the hot seat, FOMC meeting and Amer Sports IPO",Seeking Alpha,https://seekingalpha.com/news/4059230-catalyst-watch-apple-earnings-boeing-on-the-hot-seat-fomc-meeting-and-amer-sports-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9197294116020203
1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8954368233680725
1/29/2024 1:53:19 AM,Merck's Keytruda Reduces Risk Of Death By 38% In Adjuvant RCC Therapy In Phase 3 Trial ,RTTNews,/news/stocks/merck-s-keytruda-reduces-risk-of-death-by-38-in-adjuvant-rcc-therapy-in-phase-3-trial-1033003300,positive,0.8533094525337219
1/29/2024 5:14:01 PM,"Marathon Petroleum, Exxon among BofA picks for options opportunity on earnings surprise",Seeking Alpha,https://seekingalpha.com/news/4059539-marathon-petroleum-exxon-among-bofa-picks-for-options-opportunity-on-earnings-surprise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7842940092086792
1/29/2024 8:13:38 PM,Karuna’s KarXT tops Evaluate’s most anticipated drug list,Seeking Alpha,https://seekingalpha.com/news/4059673-karuna-karxt-tops-evaluate-most-anticipated-drug-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.735865592956543
1/29/2024 10:35:16 PM,Hold Rating on Merck Amid Keytruda Patent Expiry and Revenue Gap Challenges,TipRanks,/news/stocks/hold-rating-on-merck-amid-keytruda-patent-expiry-and-revenue-gap-challenges-1033007393,negative,0.9634931683540344
1/30/2024 3:22:11 PM,Arcus shares extend gains amid mixed reactions on Gilead stake purchase,Seeking Alpha,https://seekingalpha.com/news/4060081-arcus-shares-extend-gains-amid-mixed-reactions-on-gilead-stake-purchase?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9135515093803406
1/31/2024 3:25:52 AM,Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment ,RTTNews,/news/stocks/astellas-submits-snda-in-japan-for-padcev-keytruda-for-advanced-bladder-cancer-treatment-1033012097,positive,0.5388457775115967
1/31/2024 3:01:13 PM,Merck is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/merck_co-stock-price-quarter-earnings-preview-q4-1033015180,neutral,0.9350566267967224
1/31/2024 11:13:16 PM,Earnings preview: Merck slated to report before market open Thursday,Seeking Alpha,https://seekingalpha.com/news/4061019-earnings-preview-merck-slated-to-report-before-market-open-wednesday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7594013214111328
2/1/2024 5:10:11 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033019008,positive,0.5521676540374756
2/1/2024 5:52:14 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Align Tech (ALGN) and Novavax (NVAX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-align-tech-algn-and-novavax-nvax-1033019175,neutral,0.9145888686180115
2/1/2024 11:31:14 AM,"Merck Non-GAAP EPS of $0.03 beats by $0.14, revenue of $14.6B beats by $120M",Seeking Alpha,https://seekingalpha.com/news/4061125-merck-non-gaap-eps-of-0_03-beats-0_14-revenue-of-14_6b-beats-120m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6923940777778625
2/1/2024 11:57:00 AM,Merck in charts: KEYTRUDA and GARDASIL sales surged more than 20% in Q4,Seeking Alpha,https://seekingalpha.com/news/4061146-merck-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9562724232673645
2/1/2024 12:28:53 PM,Merck posts Q4 beat as Keytruda outperforms,Seeking Alpha,https://seekingalpha.com/news/4061177-merck-stock-gains-keytruda-drives-q4-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9118795394897461
2/1/2024 12:56:54 PM,Merck Q4 Results Top Estimates; Guides FY24 Adj. EPS Above Estimates ,RTTNews,/news/stocks/merck-q4-results-top-estimates-guides-fy24-adj-eps-above-estimates-1033019984,neutral,0.89332115650177
2/1/2024 1:44:00 PM,"6 stocks to watch on Thursday: Altria, Honeywell, Apple, Plug Power and more",Seeking Alpha,https://seekingalpha.com/news/4061245-6-stocks-to-watch-on-thursday-altria-honeywell-apple-plug-power-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9285150766372681
2/1/2024 3:08:36 PM,Merck Guides FY24 EPS Above Estimates As Q4 Results Top Estimates ,RTTNews,/news/stocks/merck-guides-fy24-eps-above-estimates-as-q4-results-top-estimates-1033020813,positive,0.8941148519515991
2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49058476090431213
2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49058476090431213
2/1/2024 7:16:06 PM,"Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?",Benzinga,/news/etf/stocks-recoup-post-fed-losses-as-traders-challenge-powell-regional-banks-crack-gold-rises-what-s-driving-markets-thursday-1033022149,negative,0.776782214641571
2/2/2024 4:06:18 AM,Merck & Company: A Strong Buy on Robust Growth and Strategic Clinical Advancements,TipRanks,/news/stocks/merck-company-a-strong-buy-on-robust-growth-and-strategic-clinical-advancements-1033023668,positive,0.9154688119888306
2/2/2024 8:37:15 AM,Merck & Company (MRK) Gets a Buy from Barclays,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-barclays-1033024539,neutral,0.5323359370231628
2/2/2024 12:35:52 PM,Merck & Company: A Strong Buy on Sotatercept Launch and Vaccine Growth Prospects,TipRanks,/news/stocks/merck-company-a-strong-buy-on-sotatercept-launch-and-vaccine-growth-prospects-1033025802,positive,0.9369472861289978
2/2/2024 3:00:13 PM,Beyond The Numbers: 8 Analysts Discuss Merck & Co Stock,Benzinga,/news/stocks/beyond-the-numbers-8-analysts-discuss-merck-co-stock-1033025086,neutral,0.9449957013130188
2/2/2024 3:15:19 PM,Companies with profit warnings after negative earnings season - JPM,Seeking Alpha,https://seekingalpha.com/news/4062201-companies-with-profit-warnings-after-negative-earnings-season-jpm?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9587195515632629
2/2/2024 7:39:14 PM,3 Pharma Stocks to Sell in February Before They Crash and Burn,InvestorPlace,/news/stocks/3-pharma-stocks-to-sell-in-february-before-they-crash-and-burn-1033026411,neutral,0.7678835988044739
2/3/2024 6:49:12 PM,7 Mutual Funds That Will Outperform in Any Market,InvestorPlace,/news/stocks/7-mutual-funds-that-will-outperform-in-any-market-1033026808,positive,0.5209316611289978
2/4/2024 5:00:49 PM,Pharma giants turn to China in search of targeted cancer drugs,Seeking Alpha,https://seekingalpha.com/news/4062374-pharma-antibody-drug-conjugates-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8160377740859985
2/5/2024 9:10:54 AM,"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO), Merck & Company (MRK) and Tenet Healthcare (THC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-soleno-therapeutics-slno-merck-company-mrk-and-tenet-healthcare-thc-1033029638,neutral,0.919858992099762
2/5/2024 9:16:27 AM,Merck & Co: Strong Buy Rating on Robust Q4 Earnings and Promising Pipeline Outlook,TipRanks,/news/stocks/merck-co-strong-buy-rating-on-robust-q4-earnings-and-promising-pipeline-outlook-1033029689,positive,0.9531800746917725
2/5/2024 9:31:38 AM,"Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Merck & Company (MRK) and Neurocrine (NBIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-terns-pharmaceuticals-tern-merck-company-mrk-and-neurocrine-nbix-1033029755,neutral,0.9198012948036194
2/5/2024 12:01:58 PM,Merck to buy Elanco’s aqua business for $1.3B in cash,Seeking Alpha,https://seekingalpha.com/news/4062470-merck-buy-elancos-aqua-unit-13b--cash?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8792961835861206
2/5/2024 12:57:31 PM,Merck Animal Health To Buy Elanco's Aqua Business In $1.3 Bln Cash Deal; Elanco Up In Pre-market ,RTTNews,/news/stocks/merck-animal-health-to-buy-elanco-s-aqua-business-in-1-3-bln-cash-deal-elanco-up-in-pre-market-1033029565,positive,0.9355828762054443
2/5/2024 1:58:00 PM,"4 stocks to watch on Monday: McDonald's, Palantir and more",Seeking Alpha,https://seekingalpha.com/news/4062560-4-stocks-to-watch-on-monday-mcdonalds-palantir-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9024811387062073
2/5/2024 3:06:09 PM,"Biggest stock movers today: Nvidia, Air Products and Chemicals, Estee Lauder, 4D Molecular Therapeutics, and more",Seeking Alpha,https://seekingalpha.com/news/4062421-biggest-stock-movers-today?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9143383502960205
2/6/2024 4:15:31 AM,Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-buy-rating-on-merck-company-mrk-1033033386,neutral,0.8452711701393127
2/6/2024 9:00:00 PM,3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List,InvestorPlace,/news/stocks/3-strong-buy-biotech-stocks-to-add-to-your-february-must-watch-list-1033036854,neutral,0.8592283129692078
2/7/2024 3:31:10 PM,"Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), BridgeBio Pharma (BBIO)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-axsome-therapeutics-axsm-bridgebio-pharma-bbio-1033042548,neutral,0.5683613419532776
2/8/2024 2:20:56 PM,Merck Signs Multi-Year Agreement With Vector Institute ,RTTNews,/news/stocks/merck-signs-multi-year-agreement-with-vector-institute-1033046290,positive,0.9033052921295166
2/9/2024 10:20:51 AM,"Analysts’ Top Healthcare Picks: Merck & Company (MRK), Omnicell (OMCL)",TipRanks,/news/stocks/analysts-top-healthcare-picks-merck-company-mrk-omnicell-omcl-1033051005,positive,0.5090119242668152
2/9/2024 12:24:06 PM,Pharma CEOs defend high drug prices; blame PBMs at Senate hearing,Seeking Alpha,https://seekingalpha.com/news/4065061-pharma-ceos-defend-high-drug-prices-blame-pbms-senate-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6773600578308105
2/9/2024 1:57:00 PM,"7 stocks to watch on Friday: Major drugmakers on Senate hearing, PepsiCo and more",Seeking Alpha,https://seekingalpha.com/news/4065116-7-stocks-to-watch-on-friday-major-drugmakers-on-senate-hearing-pepsico-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9030511379241943
2/12/2024 12:24:29 PM,Merck wins Canada approval for gastric cancer combination therapy,Seeking Alpha,https://seekingalpha.com/news/4065434-merck-wins-canada-approval-for-gastric-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8951753973960876
2/12/2024 1:17:31 PM,Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy ,RTTNews,/news/stocks/merck-says-health-canada-oks-keytruda-in-combination-with-trastuzumab-and-chemotherapy-1033056605,positive,0.7377395033836365
2/12/2024 5:00:04 PM,"This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate",Benzinga,/news/stocks/this-united-therapeutics-analyst-is-no-longer-bearish-expects-mid-decade-4b-revenue-run-rate-1033057764,positive,0.7889049053192139
2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6178923845291138
2/14/2024 8:30:53 AM,"Analysts Are Bullish on These Healthcare Stocks: Zoetis (ZTS), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-zoetis-zts-merck-company-mrk-1033065978,neutral,0.7487415671348572
2/14/2024 4:43:00 PM,CDC to relax COVID isolation requirements: WaPo,Seeking Alpha,https://seekingalpha.com/news/4066920-cdc-to-relax-covid-isolation-requirements?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8257278203964233
2/14/2024 5:33:26 PM,Organon gaining momentum ahead of Q4 earnings,Seeking Alpha,https://seekingalpha.com/news/4066944-organon-stock-rise-ahead-q4-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9328718781471252
2/15/2024 8:20:40 AM,"Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-health-catalyst-hcat-regeneron-regn-and-merck-company-mrk-1033071011,neutral,0.9122521281242371
2/15/2024 4:33:25 PM,Organon nears five-month high after Q4 beat,Seeking Alpha,https://seekingalpha.com/news/4067735-organon-stock-nears-five-month-high-q4-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8290205001831055
2/15/2024 7:09:36 PM,3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report,InvestorPlace,/news/stocks/3-inflation-proof-stock-picks-following-tuesdays-cpi-report-1033073269,neutral,0.5502597689628601
2/20/2024 2:37:15 PM,Merck: FDA Grants Priority Review To SBLA For KEYTRUDA Plus Chemotherapy In Endometrial Carcinoma ,RTTNews,/news/stocks/merck-fda-grants-priority-review-to-sbla-for-keytruda-plus-chemotherapy-in-endometrial-carcinoma-1033083143,positive,0.8411173224449158
2/20/2024 5:51:54 PM,FDA accepts Merck's Keytruda application for priority review,Seeking Alpha,https://seekingalpha.com/news/4069072-fda-accepts-mercks-keytruda-application-for-priority-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5794863104820251
2/22/2024 2:31:40 PM,Harpoon Therapeutics ticks higher after HSR waiting period for Merck deal expires,Seeking Alpha,https://seekingalpha.com/news/4070353-harpoon-therapeutics-ticks-higher-after-hsr-waiting-period-for-merck-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6005634069442749
2/22/2024 10:33:00 PM,3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List,InvestorPlace,/news/stocks/3-undervalued-small-cap-stocks-to-add-to-your-must-buy-list-1033095199,neutral,0.7965869903564453
2/23/2024 11:42:41 AM,Merck wins EU backing for Keytruda use in resectable lung cancer,Seeking Alpha,https://seekingalpha.com/news/4070971-merck-wins-eu-backing-keytruda-resectable-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.906796932220459
2/23/2024 12:30:21 PM,Bristol Myers blood disorder therapy endorsed in EU for label expansion,Seeking Alpha,https://seekingalpha.com/news/4070991-bristol-myers-wins-eu-backing-expand-label-reblozyl?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8798993825912476
2/23/2024 2:08:53 PM,Merck Says Keytruda Combination Gets Positive EU CHMP Opinion As Neoadjuvant Treatment For NSCLC ,RTTNews,/news/stocks/merck-says-keytruda-combination-gets-positive-eu-chmp-opinion-as-neoadjuvant-treatment-for-nsclc-1033097252,positive,0.9509735703468323
2/26/2024 4:29:29 PM,3 Top Pharma Stocks for Investors Betting on a Biotech Boom,InvestorPlace,/news/stocks/3-top-pharma-stocks-for-investors-betting-on-a-biotech-boom-1033103696,neutral,0.7925871014595032
2/27/2024 6:44:00 PM,‘Tripledemic’ burden lower this winter despite COVID impact: Airfinity,Seeking Alpha,https://seekingalpha.com/news/4072482-tripledemic-burden-lower-winter-covid-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7414758205413818
2/27/2024 9:24:40 PM,3 Long-Term Winners from Charles Schwab’s Top Picks,InvestorPlace,/news/stocks/3-long-term-winners-from-charles-schwabs-top-picks-1033109410,neutral,0.6914536356925964
2/28/2024 9:52:49 AM,Biotech Stocks Facing FDA Decision In March 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2024-1033111344,neutral,0.9174318909645081
2/29/2024 8:01:38 PM,Critical Insights From Merck & Co Analyst Ratings: What You Need To Know,Benzinga,/news/stocks/critical-insights-from-merck-co-analyst-ratings-what-you-need-to-know-1033120255,neutral,0.9345341920852661
3/1/2024 11:14:20 AM,7 Timeless Stocks to Invest in for 2024,InvestorPlace,/news/stocks/7-timeless-stocks-to-invest-in-for-2024-1033122879,neutral,0.9142293334007263
3/1/2024 4:39:59 PM,Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List,Benzinga,/news/stocks/apple-sinks-after-wall-street-titan-pulls-magnificent-7-stock-from-conviction-list-1033124291,negative,0.9297418594360352
3/1/2024 5:29:42 PM,"Merck, Vertex cut from Goldman Sachs conviction list; Amgen added",Seeking Alpha,https://seekingalpha.com/news/4074740-merck-vertex-cut-goldman-sachs-conviction-list-amgen-added?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7583416700363159
3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8509966135025024
3/3/2024 12:20:21 PM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Mach7 Technologies Ltd. (OtherTDMMF) and Ramsay Health Care (OtherRMSYF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-mach7-technologies-ltd-othertdmmf-and-ramsay-health-care-otherrmsyf-1033126178,neutral,0.9168774485588074
3/3/2024 3:33:59 PM,"Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), ANI Pharmaceuticals (ANIP) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-boston-scientific-bsx-ani-pharmaceuticals-anip-and-merck-company-mrk-1033126297,negative,0.65619295835495
3/3/2024 7:08:04 PM,Biggest contributors and detractors to the S&P's run,Seeking Alpha,https://seekingalpha.com/news/4075016-biggest-contributors-and-detractors-to-the-sps-run?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7131364941596985
3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8006861805915833
3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8196350932121277
3/4/2024 9:00:00 PM,The Top 3 Dow Stocks to Buy in March 2024,InvestorPlace,/news/stocks/the-top-3-dow-stocks-to-buy-in-march-2024-1033130270,neutral,0.9304119348526001
3/5/2024 3:53:38 PM,Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck,Seeking Alpha,https://seekingalpha.com/news/4076042-harpoon-therapeutics-ticks-higher-amid-nasdaq-delisting-notice-for-sale-to-merck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6294268369674683
3/6/2024 5:54:39 PM,"Gilead, Merck once weekly combo HIV therapy shows promise in phase 2",Seeking Alpha,https://seekingalpha.com/news/4076721-gilead-merck-once-weekly-combo-hiv-therapy-shows-promise-phase-2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8774186968803406
3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7659493088722229
3/7/2024 8:00:00 PM,3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise,InvestorPlace,/news/stocks/3-cancer-fighting-biotech-stocks-showing-clinical-trial-promise-1033143819,positive,0.5083664655685425
3/8/2024 7:02:46 PM,Merck touts new Keytruda version as patent cliff approaches,Seeking Alpha,https://seekingalpha.com/news/4077740-merck-touts-new-keytruda-patent-cliff-nears?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6696707606315613
3/10/2024 5:08:00 PM,Cantor sees strong year ahead for oncology M&A,Seeking Alpha,https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9445049166679382
3/11/2024 1:28:54 PM,Merck Completes Acquisition Of Harpoon Therapeutics - Quick Facts ,RTTNews,/news/stocks/merck-completes-acquisition-of-harpoon-therapeutics-quick-facts-1033150613,neutral,0.7818017601966858
3/11/2024 5:00:04 PM,"Societe General cuts Merck to sell, cites Keytruda patent expiry",Seeking Alpha,https://seekingalpha.com/news/4078095-societe-general-cuts-merck-to-sell-cites-keytruda-patent-expiry?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5569702386856079
3/11/2024 7:08:59 PM,What's Going On With Moderna Stock On Monday?,Benzinga,/news/stocks/what-s-going-on-with-moderna-stock-on-monday-1033152289,neutral,0.5600607395172119
3/12/2024 4:15:13 AM,Merck & Company (MRK) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-cantor-fitzgerald-1033153524,neutral,0.774139940738678
3/12/2024 11:24:55 AM,IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer ,RTTNews,/news/stocks/ideaya-in-clinical-trial-deal-with-merck-to-evaluate-ide161-with-keytruda-in-endometrial-cancer-1033154185,positive,0.7272395491600037
3/12/2024 1:29:51 PM,Ideaya inks clinical trial pact with Merck,Seeking Alpha,https://seekingalpha.com/news/4078429-ideaya-stock-gains-merck-clinical-trial-pact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8180126547813416
3/13/2024 6:11:38 AM,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-merck-company-mrk-1033158508,positive,0.4828111529350281
3/13/2024 9:59:36 AM,Merck to study single-dose regimen of HPV vaccine Gardasil 9,Seeking Alpha,https://seekingalpha.com/news/4078750-merck-to-study-single-dose-regimen-of-hpv-vaccine-gardasil-9?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7956831455230713
3/13/2024 10:30:00 AM,SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster,InvestorPlace,/news/stocks/schd-etf-spotlight-the-top-6-stocks-inside-this-dividend-monster-1033158747,neutral,0.9299678206443787
3/13/2024 7:30:16 PM,7 Dow Darlings for Investors to Buy for March Market Madness,InvestorPlace,/news/stocks/7-dow-darlings-for-investors-to-buy-for-march-market-madness-1033161196,neutral,0.8792142868041992
3/14/2024 6:54:38 PM,Biotech bankruptcies hit a record despite sector’s recovery,Seeking Alpha,https://seekingalpha.com/news/4079630-biotech-bankruptcies-hit-record-despite-sectors-recovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.761096179485321
3/15/2024 11:35:38 AM,Merck hits main goal for Keytruda in late-stage trial for cervical cancer,Seeking Alpha,https://seekingalpha.com/news/4079860-merck-wins-keytruda-trial-cervical-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8589585423469543
3/15/2024 2:06:29 PM,Geron surges after FDA AdCom backing for lead drug,Seeking Alpha,https://seekingalpha.com/news/4079976-geron-stock-surges-fda-adcom-backs-imetelstat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8468478322029114
3/15/2024 7:16:36 PM,"Catalyst Watch: Fed rates meeting, Nvidia CEO speaks at GTC 2024, Reddit IPO",Seeking Alpha,https://seekingalpha.com/news/4079763-catalsyt-watch?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9283081889152527
3/18/2024 12:30:34 PM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Legend Biotech (LEGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-legend-biotech-legn-1033173203,neutral,0.9104698896408081
3/21/2024 11:22:10 AM,Merck Phase 3 trial for Keytruda combo fails in lung cancer,Seeking Alpha,https://seekingalpha.com/news/4081962-merck-phase-3-trial-keytruda-combo-fails-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.52756667137146
3/22/2024 11:06:50 AM,Merck & Company (MRK) Receives a Buy from Truist Financial,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-truist-financial-1033188803,positive,0.5044788718223572
3/26/2024 7:36:49 PM,Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment,Benzinga,/news/stocks/analysts-eye-summit-therapeutics-ivonescimab-as-potential-challenger-to-merck-s-keytruda-in-lung-cancer-treatment-1033198410,positive,0.9199519157409668
3/26/2024 9:48:09 PM,Merck wins FDA approval of sotatercept for rare lung disease,Seeking Alpha,https://seekingalpha.com/news/4084059-merck-wins-fda-approval-sotatercept-rare-lung-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9102032780647278
3/26/2024 11:56:40 PM,Merck & Co. Buy Rating Affirmed on Strong Sotatercept Outlook and Robust Growth Trajectory,TipRanks,/news/stocks/merck-co-buy-rating-affirmed-on-strong-sotatercept-outlook-and-robust-growth-trajectory-1033198994,positive,0.951432466506958
3/27/2024 4:41:17 AM,FDA Approves Merck's Winrevair For Treatment Of Pulmonary Arterial Hypertension In Adults ,RTTNews,/news/stocks/fda-approves-merck-s-winrevair-for-treatment-of-pulmonary-arterial-hypertension-in-adults-1033199013,positive,0.859451174736023
3/27/2024 7:40:26 AM,"Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-replimune-group-repl-merck-company-mrk-1033200436,neutral,0.6757309436798096
3/27/2024 9:11:39 AM,"Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC), Merck & Company (MRK) and Zoetis (ZTS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tenet-healthcare-thc-merck-company-mrk-and-zoetis-zts-1033200803,neutral,0.923530638217926
3/27/2024 9:45:56 AM,Merck & Company: A Strong Buy Amidst Promising Drug Developments and Revenue Growth Potential,TipRanks,/news/stocks/merck-company-a-strong-buy-amidst-promising-drug-developments-and-revenue-growth-potential-1033200984,positive,0.9510942101478577
3/27/2024 9:46:21 AM,Maintaining Hold on Merck & Co. Amidst Sotatercept’s Promising Developments and Revised Sales Projections,TipRanks,/news/stocks/maintaining-hold-on-merck-co-amidst-sotatercept-s-promising-developments-and-revised-sales-projections-1033200983,negative,0.5165899395942688
3/27/2024 11:10:12 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Shockwave Medical (SWAV) and Korro Bio (KRRO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-shockwave-medical-swav-and-korro-bio-krro-1033201438,neutral,0.9161150455474854
3/27/2024 12:00:59 PM,Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Merck & Company (MRK),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-annexon-biosciences-annx-and-merck-company-mrk-1033201989,neutral,0.9100150465965271
3/27/2024 12:30:47 PM,"Analysts Offer Insights on Healthcare Companies: ProSomnus (OSA), Merck & Company (MRK) and Phreesia (PHR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-prosomnus-osa-merck-company-mrk-and-phreesia-phr-1033202079,neutral,0.9119927883148193
3/27/2024 1:50:45 PM,Merck hits all-time high after FDA nod for lung disease therapy,Seeking Alpha,https://seekingalpha.com/news/4084361-merck-stock-jumps-fda-nod-winrevair?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.705170750617981
3/27/2024 2:22:05 PM,"Biggest stock movers today: NIO, MRK, GME, DJT, and more",Seeking Alpha,https://seekingalpha.com/news/4084100-biggest-stock-movers-today-mrk-gme-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9163367748260498
3/27/2024 3:03:28 PM,"Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday",Benzinga,/news/stocks/cintas-reports-upbeat-earnings-joins-paysign-noah-holdings-and-other-big-stocks-moving-higher-on-wednesday-1033201371,positive,0.9486138224601746
3/27/2024 6:37:58 PM,"The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says",Benzinga,/news/stocks/the-most-important-catalyst-for-merck-s-stock-in-2024-could-be-sotatercept-launch-analyst-says-1033202494,neutral,0.8816502094268799
3/28/2024 4:20:16 AM,Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Merck & Company (MRK),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-resmed-rmd-and-merck-company-mrk-1033203859,neutral,0.9166278839111328
3/28/2024 3:54:15 PM,"Pfizer, Astellas first-line bladder cancer therapy accepted for review in China",Seeking Alpha,https://seekingalpha.com/news/4085046-pfizer-astellas--bladder-cancer-therapy-under-review-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7267119288444519
3/29/2024 7:06:37 AM,Buy Rating on Merck & Co. Affirmed by Daina Graybosch Amidst WINREVAIR’s Market Potential and Efficacy,TipRanks,/news/stocks/buy-rating-on-merck-co-affirmed-by-daina-graybosch-amidst-winrevair-s-market-potential-and-efficacy-1033208039,positive,0.9526662230491638
3/29/2024 2:51:29 PM,3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List,InvestorPlace,/news/stocks/3-strong-buy-healthcare-stocks-to-add-to-your-q2-must-watch-list-1033208715,neutral,0.8121646046638489
3/30/2024 4:13:00 PM,Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues,Seeking Alpha,https://seekingalpha.com/news/4084974-eli-lilly-tops-the-growth-chart-for-the-sp-500-index-in-q1-as-the-sector-gains-momentum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6530331969261169
4/1/2024 3:00:34 PM,Expert Ratings For Merck & Co,Benzinga,/news/stocks/expert-ratings-for-merck-co-1033210972,neutral,0.8768600821495056
4/2/2024 8:25:07 AM,Cantor Fitzgerald Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-remains-a-buy-on-merck-company-mrk-1033214392,neutral,0.937382698059082
4/3/2024 5:07:34 PM,Bristol Myers wins label expansion for anemia therapy in EU,Seeking Alpha,https://seekingalpha.com/news/4086933-bristol-myers-wins-eu-label-expansion-anemia-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9028072953224182
4/4/2024 12:29:09 PM,Merck to test lung cancer combo therapy in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4087198-merck-to-test-lung-cancer-combo-therapy-in-late-stage-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5875102877616882
4/4/2024 1:12:06 PM,Merck Begins Phase 3 Trial Of MK-1084 As First-Line Treatment Of Certain Metastatic NSCLC Patients ,RTTNews,/news/stocks/merck-begins-phase-3-trial-of-mk-1084-as-first-line-treatment-of-certain-metastatic-nsclc-patients-1033221966,positive,0.6513872146606445
4/6/2024 4:15:14 AM,Merck & Company (MRK) Receives a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-cantor-fitzgerald-1033227105,neutral,0.5508311986923218
4/7/2024 5:31:00 PM,Morgan Stanley sees Fed rate cut fueling biotech stocks,Seeking Alpha,https://seekingalpha.com/news/4087727-fed-rate-cut-should-fuel-biotech-outperformance-morgan-stanley-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5271168947219849
4/7/2024 6:00:00 PM,The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-sp-500-stocks-to-buy-in-april-2024-1033227751,neutral,0.7304365038871765
4/7/2024 6:09:47 PM,Citi's top recommended large-cap stocks,Seeking Alpha,https://seekingalpha.com/news/4087767-citis-top-recommended-large-cap-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8437961339950562
4/8/2024 6:00:00 PM,Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement,InvestorPlace,/news/stocks/golden-years-gainers-3-stocks-to-fund-your-dream-retirement-1033230960,neutral,0.8895826935768127
4/9/2024 3:26:54 PM,Moderna stock climbs 8% amid head/neck cancer vaccine data,Seeking Alpha,https://seekingalpha.com/news/4088291-moderna-stock-climbs-amid-head-neck-cancer-vaccine-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9191806316375732
4/10/2024 8:42:40 PM,"Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says",Benzinga,/news/stocks/vaccine-player-vaxcyte-has-advantage-over-pfizer-merck-s-pneumococcal-shots---analyst-says-1033238661,positive,0.8393562436103821
4/11/2024 12:45:05 PM,Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study,Benzinga,/news/stocks/moderna-mrna-up-6-on-upbeat-data-from-cancer-jab-study-1033240425,positive,0.9457476139068604
4/11/2024 1:47:56 PM,The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today,InvestorPlace,/news/stocks/the-5-billion-reason-alpine-immune-sciences-alpn-stock-is-up-30-today-1033241236,positive,0.9471536874771118
4/11/2024 2:33:00 PM,"Cardinal Health, Cigna, Merck among top healthcare Quant picks ahead of Q1 earnings",Seeking Alpha,https://seekingalpha.com/news/4088706-cardinal-health-medtronic-top-quant-ratings-in-the-sp-500-healthcare-sector?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7957942485809326
4/12/2024 9:06:35 AM,Merck & Company: Balancing Growth Prospects Against Rising Operational Challenges,TipRanks,/news/stocks/merck-company-balancing-growth-prospects-against-rising-operational-challenges-1033244048,positive,0.5367119908332825
4/12/2024 10:40:00 AM,7 A-Rated Aggressive Biotech Stocks to Bet On in 2024,InvestorPlace,/news/stocks/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024-1033243804,neutral,0.7495233416557312
4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.752937912940979
4/16/2024 7:17:08 PM,3 Dow Stocks to Buy Now: Q2 Edition,InvestorPlace,/news/stocks/3-dow-stocks-to-buy-now-q2-edition-1033254798,neutral,0.9223288893699646
4/17/2024 12:00:00 PM,Coming FDA Approvals Could Send These 3 Drug Stocks Soaring,InvestorPlace,/news/stocks/coming-fda-approvals-could-send-these-3-drug-stocks-soaring-1033257666,negative,0.9356775879859924
4/18/2024 8:01:15 PM,Unveiling 17 Analyst Insights On Merck & Co,Benzinga,/news/stocks/unveiling-17-analyst-insights-on-merck-co-1033263582,neutral,0.9030822515487671
4/19/2024 4:25:08 AM,Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-buy-rating-on-merck-company-mrk-1033264850,neutral,0.8452711701393127
4/19/2024 1:42:02 PM,Health Canada Approves Merck's Keytruda Plus Chemotherapy To Treat Gastric Cancers ,RTTNews,/news/stocks/health-canada-approves-merck-s-keytruda-plus-chemotherapy-to-treat-gastric-cancers-1033265747,positive,0.8148984909057617
4/19/2024 4:03:30 PM,Merck garners Canadian approval for Keytruda in first-line gastroesophageal cancer,Seeking Alpha,https://seekingalpha.com/news/4091550-merck-garners-canadian-approval-keytruda-first-line-gastroesophageal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9405097961425781
4/19/2024 7:00:19 PM,"Catalyst Watch: Tesla, Boeing and General Motors brace for earnings fireworks",Seeking Alpha,https://seekingalpha.com/news/4091531-catalyst-watch-tesla-boeing-and-general-motors-brace-for-earnings-fireworks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8319826126098633
4/21/2024 12:00:00 PM,"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",Seeking Alpha,https://seekingalpha.com/news/4091495-earnings-week-ahead-tesla-meta-platforms-google-microsoft-intel-exxon-mobil-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9310646057128906
4/21/2024 6:42:04 PM,Goldman picks top capex and R&D stocks,Seeking Alpha,https://seekingalpha.com/news/4091724-goldman-picks-top-capex-and-rd-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9173789024353027
4/23/2024 7:00:00 PM,3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge,InvestorPlace,/news/stocks/3-underappreciated-pharmaceutical-stocks-to-buy-before-they-surge-1033277779,negative,0.8864841461181641
4/23/2024 9:11:38 PM,Investor Alert: Prepare for the Market Crash With These 3 Stocks,InvestorPlace,/news/stocks/investor-alert-prepare-for-the-market-crash-with-these-3-stocks-1033278095,neutral,0.919552743434906
4/24/2024 4:08:50 AM,"Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors ",RTTNews,/news/stocks/hanmi-merck-collaborate-to-evaluate-bh3120-keytruda-combination-in-metastatic-solid-tumors-1033278343,positive,0.709919273853302
4/24/2024 2:03:42 PM,Merck Q1 Earnings Preview: Strong quarter expectations on the back of core products' growth,Seeking Alpha,https://seekingalpha.com/news/4093101-merck-q1-earnings-preview-strong-quarter-expectations-on-the-back-of-core-products-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9535902738571167
4/24/2024 3:01:13 PM,Merck earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/merck_co-q1-quarterly-earnings-preview-stock-1033281925,neutral,0.9352008700370789
4/24/2024 8:08:47 PM,Immutep reports promising efti/Keytruda data for head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/4093564-immutep-reports-promising-eftikeytruda-data-for-head-and-neck-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9478157162666321
4/25/2024 9:50:26 AM,"Analysts Conflicted on These Healthcare Names: Travere Therapeutics (TVTX), Humana (HUM) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-travere-therapeutics-tvtx-humana-hum-and-merck-company-mrk-1033287871,negative,0.657801628112793
4/25/2024 10:32:23 AM,"Merck Non-GAAP EPS of $2.07 beats by $0.15, revenue of $15.8B beats by $600M",Seeking Alpha,https://seekingalpha.com/news/4093902-merck-non-gaap-eps-of-2_07-beats-0_15-revenue-of-15_8b-beats-600m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6496161818504333
4/25/2024 10:59:26 AM,"Merck in charts: Pharmaceutical segment soars on KEYTRUDA, GARDASIL strength in Q1",Seeking Alpha,https://seekingalpha.com/news/4093946-merck-in-charts-pharmaceutical-segment-soars-on-keytruda-gardasil-strength-in-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9009860157966614
4/25/2024 11:10:53 AM,Merck raises guidance as Keytruda sales jump 20% in Q1,Seeking Alpha,https://seekingalpha.com/news/4093979-merck-stock-gains-q1-2024-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9366799592971802
4/25/2024 11:56:55 AM,Bristol-Myers posts Q1 beat despite growth headwinds,Seeking Alpha,https://seekingalpha.com/news/4094029-bristol-myers-stock-falls-despite-q1-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.934116780757904
4/25/2024 1:05:40 PM,"Merck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-market ",RTTNews,/news/stocks/merck-lifts-fy24-outlook-after-higher-q1-earnings-above-market-stock-up-in-pre-market-1033287292,positive,0.9387381076812744
4/25/2024 2:54:12 PM,"MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024",InvestorPlace,/news/stocks/mrk-stock-earnings-merck-co-for-q1-of-2024-1033289054,neutral,0.6572041511535645
4/25/2024 7:30:33 PM,"Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?",Benzinga,/news/etf/stocks-drop-tech-tumbles-with-meta-s-weak-outlook-q1-stagflation-fears-gold-miners-advance-what-s-driving-markets-thursday-1033289828,negative,0.927890419960022
4/26/2024 8:48:14 AM,Merck & Company (MRK) Gets a Buy from Barclays,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-barclays-1033293612,neutral,0.5323359370231628
4/26/2024 10:30:52 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-globus-medical-gmed-and-merck-company-mrk-1033294243,neutral,0.9149287939071655
4/26/2024 11:25:46 AM,Merck & Co. Outperforms with Strong Keytruda Sales and Raised Guidance: A Buy Rating Affirmed,TipRanks,/news/stocks/merck-co-outperforms-with-strong-keytruda-sales-and-raised-guidance-a-buy-rating-affirmed-1033294699,positive,0.9482629299163818
4/26/2024 12:16:14 PM,Merck & Company: A Strong Buy on Robust Performance and Future Growth Prospects,TipRanks,/news/stocks/merck-company-a-strong-buy-on-robust-performance-and-future-growth-prospects-1033295050,positive,0.9404977560043335
4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6158705353736877
4/29/2024 2:20:44 PM,Merck late-stage data strengthens profile of pneumonia vaccine candidate,Seeking Alpha,https://seekingalpha.com/news/4095517-merck-late-stage-data-strengthens-profile-pneumonia-vaccine-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9475334286689758
4/30/2024 6:06:16 AM,Buy Rating Affirmed on Merck & Company Following Strong Q1 Performance and Upbeat Full-Year Guidance,TipRanks,/news/stocks/buy-rating-affirmed-on-merck-company-following-strong-q1-performance-and-upbeat-full-year-guidance-1033304879,positive,0.9505518674850464
5/1/2024 12:47:27 PM,Merck Keytruda combo meets main goal in late-stage trial for advanced gastric cancer,Seeking Alpha,https://seekingalpha.com/news/4097242-merck-keytruda-combo-meets-main-goal-in-late-stage-trial-for-advanced-gastric-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8219603300094604
5/2/2024 4:40:21 PM,Cerevance receives milestone payment under Alzheimer's collaboration with Merck,Seeking Alpha,https://seekingalpha.com/news/4098971-cerevance-receives-milestone-payment-under-alzheimers-collaboration-merck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6750365495681763
5/2/2024 8:09:01 PM,Janux Therapeutics gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4099085-janux-therapeutics-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8977920413017273
5/3/2024 2:37:01 PM,"Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected (UPDATED)",Benzinga,/news/etf/job-market-cools-in-april-payrolls-miss-forecasts-wages-rise-less-than-expected-1033326343,negative,0.9582262635231018
5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9528807997703552
5/6/2024 3:52:08 PM,Calliditas releases phase 2 results on head and neck cancer asset setanaxib,Seeking Alpha,https://seekingalpha.com/news/4100462-calliditas-releases-phase-2-results-head-neck-cancer-setanaxib?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9176803827285767
5/6/2024 6:30:17 PM,3 Biotech Stocks to Double Your Money in the Next 24 Months,InvestorPlace,/news/stocks/3-biotech-stocks-to-double-your-money-in-the-next-24-months-1033334986,positive,0.7702029347419739
5/7/2024 8:52:00 PM,CytomX teams up with Merck for CX-801 clinical study,Seeking Alpha,https://seekingalpha.com/news/4101861-cytomx-teams-up-with-merck-for-cx-801-clinical-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5615400671958923
5/9/2024 11:08:52 AM,Merck says Keytruda failed as first-line therapy for uterine cancer,Seeking Alpha,https://seekingalpha.com/news/4103497-merck-stock-falls-keytruda-fails-uterine-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6833253502845764
5/9/2024 1:48:49 PM,Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults ,RTTNews,/news/stocks/merck-keytruda-receives-approval-from-health-canada-for-biliary-tract-carcinoma-in-adults-1033355459,positive,0.9222285151481628
5/9/2024 2:34:23 PM,7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025,InvestorPlace,/news/stocks/7-weight-loss-drug-stocks-poised-for-explosive-growth-by-2025-1033357058,positive,0.8605071902275085
5/9/2024 3:27:29 PM,Merck's Phase 3 Trial Of KEYTRUDA Plus Chemotherapy In Endometrial Cancer Fails To Meet Primary Goal ,RTTNews,/news/stocks/merck-s-phase-3-trial-of-keytruda-plus-chemotherapy-in-endometrial-cancer-fails-to-meet-primary-goal-1033356260,negative,0.8788601160049438
5/9/2024 4:41:08 PM,A Look at Pharma ETFs Post Q1 Earnings,Benzinga,/news/etf/a-look-at-pharma-etfs-post-q1-earnings-1033357001,neutral,0.9325221180915833
5/10/2024 10:01:00 AM,The 3 Most Undervalued Healthcare Stocks to Buy in May 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-healthcare-stocks-to-buy-in-may-2024-1033362256,neutral,0.7676414251327515
5/10/2024 10:30:00 AM,3 Biotech Stocks to Sell in May Before They Crash & Burn,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-in-may-before-they-crash-burn-1033362353,neutral,0.8534220457077026
5/13/2024 11:58:54 AM,Merck discontinues testing of experimental skin cancer combo therapy,Seeking Alpha,https://seekingalpha.com/news/4105055-merck-discontinues-testing-of-experimental-skin-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9100384712219238
5/13/2024 1:07:34 PM,Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma ,RTTNews,/news/stocks/merck-discontinues-vibostolimab-and-pembrolizumab-coformulation-arm-of-phase-3-trial-in-melanoma-1033370185,neutral,0.8543875217437744
5/14/2024 12:40:16 PM,"Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Inovio Pharmaceuticals (INO)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-merck-company-mrk-inovio-pharmaceuticals-ino-1033377744,neutral,0.5452921986579895
5/14/2024 2:00:00 PM,Health care is still very crowded but trades at a discount vs. history - BofA,Seeking Alpha,https://seekingalpha.com/news/4105408-health-care-is-still-very-crowded-but-trades-at-a-discount-vs-history-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7897588610649109
5/14/2024 8:33:50 PM,Merck Ends Keytruda Combo Melanoma Study Due to Futility,Benzinga,/news/stocks/merck-ends-keytruda-combo-melanoma-study-due-to-futility-1033378357,negative,0.9257606863975525
5/15/2024 2:21:25 PM,"Short interest in S&P 500 healthcare sector dips in April, biotechnology companies most shorted",Seeking Alpha,https://seekingalpha.com/news/4106501-short-interest-in-sp-500-healthcare-sector-dips-in-april-biotechnology-companies-most-shorted?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.96722412109375
5/16/2024 1:06:11 PM,Bank of America Securities Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-buy-rating-on-merck-company-mrk-1033394390,neutral,0.9124518632888794
5/17/2024 10:00:00 AM,Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches,InvestorPlace,/news/stocks/storm-shelter-7-safe-haven-stocks-to-batten-down-the-hatches-1033398570,neutral,0.8220119476318359
5/17/2024 11:33:51 AM,"Dow at 40K: Leaders and laggards over the last 10,000 points",Seeking Alpha,https://seekingalpha.com/news/4107853-dow-at-40k-leaders-and-laggards-over-the-last-10000-points?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7490761280059814
5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8400077223777771
5/19/2024 7:05:03 PM,SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?,Seeking Alpha,https://seekingalpha.com/news/4108152-sa-roundtable-are-eli-lilly-and-novo-nordisk-overvalued?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8515272736549377
5/22/2024 9:17:02 AM,Wells Fargo Sticks to Their Hold Rating for Merck & Company (MRK),TipRanks,/news/stocks/wells-fargo-sticks-to-their-hold-rating-for-merck-company-mrk-1033411350,neutral,0.8521066308021545
5/23/2024 8:03:26 PM,Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day,InvestorPlace,/news/stocks/bargain-bin-3-cheap-stocks-to-buy-before-memorial-day-1033417450,neutral,0.8799559473991394
5/23/2024 9:39:37 PM,Merck HPV vaccine associated with lower head and neck cancer rates in men,Seeking Alpha,https://seekingalpha.com/news/4110103-merck-hpv-vaccine-associated-with-lower-head-and-neck-cancer-rates-in-men?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5680673718452454
5/24/2024 1:36:39 PM,Merus rallies on publication of oncology study abstracts,Seeking Alpha,https://seekingalpha.com/news/4110245-merus-rallies-amid-publication-of-oncology-study-abstracts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6957870721817017
5/24/2024 3:11:26 PM,"Merck, Kelun buoyed by phase 3 results for breast cancer antibody drug conjugate",Seeking Alpha,https://seekingalpha.com/news/4110267-merck-kelun-buoyed-phase-3-results-breast-cancer-antibody-drug-cojugate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9372946619987488
5/24/2024 5:01:22 PM,CG Oncology climbs 10% on Phase 2 data for bladder cancer drug,Seeking Alpha,https://seekingalpha.com/news/4110301-cg-oncology-climbs-on-phase-2-data-for-bladder-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.933016836643219
5/24/2024 6:26:46 PM,HOOKIPA stock falls 20% in wake of Phase 1/2 study results,Seeking Alpha,https://seekingalpha.com/news/4110331-hookipa-stock-falls-in-wake-of-phase-12-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9696689248085022
5/24/2024 7:41:20 PM,Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?,Benzinga,/news/stocks/why-is-cancer-focused-merus-stock-trading-over-30-on-friday-1033421018,neutral,0.8858920335769653
5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9204940795898438
5/28/2024 1:13:56 PM,Merck Reports Positive Phase 3 KEYTRUDA Plus Chemotherapy Trial Results In TNBC Patients ,RTTNews,/news/stocks/merck-reports-positive-phase-3-keytruda-plus-chemotherapy-trial-results-in-tnbc-patients-1033426566,positive,0.9433358907699585
5/28/2024 4:45:39 PM,"Merck's Keytruda improves overall survival in high-risk, early-stage breast cancer",Seeking Alpha,https://seekingalpha.com/news/4110805-merck-keytruda-improves-overall-survival-high-risk-early-stage-breast-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9533640146255493
5/28/2024 7:21:17 PM,Merck declares $0.77 dividend,Seeking Alpha,https://seekingalpha.com/news/4110871-merck-and-co-inc-declares-0_77-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.928073525428772
5/29/2024 4:09:28 AM,"Merck Nears $1.3 Bln Cash Deal To Buy EyeBio, With Potential $1.7 Bln In Milestone Payments : Report ",RTTNews,/news/stocks/merck-nears-1-3-bln-cash-deal-to-buy-eyebio-with-potential-1-7-bln-in-milestone-payments-report-1033428900,neutral,0.5129377841949463
5/29/2024 8:11:16 AM,Merck to buy eye-care startup EyeBio for up to $3B,Seeking Alpha,https://seekingalpha.com/news/4110983-merck-buy-eye-care-startup-eyebio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.558972954750061
5/29/2024 10:25:00 AM,"No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.",InvestorPlace,/news/stocks/no-memes-maam-try-a-sensible-biotech-bet-with-cytomx-therapeutics-stock-1033431005,neutral,0.9108946919441223
5/29/2024 12:57:32 PM,Merck To Acquire EyeBio; Deal Valued Up To $3 Bln ,RTTNews,/news/stocks/merck-to-acquire-eyebio-deal-valued-up-to-3-bln-1033431074,positive,0.7369425296783447
5/29/2024 3:50:26 PM,AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin,Seeking Alpha,https://seekingalpha.com/news/4111181-astrazeneca-touts-pcsk9-inhibitor-lowering-ldl-cholesterol-added-statin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8726117014884949
5/30/2024 11:55:49 AM,Biotech Stocks Facing FDA Decision In June 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2024-1033435348,neutral,0.9173391461372375
5/30/2024 7:12:02 PM,Summit lead asset beats Merck’s Keytruda in a first in lung cancer,Seeking Alpha,https://seekingalpha.com/news/4111700-summit-stock-gains-lead-asset-beats-keytruda?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.923500657081604
5/31/2024 3:00:28 AM,Maintaining Buy Rating on Merck: Keytruda’s Dominance and Promising Growth Trajectory,TipRanks,/news/stocks/maintaining-buy-rating-on-merck-keytruda-s-dominance-and-promising-growth-trajectory-1033439824,positive,0.9398815035820007
5/31/2024 12:14:52 PM,"Dividend Roundup: Meta Platforms, Merck, Cigna, Halliburton, and more",Seeking Alpha,https://seekingalpha.com/news/4111901-dividend-roundup-meta-platforms-merck-cigna-halliburton-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9444242119789124
5/31/2024 2:02:26 PM,Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda (update),Seeking Alpha,https://seekingalpha.com/news/4111919-summit-stock-falls-despite-data-beating-merck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5685202479362488
5/31/2024 8:31:58 PM,Immunocore touts updated phase 1 results for melanoma asset brenetafusp,Seeking Alpha,https://seekingalpha.com/news/4112056-immunocore-touts-updated-phase-1-results-melanoma-asset-brenetafusp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9202130436897278
6/1/2024 12:19:05 PM,Summit lead asset approved in China for lung cancer,Seeking Alpha,https://seekingalpha.com/news/4112125-summit-lead-asset-approved-in-china-for-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5619070529937744
6/1/2024 2:20:54 PM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-glaukos-gkos-and-arcus-biosciences-rcus-1033443070,neutral,0.9174323678016663
6/1/2024 2:30:12 PM,"Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-cullinan-management-cgem-merck-company-mrk-1033443078,neutral,0.8045975565910339
6/1/2024 3:53:31 PM,Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors ,RTTNews,/news/stocks/lilly-announces-updated-data-from-phase-1-2-study-of-olomorasib-in-advanced-solid-tumors-1033442941,neutral,0.8631588816642761
6/1/2024 5:30:00 PM,BioNTech/Genmab lung cancer therapy improves survival with Keytruda,Seeking Alpha,https://seekingalpha.com/news/4112133-biontech-genmab-post-early-data-lung-cancer-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9484941959381104
6/1/2024 6:44:45 PM,FDA oncology chief says international clinical trials should be priority,Seeking Alpha,https://seekingalpha.com/news/4112136-fda-oncology-chief-international-clinical-trials-priority?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7988932728767395
6/2/2024 6:00:00 PM,Emerging and Chinese pharmas playing greater role in oncology drug development,Seeking Alpha,https://seekingalpha.com/news/4112099-emerging-chinese-pharmas-playing-greater-role-oncology-drug-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5788828134536743
6/3/2024 4:32:16 AM,Immutep Collaborates With Merck To Evaluate Efti In Combination Therapy For Metastatic NSCLC ,RTTNews,/news/stocks/immutep-collaborates-with-merck-to-evaluate-efti-in-combination-therapy-for-metastatic-nsclc-1033443711,positive,0.7337971925735474
6/3/2024 2:01:08 PM,Moderna and Merck's skin cancer vaccine shows promising survival rate,Seeking Alpha,https://seekingalpha.com/news/4112341-moderna-and-mercks-skin-cancer-vaccine-shows-promising-survival-rate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9423495531082153
6/3/2024 5:10:40 PM,Merck Says MRNA-4157-Keytruda Combination Data Shows Improvement In High-Risk Melanoma Patients ,RTTNews,/news/stocks/merck-says-mrna-4157-keytruda-combination-data-shows-improvement-in-high-risk-melanoma-patients-1033446525,positive,0.9556853175163269
6/4/2024 7:20:23 AM,"Analysts’ Top Healthcare Picks: Replimune Group (REPL), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-replimune-group-repl-merck-company-mrk-1033448736,neutral,0.512281596660614
6/4/2024 9:36:20 AM,Maintaining Hold: Merck & Co.’s Promising Trials and Strategic Partnerships Reflect Current Valuation,TipRanks,/news/stocks/maintaining-hold-merck-co-s-promising-trials-and-strategic-partnerships-reflect-current-valuation-1033449296,positive,0.8601770997047424
6/4/2024 9:58:34 AM,Merck’s Oncology Pipeline and Upcoming Product Launches Underpin Buy Rating,TipRanks,/news/stocks/merck-s-oncology-pipeline-and-upcoming-product-launches-underpin-buy-rating-1033449535,positive,0.8251714706420898
6/4/2024 11:06:59 AM,Buy Rating Affirmed: Merck’s Oncology Advances and Strategic Positioning Promote Growth,TipRanks,/news/stocks/buy-rating-affirmed-merck-s-oncology-advances-and-strategic-positioning-promote-growth-1033450068,positive,0.938823938369751
6/4/2024 11:15:27 AM,Merck & Company (MRK) Receives a Buy from Truist Financial,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-truist-financial-1033450118,positive,0.5044788718223572
6/4/2024 12:00:36 PM,Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Merck & Company (MRK),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intellia-therapeutics-ntla-and-merck-company-mrk-1033450364,neutral,0.9164083003997803
6/4/2024 1:35:42 PM,Buy Rating Affirmed on Merck’s Promising Oncology Pipeline and Keytruda’s Commercial Success,TipRanks,/news/stocks/buy-rating-affirmed-on-merck-s-promising-oncology-pipeline-and-keytruda-s-commercial-success-1033450731,positive,0.9338698387145996
6/5/2024 12:36:19 PM,Merck & Company (MRK) Receives a Buy from Argus Research,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-argus-research-1033454521,neutral,0.6658549904823303
6/6/2024 11:00:00 AM,Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate,InvestorPlace,/news/stocks/exit-strategy-3-overvalued-stocks-to-sell-before-they-deflate-1033456975,neutral,0.8150242567062378
6/7/2024 10:39:00 AM,Geron jumps as FDA approves lead asset for blood cancer,Seeking Alpha,https://seekingalpha.com/news/4113925-geron-stock-gains-rytelo-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5721278786659241
6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8829660415649414
6/8/2024 2:19:36 PM,"AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes",Seeking Alpha,https://seekingalpha.com/news/4114301-astrazeneca-dominates-merck-beaten-asco-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7508276700973511
6/10/2024 3:44:00 PM,From $10k to $100k: 3 Stocks With the Potential for Amazing Returns,InvestorPlace,/news/stocks/from-10k-to-100k-3-stocks-with-the-potential-for-amazing-returns-1033467161,positive,0.8092314600944519
6/10/2024 8:18:31 PM,Merck shares traded in the green for seven straight days,Seeking Alpha,https://seekingalpha.com/news/4114605-merck-shares-traded-in-the-green-for-seven-straight-days?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8691146969795227
6/11/2024 11:00:00 AM,3 High-Yield Dividend Stocks to Collect Impressive Payouts Year After Year,InvestorPlace,/news/stocks/3-high-yield-dividend-stocks-to-collect-impressive-payouts-year-after-year-1033468456,positive,0.9006056785583496
6/11/2024 2:00:00 PM,3 Penny Stocks to Buy if You Want to Spend Less and Earn More,InvestorPlace,/news/stocks/3-penny-stocks-to-buy-if-you-want-to-spend-less-and-earn-more-1033469513,neutral,0.8977554440498352
6/12/2024 10:00:00 AM,3 Crazy Good Stocks to Buy With $500 Right Now,InvestorPlace,/news/stocks/3-crazy-good-stocks-to-buy-with-500-right-now-1033471998,neutral,0.9045591950416565
6/12/2024 10:37:30 AM,Neutral Hold Rating for Merck’s Winrevair Amid Modest Sales Impact and Market Penetration Concerns,TipRanks,/news/stocks/neutral-hold-rating-for-merck-s-winrevair-amid-modest-sales-impact-and-market-penetration-concerns-1033472787,positive,0.6804251670837402
6/12/2024 10:51:47 AM,Merck & Company: A Strong Buy on Robust Pipeline and Strategic Growth,TipRanks,/news/stocks/merck-company-a-strong-buy-on-robust-pipeline-and-strategic-growth-1033472849,positive,0.9460827112197876
6/17/2024 5:47:48 PM,Merck's Keytruda gains approval for additional endometrial carcinoma indication,Seeking Alpha,https://seekingalpha.com/news/4116738-merck-keytruda-gains-approval-additional-endometrial-carcinoma-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9411163926124573
6/18/2024 10:10:17 AM,"Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Globus Medical (GMED) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-globus-medical-gmed-and-merck-company-mrk-1033487104,neutral,0.908467710018158
6/18/2024 1:01:00 PM,Merck gets FDA approval for Capvaxive pneumonia vaccine (update),Seeking Alpha,https://seekingalpha.com/news/4116816-merck-gets-fda-approval-for-capvaxive-21-pneumonia-vaccine?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.671528160572052
6/18/2024 2:19:37 PM,Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults ,RTTNews,/news/stocks/ligand-says-merck-receives-fda-approval-for-capvaxive-for-adults-1033486846,positive,0.8229309320449829
6/18/2024 11:00:58 PM,Cracking The Code: Understanding Analyst Reviews For Merck & Co,Benzinga,/news/stocks/cracking-the-code-understanding-analyst-reviews-for-merck-co-1033488669,neutral,0.8976748585700989
6/19/2024 4:16:42 AM,Merck & Company (MRK) Receives a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-cantor-fitzgerald-1033489328,neutral,0.5508311986923218
6/20/2024 8:10:36 PM,Esperion closes down 16% following BofA downgrade,Seeking Alpha,https://seekingalpha.com/news/4117559-esperion-down-16-following-boa-downgrade?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9725455641746521
6/21/2024 10:36:00 AM,3 Top Penny Stocks to Skyrocket Your Wealth in 2024,InvestorPlace,/news/stocks/3-top-penny-stocks-to-skyrocket-your-wealth-in-2024-1033495531,neutral,0.7693461179733276
6/24/2024 8:30:00 PM,3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains,InvestorPlace,/news/stocks/3-undervalued-pharma-stocks-to-buy-for-dividends-and-capital-gains-1033501636,positive,0.5921242833137512
6/25/2024 8:39:14 PM,"Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says",Benzinga,/news/stocks/gossamer-bio-s-clean-safety-profile-differentiates-it-from-merck-analyst-says-1033505170,neutral,0.6468334197998047
6/25/2024 8:43:20 PM,"Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth",Benzinga,/news/stocks/analyst-sees-keros-therapeutics-as-next-acceleron-set-for-major-biotech-growth-1033505169,positive,0.5376772880554199
6/25/2024 9:06:01 PM,Merck wins approval of RNA-based dog flu vaccine,Seeking Alpha,https://seekingalpha.com/news/4119206-merck-wins-approval-rna-based-dog-flu-vaccine?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7789720296859741
6/26/2024 7:37:24 AM,Buy Rating on Merck & Co. Anchored by Capvaxive’s Market Capture and Cost-Effectiveness Prospects,TipRanks,/news/stocks/buy-rating-on-merck-co-anchored-by-capvaxive-s-market-capture-and-cost-effectiveness-prospects-1033506950,positive,0.9187109470367432
6/26/2024 7:59:51 AM,"Merck : USDA Approves NOBIVAC NXT, First RNA-Particle Vaccine For Canine Flu H3N2 ",RTTNews,/news/stocks/merck-usda-approves-nobivac-nxt-first-rna-particle-vaccine-for-canine-flu-h3n2-1033506039,positive,0.8829342126846313
6/26/2024 11:15:00 AM,7 Dividend Stocks to Buy Now for Enhanced Returns,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-now-for-enhanced-returns-1033507181,neutral,0.7556409239768982
6/27/2024 2:36:28 AM,Merck : FDA Issues Complete Response Letter For Patritumab Deruxtecan In EGFR-Mutated NSCLC ,RTTNews,/news/stocks/merck-fda-issues-complete-response-letter-for-patritumab-deruxtecan-in-egfr-mutated-nsclc-1033509368,neutral,0.6793850064277649
6/27/2024 10:25:54 AM,Hold Rating on Merck Amid FDA Setback and Revenue Impact Analysis,TipRanks,/news/stocks/hold-rating-on-merck-amid-fda-setback-and-revenue-impact-analysis-1033511454,negative,0.9618094563484192
6/27/2024 10:42:11 AM,Maintaining Buy on Merck: Short-Term Hurdle Not Diminishing Long-Term Drug Success,TipRanks,/news/stocks/maintaining-buy-on-merck-short-term-hurdle-not-diminishing-long-term-drug-success-1033511508,positive,0.9231201410293579
6/27/2024 10:45:24 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Nurix Therapeutics (NRIX) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-nurix-therapeutics-nrix-and-merck-company-mrk-1033511599,neutral,0.9080982208251953
6/27/2024 11:56:32 AM,"Merck, Daiichi lung cancer therapy rejected in U.S.",Seeking Alpha,https://seekingalpha.com/news/4119964-merck-daiichi-lung-cancer-therapy-rejected-in-us?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7946624159812927
6/27/2024 8:39:20 PM,Merck's Lung Cancer Candidate Faces FDA Rejection,Benzinga,/news/stocks/merck-s-lung-cancer-candidate-faces-fda-rejection-1033512884,neutral,0.8145422339439392
6/28/2024 11:41:44 AM,Merck Capvaxive pneumonia vaccine recommended by CDC advisors,Seeking Alpha,https://seekingalpha.com/news/4120519-merck-pneumonia-vaccine-endorsed-cdc-panel?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.834309995174408
6/28/2024 12:46:37 PM,Merck lung disease therapy Winrevair endorsed in EU,Seeking Alpha,https://seekingalpha.com/news/4120554-merck-lung-disease-therapy-winrevair-endorsed-in-eu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6560484766960144
6/28/2024 1:06:06 PM,Deutsche Numis Sticks to Their Hold Rating for Merck & Company (MRK),TipRanks,/news/stocks/deutsche-numis-sticks-to-their-hold-rating-for-merck-company-mrk-1033516106,neutral,0.868819534778595
6/28/2024 2:43:48 PM,Merck: CHMP Recommends Approval Of WINREVAIR In Pulmonary Arterial Hypertension - Quick Facts ,RTTNews,/news/stocks/merck-chmp-recommends-approval-of-winrevair-in-pulmonary-arterial-hypertension-quick-facts-1033514911,positive,0.7476031184196472
6/28/2024 6:00:00 PM,7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally,InvestorPlace,/news/stocks/7-quiet-blue-chip-stocks-on-the-verge-of-a-big-breakout-rally-1033516364,neutral,0.4728260934352875
6/28/2024 6:34:33 PM,Merck's New Pneumococcal Jab Capvaxive Gets CDC Panel Vote,Benzinga,/news/stocks/merck-s-new-pneumococcal-jab-capvaxive-gets-cdc-panel-vote-1033516169,positive,0.6091179251670837
6/29/2024 10:30:00 AM,3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt,InvestorPlace,/news/stocks/3-sectors-that-could-get-slammed-by-attempts-to-reduce-u-s-debt-1033516833,negative,0.9460068345069885
6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7290321588516235
7/1/2024 3:21:52 PM,Orion Stock Up On FY24 Outlook Upgrade After Opevesostat Deal With Merck ,RTTNews,/news/stocks/orion-stock-up-on-fy24-outlook-upgrade-after-opevesostat-deal-with-merck-1033519683,positive,0.9480873942375183
7/4/2024 10:00:00 AM,Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation,InvestorPlace,/news/stocks/beat-the-cpi-7-blue-chip-stocks-growing-faster-than-inflation-1033529072,positive,0.8881319761276245
7/7/2024 3:39:52 PM,"EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",Benzinga,/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664,neutral,0.6258196830749512
7/9/2024 12:06:03 PM,"Prelude, Merck strike clinical trial collaboration and supply pact",Seeking Alpha,https://seekingalpha.com/news/4122857-prelude-merck-strike-clinical-trial-collaboration-and-supply-pact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8838716149330139
7/9/2024 1:08:57 PM,3 Undervalued Blue-Chip Stocks Ready for a Big Comeback,InvestorPlace,/news/stocks/3-undervalued-blue-chip-stocks-ready-for-a-big-comeback-1033539508,positive,0.5048560500144958
7/10/2024 8:50:20 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK), UnitedHealth (UNH) and Pfizer (PFE)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-merck-company-mrk-unitedhealth-unh-and-pfizer-pfe-1033542846,negative,0.9382280707359314
7/10/2024 7:22:59 PM,7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-for-positive-inflation-adjusted-returns-1033544701,neutral,0.5849413871765137
7/11/2024 4:51:22 PM,United Therapeutics cut at Morgan Stanley on risk-reward setup,Seeking Alpha,https://seekingalpha.com/news/4123725-united-therapeutics-stock-cut-morgan-stanley?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9065331220626831
7/11/2024 6:23:24 PM,3 Under-$10 Biotech Stocks That Could Make You Rich,InvestorPlace,/news/stocks/3-under-10-biotech-stocks-that-could-make-you-rich-1033548360,neutral,0.8671848773956299
7/11/2024 8:00:54 PM,Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock,Benzinga,/news/stocks/beyond-the-numbers-6-analysts-discuss-merck-co-stock-1033548340,neutral,0.9444010257720947
7/12/2024 4:44:10 AM,Immutep's Eftilagimod Alfa Combination Shows Positive Phase IIb Results In Head & Neck Cancer Trial ,RTTNews,/news/stocks/immutep-s-eftilagimod-alfa-combination-shows-positive-phase-iib-results-in-head-neck-cancer-trial-1033548782,positive,0.9409629106521606
7/12/2024 2:27:31 PM,Novo’s Ozempic linked to improved brain health: study,Seeking Alpha,https://seekingalpha.com/news/4123974-novos-ozempic-linked-to-improved-brain-health-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8598303198814392
7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8902468085289001
7/15/2024 9:57:55 PM,Immutep Up as Combo Therapy Meets Carcinoma Study Goals,Benzinga,/news/stocks/immutep-up-as-combo-therapy-meets-carcinoma-study-goals-1033556630,positive,0.7207992672920227
7/16/2024 10:22:52 AM,Maintaining Hold: Balancing Merck’s Product Prospects with Market Uncertainties,TipRanks,/news/stocks/maintaining-hold-balancing-merck-s-product-prospects-with-market-uncertainties-1033559338,neutral,0.8600073456764221
7/16/2024 5:33:42 PM,3 Biotech Stocks to Buy in Case of Another Pandemic,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-in-case-of-another-pandemic-1033560541,neutral,0.8967233896255493
7/17/2024 10:30:00 AM,3 Top Cancer Treatment Stocks to Buy Now,InvestorPlace,/news/stocks/3-top-cancer-treatment-stocks-to-buy-now-1033563384,neutral,0.8678482174873352
7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7739253044128418
7/22/2024 1:02:13 AM,Kamala Harris' potential impact on health care stocks,Seeking Alpha,https://seekingalpha.com/news/4126065-kamala-harris-potential-impact-health-care-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49974918365478516
7/22/2024 6:47:04 AM,Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating,TipRanks,/news/stocks/merck-co-poised-for-growth-strong-q2-performance-and-promising-pipeline-fuel-buy-rating-1033576927,positive,0.950093686580658
7/23/2024 11:31:42 AM,"Merck RSV preventative therapy succeeds in infants in challenge to Sanofi, Astra",Seeking Alpha,https://seekingalpha.com/news/4126677-merck-rsv-therapy-succeeds-trial-infants?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8949316740036011
7/23/2024 1:53:55 PM,Merck's Phase 2b/3 Study Of Clesrovimab To Protect Infants From RSV Disease Meets Primary Goals. ,RTTNews,/news/stocks/merck-s-phase-2b-3-study-of-clesrovimab-to-protect-infants-from-rsv-disease-meets-primary-goals-1033582072,positive,0.5108755826950073
7/23/2024 5:19:26 PM,Merck declares $0.77 dividend,Seeking Alpha,https://seekingalpha.com/news/4126935-merck-declares-077-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.928073525428772
7/25/2024 1:11:49 PM,"ServiceNow turns heads with impressive results, rev gains on gen-AI",Seeking Alpha,https://seekingalpha.com/news/4128264-servicenow-turns-heads-with-impressive-results-rev-gains-on-gen-ai?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.945824384689331
7/26/2024 12:09:45 PM,"Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and more",Seeking Alpha,https://seekingalpha.com/news/4128914-dividend-roundup-wells-fargo-general-motors-merck-delta-air-lines-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9455333352088928
7/26/2024 12:37:22 PM,"Pfizer, Merck bladder cancer therapy endorsed for approval in EU",Seeking Alpha,https://seekingalpha.com/news/4128941-pfizer-merck-bladder-cancer-drug-endorsed-eu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5862034559249878
7/26/2024 2:34:44 PM,Merck Gets Positive CHMP Opinion For Keytruda Plus Padcev To Treat Urothelial Carcinoma ,RTTNews,/news/stocks/merck-gets-positive-chmp-opinion-for-keytruda-plus-padcev-to-treat-urothelial-carcinoma-1033600020,positive,0.9452170729637146
7/26/2024 7:00:38 PM,"Catalyst Watch: Tech blitz with Apple, Amazon, Microsoft, and Meta on tap for earnings",Seeking Alpha,https://seekingalpha.com/news/4129063-catalyst-watch-tech-blitz-with-apple-amazon-microsoft-and-meta-on-tap-for-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9092090129852295
7/27/2024 8:56:00 PM,Wall Street in the haze of the tech selloff as the AI promise lingers - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4129216-wall-street-in-the-haze-of-the-tech-selloff-as-the-ai-promise-lingers-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6713942289352417
7/28/2024 12:00:00 PM,"Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4129069-earnings-week-ahead-msft-amzn-aapl-meta-qcom-pfe-mcd-sbux-ma-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9346819519996643
7/28/2024 2:00:00 PM,Most U.S. pharmas don't pay any U.S. income tax,Seeking Alpha,https://seekingalpha.com/news/4129257-most-us-pharmas-dont-pay-any-us-income-tax?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9261671304702759
7/29/2024 3:01:13 PM,Here's what Wall Street expects from Merck's earnings report,Markets Insider Automation,/news/stocks/merck_co-stock-q2-earnings-preview-1033606150,neutral,0.9062901735305786
7/29/2024 3:04:21 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4129508-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8660826683044434
7/29/2024 6:07:23 PM,Merck Q2 Earnings Preview: Beat/raise likely with focus on Winrevair launch,Seeking Alpha,https://seekingalpha.com/news/4129663-merck-q2-earnings-preview-beatraise-likely-with-focus-on-winrevair-launch?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8396113514900208
7/30/2024 10:31:26 AM,"Merck Non-GAAP EPS of $2.28 beats by $0.14, revenue of $16.1B beats by $260M",Seeking Alpha,https://seekingalpha.com/news/4129949-merck-non-gaap-eps-of-2_28-beats-0_14-revenue-of-16_1b-beats-260m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4978320300579071
7/30/2024 10:49:32 AM,"Merck in charts: KEYTRUDA shows consistent growth past 3 years, rises ~16% in Q2",Seeking Alpha,https://seekingalpha.com/news/4129960-merck-in-charts-keytruda-shows-consistent-growth-past-3-years-rises-16-in-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9504752159118652
7/30/2024 12:26:30 PM,Evercore ISI Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/evercore-isi-sticks-to-its-buy-rating-for-merck-company-mrk-1033613092,neutral,0.5934228897094727
7/30/2024 12:56:57 PM,"Merck Q2 Results Beat Estimates; Cuts FY24 Adj. EPS View, Lifts Sales Forecast ",RTTNews,/news/stocks/merck-q2-results-beat-estimates-cuts-fy24-adj-eps-view-lifts-sales-forecast-1033611045,positive,0.9031634330749512
7/30/2024 2:00:03 PM,"Biggest stock movers today: PYPL, SOFI, TLRY, CRWD, and more",Seeking Alpha,https://seekingalpha.com/news/4129901-biggest-stock-movers-today-tlry-crwd-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9112063050270081
7/30/2024 2:45:00 PM,Merck&Co hosts conference call for investors,Markets Insider Automation,/news/stocks/merck_co_conference-1030308362,neutral,0.9375288486480713
7/30/2024 2:53:31 PM,"MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q2 2024",InvestorPlace,/news/stocks/mrk-stock-earnings-merck-co-for-q2-of-2024-1033613046,neutral,0.6471875309944153
7/30/2024 4:13:36 PM,"Merck Q2 Results Top Estimates, But Slashes FY24 Earnings Outlook ",RTTNews,/news/stocks/merck-q2-results-top-estimates-but-slashes-fy24-earnings-outlook-1033612817,negative,0.9701875448226929
7/30/2024 5:41:24 PM,Merck nears seven-month low on guidance cut (update),Seeking Alpha,https://seekingalpha.com/news/4129994-merck-stock-watch-q2-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9281488060951233
7/30/2024 7:21:27 PM,GSK shingles vaccine cuts dementia risk,Seeking Alpha,https://seekingalpha.com/news/4130499-gsk-shingles-vaccine-cuts-dementia-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49278974533081055
7/31/2024 7:59:27 AM,Merck & Company (MRK) Receives a Buy from Barclays,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-barclays-1033617370,positive,0.5577507615089417
7/31/2024 9:48:37 AM,Maintaining a Buy: A Balanced View on Merck Amid Gardasil Setbacks and Long-Term Growth Prospects,TipRanks,/news/stocks/maintaining-a-buy-a-balanced-view-on-merck-amid-gardasil-setbacks-and-long-term-growth-prospects-1033617917,positive,0.8716249465942383
7/31/2024 10:47:11 AM,Wells Fargo Sticks to Its Hold Rating for Merck & Company (MRK),TipRanks,/news/stocks/wells-fargo-sticks-to-its-hold-rating-for-merck-company-mrk-1033618691,neutral,0.8493872284889221
7/31/2024 11:00:00 AM,Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?,InvestorPlace,/news/stocks/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making-1033617326,neutral,0.9267992377281189
7/31/2024 11:38:24 AM,Merck & Company (MRK) Gets a Buy from Truist Financial,TipRanks,/news/stocks/merck-company-mrk-gets-a-buy-from-truist-financial-1033619223,neutral,0.6960919499397278
7/31/2024 12:17:35 PM,Buy Rating on Merck & Co. Amid Temporary Setbacks and Strong Growth Outlook,TipRanks,/news/stocks/buy-rating-on-merck-co-amid-temporary-setbacks-and-strong-growth-outlook-1033619499,positive,0.9038373827934265
7/31/2024 12:28:17 PM,Merck & Company (MRK) Gets a Hold from Morgan Stanley,TipRanks,/news/stocks/merck-company-mrk-gets-a-hold-from-morgan-stanley-1033619597,neutral,0.8807441592216492
7/31/2024 1:49:13 PM,Bank of America Securities Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/bank-of-america-securities-reaffirms-their-buy-rating-on-merck-company-mrk-1033620205,neutral,0.8222776055335999
8/1/2024 6:08:15 AM,Buy Rating Affirmed for Merck: Overreaction to Gardasil Dip Offers Opportunity Amid Promising Pipeline,TipRanks,/news/stocks/buy-rating-affirmed-for-merck-overreaction-to-gardasil-dip-offers-opportunity-amid-promising-pipeline-1033625018,positive,0.9427282214164734
8/1/2024 7:27:45 AM,Buy Rating Affirmed for Merck & Co. on Strong Growth Prospects Despite Gardasil’s China Hurdles,TipRanks,/news/stocks/buy-rating-affirmed-for-merck-co-on-strong-growth-prospects-despite-gardasil-s-china-hurdles-1033625470,positive,0.952583909034729
8/1/2024 11:15:21 AM,Moderna drops as lower COVID vaccine sales prompt guidance cut,Seeking Alpha,https://seekingalpha.com/news/4132092-moderna-stock-drops-guidance-cut?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9591776728630066
8/2/2024 2:47:48 PM,Argus Research Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/argus-research-remains-a-buy-on-merck-company-mrk-1033633851,neutral,0.9467526078224182
8/2/2024 6:22:14 PM,What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.,InvestorPlace,/news/stocks/what-are-the-hottest-biotech-stocks-right-now-3-top-picks-1033633924,neutral,0.8953362703323364
8/4/2024 2:54:00 PM,19 out of 21 Healthcare companies topped profit estimates this week: Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4132480-healthcare-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6591749787330627
8/5/2024 11:16:10 AM,Buy Rating Affirmed: Merck’s Strong Long-Term Outlook in China’s HPV Vaccine Market,TipRanks,/news/stocks/buy-rating-affirmed-merck-s-strong-long-term-outlook-in-china-s-hpv-vaccine-market-1033639877,positive,0.9510130286216736
8/6/2024 11:29:00 AM,"Merck, Daiichi Sankyo expand cancer drug deal",Seeking Alpha,https://seekingalpha.com/news/4134749-merck-daiichi-sankyo-expand-cancer-drug-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8345942497253418
8/6/2024 2:11:29 PM,"Daiichi Sankyo, Merck Expand Partnership To Include Merck's MK-6070 ",RTTNews,/news/stocks/daiichi-sankyo-merck-expand-partnership-to-include-merck-s-mk-6070-1033644674,positive,0.8329144716262817
8/6/2024 6:27:02 PM,Organon extends selloff after Q2 results,Seeking Alpha,https://seekingalpha.com/news/4135250-organon-stock-extends-selloff-q2-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9131352305412292
8/8/2024 10:30:00 AM,The 3 Best Biotech Stocks to Buy in August 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-august-2024-1033659856,neutral,0.8261002898216248
8/8/2024 11:09:19 AM,Merck lung cancer combo therapy fails in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/4137016-merck-lung-cancer-combo-therapy-fails-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8015590310096741
8/8/2024 1:55:55 PM,Merck Discontinues Phase 3 KeyVibe-008 Study In Extensive-stage Small Cell Lung Cancer ,RTTNews,/news/stocks/merck-discontinues-phase-3-keyvibe-008-study-in-extensive-stage-small-cell-lung-cancer-1033660217,neutral,0.8733277320861816
8/9/2024 11:30:23 AM,Merck to buy experimental B-cell depletion therapy for $700M in cash upfront,Seeking Alpha,https://seekingalpha.com/news/4137959-merck-to-buy-experimental-b-cell-depletion-therapy-for-700m-in-cash-upfront?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5226004719734192
8/9/2024 1:14:20 PM,Merck To Buy Investigational B-Cell Depletion Therapy CN201 From Curon Biopharma For Initial $700 Mn ,RTTNews,/news/stocks/merck-to-buy-investigational-b-cell-depletion-therapy-cn201-from-curon-biopharma-for-initial-700-mn-1033668543,neutral,0.6477310657501221
8/9/2024 3:13:05 PM,74 S&P 500 stocks that can beat the cash yield - BofA,Seeking Alpha,https://seekingalpha.com/news/4138195-74-sp-500-stocks-that-can-beat-the-cash-yield-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6393481492996216
8/11/2024 5:20:50 PM,"Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray ",RTTNews,/news/stocks/weekly-review-antx-downsizes-aldx-aces-dry-eye-disease-trial-fda-oks-1st-epinephrine-nasal-spray-1033672016,neutral,0.5240261554718018
8/13/2024 12:16:53 PM,Jefferies Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/jefferies-keeps-their-buy-rating-on-merck-company-mrk-1033683012,neutral,0.9188081622123718
8/13/2024 2:12:02 PM,Buy Rating on Merck & Company: Pipeline Potential and Strategic Positioning Despite TIGIT Setbacks,TipRanks,/news/stocks/buy-rating-on-merck-company-pipeline-potential-and-strategic-positioning-despite-tigit-setbacks-1033683425,positive,0.9420907497406006
8/14/2024 10:15:00 AM,3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct,InvestorPlace,/news/stocks/3-pharmaceutical-stocks-that-can-surge-higher-even-if-the-markets-correct-1033687347,positive,0.85259610414505
8/14/2024 6:27:44 PM,Genprex stock slides 14% following Reqorsa study updates,Seeking Alpha,https://seekingalpha.com/news/4139963-genprex-stock-slides-following-reqorsa-study-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9531115293502808
8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9052250385284424
8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.802365779876709
8/17/2024 2:09:07 PM,Trending stocks this week as U.S. equities notch their best week of 2024,Seeking Alpha,https://seekingalpha.com/news/4141247-trending-stocks-this-week-as-us-equities-notch-their-best-week-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7283941507339478
8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.578403890132904
8/22/2024 12:57:00 PM,Merck receives Health Canada approval for Keytruda in the treatment of urothelial cancer,Seeking Alpha,https://seekingalpha.com/news/4142785-merck-receives-health-canada-approval-for-keytruda-in-the-treatment-of-urothelial-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9310302734375
8/22/2024 2:17:01 PM,Health Canada Approves Keytruda-Padcev Combo For Certain Patients With Urothelial Cancer ,RTTNews,/news/stocks/health-canada-approves-keytruda-padcev-combo-for-certain-patients-with-urothelial-cancer-1033714384,positive,0.8877000212669373
8/23/2024 3:25:50 PM,"Merck, Bristol Myers cancer drugs included in September FDA advisory panel meeting",Seeking Alpha,https://seekingalpha.com/news/4143379-merck-bristol-myers-cancer-drugs-included-september-fda-advisory-panel-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9249929189682007
8/26/2024 1:16:22 PM,Merck's Winrevair Gets Approval In Pulmonary Arterial Hypertension In Europe ,RTTNews,/news/stocks/merck-s-winrevair-gets-approval-in-pulmonary-arterial-hypertension-in-europe-1033721571,positive,0.9314600229263306
8/26/2024 3:40:35 PM,Merck wins EU nod for rare lung disease drug Winrevair,Seeking Alpha,https://seekingalpha.com/news/4143819-merck-wins-eu-nod-for-rare-lung-disease-drug-winrevair?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.874662458896637
8/26/2024 8:02:35 PM,Merck snaps six straight sessions of gains,Seeking Alpha,https://seekingalpha.com/news/4143920-merck-snaps-six-straight-sessions-of-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6358718872070312
8/28/2024 3:38:52 AM,Astellas : EC Approves PADCEV Combination For First-Line Treatment Of Advanced Urothelial Cancer ,RTTNews,/news/stocks/astellas-ec-approves-padcev-combination-for-first-line-treatment-of-advanced-urothelial-cancer-1033726830,positive,0.9338729381561279
8/28/2024 11:05:06 AM,Cantor Fitzgerald Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-merck-company-mrk-1033729422,neutral,0.9171469211578369
8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8434954881668091
8/29/2024 10:55:11 AM,Merck stops two more cancer trials over poor results,Seeking Alpha,https://seekingalpha.com/news/4144975-merck-stops-two-more-cancer-trials-over-poor-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9609310626983643
8/30/2024 9:17:16 AM,Hold Rating on Merck Amidst Rising Competition and Market Dynamics in China’s Vaccine Sector,TipRanks,/news/stocks/hold-rating-on-merck-amidst-rising-competition-and-market-dynamics-in-china-s-vaccine-sector-1033736605,negative,0.7551761269569397
8/30/2024 2:18:33 PM,NuCana plunges after trial setback for cancer drug,Seeking Alpha,https://seekingalpha.com/news/4145521-nucana-stock-gains-despite-trial-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9518116116523743
8/31/2024 9:37:21 AM,IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA ,RTTNews,/news/stocks/io-biotech-s-phase-3-trial-data-fails-to-show-superiority-in-orr-for-io102-io103-with-keytruda-1033737961,negative,0.8604998588562012
9/1/2024 7:26:06 PM,"Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies ",RTTNews,/news/stocks/weekly-biotech-buzz-bmrn-cuts-jobs-fda-approves-new-mpox-vaccine-mrk-halts-2-keytruda-studies-1033738673,negative,0.7506183385848999
9/2/2024 4:35:44 AM,Biotech Stocks Facing FDA Decision In September 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2024-1033738787,neutral,0.9196612238883972
9/3/2024 12:25:15 AM,Buy Rating Affirmed for Merck Amid Long-Term Growth Potential Despite Near-Term Challenges,TipRanks,/news/stocks/buy-rating-affirmed-for-merck-amid-long-term-growth-potential-despite-near-term-challenges-1033741825,positive,0.9507911801338196
9/3/2024 11:44:19 AM,Merck’s Keytruda with Pfizer’s Padcev approved in EU for first-line bladder cancer,Seeking Alpha,https://seekingalpha.com/news/4146053-mercks-keytruda-with-pfizers-padcev-approved-in-eu-for-first-line-bladder-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7387112379074097
9/3/2024 11:56:33 AM,Merck & Company (MRK) Receives a Buy from Evercore ISI,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-evercore-isi-1033744292,positive,0.5931695103645325
9/3/2024 7:29:35 PM,Keros gains after trial update on lung disorder therapy,Seeking Alpha,https://seekingalpha.com/news/4146385-keros-stock-gains-trial-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.394027978181839
9/5/2024 2:59:46 AM,Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada ,RTTNews,/news/stocks/merck-s-winrevair-approved-for-pulmonary-arterial-hypertension-in-canada-1033748977,positive,0.9041691422462463
9/6/2024 7:00:22 PM,"Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print",Seeking Alpha,https://seekingalpha.com/news/4147709-catalyst-watch-apples-iphone-event-oracle-earnings-google-antitrust-trial-and-the-august-cpi-print?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7490698099136353
9/7/2024 5:00:17 PM,"Merck, Daiichi post mid-stage data for novel lung cancer drug",Seeking Alpha,https://seekingalpha.com/news/4147833-merck-daiichi-post-trial-data-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5818043351173401
9/8/2024 4:49:26 AM,Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial ,RTTNews,/news/stocks/merck-daiichi-sankyo-s-ifinatamab-deruxtecan-shows-promising-results-in-phase-2-lung-cancer-trial-1033755152,positive,0.9275522232055664
9/9/2024 6:30:18 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033756583,positive,0.5521676540374756
9/9/2024 11:16:16 AM,Merck & Company (MRK) Receives a Buy from Truist Financial,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-truist-financial-1033757953,positive,0.5044788718223572
9/9/2024 11:40:18 AM,Summit stock soars as lung cancer drug beats Merck’s Keytruda in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4147951-summit-stock-soars-as-lung-cancer-drug-beats-mercks-keytruda-in-late-stage-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6257866621017456
9/9/2024 12:16:17 PM,Jefferies Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/jefferies-sticks-to-its-buy-rating-for-merck-company-mrk-1033758124,neutral,0.7855506539344788
9/9/2024 2:00:23 PM,"Biggest stock movers today: BIG, PLTR, SMMT, and more",Seeking Alpha,https://seekingalpha.com/news/4147894-biggest-stock-movers-today-big-pltr-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9159988164901733
9/9/2024 5:35:36 PM,"Summit a ‘top pick’ at Citi after ‘unprecedented’ trial results, bull rally",Seeking Alpha,https://seekingalpha.com/news/4148099-summit-a-top-pick-at-citi-after-unprecedented-trial-results-bull-rally?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.624699056148529
9/10/2024 7:21:12 PM,UBS updates its ‘election watch’ stocks to match new winning probabilities,Seeking Alpha,https://seekingalpha.com/news/4148454-ubs-updates-its-election-watch-stocks-to-match-new-winning-probabilities?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6845300793647766
9/10/2024 10:56:30 PM,16 new GLP-1 weight-loss drugs could be launched by 2029: report,Seeking Alpha,https://seekingalpha.com/news/4148522-16-new-glp-1-weight-loss-drugs-could-be-launched-by-2029-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8558949828147888
9/11/2024 10:56:14 AM,Merck’s HPV vaccine meets key goals in Japanese study,Seeking Alpha,https://seekingalpha.com/news/4148592-mercks-hpv-vaccine-meets-key-goals-in-japanese-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6530728340148926
9/12/2024 1:35:30 PM,Health Canada Approves Merck's Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours ,RTTNews,/news/stocks/health-canada-approves-merck-s-keytruda-as-a-monotherapy-to-treat-msi-h-or-dmmr-solid-tumours-1033766503,positive,0.7885648608207703
9/12/2024 5:46:02 PM,Moderna cites 2025 launch for Merck partnered cancer vaccine: report,Seeking Alpha,https://seekingalpha.com/news/4149193-moderna-sees-2025-launch-skin-cancer-shot?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9179738163948059
9/13/2024 5:56:21 AM,Merck’s New Cancer Treatments Poised to Transform Standard of Care: A Strong Buy Rating,TipRanks,/news/stocks/merck-s-new-cancer-treatments-poised-to-transform-standard-of-care-a-strong-buy-rating-1033769470,positive,0.8902653455734253
9/13/2024 12:17:52 PM,Moderna extends losses as R&D Day updates lead to downgrades,Seeking Alpha,https://seekingalpha.com/news/4149405-moderna-extends-losses-as-rd-day-updates-lead-to-downgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9598211050033569
9/13/2024 4:22:07 PM,Moderna continues to decline as Oppenheimer latest to downgrade,Seeking Alpha,https://seekingalpha.com/news/4149599-moderna-continues-decline-oppenheimer-latest-downgrade?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.960155725479126
9/13/2024 6:03:12 PM,Merck goes ex dividend Monday,Seeking Alpha,https://seekingalpha.com/news/4149663-merck-goes-ex-dividend-monday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8248069286346436
9/13/2024 7:22:20 PM,"Summit boosts Instil, BioNTech as lead drug beats Merck’s Keytruda",Seeking Alpha,https://seekingalpha.com/news/4149697-summit-instil-biontech-merck-beating-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.827082633972168
9/13/2024 7:36:33 PM,Arcus up 4% following Merck Welireg kidney cancer data,Seeking Alpha,https://seekingalpha.com/news/4149696-arcus-up-4-following-merck-welireg-kidney-cancer-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9366475343704224
9/14/2024 11:16:13 AM,"GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial",Seeking Alpha,https://seekingalpha.com/news/4149777-gsk-iteos-lung-cancer-drug-outperforms-jemperli?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9513912796974182
9/14/2024 11:57:19 AM,Merck Keytruda cuts mortality risk in gastric cancer by 20%,Seeking Alpha,https://seekingalpha.com/news/4149778-merck-keytruda-cuts-mortality-risk-gastric-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8964040279388428
9/14/2024 2:55:37 PM,Trending stocks this week as market bounces back from selloff,Seeking Alpha,https://seekingalpha.com/news/4149790-trending-stocks-as-market-bounces-back-from-selloff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8425265550613403
9/14/2024 4:20:02 PM,Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer,Seeking Alpha,https://seekingalpha.com/news/4149793-merck-keytruda-cuts-mortality-risk-cervical-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9111688137054443
9/14/2024 5:15:24 PM,Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer,Seeking Alpha,https://seekingalpha.com/news/4149794-merck-posts-trial-win-keytruda-liver-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7694892883300781
9/14/2024 7:37:59 PM,J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report,Seeking Alpha,https://seekingalpha.com/news/4149797-jj-leads-h1-2024-healthcare-dealmaking?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9156707525253296
9/15/2024 2:07:52 PM,Do queasy side effects mean the end of weight-loss drug stock hype?,Seeking Alpha,https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6545578837394714
9/15/2024 6:53:50 PM,Merck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer Trial ,RTTNews,/news/stocks/merck-keytruda-combination-cuts-death-risk-by-34-in-late-stage-breast-cancer-trial-1033772201,positive,0.9386938810348511
9/16/2024 9:14:16 PM,"BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC",Seeking Alpha,https://seekingalpha.com/news/4150143-beyondspring-plinabulin-merck-keytruda-combo-shows-promise-nsclc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9440937638282776
9/17/2024 10:56:01 AM,"Merck, Daiichi post late-stage trial win for novel lung cancer therapy",Seeking Alpha,https://seekingalpha.com/news/4150235-merck-daiichi-post--trial-win-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8574848771095276
9/17/2024 12:44:50 PM,"Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study ",RTTNews,/news/stocks/daiichi-sankyo-merck-s-patritumab-deruxtecan-meets-primary-goal-in-herthena-lung02-phase-3-study-1033776727,neutral,0.6121776700019836
9/17/2024 2:12:11 PM,BioNTech raised to buy at Jefferies on new cancer drug,Seeking Alpha,https://seekingalpha.com/news/4150351-biontech-stock-raised-buy-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7714704871177673
9/18/2024 11:08:48 AM,Merck’s Keytruda label expanded in the U.S. for mesothelioma,Seeking Alpha,https://seekingalpha.com/news/4150570-merck-keytruda-approved-fda-mesothelioma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9401400089263916
9/18/2024 1:52:17 PM,Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults ,RTTNews,/news/stocks/merck-keytruda-plus-chemotherapy-gets-fda-approval-for-malignant-pleural-mesothelioma-in-adults-1033779966,positive,0.9323076009750366
9/19/2024 9:18:23 AM,Merck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market Potential,TipRanks,/news/stocks/merck-company-buy-rating-justified-by-keytruda-s-performance-and-gardasil-s-market-potential-1033783146,positive,0.6933955550193787
9/20/2024 7:00:55 PM,"Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers",Seeking Alpha,https://seekingalpha.com/news/4151613-catalyst-watch-spotlight-on-micron-southwest-airlines-and-fomc-speakers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8940790295600891
9/23/2024 10:05:52 AM,Cautious Optimism for Merck’s Tulisokibart Amid Competitive Market: Hold Rating Maintained,TipRanks,/news/stocks/cautious-optimism-for-merck-s-tulisokibart-amid-competitive-market-hold-rating-maintained-1033790225,neutral,0.4890282154083252
9/24/2024 4:16:22 PM,Merck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia Virus ,RTTNews,/news/stocks/merck-announces-expansion-of-nobivac-nxt-platform-for-treatment-of-feline-leukemia-virus-1033794269,positive,0.8321091532707214
9/24/2024 6:47:46 PM,Revolution Medicines added to JPMorgan focus list due to NSCLC asset,Seeking Alpha,https://seekingalpha.com/news/4152850-revolution-medicines-added-jpmorgan-focus-list-due-nsclc-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6621286869049072
9/24/2024 9:45:22 PM,"Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting",Seeking Alpha,https://seekingalpha.com/news/4152864-bristol-merck-checkpoint-inhibitors-focus-fda-advisory-committee-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9367879033088684
9/25/2024 11:13:49 AM,Merck fails in late-stage trial for Keytruda combo in colon cancer,Seeking Alpha,https://seekingalpha.com/news/4153013-merck-fails--trial-keytruda-colon-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8743191361427307
9/25/2024 12:56:17 PM,Merck Reports Approval In Japan For KEYTRUDA Regimen For Certain Patients With NSCLC ,RTTNews,/news/stocks/merck-reports-approval-in-japan-for-keytruda-regimen-for-certain-patients-with-nsclc-1033796320,positive,0.9204087257385254
9/25/2024 1:17:24 PM,Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival ,RTTNews,/news/stocks/merck-says-phase-3-keyform-007-study-did-not-meet-primary-goal-of-overall-survival-1033796387,negative,0.8972664475440979
9/26/2024 8:22:49 AM,Barclays Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-merck-company-mrk-1033800176,neutral,0.8047251105308533
9/26/2024 8:26:54 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Merck & Company (MRK) and Omnicell (OMCL),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-merck-company-mrk-and-omnicell-omcl-1033800157,negative,0.9320059418678284
9/26/2024 11:57:34 AM,Evaxion stock jumps on expanded vaccine development pact with MSD,Seeking Alpha,https://seekingalpha.com/news/4153626-evaxion-stock-jumps-on-expanded-vaccine-development-pact-with-msd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.746958315372467
9/26/2024 5:49:21 PM,"Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use",Seeking Alpha,https://seekingalpha.com/news/4153858-merck-bristol-myers-face-setback-wider-opdivo-keytruda-use?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6757488250732422
9/27/2024 1:33:33 PM,Summit Therapeutics downgraded at Citi on valuation,Seeking Alpha,https://seekingalpha.com/news/4154099-summit-therapeutics-stock-downgraded-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6552080512046814
9/27/2024 8:02:37 PM,Merck snaps six straight sessions of losses,Seeking Alpha,https://seekingalpha.com/news/4154259-merck-snaps-six-straight-sessions-of-losses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6663822531700134
9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.941364049911499
9/29/2024 4:28:46 PM,Stocks with the highest consensus of expected ROE growth - Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/4154349-stocks-with-the-highest-consensus-of-expected-roe-growth-goldman-sachs-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5588743090629578
10/1/2024 7:35:29 PM,U.S. port strike expected to have limited impact on healthcare supply chain: HHS,Seeking Alpha,https://seekingalpha.com/news/4155196-us-port-strike-have-limited-impact-medical-supplies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9400646090507507
10/2/2024 4:38:13 PM,"Gritstone downgraded by Jones, B. Riley over cancer vaccine data",Seeking Alpha,https://seekingalpha.com/news/4155615-gritstone-downgraded-by-jones-b-riley-over-cancer-vaccine-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5238752365112305
10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7824940085411072
10/4/2024 4:11:38 PM,"EU regulators reviewing safety of finasteride, dutasteride",Seeking Alpha,https://seekingalpha.com/news/4156515-eu-regulators-reviewing-safety-of-finasteride-dutasteride?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9076415300369263
10/4/2024 6:02:06 PM,Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August,Seeking Alpha,https://seekingalpha.com/news/4156522-q3-pharma-biotech-layoffs-charts-more-than-1000-each-july-august?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9607917070388794
10/7/2024 2:15:30 AM,Barclays Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/barclays-remains-a-buy-on-merck-company-mrk-1033823281,neutral,0.9307043552398682
10/8/2024 11:21:59 AM,Merck posts late-stage trial win for Keytruda in head and neck cancer,Seeking Alpha,https://seekingalpha.com/news/4156939-merck-posts-phase-3-trial-win-keytruda?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9407768249511719
10/8/2024 6:03:33 PM,Harris home health care benefit likely funded through Medicare drug negotiations savings,Seeking Alpha,https://seekingalpha.com/news/4157079-harris-home-health-care-benefit-could-funded-through-medicare-drug-negotiations-savings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8432395458221436
10/8/2024 8:47:25 PM,Arcus a new overweight at Wells Fargo on potential of casdatifan in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/4157111-arcus-new-overweight-wells-fargo-potential-casdatifan-kidney-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.672888994216919
10/10/2024 9:31:07 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Masimo (MASI), Baxter International (BAX) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-masimo-masi-baxter-international-bax-and-merck-company-mrk-1033835349,negative,0.9378941655158997
10/11/2024 11:26:04 AM,Maintaining Hold on Merck Amid Modest Commercial Prospects for Clesrovimab,TipRanks,/news/stocks/maintaining-hold-on-merck-amid-modest-commercial-prospects-for-clesrovimab-1033839039,negative,0.6343178153038025
10/14/2024 12:53:38 PM,"Exelixis & Merck sign development collaboration for head, neck cancer treatment and renal cell carcinoma",Seeking Alpha,https://seekingalpha.com/news/4158193-exelixis-merck-sign-development-collaboration-for-head-neck-cancer-treatment-and-renal-cell-carcinoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5210965871810913
10/14/2024 2:19:01 PM,Eight stocks positioned for short sales – Oppenheimer Asset Management,Seeking Alpha,https://seekingalpha.com/news/4158231-eight-stocks-positioned-for-short-sales-oppenheimer-asset-management?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9314119219779968
10/14/2024 3:03:23 PM,"Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG ",RTTNews,/news/stocks/exelixis-merck-sign-clinical-development-deal-to-evaluate-zanzalintinib-with-keytruda-welireg-1033842874,positive,0.8665406107902527
10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7325470447540283
10/18/2024 1:06:21 AM,Merck's Clesrovimab Lowers RSV Disease And Hospitalization In Preterm And Full-term Infants ,RTTNews,/news/stocks/merck-s-clesrovimab-lowers-rsv-disease-and-hospitalization-in-preterm-and-full-term-infants-1033857248,positive,0.7543079257011414
10/18/2024 7:05:34 AM,Barclays Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-merck-company-mrk-1033858409,neutral,0.8047251105308533
10/18/2024 5:05:26 PM,BioNTech and Moderna: A tale of two mRNA developers,Seeking Alpha,https://seekingalpha.com/news/4175119-biontech-and-moderna-a-tale-of-two-m-rna-developers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9157522916793823
10/20/2024 9:23:38 AM,Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment ,RTTNews,/news/stocks/gilead-and-merck-report-phase-2-results-for-islatravir-and-lenacapavir-combination-in-hiv-treatment-1033860875,positive,0.911800742149353
10/20/2024 11:00:09 AM,"Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study",TipRanks,/news/stocks/gilead-merck-announce-from-phase-2-islatravir-lenacapavir-combo-study-1033861100,positive,0.6439176797866821
10/23/2024 5:05:17 AM,Merck & Company (MRK) Receives a Buy from Berenberg Bank,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-berenberg-bank-1033876802,positive,0.5041230916976929
10/23/2024 10:50:29 AM,"Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Disc Medicine (IRON) and R1 RCM (RCM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-disc-medicine-iron-and-r1-rcm-rcm-1033878699,neutral,0.9223805069923401
10/23/2024 11:10:39 AM,Merck acquires Modifi Biosciences for $30M upfront,TipRanks,/news/stocks/merck-acquires-modifi-biosciences-for-30m-upfront-1033879131,neutral,0.911467969417572
10/23/2024 12:06:04 PM,Merck & Company (MRK) Receives a Buy from Jefferies,TipRanks,/news/stocks/merck-company-mrk-receives-a-buy-from-jefferies-1033879727,neutral,0.5585116147994995
10/23/2024 12:20:41 PM,"PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial",TipRanks,/news/stocks/pmv-provides-update-on-phase-2-phase-1b-portions-of-pynnacle-trial-1033879806,neutral,0.9504150152206421
10/23/2024 3:43:37 PM,Merck buys Modifi for $30M plus up to $1.3B in potential payments,Seeking Alpha,https://seekingalpha.com/news/4196085-merck-buys-modifi-for-30m-plus-up-to-13b-in-potential-payments?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7593131065368652
10/23/2024 9:45:25 PM,"Pfizer, Merck pneumonia shots gain ACIP endorsement for wider indication",Seeking Alpha,https://seekingalpha.com/news/4197601-pfizer-merck-pneumonia-shots-gain-acip-endorsement-wider-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.773768961429596
10/24/2024 4:12:25 AM,Merck : CDC Recommends CAPVAXIVE For Pneumococcal Vaccination In Adults 50 And Older ,RTTNews,/news/stocks/merck-cdc-recommends-capvaxive-for-pneumococcal-vaccination-in-adults-50-and-older-1033881942,neutral,0.7023484706878662
10/24/2024 6:46:49 AM,Barclays Sticks to Its Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-merck-company-mrk-1033884974,neutral,0.8152018785476685
10/24/2024 10:57:50 AM,Merck Keytruda cleared in EU for two new indications in gynecologic cancers,Seeking Alpha,https://seekingalpha.com/news/4198764-merck-keytruda-cleared-in-eu-for-two-new-indications-in-gynecologic-cancers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.88080233335495
10/24/2024 11:16:06 AM,Merck: EC approves two new indications for Keytruda,TipRanks,/news/stocks/merck-ec-approves-two-new-indications-for-keytruda-1033887094,positive,0.9149078726768494
10/24/2024 1:55:57 PM,Bank of America Securities Sticks to Their Buy Rating for Merck & Company (MRK),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-merck-company-mrk-1033888191,neutral,0.8709543347358704
10/25/2024 10:20:15 AM,Merck price target lowered to $130 from $140 at Citi,TipRanks,/news/stocks/merck-price-target-lowered-to-130-from-140-at-citi-1033892719,negative,0.807447075843811
10/25/2024 7:00:00 PM,"Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting",Seeking Alpha,https://seekingalpha.com/news/4201499-catalyst-watch-eyes-on-tech-with-apple-amazon-alphabet-and-meta-reporting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9125537276268005
10/26/2024 5:46:00 PM,About 75% of companies that reported earnings this week delivered EPS wins-Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4205854-about-75-of-companies-that-reported-earnings-this-week-delivered-eps-wins-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8234386444091797
10/26/2024 6:36:00 PM,"M&A deals roundup: Merck, Seadrill, Kraft Heinz, Spirit Airlines and more",Seeking Alpha,https://seekingalpha.com/news/4203068-ma-deals-roundup-merck-seadrill-kraft-heinz-spirit-airlines-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9310294389724731
10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9362694025039673
10/28/2024 10:50:43 AM,"Merck, Moderna launch Phase 3 trial evaluating adjuvant V940, Keytruda combo",TipRanks,/news/stocks/merck-moderna-launch-phase-3-trial-evaluating-adjuvant-v940-keytruda-combo-1033901877,neutral,0.6083903908729553
10/29/2024 8:11:02 PM,Shionogi's Xocova effective in preventing symptomatic COVID-19: study,Seeking Alpha,https://seekingalpha.com/news/4220829-shionogi-xocova-effective-in-preventing-symptomatic-covid-19-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8585025668144226
10/30/2024 6:00:51 PM,Merck Q3 Earnings Preview: Focus on Winrevair and Keytruda,Seeking Alpha,https://seekingalpha.com/news/4225101-merck-q3-earnings-preview-focus-on-winrevair-and-keytruda?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.912969172000885
10/30/2024 6:00:59 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033921038,neutral,0.9220908284187317
10/31/2024 10:31:06 AM,"Merck Non-GAAP EPS of $1.57 in-line, revenue of $16.7B beats by $190M",Seeking Alpha,https://seekingalpha.com/news/4227626-merck-non-gaap-eps-of-1_57-in-line-revenue-of-16_7b-beats-190m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7057107090950012
10/31/2024 10:37:07 AM,Merck cuts FY24 adjusted EPS view to $7.72-$7.77 from $7.94-$8.04,TipRanks,/news/stocks/merck-cuts-fy24-adjusted-eps-view-to-7-72--7-77-from-7-94--8-04-1033928410,negative,0.8827697038650513
10/31/2024 10:38:04 AM,"Merck reports Q3 adjusted EPS $1.57, consensus $1.50",TipRanks,/news/stocks/merck-reports-q3-adjusted-eps-1-57-consensus-1-50-1033928399,neutral,0.7179715633392334
10/31/2024 10:42:11 AM,"Merck in charts: KEYTRUDA continues to show an upward trend past 3 years, rises ~17% in Q3",Seeking Alpha,https://seekingalpha.com/news/4227644-merck-in-charts-keytruda-continues-to-show-an-upward-trend-past-3-years-rises-17-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9539526104927063
10/31/2024 11:45:15 AM,Merck & Co Inc. Q3 Profit Falls ,RTTNews,/news/stocks/merck-co-inc-q3-profit-falls-1033926752,negative,0.8122668862342834
10/31/2024 11:54:28 AM,"Merck Cuts FY24 Earnings View, Narrows Sales Forecast After Weak Q3 Earnings - Update ",RTTNews,/news/stocks/merck-cuts-fy24-earnings-view-narrows-sales-forecast-after-weak-q3-earnings-update-1033926798,negative,0.9648860096931458
10/31/2024 1:01:20 PM,Morning Movers: Roblox surges and Estee Lauder sinks following earnings,TipRanks,/news/stocks/morning-movers-roblox-surges-and-estee-lauder-sinks-following-earnings-1033930078,neutral,0.5358021855354309
10/31/2024 1:55:00 PM,"5 stocks to watch on Thursday: AAPL, AMZN, PTON and more",Seeking Alpha,https://seekingalpha.com/news/4228817-5-stocks-to-watch-on-thursday-aapl-amzn-pton-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9342010617256165
10/31/2024 2:04:01 PM,Merck narrows outlook; Keytruda drives Q3 beat despite Gardasil impact,Seeking Alpha,https://seekingalpha.com/news/4227810-merck-stock-watch-after-q-3-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8987888097763062
10/31/2024 4:01:23 PM,"Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz",TipRanks,/news/stocks/microsoft-reports-q1-beat-comcast-weighs-cable-networks-spinoff-morning-buzz-1033931015,neutral,0.8997287154197693
11/1/2024 4:36:16 AM,Merck Reports Steady Q3 2024 Growth Amid Challenges,TipRanks,/news/stocks/merck-reports-steady-q3-2024-growth-amid-challenges-1033934534,positive,0.9476367831230164
11/1/2024 9:09:06 AM,Merck & Co.: Hold Rating Amid Declining Gardasil Shipments and Inventory Challenges,TipRanks,/news/stocks/merck-co-hold-rating-amid-declining-gardasil-shipments-and-inventory-challenges-1033936024,negative,0.9683005213737488
11/1/2024 9:20:18 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bristol-myers-squibb-bmy-abbott-laboratories-abt-and-merck-company-mrk-1033936132,negative,0.7605414986610413
11/1/2024 10:45:48 AM,Merck price target lowered to $120 from $140 at BofA,TipRanks,/news/stocks/merck-price-target-lowered-to-120-from-140-at-bofa-1033936825,negative,0.48778656125068665
11/1/2024 11:42:29 AM,Merck price target lowered to $110 from $125 at Wells Fargo,TipRanks,/news/stocks/merck-price-target-lowered-to-110-from-125-at-wells-fargo-1033937256,negative,0.8178372383117676
11/1/2024 12:06:46 PM,Merck & Company: Navigating One-Time Charges and Uncertainty in Gardasil Sales Amidst Strategic Shifts,TipRanks,/news/stocks/merck-company-navigating-one-time-charges-and-uncertainty-in-gardasil-sales-amidst-strategic-shifts-1033937649,negative,0.7861248850822449
11/1/2024 12:17:30 PM,Merck & Company: Overcoming Challenges with Strategic Growth Prospects,TipRanks,/news/stocks/merck-company-overcoming-challenges-with-strategic-growth-prospects-1033937736,positive,0.7643397450447083
11/1/2024 12:35:19 PM,Merck price target lowered to $123 from $130 at Morgan Stanley,TipRanks,/news/stocks/merck-price-target-lowered-to-123-from-130-at-morgan-stanley-1033937879,negative,0.7460890412330627
11/6/2024 1:45:45 PM,Merck price target lowered to $130 from $137 at Guggenheim,TipRanks,/news/stocks/merck-price-target-lowered-to-130-from-137-at-guggenheim-1033963065,negative,0.6851617693901062
11/6/2024 1:50:12 PM,Merck price target lowered to $140 from $145 at Deutsche Bank,TipRanks,/news/stocks/merck-price-target-lowered-to-140-from-145-at-deutsche-bank-1033963052,negative,0.7500989437103271
11/6/2024 8:17:19 PM,SA Asks: How will the U.S. election results impact healthcare stocks?,Seeking Alpha,https://seekingalpha.com/news/4257322-sa-asks-how-will-the-us-election-results-impact-healthcare-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7067018747329712
11/11/2024 12:28:32 PM,Medicenna announces single-agent activity of MDNA11 from dose expansion cohort,TipRanks,/news/stocks/medicenna-announces-single-agent-activity-of-mdna11-from-dose-expansion-cohort-1033993024,neutral,0.5354795455932617
11/11/2024 1:56:02 PM,"Citius Pharmaceuticals, Citius Oncology report promising cancer trial results",TipRanks,/news/stocks/citius-pharmaceuticals-citius-oncology-report-promising-cancer-trial-results-1033993575,positive,0.9439574480056763
11/11/2024 3:47:43 PM,Citius Pharmaceuticals reports positive early stage results of cancer combo treatment,Seeking Alpha,https://seekingalpha.com/news/4274423-citius-pharmaceuticals-reports-positive-early-stage-results-of-cancer-combo-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9192448258399963
11/12/2024 9:05:24 AM,AstraZeneca: Koselugo Phase III Trial Meets Primary Goal In Adults With Neurofibromatosis Type 1 ,RTTNews,/news/stocks/astrazeneca-koselugo-phase-iii-trial-meets-primary-goal-in-adults-with-neurofibromatosis-type-1-1033996886,positive,0.8379989862442017
11/12/2024 11:25:44 AM,AstraZeneca announces Koselugo met primary endpoing in KOMET Phase III trial,TipRanks,/news/stocks/astrazeneca-announces-koselugo-met-primary-endpoing-in-komet-phase-iii-trial-1033999371,positive,0.5383039712905884
11/12/2024 11:56:20 AM,Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial,TipRanks,/news/stocks/merck-and-astrazeneca-announce-results-of-koselugo-in-neurofibromatosis-trial-1033999653,neutral,0.768993079662323
11/12/2024 1:20:39 PM,Ginkgo Bioworks receives $9M milestone payment from Merck partnership,TipRanks,/news/stocks/ginkgo-bioworks-receives-9m-milestone-payment-from-merck-partnership-1034000719,positive,0.7982983589172363
11/12/2024 2:25:52 PM,Ginkgo Bioworks completes first milestone in Merck collaboration,Seeking Alpha,https://seekingalpha.com/news/4280085-ginkgo-bioworks-completes-first-milestone-in-merck-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6146179437637329
11/12/2024 5:53:46 PM,"Merck, AstraZeneca report positive data for Koselugo in adults",Seeking Alpha,https://seekingalpha.com/news/4281322-merck-astrazeneca-report-positive-data-for-koselugo-in-adults?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9457497000694275
11/13/2024 1:32:12 PM,"Zentalis appoints Eastland as CEO, Bruns as CMO, Myers as Chairperson",TipRanks,/news/stocks/zentalis-appoints-eastland-as-ceo-bruns-as-cmo-myers-as-chairperson-1034010009,neutral,0.9480273723602295
11/14/2024 11:55:54 AM,Merck enters exclusive global license for LM-299,TipRanks,/news/stocks/merck-enters-exclusive-global-license-for-lm-299-1034018124,positive,0.6080679893493652
11/14/2024 12:34:01 PM,Merck to buy rights to Chinese cancer drug for up to $3.3B,Seeking Alpha,https://seekingalpha.com/news/4289233-merck-stock-on-watch-cancer-drug-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4989635944366455
11/14/2024 1:27:43 PM,Merck Expands Oncology Pipeline By Securing License For LaNova Medicines' LM-299 ,RTTNews,/news/stocks/merck-expands-oncology-pipeline-by-securing-license-for-lanova-medicines-lm-299-1034016977,positive,0.9282352924346924
11/14/2024 8:05:27 PM,PDS Biotechnology price target lowered to $4.50 from $7 at Alliance Global Partners,TipRanks,/news/stocks/pds-biotechnology-price-target-lowered-to-4-50-from-7-at-alliance-global-partners-1034021067,negative,0.8055418133735657
11/14/2024 8:17:56 PM,Immutep stock jumps 11% on positive data for eftilagimod alpha,Seeking Alpha,https://seekingalpha.com/news/4292053-immutep-stock-jumps-on-positive-data-for-eftilagimod-alpha?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9353776574134827
11/14/2024 9:22:41 PM,Merck initiated with a Peer Perform at Wolfe Research,TipRanks,/news/stocks/merck-initiated-with-a-peer-perform-at-wolfe-research-1034021149,neutral,0.8587729334831238
11/14/2024 11:07:05 PM,Vaccine makers close lower amid reports RFK Jr may head HHS (update),Seeking Alpha,https://seekingalpha.com/news/4292433-vaccines-makers-close-lower-on-reports-rfk-jr-may-head-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9338276982307434
11/14/2024 11:45:18 PM,"Wolfe starts Merck at Peer Perform, notes competitive overhangs",TipRanks,/news/stocks/wolfe-starts-merck-at-peer-perform-notes-competitive-overhangs-1034021613,neutral,0.5149810910224915
11/15/2024 12:25:52 PM,Merck receives CHMP opinion recommending approval of Keytruda,TipRanks,/news/stocks/merck-receives-chmp-opinion-recommending-approval-of-keytruda-1034025162,neutral,0.7324424982070923
11/15/2024 1:40:18 PM,Merck Keytruda endorsed in EU for rare form of cancer,Seeking Alpha,https://seekingalpha.com/news/4294511-merck-keytruda-endorsed-eu-mesothelioma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7821514010429382
11/15/2024 3:39:20 PM,"Want dividend safety, consistency, growth, and a yield? See these 10 names",Seeking Alpha,https://seekingalpha.com/news/4295087-want-dividend-safety-consistency-growth-and-a-yield-see-these-10-names?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9250453114509583
11/15/2024 5:08:27 PM,Vaccine stocks drop on concerns about RFK Jr. heading HHS (update),Seeking Alpha,https://seekingalpha.com/news/4295685-vaccine-stocks-drop-on-concerns-about-rfk-jr-heading-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9465009570121765
11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9049097299575806
11/16/2024 5:09:00 PM,Trending stocks this week as Wall Street sells off amid Fed remarks,Seeking Alpha,https://seekingalpha.com/news/4297347-trending-stocks-this-week-as-wall-street-sells-off-amid-fed-remarks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8001051545143127
11/19/2024 11:50:48 AM,Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial,TipRanks,/news/stocks/merck-announces-positive-results-from-phase-3-mk-3475a-d77-trial-1034036860,positive,0.7702597975730896
11/19/2024 12:14:12 PM,Merck says injectable Keytruda succeeded in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4306047-merck-stock-gains-injectable-keytruda-trial-win?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6134742498397827
11/19/2024 1:51:17 PM,Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals ,RTTNews,/news/stocks/merck-s-phase-3-study-of-subcutaneous-keytruda-to-treat-nsclc-meets-primary-goals-1034035934,neutral,0.531096339225769
11/19/2024 5:05:39 PM,"Walmart higher, Lowe’s lower after earnings: Morning Buzz",TipRanks,/news/stocks/walmart-higher-lowe-s-lower-after-earnings-morning-buzz-1034038609,negative,0.8574807643890381
11/19/2024 5:25:09 PM,Merck raises quarterly dividend to 81c from 77c per share,TipRanks,/news/stocks/merck-raises-quarterly-dividend-to-81c-from-77c-per-share-1034038635,positive,0.9210619926452637
11/19/2024 5:26:41 PM,Merck raises dividend to $0.81/share,Seeking Alpha,https://seekingalpha.com/news/4307985-merck-raises-dividend-to-081share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5780619978904724
11/19/2024 6:44:27 PM,Incyte seesaws on report of potential Merck takeover interest,Seeking Alpha,https://seekingalpha.com/news/4308468-incyte-pares-some-losses-on-report-of-potential-merck-takeover-interest?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8714175820350647
11/19/2024 6:45:13 PM,"Merck ‘linked’ to takeover bid for Incyte, Sky News says",TipRanks,/news/stocks/merck-linked-to-takeover-bid-for-incyte-sky-news-says-1034038905,neutral,0.8126486539840698
11/19/2024 6:49:07 PM,Merck readies new Keytruda version ahead of major regulatory headwinds,Seeking Alpha,https://seekingalpha.com/news/4308470-merck-readies-new-keytruda-version-amid-headwinds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6837248206138611
11/20/2024 1:00:36 PM,Merck target upped at Jefferies after ‘important win’ with subcutaneous Keytruda,TipRanks,/news/stocks/merck-target-upped-at-jefferies-after-important-win-with-subcutaneous-keytruda-1034043450,positive,0.8725200891494751
11/20/2024 2:36:50 PM,"Johnson & Johnson, Merck cutting jobs in China, Bloomberg reports",TipRanks,/news/stocks/johnson-johnson-merck-cutting-jobs-in-china-bloomberg-reports-1034043953,negative,0.90489262342453
11/20/2024 5:01:17 PM,"Target reports downbeat Q3, Comcast plans cable TV spinoff: Morning Buzz",TipRanks,/news/stocks/target-reports-downbeat-q3-comcast-plans-cable-tv-spinoff-morning-buzz-1034044336,neutral,0.8804399371147156
11/20/2024 9:20:55 PM,"Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck",TipRanks,/news/stocks/pyxis-oncology-announces-preliminary-pyx-201-data-collaboration-with-merck-1034045104,neutral,0.8540433645248413
11/20/2024 11:20:12 PM,Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset,Seeking Alpha,https://seekingalpha.com/news/4314379-pyxis-oncologyplummets-38-onpreliminaryphase-1-dataforcancerasset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9697885513305664
11/20/2024 11:20:12 PM,Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset,Seeking Alpha,https://seekingalpha.com/news/4314379-pyxis-oncology-plummets-38-on-preliminary-phase-1-data-for-cancer-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9697885513305664
11/21/2024 3:20:34 PM,"Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade",Seeking Alpha,https://seekingalpha.com/news/4317287-pyxis-stock-craters-amid-phase-1-data-william-blair-downgrade?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8993014097213745
11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7575292587280273
11/22/2024 11:30:57 AM,"U.S. FDA found asthma drug Singular, montelukast impacts the brain, Reuters says",TipRanks,/news/stocks/u-s-fda-found-asthma-drug-singular-montelukast-impacts-the-brain-reuters-says-1034054951,negative,0.6859639883041382
11/22/2024 11:36:22 AM,Merck elects Surendralal Karsanbhai to board of directors,TipRanks,/news/stocks/merck-elects-surendralal-karsanbhai-to-board-of-directors-1034054929,neutral,0.9302305579185486
11/22/2024 11:51:39 AM,Merck says NMPA in China approves Welireg,TipRanks,/news/stocks/merck-says-nmpa-in-china-approves-welireg-1034055055,neutral,0.734686017036438
11/22/2024 1:10:21 PM,Merck Announces Approval For WELIREG In China - Quick Facts ,RTTNews,/news/stocks/merck-announces-approval-for-welireg-in-china-quick-facts-1034054115,neutral,0.8208183646202087
11/22/2024 1:40:48 PM,"Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and others",Seeking Alpha,https://seekingalpha.com/news/4321067-dividend-roundup-general-mills-halliburton-johnson-johnson-coca-cola-and-others?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9470468759536743
11/22/2024 3:02:06 PM,Merck gets Chinese approval for Welireg for VHL tumors,Seeking Alpha,https://seekingalpha.com/news/4321636-merck-gets-chinese-approval-for-welireg-for-vhl-tumors?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5630500912666321
11/22/2024 3:49:51 PM,Merck-marketed asthma drug linked to psychiatric issues: report,Seeking Alpha,https://seekingalpha.com/news/4321980-merck-asthma-drug-linked-to-psychiatric-issues?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.852768063545227
11/22/2024 5:05:33 PM,"Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/amazon-invests-4b-more-in-anthropic-gap-reports-q3-beat-morning-buzz-1034056598,neutral,0.6480697989463806
11/22/2024 7:49:37 PM,Merck & Co. Expands Board with New Director,TipRanks,/news/stocks/merck-co-expands-board-with-new-director-1034056832,neutral,0.8218330144882202
11/22/2024 9:20:08 PM,Merck recommends rejection of TRC Capital’s ‘mini-tender’ offer,TipRanks,/news/stocks/merck-recommends-rejection-of-trc-capital-s-mini-tender-offer-1034056905,neutral,0.7998278141021729
11/22/2024 9:29:00 PM,Merck recommends rejection of TRC Capital’s 'mini-tender' offer,Seeking Alpha,https://seekingalpha.com/news/4323501-merck-recommends-rejection-of-trc-capitals-mini-tender-offer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8383798003196716
11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9368929862976074
11/25/2024 11:50:34 AM,Merck reports ‘positive’ results from Phase 3 ZENITH trial evaluating Winrevair,TipRanks,/news/stocks/merck-reports-positive-results-from-phase-3-zenith-trial-evaluating-winrevair-1034060788,positive,0.9205068349838257
11/25/2024 1:01:14 PM,Merck Reports Positive Topline Results From The Phase 3 ZENITH Study Evaluating WINREVAIR In PAH ,RTTNews,/news/stocks/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating-winrevair-in-pah-1034059822,positive,0.9513436555862427
11/25/2024 3:27:55 PM,Merck Phase 3 study of Winrevair in PAH meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4330240-merck-phase-3-study-of-winrevair-in-pah-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7784403562545776
11/25/2024 4:15:07 PM,"Merck ZENITH data beat expert expectations, says Guggenheim",TipRanks,/news/stocks/merck-zenith-data-beat-expert-expectations-says-guggenheim-1034062536,positive,0.9346961379051208
11/26/2024 11:05:38 AM,Merck & Co. Hold Rating: Balancing Promising Trial Results with Market Dynamics and Future Uncertainties,TipRanks,/news/stocks/merck-co-hold-rating-balancing-promising-trial-results-with-market-dynamics-and-future-uncertainties-1034065895,positive,0.7805598378181458
11/26/2024 1:16:38 PM,Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-merck-company-mrk-1034067041,neutral,0.8016572594642639
11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8861560225486755
11/28/2024 3:33:22 PM,AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe,Seeking Alpha,https://seekingalpha.com/news/4344692-astrazeneca-enhertu-added-for-china-reimbursement?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8657416701316833
11/29/2024 5:00:00 PM,"Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings",Seeking Alpha,https://seekingalpha.com/news/4340728-catalyst-watch-november-jobs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8812246322631836
12/3/2024 11:50:12 AM,Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan,TipRanks,/news/stocks/merck-fda-grants-breakthrough-therapy-designation-to-sacituzumab-tirumotecan-1034092005,positive,0.9333412647247314
12/3/2024 1:49:59 PM,MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or Metastatic NSCLC ,RTTNews,/news/stocks/mrk-sac-tmt-gets-fda-breakthrough-therapy-designation-for-egfr-mutated-advanced-or-metastatic-nsclc-1034091000,positive,0.937381386756897
12/3/2024 4:15:26 PM,Merck gets FDA Breakthrough Therapy designation for sac-TMT,Seeking Alpha,https://seekingalpha.com/news/4359984-merck-gets-fda-breakthrough-therapy-designation-for-sac-tmt?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8294326663017273
12/4/2024 10:15:13 AM,Merck upgraded to Buy from Hold at HSBC,TipRanks,/news/stocks/merck-upgraded-to-buy-from-hold-at-hsbc-1034096577,neutral,0.5197024345397949
12/4/2024 12:05:32 PM,Beam Therapeutics appoints Guindo to its board of directors,TipRanks,/news/stocks/beam-therapeutics-appoints-guindo-to-its-board-of-directors-1034097505,neutral,0.9366495609283447
12/4/2024 1:45:14 PM,Largest borrow rate increases among liquid names,TipRanks,/news/stocks/largest-borrow-rate-increases-among-liquid-names-1034098091,positive,0.7579146027565002
12/4/2024 2:11:17 PM,Incyte gains amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4362559-incyte-gains-amid-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7908907532691956
12/4/2024 2:41:11 PM,"GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ge-vernova-initiated-merck-upgraded-wall-street-s-top-analyst-calls-1034098291,neutral,0.803184449672699
12/4/2024 5:15:25 PM,"Salesforce up after Q3, GM outlines $5B in China business charges: Morning Buzz",TipRanks,/news/stocks/salesforce-up-after-q3-gm-outlines-5b-in-china-business-charges-morning-buzz-1034098728,neutral,0.49498313665390015
12/5/2024 12:07:07 PM,"Merck, Ridgeback Biotherapeutics initiate Phase 3 study of Lagevrio",TipRanks,/news/stocks/merck-ridgeback-biotherapeutics-initiate-phase-3-study-of-lagevrio-1034102539,neutral,0.6911686658859253
12/5/2024 2:12:26 PM,Merck begins trial of molnupiravir for COVID-19 with high risk of disease progression,Seeking Alpha,https://seekingalpha.com/news/4366009-merck-begins-trial-of-molnupiravir-for-covidminus-19-high-risk-of-disease-progression?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5902831554412842
12/8/2024 9:55:05 PM,Merck presents data from Phase 2 waveLINE-007 trial,TipRanks,/news/stocks/merck-presents-data-from-phase-2-waveline-007-trial-1034111203,neutral,0.9408359527587891
12/9/2024 12:01:41 PM,Merck says Phase 3 KEYLYNK-001 trial met primary endpoint,TipRanks,/news/stocks/merck-says-phase-3-keylynk-001-trial-met-primary-endpoint-1034114419,positive,0.849236786365509
12/9/2024 3:07:56 PM,Merck reports positive Phase 2 data for zilovertamab vedotin,Seeking Alpha,https://seekingalpha.com/news/4378308-merck-reports-positive-phase-2-data-for-zilovertamab-vedotin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9495508074760437
12/9/2024 3:32:42 PM,Merck reports mixed results from Keytruda ovarian cancer study,Seeking Alpha,https://seekingalpha.com/news/4378549-merck-reports-mixed-results-from-keytruda-ovarian-cancer-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9665675759315491
12/10/2024 6:41:18 AM,Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Merck & Company (MRK),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cooper-co-coo-and-merck-company-mrk-1034117728,neutral,0.9266283512115479
12/10/2024 9:35:07 AM,Merck price target lowered to $125 from $135 at Berenberg,TipRanks,/news/stocks/merck-price-target-lowered-to-125-from-135-at-berenberg-1034118476,negative,0.578644871711731
12/10/2024 11:15:08 AM,"Ideaya Biosciences doses first patient in IDE161, Keytruda combination trial",TipRanks,/news/stocks/ideaya-biosciences-doses-first-patient-in-ide161-keytruda-combination-trial-1034119086,neutral,0.812957227230072
12/10/2024 12:00:48 PM,Merck reinstated with a Buy at BofA,TipRanks,/news/stocks/merck-reinstated-with-a-buy-at-bofa-1034119716,neutral,0.6365645527839661
12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8290336728096008
12/11/2024 3:25:17 PM,AstraZeneca says 87.5% of Lynparza-treated patients alive at six years in trial,TipRanks,/news/stocks/astrazeneca-says-87-5-of-lynparza-treated-patients-alive-at-six-years-in-trial-1034126300,neutral,0.8353884220123291
12/11/2024 7:04:26 PM,"AstraZeneca, Merck report positive long-term data for Lynparza",Seeking Alpha,https://seekingalpha.com/news/4385679-astrazeneca-merck-report-positive-long-term-data-for-lynparza?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9515169858932495
12/13/2024 12:10:40 PM,Merck announces CHMP opinion recommending conditional approval of Welireg,TipRanks,/news/stocks/merck-announces-chmp-opinion-recommending-conditional-approval-of-welireg-1034135618,neutral,0.8500686883926392
12/13/2024 1:59:29 PM,"Merck: WELIREG Gets Positive EU CHMP Opinion For VHL Tumors, Advanced RCC ",RTTNews,/news/stocks/merck-welireg-gets-positive-eu-chmp-opinion-for-vhl-tumors-advanced-rcc-1034134610,positive,0.9449668526649475
12/13/2024 4:01:05 PM,Merck gets positive EU regulatory opinion for Welireg,Seeking Alpha,https://seekingalpha.com/news/4386260-merck-gets-positive-eu-regulatory-opinion-for-welireg?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9510342478752136
12/16/2024 11:50:31 AM,Merck announces approval of KEYTRUDA in China in combination with chemotherapy,TipRanks,/news/stocks/merck-announces-approval-of-keytruda-in-china-in-combination-with-chemotherapy-1034140826,positive,0.5704931616783142
12/16/2024 1:42:46 PM,"China Approves Merck's Keytruda To Treat Patients With Resectable Stage II, IIIA Or IIIB NSCLC ",RTTNews,/news/stocks/china-approves-merck-s-keytruda-to-treat-patients-with-resectable-stage-ii-iiia-or-iiib-nsclc-1034140010,positive,0.8298442363739014
12/16/2024 9:35:23 PM,"Merck to discontinue Phase 3 KeyVibe-003, KeyVibe-007 trials",TipRanks,/news/stocks/merck-to-discontinue-phase-3-keyvibe-003-keyvibe-007-trials-1034143189,neutral,0.8028687834739685
12/17/2024 12:43:49 AM,Merck ends development of two antibody programs,Seeking Alpha,https://seekingalpha.com/news/4387134-merck-ends-development-two-antibody-programs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6020234227180481
12/17/2024 12:56:49 AM,Merck’s Oncology Strategy Shift: Hold Rating Amid Discontinued Immuno-Oncology Programs,TipRanks,/news/stocks/merck-s-oncology-strategy-shift-hold-rating-amid-discontinued-immuno-oncology-programs-1034143569,neutral,0.6095027923583984
12/17/2024 12:59:29 AM,Bernstein Keeps Their Hold Rating on Merck & Company (MRK),TipRanks,/news/stocks/bernstein-keeps-their-hold-rating-on-merck-company-mrk-1034143616,neutral,0.9106188416481018
12/17/2024 11:50:20 AM,Merck’s Biologics License Application for clesrovimab accepted by FDA,TipRanks,/news/stocks/merck-s-biologics-license-application-for-clesrovimab-accepted-by-fda-1034146082,positive,0.5842652916908264
12/17/2024 1:11:20 PM,Merck: FDA To Review BLA For Clesrovimab - Quick Facts ,RTTNews,/news/stocks/merck-fda-to-review-bla-for-clesrovimab-quick-facts-1034145189,neutral,0.6924546957015991
12/17/2024 5:36:01 PM,Merck application for RSV biologic for infants accepted by FDA,Seeking Alpha,https://seekingalpha.com/news/4387320-merck-application-rsv-biologic-infants-accepted-fda?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7638397216796875
12/17/2024 6:45:36 PM,Barclays fact-checked Trump comments on pharmacy benefit managers,TipRanks,/news/stocks/barclays-fact-checked-trump-comments-on-pharmacy-benefit-managers-1034148099,neutral,0.9219222068786621
12/18/2024 5:36:15 AM,Merck & Company’s Strategic Pivots and Growth Potential: A Buy Rating Justification,TipRanks,/news/stocks/merck-company-s-strategic-pivots-and-growth-potential-a-buy-rating-justification-1034149452,neutral,0.7338154911994934
12/18/2024 11:50:23 AM,Merck and Hansoh Pharma sign exclusive global license agreement for HS-10535,TipRanks,/news/stocks/merck-and-hansoh-pharma-sign-exclusive-global-license-agreement-for-hs-10535-1034151286,positive,0.9345830082893372
12/18/2024 12:19:45 PM,Merck enters obesity drug race in pact with Chinese pharma Hansoh,Seeking Alpha,https://seekingalpha.com/news/4387598-merck-enters-obesity-drug-race-in-pact-with-hansoh?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8321036100387573
12/18/2024 1:28:24 PM,Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535 ,RTTNews,/news/stocks/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-hs-10535-1034150440,positive,0.9215162992477417
12/18/2024 1:36:20 PM,Viking Therapeutics lower after Merck signs pact with Hansoh for GLP-1 drug,TipRanks,/news/stocks/viking-therapeutics-lower-after-merck-signs-pact-with-hansoh-for-glp-1-drug-1034152180,negative,0.9337723255157471
12/18/2024 3:05:23 PM,"Merck’s $2B GLP-1 deal highlights ‘market hunger,’ says H.C. Wainwright",TipRanks,/news/stocks/merck-s-2b-glp-1-deal-highlights-market-hunger-says-h-c-wainwright-1034152713,positive,0.8760968446731567
12/18/2024 3:20:29 PM,Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla,TipRanks,/news/stocks/trump-trade-analyst-says-trump-win-not-as-positive-as-you-d-think-for-tesla-1034152752,neutral,0.7262119650840759
12/18/2024 3:49:06 PM,Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers,Seeking Alpha,https://seekingalpha.com/news/4387714-merck-hansoh-deal-hurts-obesity-drug-developers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6005009412765503
12/18/2024 5:00:52 PM,"MasterCard boosts dividend, Jabil reports Q1 beat: Morning Buzz",TipRanks,/news/stocks/mastercard-boosts-dividend-jabil-reports-q1-beat-morning-buzz-1034153040,positive,0.7714218497276306
12/19/2024 11:50:25 AM,Merck’s doravirine/islatravir combination meets efficacy endpoint in HIV-1,TipRanks,/news/stocks/merck-s-doravirine-islatravir-combination-meets-efficacy-endpoint-in-hiv-1-1034156449,positive,0.9387708902359009
12/19/2024 12:17:30 PM,Merck posts mixed late-stage trial results for HIV treatment,Seeking Alpha,https://seekingalpha.com/news/4388012-merck-stock-slips-trial-data-hiv-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9608737230300903
12/19/2024 2:11:10 PM,"Personalis receives $50M investment from Merck, extends pact with Moderna",TipRanks,/news/stocks/personalis-receives-50m-investment-from-merck-extends-pact-with-moderna-1034157620,positive,0.848853349685669
12/19/2024 2:17:01 PM,Merck Reports Topline Data From Phase 3 Trials Of Doravirine + Islatravir To Treat HIV-1 Infection ,RTTNews,/news/stocks/merck-reports-topline-data-from-phase-3-trials-of-doravirine-islatravir-to-treat-hiv-1-infection-1034155672,positive,0.6108521819114685
12/19/2024 3:02:21 PM,Personalis stock rallies 25% amid $50M Merck investment,Seeking Alpha,https://seekingalpha.com/news/4388098-personalis-stock-rallies-25-amid-50m-merck-investment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.899636447429657
12/19/2024 5:01:13 PM,"Micron sinks on guidance, TripAdvisor to buy Liberty TripAdvisor: Morning Buzz",TipRanks,/news/stocks/micron-sinks-on-guidance-tripadvisor-to-buy-liberty-tripadvisor-morning-buzz-1034158380,neutral,0.8283775448799133
12/20/2024 9:30:15 AM,Merck downgraded to Market Perform from Outperform at BMO Capital,TipRanks,/news/stocks/merck-downgraded-to-market-perform-from-outperform-at-bmo-capital-1034161196,negative,0.910346508026123
12/20/2024 11:50:35 AM,Merck closes exclusive global license agreement for LM-299 from LaNova Medicines,TipRanks,/news/stocks/merck-closes-exclusive-global-license-agreement-for-lm-299-from-lanova-medicines-1034162019,positive,0.784659743309021
12/20/2024 12:30:52 PM,Personalis price target raised to $8 from $7 at BTIG,TipRanks,/news/stocks/personalis-price-target-raised-to-8-from-7-at-btig-1034162519,positive,0.948025643825531
12/20/2024 2:35:24 PM,BTIG reiterates Buy on Viking Therapeutics after Novo’s CagriSema ‘underwhelms’,TipRanks,/news/stocks/btig-reiterates-buy-on-viking-therapeutics-after-novo-s-cagrisema-underwhelms-1034163170,positive,0.9013549089431763
12/20/2024 2:45:21 PM,"Nike downgraded, FedEx upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/nike-downgraded-fedex-upgraded-wall-street-s-top-analyst-calls-1034163244,neutral,0.830590546131134
12/20/2024 3:50:26 PM,Biotech Alert: Searches spiking for these stocks today,TipRanks,/news/stocks/biotech-alert-searches-spiking-for-these-stocks-today-1034163402,neutral,0.7777097821235657
12/20/2024 3:56:59 PM,Merck downgraded by BMO over Keytruda concerns,Seeking Alpha,https://seekingalpha.com/news/4389243-merck-downgraded-by-bmo-over-keytruda-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9111292958259583
12/20/2024 5:00:48 PM,"FedEx to separate Freight unit, Nike reports Q2 beat: Morning Buzz",TipRanks,/news/stocks/fedex-to-separate-freight-unit-nike-reports-q2-beat-morning-buzz-1034163549,neutral,0.8859571218490601
12/20/2024 5:37:55 PM,Strategic Moves in Cardiometabolic Space: Merck’s Buy Rating for Innovative Combination Therapies,TipRanks,/news/stocks/strategic-moves-in-cardiometabolic-space-merck-s-buy-rating-for-innovative-combination-therapies-1034163707,positive,0.8827252984046936
12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9418226480484009
12/28/2024 3:31:10 PM,Here are Morgan Stanley’s key oncology catalysts for 2025,Seeking Alpha,https://seekingalpha.com/news/4391298-morgan-stanley-lists-2025-oncology-catalysts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9273046255111694
12/29/2024 4:55:20 PM,Bernstein Remains a Hold on Merck & Company (MRK),TipRanks,/news/stocks/bernstein-remains-a-hold-on-merck-company-mrk-1034177870,neutral,0.8768776655197144
12/30/2024 9:22:54 PM,Takeda-backed Ascentage Pharma files for $100M IPO,Seeking Alpha,https://seekingalpha.com/news/4391588-takeda-backed-ascentage-pharma-files-for-100m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9013777375221252
12/31/2024 2:20:09 PM,Merck’s sotatercept approved by MHRA to treat PAH,TipRanks,/news/stocks/merck-s-sotatercept-approved-by-mhra-to-treat-pah-1034183415,positive,0.8320227265357971
12/31/2024 2:48:51 PM,Merck gets U.K. approval for sotatercept for PAH,Seeking Alpha,https://seekingalpha.com/news/4391713-merck-gets-u_k_-approval-for-sotatercept-for-pah?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9006326794624329
1/1/2025 2:00:28 PM,Brand prescription drugs to rise an average 4.5% in 2025,Seeking Alpha,https://seekingalpha.com/news/4391754-brand-prescription-drugs-rise-average-4_5-percent-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9456416964530945
1/2/2025 7:35:12 PM,Merck put volume heavy and directionally bearish,TipRanks,/news/stocks/merck-put-volume-heavy-and-directionally-bearish-1034188386,negative,0.8441292643547058
1/5/2025 10:32:40 PM,SA Asks: Which biotechs are most likely to be acquired near-term?,Seeking Alpha,https://seekingalpha.com/news/4392553-sa-asks-which-biotechs-are-most-likely-to-be-acquired-near-term?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8929339051246643
1/6/2025 3:35:18 PM,Merck put volume heavy and directionally bearish,TipRanks,/news/stocks/merck-put-volume-heavy-and-directionally-bearish-1034196571,negative,0.8441292643547058
1/6/2025 4:24:08 PM,Merck to buy vaccine plant from WuXi Biologics: report,Seeking Alpha,https://seekingalpha.com/news/4392673-merck-to-buy-vaccine-plant-from-wuxi-biologics-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8848361968994141
1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9278177618980408
1/7/2025 1:20:53 PM,Opko Health subsidiary announces EBV vaccine enters Phase I study,TipRanks,/news/stocks/opko-health-subsidiary-announces-ebv-vaccine-enters-phase-i-study-1034201186,neutral,0.8251302242279053
1/7/2025 2:45:32 PM,"Wuxi Biologics to sell Irish vaccine facility to Merck for $500M, Reuters says",TipRanks,/news/stocks/wuxi-biologics-to-sell-irish-vaccine-facility-to-merck-for-500m-reuters-says-1034201801,neutral,0.8399558663368225
1/7/2025 5:06:02 PM,"Paychex to acquire Paycor HCM, Getty and Shutterstock to merge: Morning Buzz",TipRanks,/news/stocks/paychex-to-acquire-paycor-hcm-getty-and-shutterstock-to-merge-morning-buzz-1034202075,neutral,0.9365741610527039
1/7/2025 6:35:22 PM,Wuxi Biologics upgraded to Overweight from Neutral at JPMorgan,TipRanks,/news/stocks/wuxi-biologics-upgraded-to-overweight-from-neutral-at-jpmorgan-1034202297,positive,0.9343005418777466
1/8/2025 1:05:43 AM,Merck downgraded to Hold from Buy at Truist,TipRanks,/news/stocks/merck-downgraded-to-hold-from-buy-at-truist-1034202833,neutral,0.8557276129722595
1/8/2025 1:15:53 AM,Truist Financial downgrades Merck & Company (MRK) to a Hold,TipRanks,/news/stocks/truist-financial-downgrades-merck-company-mrk-to-a-hold-1034202850,negative,0.7444967031478882
1/8/2025 11:46:02 AM,Merck price target lowered to $120 from $125 at UBS,TipRanks,/news/stocks/merck-price-target-lowered-to-120-from-125-at-ubs-1034205556,negative,0.6201738715171814
1/8/2025 11:55:58 AM,Merck’s Gardasil receives expanded approval for males in China,TipRanks,/news/stocks/merck-s-gardasil-receives-expanded-approval-for-males-in-china-1034205510,positive,0.9378724694252014
1/8/2025 12:55:16 PM,Merck gets expanded approval from China for its HPV vaccine in males,Seeking Alpha,https://seekingalpha.com/news/4393380-merck-gets-expanded-approval-from-china-for-its-hpv-vaccine-in-males?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9142133593559265
1/8/2025 2:55:50 PM,Trump Trade: New administration to invest $20B to build data centers,TipRanks,/news/stocks/trump-trade-new-administration-to-invest-20b-to-build-data-centers-1034207027,neutral,0.6268939971923828
1/8/2025 3:19:24 PM,Merck downgraded by Truist to hold over growth concerns,Seeking Alpha,https://seekingalpha.com/news/4393442-merck-downgraded-by-truist-to-hold-over-growth-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9333776831626892
1/8/2025 4:02:32 PM,Merck rival Summit draws new buy from Truist on deal prospects,Seeking Alpha,https://seekingalpha.com/news/4393502-merck-rival-summit-draws-new-buy-truist?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4915562570095062
1/8/2025 5:00:51 PM,"Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz",TipRanks,/news/stocks/exxon-and-shell-cautious-on-q4-flutter-cuts-guidance-morning-buzz-1034207318,negative,0.5844774842262268
1/8/2025 8:14:20 PM,"Pfizer, Astellas win China nod for Padcev in bladder cancer with Merck’s Keytruda",Seeking Alpha,https://seekingalpha.com/news/4393558-pfizer-astellas-win-china-nod-padcev?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8854827880859375
1/8/2025 11:07:13 PM,Bernstein Sticks to Their Hold Rating for Merck & Company (MRK),TipRanks,/news/stocks/bernstein-sticks-to-their-hold-rating-for-merck-company-mrk-1034208001,neutral,0.8530483841896057
1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6913239359855652
1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9193293452262878
1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8774528503417969
1/14/2025 12:30:47 PM,Merck eyeing 2025 launch for easier-to-use Keytruda,Seeking Alpha,https://seekingalpha.com/news/4394826-merck-sees-2025-launch-keytruda-injectable?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5014865398406982
1/14/2025 12:45:13 PM,Merck & Company: Balancing Growth Prospects with Competitive Challenges in Oncology and Immunology,TipRanks,/news/stocks/merck-company-balancing-growth-prospects-with-competitive-challenges-in-oncology-and-immunology-1034226401,positive,0.7735592722892761
1/14/2025 1:05:16 PM,Merck & Co.’s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects,TipRanks,/news/stocks/merck-co-s-accelerated-keytruda-launch-and-strategic-updates-bolster-long-term-growth-prospects-1034226486,positive,0.9530627727508545
1/14/2025 2:40:39 PM,"Drugmakers to push Trump to pause price negotiations, Bloomberg reports",TipRanks,/news/stocks/drugmakers-to-push-trump-to-pause-price-negotiations-bloomberg-reports-1034226968,negative,0.7503699064254761
1/14/2025 11:35:17 PM,Merck CEO: We’re a much broader company than we have been,TipRanks,/news/stocks/merck-ceo-we-re-a-much-broader-company-than-we-have-been-1034227795,neutral,0.770927369594574
1/15/2025 6:25:54 AM,Berenberg Bank Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/berenberg-bank-remains-a-buy-on-merck-company-mrk-1034229433,neutral,0.9436963200569153
1/15/2025 6:59:17 AM,Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges,TipRanks,/news/stocks/merck-company-strategic-shifts-and-upcoming-catalysts-amidst-keytruda-challenges-1034229561,neutral,0.8054560422897339
1/17/2025 12:21:02 PM,Merck price target lowered to $122 from $130 at Guggenheim,TipRanks,/news/stocks/merck-price-target-lowered-to-122-from-130-at-guggenheim-1034240600,negative,0.6988741755485535
1/17/2025 1:19:18 PM,Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4396094-wegovy-latest-medicare-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9195981025695801
1/17/2025 1:20:48 PM,"Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",TipRanks,/news/stocks/ozempic-xtandi-among-next-15-drugs-selected-for-u-s-price-talks-1034240882,neutral,0.6648421883583069
1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.826055109500885
1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772,neutral,0.4902459383010864
1/18/2025 8:56:17 PM,Chinese biotech dominance in R&D is on the rise,Seeking Alpha,https://seekingalpha.com/news/4396390-chinese-biotech-dominance-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7791072726249695
1/21/2025 12:00:33 PM,Merck price target lowered to $113 from $123 at Morgan Stanley,TipRanks,/news/stocks/merck-price-target-lowered-to-113-from-123-at-morgan-stanley-1034250036,negative,0.831013023853302
1/21/2025 12:00:59 PM,"Analysts Are Neutral on These Healthcare Stocks: Inspire Medical Systems (INSP), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-inspire-medical-systems-insp-merck-company-mrk-1034250033,neutral,0.6744691133499146
1/21/2025 11:30:43 PM,Takeda-backed Ascentage Pharma sets terms for $170M IPO,Seeking Alpha,https://seekingalpha.com/news/4396905-takeda-backed-ascentage-pharma-sets-terms-for-170m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9381498694419861
1/22/2025 1:20:53 PM,Edgewise Therapeutics promotes Behrad Derakhshan to COO,TipRanks,/news/stocks/edgewise-therapeutics-promotes-behrad-derakhshan-to-coo-1034255759,neutral,0.9311155676841736
1/22/2025 4:58:54 PM,Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines,Seeking Alpha,https://seekingalpha.com/news/4397421-moderna-stock-up-oracles-ellison-touts-ai-led-shots?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.42514270544052124
1/23/2025 11:20:47 AM,"Kennedy Jr. to keep vaccine suit stake if confirmed as health chief, FT says",TipRanks,/news/stocks/kennedy-jr-to-keep-vaccine-suit-stake-if-confirmed-as-health-chief-ft-says-1034259869,neutral,0.9194737076759338
1/23/2025 1:26:12 PM,Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-merck-company-mrk-1034260945,neutral,0.8016572594642639
1/23/2025 3:10:31 PM,Trump Trade: Musk plays down Stargate AI investment announcement,TipRanks,/news/stocks/trump-trade-musk-plays-down-stargate-ai-investment-announcement-1034261610,neutral,0.9380744695663452
1/24/2025 11:51:36 AM,"Merck, Eisai provide update on Phase 3 LEAP-015 trial",TipRanks,/news/stocks/merck-eisai-provide-update-on-phase-3-leap-015-trial-1034266166,neutral,0.9439342617988586
1/24/2025 12:32:05 PM,"Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer",Seeking Alpha,https://seekingalpha.com/news/4398317-merck-eisai-post-phase-3-data-keytruda-lenvima?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.595253050327301
1/24/2025 3:27:51 PM,Ascentage Pharma raises $126M via U.S. IPO (update),Seeking Alpha,https://seekingalpha.com/news/4398391-takeda-backed-ascentage-pharma-prices-126m-u_s_-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8579893112182617
1/27/2025 6:15:46 AM,Optimistic Buy Rating for Merck & Co. Driven by Winrevair Projections and Financial Strength,TipRanks,/news/stocks/optimistic-buy-rating-for-merck-co-driven-by-winrevair-projections-and-financial-strength-1034270756,positive,0.921919584274292
1/27/2025 11:51:26 AM,Merck: FDA grants priority review to sNDA for Welireg,TipRanks,/news/stocks/merck-fda-grants-priority-review-to-snda-for-welireg-1034272029,positive,0.509494960308075
1/27/2025 12:10:42 PM,"Adagene announces updated data from Phase 1b/2 study of muzastotug, keytruda",TipRanks,/news/stocks/adagene-announces-updated-data-from-phase-1b-2-study-of-muzastotug-keytruda-1034272416,neutral,0.9013639688491821
1/27/2025 4:26:34 PM,Merck gets priority review for Welireg for PPGL,Seeking Alpha,https://seekingalpha.com/news/4398856-merck-gets-priority-review-for-welireg-for-ppgl?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7662770748138428
1/28/2025 9:49:14 AM,Wells Fargo Sticks to Their Hold Rating for Merck & Company (MRK),TipRanks,/news/stocks/wells-fargo-sticks-to-their-hold-rating-for-merck-company-mrk-1034276500,neutral,0.8521066308021545
1/28/2025 11:36:19 AM,Merck price target lowered to $125 from $130 at Citi,TipRanks,/news/stocks/merck-price-target-lowered-to-125-from-130-at-citi-1034277160,negative,0.744096577167511
1/28/2025 2:40:20 PM,Unusually active option classes on open January 28th,TipRanks,/news/stocks/unusually-active-option-classes-on-open-january-28th-1034278649,neutral,0.7369071841239929
1/28/2025 4:19:40 PM,RFK Jr. reportedly softens his antivaccine stance ahead of confirmation hearing,Seeking Alpha,https://seekingalpha.com/news/4399431-rfk-jr-says-not-antivaccine-ahead-senate-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8104958534240723
1/28/2025 6:30:14 PM,Merck announces $10B share repurchase authorization,TipRanks,/news/stocks/merck-announces-10b-share-repurchase-authorization-1034279245,neutral,0.8943043351173401
1/28/2025 7:02:18 PM,Merck declares $0.81 dividend,Seeking Alpha,https://seekingalpha.com/news/4399607-merck-declares-081-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9253928065299988
1/29/2025 1:19:52 PM,Moderna slips as Goldman Sachs downgrades on revenue outlook,Seeking Alpha,https://seekingalpha.com/news/4399960-moderna-stock-down-goldman-sachs-downgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9616147875785828
1/29/2025 6:55:13 PM,"RFK Jr. comments contradict anti-vaccine legacy, says Truist",TipRanks,/news/stocks/rfk-jr-comments-contradict-anti-vaccine-legacy-says-truist-1034284331,neutral,0.638435423374176
1/29/2025 7:30:50 PM,CMS aiming for more transparency in drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4400241-cms-aiming-for-more-transparency-in-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7420770525932312
1/30/2025 11:56:53 AM,Merck to stop Phase 3 HYPERION trial,TipRanks,/news/stocks/merck-to-stop-phase-3-hyperion-trial-1034288574,neutral,0.7792230248451233
1/30/2025 1:18:37 PM,Merck To Stop Phase 3 HYPERION Study Early ,RTTNews,/news/stocks/merck-to-stop-phase-3-hyperion-study-early-1034288871,negative,0.6646326184272766
1/30/2025 1:52:59 PM,Merck to stop late-stage HYPERION trial evaluating WINREVAIR,Seeking Alpha,https://seekingalpha.com/news/4400749-merck-to-stop-late-stage-hyperion-trial-evaluating-winrevair?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6311895251274109
1/30/2025 2:45:24 PM,Bank of America Securities Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/bank-of-america-securities-remains-a-buy-on-merck-company-mrk-1034290159,neutral,0.9385826587677002
1/31/2025 9:06:40 AM,NVS Earnings: Entresto Drugmaker Novartis Tops Estimates as Patent Expiry Looms,TipRanks,/news/stocks/nvs-earnings-entresto-drugmaker-novartis-tops-estimates as-patent-expiry-looms-1034294182,positive,0.8056170344352722
1/31/2025 11:10:08 AM,"Kennedy says he will give away rights to fees from vaccine litigation, NYT says",TipRanks,/news/stocks/kennedy-says-he-will-give-away-rights-to-fees-from-vaccine-litigation-nyt-says-1034294579,neutral,0.9193658828735352
1/31/2025 11:26:07 AM,Merck & Company Hold Rating: Promising Drug Developments Amid Uncertain Financial Outlook,TipRanks,/news/stocks/merck-company-hold-rating-promising-drug-developments-amid-uncertain-financial-outlook-1034294672,positive,0.9387081861495972
1/31/2025 11:50:42 AM,Merck’s capvaxive receives positive EU CHMP opinion for pneumococcal vaccine,TipRanks,/news/stocks/merck-s-capvaxive-receives-positive-eu-chmp-opinion-for-pneumococcal-vaccine-1034294938,positive,0.9406474232673645
1/31/2025 1:45:31 PM,Merck's CAPVAXIVE Gets Positive EU CHMP Opinion For Pneumococcal Vaccination In Adults ,RTTNews,/news/stocks/merck-s-capvaxive-gets-positive-eu-chmp-opinion-for-pneumococcal-vaccination-in-adults-1034295415,positive,0.9497389197349548
1/31/2025 4:03:46 PM,Merck gets positive EMA opinion for pneumonia vaccine,Seeking Alpha,https://seekingalpha.com/news/4401463-merck-gets-positive-ema-opinion-for-pneumonia-vaccine?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9359834790229797
1/31/2025 8:00:55 PM,"Catalyst Watch: Tariff drama, OPEC+, Alphabet and Amazon earnings, Lennar spinoff",Seeking Alpha,https://seekingalpha.com/news/4401505-catalyst-watch-tariff-drama-opec-alphabet-and-amazon-earnings-lennar-spinoff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9292561411857605
2/1/2025 12:53:24 PM,Are healthcare stocks on the rebound?,Seeking Alpha,https://seekingalpha.com/news/4401695-are-healthcare-stocks-rebound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7119130492210388
2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9316384792327881
2/3/2025 6:35:20 AM,Merck’s Winrevair: A Catalyst for Stock Growth Amid Promising Clinical Developments,TipRanks,/news/stocks/merck-s-winrevair-a-catalyst-for-stock-growth-amid-promising-clinical-developments-1034301481,positive,0.8885034322738647
2/3/2025 5:44:37 PM,"Sens. Wyden, Warren press RFK Jr. on conflicts of interest ahead of vote",Seeking Alpha,https://seekingalpha.com/news/4402094-senators-wyden-warren-press-rfk-jr-conflicts-of-interest-ahead-vote?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7472131252288818
2/3/2025 6:16:10 PM,"Merck Q4 2024 Earnings Preview: Headwinds ahead, but familiar strengths to persist",Seeking Alpha,https://seekingalpha.com/news/4402196-merck-q4-2024-earnings-preview-headwinds-ahead-but-familiar-strengths-to-persist?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4369524419307709
2/3/2025 7:10:20 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034305420,neutral,0.9220908284187317
2/3/2025 11:00:37 PM,Here's the major earnings before the open tomorrow,Seeking Alpha,https://seekingalpha.com/news/4402088-heres-the-major-earnings-before-the-open-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9330109357833862
2/4/2025 11:32:00 AM,"Merck Non-GAAP EPS of $1.72 beats by $0.04, revenue of $15.62B beats by $110M",Seeking Alpha,https://seekingalpha.com/news/4402557-merck-non-gaap-eps-of-1_72-beats-by-0_04-revenue-of-15_62b-beats-by-110m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6094211935997009
2/4/2025 11:36:33 AM,"Merck sees FY25 adjusted EPS $8.88-$9.03, consensus $9.21",TipRanks,/news/stocks/merck-sees-fy25-adjusted-eps-8-88--9-03-consensus-9-21-1034308362,neutral,0.693087100982666
2/4/2025 11:37:12 AM,"Merck reports Q4 adjusted EPS $1.72, consensus $1.67",TipRanks,/news/stocks/merck-reports-q4-adjusted-eps-1-72-consensus-1-67-1034308350,neutral,0.4983600676059723
2/4/2025 11:51:19 AM,Earnings Snapshot: Merck FY25 sales outlook falls short of estimates even as Q4 beats,Seeking Alpha,https://seekingalpha.com/news/4402578-earnings-snapshot-merck-fy25-sales-outlook-falls-short-of-estimates-even-as-q4-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9710360765457153
2/4/2025 11:56:14 AM,Merck to temporarily pause shipments of Gardasil into China,TipRanks,/news/stocks/merck-to-temporarily-pause-shipments-of-gardasil-into-china-1034308478,negative,0.8227694630622864
2/4/2025 11:56:33 AM,Merck stock slides as 2025 earnings outlook misses estimates,Seeking Alpha,https://seekingalpha.com/news/4402559-merck-stock-slides-as-2025-earnings-outlook-misses-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.966316819190979
2/4/2025 12:29:28 PM,Merck in Charts: KEYTRUDA continues growth trajectory with 18.6% rise in Q4,Seeking Alpha,https://seekingalpha.com/news/4402610-merck-in-charts-keytruda-continues-growth-trajectory-with-186-rise-in-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9526318907737732
2/4/2025 12:35:58 PM,Merck & Co Inc. Q4 Earnings Summary ,RTTNews,/news/stocks/merck-co-inc-q4-earnings-summary-1034308327,neutral,0.7235262393951416
2/4/2025 12:37:51 PM,"Pyxis Oncology initiates new PYX-201 trial, initiates cohort expansions",TipRanks,/news/stocks/pyxis-oncology-initiates-new-pyx-201-trial-initiates-cohort-expansions-1034308883,positive,0.5603454113006592
2/4/2025 12:47:39 PM,Merck Stock Down 8% On Weak FY25 Outlook - Update ,RTTNews,/news/stocks/merck-stock-down-8-on-weak-fy25-outlook-update-1034308442,negative,0.9706863164901733
2/4/2025 1:45:35 PM,Evaxion Biotech price target lowered to $6 from $35 at Lake Street,TipRanks,/news/stocks/evaxion-biotech-price-target-lowered-to-6-from-35-at-lake-street-1034309428,negative,0.6127738952636719
2/4/2025 1:58:38 PM,MRK Earnings: Weak 2025 Guidance Mangles Merck Stock Today,TipRanks,/news/stocks/mrk-earnings-weak-2025-guidance-mangles-merck-stock-today-1034309580,negative,0.9671967029571533
2/4/2025 2:00:33 PM,Morning Movers: Spotify and Pfizer climb after fourth quarter results,TipRanks,/news/stocks/morning-movers-spotify-and-pfizer-climb-after-fourth-quarter-results-1034309577,positive,0.8022207021713257
2/4/2025 2:50:16 PM,Merck falls -10.1%,TipRanks,/news/stocks/merck-falls--10-1-1034309738,negative,0.7678061723709106
2/4/2025 2:54:29 PM,"Biggest stock movers Tuesday: PLTR, PYPL, SPOT, and more",Seeking Alpha,https://seekingalpha.com/news/4402488-biggest-stock-movers-tuesday-pltr-syna-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9086858630180359
2/4/2025 3:05:18 PM,Merck falls -11.0%,TipRanks,/news/stocks/merck-falls--11-0-1034310139,negative,0.829308807849884
2/4/2025 3:10:52 PM,"Merck Stock Down 8% On Weak Outlook, Q4 Results Miss Estimates ",RTTNews,/news/stocks/merck-stock-down-8-on-weak-outlook-q4-results-miss-estimates-1034309585,negative,0.9724701046943665
2/4/2025 5:05:31 PM,"China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz",TipRanks,/news/stocks/china-retaliates-with-tariffs-on-u-s-merck-falls-after-earnings-morning-buzz-1034310568,negative,0.9223615527153015
2/4/2025 5:06:01 PM,Merck falls -10.8%,TipRanks,/news/stocks/merck-falls--10-8-1034310564,negative,0.607473611831665
2/4/2025 5:15:16 PM,"Senate panel advances Kennedy’s nomination for HHS secretary, CNBC reports",TipRanks,/news/stocks/senate-panel-advances-kennedy-s-nomination-for-hhs-secretary-cnbc-reports-1034310628,neutral,0.8860395550727844
2/5/2025 12:05:37 AM,Merck price target lowered to $106 from $113 at Morgan Stanley,TipRanks,/news/stocks/merck-price-target-lowered-to-106-from-113-at-morgan-stanley-1034311791,negative,0.8185953497886658
2/5/2025 6:18:55 AM,Merck Stock Loses 9% on Vaccine Shipment Halt to China,TipRanks,/news/stocks/merck-stock-loses-9-on-vaccine-shipment-halt-to-china-1034313484,negative,0.970179557800293
2/5/2025 10:16:02 AM,Wells Fargo Remains a Hold on Merck & Company (MRK),TipRanks,/news/stocks/wells-fargo-remains-a-hold-on-merck-company-mrk-1034314301,neutral,0.8693533539772034
2/5/2025 11:35:46 AM,Merck price target lowered to $115 from $125 at Citi,TipRanks,/news/stocks/merck-price-target-lowered-to-115-from-125-at-citi-1034314732,negative,0.7938870191574097
2/5/2025 11:37:25 AM,Citi Remains a Buy on Merck & Company (MRK),TipRanks,/news/stocks/citi-remains-a-buy-on-merck-company-mrk-1034314710,neutral,0.9372966289520264
2/5/2025 12:06:26 PM,J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/j-p-morgan-keeps-their-buy-rating-on-merck-company-mrk-1034314956,neutral,0.9019536375999451
2/5/2025 12:25:15 PM,Merck price target lowered to $96 from $105 at BMO Capital,TipRanks,/news/stocks/merck-price-target-lowered-to-96-from-105-at-bmo-capital-1034315053,negative,0.5565023422241211
2/5/2025 1:00:32 PM,Merck call buyer realizes 48% same-day gains,TipRanks,/news/stocks/merck-call-buyer-realizes-48-same-day-gains-1034315463,positive,0.8847395181655884
2/5/2025 1:15:30 PM,Merck price target lowered to $112 from $118 at BofA,TipRanks,/news/stocks/merck-price-target-lowered-to-112-from-118-at-bofa-1034315569,negative,0.7192913889884949
2/6/2025 7:15:49 AM,Evercore ISI Reaffirms Their Buy Rating on Merck & Company (MRK),TipRanks,/news/stocks/evercore-isi-reaffirms-their-buy-rating-on-merck-company-mrk-1034320749,neutral,0.8530570268630981
2/6/2025 8:57:13 AM,Bernstein Sticks to Its Hold Rating for Merck & Company (MRK),TipRanks,/news/stocks/bernstein-sticks-to-its-hold-rating-for-merck-company-mrk-1034320993,neutral,0.7829104065895081
2/6/2025 6:35:50 PM,"White House readying order to fire thousands of federal health workers, WSJ says",TipRanks,/news/stocks/white-house-readying-order-to-fire-thousands-of-federal-health-workers-wsj-says-1034324421,negative,0.9388383626937866
2/7/2025 3:21:13 PM,Trump Trade: President advocates to close carried interest tax loophole,TipRanks,/news/stocks/trump-trade-president-advocates-to-close-carried-interest-tax-loophole-1034328479,neutral,0.6031154990196228
2/8/2025 5:50:12 PM,"Trending stocks this week as markets assess tariffs, inflation news",Seeking Alpha,https://seekingalpha.com/news/4405153-trending-stocks-this-week-as-markets-assess-tariffs-inflation-news?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8234192728996277
2/8/2025 9:04:00 PM,18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4405247-18-out-of-21-healthcare-companies-beat-profit-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8692342042922974
